{"format":{"id":"small-molecule","name":"Small-molecule inhibitors","blurb":"A target and a way of hitting it: ATP-competitive, allosteric or covalent kinase inhibitors, PARP trapping, hormone receptor blockade. The grid asks which targets have been hit with which mechanism class.","axes":["target","mechanismClass"],"axisLabels":["Target","Mechanism class"],"components":[{"key":"target","label":"Target"},{"key":"mechanismClass","label":"Mechanism class"},{"key":"binding","label":"Binding mode"}]},"counts":{"approved":94,"development":33,"stopped":10,"unclear":0,"untried":1906,"drugs":300,"partial":3,"unresolved":82},"coverage":{"total":382,"full":297,"partial":3,"unresolved":82,"pct":79},"rows":[{"key":"target","id":"kras","name":"KRAS","href":"/targets/kras/"},{"key":"target","id":"egfr","name":"EGFR","href":"/targets/egfr/"},{"key":"target","id":"androgen-receptor","name":"Androgen receptor","href":"/targets/androgen-receptor/"},{"key":"target","id":"estrogen-receptor","name":"Estrogen receptor (ERα)","href":"/targets/estrogen-receptor/"},{"key":"target","id":"fgfr2","name":"FGFR2","href":"/targets/fgfr2/"},{"key":"target","id":"parp","name":"PARP","href":"/targets/parp/"},{"key":"target","id":"cdk4-6","name":"CDK4/6","href":"/targets/cdk4-6/"},{"key":"target","id":"pik3ca","name":"PIK3CA / PI3K-alpha","href":"/targets/pik3ca/"},{"key":"target","id":"idh","name":"IDH1 / IDH2","href":"/targets/idh/"},{"key":"target","id":"vegf","name":"VEGF / VEGFR","href":"/targets/vegf/"},{"key":"target","id":"alk","name":"ALK","href":"/targets/alk/"},{"key":"target","id":"braf","name":"BRAF","href":"/targets/braf/"},{"key":"target","id":"btk","name":"BTK (Bruton tyrosine kinase)","href":"/targets/btk/"},{"key":"target","id":"her2","name":"HER2","href":"/targets/her2/"},{"key":"target","id":"mek","name":"MEK1/2","href":"/targets/mek/"},{"key":"target","id":"met","name":"MET","href":"/targets/met/"},{"key":"target","id":"prmt5-mtap","name":"PRMT5 (MTAP-deleted cancers)","href":"/targets/prmt5-mtap/"},{"key":"target","id":"bcr-abl","name":"BCR::ABL1 (Philadelphia chromosome)","href":"/targets/bcr-abl/"},{"key":"target","id":"her2+egfr","name":"HER2 x EGFR","href":"/targets/her2/"},{"key":"target","id":"hdac","name":"Histone deacetylases (HDAC)","href":"/targets/hdac/"},{"key":"target","id":"parp+brca","name":"PARP x BRCA1 / BRCA2","href":"/targets/parp/"},{"key":"target","id":"smoothened","name":"Smoothened (hedgehog pathway)","href":"/targets/smoothened/"},{"key":"target","id":"vegf+kit","name":"VEGF / VEGFR x KIT","href":"/targets/vegf/"},{"key":"target","id":"cxcr4","name":"CXCR4","href":"/targets/cxcr4/"},{"key":"target","id":"flt3","name":"FLT3","href":"/targets/flt3/"},{"key":"target","id":"kit","name":"KIT","href":"/targets/kit/"},{"key":"target","id":"mtor","name":"mTOR","href":"/targets/mtor/"},{"key":"target","id":"proteasome","name":"Proteasome (PSMB5)","href":"/targets/proteasome/"},{"key":"target","id":"ret","name":"RET","href":"/targets/ret/"},{"key":"target","id":"vegf+fgfr2","name":"VEGF / VEGFR x FGFR2","href":"/targets/vegf/"},{"key":"target","id":"alk+ros1","name":"ALK x ROS1","href":"/targets/alk/"},{"key":"target","id":"aromatase","name":"Aromatase (CYP19A1)","href":"/targets/aromatase/"},{"key":"target","id":"bcl2","name":"BCL-2","href":"/targets/bcl2/"},{"key":"target","id":"bcr-abl+abl1","name":"BCR::ABL1 x ABL1","href":"/targets/bcr-abl/"},{"key":"target","id":"brd4","name":"BRD4","href":"/targets/brd4/"},{"key":"target","id":"cnr1","name":"Cannabinoid receptor 1","href":"/targets/cnr1/"},{"key":"target","id":"drd2","name":"Dopamine D2 receptor","href":"/targets/drd2/"},{"key":"target","id":"ednra","name":"EDNRA","href":"/targets/ednra/"},{"key":"target","id":"egfr+her2","name":"EGFR x HER2","href":"/targets/egfr/"},{"key":"target","id":"ezh2","name":"EZH2","href":"/targets/ezh2/"},{"key":"target","id":"fak","name":"FAK (PTK2)","href":"/targets/fak/"},{"key":"target","id":"jak2+flt3","name":"JAK2 x FLT3","href":"/targets/jak2/"},{"key":"target","id":"jak2+jak1","name":"JAK2 x JAK1","href":"/targets/jak2/"},{"key":"target","id":"mpl","name":"MPL (thrombopoietin receptor)","href":"/targets/mpl/"},{"key":"target","id":"oprm1","name":"Mu-opioid receptor","href":"/targets/oprm1/"},{"key":"target","id":"pik3ca+akt","name":"PIK3CA / PI3K-alpha x AKT","href":"/targets/pik3ca/"},{"key":"target","id":"rara+rxr","name":"Retinoic acid receptor alpha x Retinoid X receptor","href":"/targets/rara/"},{"key":"target","id":"ros1","name":"ROS1","href":"/targets/ros1/"},{"key":"target","id":"shp2","name":"SHP2 (PTPN11)","href":"/targets/shp2/"},{"key":"target","id":"sstr2","name":"Somatostatin receptor 2","href":"/targets/sstr2/"},{"key":"target","id":"tp53","name":"TP53","href":"/targets/tp53/"},{"key":"target","id":"tubulin","name":"Tubulin (microtubules)","href":"/targets/tubulin/"},{"key":"target","id":"vegf+braf","name":"VEGF / VEGFR x BRAF","href":"/targets/vegf/"},{"key":"target","id":"wrn","name":"WRN helicase (MSI-high cancers)","href":"/targets/wrn/"},{"key":"target","id":"ada","name":"Adenosine deaminase (ADA)","href":"/targets/ada/"},{"key":"target","id":"akt","name":"AKT","href":"/targets/akt/"},{"key":"target","id":"akt+pik3ca","name":"AKT x PIK3CA / PI3K-alpha","href":"/targets/akt/"},{"key":"target","id":"androgen-receptor+cyp17a1","name":"Androgen receptor x CYP17A1","href":"/targets/androgen-receptor/"},{"key":"target","id":"apc+ctnnb1","name":"APC x CTNNB1","href":"/targets/apc/"},{"key":"target","id":"aromatase+cyp11a1","name":"Aromatase x CYP11A1","href":"/targets/aromatase/"},{"key":"target","id":"atr","name":"ATR","href":"/targets/atr/"},{"key":"target","id":"bcr-abl+ddr2","name":"BCR::ABL1 x DDR2 receptor kinase","href":"/targets/bcr-abl/"},{"key":"target","id":"bcr-abl+kit","name":"BCR::ABL1 x KIT","href":"/targets/bcr-abl/"},{"key":"target","id":"braf+egfr","name":"BRAF x EGFR","href":"/targets/braf/"},{"key":"target","id":"casr","name":"CASR","href":"/targets/casr/"},{"key":"target","id":"cblb","name":"CBLB","href":"/targets/cblb/"},{"key":"target","id":"col6a3+csf1","name":"COL6A3 x CSF1","href":"/targets/col6a3/"},{"key":"target","id":"cox2","name":"COX-2 (PTGS2)","href":"/targets/cox2/"},{"key":"target","id":"csf1r+kit","name":"CSF1R x KIT","href":"/targets/csf1r/"},{"key":"target","id":"cyp11b1","name":"CYP11B1","href":"/targets/cyp11b1/"},{"key":"target","id":"cyp17a1","name":"CYP17A1 (17-alpha-hydroxylase/17,20-lyase)","href":"/targets/cyp17a1/"},{"key":"target","id":"drd2+h3-3a","name":"Dopamine D2 receptor x Histone H3.3","href":"/targets/drd2/"},{"key":"target","id":"eed","name":"EED","href":"/targets/eed/"},{"key":"target","id":"egfr+met","name":"EGFR x MET","href":"/targets/egfr/"},{"key":"target","id":"estrogen-receptor+her2","name":"Estrogen receptor x HER2","href":"/targets/estrogen-receptor/"},{"key":"target","id":"ewsr1-fli1","name":"EWSR1-FLI1 fusion","href":"/targets/ewsr1-fli1/"},{"key":"target","id":"ezh2+androgen-receptor","name":"EZH2 x Androgen receptor","href":"/targets/ezh2/"},{"key":"target","id":"fkbp12+hif1a","name":"FKBP12 x HIF-1α","href":"/targets/fkbp12/"},{"key":"target","id":"flt3+kit","name":"FLT3 x KIT","href":"/targets/flt3/"},{"key":"target","id":"gamma-secretase","name":"Gamma-secretase (PSEN1)","href":"/targets/gamma-secretase/"},{"key":"target","id":"gna11+gnaq","name":"GNA11 x GNAQ","href":"/targets/gna11/"},{"key":"target","id":"gsk3b","name":"GSK3B","href":"/targets/gsk3b/"},{"key":"target","id":"hdac10","name":"HDAC10","href":"/targets/hdac10/"},{"key":"target","id":"her2+fgfr2","name":"HER2 x FGFR2","href":"/targets/her2/"},{"key":"target","id":"hif2a","name":"HIF-2α","href":"/targets/hif2a/"},{"key":"target","id":"hdac+proteasome","name":"Histone deacetylases x Proteasome","href":"/targets/hdac/"},{"key":"target","id":"hdac+tet2","name":"Histone deacetylases x TET2","href":"/targets/hdac/"},{"key":"target","id":"itk","name":"ITK","href":"/targets/itk/"},{"key":"target","id":"jak1","name":"JAK1","href":"/targets/jak1/"},{"key":"target","id":"kit+met","name":"KIT x MET","href":"/targets/kit/"},{"key":"target","id":"kras+fak","name":"KRAS x FAK","href":"/targets/kras/"},{"key":"target","id":"kras+nras","name":"KRAS x NRAS","href":"/targets/kras/"},{"key":"target","id":"mdm2","name":"MDM2","href":"/targets/mdm2/"},{"key":"target","id":"mdm2+tp53","name":"MDM2 x TP53","href":"/targets/mdm2/"},{"key":"target","id":"menin","name":"Menin","href":"/targets/menin/"},{"key":"target","id":"menin+npm1","name":"Menin x NPM1 mutation","href":"/targets/menin/"},{"key":"target","id":"mertk","name":"MERTK","href":"/targets/mertk/"},{"key":"target","id":"met+egfr","name":"MET x EGFR","href":"/targets/met/"},{"key":"target","id":"met+ret","name":"MET x RET","href":"/targets/met/"},{"key":"target","id":"met+vegf","name":"MET x VEGF / VEGFR","href":"/targets/met/"},{"key":"target","id":"mycn","name":"MYCN (N-myc)","href":"/targets/mycn/"},{"key":"target","id":"nras","name":"NRAS","href":"/targets/nras/"},{"key":"target","id":"ntrk","name":"NTRK","href":"/targets/ntrk/"},{"key":"target","id":"ntrk+ros1","name":"NTRK x ROS1","href":"/targets/ntrk/"},{"key":"target","id":"pik3cd+psmb6","name":"PI3K delta x PSMB6","href":"/targets/pik3cd/"},{"key":"target","id":"plk1","name":"PLK1","href":"/targets/plk1/"},{"key":"target","id":"ret+vegf","name":"RET x VEGF / VEGFR","href":"/targets/ret/"},{"key":"target","id":"rxr","name":"Retinoid X receptor (RXR)","href":"/targets/rxr/"},{"key":"target","id":"rrm1","name":"Ribonucleotide reductase (RRM1)","href":"/targets/rrm1/"},{"key":"target","id":"ros1+ntrk","name":"ROS1 x NTRK","href":"/targets/ros1/"},{"key":"target","id":"stat3","name":"STAT3","href":"/targets/stat3/"},{"key":"target","id":"syk","name":"SYK","href":"/targets/syk/"},{"key":"target","id":"tbk1","name":"TBK1","href":"/targets/tbk1/"},{"key":"target","id":"tlr7","name":"Toll-like receptor 7 (TLR7)","href":"/targets/tlr7/"},{"key":"target","id":"top1","name":"Topoisomerase I (TOP1)","href":"/targets/top1/"},{"key":"target","id":"tph1","name":"Tryptophan hydroxylase 1","href":"/targets/tph1/"},{"key":"target","id":"ugt1a1","name":"UGT1A1","href":"/targets/ugt1a1/"},{"key":"target","id":"vegf+csf1r","name":"VEGF / VEGFR x CSF1R","href":"/targets/vegf/"},{"key":"target","id":"vegf+met","name":"VEGF / VEGFR x MET","href":"/targets/vegf/"},{"key":"target","id":"wee1","name":"WEE1","href":"/targets/wee1/"}],"cols":[{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},{"key":"mechanismClass","id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/"},{"key":"mechanismClass","id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/"},{"key":"mechanismClass","id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/"},{"key":"mechanismClass","id":"other-inhibitor","name":"Inhibitor (class not stated)"},{"key":"mechanismClass","id":"receptor-agonist","name":"Receptor agonist"},{"key":"mechanismClass","id":"parp-inhibitor","name":"PARP inhibitor","href":"/technologies/parp-inhibitor/"},{"key":"mechanismClass","id":"cdk-inhibitor","name":"CDK inhibitor","href":"/technologies/cdk46-inhibitor/"},{"key":"mechanismClass","id":"pi3k-akt-mtor-inhibitor","name":"PI3K, AKT or mTOR inhibitor","href":"/technologies/pi3k-akt-mtor-inhibitors/"},{"key":"mechanismClass","id":"idh-inhibitor","name":"IDH inhibitor","href":"/technologies/idh-inhibitors/"},{"key":"mechanismClass","id":"hedgehog-inhibitor","name":"Hedgehog inhibitor","href":"/technologies/hedgehog-inhibitors/"},{"key":"mechanismClass","id":"bcl2-inhibitor","name":"BCL-2 inhibitor","href":"/technologies/bcl2-inhibitors/"},{"key":"mechanismClass","id":"mdm2-inhibitor","name":"MDM2 inhibitor","href":"/technologies/mdm2-inhibitors/"},{"key":"mechanismClass","id":"ddr-inhibitor","name":"DNA damage response inhibitor"},{"key":"mechanismClass","id":"gamma-secretase-inhibitor","name":"Gamma-secretase inhibitor","href":"/technologies/gamma-secretase-inhibitors/"},{"key":"mechanismClass","id":"hif-inhibitor","name":"HIF inhibitor"},{"key":"mechanismClass","id":"proteasome-inhibitor","name":"Proteasome inhibitor"},{"key":"mechanismClass","id":"not-recorded","name":"Mechanism class not recorded"}],"cells":[{"a":{"key":"target","id":"kras","name":"KRAS","href":"/targets/kras/"},"b":{"key":"mechanismClass","id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/"},"state":"approved","drugs":[{"id":"adagrasib","name":"Adagrasib","route":"/drugs/adagrasib/","state":"approved","status":"approved"},{"id":"calderasib","name":"Calderasib","route":"/drugs/calderasib/","state":"development","status":"phase-3"},{"id":"daraxonrasib","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","state":"approved","status":"approved"},{"id":"divarasib","name":"Divarasib","route":"/drugs/divarasib/","state":"development","status":"phase-3"},{"id":"elironrasib","name":"Elironrasib","route":"/drugs/elironrasib/","state":"development","status":"phase-2"},{"id":"fulzerasib","name":"Fulzerasib","route":"/drugs/fulzerasib/","state":"approved","status":"approved"},{"id":"garsorasib","name":"Garsorasib","route":"/drugs/garsorasib/","state":"approved","status":"approved"},{"id":"gfh375","name":"GFH375","route":"/drugs/gfh375/","state":"development","status":"phase-3"},{"id":"glecirasib","name":"Glecirasib","route":"/drugs/glecirasib/","state":"approved","status":"approved"},{"id":"incb161734","name":"INCB161734","route":"/drugs/incb161734/","state":"development","status":"phase-3"},{"id":"jdq443","name":"JDQ443","route":"/drugs/jdq443/","state":"development","status":"phase-3"},{"id":"mrtx1133","name":"MRTX1133","route":"/drugs/mrtx1133/","state":"development","status":"phase-1"},{"id":"olomorasib","name":"Olomorasib","route":"/drugs/olomorasib/","state":"development","status":"phase-3"},{"id":"sotorasib","name":"Sotorasib","route":"/drugs/sotorasib/","state":"approved","status":"approved"},{"id":"vs-7375","name":"VS-7375","route":"/drugs/vs-7375/","state":"development","status":"phase-2"},{"id":"zoldonrasib","name":"Zoldonrasib","route":"/drugs/zoldonrasib/","state":"development","status":"phase-2"}],"counts":{"approved":6,"development":10,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"covalent","name":"Covalent"},{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"adagrasib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/adagrasib/"},{"record":"adagrasib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2022: KRAS G12C NSCLC (accelerated)","href":"/drugs/adagrasib/"},{"record":"adagrasib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2024: KRAS G12C colorectal cancer with cetuximab","href":"/drugs/adagrasib/"},{"record":"adagrasib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2024: KRAS G12C NSCLC after ≥1 line; 5 Jan 2024 (conditional)","href":"/drugs/adagrasib/"},{"record":"adagrasib","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2024: KRAS G12C-mutated locally advanced or metastatic colorectal cancer after fluoropyrimidine, oxaliplatin and irinotecan chemotherapy, with cetuximab","href":"/drugs/adagrasib/"},{"record":"adagrasib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2022","href":"/regulatory/regions/"},{"record":"adagrasib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2024","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/krazati"},{"record":"adagrasib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2024","href":"https://products.mhra.gov.uk/?search=Krazati"},{"record":"adagrasib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2024","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Krazati"},{"record":"adagrasib","field":"regulatoryEvents[5]","kind":"event","state":"stopped","label":"US 2026-09-01: withdrawal","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer","quote":"Withdrawn: the indication came off the label 2.3 years after its accelerated approval."},{"record":"nct06412198","field":"status","kind":"trial","state":"development","label":"A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations: phase 1/2, recruiting","href":"/trials/nct06412198/"},{"record":"nct07415031","field":"status","kind":"trial","state":"development","label":"A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies: phase 2, recruiting","href":"/trials/nct07415031/"},{"record":"nct06875310","field":"status","kind":"trial","state":"development","label":"A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4): phase 3, recruiting","href":"/trials/nct06875310/"},{"record":"nct06248606","field":"status","kind":"trial","state":"development","label":"Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases: phase 2, recruiting","href":"/trials/nct06248606/"},{"record":"nct05609578","field":"status","kind":"trial","state":"development","label":"Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation: phase 2, active","href":"/trials/nct05609578/"},{"record":"nct03785249","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1: phase 1/2, active","href":"/trials/nct03785249/"},{"record":"nct04613596","field":"status","kind":"trial","state":"development","label":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G: phase 2/3, recruiting","href":"/trials/nct04613596/"},{"record":"nct05853575","field":"status","kind":"trial","state":"development","label":"Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21): phase 2, active","href":"/trials/nct05853575/"},{"record":"registry:adagrasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 15 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/adagrasib/#registry"},{"record":"calderasib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/calderasib/"},{"record":"nct07190248","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007): phase 3, recruiting","href":"/trials/nct07190248/"},{"record":"nct07209111","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014): phase 2, recruiting","href":"/trials/nct07209111/"},{"record":"nct06997497","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012): phase 3, recruiting","href":"/trials/nct06997497/"},{"record":"nct07286149","field":"status","kind":"trial","state":"development","label":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F): phase 1/2, recruiting","href":"/trials/nct07286149/"},{"record":"nct07554339","field":"status","kind":"trial","state":"development","label":"A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015): phase 3, recruiting","href":"/trials/nct07554339/"},{"record":"nct06345729","field":"status","kind":"trial","state":"development","label":"A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004): phase 3, recruiting","href":"/trials/nct06345729/"},{"record":"nct07252739","field":"status","kind":"trial","state":"development","label":"KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J): phase 2, recruiting","href":"/trials/nct07252739/"},{"record":"nct07431827","field":"status","kind":"trial","state":"development","label":"MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013): phase 3, recruiting","href":"/trials/nct07431827/"},{"record":"registry:calderasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/calderasib/#registry"},{"record":"daraxonrasib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/daraxonrasib/"},{"record":"daraxonrasib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2026: Metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, or in adults who are not candidates for multiagent systemic therapy","href":"/drugs/daraxonrasib/"},{"record":"daraxonrasib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2026","href":"https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026"},{"record":"nct07492680","field":"status","kind":"trial","state":"development","label":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5): phase 2, recruiting","href":"/trials/nct07492680/"},{"record":"nct07793253","field":"status","kind":"trial","state":"development","label":"Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer: phase 2, planned","href":"/trials/nct07793253/"},{"record":"nct06881784","field":"status","kind":"trial","state":"development","label":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301): phase 3, recruiting","href":"/trials/nct06881784/"},{"record":"nct07252232","field":"status","kind":"trial","state":"development","label":"Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC): phase 3, recruiting","href":"/trials/nct07252232/"},{"record":"nct07491445","field":"status","kind":"trial","state":"development","label":"Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma: phase 3, recruiting","href":"/trials/nct07491445/"},{"record":"nct06128551","field":"status","kind":"trial","state":"development","label":"Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06128551/"},{"record":"nct07397338","field":"status","kind":"trial","state":"development","label":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct07397338/"},{"record":"nct06162221","field":"status","kind":"trial","state":"development","label":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC: phase 1/2, recruiting","href":"/trials/nct06162221/"},{"record":"nct06445062","field":"status","kind":"trial","state":"development","label":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06445062/"},{"record":"nct05379985","field":"status","kind":"trial","state":"development","label":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS: phase 1/2, recruiting","href":"/trials/nct05379985/"},{"record":"nct06040541","field":"status","kind":"trial","state":"development","label":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors: phase 1, recruiting","href":"/trials/nct06040541/"},{"record":"nct07805954","field":"status","kind":"trial","state":"development","label":"Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut: phase 3, recruiting","href":"/trials/nct07805954/"},{"record":"nct06922591","field":"status","kind":"trial","state":"development","label":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients: phase 1/2, recruiting","href":"/trials/nct06922591/"},{"record":"registry:daraxonrasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 10 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/daraxonrasib/#registry"},{"record":"divarasib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/divarasib/"},{"record":"nct06793215","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip: phase 3, recruiting","href":"/trials/nct06793215/"},{"record":"nct05789082","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Par: phase 1/2, recruiting","href":"/trials/nct05789082/"},{"record":"nct07541170","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese: phase 3, recruiting","href":"/trials/nct07541170/"},{"record":"registry:divarasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/divarasib/#registry"},{"record":"elironrasib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/elironrasib/"},{"record":"nct06128551","field":"status","kind":"trial","state":"development","label":"Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06128551/"},{"record":"nct07397338","field":"status","kind":"trial","state":"development","label":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct07397338/"},{"record":"nct06162221","field":"status","kind":"trial","state":"development","label":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC: phase 1/2, recruiting","href":"/trials/nct06162221/"},{"record":"registry:elironrasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/elironrasib/#registry"},{"record":"fulzerasib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/fulzerasib/"},{"record":"fulzerasib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2024: KRAS G12C-mutant advanced NSCLC after at least one systemic therapy","href":"/drugs/fulzerasib/"},{"record":"fulzerasib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2024","href":"https://english.nmpa.gov.cn/"},{"record":"nct06936644","field":"status","kind":"trial","state":"development","label":"A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation: phase 2, planned","href":"/trials/nct06936644/"},{"record":"nct07601048","field":"status","kind":"trial","state":"development","label":"A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment: phase 3, planned","href":"/trials/nct07601048/"},{"record":"nct07492342","field":"status","kind":"trial","state":"development","label":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC: phase 2, recruiting","href":"/trials/nct07492342/"},{"record":"nct07198841","field":"status","kind":"trial","state":"development","label":"IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation: phase 2, recruiting","href":"/trials/nct07198841/"},{"record":"nct07581912","field":"status","kind":"trial","state":"development","label":"Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases: phase 2, recruiting","href":"/trials/nct07581912/"},{"record":"registry:fulzerasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/fulzerasib/#registry"},{"record":"garsorasib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/garsorasib/"},{"record":"garsorasib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2024: KRAS G12C-mutant advanced NSCLC after at least one systemic therapy","href":"/drugs/garsorasib/"},{"record":"garsorasib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2024","href":"https://english.nmpa.gov.cn/"},{"record":"nct07601048","field":"status","kind":"trial","state":"development","label":"A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment: phase 3, planned","href":"/trials/nct07601048/"},{"record":"nct06300177","field":"status","kind":"trial","state":"development","label":"D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standar: phase 3, recruiting","href":"/trials/nct06300177/"},{"record":"nct05379946","field":"status","kind":"trial","state":"development","label":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors: phase 1/2, active","href":"/trials/nct05379946/"},{"record":"nct04585035","field":"status","kind":"trial","state":"development","label":"Study to Evaluate D-1553 in Subjects With Solid Tumors: phase 1/2, active","href":"/trials/nct04585035/"},{"record":"registry:garsorasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/garsorasib/#registry"},{"record":"gfh375","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/gfh375/"},{"record":"nct07784374","field":"status","kind":"trial","state":"development","label":"A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metast: phase 2, planned","href":"/trials/nct07784374/"},{"record":"nct07259590","field":"status","kind":"trial","state":"development","label":"A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation: phase 1/2, recruiting","href":"/trials/nct07259590/"},{"record":"nct06500676","field":"status","kind":"trial","state":"development","label":"A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations: phase 1/2, recruiting","href":"/trials/nct06500676/"},{"record":"nct07668752","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation: phase 3, recruiting","href":"/trials/nct07668752/"},{"record":"nct07262567","field":"status","kind":"trial","state":"development","label":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer: phase 3, recruiting","href":"/trials/nct07262567/"},{"record":"registry:gfh375","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/gfh375/#registry"},{"record":"glecirasib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/glecirasib/"},{"record":"glecirasib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2024: KRAS G12C-mutant advanced non-small cell lung cancer after prior systemic therapy","href":"/drugs/glecirasib/"},{"record":"glecirasib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2024","href":"https://english.nmpa.gov.cn/"},{"record":"nct07164170","field":"status","kind":"trial","state":"development","label":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib: phase 2, recruiting","href":"/trials/nct07164170/"},{"record":"nct06008288","field":"status","kind":"trial","state":"development","label":"A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.: phase 2, recruiting","href":"/trials/nct06008288/"},{"record":"nct07827261","field":"status","kind":"trial","state":"development","label":"A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer: phase 2, planned","href":"/trials/nct07827261/"},{"record":"nct05009329","field":"status","kind":"trial","state":"development","label":"A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China: phase 1/2, active","href":"/trials/nct05009329/"},{"record":"nct05276726","field":"status","kind":"trial","state":"development","label":"A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1: phase 1/2, recruiting","href":"/trials/nct05276726/"},{"record":"nct07601048","field":"status","kind":"trial","state":"development","label":"A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment: phase 3, planned","href":"/trials/nct07601048/"},{"record":"nct06416410","field":"status","kind":"trial","state":"development","label":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation: phase 3, recruiting","href":"/trials/nct06416410/"},{"record":"nct05194995","field":"status","kind":"trial","state":"development","label":"JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation: phase 1/2, active","href":"/trials/nct05194995/"},{"record":"nct05288205","field":"status","kind":"trial","state":"development","label":"Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation: phase 1/2, recruiting","href":"/trials/nct05288205/"},{"record":"registry:glecirasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/glecirasib/#registry"},{"record":"incb161734","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/incb161734/"},{"record":"nct07522073","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma: phase 3, recruiting","href":"/trials/nct07522073/"},{"record":"registry:incb161734","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/incb161734/#registry"},{"record":"jdq443","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/jdq443/"},{"record":"nct05358249","field":"status","kind":"trial","state":"development","label":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation: phase 1/2, active","href":"/trials/nct05358249/"},{"record":"nct07468071","field":"status","kind":"trial","state":"development","label":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other: phase 1/2, recruiting","href":"/trials/nct07468071/"},{"record":"nct05445843","field":"status","kind":"trial","state":"development","label":"Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.: phase 2, active","href":"/trials/nct05445843/"},{"record":"nct05132075","field":"status","kind":"trial","state":"development","label":"Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer: phase 3, active","href":"/trials/nct05132075/"},{"record":"nct04699188","field":"status","kind":"trial","state":"development","label":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation: phase 1/2, active","href":"/trials/nct04699188/"},{"record":"registry:jdq443","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/jdq443/#registry"},{"record":"mrtx1133","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 1","href":"/drugs/mrtx1133/"},{"record":"olomorasib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/olomorasib/"},{"record":"nct07227025","field":"status","kind":"trial","state":"development","label":"A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer: phase 1/2, recruiting","href":"/trials/nct07227025/"},{"record":"nct06119581","field":"status","kind":"trial","state":"development","label":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer: phase 3, recruiting","href":"/trials/nct06119581/"},{"record":"nct07814417","field":"status","kind":"trial","state":"development","label":"A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation: phase 2, planned","href":"/trials/nct07814417/"},{"record":"nct04956640","field":"status","kind":"trial","state":"development","label":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C): phase 1/2, active","href":"/trials/nct04956640/"},{"record":"nct06890598","field":"status","kind":"trial","state":"development","label":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer: phase 3, recruiting","href":"/trials/nct06890598/"},{"record":"registry:olomorasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/olomorasib/#registry"},{"record":"sotorasib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/sotorasib/"},{"record":"sotorasib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2021: KRAS G12C NSCLC, previously treated (accelerated)","href":"/drugs/sotorasib/"},{"record":"sotorasib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2025: KRAS G12C colorectal cancer with panitumumab","href":"/drugs/sotorasib/"},{"record":"sotorasib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2022: EU brand Lumykras","href":"/drugs/sotorasib/"},{"record":"sotorasib","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2025: KRAS G12C-mutated metastatic colorectal cancer after fluoropyrimidine, oxaliplatin and irinotecan chemotherapy, with panitumumab","href":"/drugs/sotorasib/"},{"record":"sotorasib","field":"approvals[4]","kind":"approval","state":"approved","label":"England (NICE) 2022: KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer that has progressed on, or after intolerance of, platinum-based chemotherapy or PD-1/PD-L1 immunotherapy","href":"/drugs/sotorasib/"},{"record":"sotorasib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2021","href":"/regulatory/regions/"},{"record":"sotorasib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2022","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/lumykras"},{"record":"sotorasib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2021","href":"https://products.mhra.gov.uk/?search=Lumykras"},{"record":"sotorasib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2022","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"sotorasib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2022","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Lumykras"},{"record":"sotorasib","field":"regulatoryEvents[2]","kind":"event","state":"stopped","label":"US 2023-12: complete response letter","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","quote":"FDA declines full approval based on CodeBreaK 200; postmarketing dose study required"},{"record":"nct07563738","field":"status","kind":"trial","state":"development","label":"A 2-part Phase 1/2 Open-label Trial on ODM-212: phase 1/2, recruiting","href":"/trials/nct07563738/"},{"record":"nct07172919","field":"status","kind":"trial","state":"development","label":"A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation: phase 2, recruiting","href":"/trials/nct07172919/"},{"record":"nct05920356","field":"status","kind":"trial","state":"development","label":"A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi: phase 3, recruiting","href":"/trials/nct05920356/"},{"record":"nct05074810","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients: phase 1/2, active","href":"/trials/nct05074810/"},{"record":"nct05845450","field":"status","kind":"trial","state":"development","label":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN): phase 2, recruiting","href":"/trials/nct05845450/"},{"record":"nct06252649","field":"status","kind":"trial","state":"development","label":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal: phase 3, recruiting","href":"/trials/nct06252649/"},{"record":"registry:sotorasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 17 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/sotorasib/#registry"},{"record":"vs-7375","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/vs-7375/"},{"record":"nct07020221","field":"status","kind":"trial","state":"development","label":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors: phase 1/2, recruiting","href":"/trials/nct07020221/"},{"record":"nct07659795","field":"status","kind":"trial","state":"development","label":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer: phase 2, recruiting","href":"/trials/nct07659795/"},{"record":"nct07659782","field":"status","kind":"trial","state":"development","label":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct07659782/"},{"record":"nct07644559","field":"status","kind":"trial","state":"development","label":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer: phase 2, recruiting","href":"/trials/nct07644559/"},{"record":"registry:vs-7375","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/vs-7375/#registry"},{"record":"zoldonrasib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/zoldonrasib/"},{"record":"nct07777822","field":"status","kind":"trial","state":"development","label":"Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mu: phase 3, recruiting","href":"/trials/nct07777822/"},{"record":"nct07397338","field":"status","kind":"trial","state":"development","label":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct07397338/"},{"record":"nct06445062","field":"status","kind":"trial","state":"development","label":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06445062/"},{"record":"nct06040541","field":"status","kind":"trial","state":"development","label":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors: phase 1, recruiting","href":"/trials/nct06040541/"},{"record":"nct07805954","field":"status","kind":"trial","state":"development","label":"Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut: phase 3, recruiting","href":"/trials/nct07805954/"},{"record":"nct07621718","field":"status","kind":"trial","state":"development","label":"Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta: phase 3, recruiting","href":"/trials/nct07621718/"},{"record":"nct06922591","field":"status","kind":"trial","state":"development","label":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients: phase 1/2, recruiting","href":"/trials/nct06922591/"},{"record":"registry:zoldonrasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/zoldonrasib/#registry"}],"reasons":[{"drugId":"adagrasib","drugName":"Adagrasib","drugRoute":"/drugs/adagrasib/","drugState":"approved","record":"adagrasib","kind":"event","label":"US 2026-09-01: withdrawal","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer","quote":"Withdrawn: the indication came off the label 2.3 years after its accelerated approval."},{"drugId":"sotorasib","drugName":"Sotorasib","drugRoute":"/drugs/sotorasib/","drugState":"approved","record":"sotorasib","kind":"event","label":"US 2023-12: complete response letter","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","quote":"FDA declines full approval based on CodeBreaK 200; postmarketing dose study required"}]},{"a":{"key":"target","id":"egfr","name":"EGFR","href":"/targets/egfr/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"aumolertinib","name":"Aumolertinib","route":"/drugs/aumolertinib/","state":"approved","status":"approved"},{"id":"dacomitinib","name":"Dacomitinib","route":"/drugs/dacomitinib/","state":"approved","status":"approved"},{"id":"erlotinib","name":"Erlotinib","route":"/drugs/erlotinib/","state":"approved","status":"approved"},{"id":"furmonertinib","name":"Furmonertinib","route":"/drugs/furmonertinib/","state":"approved","status":"approved"},{"id":"gefitinib","name":"Gefitinib","route":"/drugs/gefitinib/","state":"approved","status":"approved"},{"id":"icotinib","name":"Icotinib","route":"/drugs/icotinib/","state":"approved","status":"approved"},{"id":"lazertinib","name":"Lazertinib","route":"/drugs/lazertinib/","state":"approved","status":"approved"},{"id":"limertinib","name":"Limertinib","route":"/drugs/limertinib/","state":"approved","status":"approved"},{"id":"mobocertinib","name":"Mobocertinib","route":"/drugs/mobocertinib/","state":"stopped","status":"withdrawn"},{"id":"olmutinib","name":"Olmutinib","route":"/drugs/olmutinib/","state":"stopped","status":"withdrawn"},{"id":"osimertinib","name":"Osimertinib","route":"/drugs/osimertinib/","state":"approved","status":"approved"},{"id":"silevertinib","name":"Silevertinib","route":"/drugs/silevertinib/","state":"development","status":"phase-2"},{"id":"sunvozertinib","name":"Sunvozertinib","route":"/drugs/sunvozertinib/","state":"approved","status":"approved"},{"id":"vrn110755","name":"VRN110755","route":"/drugs/vrn110755/","state":"development","status":"phase-2"},{"id":"zipalertinib","name":"Zipalertinib","route":"/drugs/zipalertinib/","state":"development","status":"phase-3"}],"counts":{"approved":10,"development":3,"stopped":2,"unclear":0},"parts":{"binding":[{"key":"binding","id":"covalent","name":"Covalent"},{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"},{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"aumolertinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/aumolertinib/"},{"record":"aumolertinib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2020: EGFR T790M-positive locally advanced or metastatic NSCLC after EGFR TKI therapy","href":"/drugs/aumolertinib/"},{"record":"aumolertinib","field":"approvals[1]","kind":"approval","state":"approved","label":"China 2021: First-line EGFR exon 19 deletion or L858R NSCLC (AENEAS)","href":"/drugs/aumolertinib/"},{"record":"aumolertinib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2026: Aumseqa: first-line advanced NSCLC with EGFR exon 19 deletion or L858R; advanced EGFR T790M-positive NSCLC","href":"/drugs/aumolertinib/"},{"record":"aumolertinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2026","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/aumseqa"},{"record":"aumolertinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2020","href":"https://english.nmpa.gov.cn/"},{"record":"nct06474455","field":"status","kind":"trial","state":"development","label":"A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06474455/"},{"record":"nct04951635","field":"status","kind":"trial","state":"development","label":"A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer: phase 3, recruiting","href":"/trials/nct04951635/"},{"record":"nct07183189","field":"status","kind":"trial","state":"development","label":"A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC: phase 3, recruiting","href":"/trials/nct07183189/"},{"record":"nct06043973","field":"status","kind":"trial","state":"development","label":"Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance: phase 3, recruiting","href":"/trials/nct06043973/"},{"record":"nct04687241","field":"status","kind":"trial","state":"development","label":"Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations: phase 3, active","href":"/trials/nct04687241/"},{"record":"nct05800223","field":"status","kind":"trial","state":"development","label":"Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer: phase 3, recruiting","href":"/trials/nct05800223/"},{"record":"nct04923906","field":"status","kind":"trial","state":"development","label":"Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mut: phase 3, active","href":"/trials/nct04923906/"},{"record":"nct04762459","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Com: phase 3, recruiting","href":"/trials/nct04762459/"},{"record":"nct04841811","field":"status","kind":"trial","state":"development","label":"MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH): phase 3, active","href":"/trials/nct04841811/"},{"record":"nct05503888","field":"status","kind":"trial","state":"development","label":"Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer: phase 1/2, planned","href":"/trials/nct05503888/"},{"record":"registry:aumolertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 26 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/aumolertinib/#registry"},{"record":"dacomitinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/dacomitinib/"},{"record":"dacomitinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: First-line metastatic NSCLC with EGFR exon 19 del or L858R","href":"/drugs/dacomitinib/"},{"record":"dacomitinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2019: Same","href":"/drugs/dacomitinib/"},{"record":"dacomitinib","field":"approvals[2]","kind":"approval","state":"approved","label":"England (NICE) 2019: Untreated locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer","href":"/drugs/dacomitinib/"},{"record":"dacomitinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"dacomitinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2019","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/vizimpro"},{"record":"dacomitinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2019","href":"https://products.mhra.gov.uk/?search=Vizimpro"},{"record":"dacomitinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2019","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"dacomitinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2019","href":"https://english.nmpa.gov.cn/"},{"record":"dacomitinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Vizimpro"},{"record":"nct06486142","field":"status","kind":"trial","state":"development","label":"EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study: phase 3, recruiting","href":"/trials/nct06486142/"},{"record":"registry:dacomitinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/dacomitinib/#registry"},{"record":"erlotinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/erlotinib/"},{"record":"erlotinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2004: Locally advanced/metastatic NSCLC after chemotherapy","href":"/drugs/erlotinib/"},{"record":"erlotinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2005: Pancreatic cancer with gemcitabine","href":"/drugs/erlotinib/"},{"record":"erlotinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2013: First-line NSCLC with EGFR exon 19 del or L858R","href":"/drugs/erlotinib/"},{"record":"erlotinib","field":"approvals[3]","kind":"approval","state":"approved","label":"EU 2007: Metastatic pancreatic cancer with gemcitabine (Tarceva product information: factors associated with prolonged survival should be taken into account when prescribing; 100 mg daily); marketing authorisation for the product 19 September 2005","href":"/drugs/erlotinib/"},{"record":"erlotinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2004","href":"/regulatory/regions/"},{"record":"erlotinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2005","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva"},{"record":"erlotinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2005","href":"https://products.mhra.gov.uk/?search=Tarceva"},{"record":"erlotinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2007","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"erlotinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved","href":"https://english.nmpa.gov.cn/"},{"record":"erlotinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Tarceva"},{"record":"nct02152631","field":"status","kind":"trial","state":"development","label":"A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer: phase 3, active","href":"/trials/nct02152631/"},{"record":"nct02411448","field":"status","kind":"trial","state":"development","label":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE: phase 3, active","href":"/trials/nct02411448/"},{"record":"alchemist","field":"status","kind":"trial","state":"development","label":"ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials): phase platform, active","href":"/trials/alchemist/"},{"record":"nct06483555","field":"status","kind":"trial","state":"development","label":"Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel: phase 1/2, recruiting","href":"/trials/nct06483555/"},{"record":"conko-005","field":"result","kind":"trial","state":"stopped","label":"CONKO-005: phase 3, negative","href":"/trials/conko-005/","quote":"Median disease-free survival 11.4 months with gemcitabine plus erlotinib and 11.4 months with gemcitabine; median overall survival 24.5 against 26.5 months."},{"record":"lap07","field":"result","kind":"trial","state":"stopped","label":"LAP07: phase 3, negative","href":"/trials/lap07/","quote":"Median overall survival 15.2 months with chemoradiotherapy against 16.5 months with chemotherapy alone (hazard ratio 1.03, p 0.83); local progression 32 against 46 percent; erlotinib added nothing (13.6 against 11.9 months, hazard ratio 1.19)."},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"nct05442060","field":"status","kind":"trial","state":"development","label":"To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic N: phase 2, recruiting","href":"/trials/nct05442060/"},{"record":"registry:erlotinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/erlotinib/#registry"},{"record":"furmonertinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/furmonertinib/"},{"record":"furmonertinib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2021: EGFR T790M-positive locally advanced or metastatic NSCLC after EGFR TKI therapy","href":"/drugs/furmonertinib/"},{"record":"furmonertinib","field":"approvals[1]","kind":"approval","state":"approved","label":"China 2022: First-line EGFR exon 19 deletion or L858R NSCLC (FURLONG)","href":"/drugs/furmonertinib/"},{"record":"furmonertinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"nct06962865","field":"status","kind":"trial","state":"development","label":"A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Adv: phase 2, recruiting","href":"/trials/nct06962865/"},{"record":"nct06970639","field":"status","kind":"trial","state":"development","label":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases: phase 3, recruiting","href":"/trials/nct06970639/"},{"record":"nct07229599","field":"status","kind":"trial","state":"development","label":"A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer: phase 1/2, recruiting","href":"/trials/nct07229599/"},{"record":"nct07622186","field":"status","kind":"trial","state":"development","label":"A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC): phase 2, recruiting","href":"/trials/nct07622186/"},{"record":"nct05466149","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion: phase 2, active","href":"/trials/nct05466149/"},{"record":"nct06674343","field":"status","kind":"trial","state":"development","label":"Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations: phase 3, recruiting","href":"/trials/nct06674343/"},{"record":"nct05334277","field":"status","kind":"trial","state":"development","label":"Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA: phase 2, recruiting","href":"/trials/nct05334277/"},{"record":"nct05994131","field":"status","kind":"trial","state":"development","label":"IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC: phase 1/2, recruiting","href":"/trials/nct05994131/"},{"record":"nct05607550","field":"status","kind":"trial","state":"development","label":"Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With: phase 3, active","href":"/trials/nct05607550/"},{"record":"nct07185997","field":"status","kind":"trial","state":"development","label":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants W: phase 3, recruiting","href":"/trials/nct07185997/"},{"record":"nct04853342","field":"status","kind":"trial","state":"development","label":"To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy: phase 3, recruiting","href":"/trials/nct04853342/"},{"record":"registry:furmonertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 40 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/furmonertinib/#registry"},{"record":"gefitinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/gefitinib/"},{"record":"gefitinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2003: NSCLC after chemotherapy (accelerated; restricted 2005)","href":"/drugs/gefitinib/"},{"record":"gefitinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2009: EGFR-mutant NSCLC","href":"/drugs/gefitinib/"},{"record":"gefitinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2015: First-line NSCLC with EGFR exon 19 del or L858R","href":"/drugs/gefitinib/"},{"record":"gefitinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2003","href":"/regulatory/regions/"},{"record":"gefitinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2009","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/iressa"},{"record":"gefitinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2009","href":"https://products.mhra.gov.uk/?search=Iressa"},{"record":"gefitinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2002","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"gefitinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2005","href":"https://english.nmpa.gov.cn/"},{"record":"gefitinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Iressa"},{"record":"gefitinib","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"US 2012-04-25: withdrawal","href":"/drugs/gefitinib/","quote":"Withdrawn: the indication came off the label 9.0 years after its accelerated approval."},{"record":"nct02411448","field":"status","kind":"trial","state":"development","label":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE: phase 3, active","href":"/trials/nct02411448/"},{"record":"nct03944772","field":"status","kind":"trial","state":"development","label":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD): phase 2, active","href":"/trials/nct03944772/"},{"record":"nct03040973","field":"status","kind":"trial","state":"development","label":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone: phase 2, active","href":"/trials/nct03040973/"},{"record":"registry:gefitinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/gefitinib/#registry"},{"record":"icotinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/icotinib/"},{"record":"icotinib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2011: Advanced NSCLC after failure of at least one chemotherapy regimen (ICOGEN)","href":"/drugs/icotinib/"},{"record":"icotinib","field":"approvals[1]","kind":"approval","state":"approved","label":"China 2014: First-line EGFR-mutant NSCLC","href":"/drugs/icotinib/"},{"record":"icotinib","field":"approvals[2]","kind":"approval","state":"approved","label":"China 2021: Adjuvant treatment of resected stage II to IIIA EGFR-mutant NSCLC (EVIDENCE)","href":"/drugs/icotinib/"},{"record":"icotinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2011","href":"https://english.nmpa.gov.cn/"},{"record":"nct06041776","field":"status","kind":"trial","state":"development","label":"Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations: phase 3, recruiting","href":"/trials/nct06041776/"},{"record":"nct06955325","field":"status","kind":"trial","state":"development","label":"Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations: phase 3, planned","href":"/trials/nct06955325/"},{"record":"registry:icotinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/icotinib/#registry"},{"record":"lazertinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/lazertinib/"},{"record":"lazertinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2024: First-line EGFR exon 19 del / L858R NSCLC with amivantamab","href":"/drugs/lazertinib/"},{"record":"lazertinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2025: 1L EGFR-mutant NSCLC with amivantamab; 20 Jan 2025","href":"/drugs/lazertinib/"},{"record":"lazertinib","field":"approvals[2]","kind":"approval","state":"approved","label":"England (NICE) 2026: Untreated advanced EGFR mutation-positive non-small-cell lung cancer (exon 19 deletion or L858R), with amivantamab","href":"/drugs/lazertinib/"},{"record":"lazertinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2024","href":"/regulatory/regions/"},{"record":"lazertinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/lazcluze"},{"record":"lazertinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2025","href":"https://www.gov.uk/government/news/lazertinib-approved-for-use-in-combination-with-amivantamab-for-the-treatment-of-adults-with-non-small-cell-lung-cancer"},{"record":"lazertinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2025","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"lazertinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2025","href":"https://english.nmpa.gov.cn/"},{"record":"nct04988295","field":"status","kind":"trial","state":"development","label":"A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure: phase 3, active","href":"/trials/nct04988295/"},{"record":"nct06667076","field":"status","kind":"trial","state":"development","label":"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): phase 2, recruiting","href":"/trials/nct06667076/"},{"record":"nct05498428","field":"status","kind":"trial","state":"development","label":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct05498428/"},{"record":"nct05388669","field":"status","kind":"trial","state":"development","label":"A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR): phase 3, active","href":"/trials/nct05388669/"},{"record":"nct07586202","field":"status","kind":"trial","state":"development","label":"A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC: phase 2, recruiting","href":"/trials/nct07586202/"},{"record":"chrysalis","field":"status","kind":"trial","state":"development","label":"CHRYSALIS: phase 1, active","href":"/trials/chrysalis/"},{"record":"nct06120140","field":"status","kind":"trial","state":"development","label":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib: phase 2, active","href":"/trials/nct06120140/"},{"record":"nct05663866","field":"status","kind":"trial","state":"development","label":"Premedication to Reduce Amivantamab Associated Infusion Related Reactions: phase 2, active","href":"/trials/nct05663866/"},{"record":"nct05541822","field":"status","kind":"trial","state":"development","label":"To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation: phase 2, recruiting","href":"/trials/nct05541822/"},{"record":"registry:lazertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 19 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/lazertinib/#registry"},{"record":"limertinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/limertinib/"},{"record":"limertinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2024: Locally advanced or metastatic EGFR T790M-mutant non-small cell lung cancer after prior EGFR inhibitor therapy","href":"/drugs/limertinib/"},{"record":"limertinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2024","href":"https://english.nmpa.gov.cn/"},{"record":"nct06982924","field":"status","kind":"trial","state":"development","label":"A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.: phase 2, planned","href":"/trials/nct06982924/"},{"record":"nct04143607","field":"status","kind":"trial","state":"development","label":"ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC: phase 3, active","href":"/trials/nct04143607/"},{"record":"nct07109531","field":"status","kind":"trial","state":"development","label":"ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy: phase 3, recruiting","href":"/trials/nct07109531/"},{"record":"registry:limertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/limertinib/#registry"},{"record":"mobocertinib","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/mobocertinib/","quote":"Mobocertinib was the first oral drug for EGFR exon 20 insertion lung cancer, approved in 2021 and withdrawn in 2023-24 after its confirmatory trial failed."},{"record":"mobocertinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2021: EGFR exon 20 insertion NSCLC after platinum","href":"/drugs/mobocertinib/"},{"record":"mobocertinib","field":"regional.US","kind":"regional","state":"stopped","label":"FDA (US): withdrawn 2023","href":"/regulatory/regions/","quote":"Exkivity accelerated approval Sep 2021; withdrawn by Takeda Oct 2023 after EXCLAIM-2"},{"record":"mobocertinib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/exkivity","quote":"Marketing authorisation application withdrawn before a CHMP opinion"},{"record":"mobocertinib","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"US 2024-07-15: withdrawal","href":"/drugs/mobocertinib/","quote":"Withdrawn: the indication came off the label 2.8 years after its accelerated approval."},{"record":"nct04129502","field":"status","kind":"trial","state":"development","label":"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations: phase 3, active","href":"/trials/nct04129502/"},{"record":"registry:mobocertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/mobocertinib/#registry"},{"record":"olmutinib","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/olmutinib/","quote":"Olmutinib was a Korean-developed EGFR pill approved in South Korea in 2016 for lung cancers that had developed the T790M resistance mutation, the same niche as osimertinib; severe skin reactions and osimertinib's success ended its development."},{"record":"registry:olmutinib","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 1 terminated or withdrawn study and none active (fetched 2026-09-28)","href":"/drugs/olmutinib/#registry"},{"record":"osimertinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/osimertinib/"},{"record":"osimertinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2015: EGFR T790M NSCLC","href":"/drugs/osimertinib/"},{"record":"osimertinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2018: First-line EGFR-mutant NSCLC","href":"/drugs/osimertinib/"},{"record":"osimertinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2020: Adjuvant EGFR-mutant NSCLC","href":"/drugs/osimertinib/"},{"record":"osimertinib","field":"approvals[3]","kind":"approval","state":"approved","label":"England (NICE) 2020: Untreated locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer","href":"/drugs/osimertinib/"},{"record":"osimertinib","field":"approvals[4]","kind":"approval","state":"approved","label":"England (NICE) 2020: EGFR T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer after a first-line EGFR inhibitor","href":"/drugs/osimertinib/"},{"record":"osimertinib","field":"approvals[5]","kind":"approval","state":"approved","label":"England (NICE) 2025: Adjuvant treatment of stage IB to IIIA EGFR exon 19 deletion or L858R non-small-cell lung cancer after complete resection","href":"/drugs/osimertinib/"},{"record":"osimertinib","field":"approvals[6]","kind":"approval","state":"approved","label":"England (NICE) 2025: Untreated advanced EGFR mutation-positive non-small-cell lung cancer, with pemetrexed and platinum-based chemotherapy","href":"/drugs/osimertinib/"},{"record":"osimertinib","field":"approvals[7]","kind":"approval","state":"approved","label":"England (NICE) 2026: Unresectable stage III EGFR mutation-positive non-small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy","href":"/drugs/osimertinib/"},{"record":"osimertinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2015","href":"/regulatory/regions/"},{"record":"osimertinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2016","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso"},{"record":"osimertinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2016","href":"https://products.mhra.gov.uk/?search=Tagrisso"},{"record":"osimertinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2016","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"osimertinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2017","href":"https://english.nmpa.gov.cn/"},{"record":"osimertinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2016","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Tagrisso"},{"record":"nct05120349","field":"status","kind":"trial","state":"development","label":"A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection: phase 3, active","href":"/trials/nct05120349/"},{"record":"nct07710612","field":"status","kind":"trial","state":"development","label":"A Phase 2 Study of ABSK043 Combined With Osimertinib: phase 2, planned","href":"/trials/nct07710612/"},{"record":"nct07669779","field":"status","kind":"trial","state":"development","label":"A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct07669779/"},{"record":"nct07376382","field":"status","kind":"trial","state":"development","label":"A Phase III Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC: phase 3, planned","href":"/trials/nct07376382/"},{"record":"nct07640789","field":"status","kind":"trial","state":"development","label":"A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-s: phase 3, recruiting","href":"/trials/nct07640789/"},{"record":"nct04606771","field":"status","kind":"trial","state":"development","label":"A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC: phase 2, active","href":"/trials/nct04606771/"},{"record":"nct06970639","field":"status","kind":"trial","state":"development","label":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases: phase 3, recruiting","href":"/trials/nct06970639/"},{"record":"nct05526755","field":"status","kind":"trial","state":"development","label":"A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC): phase 2, active","href":"/trials/nct05526755/"},{"record":"nct05880706","field":"status","kind":"trial","state":"development","label":"A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung : phase 2, active","href":"/trials/nct05880706/"},{"record":"nct07642024","field":"status","kind":"trial","state":"development","label":"A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU: phase 2/3, recruiting","href":"/trials/nct07642024/"},{"record":"nct06498986","field":"status","kind":"trial","state":"development","label":"A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct06498986/"},{"record":"nct06838273","field":"status","kind":"trial","state":"development","label":"A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metas: phase 3, recruiting","href":"/trials/nct06838273/"},{"record":"nct05785741","field":"status","kind":"trial","state":"development","label":"A Study of DB-1310 in Advanced/Metastatic Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05785741/"},{"record":"nct07535437","field":"status","kind":"trial","state":"development","label":"A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer: phase 1/2, recruiting","href":"/trials/nct07535437/"},{"record":"nct04351555","field":"status","kind":"trial","state":"development","label":"A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S: phase 3, active","href":"/trials/nct04351555/"},{"record":"nct02411448","field":"status","kind":"trial","state":"development","label":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE: phase 3, active","href":"/trials/nct02411448/"},{"record":"nct07229729","field":"status","kind":"trial","state":"development","label":"A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct07229729/"},{"record":"nct05816252","field":"status","kind":"trial","state":"development","label":"A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-: phase 2, active","href":"/trials/nct05816252/"},{"record":"nct06670196","field":"status","kind":"trial","state":"development","label":"A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advan: phase 3, active","href":"/trials/nct06670196/"},{"record":"nct07622186","field":"status","kind":"trial","state":"development","label":"A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC): phase 2, recruiting","href":"/trials/nct07622186/"},{"record":"nct07256509","field":"status","kind":"trial","state":"development","label":"A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous No: phase 2, planned","href":"/trials/nct07256509/"},{"record":"nct06868485","field":"status","kind":"trial","state":"development","label":"A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct06868485/"},{"record":"nct07285148","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer: phase 1/2, planned","href":"/trials/nct07285148/"},{"record":"nct04765059","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC): phase 3, active","href":"/trials/nct04765059/"},{"record":"nct07206498","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC: phase 1/2, recruiting","href":"/trials/nct07206498/"},{"record":"nct06618287","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06618287/"},{"record":"nct05801029","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth: phase 2, active","href":"/trials/nct05801029/"},{"record":"nct06417814","field":"status","kind":"trial","state":"development","label":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan: phase 3, recruiting","href":"/trials/nct06417814/"},{"record":"nct06895928","field":"status","kind":"trial","state":"development","label":"A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors: phase 2, recruiting","href":"/trials/nct06895928/"},{"record":"nct06323148","field":"status","kind":"trial","state":"development","label":"Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022): phase 3, planned","href":"/trials/nct06323148/"},{"record":"alchemist","field":"status","kind":"trial","state":"development","label":"ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials): phase platform, active","href":"/trials/alchemist/"},{"record":"nct03833154","field":"status","kind":"trial","state":"development","label":"Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation: phase 3, active","href":"/trials/nct03833154/"},{"record":"nct06486142","field":"status","kind":"trial","state":"development","label":"EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study: phase 3, recruiting","href":"/trials/nct06486142/"},{"record":"nct05647122","field":"status","kind":"trial","state":"development","label":"First in Human Study of AZD9592 in Solid Tumors: phase 1, active","href":"/trials/nct05647122/"},{"record":"nct06391944","field":"status","kind":"trial","state":"development","label":"JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations: phase 2, active","href":"/trials/nct06391944/"},{"record":"nct07153055","field":"status","kind":"trial","state":"development","label":"Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer: phase 1/2, recruiting","href":"/trials/nct07153055/"},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"nct03381274","field":"status","kind":"trial","state":"development","label":"Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study: phase 1/2, active","href":"/trials/nct03381274/"},{"record":"nct04410796","field":"status","kind":"trial","state":"development","label":"Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers: phase 2, recruiting","href":"/trials/nct04410796/"},{"record":"nct07295821","field":"status","kind":"trial","state":"development","label":"Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study: phase 2, recruiting","href":"/trials/nct07295821/"},{"record":"nct04695925","field":"status","kind":"trial","state":"development","label":"Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations: phase 3, active","href":"/trials/nct04695925/"},{"record":"nct03778229","field":"status","kind":"trial","state":"development","label":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib: phase 2, active","href":"/trials/nct03778229/"},{"record":"nct04181060","field":"status","kind":"trial","state":"development","label":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer: phase 3, recruiting","href":"/trials/nct04181060/"},{"record":"nct07738172","field":"status","kind":"trial","state":"development","label":"Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer: phase 3, recruiting","href":"/trials/nct07738172/"},{"record":"nct04868877","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combina: phase 1/2, active","href":"/trials/nct04868877/"},{"record":"nct03944772","field":"status","kind":"trial","state":"development","label":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD): phase 2, active","href":"/trials/nct03944772/"},{"record":"nct07329322","field":"status","kind":"trial","state":"development","label":"Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Facto: phase 2, recruiting","href":"/trials/nct07329322/"},{"record":"nct06350097","field":"status","kind":"trial","state":"development","label":"Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell L: phase 3, recruiting","href":"/trials/nct06350097/"},{"record":"nct04486833","field":"status","kind":"trial","state":"development","label":"Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib: phase 1/2, recruiting","href":"/trials/nct04486833/"},{"record":"nct05629234","field":"status","kind":"trial","state":"development","label":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T): phase 3, active","href":"/trials/nct05629234/"},{"record":"nct05261399","field":"status","kind":"trial","state":"development","label":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment: phase 3, active","href":"/trials/nct05261399/"},{"record":"nct07680790","field":"status","kind":"trial","state":"development","label":"Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based C: phase 3, planned","href":"/trials/nct07680790/"},{"record":"nct07079475","field":"status","kind":"trial","state":"development","label":"Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8): phase 1/2, recruiting","href":"/trials/nct07079475/"},{"record":"nct03040973","field":"status","kind":"trial","state":"development","label":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone: phase 2, active","href":"/trials/nct03040973/"},{"record":"nct05546866","field":"status","kind":"trial","state":"development","label":"Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm: phase 2, active","href":"/trials/nct05546866/"},{"record":"nct04665206","field":"status","kind":"trial","state":"development","label":"Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors: phase 1/2, recruiting","href":"/trials/nct04665206/"},{"record":"nct07323641","field":"status","kind":"trial","state":"development","label":"Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct07323641/"},{"record":"nct05624996","field":"status","kind":"trial","state":"development","label":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer: phase 3, recruiting","href":"/trials/nct05624996/"},{"record":"nct06194448","field":"status","kind":"trial","state":"development","label":"To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations: phase 2, active","href":"/trials/nct06194448/"},{"record":"nct05948813","field":"status","kind":"trial","state":"development","label":"TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: phase 2, recruiting","href":"/trials/nct05948813/"},{"record":"nct06574347","field":"status","kind":"trial","state":"development","label":"Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.: phase 2, recruiting","href":"/trials/nct06574347/"},{"record":"registry:osimertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 58 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/osimertinib/#registry"},{"record":"silevertinib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/silevertinib/"},{"record":"nct05256290","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations: phase 1/2, active","href":"/trials/nct05256290/"},{"record":"nct07326566","field":"status","kind":"trial","state":"development","label":"Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII: phase 2, recruiting","href":"/trials/nct07326566/"},{"record":"registry:silevertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/silevertinib/#registry"},{"record":"sunvozertinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/sunvozertinib/"},{"record":"sunvozertinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2023: EGFR exon 20 insertion NSCLC after platinum","href":"/drugs/sunvozertinib/"},{"record":"sunvozertinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2025: Locally advanced/metastatic NSCLC with EGFR exon 20 insertions after platinum","href":"/drugs/sunvozertinib/"},{"record":"sunvozertinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2025","href":"/regulatory/regions/"},{"record":"sunvozertinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"nct07182682","field":"status","kind":"trial","state":"development","label":"A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Ins: phase 3, recruiting","href":"/trials/nct07182682/"},{"record":"nct06295432","field":"status","kind":"trial","state":"development","label":"A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21): phase 2, recruiting","href":"/trials/nct06295432/"},{"record":"nct05668988","field":"status","kind":"trial","state":"development","label":"A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28): phase 3, active","href":"/trials/nct05668988/"},{"record":"nct03974022","field":"status","kind":"trial","state":"development","label":"Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1): phase 1/2, active","href":"/trials/nct03974022/"},{"record":"nct06276283","field":"status","kind":"trial","state":"development","label":"DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29): phase 2, recruiting","href":"/trials/nct06276283/"},{"record":"nct06864624","field":"status","kind":"trial","state":"development","label":"Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC: phase 2, recruiting","href":"/trials/nct06864624/"},{"record":"nct07079475","field":"status","kind":"trial","state":"development","label":"Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8): phase 1/2, recruiting","href":"/trials/nct07079475/"},{"record":"nct05712902","field":"status","kind":"trial","state":"development","label":"Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6): phase 2, active","href":"/trials/nct05712902/"},{"record":"registry:sunvozertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 14 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/sunvozertinib/#registry"},{"record":"vrn110755","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/vrn110755/"},{"record":"nct07699328","field":"status","kind":"trial","state":"development","label":"A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer: phase 1/2, recruiting","href":"/trials/nct07699328/"},{"record":"registry:vrn110755","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/vrn110755/#registry"},{"record":"zipalertinib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/zipalertinib/"},{"record":"nct04036682","field":"status","kind":"trial","state":"development","label":"A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer: phase 1/2, active","href":"/trials/nct04036682/"},{"record":"nct07128199","field":"status","kind":"trial","state":"development","label":"A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection: phase 3, active","href":"/trials/nct07128199/"},{"record":"nct07802834","field":"status","kind":"trial","state":"development","label":"Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC: phase 2, planned","href":"/trials/nct07802834/"},{"record":"nct05973773","field":"status","kind":"trial","state":"development","label":"REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors): phase 3, active","href":"/trials/nct05973773/"},{"record":"nct07229339","field":"status","kind":"trial","state":"development","label":"Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer: phase 2, planned","href":"/trials/nct07229339/"},{"record":"registry:zipalertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/zipalertinib/#registry"}],"reasons":[{"drugId":"erlotinib","drugName":"Erlotinib","drugRoute":"/drugs/erlotinib/","drugState":"approved","record":"conko-005","kind":"trial","label":"CONKO-005: phase 3, negative","href":"/trials/conko-005/","quote":"Median disease-free survival 11.4 months with gemcitabine plus erlotinib and 11.4 months with gemcitabine; median overall survival 24.5 against 26.5 months."},{"drugId":"erlotinib","drugName":"Erlotinib","drugRoute":"/drugs/erlotinib/","drugState":"approved","record":"lap07","kind":"trial","label":"LAP07: phase 3, negative","href":"/trials/lap07/","quote":"Median overall survival 15.2 months with chemoradiotherapy against 16.5 months with chemotherapy alone (hazard ratio 1.03, p 0.83); local progression 32 against 46 percent; erlotinib added nothing (13.6 against 11.9 months, hazard ratio 1.19)."},{"drugId":"gefitinib","drugName":"Gefitinib","drugRoute":"/drugs/gefitinib/","drugState":"approved","record":"gefitinib","kind":"event","label":"US 2012-04-25: withdrawal","href":"/drugs/gefitinib/","quote":"Withdrawn: the indication came off the label 9.0 years after its accelerated approval."},{"drugId":"mobocertinib","drugName":"Mobocertinib","drugRoute":"/drugs/mobocertinib/","drugState":"stopped","record":"mobocertinib","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/mobocertinib/","quote":"Mobocertinib was the first oral drug for EGFR exon 20 insertion lung cancer, approved in 2021 and withdrawn in 2023-24 after its confirmatory trial failed."},{"drugId":"mobocertinib","drugName":"Mobocertinib","drugRoute":"/drugs/mobocertinib/","drugState":"stopped","record":"mobocertinib","kind":"regional","label":"FDA (US): withdrawn 2023","href":"/regulatory/regions/","quote":"Exkivity accelerated approval Sep 2021; withdrawn by Takeda Oct 2023 after EXCLAIM-2"},{"drugId":"mobocertinib","drugName":"Mobocertinib","drugRoute":"/drugs/mobocertinib/","drugState":"stopped","record":"mobocertinib","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/exkivity","quote":"Marketing authorisation application withdrawn before a CHMP opinion"},{"drugId":"mobocertinib","drugName":"Mobocertinib","drugRoute":"/drugs/mobocertinib/","drugState":"stopped","record":"mobocertinib","kind":"event","label":"US 2024-07-15: withdrawal","href":"/drugs/mobocertinib/","quote":"Withdrawn: the indication came off the label 2.8 years after its accelerated approval."},{"drugId":"olmutinib","drugName":"Olmutinib","drugRoute":"/drugs/olmutinib/","drugState":"stopped","record":"olmutinib","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/olmutinib/","quote":"Olmutinib was a Korean-developed EGFR pill approved in South Korea in 2016 for lung cancers that had developed the T790M resistance mutation, the same niche as osimertinib; severe skin reactions and osimertinib's success ended its development."}]},{"a":{"key":"target","id":"androgen-receptor","name":"Androgen receptor","href":"/targets/androgen-receptor/"},"b":{"key":"mechanismClass","id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/"},"state":"approved","drugs":[{"id":"abiraterone","name":"Abiraterone acetate","route":"/drugs/abiraterone/","state":"approved","status":"approved"},{"id":"bicalutamide","name":"Bicalutamide","route":"/drugs/bicalutamide/","state":"approved","status":"approved"},{"id":"ep0062","name":"EP0062","route":"/drugs/ep0062/","state":"development","status":"phase-2"},{"id":"flutamide","name":"Flutamide","route":"/drugs/flutamide/","state":"approved","status":"approved"},{"id":"nilutamide","name":"Nilutamide","route":"/drugs/nilutamide/","state":"approved","status":"approved"},{"id":"rezvilutamide","name":"Rezvilutamide","route":"/drugs/rezvilutamide/","state":"approved","status":"approved"}],"counts":{"approved":5,"development":1,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"covalent","name":"Covalent"}]},"evidence":[{"record":"abiraterone","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/abiraterone/"},{"record":"abiraterone","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2011: mCRPC after docetaxel","href":"/drugs/abiraterone/"},{"record":"abiraterone","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2012: mCRPC pre-chemotherapy","href":"/drugs/abiraterone/"},{"record":"abiraterone","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2018: High-risk mHSPC (LATITUDE)","href":"/drugs/abiraterone/"},{"record":"abiraterone","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2011","href":"/regulatory/regions/"},{"record":"abiraterone","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2011","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga"},{"record":"abiraterone","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2011","href":"https://products.mhra.gov.uk/?search=Zytiga"},{"record":"abiraterone","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2014","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"abiraterone","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2015","href":"https://english.nmpa.gov.cn/"},{"record":"abiraterone","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2012","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Zytiga"},{"record":"abiraterone","field":"regional.IN","kind":"regional","state":"approved","label":"CDSCO (DCGI) (IN): approved","href":"https://en.wikipedia.org/wiki/Abiraterone_acetate"},{"record":"nct07198633","field":"status","kind":"trial","state":"development","label":"A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct07198633/"},{"record":"nct07553988","field":"status","kind":"trial","state":"development","label":"A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer: phase 2, active","href":"/trials/nct07553988/"},{"record":"nct04691804","field":"status","kind":"trial","state":"development","label":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Ver: phase 3, active","href":"/trials/nct04691804/"},{"record":"nct07005154","field":"status","kind":"trial","state":"development","label":"A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer: phase 2, recruiting","href":"/trials/nct07005154/"},{"record":"nct07226986","field":"status","kind":"trial","state":"development","label":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA: phase 1/2, recruiting","href":"/trials/nct07226986/"},{"record":"nct02960022","field":"status","kind":"trial","state":"development","label":"A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study: phase 2, active","href":"/trials/nct02960022/"},{"record":"nct03706365","field":"status","kind":"trial","state":"development","label":"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer: phase 2/3, active","href":"/trials/nct03706365/"},{"record":"nct05067140","field":"status","kind":"trial","state":"development","label":"A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer: phase 1/2, active","href":"/trials/nct05067140/"},{"record":"nct03431350","field":"status","kind":"trial","state":"development","label":"A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer: phase 2, active","href":"/trials/nct03431350/"},{"record":"nct04497844","field":"status","kind":"trial","state":"development","label":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC): phase 3, active","href":"/trials/nct04497844/"},{"record":"nct07230106","field":"status","kind":"trial","state":"development","label":"A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer: phase 2, recruiting","href":"/trials/nct07230106/"},{"record":"nct07213674","field":"status","kind":"trial","state":"development","label":"A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate : phase 3, recruiting","href":"/trials/nct07213674/"},{"record":"nct07287150","field":"status","kind":"trial","state":"development","label":"A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer: phase 2, recruiting","href":"/trials/nct07287150/"},{"record":"nct05422911","field":"status","kind":"trial","state":"development","label":"Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.: phase 2, recruiting","href":"/trials/nct05422911/"},{"record":"nct02257736","field":"status","kind":"trial","state":"development","label":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC): phase 3, active","href":"/trials/nct02257736/"},{"record":"nct06991556","field":"status","kind":"trial","state":"development","label":"An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc: phase 2, active","href":"/trials/nct06991556/"},{"record":"nct07611110","field":"status","kind":"trial","state":"development","label":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01): phase 3, recruiting","href":"/trials/nct07611110/"},{"record":"era-223","field":"result","kind":"trial","state":"stopped","label":"ERA 223: phase 3, negative","href":"/trials/era-223/","quote":"Median symptomatic skeletal event-free survival 22.3 against 26.0 months (hazard ratio 1.122, 95 percent confidence interval 0.917 to 1.374, p=0.2636): no benefit. Fractures of any grade in 29 against 11 percent, grade 3 to 4 fractures in 9 against 3 percent."},{"record":"nct07620574","field":"status","kind":"trial","state":"development","label":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study: phase 3, recruiting","href":"/trials/nct07620574/"},{"record":"nct03348670","field":"status","kind":"trial","state":"development","label":"Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms: phase 2/3, active","href":"/trials/nct03348670/"},{"record":"nct03678025","field":"status","kind":"trial","state":"development","label":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer: phase 3, recruiting","href":"/trials/nct03678025/"},{"record":"nct05367440","field":"status","kind":"trial","state":"development","label":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer: phase 1/2, active","href":"/trials/nct05367440/"},{"record":"nct04446117","field":"status","kind":"trial","state":"development","label":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC: phase 3, active","href":"/trials/nct04446117/"},{"record":"nct02861573","field":"status","kind":"trial","state":"development","label":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365): phase 1/2, active","href":"/trials/nct02861573/"},{"record":"nct05171816","field":"status","kind":"trial","state":"development","label":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort): phase 3, active","href":"/trials/nct05171816/"},{"record":"nct06520345","field":"status","kind":"trial","state":"development","label":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global): phase 3, recruiting","href":"/trials/nct06520345/"},{"record":"nct07190300","field":"status","kind":"trial","state":"development","label":"TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in : phase 1/2, recruiting","href":"/trials/nct07190300/"},{"record":"registry:abiraterone","kind":"registry","state":"development","label":"ClinicalTrials.gov: 34 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/abiraterone/#registry"},{"record":"bicalutamide","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/bicalutamide/"},{"record":"bicalutamide","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1995: Metastatic prostate cancer with LHRH analogue","href":"/drugs/bicalutamide/"},{"record":"bicalutamide","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 1995: Advanced prostate cancer; 150 mg for locally advanced","href":"/drugs/bicalutamide/"},{"record":"bicalutamide","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 1995","href":"/regulatory/regions/"},{"record":"bicalutamide","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 1995","href":"/regulatory/regions/"},{"record":"bicalutamide","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 1995","href":"https://products.mhra.gov.uk/?search=Casodex"},{"record":"bicalutamide","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 1999","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"bicalutamide","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved","href":"https://english.nmpa.gov.cn/"},{"record":"bicalutamide","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Casodex"},{"record":"nct02531516","field":"status","kind":"trial","state":"development","label":"An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS: phase 3, active","href":"/trials/nct02531516/"},{"record":"nct07455903","field":"status","kind":"trial","state":"development","label":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT: phase 2, recruiting","href":"/trials/nct07455903/"},{"record":"nct06365788","field":"status","kind":"trial","state":"development","label":"Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer: phase 2, recruiting","href":"/trials/nct06365788/"},{"record":"nct03678025","field":"status","kind":"trial","state":"development","label":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer: phase 3, recruiting","href":"/trials/nct03678025/"},{"record":"nct04513717","field":"status","kind":"trial","state":"development","label":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial: phase 3, active","href":"/trials/nct04513717/"},{"record":"registry:bicalutamide","kind":"registry","state":"development","label":"ClinicalTrials.gov: 18 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/bicalutamide/#registry"},{"record":"ep0062","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/ep0062/"},{"record":"nct05573126","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer: phase 1/2, recruiting","href":"/trials/nct05573126/"},{"record":"registry:ep0062","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/ep0062/#registry"},{"record":"flutamide","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/flutamide/"},{"record":"flutamide","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1989: Locally advanced (B2 to C) and metastatic (D2) prostate cancer in combination with an LHRH agonist","href":"/drugs/flutamide/"},{"record":"nct03678025","field":"status","kind":"trial","state":"development","label":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer: phase 3, recruiting","href":"/trials/nct03678025/"},{"record":"nct04513717","field":"status","kind":"trial","state":"development","label":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial: phase 3, active","href":"/trials/nct04513717/"},{"record":"registry:flutamide","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/flutamide/#registry"},{"record":"nilutamide","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/nilutamide/"},{"record":"nilutamide","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1996: Metastatic (stage D2) prostate cancer in combination with surgical castration","href":"/drugs/nilutamide/"},{"record":"nct03678025","field":"status","kind":"trial","state":"development","label":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer: phase 3, recruiting","href":"/trials/nct03678025/"},{"record":"registry:nilutamide","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/nilutamide/#registry"},{"record":"rezvilutamide","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/rezvilutamide/"},{"record":"rezvilutamide","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2022: High-volume metastatic hormone-sensitive prostate cancer with androgen deprivation therapy","href":"/drugs/rezvilutamide/"},{"record":"rezvilutamide","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2022","href":"https://english.nmpa.gov.cn/"},{"record":"nct07407283","field":"status","kind":"trial","state":"development","label":"A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct07407283/"},{"record":"nct07241416","field":"status","kind":"trial","state":"development","label":"A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer: phase 3, recruiting","href":"/trials/nct07241416/"},{"record":"nct07230106","field":"status","kind":"trial","state":"development","label":"A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer: phase 2, recruiting","href":"/trials/nct07230106/"},{"record":"registry:rezvilutamide","kind":"registry","state":"development","label":"ClinicalTrials.gov: 16 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/rezvilutamide/#registry"}],"reasons":[{"drugId":"abiraterone","drugName":"Abiraterone acetate","drugRoute":"/drugs/abiraterone/","drugState":"approved","record":"era-223","kind":"trial","label":"ERA 223: phase 3, negative","href":"/trials/era-223/","quote":"Median symptomatic skeletal event-free survival 22.3 against 26.0 months (hazard ratio 1.122, 95 percent confidence interval 0.917 to 1.374, p=0.2636): no benefit. Fractures of any grade in 29 against 11 percent, grade 3 to 4 fractures in 9 against 3 percent."}]},{"a":{"key":"target","id":"androgen-receptor","name":"Androgen receptor","href":"/targets/androgen-receptor/"},"b":{"key":"mechanismClass","id":"other-inhibitor","name":"Inhibitor (class not stated)"},"state":"stopped","drugs":[{"id":"masofaniten","name":"Masofaniten","route":"/drugs/masofaniten/","state":"stopped","status":"withdrawn"}],"counts":{"approved":0,"development":0,"stopped":1,"unclear":0},"parts":{},"evidence":[{"record":"masofaniten","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/masofaniten/","quote":"A drug designed to block the part of the androgen receptor that resistant variants keep; its phase 2 was stopped for futility and development ended."}],"reasons":[{"drugId":"masofaniten","drugName":"Masofaniten","drugRoute":"/drugs/masofaniten/","drugState":"stopped","record":"masofaniten","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/masofaniten/","quote":"A drug designed to block the part of the androgen receptor that resistant variants keep; its phase 2 was stopped for futility and development ended."}]},{"a":{"key":"target","id":"androgen-receptor","name":"Androgen receptor","href":"/targets/androgen-receptor/"},"b":{"key":"mechanismClass","id":"receptor-agonist","name":"Receptor agonist"},"state":"approved","drugs":[{"id":"apalutamide","name":"Apalutamide","route":"/drugs/apalutamide/","state":"approved","status":"approved"},{"id":"darolutamide","name":"Darolutamide","route":"/drugs/darolutamide/","state":"approved","status":"approved"},{"id":"enzalutamide","name":"Enzalutamide","route":"/drugs/enzalutamide/","state":"approved","status":"approved"}],"counts":{"approved":3,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"apalutamide","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/apalutamide/"},{"record":"apalutamide","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: Non-metastatic CRPC (SPARTAN)","href":"/drugs/apalutamide/"},{"record":"apalutamide","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2019: mHSPC (TITAN)","href":"/drugs/apalutamide/"},{"record":"apalutamide","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"apalutamide","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2019","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/erleada"},{"record":"apalutamide","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2019","href":"https://products.mhra.gov.uk/?search=Erleada"},{"record":"apalutamide","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2019","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"apalutamide","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2019","href":"https://english.nmpa.gov.cn/"},{"record":"apalutamide","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2018","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Erleada"},{"record":"nct04557059","field":"status","kind":"trial","state":"development","label":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer: phase 3, active","href":"/trials/nct04557059/"},{"record":"nct05884398","field":"status","kind":"trial","state":"development","label":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC: phase 3, active","href":"/trials/nct05884398/"},{"record":"nct01946204","field":"status","kind":"trial","state":"development","label":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer: phase 3, active","href":"/trials/nct01946204/"},{"record":"nct02489318","field":"status","kind":"trial","state":"development","label":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC: phase 3, active","href":"/trials/nct02489318/"},{"record":"nct04325828","field":"status","kind":"trial","state":"development","label":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma: phase 2, active","href":"/trials/nct04325828/"},{"record":"nct03767244","field":"status","kind":"trial","state":"development","label":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy: phase 3, active","href":"/trials/nct03767244/"},{"record":"nct05422911","field":"status","kind":"trial","state":"development","label":"Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.: phase 2, recruiting","href":"/trials/nct05422911/"},{"record":"nct02257736","field":"status","kind":"trial","state":"development","label":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC): phase 3, active","href":"/trials/nct02257736/"},{"record":"nct02531516","field":"status","kind":"trial","state":"development","label":"An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS: phase 3, active","href":"/trials/nct02531516/"},{"record":"nct07611110","field":"status","kind":"trial","state":"development","label":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01): phase 3, recruiting","href":"/trials/nct07611110/"},{"record":"nct05367440","field":"status","kind":"trial","state":"development","label":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer: phase 1/2, active","href":"/trials/nct05367440/"},{"record":"nct07745361","field":"status","kind":"trial","state":"development","label":"Study of Oral MRT-2359 With Apalutamide in Prostate Cancer: phase 2, recruiting","href":"/trials/nct07745361/"},{"record":"nct04423211","field":"status","kind":"trial","state":"development","label":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging: phase 3, recruiting","href":"/trials/nct04423211/"},{"record":"nct04513717","field":"status","kind":"trial","state":"development","label":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial: phase 3, active","href":"/trials/nct04513717/"},{"record":"registry:apalutamide","kind":"registry","state":"development","label":"ClinicalTrials.gov: 62 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/apalutamide/#registry"},{"record":"darolutamide","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/darolutamide/"},{"record":"darolutamide","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2019: Non-metastatic CRPC","href":"/drugs/darolutamide/"},{"record":"darolutamide","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2022: mHSPC with docetaxel (ARASENS)","href":"/drugs/darolutamide/"},{"record":"darolutamide","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2025: mHSPC with ADT alone (ARANOTE)","href":"/drugs/darolutamide/"},{"record":"darolutamide","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2019","href":"/regulatory/regions/"},{"record":"darolutamide","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2020","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/nubeqa"},{"record":"darolutamide","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2020","href":"https://products.mhra.gov.uk/?search=Nubeqa"},{"record":"darolutamide","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2020","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"darolutamide","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"darolutamide","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2020","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Nubeqa"},{"record":"nct06785636","field":"status","kind":"trial","state":"development","label":"A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC: phase 1/2, recruiting","href":"/trials/nct06785636/"},{"record":"nct06568094","field":"status","kind":"trial","state":"development","label":"A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct06568094/"},{"record":"nct05794906","field":"status","kind":"trial","state":"development","label":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer: phase 3, active","href":"/trials/nct05794906/"},{"record":"nct07450599","field":"status","kind":"trial","state":"development","label":"A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have Hi: phase 2, recruiting","href":"/trials/nct07450599/"},{"record":"nct07611110","field":"status","kind":"trial","state":"development","label":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01): phase 3, recruiting","href":"/trials/nct07611110/"},{"record":"nct06190899","field":"status","kind":"trial","state":"development","label":"Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct06190899/"},{"record":"nct07016399","field":"status","kind":"trial","state":"development","label":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC: phase 2, recruiting","href":"/trials/nct07016399/"},{"record":"nct05367440","field":"status","kind":"trial","state":"development","label":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer: phase 1/2, active","href":"/trials/nct05367440/"},{"record":"nct04464226","field":"status","kind":"trial","state":"development","label":"Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer: phase 3, active","href":"/trials/nct04464226/"},{"record":"nct07190300","field":"status","kind":"trial","state":"development","label":"TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in : phase 1/2, recruiting","href":"/trials/nct07190300/"},{"record":"registry:darolutamide","kind":"registry","state":"development","label":"ClinicalTrials.gov: 70 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/darolutamide/#registry"},{"record":"enzalutamide","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/enzalutamide/"},{"record":"enzalutamide","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2012: mCRPC after docetaxel (pre-chemo 2014)","href":"/drugs/enzalutamide/"},{"record":"enzalutamide","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2018: Non-metastatic CRPC","href":"/drugs/enzalutamide/"},{"record":"enzalutamide","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2019: mHSPC (ARCHES)","href":"/drugs/enzalutamide/"},{"record":"enzalutamide","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2023: High-risk biochemical recurrence (EMBARK)","href":"/drugs/enzalutamide/"},{"record":"enzalutamide","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2012","href":"/regulatory/regions/"},{"record":"enzalutamide","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2013","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi"},{"record":"enzalutamide","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2013","href":"https://products.mhra.gov.uk/?search=Xtandi"},{"record":"enzalutamide","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2014","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"enzalutamide","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2019","href":"https://english.nmpa.gov.cn/"},{"record":"enzalutamide","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2014","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Xtandi"},{"record":"nct06863272","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02): phase 1/2, recruiting","href":"/trials/nct06863272/"},{"record":"nct07198633","field":"status","kind":"trial","state":"development","label":"A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct07198633/"},{"record":"nct05914116","field":"status","kind":"trial","state":"development","label":"A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05914116/"},{"record":"nct07226986","field":"status","kind":"trial","state":"development","label":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA: phase 1/2, recruiting","href":"/trials/nct07226986/"},{"record":"nct02960022","field":"status","kind":"trial","state":"development","label":"A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study: phase 2, active","href":"/trials/nct02960022/"},{"record":"nct06099769","field":"status","kind":"trial","state":"development","label":"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer: phase 2, recruiting","href":"/trials/nct06099769/"},{"record":"nct07230106","field":"status","kind":"trial","state":"development","label":"A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer: phase 2, recruiting","href":"/trials/nct07230106/"},{"record":"nct04104776","field":"status","kind":"trial","state":"development","label":"A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas: phase 1/2, recruiting","href":"/trials/nct04104776/"},{"record":"nct06629779","field":"status","kind":"trial","state":"development","label":"A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.: phase 3, recruiting","href":"/trials/nct06629779/"},{"record":"nct07287150","field":"status","kind":"trial","state":"development","label":"A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer: phase 2, recruiting","href":"/trials/nct07287150/"},{"record":"nct05422911","field":"status","kind":"trial","state":"development","label":"Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.: phase 2, recruiting","href":"/trials/nct05422911/"},{"record":"nct04076059","field":"status","kind":"trial","state":"development","label":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormo: phase 3, active","href":"/trials/nct04076059/"},{"record":"nct05112965","field":"status","kind":"trial","state":"development","label":"An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C): phase 3, active","href":"/trials/nct05112965/"},{"record":"nct06991556","field":"status","kind":"trial","state":"development","label":"An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc: phase 2, active","href":"/trials/nct06991556/"},{"record":"armor3-sv","field":"result","kind":"trial","state":"stopped","label":"ARMOR3-SV: phase 3, negative","href":"/trials/armor3-sv/","quote":"Closed early after 38 of a planned 148 men were randomised; AR-V7 prevalence 8 percent (95 percent confidence interval 6 to 10) among 953 prescreened men. PSA50 response 13 percent with galeterone against 42 percent with enzalutamide. Galeterone development stopped."},{"record":"nct07611110","field":"status","kind":"trial","state":"development","label":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01): phase 3, recruiting","href":"/trials/nct07611110/"},{"record":"imbassador250","field":"result","kind":"trial","state":"stopped","label":"IMbassador250: phase 3, negative","href":"/trials/imbassador250/","quote":"Overall survival not improved: stratified hazard ratio 1.12 (95 percent confidence interval 0.91 to 1.37, p=0.28) for atezolizumab with enzalutamide against enzalutamide alone."},{"record":"keynote-641","field":"result","kind":"trial","state":"stopped","label":"KEYNOTE-641: phase 3, negative","href":"/trials/keynote-641/","quote":"Median overall survival 24.7 against 27.3 months (hazard ratio 1.04, 95 percent confidence interval 0.88 to 1.22) and radiographic progression-free survival 10.4 against 9.0 months (0.98, 0.84 to 1.14); stopped for futility. Grade 3 or higher treatment-related adverse events 31.2 against 10.8 percent."},{"record":"keynote-991","field":"result","kind":"trial","state":"stopped","label":"KEYNOTE-991: phase 3, negative","href":"/trials/keynote-991/","quote":"Radiographic progression-free survival hazard ratio 1.20 (95 percent confidence interval 0.96 to 1.49, p=0.9467), medians not reached; stopped for futility. Grade 3 or higher adverse events 61.9 against 38.1 percent and rash 25.1 against 9.3 percent."},{"record":"nct07620574","field":"status","kind":"trial","state":"development","label":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study: phase 3, recruiting","href":"/trials/nct07620574/"},{"record":"mevpro-1","field":"status","kind":"trial","state":"development","label":"MEVPRO-1: phase 3, active","href":"/trials/mevpro-1/"},{"record":"nct05367440","field":"status","kind":"trial","state":"development","label":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer: phase 1/2, active","href":"/trials/nct05367440/"},{"record":"nct04446117","field":"status","kind":"trial","state":"development","label":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC: phase 3, active","href":"/trials/nct04446117/"},{"record":"nct02861573","field":"status","kind":"trial","state":"development","label":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365): phase 1/2, active","href":"/trials/nct02861573/"},{"record":"nct06228053","field":"status","kind":"trial","state":"development","label":"Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer: phase 2, recruiting","href":"/trials/nct06228053/"},{"record":"nct04821622","field":"status","kind":"trial","state":"development","label":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC: phase 3, active","href":"/trials/nct04821622/"},{"record":"nct06702995","field":"status","kind":"trial","state":"development","label":"Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct06702995/"},{"record":"nct04557449","field":"status","kind":"trial","state":"development","label":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors: phase 2, active","href":"/trials/nct04557449/"},{"record":"nct06520345","field":"status","kind":"trial","state":"development","label":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global): phase 3, recruiting","href":"/trials/nct06520345/"},{"record":"nct07028853","field":"status","kind":"trial","state":"development","label":"This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking En: phase 3, recruiting","href":"/trials/nct07028853/"},{"record":"nct04986423","field":"status","kind":"trial","state":"development","label":"ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer: phase 2, recruiting","href":"/trials/nct04986423/"},{"record":"registry:enzalutamide","kind":"registry","state":"development","label":"ClinicalTrials.gov: 46 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/enzalutamide/#registry"}],"reasons":[{"drugId":"enzalutamide","drugName":"Enzalutamide","drugRoute":"/drugs/enzalutamide/","drugState":"approved","record":"armor3-sv","kind":"trial","label":"ARMOR3-SV: phase 3, negative","href":"/trials/armor3-sv/","quote":"Closed early after 38 of a planned 148 men were randomised; AR-V7 prevalence 8 percent (95 percent confidence interval 6 to 10) among 953 prescreened men. PSA50 response 13 percent with galeterone against 42 percent with enzalutamide. Galeterone development stopped."},{"drugId":"enzalutamide","drugName":"Enzalutamide","drugRoute":"/drugs/enzalutamide/","drugState":"approved","record":"imbassador250","kind":"trial","label":"IMbassador250: phase 3, negative","href":"/trials/imbassador250/","quote":"Overall survival not improved: stratified hazard ratio 1.12 (95 percent confidence interval 0.91 to 1.37, p=0.28) for atezolizumab with enzalutamide against enzalutamide alone."},{"drugId":"enzalutamide","drugName":"Enzalutamide","drugRoute":"/drugs/enzalutamide/","drugState":"approved","record":"keynote-641","kind":"trial","label":"KEYNOTE-641: phase 3, negative","href":"/trials/keynote-641/","quote":"Median overall survival 24.7 against 27.3 months (hazard ratio 1.04, 95 percent confidence interval 0.88 to 1.22) and radiographic progression-free survival 10.4 against 9.0 months (0.98, 0.84 to 1.14); stopped for futility. Grade 3 or higher treatment-related adverse events 31.2 against 10.8 percent."},{"drugId":"enzalutamide","drugName":"Enzalutamide","drugRoute":"/drugs/enzalutamide/","drugState":"approved","record":"keynote-991","kind":"trial","label":"KEYNOTE-991: phase 3, negative","href":"/trials/keynote-991/","quote":"Radiographic progression-free survival hazard ratio 1.20 (95 percent confidence interval 0.96 to 1.49, p=0.9467), medians not reached; stopped for futility. Grade 3 or higher adverse events 61.9 against 38.1 percent and rash 25.1 against 9.3 percent."}]},{"a":{"key":"target","id":"estrogen-receptor","name":"Estrogen receptor (ERα)","href":"/targets/estrogen-receptor/"},"b":{"key":"mechanismClass","id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/"},"state":"approved","drugs":[{"id":"camizestrant","name":"Camizestrant","route":"/drugs/camizestrant/","state":"approved","status":"approved"},{"id":"elacestrant","name":"Elacestrant","route":"/drugs/elacestrant/","state":"approved","status":"approved"},{"id":"exemestane","name":"Exemestane","route":"/drugs/exemestane/","state":"approved","status":"approved"},{"id":"fulvestrant","name":"Fulvestrant","route":"/drugs/fulvestrant/","state":"approved","status":"approved"},{"id":"giredestrant","name":"Giredestrant","route":"/drugs/giredestrant/","state":"development","status":"phase-3"},{"id":"imlunestrant","name":"Imlunestrant","route":"/drugs/imlunestrant/","state":"approved","status":"approved"},{"id":"letrozole","name":"Letrozole (and other aromatase inhibitors)","route":"/drugs/letrozole/","state":"approved","status":"approved"},{"id":"raloxifene","name":"Raloxifene","route":"/drugs/raloxifene/","state":"approved","status":"approved"},{"id":"tamoxifen","name":"Tamoxifen","route":"/drugs/tamoxifen/","state":"approved","status":"approved"},{"id":"toremifene","name":"Toremifene","route":"/drugs/toremifene/","state":"approved","status":"approved"}],"counts":{"approved":9,"development":1,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"},{"key":"binding","id":"covalent","name":"Covalent"}]},"evidence":[{"record":"camizestrant","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/camizestrant/"},{"record":"camizestrant","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2026: HR+/HER2- advanced breast cancer with an emergent ESR1 mutation on AI + CDK4/6, with a CDK4/6 inhibitor (accelerated, 4 Sep 2026)","href":"/drugs/camizestrant/"},{"record":"camizestrant","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2026: ER+/HER2- advanced breast cancer with emergent ESR1 mutation, with a CDK4/6 inhibitor; 20 Jul 2026","href":"/drugs/camizestrant/"},{"record":"camizestrant","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2026","href":"/regulatory/regions/"},{"record":"camizestrant","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2026","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/etcamah"},{"record":"nct04711252","field":"status","kind":"trial","state":"development","label":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease: phase 3, active","href":"/trials/nct04711252/"},{"record":"nct06188520","field":"status","kind":"trial","state":"development","label":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With : phase 1/2, recruiting","href":"/trials/nct06188520/"},{"record":"nct07647328","field":"status","kind":"trial","state":"development","label":"A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct07647328/"},{"record":"nct05774951","field":"status","kind":"trial","state":"development","label":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy: phase 3, recruiting","href":"/trials/nct05774951/"},{"record":"nct04214288","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer: phase 2, active","href":"/trials/nct04214288/"},{"record":"cambria","field":"status","kind":"trial","state":"development","label":"CAMBRIA-1 & CAMBRIA-2: phase 3, active","href":"/trials/cambria/"},{"record":"nct06380751","field":"status","kind":"trial","state":"development","label":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct06380751/"},{"record":"nct04644068","field":"status","kind":"trial","state":"development","label":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies: phase 1/2, active","href":"/trials/nct04644068/"},{"record":"nct07427394","field":"status","kind":"trial","state":"development","label":"Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer: phase 2, recruiting","href":"/trials/nct07427394/"},{"record":"registry:camizestrant","kind":"registry","state":"development","label":"ClinicalTrials.gov: 13 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/camizestrant/#registry"},{"record":"elacestrant","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/elacestrant/"},{"record":"elacestrant","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2023: ESR1-mutant ER+/HER2- advanced breast cancer after ≥1 endocrine therapy","href":"/drugs/elacestrant/"},{"record":"elacestrant","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2023","href":"/regulatory/regions/"},{"record":"elacestrant","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2023","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/orserdu"},{"record":"elacestrant","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2024","href":"https://products.mhra.gov.uk/?search=Orserdu"},{"record":"elacestrant","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2024","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Orserdu"},{"record":"nct07766018","field":"status","kind":"trial","state":"development","label":"A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer: phase 2, recruiting","href":"/trials/nct07766018/"},{"record":"nct06492616","field":"status","kind":"trial","state":"development","label":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence: phase 3, recruiting","href":"/trials/nct06492616/"},{"record":"nct05596409","field":"status","kind":"trial","state":"development","label":"ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study: phase 2, active","href":"/trials/nct05596409/"},{"record":"nct05563220","field":"status","kind":"trial","state":"development","label":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer: phase 1/2, active","href":"/trials/nct05563220/"},{"record":"nct05573126","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer: phase 1/2, recruiting","href":"/trials/nct05573126/"},{"record":"nct05386108","field":"status","kind":"trial","state":"development","label":"Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer: phase 1/2, recruiting","href":"/trials/nct05386108/"},{"record":"registry:elacestrant","kind":"registry","state":"development","label":"ClinicalTrials.gov: 26 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/elacestrant/#registry"},{"record":"exemestane","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/exemestane/"},{"record":"exemestane","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1999: Advanced breast cancer after tamoxifen","href":"/drugs/exemestane/"},{"record":"exemestane","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2005: Adjuvant after 2-3 years of tamoxifen","href":"/drugs/exemestane/"},{"record":"exemestane","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 1999","href":"/regulatory/regions/"},{"record":"exemestane","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 1999","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/aromasin"},{"record":"exemestane","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 1999","href":"https://products.mhra.gov.uk/?search=Aromasin"},{"record":"exemestane","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2002","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"exemestane","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2001","href":"https://english.nmpa.gov.cn/"},{"record":"exemestane","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2000","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Aromasin"},{"record":"nct05774951","field":"status","kind":"trial","state":"development","label":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy: phase 3, recruiting","href":"/trials/nct05774951/"},{"record":"nct06492616","field":"status","kind":"trial","state":"development","label":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence: phase 3, recruiting","href":"/trials/nct06492616/"},{"record":"nct05514054","field":"status","kind":"trial","state":"development","label":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer: phase 3, active","href":"/trials/nct05514054/"},{"record":"nct06979596","field":"status","kind":"trial","state":"development","label":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015): phase 2, recruiting","href":"/trials/nct06979596/"},{"record":"nct05768139","field":"status","kind":"trial","state":"development","label":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05768139/"},{"record":"nct06016738","field":"status","kind":"trial","state":"development","label":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer: phase 3, active","href":"/trials/nct06016738/"},{"record":"nct04906395","field":"status","kind":"trial","state":"development","label":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer: phase 3, active","href":"/trials/nct04906395/"},{"record":"nct05573126","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer: phase 1/2, recruiting","href":"/trials/nct05573126/"},{"record":"nct05827081","field":"status","kind":"trial","state":"development","label":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer: phase 3, recruiting","href":"/trials/nct05827081/"},{"record":"nct06957379","field":"status","kind":"trial","state":"development","label":"Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy: phase 2, active","href":"/trials/nct06957379/"},{"record":"nct06428396","field":"status","kind":"trial","state":"development","label":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029): phase 2, active","href":"/trials/nct06428396/"},{"record":"registry:exemestane","kind":"registry","state":"development","label":"ClinicalTrials.gov: 42 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/exemestane/#registry"},{"record":"fulvestrant","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/fulvestrant/"},{"record":"fulvestrant","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2002: HR+ advanced breast cancer after antioestrogen therapy","href":"/drugs/fulvestrant/"},{"record":"fulvestrant","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2017: First-line HR+ advanced breast cancer (FALCON)","href":"/drugs/fulvestrant/"},{"record":"fulvestrant","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2002","href":"/regulatory/regions/"},{"record":"fulvestrant","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2004","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/faslodex"},{"record":"fulvestrant","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2004","href":"https://products.mhra.gov.uk/?search=Faslodex"},{"record":"fulvestrant","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2011","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"fulvestrant","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2010","href":"https://english.nmpa.gov.cn/"},{"record":"fulvestrant","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2004","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Faslodex"},{"record":"nct06208410","field":"status","kind":"trial","state":"development","label":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06208410/"},{"record":"nct07109726","field":"status","kind":"trial","state":"development","label":"A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations: phase 1/2, recruiting","href":"/trials/nct07109726/"},{"record":"nct04539496","field":"status","kind":"trial","state":"development","label":"A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors: phase 1/2, active","href":"/trials/nct04539496/"},{"record":"nct07405801","field":"status","kind":"trial","state":"development","label":"A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer: phase 2, recruiting","href":"/trials/nct07405801/"},{"record":"nct06764186","field":"status","kind":"trial","state":"development","label":"A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain: phase 3, active","href":"/trials/nct06764186/"},{"record":"nct04576455","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer): phase 2, active","href":"/trials/nct04576455/"},{"record":"nct05646862","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy: phase 3, recruiting","href":"/trials/nct05646862/"},{"record":"nct02107703","field":"status","kind":"trial","state":"development","label":"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer: phase 3, active","href":"/trials/nct02107703/"},{"record":"nct02763566","field":"status","kind":"trial","state":"development","label":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer: phase 3, active","href":"/trials/nct02763566/"},{"record":"nct07389733","field":"status","kind":"trial","state":"development","label":"A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer: phase 1/2, recruiting","href":"/trials/nct07389733/"},{"record":"nct06979596","field":"status","kind":"trial","state":"development","label":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015): phase 2, recruiting","href":"/trials/nct06979596/"},{"record":"nct06202261","field":"status","kind":"trial","state":"development","label":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer: phase 1/2, recruiting","href":"/trials/nct06202261/"},{"record":"nct06065748","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer): phase 3, active","href":"/trials/nct06065748/"},{"record":"nct04214288","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer: phase 2, active","href":"/trials/nct04214288/"},{"record":"nct05262400","field":"status","kind":"trial","state":"development","label":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors: phase 1/2, active","href":"/trials/nct05262400/"},{"record":"nct06555068","field":"status","kind":"trial","state":"development","label":"A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients: phase 1/2, recruiting","href":"/trials/nct06555068/"},{"record":"nct04579380","field":"status","kind":"trial","state":"development","label":"Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations: phase 2, active","href":"/trials/nct04579380/"},{"record":"nct04862663","field":"status","kind":"trial","state":"development","label":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292): phase 3, active","href":"/trials/nct04862663/"},{"record":"nct06635447","field":"status","kind":"trial","state":"development","label":"Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients: phase 3, active","href":"/trials/nct06635447/"},{"record":"nct05251714","field":"status","kind":"trial","state":"development","label":"CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer: phase 1/2, active","href":"/trials/nct05251714/"},{"record":"nct05230810","field":"status","kind":"trial","state":"development","label":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.: phase 1/2, active","href":"/trials/nct05230810/"},{"record":"nct00099437","field":"status","kind":"trial","state":"development","label":"Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.: phase 3, active","href":"/trials/nct00099437/"},{"record":"nct04567420","field":"status","kind":"trial","state":"development","label":"DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE): phase 2, active","href":"/trials/nct04567420/"},{"record":"nct07498478","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment: phase 2, recruiting","href":"/trials/nct07498478/"},{"record":"nct05696626","field":"status","kind":"trial","state":"development","label":"Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation: phase 3, recruiting","href":"/trials/nct05696626/"},{"record":"nct06702618","field":"status","kind":"trial","state":"development","label":"Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer: phase 2, active","href":"/trials/nct06702618/"},{"record":"nct05768139","field":"status","kind":"trial","state":"development","label":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05768139/"},{"record":"nct06506955","field":"status","kind":"trial","state":"development","label":"Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.: phase 2/3, active","href":"/trials/nct06506955/"},{"record":"nct05501886","field":"status","kind":"trial","state":"development","label":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1): phase 3, active","href":"/trials/nct05501886/"},{"record":"nct06016738","field":"status","kind":"trial","state":"development","label":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer: phase 3, active","href":"/trials/nct06016738/"},{"record":"nct05735080","field":"status","kind":"trial","state":"development","label":"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer: phase 1/2, recruiting","href":"/trials/nct05735080/"},{"record":"nct06998407","field":"status","kind":"trial","state":"development","label":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06998407/"},{"record":"nct04553133","field":"status","kind":"trial","state":"development","label":"PF-07104091 as a Single Agent and in Combination Therapy: phase 2, active","href":"/trials/nct04553133/"},{"record":"nct04115306","field":"status","kind":"trial","state":"development","label":"Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer: phase 1/2, active","href":"/trials/nct04115306/"},{"record":"nct06993844","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06993844/"},{"record":"nct05573126","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer: phase 1/2, recruiting","href":"/trials/nct05573126/"},{"record":"nct06757634","field":"status","kind":"trial","state":"development","label":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2): phase 3, recruiting","href":"/trials/nct06757634/"},{"record":"nct07235176","field":"status","kind":"trial","state":"development","label":"Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients: phase 1/2, recruiting","href":"/trials/nct07235176/"},{"record":"nct07558733","field":"status","kind":"trial","state":"development","label":"Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer: phase 1/2, recruiting","href":"/trials/nct07558733/"},{"record":"nct06380751","field":"status","kind":"trial","state":"development","label":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct06380751/"},{"record":"nct06957379","field":"status","kind":"trial","state":"development","label":"Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy: phase 2, active","href":"/trials/nct06957379/"},{"record":"nct06736704","field":"status","kind":"trial","state":"development","label":"SNV4818 in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06736704/"},{"record":"nct04524000","field":"status","kind":"trial","state":"development","label":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer: phase 2, active","href":"/trials/nct04524000/"},{"record":"nct04544189","field":"status","kind":"trial","state":"development","label":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer: phase 2, active","href":"/trials/nct04544189/"},{"record":"nct05226871","field":"status","kind":"trial","state":"development","label":"Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies: phase 2, active","href":"/trials/nct05226871/"},{"record":"nct07287917","field":"status","kind":"trial","state":"development","label":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct07287917/"},{"record":"nct05867251","field":"status","kind":"trial","state":"development","label":"Study of AVZO-021 in Patients With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05867251/"},{"record":"nct06428396","field":"status","kind":"trial","state":"development","label":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029): phase 2, active","href":"/trials/nct06428396/"},{"record":"nct06726148","field":"status","kind":"trial","state":"development","label":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06726148/"},{"record":"nct07288359","field":"status","kind":"trial","state":"development","label":"Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct07288359/"},{"record":"nct04606446","field":"status","kind":"trial","state":"development","label":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors: phase 2, recruiting","href":"/trials/nct04606446/"},{"record":"nct05038735","field":"status","kind":"trial","state":"development","label":"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.: phase 3, active","href":"/trials/nct05038735/"},{"record":"nct04851613","field":"status","kind":"trial","state":"development","label":"Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer: phase 3, active","href":"/trials/nct04851613/"},{"record":"nct04557449","field":"status","kind":"trial","state":"development","label":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors: phase 2, active","href":"/trials/nct04557449/"},{"record":"nct07368998","field":"status","kind":"trial","state":"development","label":"To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer: phase 2, recruiting","href":"/trials/nct07368998/"},{"record":"registry:fulvestrant","kind":"registry","state":"development","label":"ClinicalTrials.gov: 42 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/fulvestrant/#registry"},{"record":"giredestrant","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/giredestrant/"},{"record":"nct07541079","field":"status","kind":"trial","state":"development","label":"A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer): phase 3, recruiting","href":"/trials/nct07541079/"},{"record":"nct04576455","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer): phase 2, active","href":"/trials/nct04576455/"},{"record":"nct04802759","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer: phase 1/2, recruiting","href":"/trials/nct04802759/"},{"record":"nct06065748","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer): phase 3, active","href":"/trials/nct06065748/"},{"record":"nct07100106","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer: phase 1/2, recruiting","href":"/trials/nct07100106/"},{"record":"nct05296798","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer): phase 3, active","href":"/trials/nct05296798/"},{"record":"nct07054190","field":"status","kind":"trial","state":"development","label":"A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer: phase 2, recruiting","href":"/trials/nct07054190/"},{"record":"persevera","field":"result","kind":"trial","state":"stopped","label":"persevERA: phase 3, negative","href":"/trials/persevera/","quote":"PFS 33.1 vs 28.2 months, not significant."},{"record":"registry:giredestrant","kind":"registry","state":"development","label":"ClinicalTrials.gov: 16 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/giredestrant/#registry"},{"record":"imlunestrant","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/imlunestrant/"},{"record":"imlunestrant","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2025: ER+/HER2- ESR1-mutated advanced breast cancer after ≥1 line of endocrine therapy","href":"/drugs/imlunestrant/"},{"record":"imlunestrant","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2026: ESR1-mutant ER+/HER2- mBC; 9 Jan 2026","href":"/drugs/imlunestrant/"},{"record":"imlunestrant","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2025","href":"/regulatory/regions/"},{"record":"imlunestrant","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2026","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/inluriyo"},{"record":"imlunestrant","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2026","href":"https://www.gov.uk/government/news/mhra-approves-imlunestrant-tosylate-inluryo-a-new-treatment-for-breast-cancer"},{"record":"imlunestrant","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2025","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"nct07287098","field":"status","kind":"trial","state":"development","label":"A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer: phase 2, recruiting","href":"/trials/nct07287098/"},{"record":"nct05514054","field":"status","kind":"trial","state":"development","label":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer: phase 3, active","href":"/trials/nct05514054/"},{"record":"registry:imlunestrant","kind":"registry","state":"development","label":"ClinicalTrials.gov: 9 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/imlunestrant/#registry"},{"record":"letrozole","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/letrozole/"},{"record":"letrozole","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1997: Advanced breast cancer after tamoxifen (letrozole)","href":"/drugs/letrozole/"},{"record":"letrozole","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2005: Adjuvant early breast cancer (letrozole)","href":"/drugs/letrozole/"},{"record":"letrozole","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 1997","href":"/regulatory/regions/"},{"record":"letrozole","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 1996","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/femara"},{"record":"letrozole","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 1996","href":"https://products.mhra.gov.uk/?search=Femara"},{"record":"letrozole","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2006","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"letrozole","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2000","href":"https://english.nmpa.gov.cn/"},{"record":"letrozole","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 1997","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Femara"},{"record":"nct06072781","field":"status","kind":"trial","state":"development","label":"A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer: phase 3, recruiting","href":"/trials/nct06072781/"},{"record":"nct04553133","field":"status","kind":"trial","state":"development","label":"PF-07104091 as a Single Agent and in Combination Therapy: phase 2, active","href":"/trials/nct04553133/"},{"record":"nct05867251","field":"status","kind":"trial","state":"development","label":"Study of AVZO-021 in Patients With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05867251/"},{"record":"nct07288359","field":"status","kind":"trial","state":"development","label":"Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct07288359/"},{"record":"nct04606446","field":"status","kind":"trial","state":"development","label":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors: phase 2, recruiting","href":"/trials/nct04606446/"},{"record":"nct04557449","field":"status","kind":"trial","state":"development","label":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors: phase 2, active","href":"/trials/nct04557449/"},{"record":"registry:letrozole","kind":"registry","state":"development","label":"ClinicalTrials.gov: 30 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/letrozole/#registry"},{"record":"raloxifene","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/raloxifene/"},{"record":"raloxifene","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1997: Treatment and prevention of postmenopausal osteoporosis","href":"/drugs/raloxifene/"},{"record":"raloxifene","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2007: Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk","href":"/drugs/raloxifene/"},{"record":"nct06062810","field":"status","kind":"trial","state":"development","label":"Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms: phase 2/3, active","href":"/trials/nct06062810/"},{"record":"registry:raloxifene","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/raloxifene/#registry"},{"record":"tamoxifen","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/tamoxifen/"},{"record":"tamoxifen","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1977: Advanced breast cancer","href":"/drugs/tamoxifen/"},{"record":"tamoxifen","field":"approvals[1]","kind":"approval","state":"approved","label":"US 1998: Risk reduction in high-risk women","href":"/drugs/tamoxifen/"},{"record":"tamoxifen","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 1977","href":"/regulatory/regions/"},{"record":"tamoxifen","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 1973","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/nolvadex"},{"record":"tamoxifen","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 1973","href":"https://products.mhra.gov.uk/?search=Nolvadex"},{"record":"tamoxifen","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 1981","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"tamoxifen","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 1990","href":"https://english.nmpa.gov.cn/"},{"record":"tamoxifen","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 1976","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Nolvadex"},{"record":"nct02747004","field":"status","kind":"trial","state":"development","label":"A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer: phase 2, active","href":"/trials/nct02747004/"},{"record":"nct05774951","field":"status","kind":"trial","state":"development","label":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy: phase 3, recruiting","href":"/trials/nct05774951/"},{"record":"nct06492616","field":"status","kind":"trial","state":"development","label":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence: phase 3, recruiting","href":"/trials/nct06492616/"},{"record":"nct07287098","field":"status","kind":"trial","state":"development","label":"A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer: phase 2, recruiting","href":"/trials/nct07287098/"},{"record":"nct05514054","field":"status","kind":"trial","state":"development","label":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer: phase 3, active","href":"/trials/nct05514054/"},{"record":"nct06979596","field":"status","kind":"trial","state":"development","label":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015): phase 2, recruiting","href":"/trials/nct06979596/"},{"record":"nct05768139","field":"status","kind":"trial","state":"development","label":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05768139/"},{"record":"nct04906395","field":"status","kind":"trial","state":"development","label":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer: phase 3, active","href":"/trials/nct04906395/"},{"record":"nct06434064","field":"status","kind":"trial","state":"development","label":"Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer: phase 2, recruiting","href":"/trials/nct06434064/"},{"record":"registry:tamoxifen","kind":"registry","state":"development","label":"ClinicalTrials.gov: 21 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tamoxifen/#registry"},{"record":"toremifene","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/toremifene/"},{"record":"toremifene","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1997: Metastatic breast cancer in postmenopausal women with ER-positive or unknown tumours","href":"/drugs/toremifene/"},{"record":"toremifene","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 1996: First-line hormonal treatment of hormone-dependent metastatic breast cancer in postmenopausal women","href":"/drugs/toremifene/"},{"record":"toremifene","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 1996","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/fareston"},{"record":"registry:toremifene","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/toremifene/#registry"}],"reasons":[{"drugId":"giredestrant","drugName":"Giredestrant","drugRoute":"/drugs/giredestrant/","drugState":"development","record":"persevera","kind":"trial","label":"persevERA: phase 3, negative","href":"/trials/persevera/","quote":"PFS 33.1 vs 28.2 months, not significant."}]},{"a":{"key":"target","id":"fgfr2","name":"FGFR2","href":"/targets/fgfr2/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"cgt4859","name":"CGT4859","route":"/drugs/cgt4859/","state":"development","status":"phase-2"},{"id":"erdafitinib","name":"Erdafitinib","route":"/drugs/erdafitinib/","state":"approved","status":"approved"},{"id":"futibatinib","name":"Futibatinib","route":"/drugs/futibatinib/","state":"approved","status":"approved"},{"id":"hmpl-453","name":"HMPL-453","route":"/drugs/hmpl-453/","state":"development","status":"phase-3"},{"id":"infigratinib","name":"Infigratinib","route":"/drugs/infigratinib/","state":"stopped","status":"withdrawn"},{"id":"lirafugratinib","name":"Lirafugratinib","route":"/drugs/lirafugratinib/","state":"approved","status":"approved"},{"id":"pemigatinib","name":"Pemigatinib","route":"/drugs/pemigatinib/","state":"approved","status":"approved"},{"id":"tar-210","name":"TAR-210","route":"/drugs/tar-210/","state":"development","status":"phase-3"},{"id":"tinengotinib","name":"Tinengotinib","route":"/drugs/tinengotinib/","state":"development","status":"phase-3"},{"id":"tyra-300","name":"TYRA-300","route":"/drugs/tyra-300/","state":"development","status":"phase-2"}],"counts":{"approved":4,"development":5,"stopped":1,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"},{"key":"binding","id":"covalent","name":"Covalent"},{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"}]},"evidence":[{"record":"cgt4859","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/cgt4859/"},{"record":"nct06777316","field":"status","kind":"trial","state":"development","label":"A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors: phase 1/2, active","href":"/trials/nct06777316/"},{"record":"registry:cgt4859","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/cgt4859/#registry"},{"record":"erdafitinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/erdafitinib/"},{"record":"erdafitinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2019: FGFR3/2-altered advanced urothelial cancer after platinum (accelerated)","href":"/drugs/erdafitinib/"},{"record":"erdafitinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2024: FGFR3-altered advanced urothelial cancer after ≥1 systemic therapy incl. PD-1/PD-L1 (full)","href":"/drugs/erdafitinib/"},{"record":"erdafitinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2019","href":"/regulatory/regions/"},{"record":"erdafitinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2024","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/balversa"},{"record":"erdafitinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2024","href":"https://products.mhra.gov.uk/?search=Balversa"},{"record":"erdafitinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2024","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"erdafitinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2025","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Balversa"},{"record":"nct03473743","field":"status","kind":"trial","state":"development","label":"A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer: phase 1/2, active","href":"/trials/nct03473743/"},{"record":"nct02365597","field":"status","kind":"trial","state":"development","label":"An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer: phase 2, active","href":"/trials/nct02365597/"},{"record":"pediatric-match","field":"status","kind":"trial","state":"development","label":"NCI-COG Pediatric MATCH (APEC1621): phase platform, active","href":"/trials/pediatric-match/"},{"record":"nct05316155","field":"status","kind":"trial","state":"development","label":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer: phase 1/2, active","href":"/trials/nct05316155/"},{"record":"registry:erdafitinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 16 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/erdafitinib/#registry"},{"record":"futibatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/futibatinib/"},{"record":"futibatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2022: Previously treated FGFR2-fusion/rearranged intrahepatic cholangiocarcinoma (accelerated)","href":"/drugs/futibatinib/"},{"record":"futibatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2023: Same","href":"/drugs/futibatinib/"},{"record":"futibatinib","field":"approvals[2]","kind":"approval","state":"approved","label":"UK 2024: Locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement after at least one systemic treatment; NICE TA1005 recommended 11 September 2024 as an alternative to pemigatinib","href":"/drugs/futibatinib/"},{"record":"futibatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2022","href":"/regulatory/regions/"},{"record":"futibatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2023","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/lytgobi"},{"record":"futibatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2023","href":"https://products.mhra.gov.uk/?search=Lytgobi"},{"record":"futibatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2023","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"nct07710885","field":"status","kind":"trial","state":"development","label":"Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer: phase 3, recruiting","href":"/trials/nct07710885/"},{"record":"nct06506955","field":"status","kind":"trial","state":"development","label":"Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.: phase 2/3, active","href":"/trials/nct06506955/"},{"record":"nct07745296","field":"status","kind":"trial","state":"development","label":"Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer: phase 3, planned","href":"/trials/nct07745296/"},{"record":"nct05945823","field":"status","kind":"trial","state":"development","label":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors: phase 2, active","href":"/trials/nct05945823/"},{"record":"safir-abc10","field":"status","kind":"trial","state":"development","label":"SAFIR-ABC10: phase 3, recruiting","href":"/trials/safir-abc10/"},{"record":"registry:futibatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 12 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/futibatinib/#registry"},{"record":"hmpl-453","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/hmpl-453/"},{"record":"nct04353375","field":"status","kind":"trial","state":"development","label":"HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma: phase 2/3, recruiting","href":"/trials/nct04353375/"},{"record":"registry:hmpl-453","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/hmpl-453/#registry"},{"record":"infigratinib","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/infigratinib/","quote":"Infigratinib is an FGFR inhibitor pill given accelerated approval in the United States in 2021 for bile duct cancer with an FGFR2 fusion, then withdrawn in 2024 when its confirmatory trial could not enrol; it is now being developed for achondroplasia instead."},{"record":"infigratinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2021: Previously treated unresectable or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement (accelerated approval)","href":"/drugs/infigratinib/"},{"record":"infigratinib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/febseltiq","quote":"Febseltiq (Helsinn Birex Pharmaceuticals Ltd): marketing authorisation application withdrawn before a Commission decision. EMA register: 'Application withdrawn: The application for this medicine has been withdrawn'; checked 2026-09-24"},{"record":"infigratinib","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"US 2024-05-16: withdrawal","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma","quote":"Withdrawn: the indication came off the label 3.0 years after its accelerated approval."},{"record":"registry:infigratinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/infigratinib/#registry"},{"record":"lirafugratinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/lirafugratinib/"},{"record":"lirafugratinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2026: Previously treated unresectable, locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement","href":"/drugs/lirafugratinib/"},{"record":"lirafugratinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2026","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic"},{"record":"nct07359820","field":"status","kind":"trial","state":"development","label":"A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement: phase 2, recruiting","href":"/trials/nct07359820/"},{"record":"registry:lirafugratinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/lirafugratinib/#registry"},{"record":"pemigatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/pemigatinib/"},{"record":"pemigatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2020: Previously treated FGFR2-fusion/rearranged cholangiocarcinoma (accelerated)","href":"/drugs/pemigatinib/"},{"record":"pemigatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2021: Same","href":"/drugs/pemigatinib/"},{"record":"pemigatinib","field":"approvals[2]","kind":"approval","state":"approved","label":"UK 2021: Locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement after systemic therapy; NICE TA722 recommended 25 August 2021 with a commercial arrangement","href":"/drugs/pemigatinib/"},{"record":"pemigatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2020","href":"/regulatory/regions/"},{"record":"pemigatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2021","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/pemazyre"},{"record":"pemigatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2021","href":"https://products.mhra.gov.uk/?search=Pemazyre"},{"record":"pemigatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2021","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"pemigatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2022","href":"https://english.nmpa.gov.cn/"},{"record":"pemigatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2022","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Pemazyre"},{"record":"nct06906562","field":"status","kind":"trial","state":"development","label":"A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic: phase 2, recruiting","href":"/trials/nct06906562/"},{"record":"nct06728410","field":"status","kind":"trial","state":"development","label":"A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement: phase 2, recruiting","href":"/trials/nct06728410/"},{"record":"nct07780838","field":"status","kind":"trial","state":"development","label":"Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma: phase 2, recruiting","href":"/trials/nct07780838/"},{"record":"fight-302","field":"notes (registry whyStopped)","kind":"trial","state":"stopped","label":"FIGHT-302: phase 3, terminated or withdrawn","href":"/trials/fight-302/","quote":"The study was terminated due to lack of enrollment resulting from a change in the standard of care for the first-line treatment of patients with cholangiocarcinoma. There were no safety concerns that contributed to this decision."},{"record":"nct06530823","field":"status","kind":"trial","state":"development","label":"Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma: phase 2, planned","href":"/trials/nct06530823/"},{"record":"nct07786766","field":"status","kind":"trial","state":"development","label":"Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma: phase 2, recruiting","href":"/trials/nct07786766/"},{"record":"registry:pemigatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 15 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pemigatinib/#registry"},{"record":"tar-210","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/tar-210/"},{"record":"nct06919965","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer: phase 3, recruiting","href":"/trials/nct06919965/"},{"record":"nct06319820","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer: phase 3, recruiting","href":"/trials/nct06319820/"},{"record":"registry:tar-210","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tar-210/#registry"},{"record":"tinengotinib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/tinengotinib/"},{"record":"nct07052253","field":"status","kind":"trial","state":"development","label":"A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.: phase 2, recruiting","href":"/trials/nct07052253/"},{"record":"nct07498478","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment: phase 2, recruiting","href":"/trials/nct07498478/"},{"record":"first-308","field":"status","kind":"trial","state":"development","label":"FIRST-308: phase 3, recruiting","href":"/trials/first-308/"},{"record":"nct05948475","field":"status","kind":"trial","state":"development","label":"Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma: phase 3, active","href":"/trials/nct05948475/"},{"record":"registry:tinengotinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tinengotinib/#registry"},{"record":"tyra-300","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/tyra-300/"},{"record":"nct06995677","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer: phase 2, recruiting","href":"/trials/nct06995677/"},{"record":"nct05544552","field":"status","kind":"trial","state":"development","label":"Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations: phase 1/2, active","href":"/trials/nct05544552/"},{"record":"registry:tyra-300","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tyra-300/#registry"}],"reasons":[{"drugId":"infigratinib","drugName":"Infigratinib","drugRoute":"/drugs/infigratinib/","drugState":"stopped","record":"infigratinib","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/infigratinib/","quote":"Infigratinib is an FGFR inhibitor pill given accelerated approval in the United States in 2021 for bile duct cancer with an FGFR2 fusion, then withdrawn in 2024 when its confirmatory trial could not enrol; it is now being developed for achondroplasia instead."},{"drugId":"infigratinib","drugName":"Infigratinib","drugRoute":"/drugs/infigratinib/","drugState":"stopped","record":"infigratinib","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/febseltiq","quote":"Febseltiq (Helsinn Birex Pharmaceuticals Ltd): marketing authorisation application withdrawn before a Commission decision. EMA register: 'Application withdrawn: The application for this medicine has been withdrawn'; checked 2026-09-24"},{"drugId":"infigratinib","drugName":"Infigratinib","drugRoute":"/drugs/infigratinib/","drugState":"stopped","record":"infigratinib","kind":"event","label":"US 2024-05-16: withdrawal","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma","quote":"Withdrawn: the indication came off the label 3.0 years after its accelerated approval."},{"drugId":"pemigatinib","drugName":"Pemigatinib","drugRoute":"/drugs/pemigatinib/","drugState":"approved","record":"fight-302","kind":"trial","label":"FIGHT-302: phase 3, terminated or withdrawn","href":"/trials/fight-302/","quote":"The study was terminated due to lack of enrollment resulting from a change in the standard of care for the first-line treatment of patients with cholangiocarcinoma. There were no safety concerns that contributed to this decision."}]},{"a":{"key":"target","id":"parp","name":"PARP","href":"/targets/parp/"},"b":{"key":"mechanismClass","id":"parp-inhibitor","name":"PARP inhibitor","href":"/technologies/parp-inhibitor/"},"state":"approved","drugs":[{"id":"fluzoparib","name":"Fluzoparib","route":"/drugs/fluzoparib/","state":"approved","status":"phase-2"},{"id":"imp1734","name":"IMP1734","route":"/drugs/imp1734/","state":"development","status":"phase-2"},{"id":"iniparib","name":"Iniparib","route":"/drugs/iniparib/","state":"stopped","status":"negative"},{"id":"niraparib","name":"Niraparib","route":"/drugs/niraparib/","state":"approved","status":"approved"},{"id":"palacaparib","name":"Palacaparib","route":"/drugs/palacaparib/","state":"development","status":"phase-2"},{"id":"pamiparib","name":"Pamiparib","route":"/drugs/pamiparib/","state":"approved","status":"phase-3"},{"id":"saruparib","name":"Saruparib","route":"/drugs/saruparib/","state":"development","status":"phase-3"},{"id":"imp4927","name":"Senaparib (IMP4297)","route":"/drugs/imp4927/","state":"development","status":"phase-3"},{"id":"vb15010","name":"VB15010","route":"/drugs/vb15010/","state":"development","status":"phase-2"}],"counts":{"approved":3,"development":5,"stopped":1,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"fluzoparib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/fluzoparib/"},{"record":"fluzoparib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2020","href":"https://english.nmpa.gov.cn/"},{"record":"nct06208410","field":"status","kind":"trial","state":"development","label":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06208410/"},{"record":"nct07752550","field":"status","kind":"trial","state":"development","label":"Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer: phase 2, planned","href":"/trials/nct07752550/"},{"record":"registry:fluzoparib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 38 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/fluzoparib/#registry"},{"record":"imp1734","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/imp1734/"},{"record":"nct06253130","field":"status","kind":"trial","state":"development","label":"A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06253130/"},{"record":"registry:imp1734","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/imp1734/#registry"},{"record":"iniparib","field":"status","kind":"drug","state":"stopped","label":"Drug record status: negative","href":"/drugs/iniparib/","quote":"Billed as the first PARP inhibitor for triple-negative breast cancer, it failed its phase 3 in 2011. It turned out not to inhibit PARP at all."},{"record":"niraparib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/niraparib/"},{"record":"niraparib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2017: Recurrent ovarian cancer maintenance","href":"/drugs/niraparib/"},{"record":"niraparib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2020: First-line ovarian maintenance","href":"/drugs/niraparib/"},{"record":"niraparib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2017","href":"/regulatory/regions/"},{"record":"niraparib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2017","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zejula"},{"record":"niraparib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2017","href":"https://products.mhra.gov.uk/?search=Zejula"},{"record":"niraparib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2020","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"niraparib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2019","href":"https://english.nmpa.gov.cn/"},{"record":"niraparib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2018","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Zejula"},{"record":"nct05335993","field":"status","kind":"trial","state":"development","label":"A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.: phase 2, active","href":"/trials/nct05335993/"},{"record":"nct03602859","field":"status","kind":"trial","state":"development","label":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer: phase 3, active","href":"/trials/nct03602859/"},{"record":"nct04641247","field":"status","kind":"trial","state":"development","label":"A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study: phase 2, recruiting","href":"/trials/nct04641247/"},{"record":"nct06682780","field":"status","kind":"trial","state":"development","label":"A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours: phase 1/2, recruiting","href":"/trials/nct06682780/"},{"record":"nct06953323","field":"status","kind":"trial","state":"development","label":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06953323/"},{"record":"nct03431350","field":"status","kind":"trial","state":"development","label":"A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer: phase 2, active","href":"/trials/nct03431350/"},{"record":"nct04497844","field":"status","kind":"trial","state":"development","label":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC): phase 3, active","href":"/trials/nct04497844/"},{"record":"nct06077877","field":"status","kind":"trial","state":"development","label":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors: phase 1/2, active","href":"/trials/nct06077877/"},{"record":"nct04915755","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease: phase 3, active","href":"/trials/nct04915755/"},{"record":"nct06747845","field":"status","kind":"trial","state":"development","label":"Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy: phase 2, recruiting","href":"/trials/nct06747845/"},{"record":"nct05718323","field":"status","kind":"trial","state":"development","label":"Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC: phase 2, recruiting","href":"/trials/nct05718323/"},{"record":"nct06915025","field":"status","kind":"trial","state":"development","label":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Pat: phase 3, recruiting","href":"/trials/nct06915025/"},{"record":"safir-abc10","field":"status","kind":"trial","state":"development","label":"SAFIR-ABC10: phase 3, recruiting","href":"/trials/safir-abc10/"},{"record":"registry:niraparib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 46 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/niraparib/#registry"},{"record":"palacaparib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/palacaparib/"},{"record":"nct05123482","field":"status","kind":"trial","state":"development","label":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies: phase 1/2, recruiting","href":"/trials/nct05123482/"},{"record":"nct05797168","field":"status","kind":"trial","state":"development","label":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05797168/"},{"record":"nct07590934","field":"status","kind":"trial","state":"development","label":"Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct07590934/"},{"record":"nct07181161","field":"status","kind":"trial","state":"development","label":"Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct07181161/"},{"record":"nct05417594","field":"status","kind":"trial","state":"development","label":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies: phase 1/2, recruiting","href":"/trials/nct05417594/"},{"record":"registry:palacaparib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/palacaparib/#registry"},{"record":"pamiparib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/pamiparib/"},{"record":"pamiparib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"nct03519230","field":"status","kind":"trial","state":"development","label":"Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer: phase 3, active","href":"/trials/nct03519230/"},{"record":"registry:pamiparib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pamiparib/#registry"},{"record":"saruparib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/saruparib/"},{"record":"nct05123482","field":"status","kind":"trial","state":"development","label":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies: phase 1/2, recruiting","href":"/trials/nct05123482/"},{"record":"nct06952803","field":"status","kind":"trial","state":"development","label":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation: phase 3, recruiting","href":"/trials/nct06952803/"},{"record":"nct07336446","field":"status","kind":"trial","state":"development","label":"A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs: phase 1/2, recruiting","href":"/trials/nct07336446/"},{"record":"nct05797168","field":"status","kind":"trial","state":"development","label":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05797168/"},{"record":"nct06380751","field":"status","kind":"trial","state":"development","label":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct06380751/"},{"record":"nct06120491","field":"status","kind":"trial","state":"development","label":"Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents: phase 3, active","href":"/trials/nct06120491/"},{"record":"nct07446855","field":"status","kind":"trial","state":"development","label":"Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours: phase 1/2, recruiting","href":"/trials/nct07446855/"},{"record":"nct04644068","field":"status","kind":"trial","state":"development","label":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies: phase 1/2, active","href":"/trials/nct04644068/"},{"record":"nct05367440","field":"status","kind":"trial","state":"development","label":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer: phase 1/2, active","href":"/trials/nct05367440/"},{"record":"registry:saruparib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 10 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/saruparib/#registry"},{"record":"imp4927","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/imp4927/"},{"record":"nct04169997","field":"status","kind":"trial","state":"development","label":"A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer: phase 3, active","href":"/trials/nct04169997/"},{"record":"registry:imp4927","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/imp4927/#registry"},{"record":"vb15010","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/vb15010/"},{"record":"nct06819215","field":"status","kind":"trial","state":"development","label":"Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06819215/"},{"record":"registry:vb15010","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/vb15010/#registry"}],"reasons":[{"drugId":"iniparib","drugName":"Iniparib","drugRoute":"/drugs/iniparib/","drugState":"stopped","record":"iniparib","kind":"drug","label":"Drug record status: negative","href":"/drugs/iniparib/","quote":"Billed as the first PARP inhibitor for triple-negative breast cancer, it failed its phase 3 in 2011. It turned out not to inhibit PARP at all."}]},{"a":{"key":"target","id":"cdk4-6","name":"CDK4/6","href":"/targets/cdk4-6/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"development","drugs":[{"id":"lerociclib","name":"Lerociclib","route":"/drugs/lerociclib/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"lerociclib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/lerociclib/"},{"record":"nct05851014","field":"status","kind":"trial","state":"development","label":"A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct05851014/"},{"record":"registry:lerociclib","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 2 terminated or withdrawn studies and none active (fetched 2026-09-28)","href":"/drugs/lerociclib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"cdk4-6","name":"CDK4/6","href":"/targets/cdk4-6/"},"b":{"key":"mechanismClass","id":"cdk-inhibitor","name":"CDK inhibitor","href":"/technologies/cdk46-inhibitor/"},"state":"approved","drugs":[{"id":"abemaciclib","name":"Abemaciclib","route":"/drugs/abemaciclib/","state":"approved","status":"approved"},{"id":"atirmociclib","name":"Atirmociclib","route":"/drugs/atirmociclib/","state":"development","status":"phase-3"},{"id":"avzo-023","name":"AVZO-023","route":"/drugs/avzo-023/","state":"development","status":"phase-2"},{"id":"dalpiciclib","name":"Dalpiciclib","route":"/drugs/dalpiciclib/","state":"approved","status":"approved"},{"id":"palbociclib","name":"Palbociclib","route":"/drugs/palbociclib/","state":"approved","status":"approved"},{"id":"ribociclib","name":"Ribociclib","route":"/drugs/ribociclib/","state":"approved","status":"approved"},{"id":"tqb3616","name":"TQB3616","route":"/drugs/tqb3616/","state":"development","status":"phase-3"}],"counts":{"approved":4,"development":3,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"},{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"abemaciclib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/abemaciclib/"},{"record":"abemaciclib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2017: HR+/HER2- advanced breast cancer","href":"/drugs/abemaciclib/"},{"record":"abemaciclib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2021: Adjuvant high-risk node-positive HR+/HER2- early breast cancer","href":"/drugs/abemaciclib/"},{"record":"abemaciclib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2017","href":"/regulatory/regions/"},{"record":"abemaciclib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2018","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios"},{"record":"abemaciclib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2018","href":"https://products.mhra.gov.uk/?search=Verzenio"},{"record":"abemaciclib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2018","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"abemaciclib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2020","href":"https://english.nmpa.gov.cn/"},{"record":"abemaciclib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2019","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Verzenio"},{"record":"nct06188520","field":"status","kind":"trial","state":"development","label":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With : phase 1/2, recruiting","href":"/trials/nct06188520/"},{"record":"nct05999994","field":"status","kind":"trial","state":"development","label":"A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer: phase 2, recruiting","href":"/trials/nct05999994/"},{"record":"nct07002177","field":"status","kind":"trial","state":"development","label":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC: phase 1/2, recruiting","href":"/trials/nct07002177/"},{"record":"nct06413706","field":"status","kind":"trial","state":"development","label":"A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy: phase 2, active","href":"/trials/nct06413706/"},{"record":"nct04802759","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer: phase 1/2, recruiting","href":"/trials/nct04802759/"},{"record":"nct02107703","field":"status","kind":"trial","state":"development","label":"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer: phase 3, active","href":"/trials/nct02107703/"},{"record":"nct02763566","field":"status","kind":"trial","state":"development","label":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer: phase 3, active","href":"/trials/nct02763566/"},{"record":"nct02152631","field":"status","kind":"trial","state":"development","label":"A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer: phase 3, active","href":"/trials/nct02152631/"},{"record":"nct02747004","field":"status","kind":"trial","state":"development","label":"A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer: phase 2, active","href":"/trials/nct02747004/"},{"record":"nct05288166","field":"status","kind":"trial","state":"development","label":"A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer): phase 3, active","href":"/trials/nct05288166/"},{"record":"nct03706365","field":"status","kind":"trial","state":"development","label":"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer: phase 2/3, active","href":"/trials/nct03706365/"},{"record":"nct06065748","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer): phase 3, active","href":"/trials/nct06065748/"},{"record":"nct07100106","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer: phase 1/2, recruiting","href":"/trials/nct07100106/"},{"record":"nct07441369","field":"status","kind":"trial","state":"development","label":"Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer: phase 2, recruiting","href":"/trials/nct07441369/"},{"record":"nct06365788","field":"status","kind":"trial","state":"development","label":"Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer: phase 2, recruiting","href":"/trials/nct06365788/"},{"record":"nct05440786","field":"status","kind":"trial","state":"development","label":"CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma: phase 2, active","href":"/trials/nct05440786/"},{"record":"nct04862663","field":"status","kind":"trial","state":"development","label":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292): phase 3, active","href":"/trials/nct04862663/"},{"record":"nct05696626","field":"status","kind":"trial","state":"development","label":"Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation: phase 3, recruiting","href":"/trials/nct05696626/"},{"record":"nct07340541","field":"status","kind":"trial","state":"development","label":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies: phase 2, recruiting","href":"/trials/nct07340541/"},{"record":"nct05768139","field":"status","kind":"trial","state":"development","label":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05768139/"},{"record":"nct05735080","field":"status","kind":"trial","state":"development","label":"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer: phase 1/2, recruiting","href":"/trials/nct05735080/"},{"record":"nct05573126","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer: phase 1/2, recruiting","href":"/trials/nct05573126/"},{"record":"nct07605728","field":"status","kind":"trial","state":"development","label":"Probiotics for Abemaciclib-Induced Abdominal Discomfort.: phase 2, recruiting","href":"/trials/nct07605728/"},{"record":"nct06810544","field":"status","kind":"trial","state":"development","label":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss: phase 1/2, recruiting","href":"/trials/nct06810544/"},{"record":"nct06380751","field":"status","kind":"trial","state":"development","label":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct06380751/"},{"record":"nct05386108","field":"status","kind":"trial","state":"development","label":"Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer: phase 1/2, recruiting","href":"/trials/nct05386108/"},{"record":"nct05867251","field":"status","kind":"trial","state":"development","label":"Study of AVZO-021 in Patients With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05867251/"},{"record":"nct06760637","field":"status","kind":"trial","state":"development","label":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease: phase 3, active","href":"/trials/nct06760637/"},{"record":"nct05548127","field":"status","kind":"trial","state":"development","label":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A): phase 1/2, active","href":"/trials/nct05548127/"},{"record":"nct06813079","field":"status","kind":"trial","state":"development","label":"Using Tumor Models to Determine Treatments: phase 2, recruiting","href":"/trials/nct06813079/"},{"record":"zen-3694-abemaciclib-nut","field":"status","kind":"trial","state":"development","label":"ZEN-3694 with abemaciclib in NUT carcinoma, breast cancer and other solid tumours (NCI phase 1): phase 1, recruiting","href":"/trials/zen-3694-abemaciclib-nut/"},{"record":"registry:abemaciclib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 68 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/abemaciclib/#registry"},{"record":"atirmociclib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/atirmociclib/"},{"record":"nct05262400","field":"status","kind":"trial","state":"development","label":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors: phase 1/2, active","href":"/trials/nct05262400/"},{"record":"nct06206837","field":"status","kind":"trial","state":"development","label":"A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.: phase 1/2, active","href":"/trials/nct06206837/"},{"record":"nct06760637","field":"status","kind":"trial","state":"development","label":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease: phase 3, active","href":"/trials/nct06760637/"},{"record":"nct04606446","field":"status","kind":"trial","state":"development","label":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors: phase 2, recruiting","href":"/trials/nct04606446/"},{"record":"nct07427394","field":"status","kind":"trial","state":"development","label":"Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer: phase 2, recruiting","href":"/trials/nct07427394/"},{"record":"nct04557449","field":"status","kind":"trial","state":"development","label":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors: phase 2, active","href":"/trials/nct04557449/"},{"record":"registry:atirmociclib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/atirmociclib/#registry"},{"record":"avzo-023","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/avzo-023/"},{"record":"nct06998407","field":"status","kind":"trial","state":"development","label":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06998407/"},{"record":"registry:avzo-023","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/avzo-023/#registry"},{"record":"dalpiciclib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/dalpiciclib/"},{"record":"dalpiciclib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2021: HR-positive, HER2-negative advanced breast cancer with fulvestrant after endocrine therapy (DAWNA-1)","href":"/drugs/dalpiciclib/"},{"record":"dalpiciclib","field":"approvals[1]","kind":"approval","state":"approved","label":"China 2023: First-line HR-positive, HER2-negative advanced breast cancer with an aromatase inhibitor (DAWNA-2)","href":"/drugs/dalpiciclib/"},{"record":"dalpiciclib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"nct06208410","field":"status","kind":"trial","state":"development","label":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06208410/"},{"record":"nct06167694","field":"status","kind":"trial","state":"development","label":"Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer: phase 1/2, recruiting","href":"/trials/nct06167694/"},{"record":"nct05463601","field":"status","kind":"trial","state":"development","label":"Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer: phase 2, active","href":"/trials/nct05463601/"},{"record":"nct04842617","field":"status","kind":"trial","state":"development","label":"Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Ne: phase 3, active","href":"/trials/nct04842617/"},{"record":"registry:dalpiciclib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 54 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/dalpiciclib/#registry"},{"record":"palbociclib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/palbociclib/"},{"record":"palbociclib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2015: HR+/HER2- advanced breast cancer with endocrine therapy","href":"/drugs/palbociclib/"},{"record":"palbociclib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2026: HR+/HER2+ advanced breast cancer maintenance with anti-HER2 and endocrine therapy","href":"/drugs/palbociclib/"},{"record":"palbociclib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2015","href":"/regulatory/regions/"},{"record":"palbociclib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2016","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance"},{"record":"palbociclib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2016","href":"https://products.mhra.gov.uk/?search=Ibrance"},{"record":"palbociclib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2017","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"palbociclib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2018","href":"https://english.nmpa.gov.cn/"},{"record":"palbociclib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2017","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Ibrance"},{"record":"nct04711252","field":"status","kind":"trial","state":"development","label":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease: phase 3, active","href":"/trials/nct04711252/"},{"record":"nct06188520","field":"status","kind":"trial","state":"development","label":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With : phase 1/2, recruiting","href":"/trials/nct06188520/"},{"record":"nct07002177","field":"status","kind":"trial","state":"development","label":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC: phase 1/2, recruiting","href":"/trials/nct07002177/"},{"record":"nct05468697","field":"status","kind":"trial","state":"development","label":"A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6: phase 1/2, active","href":"/trials/nct05468697/"},{"record":"nct06065748","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer): phase 3, active","href":"/trials/nct06065748/"},{"record":"nct04862663","field":"status","kind":"trial","state":"development","label":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292): phase 3, active","href":"/trials/nct04862663/"},{"record":"nct05067530","field":"status","kind":"trial","state":"development","label":"Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a \"Window of Opportunity\" Study: phase 2, planned","href":"/trials/nct05067530/"},{"record":"nct04567420","field":"status","kind":"trial","state":"development","label":"DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE): phase 2, active","href":"/trials/nct04567420/"},{"record":"nct05768139","field":"status","kind":"trial","state":"development","label":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05768139/"},{"record":"nct05501886","field":"status","kind":"trial","state":"development","label":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1): phase 3, active","href":"/trials/nct05501886/"},{"record":"pediatric-match","field":"status","kind":"trial","state":"development","label":"NCI-COG Pediatric MATCH (APEC1621): phase platform, active","href":"/trials/pediatric-match/"},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"nct05563220","field":"status","kind":"trial","state":"development","label":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer: phase 1/2, active","href":"/trials/nct05563220/"},{"record":"pallas-penelope-b","field":"result","kind":"trial","state":"stopped","label":"PALLAS & PENELOPE-B: phase 3, negative","href":"/trials/pallas-penelope-b/","quote":"PALLAS iDFS HR 0.96; PENELOPE-B iDFS HR 0.93; both null."},{"record":"penelope-b","field":"result","kind":"trial","state":"stopped","label":"PENELOPE-B: phase 3, negative","href":"/trials/penelope-b/","quote":"One year of palbociclib added to endocrine therapy did not improve invasive disease-free survival."},{"record":"persevera","field":"result","kind":"trial","state":"stopped","label":"persevERA: phase 3, negative","href":"/trials/persevera/","quote":"PFS 33.1 vs 28.2 months, not significant."},{"record":"nct04553133","field":"status","kind":"trial","state":"development","label":"PF-07104091 as a Single Agent and in Combination Therapy: phase 2, active","href":"/trials/nct04553133/"},{"record":"nct06757634","field":"status","kind":"trial","state":"development","label":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2): phase 3, recruiting","href":"/trials/nct06757634/"},{"record":"nct06380751","field":"status","kind":"trial","state":"development","label":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct06380751/"},{"record":"nct06736704","field":"status","kind":"trial","state":"development","label":"SNV4818 in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06736704/"},{"record":"nct05226871","field":"status","kind":"trial","state":"development","label":"Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies: phase 2, active","href":"/trials/nct05226871/"},{"record":"nct05867251","field":"status","kind":"trial","state":"development","label":"Study of AVZO-021 in Patients With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05867251/"},{"record":"nct03709680","field":"status","kind":"trial","state":"development","label":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors: phase 2, active","href":"/trials/nct03709680/"},{"record":"nct06760637","field":"status","kind":"trial","state":"development","label":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease: phase 3, active","href":"/trials/nct06760637/"},{"record":"nct04606446","field":"status","kind":"trial","state":"development","label":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors: phase 2, recruiting","href":"/trials/nct04606446/"},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"nct05909397","field":"status","kind":"trial","state":"development","label":"Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer: phase 3, active","href":"/trials/nct05909397/"},{"record":"registry:palbociclib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 50 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/palbociclib/#registry"},{"record":"ribociclib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ribociclib/"},{"record":"ribociclib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2017: HR+/HER2- advanced breast cancer","href":"/drugs/ribociclib/"},{"record":"ribociclib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2024: Adjuvant stage II-III HR+/HER2- breast cancer at high risk of recurrence","href":"/drugs/ribociclib/"},{"record":"ribociclib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2017","href":"/regulatory/regions/"},{"record":"ribociclib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2017","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali"},{"record":"ribociclib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2017","href":"https://products.mhra.gov.uk/?search=Kisqali"},{"record":"ribociclib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2019","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"ribociclib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"ribociclib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2017","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Kisqali"},{"record":"nct06188520","field":"status","kind":"trial","state":"development","label":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With : phase 1/2, recruiting","href":"/trials/nct06188520/"},{"record":"nct07002177","field":"status","kind":"trial","state":"development","label":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC: phase 1/2, recruiting","href":"/trials/nct07002177/"},{"record":"nct07405801","field":"status","kind":"trial","state":"development","label":"A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer: phase 2, recruiting","href":"/trials/nct07405801/"},{"record":"nct07647328","field":"status","kind":"trial","state":"development","label":"A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct07647328/"},{"record":"nct04802759","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer: phase 1/2, recruiting","href":"/trials/nct04802759/"},{"record":"nct06065748","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer): phase 3, active","href":"/trials/nct06065748/"},{"record":"nct07054190","field":"status","kind":"trial","state":"development","label":"A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer: phase 2, recruiting","href":"/trials/nct07054190/"},{"record":"nct04862663","field":"status","kind":"trial","state":"development","label":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292): phase 3, active","href":"/trials/nct04862663/"},{"record":"nct05768139","field":"status","kind":"trial","state":"development","label":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05768139/"},{"record":"nct05563220","field":"status","kind":"trial","state":"development","label":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer: phase 1/2, active","href":"/trials/nct05563220/"},{"record":"nct07085767","field":"status","kind":"trial","state":"development","label":"Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct07085767/"},{"record":"nct06757634","field":"status","kind":"trial","state":"development","label":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2): phase 3, recruiting","href":"/trials/nct06757634/"},{"record":"nct05827081","field":"status","kind":"trial","state":"development","label":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer: phase 3, recruiting","href":"/trials/nct05827081/"},{"record":"nct05358249","field":"status","kind":"trial","state":"development","label":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation: phase 1/2, active","href":"/trials/nct05358249/"},{"record":"nct06380751","field":"status","kind":"trial","state":"development","label":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct06380751/"},{"record":"nct05867251","field":"status","kind":"trial","state":"development","label":"Study of AVZO-021 in Patients With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05867251/"},{"record":"nct06726148","field":"status","kind":"trial","state":"development","label":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06726148/"},{"record":"nct04417621","field":"status","kind":"trial","state":"development","label":"Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma: phase 2, active","href":"/trials/nct04417621/"},{"record":"nct06760637","field":"status","kind":"trial","state":"development","label":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease: phase 3, active","href":"/trials/nct06760637/"},{"record":"nct05573555","field":"status","kind":"trial","state":"development","label":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B): phase 1/2, active","href":"/trials/nct05573555/"},{"record":"registry:ribociclib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 64 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ribociclib/#registry"},{"record":"tqb3616","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/tqb3616/"},{"record":"nct06202261","field":"status","kind":"trial","state":"development","label":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer: phase 1/2, recruiting","href":"/trials/nct06202261/"},{"record":"nct05780567","field":"status","kind":"trial","state":"development","label":"Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer: phase 3, active","href":"/trials/nct05780567/"},{"record":"nct06702618","field":"status","kind":"trial","state":"development","label":"Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer: phase 2, active","href":"/trials/nct06702618/"},{"record":"nct05365178","field":"status","kind":"trial","state":"development","label":"To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer: phase 3, active","href":"/trials/nct05365178/"},{"record":"registry:tqb3616","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tqb3616/#registry"}],"reasons":[{"drugId":"palbociclib","drugName":"Palbociclib","drugRoute":"/drugs/palbociclib/","drugState":"approved","record":"pallas-penelope-b","kind":"trial","label":"PALLAS & PENELOPE-B: phase 3, negative","href":"/trials/pallas-penelope-b/","quote":"PALLAS iDFS HR 0.96; PENELOPE-B iDFS HR 0.93; both null."},{"drugId":"palbociclib","drugName":"Palbociclib","drugRoute":"/drugs/palbociclib/","drugState":"approved","record":"penelope-b","kind":"trial","label":"PENELOPE-B: phase 3, negative","href":"/trials/penelope-b/","quote":"One year of palbociclib added to endocrine therapy did not improve invasive disease-free survival."},{"drugId":"palbociclib","drugName":"Palbociclib","drugRoute":"/drugs/palbociclib/","drugState":"approved","record":"persevera","kind":"trial","label":"persevERA: phase 3, negative","href":"/trials/persevera/","quote":"PFS 33.1 vs 28.2 months, not significant."}]},{"a":{"key":"target","id":"pik3ca","name":"PIK3CA / PI3K-alpha","href":"/targets/pik3ca/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"copanlisib","name":"Copanlisib","route":"/drugs/copanlisib/","state":"stopped","status":"withdrawn"},{"id":"duvelisib","name":"Duvelisib","route":"/drugs/duvelisib/","state":"approved","status":"approved"},{"id":"idelalisib","name":"Idelalisib","route":"/drugs/idelalisib/","state":"approved","status":"approved"},{"id":"umbralisib","name":"Umbralisib","route":"/drugs/umbralisib/","state":"stopped","status":"withdrawn"}],"counts":{"approved":2,"development":0,"stopped":2,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"copanlisib","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/copanlisib/","quote":"Copanlisib is an intravenous PI3K inhibitor for relapsed follicular lymphoma, approved in 2017 and withdrawn in 2023 when its confirmatory trial failed."},{"record":"copanlisib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2017: Relapsed follicular lymphoma after ≥2 therapies","href":"/drugs/copanlisib/"},{"record":"copanlisib","field":"regional.US","kind":"regional","state":"stopped","label":"FDA (US): withdrawn 2023","href":"/regulatory/regions/","quote":"Aliqopa accelerated approval Sep 2017; withdrawn by Bayer Nov 2023 after CHRONOS-4"},{"record":"copanlisib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/aliqopa","quote":"Marketing authorisation application withdrawn before a CHMP opinion"},{"record":"copanlisib","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"US 2024-03-18: withdrawal","href":"/drugs/copanlisib/","quote":"Withdrawn: the indication came off the label 6.5 years after its accelerated approval."},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"registry:copanlisib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 11 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/copanlisib/#registry"},{"record":"duvelisib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/duvelisib/"},{"record":"duvelisib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: Relapsed/refractory CLL/SLL after ≥2 prior therapies; FL (withdrawn 2021)","href":"/drugs/duvelisib/"},{"record":"duvelisib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2021: CLL after ≥2 therapies; FL after ≥2 therapies","href":"/drugs/duvelisib/"},{"record":"duvelisib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"duvelisib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn 2026","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra","quote":"Authorised May 2021; marketing authorisation withdrawn at Secura Bio's request 16 Feb 2026 (commercial reasons)"},{"record":"duvelisib","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"US 2021-12-17: withdrawal","href":"/drugs/duvelisib/","quote":"Withdrawn: the indication came off the label 3.2 years after its accelerated approval."},{"record":"nct06522737","field":"status","kind":"trial","state":"development","label":"A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype: phase 3, recruiting","href":"/trials/nct06522737/"},{"record":"registry:duvelisib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 10 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/duvelisib/#registry"},{"record":"idelalisib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/idelalisib/"},{"record":"idelalisib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2014: Relapsed CLL with rituximab; relapsed FL and SLL (accelerated, withdrawn 2022)","href":"/drugs/idelalisib/"},{"record":"idelalisib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2014: CLL, FL","href":"/drugs/idelalisib/"},{"record":"idelalisib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2014","href":"/regulatory/regions/"},{"record":"idelalisib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2014","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig"},{"record":"idelalisib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2014","href":"https://products.mhra.gov.uk/?search=Zydelig"},{"record":"idelalisib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Zydelig"},{"record":"idelalisib","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"US 2022-02-18: withdrawal","href":"/drugs/idelalisib/","quote":"Withdrawn: the indication came off the label 7.6 years after its accelerated approval."},{"record":"nct02970318","field":"status","kind":"trial","state":"development","label":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL: phase 3, active","href":"/trials/nct02970318/"},{"record":"nct06846671","field":"status","kind":"trial","state":"development","label":"A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors: phase 3, recruiting","href":"/trials/nct06846671/"},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"registry:idelalisib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/idelalisib/#registry"},{"record":"umbralisib","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/umbralisib/","quote":"A PI3K inhibitor for marginal zone and follicular lymphoma approved in 2021 and withdrawn in 2022 after the UNITY-CLL trial suggested more deaths."},{"record":"umbralisib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2021: Relapsed marginal zone lymphoma and follicular lymphoma","href":"/drugs/umbralisib/"},{"record":"umbralisib","field":"regulatoryEvents[2]","kind":"event","state":"stopped","label":"US 2022-05-31: withdrawal","href":"/drugs/umbralisib/","quote":"Withdrawn: the indication came off the label 1.3 years after its accelerated approval."},{"record":"umbralisib","field":"regulatoryEvents[3]","kind":"event","state":"stopped","label":"US 2022-05-31: withdrawal","href":"/drugs/umbralisib/","quote":"Withdrawn: the indication came off the label 1.3 years after its accelerated approval."},{"record":"nct04624633","field":"status","kind":"trial","state":"development","label":"Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL: phase 2, active","href":"/trials/nct04624633/"},{"record":"registry:umbralisib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/umbralisib/#registry"}],"reasons":[{"drugId":"copanlisib","drugName":"Copanlisib","drugRoute":"/drugs/copanlisib/","drugState":"stopped","record":"copanlisib","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/copanlisib/","quote":"Copanlisib is an intravenous PI3K inhibitor for relapsed follicular lymphoma, approved in 2017 and withdrawn in 2023 when its confirmatory trial failed."},{"drugId":"copanlisib","drugName":"Copanlisib","drugRoute":"/drugs/copanlisib/","drugState":"stopped","record":"copanlisib","kind":"regional","label":"FDA (US): withdrawn 2023","href":"/regulatory/regions/","quote":"Aliqopa accelerated approval Sep 2017; withdrawn by Bayer Nov 2023 after CHRONOS-4"},{"drugId":"copanlisib","drugName":"Copanlisib","drugRoute":"/drugs/copanlisib/","drugState":"stopped","record":"copanlisib","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/aliqopa","quote":"Marketing authorisation application withdrawn before a CHMP opinion"},{"drugId":"copanlisib","drugName":"Copanlisib","drugRoute":"/drugs/copanlisib/","drugState":"stopped","record":"copanlisib","kind":"event","label":"US 2024-03-18: withdrawal","href":"/drugs/copanlisib/","quote":"Withdrawn: the indication came off the label 6.5 years after its accelerated approval."},{"drugId":"duvelisib","drugName":"Duvelisib","drugRoute":"/drugs/duvelisib/","drugState":"approved","record":"duvelisib","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2026","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra","quote":"Authorised May 2021; marketing authorisation withdrawn at Secura Bio's request 16 Feb 2026 (commercial reasons)"},{"drugId":"duvelisib","drugName":"Duvelisib","drugRoute":"/drugs/duvelisib/","drugState":"approved","record":"duvelisib","kind":"event","label":"US 2021-12-17: withdrawal","href":"/drugs/duvelisib/","quote":"Withdrawn: the indication came off the label 3.2 years after its accelerated approval."},{"drugId":"idelalisib","drugName":"Idelalisib","drugRoute":"/drugs/idelalisib/","drugState":"approved","record":"idelalisib","kind":"event","label":"US 2022-02-18: withdrawal","href":"/drugs/idelalisib/","quote":"Withdrawn: the indication came off the label 7.6 years after its accelerated approval."},{"drugId":"umbralisib","drugName":"Umbralisib","drugRoute":"/drugs/umbralisib/","drugState":"stopped","record":"umbralisib","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/umbralisib/","quote":"A PI3K inhibitor for marginal zone and follicular lymphoma approved in 2021 and withdrawn in 2022 after the UNITY-CLL trial suggested more deaths."},{"drugId":"umbralisib","drugName":"Umbralisib","drugRoute":"/drugs/umbralisib/","drugState":"stopped","record":"umbralisib","kind":"event","label":"US 2022-05-31: withdrawal","href":"/drugs/umbralisib/","quote":"Withdrawn: the indication came off the label 1.3 years after its accelerated approval."},{"drugId":"umbralisib","drugName":"Umbralisib","drugRoute":"/drugs/umbralisib/","drugState":"stopped","record":"umbralisib","kind":"event","label":"US 2022-05-31: withdrawal","href":"/drugs/umbralisib/","quote":"Withdrawn: the indication came off the label 1.3 years after its accelerated approval."}]},{"a":{"key":"target","id":"pik3ca","name":"PIK3CA / PI3K-alpha","href":"/targets/pik3ca/"},"b":{"key":"mechanismClass","id":"cdk-inhibitor","name":"CDK inhibitor","href":"/technologies/cdk46-inhibitor/"},"state":"development","drugs":[{"id":"tersolisib","name":"Tersolisib","route":"/drugs/tersolisib/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"tersolisib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/tersolisib/"},{"record":"pik3ca-2","field":"status","kind":"trial","state":"development","label":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA): phase 3, recruiting","href":"/trials/pik3ca-2/"},{"record":"registry:tersolisib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tersolisib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"pik3ca","name":"PIK3CA / PI3K-alpha","href":"/targets/pik3ca/"},"b":{"key":"mechanismClass","id":"pi3k-akt-mtor-inhibitor","name":"PI3K, AKT or mTOR inhibitor","href":"/technologies/pi3k-akt-mtor-inhibitors/"},"state":"approved","drugs":[{"id":"alpelisib","name":"Alpelisib","route":"/drugs/alpelisib/","state":"approved","status":"approved"},{"id":"serabelisib","name":"Serabelisib","route":"/drugs/serabelisib/","state":"development","status":"phase-2"},{"id":"zovegalisib","name":"Zovegalisib","route":"/drugs/zovegalisib/","state":"development","status":"phase-3"}],"counts":{"approved":1,"development":2,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"},{"key":"binding","id":"allosteric","name":"Allosteric"}]},"evidence":[{"record":"alpelisib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/alpelisib/"},{"record":"alpelisib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2019: PIK3CA-mutant HR+/HER2- advanced breast cancer with fulvestrant after endocrine therapy","href":"/drugs/alpelisib/"},{"record":"alpelisib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2019","href":"/regulatory/regions/"},{"record":"alpelisib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2020","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/piqray"},{"record":"alpelisib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2020","href":"https://products.mhra.gov.uk/?search=Piqray"},{"record":"alpelisib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2022","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"alpelisib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2024","href":"https://english.nmpa.gov.cn/"},{"record":"alpelisib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2020","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Piqray"},{"record":"nct05646862","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy: phase 3, recruiting","href":"/trials/nct05646862/"},{"record":"nct05948943","field":"status","kind":"trial","state":"development","label":"Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.: phase 2/3, recruiting","href":"/trials/nct05948943/"},{"record":"nct05230810","field":"status","kind":"trial","state":"development","label":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.: phase 1/2, active","href":"/trials/nct05230810/"},{"record":"nct05501886","field":"status","kind":"trial","state":"development","label":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1): phase 3, active","href":"/trials/nct05501886/"},{"record":"nct05563220","field":"status","kind":"trial","state":"development","label":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer: phase 1/2, active","href":"/trials/nct05563220/"},{"record":"nct04524000","field":"status","kind":"trial","state":"development","label":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer: phase 2, active","href":"/trials/nct04524000/"},{"record":"nct04544189","field":"status","kind":"trial","state":"development","label":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer: phase 2, active","href":"/trials/nct04544189/"},{"record":"nct04208178","field":"status","kind":"trial","state":"development","label":"Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation: phase 3, active","href":"/trials/nct04208178/"},{"record":"nct05038735","field":"status","kind":"trial","state":"development","label":"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.: phase 3, active","href":"/trials/nct05038735/"},{"record":"registry:alpelisib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 35 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/alpelisib/#registry"},{"record":"serabelisib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/serabelisib/"},{"record":"nct07558733","field":"status","kind":"trial","state":"development","label":"Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer: phase 1/2, recruiting","href":"/trials/nct07558733/"},{"record":"nct06463028","field":"status","kind":"trial","state":"development","label":"Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial : phase 2, recruiting","href":"/trials/nct06463028/"},{"record":"registry:serabelisib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/serabelisib/#registry"},{"record":"zovegalisib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/zovegalisib/"},{"record":"nct06982521","field":"status","kind":"trial","state":"development","label":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer: phase 3, recruiting","href":"/trials/nct06982521/"},{"record":"registry:zovegalisib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/zovegalisib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"idh","name":"IDH1 / IDH2","href":"/targets/idh/"},"b":{"key":"mechanismClass","id":"idh-inhibitor","name":"IDH inhibitor","href":"/technologies/idh-inhibitors/"},"state":"approved","drugs":[{"id":"enasidenib","name":"Enasidenib","route":"/drugs/enasidenib/","state":"approved","status":"approved"},{"id":"hmpl-306","name":"HMPL-306","route":"/drugs/hmpl-306/","state":"development","status":"phase-3"},{"id":"ivosidenib","name":"Ivosidenib","route":"/drugs/ivosidenib/","state":"approved","status":"approved"},{"id":"olutasidenib","name":"Olutasidenib","route":"/drugs/olutasidenib/","state":"approved","status":"approved"},{"id":"safusidenib","name":"Safusidenib","route":"/drugs/safusidenib/","state":"development","status":"phase-3"},{"id":"tqb3454","name":"TQB3454","route":"/drugs/tqb3454/","state":"development","status":"phase-3"},{"id":"vorasidenib","name":"Vorasidenib","route":"/drugs/vorasidenib/","state":"approved","status":"approved"}],"counts":{"approved":4,"development":3,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"allosteric","name":"Allosteric"},{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"enasidenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/enasidenib/"},{"record":"enasidenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2017: Relapsed/refractory IDH2-mutated AML","href":"/drugs/enasidenib/"},{"record":"enasidenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2017","href":"/regulatory/regions/"},{"record":"enasidenib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn 2021","href":"/regulatory/regions/","quote":"MAA withdrawn 2021"},{"record":"enasidenib","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"EU 2019-12-01: withdrawal","href":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_en.pdf","quote":"Marketing application withdrawn after EMA objections on efficacy"},{"record":"beat-aml-master-trial","field":"status","kind":"trial","state":"development","label":"Beat AML Master Trial: phase platform, recruiting","href":"/trials/beat-aml-master-trial/"},{"record":"registry:enasidenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 18 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/enasidenib/#registry"},{"record":"hmpl-306","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/hmpl-306/"},{"record":"nct06387069","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia: phase 3, recruiting","href":"/trials/nct06387069/"},{"record":"registry:hmpl-306","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/hmpl-306/#registry"},{"record":"ivosidenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ivosidenib/"},{"record":"ivosidenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: Relapsed/refractory IDH1-mutated AML","href":"/drugs/ivosidenib/"},{"record":"ivosidenib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2019: Newly diagnosed IDH1-mutated AML unfit for intensive chemotherapy","href":"/drugs/ivosidenib/"},{"record":"ivosidenib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2021: Previously treated IDH1-mutated cholangiocarcinoma","href":"/drugs/ivosidenib/"},{"record":"ivosidenib","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2022: Newly diagnosed IDH1-mutated AML with azacitidine (AGILE)","href":"/drugs/ivosidenib/"},{"record":"ivosidenib","field":"approvals[4]","kind":"approval","state":"approved","label":"US 2023: Relapsed/refractory IDH1-mutated MDS","href":"/drugs/ivosidenib/"},{"record":"ivosidenib","field":"approvals[5]","kind":"approval","state":"approved","label":"UK 2024: Locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation after one or more systemic treatments; NICE TA948 recommended 31 January 2024 with a commercial arrangement","href":"/drugs/ivosidenib/"},{"record":"ivosidenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"ivosidenib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2023","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tibsovo"},{"record":"ivosidenib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2023","href":"https://products.mhra.gov.uk/?search=Tibsovo"},{"record":"ivosidenib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2025","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"ivosidenib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2022","href":"https://english.nmpa.gov.cn/"},{"record":"ivosidenib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2023","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Tibsovo"},{"record":"nct05876754","field":"status","kind":"trial","state":"development","label":"An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma: phase 3, active","href":"/trials/nct05876754/"},{"record":"nct07282262","field":"status","kind":"trial","state":"development","label":"An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.: phase 2, recruiting","href":"/trials/nct07282262/"},{"record":"nct05907057","field":"status","kind":"trial","state":"development","label":"An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.: phase 3, recruiting","href":"/trials/nct05907057/"},{"record":"beat-aml-master-trial","field":"status","kind":"trial","state":"development","label":"Beat AML Master Trial: phase platform, recruiting","href":"/trials/beat-aml-master-trial/"},{"record":"nct07745296","field":"status","kind":"trial","state":"development","label":"Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer: phase 3, planned","href":"/trials/nct07745296/"},{"record":"nct06127407","field":"status","kind":"trial","state":"development","label":"Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen: phase 3, recruiting","href":"/trials/nct06127407/"},{"record":"nct06593548","field":"status","kind":"trial","state":"development","label":"Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer: phase 2, planned","href":"/trials/nct06593548/"},{"record":"pediatric-match","field":"status","kind":"trial","state":"development","label":"NCI-COG Pediatric MATCH (APEC1621): phase platform, active","href":"/trials/pediatric-match/"},{"record":"safir-abc10","field":"status","kind":"trial","state":"development","label":"SAFIR-ABC10: phase 3, recruiting","href":"/trials/safir-abc10/"},{"record":"registry:ivosidenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 37 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ivosidenib/#registry"},{"record":"olutasidenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/olutasidenib/"},{"record":"olutasidenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2022: Relapsed/refractory IDH1-mutated AML","href":"/drugs/olutasidenib/"},{"record":"olutasidenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2022","href":"/regulatory/regions/"},{"record":"nct06161974","field":"status","kind":"trial","state":"development","label":"Study of Olutasidenib and Temozolomide in HGG: phase 2, recruiting","href":"/trials/nct06161974/"},{"record":"registry:olutasidenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 11 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/olutasidenib/#registry"},{"record":"safusidenib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/safusidenib/"},{"record":"nct04458272","field":"status","kind":"trial","state":"development","label":"A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma: phase 2, active","href":"/trials/nct04458272/"},{"record":"nct05303519","field":"status","kind":"trial","state":"development","label":"SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance): phase 3, recruiting","href":"/trials/nct05303519/"},{"record":"registry:safusidenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/safusidenib/#registry"},{"record":"tqb3454","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/tqb3454/"},{"record":"nct05987358","field":"status","kind":"trial","state":"development","label":"A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma: phase 3, active","href":"/trials/nct05987358/"},{"record":"registry:tqb3454","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tqb3454/#registry"},{"record":"vorasidenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/vorasidenib/"},{"record":"vorasidenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2024: Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, age ≥12","href":"/drugs/vorasidenib/"},{"record":"vorasidenib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2025: Grade 2 IDH-mutant glioma ≥12 yrs; 17 Sep 2025","href":"/drugs/vorasidenib/"},{"record":"vorasidenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2024","href":"/regulatory/regions/"},{"record":"vorasidenib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/voranigo"},{"record":"vorasidenib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2025","href":"https://www.gov.uk/government/news/vorasidenib-approved-to-treat-patients-12-years-and-older-with-grade-2-astrocytoma-or-oligodendroglioma-with-a-susceptible-idh1-or-idh2-mutation"},{"record":"vorasidenib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2025","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Voranigo"},{"record":"registry:vorasidenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/vorasidenib/#registry"}],"reasons":[{"drugId":"enasidenib","drugName":"Enasidenib","drugRoute":"/drugs/enasidenib/","drugState":"approved","record":"enasidenib","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2021","href":"/regulatory/regions/","quote":"MAA withdrawn 2021"},{"drugId":"enasidenib","drugName":"Enasidenib","drugRoute":"/drugs/enasidenib/","drugState":"approved","record":"enasidenib","kind":"event","label":"EU 2019-12-01: withdrawal","href":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_en.pdf","quote":"Marketing application withdrawn after EMA objections on efficacy"}]},{"a":{"key":"target","id":"vegf","name":"VEGF / VEGFR","href":"/targets/vegf/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"axitinib","name":"Axitinib","route":"/drugs/axitinib/","state":"approved","status":"approved"},{"id":"cediranib","name":"Cediranib","route":"/drugs/cediranib/","state":"development","status":"phase-2"},{"id":"fruquintinib","name":"Fruquintinib","route":"/drugs/fruquintinib/","state":"approved","status":"approved"},{"id":"rivoceranib","name":"Rivoceranib (apatinib)","route":"/drugs/rivoceranib/","state":"approved","status":"approved"},{"id":"tivozanib","name":"Tivozanib","route":"/drugs/tivozanib/","state":"approved","status":"approved"},{"id":"vorolanib","name":"Vorolanib","route":"/drugs/vorolanib/","state":"approved","status":"approved"}],"counts":{"approved":5,"development":1,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"},{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"}]},"evidence":[{"record":"axitinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/axitinib/"},{"record":"axitinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2012: Advanced RCC after one prior systemic therapy","href":"/drugs/axitinib/"},{"record":"axitinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2019: First-line advanced RCC with pembrolizumab or avelumab","href":"/drugs/axitinib/"},{"record":"axitinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2012","href":"/regulatory/regions/"},{"record":"axitinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2012","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta"},{"record":"axitinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2012","href":"https://products.mhra.gov.uk/?search=Inlyta"},{"record":"axitinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2012","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"axitinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2015","href":"https://english.nmpa.gov.cn/"},{"record":"axitinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2012","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Inlyta"},{"record":"nct06962787","field":"status","kind":"trial","state":"development","label":"A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer: phase 2, recruiting","href":"/trials/nct06962787/"},{"record":"nct05805501","field":"status","kind":"trial","state":"development","label":"A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cel: phase 2, active","href":"/trials/nct05805501/"},{"record":"nct05059522","field":"status","kind":"trial","state":"development","label":"Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing: phase 3, active","href":"/trials/nct05059522/"},{"record":"nct07227415","field":"status","kind":"trial","state":"development","label":"Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With : phase 1/2, recruiting","href":"/trials/nct07227415/"},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"registry:axitinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 34 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/axitinib/#registry"},{"record":"cediranib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/cediranib/"},{"record":"cediranib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zemfirza","quote":"Zemfirza (AstraZeneca AB): marketing authorisation application for relapsed ovarian cancer withdrawn 19 Sep 2016 before a Commission decision. EMA register: 'Application withdrawn: The application for this medicine has been withdrawn'; checked 2026-09-24"},{"record":"registry:cediranib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 16 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/cediranib/#registry"},{"record":"fruquintinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/fruquintinib/"},{"record":"fruquintinib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2018: Refractory mCRC (FRESCO)","href":"/drugs/fruquintinib/"},{"record":"fruquintinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2023: Refractory mCRC after fluoropyrimidine, oxaliplatin, irinotecan, anti-VEGF, and anti-EGFR if appropriate","href":"/drugs/fruquintinib/"},{"record":"fruquintinib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2024: Previously treated metastatic colorectal cancer","href":"/drugs/fruquintinib/"},{"record":"fruquintinib","field":"approvals[3]","kind":"approval","state":"approved","label":"England (NICE) 2025: Metastatic colorectal cancer at third line or later, only when trifluridine-tipiracil with bevacizumab is unsuitable","href":"/drugs/fruquintinib/"},{"record":"fruquintinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2023","href":"/regulatory/regions/"},{"record":"fruquintinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2024","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/fruzaqla"},{"record":"fruquintinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2024","href":"https://www.gov.uk/government/news/fruquintinib-approved-to-treat-adult-patients-with-metastatic-colorectal-cancer"},{"record":"fruquintinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2024","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"fruquintinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2018","href":"https://english.nmpa.gov.cn/"},{"record":"fruquintinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2025","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Fruzaqla"},{"record":"nct06856837","field":"status","kind":"trial","state":"development","label":"- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorec: phase 2, recruiting","href":"/trials/nct06856837/"},{"record":"nct07502014","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line: phase 2, planned","href":"/trials/nct07502014/"},{"record":"nct06979908","field":"status","kind":"trial","state":"development","label":"A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal C: phase 2, recruiting","href":"/trials/nct06979908/"},{"record":"nct07591597","field":"status","kind":"trial","state":"development","label":"A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus F: phase 1/2, planned","href":"/trials/nct07591597/"},{"record":"nct07621159","field":"status","kind":"trial","state":"development","label":"A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer: phase 1/2, planned","href":"/trials/nct07621159/"},{"record":"nct07229872","field":"status","kind":"trial","state":"development","label":"A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer: phase 2, planned","href":"/trials/nct07229872/"},{"record":"nct06218888","field":"status","kind":"trial","state":"development","label":"A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Micro: phase 2, planned","href":"/trials/nct06218888/"},{"record":"nct06746545","field":"status","kind":"trial","state":"development","label":"A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.: phase 2, planned","href":"/trials/nct06746545/"},{"record":"nct06992258","field":"status","kind":"trial","state":"development","label":"A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct06992258/"},{"record":"nct07730489","field":"status","kind":"trial","state":"development","label":"A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, F: phase 3, planned","href":"/trials/nct07730489/"},{"record":"nct05867420","field":"status","kind":"trial","state":"development","label":"A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.: phase 1/2, recruiting","href":"/trials/nct05867420/"},{"record":"nct07011576","field":"status","kind":"trial","state":"development","label":"A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL): phase 2, recruiting","href":"/trials/nct07011576/"},{"record":"nct06497985","field":"status","kind":"trial","state":"development","label":"A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients: phase 3, recruiting","href":"/trials/nct06497985/"},{"record":"nct05954429","field":"status","kind":"trial","state":"development","label":"A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-cente: phase 2, recruiting","href":"/trials/nct05954429/"},{"record":"nct07235293","field":"status","kind":"trial","state":"development","label":"A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.: phase 2, recruiting","href":"/trials/nct07235293/"},{"record":"nct05405595","field":"status","kind":"trial","state":"development","label":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05405595/"},{"record":"nct07130903","field":"status","kind":"trial","state":"development","label":"Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct07130903/"},{"record":"nct06168786","field":"status","kind":"trial","state":"development","label":"Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC: phase 2, recruiting","href":"/trials/nct06168786/"},{"record":"nct06484153","field":"status","kind":"trial","state":"development","label":"Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma: phase 2, recruiting","href":"/trials/nct06484153/"},{"record":"nct07510932","field":"status","kind":"trial","state":"development","label":"Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K): phase 2, planned","href":"/trials/nct07510932/"},{"record":"nct07724223","field":"status","kind":"trial","state":"development","label":"Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC: phase 2, recruiting","href":"/trials/nct07724223/"},{"record":"nct07362836","field":"status","kind":"trial","state":"development","label":"Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS): phase 3, planned","href":"/trials/nct07362836/"},{"record":"nct07051785","field":"status","kind":"trial","state":"development","label":"Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer: phase 2, planned","href":"/trials/nct07051785/"},{"record":"nct06441565","field":"status","kind":"trial","state":"development","label":"Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer: phase 2/3, recruiting","href":"/trials/nct06441565/"},{"record":"nct06980532","field":"status","kind":"trial","state":"development","label":"Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer: phase 1/2, recruiting","href":"/trials/nct06980532/"},{"record":"nct06199973","field":"status","kind":"trial","state":"development","label":"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, : phase 3, active","href":"/trials/nct06199973/"},{"record":"nct06443671","field":"status","kind":"trial","state":"development","label":"Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer: phase 2/3, planned","href":"/trials/nct06443671/"},{"record":"nct07353268","field":"status","kind":"trial","state":"development","label":"Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerabil: phase 2, planned","href":"/trials/nct07353268/"},{"record":"nct06685276","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct06685276/"},{"record":"nct07150403","field":"status","kind":"trial","state":"development","label":"Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal: phase 2, planned","href":"/trials/nct07150403/"},{"record":"nct07515820","field":"status","kind":"trial","state":"development","label":"SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study: phase 2, planned","href":"/trials/nct07515820/"},{"record":"nct06584032","field":"status","kind":"trial","state":"development","label":"Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer: phase 3, recruiting","href":"/trials/nct06584032/"},{"record":"nct05565417","field":"status","kind":"trial","state":"development","label":"Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas: phase 1/2, active","href":"/trials/nct05565417/"},{"record":"nct05771181","field":"status","kind":"trial","state":"development","label":"Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients: phase 2, recruiting","href":"/trials/nct05771181/"},{"record":"registry:fruquintinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 55 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/fruquintinib/#registry"},{"record":"rivoceranib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/rivoceranib/"},{"record":"rivoceranib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2014: Advanced gastric or gastro-oesophageal junction adenocarcinoma after two or more lines","href":"/drugs/rivoceranib/"},{"record":"rivoceranib","field":"approvals[1]","kind":"approval","state":"approved","label":"China 2020: Advanced hepatocellular carcinoma after prior systemic therapy","href":"/drugs/rivoceranib/"},{"record":"rivoceranib","field":"approvals[2]","kind":"approval","state":"approved","label":"China 2023: First-line unresectable hepatocellular carcinoma with camrelizumab (CARES-310)","href":"/drugs/rivoceranib/"},{"record":"rivoceranib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2014","href":"https://english.nmpa.gov.cn/"},{"record":"nct05934331","field":"status","kind":"trial","state":"development","label":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study: phase 2, recruiting","href":"/trials/nct05934331/"},{"record":"nct05320692","field":"status","kind":"trial","state":"development","label":"A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma: phase 3, active","href":"/trials/nct05320692/"},{"record":"nct04639180","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recur: phase 3, active","href":"/trials/nct04639180/"},{"record":"nct06475209","field":"status","kind":"trial","state":"development","label":"Adebrelimab + Apatinib in SCLC Maintenance Therapy: phase 2, recruiting","href":"/trials/nct06475209/"},{"record":"nct05192798","field":"status","kind":"trial","state":"development","label":"Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC: phase 2, recruiting","href":"/trials/nct05192798/"},{"record":"nct05019690","field":"status","kind":"trial","state":"development","label":"Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer: phase 1/2, recruiting","href":"/trials/nct05019690/"},{"record":"nct07802184","field":"status","kind":"trial","state":"development","label":"GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC: phase 1/2, planned","href":"/trials/nct07802184/"},{"record":"nct06889688","field":"status","kind":"trial","state":"development","label":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer: phase 3, recruiting","href":"/trials/nct06889688/"},{"record":"nct07773363","field":"status","kind":"trial","state":"development","label":"Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer: phase 2, planned","href":"/trials/nct07773363/"},{"record":"nct05447702","field":"status","kind":"trial","state":"development","label":"Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC): phase 2, recruiting","href":"/trials/nct05447702/"},{"record":"nct04342910","field":"status","kind":"trial","state":"development","label":"Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC: phase 3, recruiting","href":"/trials/nct04342910/"},{"record":"registry:rivoceranib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 10 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/rivoceranib/#registry"},{"record":"tivozanib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/tivozanib/"},{"record":"tivozanib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2021: Relapsed/refractory advanced RCC after ≥2 prior systemic therapies","href":"/drugs/tivozanib/"},{"record":"tivozanib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2017: EU first (Aug 2017)","href":"/drugs/tivozanib/"},{"record":"tivozanib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2021","href":"/regulatory/regions/"},{"record":"tivozanib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2017","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/fotivda"},{"record":"tivozanib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2017","href":"https://products.mhra.gov.uk/?search=Fotivda"},{"record":"nct05000294","field":"status","kind":"trial","state":"development","label":"Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types: phase 1/2, recruiting","href":"/trials/nct05000294/"},{"record":"nct04645160","field":"status","kind":"trial","state":"development","label":"Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers: phase 1/2, recruiting","href":"/trials/nct04645160/"},{"record":"tinivo-2","field":"result","kind":"trial","state":"stopped","label":"TiNivo-2: phase 3, negative","href":"/trials/tinivo-2/","quote":"PFS HR 1.10; no benefit from nivolumab rechallenge."},{"record":"registry:tivozanib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tivozanib/#registry"},{"record":"vorolanib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/vorolanib/"},{"record":"vorolanib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2023: Advanced renal cell carcinoma after a prior tyrosine kinase inhibitor, with everolimus (June 2023)","href":"/drugs/vorolanib/"},{"record":"vorolanib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"nct07047001","field":"status","kind":"trial","state":"development","label":"Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma: phase 2, active","href":"/trials/nct07047001/"},{"record":"nct06523049","field":"status","kind":"trial","state":"development","label":"Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy: phase 2, planned","href":"/trials/nct06523049/"},{"record":"registry:vorolanib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/vorolanib/#registry"}],"reasons":[{"drugId":"cediranib","drugName":"Cediranib","drugRoute":"/drugs/cediranib/","drugState":"development","record":"cediranib","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zemfirza","quote":"Zemfirza (AstraZeneca AB): marketing authorisation application for relapsed ovarian cancer withdrawn 19 Sep 2016 before a Commission decision. EMA register: 'Application withdrawn: The application for this medicine has been withdrawn'; checked 2026-09-24"},{"drugId":"tivozanib","drugName":"Tivozanib","drugRoute":"/drugs/tivozanib/","drugState":"approved","record":"tinivo-2","kind":"trial","label":"TiNivo-2: phase 3, negative","href":"/trials/tinivo-2/","quote":"PFS HR 1.10; no benefit from nivolumab rechallenge."}]},{"a":{"key":"target","id":"vegf","name":"VEGF / VEGFR","href":"/targets/vegf/"},"b":{"key":"mechanismClass","id":"not-recorded","name":"Mechanism class not recorded"},"state":"approved","drugs":[{"id":"propranolol-hemangeol","name":"Propranolol (Hemangeol)","route":"/drugs/propranolol-hemangeol/","state":"approved","status":"established"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"propranolol-hemangeol","field":"status","kind":"drug","state":"approved","label":"Drug record status: established","href":"/drugs/propranolol-hemangeol/"},{"record":"propranolol-hemangeol","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2014: Proliferating infantile haemangioma requiring systemic therapy","href":"/drugs/propranolol-hemangeol/"},{"record":"nct07125391","field":"status","kind":"trial","state":"development","label":"Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer: phase 2, recruiting","href":"/trials/nct07125391/"},{"record":"nct03919461","field":"status","kind":"trial","state":"development","label":"Colorectal Metastasis Prevention International Trial 2: phase 2, recruiting","href":"/trials/nct03919461/"},{"record":"nct06145074","field":"status","kind":"trial","state":"development","label":"Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.: phase 2, recruiting","href":"/trials/nct06145074/"},{"record":"nct07549906","field":"status","kind":"trial","state":"development","label":"Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospecti: phase 2, planned","href":"/trials/nct07549906/"},{"record":"nct05741164","field":"status","kind":"trial","state":"development","label":"Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer: phase 2, recruiting","href":"/trials/nct05741164/"},{"record":"registry:propranolol-hemangeol","kind":"registry","state":"development","label":"ClinicalTrials.gov: 16 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/propranolol-hemangeol/#registry"}],"reasons":[]},{"a":{"key":"target","id":"alk","name":"ALK","href":"/targets/alk/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"alectinib","name":"Alectinib","route":"/drugs/alectinib/","state":"approved","status":"approved"},{"id":"brigatinib","name":"Brigatinib","route":"/drugs/brigatinib/","state":"approved","status":"approved"},{"id":"ceritinib","name":"Ceritinib","route":"/drugs/ceritinib/","state":"approved","status":"approved"},{"id":"ensartinib","name":"Ensartinib","route":"/drugs/ensartinib/","state":"approved","status":"approved"},{"id":"lorlatinib","name":"Lorlatinib","route":"/drugs/lorlatinib/","state":"approved","status":"approved"},{"id":"neladalkib","name":"Neladalkib","route":"/drugs/neladalkib/","state":"development","status":"phase-3"}],"counts":{"approved":5,"development":1,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"},{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"alectinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/alectinib/"},{"record":"alectinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2015: ALK+ NSCLC after crizotinib","href":"/drugs/alectinib/"},{"record":"alectinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2017: First-line ALK+ NSCLC","href":"/drugs/alectinib/"},{"record":"alectinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2024: Adjuvant ALK+ NSCLC after resection (stage IB ≥4 cm to IIIA)","href":"/drugs/alectinib/"},{"record":"alectinib","field":"approvals[3]","kind":"approval","state":"approved","label":"England (NICE) 2018: Untreated ALK-positive advanced non-small-cell lung cancer","href":"/drugs/alectinib/"},{"record":"alectinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2015","href":"/regulatory/regions/"},{"record":"alectinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2017","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa"},{"record":"alectinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2017","href":"https://products.mhra.gov.uk/?search=Alecensa"},{"record":"alectinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2014","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"alectinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2018","href":"https://english.nmpa.gov.cn/"},{"record":"alectinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2016","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Alecensa"},{"record":"nct05170204","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C: phase 3, active","href":"/trials/nct05170204/"},{"record":"nct04774718","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors: phase 1/2, active","href":"/trials/nct04774718/"},{"record":"nct04302025","field":"status","kind":"trial","state":"development","label":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC): phase 2, recruiting","href":"/trials/nct04302025/"},{"record":"nct03178552","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC): phase 2/3, active","href":"/trials/nct03178552/"},{"record":"alchemist","field":"status","kind":"trial","state":"development","label":"ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials): phase platform, active","href":"/trials/alchemist/"},{"record":"nct05987644","field":"status","kind":"trial","state":"development","label":"Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements: phase 1/2, recruiting","href":"/trials/nct05987644/"},{"record":"determine-trial","field":"status","kind":"trial","state":"development","label":"DETERMINE: phase platform, recruiting","href":"/trials/determine-trial/"},{"record":"nct06765109","field":"status","kind":"trial","state":"development","label":"Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC: phase 3, recruiting","href":"/trials/nct06765109/"},{"record":"nct05987956","field":"status","kind":"trial","state":"development","label":"Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms: phase 2/3, active","href":"/trials/nct05987956/"},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"nct04589845","field":"status","kind":"trial","state":"development","label":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study: phase 2, active","href":"/trials/nct04589845/"},{"record":"registry:alectinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 32 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/alectinib/#registry"},{"record":"brigatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/brigatinib/"},{"record":"brigatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2017: ALK-positive metastatic NSCLC after crizotinib","href":"/drugs/brigatinib/"},{"record":"brigatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2020: First-line ALK-positive metastatic NSCLC","href":"/drugs/brigatinib/"},{"record":"brigatinib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2018: ALK-positive NSCLC","href":"/drugs/brigatinib/"},{"record":"brigatinib","field":"approvals[3]","kind":"approval","state":"approved","label":"England (NICE) 2019: ALK-positive advanced non-small-cell lung cancer after crizotinib","href":"/drugs/brigatinib/"},{"record":"brigatinib","field":"approvals[4]","kind":"approval","state":"approved","label":"England (NICE) 2021: ALK-positive advanced non-small-cell lung cancer not previously treated with an ALK inhibitor","href":"/drugs/brigatinib/"},{"record":"brigatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2017","href":"/regulatory/regions/"},{"record":"brigatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2018","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig"},{"record":"brigatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2018","href":"https://products.mhra.gov.uk/?search=Alunbrig"},{"record":"brigatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2021","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"brigatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2022","href":"https://english.nmpa.gov.cn/"},{"record":"brigatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Alunbrig"},{"record":"intuitt-nf2","field":"status","kind":"trial","state":"development","label":"INTUITT-NF2: phase 2, recruiting","href":"/trials/intuitt-nf2/"},{"record":"nct06813079","field":"status","kind":"trial","state":"development","label":"Using Tumor Models to Determine Treatments: phase 2, recruiting","href":"/trials/nct06813079/"},{"record":"registry:brigatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 10 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/brigatinib/#registry"},{"record":"ceritinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ceritinib/"},{"record":"ceritinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2014: ALK-positive metastatic NSCLC after crizotinib","href":"/drugs/ceritinib/"},{"record":"ceritinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2017: First-line ALK-positive metastatic NSCLC","href":"/drugs/ceritinib/"},{"record":"ceritinib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2015: Conditional May 2015; full approval 2017","href":"/drugs/ceritinib/"},{"record":"ceritinib","field":"approvals[3]","kind":"approval","state":"approved","label":"England (NICE) 2018: Untreated ALK-positive advanced non-small-cell lung cancer","href":"/drugs/ceritinib/"},{"record":"ceritinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2014","href":"/regulatory/regions/"},{"record":"ceritinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia"},{"record":"ceritinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2015","href":"https://products.mhra.gov.uk/?search=Zykadia"},{"record":"ceritinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2016","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"ceritinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2018","href":"https://english.nmpa.gov.cn/"},{"record":"ceritinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Zykadia"},{"record":"nct06813079","field":"status","kind":"trial","state":"development","label":"Using Tumor Models to Determine Treatments: phase 2, recruiting","href":"/trials/nct06813079/"},{"record":"registry:ceritinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ceritinib/#registry"},{"record":"ensartinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ensartinib/"},{"record":"ensartinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2020: ALK-positive NSCLC after crizotinib","href":"/drugs/ensartinib/"},{"record":"ensartinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2024: ALK-positive locally advanced or metastatic NSCLC, ALK-inhibitor-naive","href":"/drugs/ensartinib/"},{"record":"ensartinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2024","href":"/regulatory/regions/"},{"record":"ensartinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2020","href":"https://english.nmpa.gov.cn/"},{"record":"nct06780839","field":"status","kind":"trial","state":"development","label":"Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD: phase 2, planned","href":"/trials/nct06780839/"},{"record":"nct07448116","field":"status","kind":"trial","state":"development","label":"Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.: phase 1/2, recruiting","href":"/trials/nct07448116/"},{"record":"nct06955325","field":"status","kind":"trial","state":"development","label":"Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations: phase 3, planned","href":"/trials/nct06955325/"},{"record":"registry:ensartinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 17 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ensartinib/#registry"},{"record":"lorlatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/lorlatinib/"},{"record":"lorlatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: ALK+ NSCLC after prior ALK TKI","href":"/drugs/lorlatinib/"},{"record":"lorlatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2021: First-line ALK+ NSCLC","href":"/drugs/lorlatinib/"},{"record":"lorlatinib","field":"approvals[2]","kind":"approval","state":"approved","label":"England (NICE) 2020: ALK-positive advanced non-small-cell lung cancer progressing after alectinib or ceritinib as the first ALK inhibitor, or after crizotinib and at least one other ALK inhibitor","href":"/drugs/lorlatinib/"},{"record":"lorlatinib","field":"approvals[3]","kind":"approval","state":"approved","label":"England (NICE) 2025: ALK-positive advanced non-small-cell lung cancer not previously treated with an ALK inhibitor","href":"/drugs/lorlatinib/"},{"record":"lorlatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"lorlatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2019","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/lorviqua"},{"record":"lorlatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2019","href":"https://products.mhra.gov.uk/?search=Lorbrena"},{"record":"lorlatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2018","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"lorlatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2022","href":"https://english.nmpa.gov.cn/"},{"record":"lorlatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2019","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Lorbrena"},{"record":"nct05297890","field":"status","kind":"trial","state":"development","label":"A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer: phase 2, active","href":"/trials/nct05297890/"},{"record":"anbl1531","field":"status","kind":"trial","state":"development","label":"COG ANBL1531: phase 3, active","href":"/trials/anbl1531/"},{"record":"nct06858410","field":"status","kind":"trial","state":"development","label":"Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma: phase 3, planned","href":"/trials/nct06858410/"},{"record":"registry:lorlatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 19 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/lorlatinib/#registry"},{"record":"neladalkib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/neladalkib/"},{"record":"nct06765109","field":"status","kind":"trial","state":"development","label":"Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC: phase 3, recruiting","href":"/trials/nct06765109/"},{"record":"registry:neladalkib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/neladalkib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"braf","name":"BRAF","href":"/targets/braf/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"binimetinib","name":"Binimetinib","route":"/drugs/binimetinib/","state":"approved","status":"approved"},{"id":"cobimetinib","name":"Cobimetinib","route":"/drugs/cobimetinib/","state":"approved","status":"approved"},{"id":"dabrafenib","name":"Dabrafenib","route":"/drugs/dabrafenib/","state":"approved","status":"approved"},{"id":"dabrafenib-trametinib","name":"Dabrafenib + trametinib","route":"/drugs/dabrafenib-trametinib/","state":"approved","status":"approved"},{"id":"tovorafenib","name":"Tovorafenib","route":"/drugs/tovorafenib/","state":"approved","status":"approved"},{"id":"vemurafenib","name":"Vemurafenib","route":"/drugs/vemurafenib/","state":"approved","status":"approved"}],"counts":{"approved":6,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"allosteric","name":"Allosteric"},{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"}]},"evidence":[{"record":"binimetinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/binimetinib/"},{"record":"binimetinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: BRAF V600E/K melanoma with encorafenib","href":"/drugs/binimetinib/"},{"record":"binimetinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2023: BRAF V600E metastatic NSCLC with encorafenib","href":"/drugs/binimetinib/"},{"record":"binimetinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"binimetinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2018","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/mektovi"},{"record":"binimetinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2018","href":"https://products.mhra.gov.uk/?search=Mektovi"},{"record":"binimetinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2019","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"binimetinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2019","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Mektovi"},{"record":"nct04657991","field":"status","kind":"trial","state":"development","label":"A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma: phase 3, active","href":"/trials/nct04657991/"},{"record":"nct05270044","field":"status","kind":"trial","state":"development","label":"Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.: phase 3, active","href":"/trials/nct05270044/"},{"record":"combomatch-binimetinib-folfox","field":"status","kind":"trial","state":"development","label":"ComboMATCH: FOLFOX with or without binimetinib in second-line biliary tract cancer with MAPK pathway alterations: phase 2, active","href":"/trials/combomatch-binimetinib-folfox/"},{"record":"nct03803553","field":"status","kind":"trial","state":"development","label":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer: phase 3, active","href":"/trials/nct03803553/"},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"nct05195632","field":"status","kind":"trial","state":"development","label":"Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung: phase 2, active","href":"/trials/nct05195632/"},{"record":"nct03947385","field":"status","kind":"trial","state":"development","label":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions: phase 1/2, recruiting","href":"/trials/nct03947385/"},{"record":"registry:binimetinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 32 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/binimetinib/#registry"},{"record":"cobimetinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/cobimetinib/"},{"record":"cobimetinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2015: BRAF V600 melanoma with vemurafenib","href":"/drugs/cobimetinib/"},{"record":"cobimetinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2020: With atezolizumab and vemurafenib in BRAF V600 melanoma","href":"/drugs/cobimetinib/"},{"record":"cobimetinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2022: Histiocytic neoplasms","href":"/drugs/cobimetinib/"},{"record":"cobimetinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2015","href":"/regulatory/regions/"},{"record":"cobimetinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic"},{"record":"cobimetinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2015","href":"https://products.mhra.gov.uk/?search=Cotellic"},{"record":"cobimetinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2018","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"cobimetinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2016","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Cotellic"},{"record":"nct04931342","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors: phase 2, active","href":"/trials/nct04931342/"},{"record":"nct04302025","field":"status","kind":"trial","state":"development","label":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC): phase 2, recruiting","href":"/trials/nct04302025/"},{"record":"nct07449754","field":"status","kind":"trial","state":"development","label":"Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma: phase 2, recruiting","href":"/trials/nct07449754/"},{"record":"determine-trial","field":"status","kind":"trial","state":"development","label":"DETERMINE: phase platform, recruiting","href":"/trials/determine-trial/"},{"record":"nct05768178","field":"status","kind":"trial","state":"development","label":"DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.: phase 2/3, recruiting","href":"/trials/nct05768178/"},{"record":"imblaze370","field":"result","kind":"trial","state":"stopped","label":"IMblaze370: phase 3, negative","href":"/trials/imblaze370/","quote":"Median overall survival 8.87 months with atezolizumab and cobimetinib against 8.51 months with regorafenib (hazard ratio 1.00)."},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"nct04941287","field":"status","kind":"trial","state":"development","label":"Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer: phase 2, active","href":"/trials/nct04941287/"},{"record":"nct06813079","field":"status","kind":"trial","state":"development","label":"Using Tumor Models to Determine Treatments: phase 2, recruiting","href":"/trials/nct06813079/"},{"record":"registry:cobimetinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 26 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/cobimetinib/#registry"},{"record":"dabrafenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/dabrafenib/"},{"record":"dabrafenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2013: BRAF V600E unresectable or metastatic melanoma (single agent)","href":"/drugs/dabrafenib/"},{"record":"dabrafenib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2014: With trametinib: BRAF V600E/K metastatic melanoma; later adjuvant melanoma, BRAF V600E NSCLC, anaplastic thyroid cancer, tumour-agnostic solid tumours and paediatric low-grade glioma","href":"/drugs/dabrafenib/"},{"record":"dabrafenib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2013: BRAF V600 melanoma; later NSCLC and adjuvant melanoma with trametinib","href":"/drugs/dabrafenib/"},{"record":"dabrafenib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2013","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar"},{"record":"dabrafenib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2019","href":"https://english.nmpa.gov.cn/"},{"record":"nct05585320","field":"status","kind":"trial","state":"development","label":"A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors: phase 1/2, active","href":"/trials/nct05585320/"},{"record":"nct07506109","field":"status","kind":"trial","state":"development","label":"A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colo: phase 2, recruiting","href":"/trials/nct07506109/"},{"record":"nct07440290","field":"status","kind":"trial","state":"development","label":"DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positi: phase 2/3, recruiting","href":"/trials/nct07440290/"},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"nct04940052","field":"status","kind":"trial","state":"development","label":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refracto: phase 3, active","href":"/trials/nct04940052/"},{"record":"registry:dabrafenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 39 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/dabrafenib/#registry"},{"record":"dabrafenib-trametinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/dabrafenib-trametinib/"},{"record":"dabrafenib-trametinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2014: BRAF V600E/K unresectable or metastatic melanoma, combination (accelerated; each drug alone approved 2013)","href":"/drugs/dabrafenib-trametinib/"},{"record":"dabrafenib-trametinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2017: BRAF V600E metastatic NSCLC","href":"/drugs/dabrafenib-trametinib/"},{"record":"dabrafenib-trametinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2022: BRAF V600E solid tumours, tumour-agnostic (age ≥6)","href":"/drugs/dabrafenib-trametinib/"},{"record":"dabrafenib-trametinib","field":"approvals[3]","kind":"approval","state":"approved","label":"England (NICE) 2023: BRAF V600 mutation-positive advanced non-small-cell lung cancer, first line only","href":"/drugs/dabrafenib-trametinib/"},{"record":"dabrafenib-trametinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2014","href":"/regulatory/regions/"},{"record":"dabrafenib-trametinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2013","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar"},{"record":"dabrafenib-trametinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2013","href":"https://products.mhra.gov.uk/?search=Tafinlar%20%2B%20Mekinist"},{"record":"dabrafenib-trametinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2016","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"dabrafenib-trametinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2019","href":"https://english.nmpa.gov.cn/"},{"record":"dabrafenib-trametinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2013","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Tafinlar%20%2B%20Mekinist"},{"record":"registry:dabrafenib-trametinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 39 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/dabrafenib-trametinib/#registry"},{"record":"tovorafenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/tovorafenib/"},{"record":"tovorafenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2024: Relapsed/refractory BRAF-altered paediatric low-grade glioma (accelerated)","href":"/drugs/tovorafenib/"},{"record":"tovorafenib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2026: Relapsed/refractory paediatric low-grade glioma (conditional)","href":"/drugs/tovorafenib/"},{"record":"tovorafenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2024","href":"/regulatory/regions/"},{"record":"tovorafenib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2026","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/ojemda"},{"record":"tovorafenib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2026","href":"https://products.mhra.gov.uk/?search=Ojemda"},{"record":"nct05566795","field":"status","kind":"trial","state":"development","label":"DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2): phase 3, active","href":"/trials/nct05566795/"},{"record":"registry:tovorafenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tovorafenib/#registry"},{"record":"vemurafenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/vemurafenib/"},{"record":"vemurafenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2011: Unresectable or metastatic BRAF V600E melanoma","href":"/drugs/vemurafenib/"},{"record":"vemurafenib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2017: Erdheim-Chester disease with BRAF V600 mutation","href":"/drugs/vemurafenib/"},{"record":"vemurafenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2011","href":"/regulatory/regions/"},{"record":"vemurafenib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2012","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf"},{"record":"vemurafenib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2012","href":"https://products.mhra.gov.uk/?search=Zelboraf"},{"record":"vemurafenib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2014","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"vemurafenib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2017","href":"https://english.nmpa.gov.cn/"},{"record":"vemurafenib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2012","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Zelboraf"},{"record":"nct04302025","field":"status","kind":"trial","state":"development","label":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC): phase 2, recruiting","href":"/trials/nct04302025/"},{"record":"determine-trial","field":"status","kind":"trial","state":"development","label":"DETERMINE: phase platform, recruiting","href":"/trials/determine-trial/"},{"record":"nct05768178","field":"status","kind":"trial","state":"development","label":"DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.: phase 2/3, recruiting","href":"/trials/nct05768178/"},{"record":"pediatric-match","field":"status","kind":"trial","state":"development","label":"NCI-COG Pediatric MATCH (APEC1621): phase platform, active","href":"/trials/pediatric-match/"},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"registry:vemurafenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 28 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/vemurafenib/#registry"}],"reasons":[{"drugId":"cobimetinib","drugName":"Cobimetinib","drugRoute":"/drugs/cobimetinib/","drugState":"approved","record":"imblaze370","kind":"trial","label":"IMblaze370: phase 3, negative","href":"/trials/imblaze370/","quote":"Median overall survival 8.87 months with atezolizumab and cobimetinib against 8.51 months with regorafenib (hazard ratio 1.00)."}]},{"a":{"key":"target","id":"btk","name":"BTK (Bruton tyrosine kinase)","href":"/targets/btk/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"acalabrutinib","name":"Acalabrutinib","route":"/drugs/acalabrutinib/","state":"approved","status":"approved"},{"id":"ibrutinib","name":"Ibrutinib","route":"/drugs/ibrutinib/","state":"approved","status":"approved"},{"id":"nemtabrutinib","name":"Nemtabrutinib","route":"/drugs/nemtabrutinib/","state":"development","status":"phase-3"},{"id":"orelabrutinib","name":"Orelabrutinib","route":"/drugs/orelabrutinib/","state":"approved","status":"approved"},{"id":"pirtobrutinib","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/","state":"approved","status":"approved"},{"id":"zanubrutinib","name":"Zanubrutinib","route":"/drugs/zanubrutinib/","state":"approved","status":"approved"}],"counts":{"approved":5,"development":1,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"covalent","name":"Covalent"}]},"evidence":[{"record":"acalabrutinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/acalabrutinib/"},{"record":"acalabrutinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2017: Relapsed MCL (accelerated)","href":"/drugs/acalabrutinib/"},{"record":"acalabrutinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2019: CLL/SLL, first-line and relapsed (ELEVATE-TN, ASCEND)","href":"/drugs/acalabrutinib/"},{"record":"acalabrutinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2026: Fixed-duration acalabrutinib + venetoclax, previously untreated CLL/SLL without del(17p)/TP53 (AMPLIFY)","href":"/drugs/acalabrutinib/"},{"record":"acalabrutinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2017","href":"/regulatory/regions/"},{"record":"acalabrutinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2020","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/calquence"},{"record":"acalabrutinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2020","href":"https://products.mhra.gov.uk/?search=Calquence"},{"record":"acalabrutinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2021","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"acalabrutinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"acalabrutinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2020","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Calquence"},{"record":"nct04529772","field":"status","kind":"trial","state":"development","label":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312): phase 3, active","href":"/trials/nct04529772/"},{"record":"nct05951959","field":"status","kind":"trial","state":"development","label":"A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma: phase 2, active","href":"/trials/nct05951959/"},{"record":"nct05057494","field":"status","kind":"trial","state":"development","label":"A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: phase 3, active","href":"/trials/nct05057494/"},{"record":"nct02970318","field":"status","kind":"trial","state":"development","label":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL: phase 3, active","href":"/trials/nct02970318/"},{"record":"nct02717611","field":"status","kind":"trial","state":"development","label":"A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy: phase 2, active","href":"/trials/nct02717611/"},{"record":"nct02972840","field":"status","kind":"trial","state":"development","label":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL: phase 3, active","href":"/trials/nct02972840/"},{"record":"nct07029737","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain: phase 2, recruiting","href":"/trials/nct07029737/"},{"record":"nct06428019","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL): phase 3, recruiting","href":"/trials/nct06428019/"},{"record":"nct07277231","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia: phase 3, recruiting","href":"/trials/nct07277231/"},{"record":"nct04624633","field":"status","kind":"trial","state":"development","label":"Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL: phase 2, active","href":"/trials/nct04624633/"},{"record":"nct02029443","field":"status","kind":"trial","state":"development","label":"ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia: phase 1/2, active","href":"/trials/nct02029443/"},{"record":"nct02213926","field":"status","kind":"trial","state":"development","label":"An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma: phase 2, active","href":"/trials/nct02213926/"},{"record":"nct02180724","field":"status","kind":"trial","state":"development","label":"An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia: phase 2, active","href":"/trials/nct02180724/"},{"record":"arched","field":"status","kind":"trial","state":"development","label":"ARCHED: phase 3, active","href":"/trials/arched/"},{"record":"bellwave-011","field":"status","kind":"trial","state":"development","label":"BELLWAVE-011: phase 3, recruiting","href":"/trials/bellwave-011/"},{"record":"nct07024706","field":"status","kind":"trial","state":"development","label":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab: phase 2, recruiting","href":"/trials/nct07024706/"},{"record":"nct04502394","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL: phase 1/2, recruiting","href":"/trials/nct04502394/"},{"record":"nct02477696","field":"status","kind":"trial","state":"development","label":"Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL): phase 3, active","href":"/trials/nct02477696/"},{"record":"nct02180711","field":"status","kind":"trial","state":"development","label":"Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma: phase 1/2, active","href":"/trials/nct02180711/"},{"record":"nct05952024","field":"status","kind":"trial","state":"development","label":"Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL: phase 2, recruiting","href":"/trials/nct05952024/"},{"record":"nct03932331","field":"status","kind":"trial","state":"development","label":"Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malign: phase 1/2, active","href":"/trials/nct03932331/"},{"record":"nct04075292","field":"status","kind":"trial","state":"development","label":"Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia: phase 3, active","href":"/trials/nct04075292/"},{"record":"nct04662255","field":"status","kind":"trial","state":"development","label":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL): phase 3, active","href":"/trials/nct04662255/"},{"record":"registry:acalabrutinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 67 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/acalabrutinib/#registry"},{"record":"ibrutinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ibrutinib/"},{"record":"ibrutinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2013: Relapsed mantle cell lymphoma (accelerated); first BTK inhibitor","href":"/drugs/ibrutinib/"},{"record":"ibrutinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2014: Relapsed CLL (RESONATE); del(17p) CLL","href":"/drugs/ibrutinib/"},{"record":"ibrutinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2016: First-line CLL (RESONATE-2)","href":"/drugs/ibrutinib/"},{"record":"ibrutinib","field":"approvals[3]","kind":"approval","state":"approved","label":"EU 2014: Relapsed mantle cell lymphoma; CLL after one prior therapy or with del(17p)/TP53 mutation","href":"/drugs/ibrutinib/"},{"record":"ibrutinib","field":"approvals[4]","kind":"approval","state":"approved","label":"EU 2022: Fixed-duration ibrutinib + venetoclax, first-line CLL (GLOW, CAPTIVATE)","href":"/drugs/ibrutinib/"},{"record":"ibrutinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2013","href":"/regulatory/regions/"},{"record":"ibrutinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2014","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica"},{"record":"ibrutinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2014","href":"https://products.mhra.gov.uk/?search=Imbruvica"},{"record":"ibrutinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2016","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"ibrutinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2017","href":"https://english.nmpa.gov.cn/"},{"record":"ibrutinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2015","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Imbruvica"},{"record":"ibrutinib","field":"regulatoryEvents[5]","kind":"event","state":"stopped","label":"US 2023-04-06: withdrawal","href":"/drugs/ibrutinib/","quote":"MCL and MZL indications voluntarily withdrawn after confirmatory trials missed"},{"record":"ibrutinib","field":"regulatoryEvents[6]","kind":"event","state":"stopped","label":"US 2023-05-18: withdrawal","href":"/drugs/ibrutinib/","quote":"Withdrawn: the indication came off the label 9.5 years after its accelerated approval."},{"record":"ibrutinib","field":"regulatoryEvents[7]","kind":"event","state":"stopped","label":"US 2023-05-18: withdrawal","href":"/drugs/ibrutinib/","quote":"Withdrawn: the indication came off the label 6.3 years after its accelerated approval."},{"record":"nct01804686","field":"status","kind":"trial","state":"development","label":"A Long-term Extension Study of PCI-32765 (Ibrutinib): phase 3, recruiting","href":"/trials/nct01804686/"},{"record":"nct05254743","field":"status","kind":"trial","state":"development","label":"A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): phase 3, recruiting","href":"/trials/nct05254743/"},{"record":"nct05963074","field":"status","kind":"trial","state":"development","label":"A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia: phase 2, active","href":"/trials/nct05963074/"},{"record":"nct05283720","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neopl: phase 2, active","href":"/trials/nct05283720/"},{"record":"bellwave-011","field":"status","kind":"trial","state":"development","label":"BELLWAVE-011: phase 3, recruiting","href":"/trials/bellwave-011/"},{"record":"nct03328078","field":"status","kind":"trial","state":"development","label":"CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL): phase 1/2, recruiting","href":"/trials/nct03328078/"},{"record":"nct03960840","field":"status","kind":"trial","state":"development","label":"Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL: phase 1/2, active","href":"/trials/nct03960840/"},{"record":"resolve","field":"result","kind":"trial","state":"stopped","label":"RESOLVE: phase 3, negative","href":"/trials/resolve/","quote":"Median overall survival 9.7 months with ibrutinib plus nab-paclitaxel and gemcitabine against 10.8 months with placebo (p 0.3225); progression-free survival 5.3 against 6.0 months (p below 0.0001); response 29 against 42 percent."},{"record":"nct04509700","field":"status","kind":"trial","state":"development","label":"Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465): phase 2, active","href":"/trials/nct04509700/"},{"record":"nct02477696","field":"status","kind":"trial","state":"development","label":"Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL): phase 3, active","href":"/trials/nct02477696/"},{"record":"nct04494503","field":"status","kind":"trial","state":"development","label":"Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL: phase 1/2, recruiting","href":"/trials/nct04494503/"},{"record":"nct04662255","field":"status","kind":"trial","state":"development","label":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL): phase 3, active","href":"/trials/nct04662255/"},{"record":"nct03379428","field":"status","kind":"trial","state":"development","label":"Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer: phase 1/2, active","href":"/trials/nct03379428/"},{"record":"registry:ibrutinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 29 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ibrutinib/#registry"},{"record":"nemtabrutinib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/nemtabrutinib/"},{"record":"nct03162536","field":"status","kind":"trial","state":"development","label":"A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001): phase 1/2, active","href":"/trials/nct03162536/"},{"record":"nct05947851","field":"status","kind":"trial","state":"development","label":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).: phase 3, recruiting","href":"/trials/nct05947851/"},{"record":"nct05624554","field":"status","kind":"trial","state":"development","label":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008): phase 3, active","href":"/trials/nct05624554/"},{"record":"nct05458297","field":"status","kind":"trial","state":"development","label":"A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-: phase 2, active","href":"/trials/nct05458297/"},{"record":"bellwave-011","field":"status","kind":"trial","state":"development","label":"BELLWAVE-011: phase 3, recruiting","href":"/trials/bellwave-011/"},{"record":"nct04728893","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003): phase 2, recruiting","href":"/trials/nct04728893/"},{"record":"registry:nemtabrutinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 15 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/nemtabrutinib/#registry"},{"record":"orelabrutinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/orelabrutinib/"},{"record":"orelabrutinib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2020: Relapsed or refractory CLL/SLL; relapsed or refractory mantle cell lymphoma","href":"/drugs/orelabrutinib/"},{"record":"orelabrutinib","field":"approvals[1]","kind":"approval","state":"approved","label":"China 2023: Relapsed or refractory marginal zone lymphoma","href":"/drugs/orelabrutinib/"},{"record":"orelabrutinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2020","href":"https://english.nmpa.gov.cn/"},{"record":"nct06363994","field":"status","kind":"trial","state":"development","label":"A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL: phase 3, recruiting","href":"/trials/nct06363994/"},{"record":"nct04014205","field":"status","kind":"trial","state":"development","label":"A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies: phase 1/2, active","href":"/trials/nct04014205/"},{"record":"nct06082102","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma: phase 3, recruiting","href":"/trials/nct06082102/"},{"record":"registry:orelabrutinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 58 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/orelabrutinib/#registry"},{"record":"pirtobrutinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/pirtobrutinib/"},{"record":"pirtobrutinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2023: Relapsed MCL after BTK inhibitor (accelerated, January); CLL/SLL after BTK and BCL-2 inhibitors (accelerated, December)","href":"/drugs/pirtobrutinib/"},{"record":"pirtobrutinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2025: Relapsed/refractory CLL/SLL after a covalent BTK inhibitor (traditional approval, BRUIN CLL-321)","href":"/drugs/pirtobrutinib/"},{"record":"pirtobrutinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2023","href":"/regulatory/regions/"},{"record":"pirtobrutinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2023","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/jaypirca"},{"record":"pirtobrutinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2024","href":"https://products.mhra.gov.uk/?search=Jaypirca"},{"record":"pirtobrutinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2024","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"nct06588478","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: phase 2, recruiting","href":"/trials/nct06588478/"},{"record":"nct05023980","field":"status","kind":"trial","state":"development","label":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): phase 3, active","href":"/trials/nct05023980/"},{"record":"nct05254743","field":"status","kind":"trial","state":"development","label":"A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): phase 3, recruiting","href":"/trials/nct05254743/"},{"record":"nct06973187","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: phase 3, recruiting","href":"/trials/nct06973187/"},{"record":"nct04965493","field":"status","kind":"trial","state":"development","label":"A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): phase 3, active","href":"/trials/nct04965493/"},{"record":"cadance-304","field":"status","kind":"trial","state":"development","label":"CaDAnCe-304: phase 3, recruiting","href":"/trials/cadance-304/"},{"record":"nct06252675","field":"status","kind":"trial","state":"development","label":"Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma: phase 2, recruiting","href":"/trials/nct06252675/"},{"record":"nct07162181","field":"status","kind":"trial","state":"development","label":"Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers: phase 2, active","href":"/trials/nct07162181/"},{"record":"nct04662255","field":"status","kind":"trial","state":"development","label":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL): phase 3, active","href":"/trials/nct04662255/"},{"record":"registry:pirtobrutinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 52 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pirtobrutinib/#registry"},{"record":"zanubrutinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/zanubrutinib/"},{"record":"zanubrutinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2019: Relapsed MCL (accelerated)","href":"/drugs/zanubrutinib/"},{"record":"zanubrutinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2023: CLL/SLL, all lines (SEQUOIA, ALPINE)","href":"/drugs/zanubrutinib/"},{"record":"zanubrutinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2019","href":"/regulatory/regions/"},{"record":"zanubrutinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2021","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/brukinsa"},{"record":"zanubrutinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2021","href":"https://products.mhra.gov.uk/?search=Brukinsa"},{"record":"zanubrutinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2024","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"zanubrutinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2020","href":"https://english.nmpa.gov.cn/"},{"record":"zanubrutinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2020","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Brukinsa"},{"record":"nct07271667","field":"status","kind":"trial","state":"development","label":"A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies: phase 2, recruiting","href":"/trials/nct07271667/"},{"record":"nct06375733","field":"status","kind":"trial","state":"development","label":"A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL: phase 1/2, recruiting","href":"/trials/nct06375733/"},{"record":"nct05100862","field":"status","kind":"trial","state":"development","label":"A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphom: phase 3, active","href":"/trials/nct05100862/"},{"record":"nct04170283","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib: phase 3, active","href":"/trials/nct04170283/"},{"record":"nct05952037","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia: phase 2, active","href":"/trials/nct05952037/"},{"record":"nct06634589","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies: phase 1/2, recruiting","href":"/trials/nct06634589/"},{"record":"nct07277231","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia: phase 3, recruiting","href":"/trials/nct07277231/"},{"record":"nct06637501","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia: phase 2, active","href":"/trials/nct06637501/"},{"record":"nct06742996","field":"status","kind":"trial","state":"development","label":"A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refrac: phase 3, recruiting","href":"/trials/nct06742996/"},{"record":"nct04002297","field":"status","kind":"trial","state":"development","label":"A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantl: phase 3, active","href":"/trials/nct04002297/"},{"record":"nct06697184","field":"status","kind":"trial","state":"development","label":"A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.: phase 1/2, recruiting","href":"/trials/nct06697184/"},{"record":"celestial-tncll","field":"status","kind":"trial","state":"development","label":"CELESTIAL-TNCLL: phase 3, active","href":"/trials/celestial-tncll/"},{"record":"nct04662255","field":"status","kind":"trial","state":"development","label":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL): phase 3, active","href":"/trials/nct04662255/"},{"record":"registry:zanubrutinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 67 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/zanubrutinib/#registry"}],"reasons":[{"drugId":"ibrutinib","drugName":"Ibrutinib","drugRoute":"/drugs/ibrutinib/","drugState":"approved","record":"ibrutinib","kind":"event","label":"US 2023-04-06: withdrawal","href":"/drugs/ibrutinib/","quote":"MCL and MZL indications voluntarily withdrawn after confirmatory trials missed"},{"drugId":"ibrutinib","drugName":"Ibrutinib","drugRoute":"/drugs/ibrutinib/","drugState":"approved","record":"ibrutinib","kind":"event","label":"US 2023-05-18: withdrawal","href":"/drugs/ibrutinib/","quote":"Withdrawn: the indication came off the label 9.5 years after its accelerated approval."},{"drugId":"ibrutinib","drugName":"Ibrutinib","drugRoute":"/drugs/ibrutinib/","drugState":"approved","record":"ibrutinib","kind":"event","label":"US 2023-05-18: withdrawal","href":"/drugs/ibrutinib/","quote":"Withdrawn: the indication came off the label 6.3 years after its accelerated approval."},{"drugId":"ibrutinib","drugName":"Ibrutinib","drugRoute":"/drugs/ibrutinib/","drugState":"approved","record":"resolve","kind":"trial","label":"RESOLVE: phase 3, negative","href":"/trials/resolve/","quote":"Median overall survival 9.7 months with ibrutinib plus nab-paclitaxel and gemcitabine against 10.8 months with placebo (p 0.3225); progression-free survival 5.3 against 6.0 months (p below 0.0001); response 29 against 42 percent."}]},{"a":{"key":"target","id":"her2","name":"HER2","href":"/targets/her2/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"ro7771950","name":"RO7771950","route":"/drugs/ro7771950/","state":"development","status":"phase-3"},{"id":"sevabertinib","name":"Sevabertinib","route":"/drugs/sevabertinib/","state":"approved","status":"approved"},{"id":"tucatinib","name":"Tucatinib","route":"/drugs/tucatinib/","state":"approved","status":"approved"},{"id":"zongertinib","name":"Zongertinib","route":"/drugs/zongertinib/","state":"approved","status":"approved"}],"counts":{"approved":3,"development":1,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"},{"key":"binding","id":"covalent","name":"Covalent"}]},"evidence":[{"record":"ro7771950","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/ro7771950/"},{"record":"nct05593094","field":"status","kind":"trial","state":"development","label":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced So: phase 1/2, active","href":"/trials/nct05593094/"},{"record":"nct07413939","field":"status","kind":"trial","state":"development","label":"RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive: phase 2/3, recruiting","href":"/trials/nct07413939/"},{"record":"registry:ro7771950","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/ro7771950/#registry"},{"record":"sevabertinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/sevabertinib/"},{"record":"sevabertinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2025: HER2 TKD-mutant non-squamous NSCLC after prior systemic therapy (accelerated)","href":"/drugs/sevabertinib/"},{"record":"sevabertinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2025","href":"/regulatory/regions/"},{"record":"sevabertinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2026","href":"https://www.gov.uk/government/news/sevabertinib-approved-to-treat-adults-with-her2-positive-lung-cancer-that-has-spread-or-cannot-be-removed-by-surgery"},{"record":"nct06452277","field":"status","kind":"trial","state":"development","label":"A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-sma: phase 3, recruiting","href":"/trials/nct06452277/"},{"record":"registry:sevabertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/sevabertinib/#registry"},{"record":"tucatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/tucatinib/"},{"record":"tucatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2020: HER2+ metastatic breast cancer including brain metastases, with trastuzumab and capecitabine","href":"/drugs/tucatinib/"},{"record":"tucatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2023: HER2+ RAS-wild-type mCRC with trastuzumab","href":"/drugs/tucatinib/"},{"record":"tucatinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2023: HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer that has progressed after fluoropyrimidine, oxaliplatin and irinotecan, with trastuzumab","href":"/drugs/tucatinib/"},{"record":"tucatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2020","href":"/regulatory/regions/"},{"record":"tucatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2021","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tukysa"},{"record":"tucatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2021","href":"https://products.mhra.gov.uk/?search=Tukysa"},{"record":"tucatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2026","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"tucatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"tucatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2021","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Tukysa"},{"record":"nct04538742","field":"status","kind":"trial","state":"development","label":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer: phase 1/2, active","href":"/trials/nct04538742/"},{"record":"nct06157892","field":"status","kind":"trial","state":"development","label":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors: phase 2, active","href":"/trials/nct06157892/"},{"record":"nct04721977","field":"status","kind":"trial","state":"development","label":"A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001): phase 2, active","href":"/trials/nct04721977/"},{"record":"nct05672524","field":"status","kind":"trial","state":"development","label":"A Study of Tucatinib and Trastuzumab in People With Rectal Cancer: phase 2, recruiting","href":"/trials/nct05672524/"},{"record":"nct04579380","field":"status","kind":"trial","state":"development","label":"Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations: phase 2, active","href":"/trials/nct04579380/"},{"record":"nct05190445","field":"status","kind":"trial","state":"development","label":"Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma: phase 2, active","href":"/trials/nct05190445/"},{"record":"nct05230810","field":"status","kind":"trial","state":"development","label":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.: phase 1/2, active","href":"/trials/nct05230810/"},{"record":"mountaineer-03","field":"status","kind":"trial","state":"development","label":"MOUNTAINEER-03: phase 3, recruiting","href":"/trials/mountaineer-03/"},{"record":"nct05868226","field":"status","kind":"trial","state":"development","label":"PRE-ISPY Phase I/II Oncology Platform Program: phase 1/2, recruiting","href":"/trials/nct05868226/"},{"record":"nct06686394","field":"status","kind":"trial","state":"development","label":"Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009): phase 1/2, recruiting","href":"/trials/nct06686394/"},{"record":"nct04430738","field":"status","kind":"trial","state":"development","label":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers: phase 2, active","href":"/trials/nct04430738/"},{"record":"nct05458674","field":"status","kind":"trial","state":"development","label":"Tucatinib+Trastuzumab+Eribulin in HER2+ MBC: phase 2, active","href":"/trials/nct05458674/"},{"record":"registry:tucatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 31 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tucatinib/#registry"},{"record":"zongertinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/zongertinib/"},{"record":"zongertinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2025: HER2-mutant NSCLC, previously treated (accelerated)","href":"/drugs/zongertinib/"},{"record":"zongertinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2026: First-line HER2-mutant non-squamous NSCLC","href":"/drugs/zongertinib/"},{"record":"zongertinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2025","href":"/regulatory/regions/"},{"record":"zongertinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2025","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"zongertinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2025","href":"https://english.nmpa.gov.cn/"},{"record":"nct07486817","field":"status","kind":"trial","state":"development","label":"Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab: phase 2, recruiting","href":"/trials/nct07486817/"},{"record":"nct06324357","field":"status","kind":"trial","state":"development","label":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People Wit: phase 1/2, recruiting","href":"/trials/nct06324357/"},{"record":"nct06151574","field":"status","kind":"trial","state":"development","label":"Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment: phase 3, active","href":"/trials/nct06151574/"},{"record":"nct07195695","field":"status","kind":"trial","state":"development","label":"Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati: phase 3, recruiting","href":"/trials/nct07195695/"},{"record":"nct06581432","field":"status","kind":"trial","state":"development","label":"Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations: phase 2, recruiting","href":"/trials/nct06581432/"},{"record":"registry:zongertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/zongertinib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"her2","name":"HER2","href":"/targets/her2/"},"b":{"key":"mechanismClass","id":"cdk-inhibitor","name":"CDK inhibitor","href":"/technologies/cdk46-inhibitor/"},"state":"development","drugs":[{"id":"avzo-021","name":"AVZO-021","route":"/drugs/avzo-021/","state":"development","status":"phase-2"},{"id":"pf-07248144","name":"PF-07248144","route":"/drugs/pf-07248144/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":2,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"avzo-021","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/avzo-021/"},{"record":"nct06998407","field":"status","kind":"trial","state":"development","label":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06998407/"},{"record":"nct05867251","field":"status","kind":"trial","state":"development","label":"Study of AVZO-021 in Patients With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05867251/"},{"record":"registry:avzo-021","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/avzo-021/#registry"},{"record":"pf-07248144","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/pf-07248144/"},{"record":"nct07062965","field":"status","kind":"trial","state":"development","label":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment: phase 3, recruiting","href":"/trials/nct07062965/"},{"record":"nct04606446","field":"status","kind":"trial","state":"development","label":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors: phase 2, recruiting","href":"/trials/nct04606446/"},{"record":"registry:pf-07248144","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pf-07248144/#registry"}],"reasons":[]},{"a":{"key":"target","id":"mek","name":"MEK1/2","href":"/targets/mek/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"atebimetinib","name":"Atebimetinib","route":"/drugs/atebimetinib/","state":"development","status":"phase-3"},{"id":"mirdametinib","name":"Mirdametinib","route":"/drugs/mirdametinib/","state":"approved","status":"approved"},{"id":"selumetinib","name":"Selumetinib","route":"/drugs/selumetinib/","state":"approved","status":"approved"},{"id":"tq-b3234","name":"TQ-B3234","route":"/drugs/tq-b3234/","state":"development","status":"phase-3"},{"id":"trametinib","name":"Trametinib","route":"/drugs/trametinib/","state":"approved","status":"approved"},{"id":"tunlametinib","name":"Tunlametinib","route":"/drugs/tunlametinib/","state":"approved","status":"approved"}],"counts":{"approved":4,"development":2,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"allosteric","name":"Allosteric"},{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"atebimetinib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/atebimetinib/"},{"record":"nct07562152","field":"status","kind":"trial","state":"development","label":"Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma: phase 3, recruiting","href":"/trials/nct07562152/"},{"record":"registry:atebimetinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/atebimetinib/#registry"},{"record":"mirdametinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/mirdametinib/"},{"record":"mirdametinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2025: NF1 with symptomatic plexiform neurofibromas not amenable to complete resection, adults and children 2 and over (Gomekli)","href":"/drugs/mirdametinib/"},{"record":"mirdametinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2025: Symptomatic, inoperable plexiform neurofibromas in NF1, age 2 and over (Ezmekly, conditional)","href":"/drugs/mirdametinib/"},{"record":"mirdametinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/ezmekly"},{"record":"nct06153173","field":"status","kind":"trial","state":"development","label":"Mirdametinib in Histiocytic Disorders: phase 2, recruiting","href":"/trials/nct06153173/"},{"record":"nct07237100","field":"status","kind":"trial","state":"development","label":"Mirdametinib in Patients With Advanced NF1-mutant Melanoma: phase 2, recruiting","href":"/trials/nct07237100/"},{"record":"nct07061951","field":"status","kind":"trial","state":"development","label":"Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia: phase 2, recruiting","href":"/trials/nct07061951/"},{"record":"registry:mirdametinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 12 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/mirdametinib/#registry"},{"record":"selumetinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/selumetinib/"},{"record":"selumetinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2020: NF1 with symptomatic, inoperable plexiform neurofibromas, children 2 and over (extended to adults and to age 1 and over in 2025)","href":"/drugs/selumetinib/"},{"record":"selumetinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2021: Symptomatic, inoperable plexiform neurofibromas in NF1, children 3 and over (conditional)","href":"/drugs/selumetinib/"},{"record":"selumetinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2021","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/koselugo"},{"record":"nct02151084","field":"status","kind":"trial","state":"development","label":"A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer: phase 2, active","href":"/trials/nct02151084/"},{"record":"nct01933932","field":"status","kind":"trial","state":"development","label":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral: phase 3, active","href":"/trials/nct01933932/"},{"record":"nct07619521","field":"status","kind":"trial","state":"development","label":"Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma: phase 1/2, recruiting","href":"/trials/nct07619521/"},{"record":"registry:selumetinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 28 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/selumetinib/#registry"},{"record":"tq-b3234","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/tq-b3234/"},{"record":"nct07407803","field":"status","kind":"trial","state":"development","label":"Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas: phase 3, recruiting","href":"/trials/nct07407803/"},{"record":"registry:tq-b3234","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/tq-b3234/#registry"},{"record":"trametinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/trametinib/"},{"record":"trametinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2013: BRAF V600E/K unresectable or metastatic melanoma (single agent)","href":"/drugs/trametinib/"},{"record":"trametinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2014: With dabrafenib: metastatic melanoma; later adjuvant melanoma, NSCLC, anaplastic thyroid cancer, tumour-agnostic BRAF V600E solid tumours, paediatric low-grade glioma","href":"/drugs/trametinib/"},{"record":"trametinib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2014: BRAF V600 melanoma alone or with dabrafenib; later NSCLC and adjuvant melanoma","href":"/drugs/trametinib/"},{"record":"trametinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2014","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist"},{"record":"nct05372354","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed : phase 1/2, recruiting","href":"/trials/nct05372354/"},{"record":"nct05874414","field":"status","kind":"trial","state":"development","label":"Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma: phase 1/2, recruiting","href":"/trials/nct05874414/"},{"record":"nct07440290","field":"status","kind":"trial","state":"development","label":"DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positi: phase 2/3, recruiting","href":"/trials/nct07440290/"},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"nct03899155","field":"status","kind":"trial","state":"development","label":"Pan Tumor Rollover Study: phase 2, recruiting","href":"/trials/nct03899155/"},{"record":"nct05358249","field":"status","kind":"trial","state":"development","label":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation: phase 1/2, active","href":"/trials/nct05358249/"},{"record":"nct07468071","field":"status","kind":"trial","state":"development","label":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other: phase 1/2, recruiting","href":"/trials/nct07468071/"},{"record":"nct04940052","field":"status","kind":"trial","state":"development","label":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refracto: phase 3, active","href":"/trials/nct04940052/"},{"record":"nct04417621","field":"status","kind":"trial","state":"development","label":"Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma: phase 2, active","href":"/trials/nct04417621/"},{"record":"nct06456138","field":"status","kind":"trial","state":"development","label":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC: phase 1/2, planned","href":"/trials/nct06456138/"},{"record":"nct05275374","field":"status","kind":"trial","state":"development","label":"XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation: phase 1/2, planned","href":"/trials/nct05275374/"},{"record":"registry:trametinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 41 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/trametinib/#registry"},{"record":"tunlametinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/tunlametinib/"},{"record":"tunlametinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2024: Advanced NRAS-mutant melanoma after prior immunotherapy","href":"/drugs/tunlametinib/"},{"record":"tunlametinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2024","href":"https://english.nmpa.gov.cn/"},{"record":"nct06008106","field":"status","kind":"trial","state":"development","label":"Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma: phase 3, recruiting","href":"/trials/nct06008106/"},{"record":"nct06008119","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer: phase 3, recruiting","href":"/trials/nct06008119/"},{"record":"registry:tunlametinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 10 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tunlametinib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"met","name":"MET","href":"/targets/met/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"capmatinib","name":"Capmatinib","route":"/drugs/capmatinib/","state":"approved","status":"approved"},{"id":"capmatinib-tepotinib","name":"Capmatinib & tepotinib","route":"/drugs/capmatinib-tepotinib/","state":"approved","status":"approved"},{"id":"glumetinib","name":"Glumetinib","route":"/drugs/glumetinib/","state":"approved","status":"approved"},{"id":"lam561","name":"LAM561","route":"/drugs/lam561/","state":"development","status":"phase-3"},{"id":"tepotinib","name":"Tepotinib","route":"/drugs/tepotinib/","state":"approved","status":"approved"},{"id":"vebreltinib","name":"Vebreltinib","route":"/drugs/vebreltinib/","state":"approved","status":"approved"}],"counts":{"approved":5,"development":1,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"},{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"capmatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/capmatinib/"},{"record":"capmatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2020: Metastatic NSCLC with a MET exon 14 skipping mutation (accelerated approval)","href":"/drugs/capmatinib/"},{"record":"capmatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2022","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tabrecta"},{"record":"nct05488314","field":"status","kind":"trial","state":"development","label":"A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer: phase 1/2, active","href":"/trials/nct05488314/"},{"record":"nct03040973","field":"status","kind":"trial","state":"development","label":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone: phase 2, active","href":"/trials/nct03040973/"},{"record":"registry:capmatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/capmatinib/#registry"},{"record":"capmatinib-tepotinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/capmatinib-tepotinib/"},{"record":"capmatinib-tepotinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2020: MET exon 14 skipping NSCLC (capmatinib; tepotinib 2021)","href":"/drugs/capmatinib-tepotinib/"},{"record":"capmatinib-tepotinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2022: Tepmetko 2022; Tabrecta 2022","href":"/drugs/capmatinib-tepotinib/"},{"record":"capmatinib-tepotinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2020","href":"/regulatory/regions/"},{"record":"capmatinib-tepotinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2022","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tepmetko"},{"record":"capmatinib-tepotinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2022","href":"https://products.mhra.gov.uk/?search=Tepmetko"},{"record":"capmatinib-tepotinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2020","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"capmatinib-tepotinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"capmatinib-tepotinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2021","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Tabrecta"},{"record":"glumetinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/glumetinib/"},{"record":"glumetinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2023: Locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping","href":"/drugs/glumetinib/"},{"record":"glumetinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"nct06829459","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N: phase 3, recruiting","href":"/trials/nct06829459/"},{"record":"nct04270591","field":"status","kind":"trial","state":"development","label":"Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer: phase 1/2, recruiting","href":"/trials/nct04270591/"},{"record":"nct06947291","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors: phase 2, recruiting","href":"/trials/nct06947291/"},{"record":"registry:glumetinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/glumetinib/#registry"},{"record":"lam561","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/lam561/"},{"record":"nct04250922","field":"status","kind":"trial","state":"development","label":"LAM561 With RT and TMZ for Adults With Glioblastoma: phase 2/3, active","href":"/trials/nct04250922/"},{"record":"nct04299191","field":"status","kind":"trial","state":"development","label":"Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct04299191/"},{"record":"registry:lam561","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/lam561/#registry"},{"record":"tepotinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/tepotinib/"},{"record":"tepotinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2021: Metastatic NSCLC with MET exon 14 skipping alterations","href":"/drugs/tepotinib/"},{"record":"tepotinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2022: Advanced NSCLC with MET exon 14 skipping alterations after immunotherapy or platinum chemotherapy","href":"/drugs/tepotinib/"},{"record":"tepotinib","field":"approvals[2]","kind":"approval","state":"approved","label":"JP 2020: Unresectable advanced or recurrent NSCLC with MET exon 14 skipping","href":"/drugs/tepotinib/"},{"record":"tepotinib","field":"approvals[3]","kind":"approval","state":"approved","label":"England (NICE) 2022: Advanced non-small-cell lung cancer with MET exon 14 skipping alterations","href":"/drugs/tepotinib/"},{"record":"tepotinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2022","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tepmetko"},{"record":"nct06908993","field":"status","kind":"trial","state":"development","label":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated: phase 3, recruiting","href":"/trials/nct06908993/"},{"record":"registry:tepotinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tepotinib/#registry"},{"record":"vebreltinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/vebreltinib/"},{"record":"vebreltinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2023: Locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping","href":"/drugs/vebreltinib/"},{"record":"vebreltinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"nct05989542","field":"status","kind":"trial","state":"development","label":"A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2): phase 3, recruiting","href":"/trials/nct05989542/"},{"record":"nct06105619","field":"status","kind":"trial","state":"development","label":"A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).: phase 2/3, active","href":"/trials/nct06105619/"},{"record":"nct06930794","field":"status","kind":"trial","state":"development","label":"A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive: phase 3, recruiting","href":"/trials/nct06930794/"},{"record":"nct03175224","field":"status","kind":"trial","state":"development","label":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors: phase 2, recruiting","href":"/trials/nct03175224/"},{"record":"nct07655622","field":"status","kind":"trial","state":"development","label":"Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: phase 1/2, recruiting","href":"/trials/nct07655622/"},{"record":"nct06574347","field":"status","kind":"trial","state":"development","label":"Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.: phase 2, recruiting","href":"/trials/nct06574347/"},{"record":"nct06343064","field":"status","kind":"trial","state":"development","label":"Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI: phase 1/2, recruiting","href":"/trials/nct06343064/"},{"record":"nct06970782","field":"status","kind":"trial","state":"development","label":"Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failur: phase 3, planned","href":"/trials/nct06970782/"},{"record":"registry:vebreltinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 16 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/vebreltinib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"prmt5-mtap","name":"PRMT5 (MTAP-deleted cancers)","href":"/targets/prmt5-mtap/"},"b":{"key":"mechanismClass","id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/"},"state":"development","drugs":[{"id":"anvumetostat","name":"Anvumetostat","route":"/drugs/anvumetostat/","state":"development","status":"phase-2"},{"id":"azd3470","name":"AZD3470","route":"/drugs/azd3470/","state":"development","status":"phase-2"},{"id":"navlimetostat","name":"Navlimetostat","route":"/drugs/navlimetostat/","state":"development","status":"phase-3"},{"id":"tng456","name":"TNG456","route":"/drugs/tng456/","state":"development","status":"phase-2"},{"id":"tng462","name":"TNG462","route":"/drugs/tng462/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":5,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"anvumetostat","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/anvumetostat/"},{"record":"nct06593522","field":"status","kind":"trial","state":"development","label":"A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201): phase 2, active","href":"/trials/nct06593522/"},{"record":"nct05094336","field":"status","kind":"trial","state":"development","label":"A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101): phase 1/2, active","href":"/trials/nct05094336/"},{"record":"registry:anvumetostat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/anvumetostat/#registry"},{"record":"azd3470","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/azd3470/"},{"record":"nct06130553","field":"status","kind":"trial","state":"development","label":"A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06130553/"},{"record":"nct06137144","field":"status","kind":"trial","state":"development","label":"AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.: phase 1/2, recruiting","href":"/trials/nct06137144/"},{"record":"registry:azd3470","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/azd3470/#registry"},{"record":"navlimetostat","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/navlimetostat/"},{"record":"nct07283705","field":"status","kind":"trial","state":"development","label":"A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer: phase 2, recruiting","href":"/trials/nct07283705/"},{"record":"mountaintap-30","field":"status","kind":"trial","state":"development","label":"A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30): phase 2/3, active","href":"/trials/mountaintap-30/"},{"record":"nct07063745","field":"status","kind":"trial","state":"development","label":"A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion: phase 2/3, recruiting","href":"/trials/nct07063745/"},{"record":"registry:navlimetostat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/navlimetostat/#registry"},{"record":"tng456","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/tng456/"},{"record":"nct06810544","field":"status","kind":"trial","state":"development","label":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss: phase 1/2, recruiting","href":"/trials/nct06810544/"},{"record":"registry:tng456","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/tng456/#registry"},{"record":"tng462","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/tng462/"},{"record":"nct06188702","field":"status","kind":"trial","state":"development","label":"S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP: phase 1/2, active","href":"/trials/nct06188702/"},{"record":"nct05732831","field":"status","kind":"trial","state":"development","label":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05732831/"},{"record":"nct06922591","field":"status","kind":"trial","state":"development","label":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients: phase 1/2, recruiting","href":"/trials/nct06922591/"},{"record":"registry:tng462","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tng462/#registry"}],"reasons":[]},{"a":{"key":"target","id":"bcr-abl","name":"BCR::ABL1 (Philadelphia chromosome)","href":"/targets/bcr-abl/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"bosutinib","name":"Bosutinib","route":"/drugs/bosutinib/","state":"approved","status":"approved"},{"id":"flumatinib","name":"Flumatinib","route":"/drugs/flumatinib/","state":"approved","status":"approved"},{"id":"olverembatinib","name":"Olverembatinib","route":"/drugs/olverembatinib/","state":"approved","status":"approved"}],"counts":{"approved":3,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"bosutinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/bosutinib/"},{"record":"bosutinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2012: Ph+ CML after prior TKI","href":"/drugs/bosutinib/"},{"record":"bosutinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2017: Newly diagnosed Ph+ CML chronic phase","href":"/drugs/bosutinib/"},{"record":"bosutinib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2013: Ph+ CML","href":"/drugs/bosutinib/"},{"record":"bosutinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2012","href":"/regulatory/regions/"},{"record":"bosutinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2013","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif"},{"record":"bosutinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2013","href":"https://products.mhra.gov.uk/?search=Bosulif"},{"record":"bosutinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2014","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"bosutinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Bosulif"},{"record":"nct04971226","field":"status","kind":"trial","state":"development","label":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP: phase 3, active","href":"/trials/nct04971226/"},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"registry:bosutinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/bosutinib/#registry"},{"record":"flumatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/flumatinib/"},{"record":"flumatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2019: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia, chronic phase","href":"/drugs/flumatinib/"},{"record":"flumatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2019","href":"https://english.nmpa.gov.cn/"},{"record":"olverembatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/olverembatinib/"},{"record":"olverembatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2021: Chronic myeloid leukaemia (chronic or accelerated phase) with the T315I mutation after prior tyrosine kinase inhibitors","href":"/drugs/olverembatinib/"},{"record":"olverembatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"nct06051409","field":"status","kind":"trial","state":"development","label":"A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1): phase 3, recruiting","href":"/trials/nct06051409/"},{"record":"nct06640361","field":"status","kind":"trial","state":"development","label":"A Study of Olverembatinib in SDH-deficient GIST.: phase 3, recruiting","href":"/trials/nct06640361/"},{"record":"nct04501120","field":"status","kind":"trial","state":"development","label":"Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML: phase 1/2, recruiting","href":"/trials/nct04501120/"},{"record":"nct06423911","field":"status","kind":"trial","state":"development","label":"Study of Olverembatinib (HQP1351) in Patients With CML-CP: phase 3, recruiting","href":"/trials/nct06423911/"},{"record":"registry:olverembatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 16 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/olverembatinib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"bcr-abl","name":"BCR::ABL1 (Philadelphia chromosome)","href":"/targets/bcr-abl/"},"b":{"key":"mechanismClass","id":"bcl2-inhibitor","name":"BCL-2 inhibitor","href":"/technologies/bcl2-inhibitors/"},"state":"approved","drugs":[{"id":"omacetaxine","name":"Omacetaxine mepesuccinate","route":"/drugs/omacetaxine/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"omacetaxine","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/omacetaxine/"},{"record":"omacetaxine","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2012: Chronic or accelerated phase CML resistant or intolerant to two or more TKIs (accelerated; full approval 2014)","href":"/drugs/omacetaxine/"},{"record":"omacetaxine","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tekinex","quote":"Tekinex for chronic myeloid leukaemia after imatinib failure, including T315I: marketing authorisation application withdrawn by ChemGenex 11 Jan 2011 at day 120; the CHMP's provisional view was that benefits did not outweigh risks"},{"record":"nct04501120","field":"status","kind":"trial","state":"development","label":"Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML: phase 1/2, recruiting","href":"/trials/nct04501120/"},{"record":"registry:omacetaxine","kind":"registry","state":"development","label":"ClinicalTrials.gov: 30 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/omacetaxine/#registry"}],"reasons":[{"drugId":"omacetaxine","drugName":"Omacetaxine mepesuccinate","drugRoute":"/drugs/omacetaxine/","drugState":"approved","record":"omacetaxine","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tekinex","quote":"Tekinex for chronic myeloid leukaemia after imatinib failure, including T315I: marketing authorisation application withdrawn by ChemGenex 11 Jan 2011 at day 120; the CHMP's provisional view was that benefits did not outweigh risks"}]},{"a":{"key":"target","id":"her2+egfr","name":"HER2 x EGFR","href":"/targets/her2/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/her2-tyrosine-kinase-inhibitors/"},"state":"approved","drugs":[{"id":"lapatinib","name":"Lapatinib","route":"/drugs/lapatinib/","state":"approved","status":"approved"},{"id":"neratinib","name":"Neratinib","route":"/drugs/neratinib/","state":"approved","status":"approved"},{"id":"poziotinib","name":"Poziotinib","route":"/drugs/poziotinib/","state":"stopped","status":"negative"},{"id":"pyrotinib","name":"Pyrotinib","route":"/drugs/pyrotinib/","state":"approved","status":"approved"}],"counts":{"approved":3,"development":0,"stopped":1,"unclear":0},"parts":{"binding":[{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"},{"key":"binding","id":"covalent","name":"Covalent"}]},"evidence":[{"record":"lapatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/lapatinib/"},{"record":"lapatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2007: HER2+ advanced breast cancer with capecitabine after trastuzumab","href":"/drugs/lapatinib/"},{"record":"lapatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2010: HR+/HER2+ metastatic breast cancer with letrozole","href":"/drugs/lapatinib/"},{"record":"lapatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2007","href":"/regulatory/regions/"},{"record":"lapatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2008","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb"},{"record":"lapatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2008","href":"https://products.mhra.gov.uk/?search=Tykerb"},{"record":"lapatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2009","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"lapatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2013","href":"https://english.nmpa.gov.cn/"},{"record":"lapatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2007","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Tykerb"},{"record":"nct06313983","field":"status","kind":"trial","state":"development","label":"A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct06313983/"},{"record":"registry:lapatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/lapatinib/#registry"},{"record":"neratinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/neratinib/"},{"record":"neratinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2017: Extended adjuvant HER2+ early breast cancer after trastuzumab","href":"/drugs/neratinib/"},{"record":"neratinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2020: HER2+ metastatic breast cancer with capecitabine after ≥2 anti-HER2 regimens","href":"/drugs/neratinib/"},{"record":"neratinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2017","href":"/regulatory/regions/"},{"record":"neratinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2018","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/nerlynx"},{"record":"neratinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2018","href":"https://products.mhra.gov.uk/?search=Nerlynx"},{"record":"neratinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2019","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Nerlynx"},{"record":"i-spy-2","field":"status","kind":"trial","state":"development","label":"I-SPY 2: phase platform, active","href":"/trials/i-spy-2/"},{"record":"intuitt-nf2","field":"status","kind":"trial","state":"development","label":"INTUITT-NF2: phase 2, recruiting","href":"/trials/intuitt-nf2/"},{"record":"safir-abc10","field":"status","kind":"trial","state":"development","label":"SAFIR-ABC10: phase 3, recruiting","href":"/trials/safir-abc10/"},{"record":"nct06813079","field":"status","kind":"trial","state":"development","label":"Using Tumor Models to Determine Treatments: phase 2, recruiting","href":"/trials/nct06813079/"},{"record":"registry:neratinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 24 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/neratinib/#registry"},{"record":"poziotinib","field":"status","kind":"drug","state":"stopped","label":"Drug record status: negative","href":"/drugs/poziotinib/","quote":"Poziotinib was a tablet designed to fit the awkward shape of HER2 and EGFR exon 20 mutations in lung cancer. It shrank tumours in some patients but caused severe rash and diarrhoea, and the FDA declined to approve it in 2022."},{"record":"registry:poziotinib","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 8 terminated or withdrawn studies and none active (fetched 2026-09-28)","href":"/drugs/poziotinib/#registry"},{"record":"pyrotinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/pyrotinib/"},{"record":"pyrotinib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2018: HER2+ advanced breast cancer with capecitabine","href":"/drugs/pyrotinib/"},{"record":"pyrotinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2018","href":"https://english.nmpa.gov.cn/"},{"record":"nct06208410","field":"status","kind":"trial","state":"development","label":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06208410/"},{"record":"nct03980054","field":"status","kind":"trial","state":"development","label":"A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer: phase 3, active","href":"/trials/nct03980054/"},{"record":"nct05745740","field":"status","kind":"trial","state":"development","label":"A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation: phase 1/2, planned","href":"/trials/nct05745740/"},{"record":"nct05482568","field":"status","kind":"trial","state":"development","label":"A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer: phase 1/2, recruiting","href":"/trials/nct05482568/"},{"record":"nct06015048","field":"status","kind":"trial","state":"development","label":"A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.: phase 1/2, recruiting","href":"/trials/nct06015048/"},{"record":"nct04736589","field":"status","kind":"trial","state":"development","label":"Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway: phase 3, planned","href":"/trials/nct04736589/"},{"record":"registry:pyrotinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 44 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pyrotinib/#registry"}],"reasons":[{"drugId":"poziotinib","drugName":"Poziotinib","drugRoute":"/drugs/poziotinib/","drugState":"stopped","record":"poziotinib","kind":"drug","label":"Drug record status: negative","href":"/drugs/poziotinib/","quote":"Poziotinib was a tablet designed to fit the awkward shape of HER2 and EGFR exon 20 mutations in lung cancer. It shrank tumours in some patients but caused severe rash and diarrhoea, and the FDA declined to approve it in 2022."}]},{"a":{"key":"target","id":"hdac","name":"Histone deacetylases (HDAC)","href":"/targets/hdac/"},"b":{"key":"mechanismClass","id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/"},"state":"approved","drugs":[{"id":"abt-301","name":"ABT-301","route":"/drugs/abt-301/","state":"development","status":"phase-2"},{"id":"belinostat","name":"Belinostat","route":"/drugs/belinostat/","state":"approved","status":"approved"},{"id":"resminostat","name":"Resminostat","route":"/drugs/resminostat/","state":"stopped"},{"id":"vorinostat","name":"Vorinostat","route":"/drugs/vorinostat/","state":"approved","status":"approved"}],"counts":{"approved":2,"development":1,"stopped":1,"unclear":0},"parts":{},"evidence":[{"record":"abt-301","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/abt-301/"},{"record":"nct07244705","field":"status","kind":"trial","state":"development","label":"A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC: phase 1/2, recruiting","href":"/trials/nct07244705/"},{"record":"registry:abt-301","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/abt-301/#registry"},{"record":"belinostat","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/belinostat/"},{"record":"belinostat","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2014: Relapsed/refractory peripheral T-cell lymphoma","href":"/drugs/belinostat/"},{"record":"belinostat","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2014","href":"/regulatory/regions/"},{"record":"nct04747236","field":"status","kind":"trial","state":"development","label":"Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL: phase 2, recruiting","href":"/trials/nct04747236/"},{"record":"nct06072131","field":"status","kind":"trial","state":"development","label":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL: phase 3, recruiting","href":"/trials/nct06072131/"},{"record":"registry:belinostat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/belinostat/#registry"},{"record":"resminostat","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): rejected 2025","href":"/regulatory/regions/","quote":"CHMP negative opinion 22 May 2025 on Kinselby (4SC) for advanced mycosis fungoides and Sézary syndrome"},{"record":"resminostat","field":"regulatoryEvents[0]","kind":"event","state":"stopped","label":"EU 2025-05-22: complete response letter","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/kinselby","quote":"CHMP negative opinion on Kinselby (resminostat) for advanced mycosis fungoides and Sézary syndrome"},{"record":"vorinostat","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/vorinostat/"},{"record":"vorinostat","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2006: Cutaneous manifestations of CTCL with progressive, persistent or recurrent disease after two systemic therapies","href":"/drugs/vorinostat/"},{"record":"vorinostat","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/vorinostat-msd","quote":"Vorinostat MSD for advanced cutaneous T-cell lymphoma after two systemic therapies: marketing authorisation application withdrawn by MSD 13 Feb 2009 at day 206; the CHMP found benefit not sufficiently demonstrated"},{"record":"registry:vorinostat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 13 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/vorinostat/#registry"}],"reasons":[{"drugId":"resminostat","drugName":"Resminostat","drugRoute":"/drugs/resminostat/","drugState":"stopped","record":"resminostat","kind":"regional","label":"EMA / European Commission (EU): rejected 2025","href":"/regulatory/regions/","quote":"CHMP negative opinion 22 May 2025 on Kinselby (4SC) for advanced mycosis fungoides and Sézary syndrome"},{"drugId":"resminostat","drugName":"Resminostat","drugRoute":"/drugs/resminostat/","drugState":"stopped","record":"resminostat","kind":"event","label":"EU 2025-05-22: complete response letter","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/kinselby","quote":"CHMP negative opinion on Kinselby (resminostat) for advanced mycosis fungoides and Sézary syndrome"},{"drugId":"vorinostat","drugName":"Vorinostat","drugRoute":"/drugs/vorinostat/","drugState":"approved","record":"vorinostat","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/vorinostat-msd","quote":"Vorinostat MSD for advanced cutaneous T-cell lymphoma after two systemic therapies: marketing authorisation application withdrawn by MSD 13 Feb 2009 at day 206; the CHMP found benefit not sufficiently demonstrated"}]},{"a":{"key":"target","id":"parp+brca","name":"PARP x BRCA1 / BRCA2","href":"/targets/parp/"},"b":{"key":"mechanismClass","id":"parp-inhibitor","name":"PARP inhibitor","href":"/technologies/parp-inhibitor/"},"state":"approved","drugs":[{"id":"olaparib","name":"Olaparib","route":"/drugs/olaparib/","state":"approved","status":"approved"},{"id":"rucaparib","name":"Rucaparib","route":"/drugs/rucaparib/","state":"approved","status":"approved"},{"id":"talazoparib","name":"Talazoparib","route":"/drugs/talazoparib/","state":"approved","status":"approved"},{"id":"veliparib","name":"Veliparib","route":"/drugs/veliparib/","state":"stopped","status":"negative"}],"counts":{"approved":3,"development":0,"stopped":1,"unclear":0},"parts":{},"evidence":[{"record":"olaparib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/olaparib/"},{"record":"olaparib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2014: gBRCA ovarian cancer ≥3 lines","href":"/drugs/olaparib/"},{"record":"olaparib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2018: gBRCA HER2- metastatic breast cancer","href":"/drugs/olaparib/"},{"record":"olaparib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2022: Adjuvant gBRCA high-risk HER2- early breast cancer","href":"/drugs/olaparib/"},{"record":"olaparib","field":"approvals[3]","kind":"approval","state":"approved","label":"EU 2019: Germline BRCA1/2-mutated HER2-negative locally advanced or metastatic breast cancer after an anthracycline and a taxane (OlympiAD)","href":"/drugs/olaparib/"},{"record":"olaparib","field":"approvals[4]","kind":"approval","state":"approved","label":"EU 2022: Adjuvant treatment, alone or with endocrine therapy, of germline BRCA1/2-mutated HER2-negative high-risk early breast cancer after neoadjuvant or adjuvant chemotherapy (OlympiA)","href":"/drugs/olaparib/"},{"record":"olaparib","field":"approvals[5]","kind":"approval","state":"approved","label":"UK 2023: Adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy; NICE TA886 (10 May 2023) recommends within the marketing authorisation with a commercial arrangement","href":"/drugs/olaparib/"},{"record":"olaparib","field":"approvals[6]","kind":"approval","state":"approved","label":"UK 2025: BRCA mutation-positive HER2-negative locally advanced or metastatic breast cancer after an anthracycline and a taxane; NICE TA1040 (12 February 2025) recommends with a commercial arrangement, the lowest-cost option to be used where talazoparib is also suitable","href":"/drugs/olaparib/"},{"record":"olaparib","field":"approvals[7]","kind":"approval","state":"approved","label":"US 2019: Maintenance treatment of deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of first-line platinum-based chemotherapy (POLO), with an FDA-approved companion diagnostic","href":"/drugs/olaparib/"},{"record":"olaparib","field":"approvals[8]","kind":"approval","state":"approved","label":"EU 2020: Maintenance treatment of germline BRCA1/2-mutated metastatic pancreatic adenocarcinoma that has not progressed after at least 16 weeks of platinum-based first-line chemotherapy; listed in the EMA Lynparza product information read on 24 September 2026 (extension of indication in 2020)","href":"/drugs/olaparib/"},{"record":"olaparib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2014","href":"/regulatory/regions/"},{"record":"olaparib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2014","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza"},{"record":"olaparib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2014","href":"https://products.mhra.gov.uk/?search=Lynparza"},{"record":"olaparib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2018","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"olaparib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2018","href":"https://english.nmpa.gov.cn/"},{"record":"olaparib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2016","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Lynparza"},{"record":"nct02734004","field":"status","kind":"trial","state":"development","label":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.: phase 1/2, active","href":"/trials/nct02734004/"},{"record":"nct06112379","field":"status","kind":"trial","state":"development","label":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer: phase 3, active","href":"/trials/nct06112379/"},{"record":"nct03459846","field":"status","kind":"trial","state":"development","label":"A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU): phase 2, active","href":"/trials/nct03459846/"},{"record":"nct04683679","field":"status","kind":"trial","state":"development","label":"A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negat: phase 2, recruiting","href":"/trials/nct04683679/"},{"record":"nct07024784","field":"status","kind":"trial","state":"development","label":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN1: phase 2, recruiting","href":"/trials/nct07024784/"},{"record":"nct04858334","field":"status","kind":"trial","state":"development","label":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a: phase 2, recruiting","href":"/trials/nct04858334/"},{"record":"nct07005583","field":"status","kind":"trial","state":"development","label":"Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent: phase 2, planned","href":"/trials/nct07005583/"},{"record":"nct06686030","field":"status","kind":"trial","state":"development","label":"Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer: phase 2, recruiting","href":"/trials/nct06686030/"},{"record":"nct04884360","field":"status","kind":"trial","state":"development","label":"D9319C00001- 1L OC Mono Global RCT: phase 3, active","href":"/trials/nct04884360/"},{"record":"nct03742895","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002): phase 2, active","href":"/trials/nct03742895/"},{"record":"nct06525298","field":"status","kind":"trial","state":"development","label":"EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06525298/"},{"record":"nct06909825","field":"status","kind":"trial","state":"development","label":"FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC): phase 2, active","href":"/trials/nct06909825/"},{"record":"i-spy-2","field":"status","kind":"trial","state":"development","label":"I-SPY 2: phase platform, active","href":"/trials/i-spy-2/"},{"record":"nct06419179","field":"status","kind":"trial","state":"development","label":"Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extens: phase 2, recruiting","href":"/trials/nct06419179/"},{"record":"pediatric-match","field":"status","kind":"trial","state":"development","label":"NCI-COG Pediatric MATCH (APEC1621): phase platform, active","href":"/trials/pediatric-match/"},{"record":"nct05485766","field":"status","kind":"trial","state":"development","label":"Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer: phase 2, recruiting","href":"/trials/nct05485766/"},{"record":"nct05522491","field":"status","kind":"trial","state":"development","label":"Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer: phase 2, planned","href":"/trials/nct05522491/"},{"record":"nct04042831","field":"status","kind":"trial","state":"development","label":"Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations: phase 2, active","href":"/trials/nct04042831/"},{"record":"nct01874353","field":"status","kind":"trial","state":"development","label":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy: phase 3, active","href":"/trials/nct01874353/"},{"record":"nct05222971","field":"status","kind":"trial","state":"development","label":"Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy: phase 2, recruiting","href":"/trials/nct05222971/"},{"record":"nct07486687","field":"status","kind":"trial","state":"development","label":"Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy: phase 3, planned","href":"/trials/nct07486687/"},{"record":"nct05623319","field":"status","kind":"trial","state":"development","label":"Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC): phase 2, recruiting","href":"/trials/nct05623319/"},{"record":"nct05093231","field":"status","kind":"trial","state":"development","label":"Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer: phase 2, recruiting","href":"/trials/nct05093231/"},{"record":"nct06245889","field":"status","kind":"trial","state":"development","label":"PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC: phase 2, recruiting","href":"/trials/nct06245889/"},{"record":"nct06915025","field":"status","kind":"trial","state":"development","label":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Pat: phase 3, recruiting","href":"/trials/nct06915025/"},{"record":"nct03334617","field":"status","kind":"trial","state":"development","label":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy: phase 2, active","href":"/trials/nct03334617/"},{"record":"phoenix","field":"status","kind":"trial","state":"development","label":"PHOENIX DDR/Anti-PD-L1: phase 2, recruiting","href":"/trials/phoenix/"},{"record":"nct04624204","field":"status","kind":"trial","state":"development","label":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-: phase 3, active","href":"/trials/nct04624204/"},{"record":"nct07453394","field":"status","kind":"trial","state":"development","label":"QLS5132 Combination Therapy in Advanced Solid Tumors: phase 1/2, planned","href":"/trials/nct07453394/"},{"record":"rainbo","field":"status","kind":"trial","state":"development","label":"RAINBO: phase 2/3, recruiting","href":"/trials/rainbo/"},{"record":"nct04421963","field":"status","kind":"trial","state":"development","label":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib: phase 3, active","href":"/trials/nct04421963/"},{"record":"nct05898399","field":"status","kind":"trial","state":"development","label":"Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA): phase 1/2, recruiting","href":"/trials/nct05898399/"},{"record":"nct03775486","field":"status","kind":"trial","state":"development","label":"Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION): phase 2, active","href":"/trials/nct03775486/"},{"record":"nct05933265","field":"status","kind":"trial","state":"development","label":"Study of LP-184 in Patients With Advanced Solid Tumors: phase 1/2, active","href":"/trials/nct05933265/"},{"record":"nct05498155","field":"status","kind":"trial","state":"development","label":"Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer: phase 2, active","href":"/trials/nct05498155/"},{"record":"nct02861573","field":"status","kind":"trial","state":"development","label":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365): phase 1/2, active","href":"/trials/nct02861573/"},{"record":"nct04380636","field":"status","kind":"trial","state":"development","label":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012): phase 3, active","href":"/trials/nct04380636/"},{"record":"nct05171816","field":"status","kind":"trial","state":"development","label":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort): phase 3, active","href":"/trials/nct05171816/"},{"record":"nct01081951","field":"status","kind":"trial","state":"development","label":"Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax: phase 2, active","href":"/trials/nct01081951/"},{"record":"nct06353386","field":"status","kind":"trial","state":"development","label":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A): phase 1/2, recruiting","href":"/trials/nct06353386/"},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"nct05128734","field":"status","kind":"trial","state":"development","label":"Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC): phase 2, planned","href":"/trials/nct05128734/"},{"record":"nct03330847","field":"status","kind":"trial","state":"development","label":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.: phase 2, active","href":"/trials/nct03330847/"},{"record":"nct04644289","field":"status","kind":"trial","state":"development","label":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC: phase 2, recruiting","href":"/trials/nct04644289/"},{"record":"registry:olaparib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 54 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/olaparib/#registry"},{"record":"rucaparib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/rucaparib/"},{"record":"rucaparib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2016: BRCA-mutated advanced ovarian cancer after ≥2 chemotherapies (later narrowed)","href":"/drugs/rucaparib/"},{"record":"rucaparib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2018: Maintenance in recurrent ovarian cancer after platinum response (now BRCA-mutated only)","href":"/drugs/rucaparib/"},{"record":"rucaparib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2020: BRCA-mutated mCRPC after ARPI and taxane","href":"/drugs/rucaparib/"},{"record":"rucaparib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2016","href":"/regulatory/regions/"},{"record":"rucaparib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2018","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/rubraca"},{"record":"rucaparib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2018","href":"https://products.mhra.gov.uk/?search=Rubraca"},{"record":"rucaparib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2020","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Rubraca"},{"record":"rucaparib","field":"regulatoryEvents[4]","kind":"event","state":"stopped","label":"US 2022-12-11: withdrawal","href":"/drugs/rucaparib/","quote":"Clovis Oncology bankruptcy; asset sold to pharma&"},{"record":"registry:rucaparib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 9 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/rucaparib/#registry"},{"record":"talazoparib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/talazoparib/"},{"record":"talazoparib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: gBRCA HER2- locally advanced/metastatic breast cancer","href":"/drugs/talazoparib/"},{"record":"talazoparib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2023: HRR-mutant mCRPC with enzalutamide","href":"/drugs/talazoparib/"},{"record":"talazoparib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2019: Germline BRCA1/2-mutated HER2-negative locally advanced or metastatic breast cancer (EMBRACA); marketing authorisation issued 20 June 2019","href":"/drugs/talazoparib/"},{"record":"talazoparib","field":"approvals[3]","kind":"approval","state":"approved","label":"UK 2024: HER2-negative locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations after an anthracycline or a taxane; NICE TA952 (21 February 2024) recommends within the marketing authorisation with a commercial arrangement","href":"/drugs/talazoparib/"},{"record":"talazoparib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"talazoparib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2019","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/talzenna"},{"record":"talazoparib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2019","href":"https://products.mhra.gov.uk/?search=Talzenna"},{"record":"talazoparib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2024","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"talazoparib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"talazoparib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2019","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Talzenna"},{"record":"nct05059522","field":"status","kind":"trial","state":"development","label":"Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing: phase 3, active","href":"/trials/nct05059522/"},{"record":"nct05035745","field":"status","kind":"trial","state":"development","label":"Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START): phase 1/2, recruiting","href":"/trials/nct05035745/"},{"record":"nct04821622","field":"status","kind":"trial","state":"development","label":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC: phase 3, active","href":"/trials/nct04821622/"},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"registry:talazoparib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 34 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/talazoparib/#registry"},{"record":"veliparib","field":"status","kind":"drug","state":"stopped","label":"Drug record status: negative","href":"/drugs/veliparib/","quote":"Veliparib is a PARP inhibitor that AbbVie tested with chemotherapy in breast cancer. It added nothing to carboplatin before surgery (BrighTNess) and lengthened progression-free but not overall survival with carboplatin and paclitaxel in inherited BRCA advanced disease (BROCADE3), so it was never licensed."},{"record":"registry:veliparib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/veliparib/#registry"}],"reasons":[{"drugId":"rucaparib","drugName":"Rucaparib","drugRoute":"/drugs/rucaparib/","drugState":"approved","record":"rucaparib","kind":"event","label":"US 2022-12-11: withdrawal","href":"/drugs/rucaparib/","quote":"Clovis Oncology bankruptcy; asset sold to pharma&"},{"drugId":"veliparib","drugName":"Veliparib","drugRoute":"/drugs/veliparib/","drugState":"stopped","record":"veliparib","kind":"drug","label":"Drug record status: negative","href":"/drugs/veliparib/","quote":"Veliparib is a PARP inhibitor that AbbVie tested with chemotherapy in breast cancer. It added nothing to carboplatin before surgery (BrighTNess) and lengthened progression-free but not overall survival with carboplatin and paclitaxel in inherited BRCA advanced disease (BROCADE3), so it was never licensed."}]},{"a":{"key":"target","id":"smoothened","name":"Smoothened (hedgehog pathway)","href":"/targets/smoothened/"},"b":{"key":"mechanismClass","id":"hedgehog-inhibitor","name":"Hedgehog inhibitor","href":"/technologies/hedgehog-inhibitors/"},"state":"approved","drugs":[{"id":"glasdegib","name":"Glasdegib","route":"/drugs/glasdegib/","state":"approved","status":"approved"},{"id":"patidegib","name":"Patidegib","route":"/drugs/patidegib/","state":"development","status":"phase-3"},{"id":"sonidegib","name":"Sonidegib","route":"/drugs/sonidegib/","state":"approved","status":"approved"},{"id":"vismodegib","name":"Vismodegib","route":"/drugs/vismodegib/","state":"approved","status":"approved"}],"counts":{"approved":3,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"glasdegib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/glasdegib/"},{"record":"glasdegib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: Newly diagnosed AML in adults ≥75 or unfit for intensive chemotherapy, with low-dose cytarabine","href":"/drugs/glasdegib/"},{"record":"glasdegib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2020: Same","href":"/drugs/glasdegib/"},{"record":"glasdegib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"glasdegib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2020","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/daurismo"},{"record":"glasdegib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2020","href":"https://products.mhra.gov.uk/?search=Daurismo"},{"record":"registry:glasdegib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/glasdegib/#registry"},{"record":"patidegib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/patidegib/"},{"record":"registry:patidegib","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 2 terminated or withdrawn studies and none active (fetched 2026-09-28)","href":"/drugs/patidegib/#registry"},{"record":"sonidegib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/sonidegib/"},{"record":"sonidegib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2015: Locally advanced BCC recurrent after surgery or radiation, or not candidates","href":"/drugs/sonidegib/"},{"record":"sonidegib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2015: Same","href":"/drugs/sonidegib/"},{"record":"sonidegib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2015","href":"/regulatory/regions/"},{"record":"sonidegib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/odomzo"},{"record":"sonidegib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2015","href":"https://products.mhra.gov.uk/?search=Odomzo"},{"record":"sonidegib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Odomzo"},{"record":"registry:sonidegib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/sonidegib/#registry"},{"record":"vismodegib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/vismodegib/"},{"record":"vismodegib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2012: Metastatic BCC or locally advanced BCC recurrent after surgery or not amenable to surgery/radiation","href":"/drugs/vismodegib/"},{"record":"vismodegib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2013: Same","href":"/drugs/vismodegib/"},{"record":"vismodegib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2012","href":"/regulatory/regions/"},{"record":"vismodegib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2013","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/erivedge"},{"record":"vismodegib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2013","href":"https://products.mhra.gov.uk/?search=Erivedge"},{"record":"vismodegib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Erivedge"},{"record":"determine-trial","field":"status","kind":"trial","state":"development","label":"DETERMINE: phase platform, recruiting","href":"/trials/determine-trial/"},{"record":"sjmb12","field":"status","kind":"trial","state":"development","label":"SJMB12: phase 2, active","href":"/trials/sjmb12/"},{"record":"nct06344052","field":"status","kind":"trial","state":"development","label":"To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma: phase 2, recruiting","href":"/trials/nct06344052/"},{"record":"registry:vismodegib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 14 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/vismodegib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"vegf+kit","name":"VEGF / VEGFR x KIT","href":"/targets/vegf/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"chiauranib","name":"Chiauranib","route":"/drugs/chiauranib/","state":"development","status":"phase-3"},{"id":"pazopanib","name":"Pazopanib","route":"/drugs/pazopanib/","state":"approved","status":"approved"},{"id":"regorafenib","name":"Regorafenib","route":"/drugs/regorafenib/","state":"approved","status":"approved"},{"id":"sunitinib","name":"Sunitinib","route":"/drugs/sunitinib/","state":"approved","status":"approved"}],"counts":{"approved":3,"development":1,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"}]},"evidence":[{"record":"chiauranib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/chiauranib/"},{"record":"nct04921527","field":"status","kind":"trial","state":"development","label":"Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer: phase 3, recruiting","href":"/trials/nct04921527/"},{"record":"registry:chiauranib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/chiauranib/#registry"},{"record":"pazopanib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/pazopanib/"},{"record":"pazopanib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2009: Advanced renal cell carcinoma","href":"/drugs/pazopanib/"},{"record":"pazopanib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2012: Advanced non-adipocytic soft-tissue sarcoma after chemotherapy","href":"/drugs/pazopanib/"},{"record":"pazopanib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2009","href":"/regulatory/regions/"},{"record":"pazopanib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2010","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/votrient"},{"record":"pazopanib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2010","href":"https://products.mhra.gov.uk/?search=Votrient"},{"record":"pazopanib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2012","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"pazopanib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2017","href":"https://english.nmpa.gov.cn/"},{"record":"pazopanib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2010","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Votrient"},{"record":"nct07087158","field":"status","kind":"trial","state":"development","label":"A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma: phase 2, recruiting","href":"/trials/nct07087158/"},{"record":"aldoxorubicin-phase-3-sts","field":"outcomes (primary)","kind":"trial","state":"stopped","label":"Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma: phase 3, negative","href":"/trials/aldoxorubicin-phase-3-sts/","quote":"Primary endpoint Progression-free survival"},{"record":"tappas","field":"result","kind":"trial","state":"stopped","label":"TAPPAS: phase 3, negative","href":"/trials/tappas/","quote":"Adding TRC105 to pazopanib did not improve progression-free survival; stopped for futility."},{"record":"registry:pazopanib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 12 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pazopanib/#registry"},{"record":"regorafenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/regorafenib/"},{"record":"regorafenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2012: Metastatic colorectal cancer, previously treated","href":"/drugs/regorafenib/"},{"record":"regorafenib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2013: GIST after imatinib and sunitinib","href":"/drugs/regorafenib/"},{"record":"regorafenib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2017: HCC previously treated with sorafenib","href":"/drugs/regorafenib/"},{"record":"regorafenib","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2012: Metastatic colorectal cancer after fluoropyrimidine, oxaliplatin, irinotecan, anti-VEGF and, if RAS wild-type, anti-EGFR therapy","href":"/drugs/regorafenib/"},{"record":"regorafenib","field":"approvals[4]","kind":"approval","state":"approved","label":"EU 2013: Metastatic colorectal cancer after available therapies","href":"/drugs/regorafenib/"},{"record":"regorafenib","field":"approvals[5]","kind":"approval","state":"approved","label":"England (NICE) 2023: Metastatic colorectal cancer after previous treatment or when those treatments are unsuitable","href":"/drugs/regorafenib/"},{"record":"regorafenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2012","href":"/regulatory/regions/"},{"record":"regorafenib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2013","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga"},{"record":"regorafenib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2013","href":"https://products.mhra.gov.uk/?search=Stivarga"},{"record":"regorafenib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2013","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"regorafenib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2017","href":"https://english.nmpa.gov.cn/"},{"record":"regorafenib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2013","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Stivarga"},{"record":"nct06829355","field":"status","kind":"trial","state":"development","label":"\"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer\": phase 2, recruiting","href":"/trials/nct06829355/"},{"record":"nct06887218","field":"status","kind":"trial","state":"development","label":"5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct06887218/"},{"record":"nct07040228","field":"status","kind":"trial","state":"development","label":"A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer: phase 1/2, recruiting","href":"/trials/nct07040228/"},{"record":"nct07750041","field":"status","kind":"trial","state":"development","label":"A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer: phase 1/2, planned","href":"/trials/nct07750041/"},{"record":"nct07730489","field":"status","kind":"trial","state":"development","label":"A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, F: phase 3, planned","href":"/trials/nct07730489/"},{"record":"nct06246643","field":"status","kind":"trial","state":"development","label":"A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies: phase 2, active","href":"/trials/nct06246643/"},{"record":"nct02955940","field":"status","kind":"trial","state":"development","label":"An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib: phase 2, active","href":"/trials/nct02955940/"},{"record":"nct03829462","field":"status","kind":"trial","state":"development","label":"Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients: phase 3, active","href":"/trials/nct03829462/"},{"record":"nct05057052","field":"status","kind":"trial","state":"development","label":"Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis: phase 2, recruiting","href":"/trials/nct05057052/"},{"record":"nct06949982","field":"status","kind":"trial","state":"development","label":"Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Co: phase 2, recruiting","href":"/trials/nct06949982/"},{"record":"gbm-agile","field":"status","kind":"trial","state":"development","label":"GBM AGILE: phase platform, recruiting","href":"/trials/gbm-agile/"},{"record":"nct06558773","field":"status","kind":"trial","state":"development","label":"GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.: phase 2, recruiting","href":"/trials/nct06558773/"},{"record":"imblaze370","field":"result","kind":"trial","state":"stopped","label":"IMblaze370: phase 3, negative","href":"/trials/imblaze370/","quote":"Median overall survival 8.87 months with atezolizumab and cobimetinib against 8.51 months with regorafenib (hazard ratio 1.00)."},{"record":"nct06199973","field":"status","kind":"trial","state":"development","label":"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, : phase 3, active","href":"/trials/nct06199973/"},{"record":"nct05985109","field":"status","kind":"trial","state":"development","label":"KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05985109/"},{"record":"nct07310173","field":"status","kind":"trial","state":"development","label":"Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma: phase 2, recruiting","href":"/trials/nct07310173/"},{"record":"nct06911684","field":"status","kind":"trial","state":"development","label":"Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.: phase 2, recruiting","href":"/trials/nct06911684/"},{"record":"nct07071961","field":"status","kind":"trial","state":"development","label":"Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Di: phase 2, recruiting","href":"/trials/nct07071961/"},{"record":"nct05963490","field":"status","kind":"trial","state":"development","label":"Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05963490/"},{"record":"nct05794971","field":"status","kind":"trial","state":"development","label":"Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases: phase 3, recruiting","href":"/trials/nct05794971/"},{"record":"nct06425133","field":"status","kind":"trial","state":"development","label":"Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers: phase 2, recruiting","href":"/trials/nct06425133/"},{"record":"nct05462613","field":"status","kind":"trial","state":"development","label":"Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer: phase 2/3, recruiting","href":"/trials/nct05462613/"},{"record":"nct06047379","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis: phase 1/2, recruiting","href":"/trials/nct06047379/"},{"record":"nct07213570","field":"status","kind":"trial","state":"development","label":"STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer: phase 2, recruiting","href":"/trials/nct07213570/"},{"record":"nct05425940","field":"status","kind":"trial","state":"development","label":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer: phase 3, active","href":"/trials/nct05425940/"},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"nct04701476","field":"status","kind":"trial","state":"development","label":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC: phase 2, recruiting","href":"/trials/nct04701476/"},{"record":"nct04781192","field":"status","kind":"trial","state":"development","label":"The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers: phase 1/2, active","href":"/trials/nct04781192/"},{"record":"nct07134205","field":"status","kind":"trial","state":"development","label":"The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer: phase 3, planned","href":"/trials/nct07134205/"},{"record":"registry:regorafenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 32 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/regorafenib/#registry"},{"record":"sunitinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/sunitinib/"},{"record":"sunitinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2006: Advanced RCC; GIST after imatinib","href":"/drugs/sunitinib/"},{"record":"sunitinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2011: Progressive pancreatic NETs","href":"/drugs/sunitinib/"},{"record":"sunitinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2017: Adjuvant RCC at high risk (S-TRAC), little used","href":"/drugs/sunitinib/"},{"record":"sunitinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2006","href":"/regulatory/regions/"},{"record":"sunitinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2006","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/sutent"},{"record":"sunitinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2006","href":"https://products.mhra.gov.uk/?search=Sutent"},{"record":"sunitinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2008","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"sunitinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2007","href":"https://english.nmpa.gov.cn/"},{"record":"sunitinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2006","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Sutent"},{"record":"nct03673501","field":"status","kind":"trial","state":"development","label":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib: phase 3, active","href":"/trials/nct03673501/"},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"nct05024214","field":"status","kind":"trial","state":"development","label":"Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05024214/"},{"record":"nct05043090","field":"status","kind":"trial","state":"development","label":"Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC: phase 3, active","href":"/trials/nct05043090/"},{"record":"nct03091192","field":"status","kind":"trial","state":"development","label":"Savolitinib vs. Sunitinib in MET-driven PRCC.: phase 3, active","href":"/trials/nct03091192/"},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"registry:sunitinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/sunitinib/#registry"}],"reasons":[{"drugId":"pazopanib","drugName":"Pazopanib","drugRoute":"/drugs/pazopanib/","drugState":"approved","record":"aldoxorubicin-phase-3-sts","kind":"trial","label":"Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma: phase 3, negative","href":"/trials/aldoxorubicin-phase-3-sts/","quote":"Primary endpoint Progression-free survival"},{"drugId":"pazopanib","drugName":"Pazopanib","drugRoute":"/drugs/pazopanib/","drugState":"approved","record":"tappas","kind":"trial","label":"TAPPAS: phase 3, negative","href":"/trials/tappas/","quote":"Adding TRC105 to pazopanib did not improve progression-free survival; stopped for futility."},{"drugId":"regorafenib","drugName":"Regorafenib","drugRoute":"/drugs/regorafenib/","drugState":"approved","record":"imblaze370","kind":"trial","label":"IMblaze370: phase 3, negative","href":"/trials/imblaze370/","quote":"Median overall survival 8.87 months with atezolizumab and cobimetinib against 8.51 months with regorafenib (hazard ratio 1.00)."}]},{"a":{"key":"target","id":"cxcr4","name":"CXCR4","href":"/targets/cxcr4/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"mavorixafor","name":"Mavorixafor","route":"/drugs/mavorixafor/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"mavorixafor","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/mavorixafor/"},{"record":"mavorixafor","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2024: WHIM syndrome (warts, hypogammaglobulinaemia, infections and myelokathexis) in patients aged 12 and over","href":"/drugs/mavorixafor/"},{"record":"registry:mavorixafor","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/mavorixafor/#registry"}],"reasons":[]},{"a":{"key":"target","id":"cxcr4","name":"CXCR4","href":"/targets/cxcr4/"},"b":{"key":"mechanismClass","id":"receptor-agonist","name":"Receptor agonist"},"state":"approved","drugs":[{"id":"motixafortide","name":"Motixafortide","route":"/drugs/motixafortide/","state":"approved","status":"approved"},{"id":"plerixafor","name":"Plerixafor","route":"/drugs/plerixafor/","state":"approved","status":"approved"}],"counts":{"approved":2,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"motixafortide","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/motixafortide/"},{"record":"motixafortide","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2023: With filgrastim, to mobilise haematopoietic stem cells for collection and autologous transplantation in multiple myeloma","href":"/drugs/motixafortide/"},{"record":"nct06514508","field":"status","kind":"trial","state":"development","label":"Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients: phase 3, recruiting","href":"/trials/nct06514508/"},{"record":"registry:motixafortide","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/motixafortide/#registry"},{"record":"plerixafor","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/plerixafor/"},{"record":"plerixafor","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2008: Stem cell mobilisation with filgrastim for autologous transplantation in NHL and multiple myeloma","href":"/drugs/plerixafor/"},{"record":"plerixafor","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2009: Stem cell mobilisation with G-CSF in lymphoma and multiple myeloma with poor mobilisation (Mozobil)","href":"/drugs/plerixafor/"},{"record":"plerixafor","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2009","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/mozobil"},{"record":"registry:plerixafor","kind":"registry","state":"development","label":"ClinicalTrials.gov: 19 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/plerixafor/#registry"}],"reasons":[]},{"a":{"key":"target","id":"flt3","name":"FLT3","href":"/targets/flt3/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"gilteritinib","name":"Gilteritinib","route":"/drugs/gilteritinib/","state":"approved","status":"approved"},{"id":"men1703","name":"MEN1703","route":"/drugs/men1703/","state":"development","status":"phase-2"},{"id":"quizartinib","name":"Quizartinib","route":"/drugs/quizartinib/","state":"approved","status":"approved"}],"counts":{"approved":2,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"gilteritinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/gilteritinib/"},{"record":"gilteritinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: Relapsed or refractory FLT3-mutated AML","href":"/drugs/gilteritinib/"},{"record":"gilteritinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"gilteritinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2019","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/xospata"},{"record":"gilteritinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2019","href":"https://products.mhra.gov.uk/?search=Xospata"},{"record":"gilteritinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2018","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"gilteritinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"gilteritinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2019","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Xospata"},{"record":"nct04988555","field":"status","kind":"trial","state":"development","label":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1): phase 1/2, recruiting","href":"/trials/nct04988555/"},{"record":"nct05520567","field":"status","kind":"trial","state":"development","label":"A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia: phase 1/2, active","href":"/trials/nct05520567/"},{"record":"nct04293562","field":"status","kind":"trial","state":"development","label":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations: phase 3, recruiting","href":"/trials/nct04293562/"},{"record":"beat-aml-master-trial","field":"status","kind":"trial","state":"development","label":"Beat AML Master Trial: phase platform, recruiting","href":"/trials/beat-aml-master-trial/"},{"record":"registry:gilteritinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 29 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/gilteritinib/#registry"},{"record":"men1703","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/men1703/"},{"record":"nct06534437","field":"status","kind":"trial","state":"development","label":"MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01): phase 2, recruiting","href":"/trials/nct06534437/"},{"record":"registry:men1703","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/men1703/#registry"},{"record":"quizartinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/quizartinib/"},{"record":"quizartinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2023: Newly diagnosed FLT3-ITD AML with 7+3, consolidation, and maintenance","href":"/drugs/quizartinib/"},{"record":"quizartinib","field":"approvals[1]","kind":"approval","state":"approved","label":"Japan 2019: Relapsed/refractory FLT3-ITD AML","href":"/drugs/quizartinib/"},{"record":"quizartinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2023","href":"/regulatory/regions/"},{"record":"quizartinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2023","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/vanflyta"},{"record":"quizartinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2024","href":"https://www.gov.uk/government/news/quizartinib-approved-to-treat-adult-patients-with-a-type-of-blood-cancer"},{"record":"quizartinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2019","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"quizartinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2025","href":"https://english.nmpa.gov.cn/"},{"record":"quizartinib","field":"regulatoryEvents[0]","kind":"event","state":"stopped","label":"US 2019-06-14: complete response letter","href":"/drugs/quizartinib/","quote":"Complete response letter for relapsed/refractory indication (QuANTUM-R)"},{"record":"nct06824168","field":"status","kind":"trial","state":"development","label":"Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission: phase 2, recruiting","href":"/trials/nct06824168/"},{"record":"nct03793478","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood: phase 1/2, active","href":"/trials/nct03793478/"},{"record":"registry:quizartinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 11 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/quizartinib/#registry"}],"reasons":[{"drugId":"quizartinib","drugName":"Quizartinib","drugRoute":"/drugs/quizartinib/","drugState":"approved","record":"quizartinib","kind":"event","label":"US 2019-06-14: complete response letter","href":"/drugs/quizartinib/","quote":"Complete response letter for relapsed/refractory indication (QuANTUM-R)"}]},{"a":{"key":"target","id":"kit","name":"KIT","href":"/targets/kit/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"avapritinib","name":"Avapritinib","route":"/drugs/avapritinib/","state":"approved","status":"approved"},{"id":"imatinib","name":"Imatinib","route":"/drugs/imatinib/","state":"approved","status":"approved"},{"id":"ripretinib","name":"Ripretinib","route":"/drugs/ripretinib/","state":"approved","status":"approved"}],"counts":{"approved":3,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"}]},"evidence":[{"record":"avapritinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/avapritinib/"},{"record":"avapritinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2020: Unresectable/metastatic GIST with PDGFRA exon 18 mutation including D842V","href":"/drugs/avapritinib/"},{"record":"avapritinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2021: Advanced systemic mastocytosis","href":"/drugs/avapritinib/"},{"record":"avapritinib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2020: EU brand Ayvakyt","href":"/drugs/avapritinib/"},{"record":"avapritinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2020","href":"/regulatory/regions/"},{"record":"avapritinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2020","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/ayvakyt"},{"record":"avapritinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2020","href":"https://products.mhra.gov.uk/?search=Ayvakyt"},{"record":"avapritinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"avapritinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2022","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Ayvakyt"},{"record":"nct03731260","field":"status","kind":"trial","state":"development","label":"(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo : phase 2, active","href":"/trials/nct03731260/"},{"record":"nct04771520","field":"status","kind":"trial","state":"development","label":"Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors: phase 2, recruiting","href":"/trials/nct04771520/"},{"record":"voyager","field":"result","kind":"trial","state":"stopped","label":"VOYAGER: phase 3, negative","href":"/trials/voyager/","quote":"PFS HR 1.25 (negative)."},{"record":"registry:avapritinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/avapritinib/#registry"},{"record":"imatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/imatinib/"},{"record":"imatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2001: Chronic myeloid leukaemia","href":"/drugs/imatinib/"},{"record":"imatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2002: KIT+ GIST","href":"/drugs/imatinib/"},{"record":"imatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2001","href":"/regulatory/regions/"},{"record":"imatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2001","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/glivec"},{"record":"imatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2001","href":"https://products.mhra.gov.uk/?search=Gleevec"},{"record":"imatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2001","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"imatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2002","href":"https://english.nmpa.gov.cn/"},{"record":"imatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2001","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Gleevec"},{"record":"imatinib","field":"regional.IN","kind":"regional","state":"approved","label":"CDSCO (DCGI) (IN): approved","href":"https://en.wikipedia.org/wiki/Novartis_v._Union_of_India_%26_Others"},{"record":"nct03459534","field":"status","kind":"trial","state":"development","label":"A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs: phase 3, recruiting","href":"/trials/nct03459534/"},{"record":"nct04971226","field":"status","kind":"trial","state":"development","label":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP: phase 3, active","href":"/trials/nct04971226/"},{"record":"nct07406633","field":"status","kind":"trial","state":"development","label":"KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line): phase 2, recruiting","href":"/trials/nct07406633/"},{"record":"nct03722420","field":"status","kind":"trial","state":"development","label":"Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China): phase 3, active","href":"/trials/nct03722420/"},{"record":"registry:imatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 9 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/imatinib/#registry"},{"record":"ripretinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ripretinib/"},{"record":"ripretinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2020: Advanced GIST after ≥3 prior kinase inhibitors including imatinib","href":"/drugs/ripretinib/"},{"record":"ripretinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2020","href":"/regulatory/regions/"},{"record":"ripretinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2021","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/qinlock"},{"record":"ripretinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2021","href":"https://products.mhra.gov.uk/?search=Qinlock"},{"record":"ripretinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"ripretinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2020","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Qinlock"},{"record":"nct05957367","field":"status","kind":"trial","state":"development","label":"A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies: phase 1/2, recruiting","href":"/trials/nct05957367/"},{"record":"nct03673501","field":"status","kind":"trial","state":"development","label":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib: phase 3, active","href":"/trials/nct03673501/"},{"record":"insight-gist","field":"status","kind":"trial","state":"development","label":"INSIGHT: phase 3, active","href":"/trials/insight-gist/"},{"record":"registry:ripretinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ripretinib/#registry"}],"reasons":[{"drugId":"avapritinib","drugName":"Avapritinib","drugRoute":"/drugs/avapritinib/","drugState":"approved","record":"voyager","kind":"trial","label":"VOYAGER: phase 3, negative","href":"/trials/voyager/","quote":"PFS HR 1.25 (negative)."}]},{"a":{"key":"target","id":"mtor","name":"mTOR","href":"/targets/mtor/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"sirolimus-albumin-bound","name":"Sirolimus protein-bound particles","route":"/drugs/sirolimus-albumin-bound/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"allosteric","name":"Allosteric"}]},"evidence":[{"record":"sirolimus-albumin-bound","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/sirolimus-albumin-bound/"},{"record":"sirolimus-albumin-bound","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2021: Locally advanced unresectable or metastatic malignant PEComa","href":"/drugs/sirolimus-albumin-bound/"},{"record":"nct04736589","field":"status","kind":"trial","state":"development","label":"Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway: phase 3, planned","href":"/trials/nct04736589/"},{"record":"nct05103358","field":"status","kind":"trial","state":"development","label":"Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1): phase 2, active","href":"/trials/nct05103358/"},{"record":"nct05997017","field":"status","kind":"trial","state":"development","label":"Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer: phase 2, recruiting","href":"/trials/nct05997017/"},{"record":"registry:sirolimus-albumin-bound","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 1 terminated or withdrawn study and none active (fetched 2026-09-28)","href":"/drugs/sirolimus-albumin-bound/#registry"}],"reasons":[]},{"a":{"key":"target","id":"mtor","name":"mTOR","href":"/targets/mtor/"},"b":{"key":"mechanismClass","id":"pi3k-akt-mtor-inhibitor","name":"PI3K, AKT or mTOR inhibitor","href":"/technologies/pi3k-akt-mtor-inhibitors/"},"state":"approved","drugs":[{"id":"sapanisertib","name":"Sapanisertib","route":"/drugs/sapanisertib/","state":"development","status":"phase-2"},{"id":"sirolimus","name":"Sirolimus","route":"/drugs/sirolimus/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"sapanisertib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/sapanisertib/"},{"record":"nct07558733","field":"status","kind":"trial","state":"development","label":"Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer: phase 1/2, recruiting","href":"/trials/nct07558733/"},{"record":"nct06463028","field":"status","kind":"trial","state":"development","label":"Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial : phase 2, recruiting","href":"/trials/nct06463028/"},{"record":"registry:sapanisertib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/sapanisertib/#registry"},{"record":"sirolimus","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/sirolimus/"},{"record":"sirolimus","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1999: Prophylaxis of organ rejection in kidney transplant recipients","href":"/drugs/sirolimus/"},{"record":"registry:sirolimus","kind":"registry","state":"development","label":"ClinicalTrials.gov: 26 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/sirolimus/#registry"}],"reasons":[]},{"a":{"key":"target","id":"proteasome","name":"Proteasome (PSMB5)","href":"/targets/proteasome/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"bortezomib","name":"Bortezomib","route":"/drugs/bortezomib/","state":"approved","status":"approved"},{"id":"ixazomib","name":"Ixazomib","route":"/drugs/ixazomib/","state":"approved","status":"approved"}],"counts":{"approved":2,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"}]},"evidence":[{"record":"bortezomib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/bortezomib/"},{"record":"bortezomib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2003: Relapsed myeloma (accelerated)","href":"/drugs/bortezomib/"},{"record":"bortezomib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2008: Newly diagnosed myeloma","href":"/drugs/bortezomib/"},{"record":"bortezomib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2003","href":"/regulatory/regions/"},{"record":"bortezomib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2004","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/velcade"},{"record":"bortezomib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2004","href":"https://products.mhra.gov.uk/?search=Velcade"},{"record":"bortezomib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2006","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"bortezomib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2005","href":"https://english.nmpa.gov.cn/"},{"record":"bortezomib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2005","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Velcade"},{"record":"nct06464991","field":"status","kind":"trial","state":"development","label":"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03): phase 3, recruiting","href":"/trials/nct06464991/"},{"record":"nct06413498","field":"status","kind":"trial","state":"development","label":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma: phase 3, active","href":"/trials/nct06413498/"},{"record":"nct07391657","field":"status","kind":"trial","state":"development","label":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela: phase 3, recruiting","href":"/trials/nct07391657/"},{"record":"nct06208150","field":"status","kind":"trial","state":"development","label":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez: phase 3, active","href":"/trials/nct06208150/"},{"record":"nct05572515","field":"status","kind":"trial","state":"development","label":"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With: phase 3, active","href":"/trials/nct05572515/"},{"record":"nct03314181","field":"status","kind":"trial","state":"development","label":"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor: phase 2, active","href":"/trials/nct03314181/"},{"record":"nct06577025","field":"status","kind":"trial","state":"development","label":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind: phase 2, active","href":"/trials/nct06577025/"},{"record":"nct04133636","field":"status","kind":"trial","state":"development","label":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul: phase 2, active","href":"/trials/nct04133636/"},{"record":"nct04414475","field":"status","kind":"trial","state":"development","label":"A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refrac: phase 2, recruiting","href":"/trials/nct04414475/"},{"record":"nct02773030","field":"status","kind":"trial","state":"development","label":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple: phase 1/2, active","href":"/trials/nct02773030/"},{"record":"nct03989414","field":"status","kind":"trial","state":"development","label":"A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre: phase 1/2, active","href":"/trials/nct03989414/"},{"record":"nct05519085","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re: phase 3, recruiting","href":"/trials/nct05519085/"},{"record":"nct07227311","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult: phase 2, recruiting","href":"/trials/nct07227311/"},{"record":"nct05623020","field":"status","kind":"trial","state":"development","label":"A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide: phase 3, recruiting","href":"/trials/nct05623020/"},{"record":"nct06956170","field":"status","kind":"trial","state":"development","label":"All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo: phase 3, active","href":"/trials/nct06956170/"},{"record":"cartitude-6","field":"status","kind":"trial","state":"development","label":"CARTITUDE-6: phase 3, active","href":"/trials/cartitude-6/"},{"record":"nct06868654","field":"status","kind":"trial","state":"development","label":"China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame: phase 3, active","href":"/trials/nct06868654/"},{"record":"nct06868667","field":"status","kind":"trial","state":"development","label":"Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex: phase 3, active","href":"/trials/nct06868667/"},{"record":"nct06152575","field":"status","kind":"trial","state":"development","label":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other: phase 3, recruiting","href":"/trials/nct06152575/"},{"record":"nct04975997","field":"status","kind":"trial","state":"development","label":"Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants : phase 3, active","href":"/trials/nct04975997/"},{"record":"nct07018050","field":"status","kind":"trial","state":"development","label":"Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma: phase 2, recruiting","href":"/trials/nct07018050/"},{"record":"nct02343042","field":"status","kind":"trial","state":"development","label":"Selinexor and Backbone Treatments of Multiple Myeloma Patients: phase 1/2, recruiting","href":"/trials/nct02343042/"},{"record":"nct06158841","field":"status","kind":"trial","state":"development","label":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto: phase 3, active","href":"/trials/nct06158841/"},{"record":"nct07764978","field":"status","kind":"trial","state":"development","label":"Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT: phase 3, recruiting","href":"/trials/nct07764978/"},{"record":"nct04068597","field":"status","kind":"trial","state":"development","label":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies: phase 1/2, recruiting","href":"/trials/nct04068597/"},{"record":"registry:bortezomib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 19 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/bortezomib/#registry"},{"record":"ixazomib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ixazomib/"},{"record":"ixazomib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2015: Multiple myeloma after ≥1 prior therapy, with lenalidomide and dexamethasone","href":"/drugs/ixazomib/"},{"record":"ixazomib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2016: Same","href":"/drugs/ixazomib/"},{"record":"ixazomib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2015","href":"/regulatory/regions/"},{"record":"ixazomib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2016","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/ninlaro"},{"record":"ixazomib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2016","href":"https://products.mhra.gov.uk/?search=Ninlaro"},{"record":"ixazomib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2017","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"ixazomib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2018","href":"https://english.nmpa.gov.cn/"},{"record":"ixazomib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Ninlaro"},{"record":"nct04068597","field":"status","kind":"trial","state":"development","label":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies: phase 1/2, recruiting","href":"/trials/nct04068597/"},{"record":"registry:ixazomib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 17 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ixazomib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"proteasome","name":"Proteasome (PSMB5)","href":"/targets/proteasome/"},"b":{"key":"mechanismClass","id":"proteasome-inhibitor","name":"Proteasome inhibitor"},"state":"approved","drugs":[{"id":"carfilzomib","name":"Carfilzomib","route":"/drugs/carfilzomib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"covalent","name":"Covalent"}]},"evidence":[{"record":"carfilzomib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/carfilzomib/"},{"record":"carfilzomib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2012: Relapsed myeloma (accelerated)","href":"/drugs/carfilzomib/"},{"record":"carfilzomib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2015: With lenalidomide-dexamethasone; with dexamethasone (ENDEAVOR)","href":"/drugs/carfilzomib/"},{"record":"carfilzomib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2012","href":"/regulatory/regions/"},{"record":"carfilzomib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/kyprolis"},{"record":"carfilzomib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2015","href":"https://products.mhra.gov.uk/?search=Kyprolis"},{"record":"carfilzomib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2016","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"carfilzomib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"carfilzomib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2015","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Kyprolis"},{"record":"nct04973605","field":"status","kind":"trial","state":"development","label":"A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat: phase 1/2, recruiting","href":"/trials/nct04973605/"},{"record":"nct07391657","field":"status","kind":"trial","state":"development","label":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela: phase 3, recruiting","href":"/trials/nct07391657/"},{"record":"nct05572515","field":"status","kind":"trial","state":"development","label":"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With: phase 3, active","href":"/trials/nct05572515/"},{"record":"nct05438043","field":"status","kind":"trial","state":"development","label":"A Study of Daratumumab: phase 3, active","href":"/trials/nct05438043/"},{"record":"nct06892522","field":"status","kind":"trial","state":"development","label":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe: phase 1/2, recruiting","href":"/trials/nct06892522/"},{"record":"nct02773030","field":"status","kind":"trial","state":"development","label":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple: phase 1/2, active","href":"/trials/nct02773030/"},{"record":"nct03989414","field":"status","kind":"trial","state":"development","label":"A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre: phase 1/2, active","href":"/trials/nct03989414/"},{"record":"nct05552976","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W: phase 3, active","href":"/trials/nct05552976/"},{"record":"nct07227311","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult: phase 2, recruiting","href":"/trials/nct07227311/"},{"record":"nct05704049","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory: phase 2, active","href":"/trials/nct05704049/"},{"record":"nct06152575","field":"status","kind":"trial","state":"development","label":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other: phase 3, recruiting","href":"/trials/nct06152575/"},{"record":"nct06158841","field":"status","kind":"trial","state":"development","label":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto: phase 3, active","href":"/trials/nct06158841/"},{"record":"nct02899052","field":"status","kind":"trial","state":"development","label":"Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM): phase 2, active","href":"/trials/nct02899052/"},{"record":"registry:carfilzomib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 46 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/carfilzomib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"ret","name":"RET","href":"/targets/ret/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"ep0031","name":"EP0031","route":"/drugs/ep0031/","state":"development","status":"phase-2"},{"id":"pralsetinib","name":"Pralsetinib","route":"/drugs/pralsetinib/","state":"approved","status":"approved"},{"id":"selpercatinib","name":"Selpercatinib","route":"/drugs/selpercatinib/","state":"approved","status":"approved"}],"counts":{"approved":2,"development":1,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"ep0031","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/ep0031/"},{"record":"nct05443126","field":"status","kind":"trial","state":"development","label":"A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies: phase 1/2, recruiting","href":"/trials/nct05443126/"},{"record":"registry:ep0031","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/ep0031/#registry"},{"record":"pralsetinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/pralsetinib/"},{"record":"pralsetinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2020: RET-fusion metastatic NSCLC (full approval 2023)","href":"/drugs/pralsetinib/"},{"record":"pralsetinib","field":"approvals[1]","kind":"approval","state":"approved","label":"England (NICE) 2022: RET fusion-positive advanced non-small-cell lung cancer in patients who have not had a RET inhibitor: not recommended","href":"/drugs/pralsetinib/"},{"record":"pralsetinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2020","href":"/regulatory/regions/"},{"record":"pralsetinib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn 2024","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/gavreto","quote":"Authorised Nov 2021; marketing authorisation withdrawn at Blueprint's request 24 Oct 2024"},{"record":"pralsetinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2021","href":"https://products.mhra.gov.uk/?search=Gavreto"},{"record":"pralsetinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"pralsetinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2022","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Gavreto"},{"record":"pralsetinib","field":"regulatoryEvents[3]","kind":"event","state":"stopped","label":"US 2023-07-20: withdrawal","href":"/drugs/pralsetinib/","quote":"Withdrawn: the indication came off the label 2.6 years after its accelerated approval."},{"record":"nct04302025","field":"status","kind":"trial","state":"development","label":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC): phase 2, recruiting","href":"/trials/nct04302025/"},{"record":"registry:pralsetinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pralsetinib/#registry"},{"record":"selpercatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/selpercatinib/"},{"record":"selpercatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2020: RET-fusion NSCLC and thyroid; RET-mutant MTC","href":"/drugs/selpercatinib/"},{"record":"selpercatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2022: RET-fusion solid tumours (tumour-agnostic)","href":"/drugs/selpercatinib/"},{"record":"selpercatinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2026: Label update (July 2026)","href":"/drugs/selpercatinib/"},{"record":"selpercatinib","field":"approvals[3]","kind":"approval","state":"approved","label":"EU 2021: EU brand Retsevmo","href":"/drugs/selpercatinib/"},{"record":"selpercatinib","field":"approvals[4]","kind":"approval","state":"approved","label":"England (NICE) 2023: Untreated RET fusion-positive advanced non-small-cell lung cancer","href":"/drugs/selpercatinib/"},{"record":"selpercatinib","field":"approvals[5]","kind":"approval","state":"approved","label":"England (NICE) 2025: Previously treated RET fusion-positive advanced non-small-cell lung cancer not previously treated with a RET inhibitor","href":"/drugs/selpercatinib/"},{"record":"selpercatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2020","href":"/regulatory/regions/"},{"record":"selpercatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2021","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo"},{"record":"selpercatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2021","href":"https://products.mhra.gov.uk/?search=Retsevmo"},{"record":"selpercatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2021","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"selpercatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2022","href":"https://english.nmpa.gov.cn/"},{"record":"selpercatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2021","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Retsevmo"},{"record":"nct03899792","field":"status","kind":"trial","state":"development","label":"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors: phase 1/2, active","href":"/trials/nct03899792/"},{"record":"nct03157128","field":"status","kind":"trial","state":"development","label":"A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET: phase 1/2, active","href":"/trials/nct03157128/"},{"record":"nct04280081","field":"status","kind":"trial","state":"development","label":"A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer a: phase 2, active","href":"/trials/nct04280081/"},{"record":"nct04819100","field":"status","kind":"trial","state":"development","label":"A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC): phase 3, active","href":"/trials/nct04819100/"},{"record":"pediatric-match","field":"status","kind":"trial","state":"development","label":"NCI-COG Pediatric MATCH (APEC1621): phase platform, active","href":"/trials/pediatric-match/"},{"record":"registry:selpercatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 17 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/selpercatinib/#registry"}],"reasons":[{"drugId":"pralsetinib","drugName":"Pralsetinib","drugRoute":"/drugs/pralsetinib/","drugState":"approved","record":"pralsetinib","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2024","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/gavreto","quote":"Authorised Nov 2021; marketing authorisation withdrawn at Blueprint's request 24 Oct 2024"},{"drugId":"pralsetinib","drugName":"Pralsetinib","drugRoute":"/drugs/pralsetinib/","drugState":"approved","record":"pralsetinib","kind":"event","label":"US 2023-07-20: withdrawal","href":"/drugs/pralsetinib/","quote":"Withdrawn: the indication came off the label 2.6 years after its accelerated approval."}]},{"a":{"key":"target","id":"vegf+fgfr2","name":"VEGF / VEGFR x FGFR2","href":"/targets/vegf/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"anlotinib","name":"Anlotinib","route":"/drugs/anlotinib/","state":"approved","status":"approved"},{"id":"lenvatinib","name":"Lenvatinib","route":"/drugs/lenvatinib/","state":"approved","status":"approved"},{"id":"nintedanib","name":"Nintedanib","route":"/drugs/nintedanib/","state":"approved","status":"approved"}],"counts":{"approved":3,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"anlotinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/anlotinib/"},{"record":"anlotinib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2018: Advanced NSCLC after at least two lines of systemic therapy (ALTER 0303)","href":"/drugs/anlotinib/"},{"record":"anlotinib","field":"approvals[1]","kind":"approval","state":"approved","label":"China 2019: Advanced soft tissue sarcoma after chemotherapy; small cell lung cancer after at least two lines","href":"/drugs/anlotinib/"},{"record":"anlotinib","field":"approvals[2]","kind":"approval","state":"approved","label":"China 2020: Advanced medullary thyroid cancer","href":"/drugs/anlotinib/"},{"record":"anlotinib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): rejected 2026","href":"/regulatory/regions/","quote":"CHMP negative opinion 23 Jul 2026 on Qezzaqar (catequentinib; applicant CATS Consultants) for synovial sarcoma and leiomyosarcoma"},{"record":"anlotinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2018","href":"https://english.nmpa.gov.cn/"},{"record":"nct06469879","field":"status","kind":"trial","state":"development","label":"A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients: phase 3, planned","href":"/trials/nct06469879/"},{"record":"nct05913089","field":"status","kind":"trial","state":"development","label":"A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct05913089/"},{"record":"nct07562581","field":"status","kind":"trial","state":"development","label":"A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC: phase 2, recruiting","href":"/trials/nct07562581/"},{"record":"nct07815223","field":"status","kind":"trial","state":"development","label":"A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC: phase 2, recruiting","href":"/trials/nct07815223/"},{"record":"nct06048315","field":"status","kind":"trial","state":"development","label":"A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs W: phase 3, planned","href":"/trials/nct06048315/"},{"record":"nct07728955","field":"status","kind":"trial","state":"development","label":"A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for: phase 3, planned","href":"/trials/nct07728955/"},{"record":"nct04854668","field":"status","kind":"trial","state":"development","label":"A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Can: phase 3, active","href":"/trials/nct04854668/"},{"record":"nct07538271","field":"status","kind":"trial","state":"development","label":"A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer: phase 2, planned","href":"/trials/nct07538271/"},{"record":"nct07398326","field":"status","kind":"trial","state":"development","label":"Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct07398326/"},{"record":"nct05862337","field":"status","kind":"trial","state":"development","label":"Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.: phase 3, recruiting","href":"/trials/nct05862337/"},{"record":"nct04322617","field":"status","kind":"trial","state":"development","label":"Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer: phase 2/3, recruiting","href":"/trials/nct04322617/"},{"record":"nct06662877","field":"status","kind":"trial","state":"development","label":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment: phase 2/3, planned","href":"/trials/nct06662877/"},{"record":"nct07443397","field":"status","kind":"trial","state":"development","label":"Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.: phase 3, recruiting","href":"/trials/nct07443397/"},{"record":"nct07635290","field":"status","kind":"trial","state":"development","label":"Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer: phase 2, active","href":"/trials/nct07635290/"},{"record":"nct06901622","field":"status","kind":"trial","state":"development","label":"Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma: phase 2, recruiting","href":"/trials/nct06901622/"},{"record":"nct06992336","field":"status","kind":"trial","state":"development","label":"Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy: phase 2, recruiting","href":"/trials/nct06992336/"},{"record":"nct06767813","field":"status","kind":"trial","state":"development","label":"Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms: phase 2, recruiting","href":"/trials/nct06767813/"},{"record":"nct07548177","field":"status","kind":"trial","state":"development","label":"Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma: phase 2, recruiting","href":"/trials/nct07548177/"},{"record":"nct06761027","field":"status","kind":"trial","state":"development","label":"mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer: phase 1/2, recruiting","href":"/trials/nct06761027/"},{"record":"nct04846634","field":"status","kind":"trial","state":"development","label":"Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (A: phase 2, planned","href":"/trials/nct04846634/"},{"record":"nct03016819","field":"status","kind":"trial","state":"development","label":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS): phase 3, recruiting","href":"/trials/nct03016819/"},{"record":"nct07636226","field":"status","kind":"trial","state":"development","label":"QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer: phase 2/3, planned","href":"/trials/nct07636226/"},{"record":"nct07601178","field":"status","kind":"trial","state":"development","label":"QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride: phase 2, recruiting","href":"/trials/nct07601178/"},{"record":"nct07501169","field":"status","kind":"trial","state":"development","label":"Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC): phase 2, planned","href":"/trials/nct07501169/"},{"record":"nct07139470","field":"status","kind":"trial","state":"development","label":"Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer: phase 1/2, planned","href":"/trials/nct07139470/"},{"record":"nct07025174","field":"status","kind":"trial","state":"development","label":"Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer: phase 2, recruiting","href":"/trials/nct07025174/"},{"record":"nct06441344","field":"status","kind":"trial","state":"development","label":"Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell: phase 3, planned","href":"/trials/nct06441344/"},{"record":"nct06456138","field":"status","kind":"trial","state":"development","label":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC: phase 1/2, planned","href":"/trials/nct06456138/"},{"record":"registry:anlotinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 32 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/anlotinib/#registry"},{"record":"lenvatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/lenvatinib/"},{"record":"lenvatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2015: Radioiodine-refractory thyroid cancer","href":"/drugs/lenvatinib/"},{"record":"lenvatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2018: First-line unresectable HCC","href":"/drugs/lenvatinib/"},{"record":"lenvatinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2021: Advanced RCC with pembrolizumab; endometrial cancer with pembrolizumab","href":"/drugs/lenvatinib/"},{"record":"lenvatinib","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2016: Advanced RCC with everolimus after anti-angiogenic therapy","href":"/drugs/lenvatinib/"},{"record":"lenvatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2015","href":"/regulatory/regions/"},{"record":"lenvatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima"},{"record":"lenvatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2015","href":"https://products.mhra.gov.uk/?search=Lenvima"},{"record":"lenvatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2015","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"lenvatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2018","href":"https://english.nmpa.gov.cn/"},{"record":"lenvatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2015","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Lenvima"},{"record":"nct06682780","field":"status","kind":"trial","state":"development","label":"A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours: phase 1/2, recruiting","href":"/trials/nct06682780/"},{"record":"nct07679399","field":"status","kind":"trial","state":"development","label":"A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.: phase 2, recruiting","href":"/trials/nct07679399/"},{"record":"nct07269158","field":"status","kind":"trial","state":"development","label":"A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer: phase 1/2, planned","href":"/trials/nct07269158/"},{"record":"nct07099794","field":"status","kind":"trial","state":"development","label":"A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen: phase 2, planned","href":"/trials/nct07099794/"},{"record":"nct06371157","field":"status","kind":"trial","state":"development","label":"A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat: phase 3, recruiting","href":"/trials/nct06371157/"},{"record":"nct06962787","field":"status","kind":"trial","state":"development","label":"A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer: phase 2, recruiting","href":"/trials/nct06962787/"},{"record":"nct04008797","field":"status","kind":"trial","state":"development","label":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor: phase 1/2, active","href":"/trials/nct04008797/"},{"record":"nct04194775","field":"status","kind":"trial","state":"development","label":"A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma: phase 3, active","href":"/trials/nct04194775/"},{"record":"nct05899049","field":"status","kind":"trial","state":"development","label":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study: phase 3, active","href":"/trials/nct05899049/"},{"record":"nct05319730","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B): phase 1/2, recruiting","href":"/trials/nct05319730/"},{"record":"nct04300556","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types: phase 1/2, recruiting","href":"/trials/nct04300556/"},{"record":"nct07282262","field":"status","kind":"trial","state":"development","label":"An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.: phase 2, recruiting","href":"/trials/nct07282262/"},{"record":"nct07829874","field":"status","kind":"trial","state":"development","label":"Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.: phase 2, planned","href":"/trials/nct07829874/"},{"record":"nct07159217","field":"status","kind":"trial","state":"development","label":"Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer: phase 2, planned","href":"/trials/nct07159217/"},{"record":"nct07081633","field":"status","kind":"trial","state":"development","label":"Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma: phase 2, active","href":"/trials/nct07081633/"},{"record":"nct06028633","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients: phase 2, planned","href":"/trials/nct06028633/"},{"record":"nct07405164","field":"status","kind":"trial","state":"development","label":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043): phase 3, recruiting","href":"/trials/nct07405164/"},{"record":"nct06963060","field":"status","kind":"trial","state":"development","label":"Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT): phase 2, recruiting","href":"/trials/nct06963060/"},{"record":"nct04977453","field":"status","kind":"trial","state":"development","label":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct04977453/"},{"record":"nct06389500","field":"status","kind":"trial","state":"development","label":"HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer: phase 2, planned","href":"/trials/nct06389500/"},{"record":"nct07636798","field":"status","kind":"trial","state":"development","label":"Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer: phase 1/2, recruiting","href":"/trials/nct07636798/"},{"record":"nct06849492","field":"status","kind":"trial","state":"development","label":"HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer: phase 2, planned","href":"/trials/nct06849492/"},{"record":"nct07263360","field":"status","kind":"trial","state":"development","label":"Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: phase 2, planned","href":"/trials/nct07263360/"},{"record":"leap-002","field":"result","kind":"trial","state":"stopped","label":"LEAP-002: phase 3, negative","href":"/trials/leap-002/","quote":"OS HR 0.84, not significant."},{"record":"nct05170438","field":"status","kind":"trial","state":"development","label":"Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment: phase 2, active","href":"/trials/nct05170438/"},{"record":"litespark-012","field":"result","kind":"trial","state":"stopped","label":"LITESPARK-012: phase 3, negative","href":"/trials/litespark-012/","quote":"Primary endpoint not met (ASCO GU 2026)."},{"record":"nct06919848","field":"status","kind":"trial","state":"development","label":"Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06): phase 2, planned","href":"/trials/nct06919848/"},{"record":"nct05903833","field":"status","kind":"trial","state":"development","label":"Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge: phase 2, recruiting","href":"/trials/nct05903833/"},{"record":"nct04976634","field":"status","kind":"trial","state":"development","label":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016): phase 2, active","href":"/trials/nct04976634/"},{"record":"nct06230471","field":"status","kind":"trial","state":"development","label":"Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer: phase 2, recruiting","href":"/trials/nct06230471/"},{"record":"nct05024214","field":"status","kind":"trial","state":"development","label":"Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05024214/"},{"record":"nct06852287","field":"status","kind":"trial","state":"development","label":"Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: phase 2, recruiting","href":"/trials/nct06852287/"},{"record":"nct07530445","field":"status","kind":"trial","state":"development","label":"Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer: phase 2, recruiting","href":"/trials/nct07530445/"},{"record":"nct07670273","field":"status","kind":"trial","state":"development","label":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer: phase 2, recruiting","href":"/trials/nct07670273/"},{"record":"nct07704177","field":"status","kind":"trial","state":"development","label":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer: phase 2, recruiting","href":"/trials/nct07704177/"},{"record":"nct06892925","field":"status","kind":"trial","state":"development","label":"QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors: phase 2, active","href":"/trials/nct06892925/"},{"record":"nct07110064","field":"status","kind":"trial","state":"development","label":"QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer: phase 2, recruiting","href":"/trials/nct07110064/"},{"record":"nct04938817","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98): phase 1/2, active","href":"/trials/nct04938817/"},{"record":"nct05112991","field":"status","kind":"trial","state":"development","label":"Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer: phase 2, recruiting","href":"/trials/nct05112991/"},{"record":"nct05775159","field":"status","kind":"trial","state":"development","label":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer: phase 2, active","href":"/trials/nct05775159/"},{"record":"nct02861573","field":"status","kind":"trial","state":"development","label":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365): phase 1/2, active","href":"/trials/nct02861573/"},{"record":"nct05822752","field":"status","kind":"trial","state":"development","label":"Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Bu: phase 2, active","href":"/trials/nct05822752/"},{"record":"nct04626479","field":"status","kind":"trial","state":"development","label":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A): phase 1/2, active","href":"/trials/nct04626479/"},{"record":"nct04626518","field":"status","kind":"trial","state":"development","label":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03): phase 1/2, active","href":"/trials/nct04626518/"},{"record":"nct06140576","field":"status","kind":"trial","state":"development","label":"The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breas: phase 1/2, planned","href":"/trials/nct06140576/"},{"record":"nct04875585","field":"status","kind":"trial","state":"development","label":"Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC: phase 2, recruiting","href":"/trials/nct04875585/"},{"record":"nct07219459","field":"status","kind":"trial","state":"development","label":"Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L): phase 2, recruiting","href":"/trials/nct07219459/"},{"record":"registry:lenvatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 47 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/lenvatinib/#registry"},{"record":"nintedanib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/nintedanib/"},{"record":"nintedanib","field":"approvals[0]","kind":"approval","state":"approved","label":"EU 2014: Adenocarcinoma NSCLC after first-line chemotherapy, with docetaxel","href":"/drugs/nintedanib/"},{"record":"nintedanib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2014: Idiopathic pulmonary fibrosis (non-oncology)","href":"/drugs/nintedanib/"},{"record":"nintedanib","field":"approvals[2]","kind":"approval","state":"approved","label":"England (NICE) 2015: Locally advanced, metastatic or locally recurrent non-small-cell lung cancer of adenocarcinoma histology progressing after first-line chemotherapy, with docetaxel","href":"/drugs/nintedanib/"},{"record":"nintedanib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2014","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef"},{"record":"nintedanib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2014","href":"https://products.mhra.gov.uk/?search=Vargatef"},{"record":"lume-meso","field":"result","kind":"trial","state":"stopped","label":"LUME-Meso: phase 2/3, negative","href":"/trials/lume-meso/","quote":"PFS HR 1.01, negative."},{"record":"registry:nintedanib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 13 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/nintedanib/#registry"}],"reasons":[{"drugId":"anlotinib","drugName":"Anlotinib","drugRoute":"/drugs/anlotinib/","drugState":"approved","record":"anlotinib","kind":"regional","label":"EMA / European Commission (EU): rejected 2026","href":"/regulatory/regions/","quote":"CHMP negative opinion 23 Jul 2026 on Qezzaqar (catequentinib; applicant CATS Consultants) for synovial sarcoma and leiomyosarcoma"},{"drugId":"lenvatinib","drugName":"Lenvatinib","drugRoute":"/drugs/lenvatinib/","drugState":"approved","record":"leap-002","kind":"trial","label":"LEAP-002: phase 3, negative","href":"/trials/leap-002/","quote":"OS HR 0.84, not significant."},{"drugId":"lenvatinib","drugName":"Lenvatinib","drugRoute":"/drugs/lenvatinib/","drugState":"approved","record":"litespark-012","kind":"trial","label":"LITESPARK-012: phase 3, negative","href":"/trials/litespark-012/","quote":"Primary endpoint not met (ASCO GU 2026)."},{"drugId":"nintedanib","drugName":"Nintedanib","drugRoute":"/drugs/nintedanib/","drugState":"approved","record":"lume-meso","kind":"trial","label":"LUME-Meso: phase 2/3, negative","href":"/trials/lume-meso/","quote":"PFS HR 1.01, negative."}]},{"a":{"key":"target","id":"alk+ros1","name":"ALK x ROS1","href":"/targets/alk/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"crizotinib","name":"Crizotinib","route":"/drugs/crizotinib/","state":"approved","status":"approved"},{"id":"iruplinalkib","name":"Iruplinalkib","route":"/drugs/iruplinalkib/","state":"approved","status":"approved"}],"counts":{"approved":2,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"}]},"evidence":[{"record":"crizotinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/crizotinib/"},{"record":"crizotinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2011: ALK-positive metastatic NSCLC","href":"/drugs/crizotinib/"},{"record":"crizotinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2016: ROS1-positive metastatic NSCLC","href":"/drugs/crizotinib/"},{"record":"crizotinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2021: Relapsed ALK-positive ALCL in patients 1-21 years","href":"/drugs/crizotinib/"},{"record":"crizotinib","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2022: ALK-positive inflammatory myofibroblastic tumour","href":"/drugs/crizotinib/"},{"record":"crizotinib","field":"approvals[4]","kind":"approval","state":"approved","label":"EU 2012: Conditional Oct 2012; full approval 2015","href":"/drugs/crizotinib/"},{"record":"crizotinib","field":"approvals[5]","kind":"approval","state":"approved","label":"England (NICE) 2024: ROS1-positive advanced non-small-cell lung cancer in patients who have not had a ROS1 inhibitor","href":"/drugs/crizotinib/"},{"record":"crizotinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2011","href":"/regulatory/regions/"},{"record":"crizotinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2012","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori"},{"record":"crizotinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2012","href":"https://products.mhra.gov.uk/?search=Xalkori"},{"record":"crizotinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2012","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"crizotinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2013","href":"https://english.nmpa.gov.cn/"},{"record":"crizotinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Xalkori"},{"record":"nct06564324","field":"status","kind":"trial","state":"development","label":"A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients: phase 3, recruiting","href":"/trials/nct06564324/"},{"record":"nct06140836","field":"status","kind":"trial","state":"development","label":"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3): phase 3, active","href":"/trials/nct06140836/"},{"record":"nct04603807","field":"status","kind":"trial","state":"development","label":"A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases: phase 3, active","href":"/trials/nct04603807/"},{"record":"alchemist","field":"status","kind":"trial","state":"development","label":"ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials): phase platform, active","href":"/trials/alchemist/"},{"record":"nct05987332","field":"status","kind":"trial","state":"development","label":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma: phase 2/3, active","href":"/trials/nct05987332/"},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"nct03947385","field":"status","kind":"trial","state":"development","label":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions: phase 1/2, recruiting","href":"/trials/nct03947385/"},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"registry:crizotinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 31 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/crizotinib/#registry"},{"record":"iruplinalkib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/iruplinalkib/"},{"record":"iruplinalkib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2023: ALK-positive non-small-cell lung cancer after crizotinib; first line from 2024","href":"/drugs/iruplinalkib/"},{"record":"iruplinalkib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"nct05765877","field":"status","kind":"trial","state":"development","label":"Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct05765877/"},{"record":"registry:iruplinalkib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/iruplinalkib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"aromatase","name":"Aromatase (CYP19A1)","href":"/targets/aromatase/"},"b":{"key":"mechanismClass","id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/"},"state":"approved","drugs":[{"id":"anastrozole","name":"Anastrozole","route":"/drugs/anastrozole/","state":"approved","status":"approved"},{"id":"formestane","name":"Formestane","route":"/drugs/formestane/","state":"stopped","status":"historic"}],"counts":{"approved":1,"development":0,"stopped":1,"unclear":0},"parts":{},"evidence":[{"record":"anastrozole","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/anastrozole/"},{"record":"anastrozole","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1995: Advanced breast cancer in postmenopausal women after tamoxifen","href":"/drugs/anastrozole/"},{"record":"anastrozole","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2002: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer","href":"/drugs/anastrozole/"},{"record":"nct04711252","field":"status","kind":"trial","state":"development","label":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease: phase 3, active","href":"/trials/nct04711252/"},{"record":"nct02763566","field":"status","kind":"trial","state":"development","label":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer: phase 3, active","href":"/trials/nct02763566/"},{"record":"nct05257395","field":"status","kind":"trial","state":"development","label":"A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer: phase 3, active","href":"/trials/nct05257395/"},{"record":"registry:anastrozole","kind":"registry","state":"development","label":"ClinicalTrials.gov: 34 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/anastrozole/#registry"},{"record":"formestane","field":"status","kind":"drug","state":"stopped","label":"Drug record status: historic","href":"/drugs/formestane/","quote":"Formestane, launched in Europe in 1993, was the first selective aromatase inhibitor for advanced breast cancer, given by injection every two weeks; oral exemestane and the non-steroidal inhibitors made it redundant within a few years."}],"reasons":[{"drugId":"formestane","drugName":"Formestane","drugRoute":"/drugs/formestane/","drugState":"stopped","record":"formestane","kind":"drug","label":"Drug record status: historic","href":"/drugs/formestane/","quote":"Formestane, launched in Europe in 1993, was the first selective aromatase inhibitor for advanced breast cancer, given by injection every two weeks; oral exemestane and the non-steroidal inhibitors made it redundant within a few years."}]},{"a":{"key":"target","id":"bcl2","name":"BCL-2","href":"/targets/bcl2/"},"b":{"key":"mechanismClass","id":"bcl2-inhibitor","name":"BCL-2 inhibitor","href":"/technologies/bcl2-inhibitors/"},"state":"approved","drugs":[{"id":"sonrotoclax","name":"Sonrotoclax","route":"/drugs/sonrotoclax/","state":"approved","status":"approved"},{"id":"venetoclax","name":"Venetoclax","route":"/drugs/venetoclax/","state":"approved","status":"approved"}],"counts":{"approved":2,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"sonrotoclax","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/sonrotoclax/"},{"record":"sonrotoclax","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2025: Relapsed/refractory MCL and CLL/SLL after BTK inhibitor","href":"/drugs/sonrotoclax/"},{"record":"sonrotoclax","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2026: Relapsed/refractory mantle cell lymphoma after ≥2 lines including a BTK inhibitor (accelerated)","href":"/drugs/sonrotoclax/"},{"record":"sonrotoclax","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2026","href":"/regulatory/regions/"},{"record":"sonrotoclax","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2025","href":"https://english.nmpa.gov.cn/"},{"record":"nct04973605","field":"status","kind":"trial","state":"development","label":"A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat: phase 1/2, recruiting","href":"/trials/nct04973605/"},{"record":"nct04771130","field":"status","kind":"trial","state":"development","label":"A Study of BGB-11417 in Participants With Myeloid Malignancies: phase 1/2, recruiting","href":"/trials/nct04771130/"},{"record":"nct05952037","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia: phase 2, active","href":"/trials/nct05952037/"},{"record":"nct06943872","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL): phase 3, recruiting","href":"/trials/nct06943872/"},{"record":"nct06634589","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies: phase 1/2, recruiting","href":"/trials/nct06634589/"},{"record":"nct07277231","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia: phase 3, recruiting","href":"/trials/nct07277231/"},{"record":"nct06637501","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia: phase 2, active","href":"/trials/nct06637501/"},{"record":"nct06742996","field":"status","kind":"trial","state":"development","label":"A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refrac: phase 3, recruiting","href":"/trials/nct06742996/"},{"record":"nct06697184","field":"status","kind":"trial","state":"development","label":"A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.: phase 1/2, recruiting","href":"/trials/nct06697184/"},{"record":"celestial-tncll","field":"status","kind":"trial","state":"development","label":"CELESTIAL-TNCLL: phase 3, active","href":"/trials/celestial-tncll/"},{"record":"nct05479994","field":"status","kind":"trial","state":"development","label":"Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: phase 2, active","href":"/trials/nct05479994/"},{"record":"nct05471843","field":"status","kind":"trial","state":"development","label":"Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma: phase 1/2, active","href":"/trials/nct05471843/"},{"record":"registry:sonrotoclax","kind":"registry","state":"development","label":"ClinicalTrials.gov: 37 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/sonrotoclax/#registry"},{"record":"venetoclax","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/venetoclax/"},{"record":"venetoclax","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2016: CLL with 17p deletion","href":"/drugs/venetoclax/"},{"record":"venetoclax","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2018: AML with azacitidine/decitabine/LDAC in unfit patients","href":"/drugs/venetoclax/"},{"record":"venetoclax","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2016","href":"/regulatory/regions/"},{"record":"venetoclax","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2016","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto"},{"record":"venetoclax","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2016","href":"https://products.mhra.gov.uk/?search=Venclexta"},{"record":"venetoclax","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2019","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"venetoclax","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2020","href":"https://english.nmpa.gov.cn/"},{"record":"venetoclax","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2017","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Venclexta"},{"record":"nct04256317","field":"status","kind":"trial","state":"development","label":"A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study): phase 2/3, recruiting","href":"/trials/nct04256317/"},{"record":"nct04988555","field":"status","kind":"trial","state":"development","label":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1): phase 1/2, recruiting","href":"/trials/nct04988555/"},{"record":"nct07743112","field":"status","kind":"trial","state":"development","label":"A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia: phase 2, recruiting","href":"/trials/nct07743112/"},{"record":"nct03539744","field":"status","kind":"trial","state":"development","label":"A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) : phase 3, active","href":"/trials/nct03539744/"},{"record":"nct05951959","field":"status","kind":"trial","state":"development","label":"A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma: phase 2, active","href":"/trials/nct05951959/"},{"record":"nct05057494","field":"status","kind":"trial","state":"development","label":"A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: phase 3, active","href":"/trials/nct05057494/"},{"record":"nct07255872","field":"status","kind":"trial","state":"development","label":"A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia: phase 2/3, recruiting","href":"/trials/nct07255872/"},{"record":"nct03314181","field":"status","kind":"trial","state":"development","label":"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor: phase 2, active","href":"/trials/nct03314181/"},{"record":"nct07154264","field":"status","kind":"trial","state":"development","label":"A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10): phase 2, recruiting","href":"/trials/nct07154264/"},{"record":"nct05520567","field":"status","kind":"trial","state":"development","label":"A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia: phase 1/2, active","href":"/trials/nct05520567/"},{"record":"nct05947851","field":"status","kind":"trial","state":"development","label":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).: phase 3, recruiting","href":"/trials/nct05947851/"},{"record":"nct06846671","field":"status","kind":"trial","state":"development","label":"A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors: phase 3, recruiting","href":"/trials/nct06846671/"},{"record":"nct06456463","field":"status","kind":"trial","state":"development","label":"A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy: phase 2, active","href":"/trials/nct06456463/"},{"record":"nct06115135","field":"status","kind":"trial","state":"development","label":"A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma: phase 2, recruiting","href":"/trials/nct06115135/"},{"record":"nct02966756","field":"status","kind":"trial","state":"development","label":"A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: phase 2, active","href":"/trials/nct02966756/"},{"record":"nct07581002","field":"status","kind":"trial","state":"development","label":"A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML): phase 2/3, recruiting","href":"/trials/nct07581002/"},{"record":"nct05428969","field":"status","kind":"trial","state":"development","label":"A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies: phase 1/2, active","href":"/trials/nct05428969/"},{"record":"nct05963074","field":"status","kind":"trial","state":"development","label":"A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia: phase 2, active","href":"/trials/nct05963074/"},{"record":"nct06524375","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period: phase 2, active","href":"/trials/nct06524375/"},{"record":"nct06428019","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL): phase 3, recruiting","href":"/trials/nct06428019/"},{"record":"nct06943872","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL): phase 3, recruiting","href":"/trials/nct06943872/"},{"record":"nct07277231","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia: phase 3, recruiting","href":"/trials/nct07277231/"},{"record":"nct04965493","field":"status","kind":"trial","state":"development","label":"A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): phase 3, active","href":"/trials/nct04965493/"},{"record":"nct05211570","field":"status","kind":"trial","state":"development","label":"AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia: phase 1/2, recruiting","href":"/trials/nct05211570/"},{"record":"nct03844048","field":"status","kind":"trial","state":"development","label":"An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial: phase 3, active","href":"/trials/nct03844048/"},{"record":"beat-aml-master-trial","field":"status","kind":"trial","state":"development","label":"Beat AML Master Trial: phase platform, recruiting","href":"/trials/beat-aml-master-trial/"},{"record":"celestial-tncll","field":"status","kind":"trial","state":"development","label":"CELESTIAL-TNCLL: phase 3, active","href":"/trials/celestial-tncll/"},{"record":"nct03850574","field":"status","kind":"trial","state":"development","label":"Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia: phase 1/2, recruiting","href":"/trials/nct03850574/"},{"record":"nct06382168","field":"status","kind":"trial","state":"development","label":"DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia: phase 1/2, recruiting","href":"/trials/nct06382168/"},{"record":"nct04229979","field":"status","kind":"trial","state":"development","label":"Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2: phase 3, active","href":"/trials/nct04229979/"},{"record":"nct04086264","field":"status","kind":"trial","state":"development","label":"IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia: phase 1/2, active","href":"/trials/nct04086264/"},{"record":"myelomatch","field":"status","kind":"trial","state":"development","label":"myeloMATCH: phase platform, recruiting","href":"/trials/myelomatch/"},{"record":"nct07024706","field":"status","kind":"trial","state":"development","label":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab: phase 2, recruiting","href":"/trials/nct07024706/"},{"record":"nct05201066","field":"status","kind":"trial","state":"development","label":"Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.: phase 2, active","href":"/trials/nct05201066/"},{"record":"nct06191263","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML: phase 2, recruiting","href":"/trials/nct06191263/"},{"record":"nct07007312","field":"status","kind":"trial","state":"development","label":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML: phase 3, recruiting","href":"/trials/nct07007312/"},{"record":"nct05673057","field":"status","kind":"trial","state":"development","label":"Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome: phase 1/2, active","href":"/trials/nct05673057/"},{"record":"nct07520006","field":"status","kind":"trial","state":"development","label":"Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies: phase 1/2, recruiting","href":"/trials/nct07520006/"},{"record":"nct04588922","field":"status","kind":"trial","state":"development","label":"Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML: phase 1/2, recruiting","href":"/trials/nct04588922/"},{"record":"nct02899052","field":"status","kind":"trial","state":"development","label":"Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM): phase 2, active","href":"/trials/nct02899052/"},{"record":"nct04895436","field":"status","kind":"trial","state":"development","label":"Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL): phase 2, recruiting","href":"/trials/nct04895436/"},{"record":"nct07387471","field":"status","kind":"trial","state":"development","label":"Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobu: phase 2, active","href":"/trials/nct07387471/"},{"record":"nct04068597","field":"status","kind":"trial","state":"development","label":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies: phase 1/2, recruiting","href":"/trials/nct04068597/"},{"record":"nct04581512","field":"status","kind":"trial","state":"development","label":"Study to Evaluate the Safety and Tolerability of EP0042: phase 1/2, recruiting","href":"/trials/nct04581512/"},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"verona","field":"result","kind":"trial","state":"stopped","label":"VERONA: phase 3, negative","href":"/trials/verona/","quote":"Venetoclax added to azacitidine did not significantly improve overall survival in untreated higher-risk myelodysplastic syndromes."},{"record":"registry:venetoclax","kind":"registry","state":"development","label":"ClinicalTrials.gov: 69 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/venetoclax/#registry"}],"reasons":[{"drugId":"venetoclax","drugName":"Venetoclax","drugRoute":"/drugs/venetoclax/","drugState":"approved","record":"verona","kind":"trial","label":"VERONA: phase 3, negative","href":"/trials/verona/","quote":"Venetoclax added to azacitidine did not significantly improve overall survival in untreated higher-risk myelodysplastic syndromes."}]},{"a":{"key":"target","id":"bcr-abl+abl1","name":"BCR::ABL1 x ABL1","href":"/targets/bcr-abl/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"asciminib","name":"Asciminib","route":"/drugs/asciminib/","state":"approved","status":"approved"},{"id":"ponatinib","name":"Ponatinib","route":"/drugs/ponatinib/","state":"approved","status":"approved"}],"counts":{"approved":2,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"allosteric","name":"Allosteric"}]},"evidence":[{"record":"asciminib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/asciminib/"},{"record":"asciminib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2021: CML after ≥2 prior TKIs; T315I CML","href":"/drugs/asciminib/"},{"record":"asciminib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2024: Newly diagnosed Ph+ CML in chronic phase (ASC4FIRST)","href":"/drugs/asciminib/"},{"record":"asciminib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2021","href":"/regulatory/regions/"},{"record":"asciminib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2022","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/scemblix"},{"record":"asciminib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2022","href":"https://products.mhra.gov.uk/?search=Scemblix"},{"record":"asciminib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2022","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"asciminib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"asciminib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2022","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Scemblix"},{"record":"nct04971226","field":"status","kind":"trial","state":"development","label":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP: phase 3, active","href":"/trials/nct04971226/"},{"record":"nct05456191","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP): phase 3, active","href":"/trials/nct05456191/"},{"record":"nct05384587","field":"status","kind":"trial","state":"development","label":"Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia: phase 2, active","href":"/trials/nct05384587/"},{"record":"nct06514534","field":"status","kind":"trial","state":"development","label":"Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.: phase 2, recruiting","href":"/trials/nct06514534/"},{"record":"nct07387926","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL): phase 1/2, recruiting","href":"/trials/nct07387926/"},{"record":"nct04925479","field":"status","kind":"trial","state":"development","label":"Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia: phase 1/2, recruiting","href":"/trials/nct04925479/"},{"record":"nct07354074","field":"status","kind":"trial","state":"development","label":"Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP: phase 2, recruiting","href":"/trials/nct07354074/"},{"record":"registry:asciminib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 23 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/asciminib/#registry"},{"record":"ponatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ponatinib/"},{"record":"ponatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2012: CML and Ph+ ALL resistant to prior TKIs or with T315I","href":"/drugs/ponatinib/"},{"record":"ponatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2024: Newly diagnosed Ph+ ALL with chemotherapy (accelerated)","href":"/drugs/ponatinib/"},{"record":"ponatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2012","href":"/regulatory/regions/"},{"record":"ponatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2013","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig"},{"record":"ponatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2013","href":"https://products.mhra.gov.uk/?search=Iclusig"},{"record":"ponatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2016","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"ponatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2015","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Iclusig"},{"record":"ponatinib","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"US 2013-10-31: withdrawal","href":"/drugs/ponatinib/","quote":"Temporary marketing suspension for arterial occlusion; returned with narrowed label December 2013"},{"record":"nct03934372","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors: phase 1/2, recruiting","href":"/trials/nct03934372/"},{"record":"nct04233346","field":"status","kind":"trial","state":"development","label":"The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation: phase 2, active","href":"/trials/nct04233346/"},{"record":"nct06813079","field":"status","kind":"trial","state":"development","label":"Using Tumor Models to Determine Treatments: phase 2, recruiting","href":"/trials/nct06813079/"},{"record":"registry:ponatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 22 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ponatinib/#registry"}],"reasons":[{"drugId":"ponatinib","drugName":"Ponatinib","drugRoute":"/drugs/ponatinib/","drugState":"approved","record":"ponatinib","kind":"event","label":"US 2013-10-31: withdrawal","href":"/drugs/ponatinib/","quote":"Temporary marketing suspension for arterial occlusion; returned with narrowed label December 2013"}]},{"a":{"key":"target","id":"brd4","name":"BRD4","href":"/targets/brd4/"},"b":{"key":"mechanismClass","id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/"},"state":"development","drugs":[{"id":"pelabresib","name":"Pelabresib","route":"/drugs/pelabresib/","state":"development","status":"phase-3"},{"id":"zen-3694","name":"ZEN-3694","route":"/drugs/zen-3694/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":2,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"pelabresib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/pelabresib/"},{"record":"nct06401356","field":"status","kind":"trial","state":"development","label":"An Extension Study for Patients Previously Enrolled in Studies With Pelabresib: phase 3, recruiting","href":"/trials/nct06401356/"},{"record":"registry:pelabresib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pelabresib/#registry"},{"record":"zen-3694","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/zen-3694/"},{"record":"nct05607108","field":"status","kind":"trial","state":"development","label":"A Study of ZEN003694 in People With Squamous Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct05607108/"},{"record":"zen-3694-abemaciclib-nut","field":"status","kind":"trial","state":"development","label":"ZEN-3694 with abemaciclib in NUT carcinoma, breast cancer and other solid tumours (NCI phase 1): phase 1, recruiting","href":"/trials/zen-3694-abemaciclib-nut/"},{"record":"zen-3694-platinum-nut","field":"status","kind":"trial","state":"development","label":"ZEN-3694 with platinum chemotherapy in NUT carcinoma (NCI phase 1/2): phase 1/2, recruiting","href":"/trials/zen-3694-platinum-nut/"},{"record":"nct04986423","field":"status","kind":"trial","state":"development","label":"ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer: phase 2, recruiting","href":"/trials/nct04986423/"},{"record":"registry:zen-3694","kind":"registry","state":"development","label":"ClinicalTrials.gov: 10 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/zen-3694/#registry"}],"reasons":[]},{"a":{"key":"target","id":"cnr1","name":"Cannabinoid receptor 1","href":"/targets/cnr1/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"dronabinol","name":"Dronabinol","route":"/drugs/dronabinol/","state":"approved","status":"established"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"dronabinol","field":"status","kind":"drug","state":"approved","label":"Drug record status: established","href":"/drugs/dronabinol/"},{"record":"dronabinol","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1985: Nausea and vomiting from cancer chemotherapy in patients who have failed conventional antiemetics","href":"/drugs/dronabinol/"},{"record":"nct06731894","field":"status","kind":"trial","state":"development","label":"Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors: phase 2, recruiting","href":"/trials/nct06731894/"},{"record":"registry:dronabinol","kind":"registry","state":"development","label":"ClinicalTrials.gov: 24 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/dronabinol/#registry"}],"reasons":[]},{"a":{"key":"target","id":"cnr1","name":"Cannabinoid receptor 1","href":"/targets/cnr1/"},"b":{"key":"mechanismClass","id":"not-recorded","name":"Mechanism class not recorded"},"state":"approved","drugs":[{"id":"nabilone","name":"Nabilone","route":"/drugs/nabilone/","state":"approved","status":"established"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"nabilone","field":"status","kind":"drug","state":"approved","label":"Drug record status: established","href":"/drugs/nabilone/"},{"record":"nabilone","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1985: Nausea and vomiting from cancer chemotherapy in patients who have failed conventional antiemetics","href":"/drugs/nabilone/"},{"record":"registry:nabilone","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/nabilone/#registry"}],"reasons":[]},{"a":{"key":"target","id":"drd2","name":"Dopamine D2 receptor","href":"/targets/drd2/"},"b":{"key":"mechanismClass","id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/"},"state":"approved","drugs":[{"id":"bromocriptine","name":"Bromocriptine","route":"/drugs/bromocriptine/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"bromocriptine","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/bromocriptine/"},{"record":"bromocriptine","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1978: Hyperprolactinaemia-associated dysfunction including prolactin-secreting adenomas; acromegaly; Parkinson's disease","href":"/drugs/bromocriptine/"},{"record":"registry:bromocriptine","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/bromocriptine/#registry"}],"reasons":[]},{"a":{"key":"target","id":"drd2","name":"Dopamine D2 receptor","href":"/targets/drd2/"},"b":{"key":"mechanismClass","id":"receptor-agonist","name":"Receptor agonist"},"state":"approved","drugs":[{"id":"cabergoline","name":"Cabergoline","route":"/drugs/cabergoline/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"cabergoline","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/cabergoline/"},{"record":"cabergoline","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1996: Hyperprolactinaemic disorders, idiopathic or due to pituitary adenomas","href":"/drugs/cabergoline/"},{"record":"nct07463235","field":"status","kind":"trial","state":"development","label":"Safety and Potency of a High Cabergoline Dosage in Microprolactinomas: phase 3, recruiting","href":"/trials/nct07463235/"},{"record":"registry:cabergoline","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/cabergoline/#registry"}],"reasons":[]},{"a":{"key":"target","id":"ednra","name":"EDNRA","href":"/targets/ednra/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"stopped","drugs":[{"id":"zibotentan","name":"Zibotentan","route":"/drugs/zibotentan/","state":"stopped","status":"withdrawn"}],"counts":{"approved":0,"development":0,"stopped":1,"unclear":0},"parts":{},"evidence":[{"record":"zibotentan","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/zibotentan/","quote":"A drug blocking a signal that prostate cancer uses to grow in bone. Three trials in prostate cancer found no survival benefit and it was dropped."},{"record":"enthuse-m1-zibotentan","field":"result","kind":"trial","state":"stopped","label":"ENTHUSE M1: phase 3, negative","href":"/trials/enthuse-m1-zibotentan/","quote":"Median overall survival 24.5 against 22.5 months (hazard ratio 0.87, 95.2 percent confidence interval 0.69 to 1.10, p=0.240): not significant, with peripheral oedema in 44 percent and cardiac failure of any grade in 5.7 against 1.7 percent."},{"record":"swog-s0421-atrasentan","field":"result","kind":"trial","state":"stopped","label":"SWOG S0421: phase 3, negative","href":"/trials/swog-s0421-atrasentan/","quote":"Median overall survival 17.8 against 17.6 months (hazard ratio 1.04, 95 percent confidence interval 0.90 to 1.19) and progression-free survival 9.2 against 9.1 months (1.02, 0.89 to 1.16); halted early for futility, and no difference in pain palliation."},{"record":"registry:zibotentan","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/zibotentan/#registry"}],"reasons":[{"drugId":"zibotentan","drugName":"Zibotentan","drugRoute":"/drugs/zibotentan/","drugState":"stopped","record":"zibotentan","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/zibotentan/","quote":"A drug blocking a signal that prostate cancer uses to grow in bone. Three trials in prostate cancer found no survival benefit and it was dropped."},{"drugId":"zibotentan","drugName":"Zibotentan","drugRoute":"/drugs/zibotentan/","drugState":"stopped","record":"enthuse-m1-zibotentan","kind":"trial","label":"ENTHUSE M1: phase 3, negative","href":"/trials/enthuse-m1-zibotentan/","quote":"Median overall survival 24.5 against 22.5 months (hazard ratio 0.87, 95.2 percent confidence interval 0.69 to 1.10, p=0.240): not significant, with peripheral oedema in 44 percent and cardiac failure of any grade in 5.7 against 1.7 percent."},{"drugId":"zibotentan","drugName":"Zibotentan","drugRoute":"/drugs/zibotentan/","drugState":"stopped","record":"swog-s0421-atrasentan","kind":"trial","label":"SWOG S0421: phase 3, negative","href":"/trials/swog-s0421-atrasentan/","quote":"Median overall survival 17.8 against 17.6 months (hazard ratio 1.04, 95 percent confidence interval 0.90 to 1.19) and progression-free survival 9.2 against 9.1 months (1.02, 0.89 to 1.16); halted early for futility, and no difference in pain palliation."}]},{"a":{"key":"target","id":"ednra","name":"EDNRA","href":"/targets/ednra/"},"b":{"key":"mechanismClass","id":"receptor-agonist","name":"Receptor agonist"},"state":"stopped","drugs":[{"id":"atrasentan","name":"Atrasentan","route":"/drugs/atrasentan/","state":"stopped","status":"withdrawn"}],"counts":{"approved":0,"development":0,"stopped":1,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"atrasentan","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/atrasentan/","quote":"The other endothelin blocker. Adding it to chemotherapy for advanced prostate cancer changed nothing, and the trial was stopped for futility."},{"record":"enthuse-m1-zibotentan","field":"result","kind":"trial","state":"stopped","label":"ENTHUSE M1: phase 3, negative","href":"/trials/enthuse-m1-zibotentan/","quote":"Median overall survival 24.5 against 22.5 months (hazard ratio 0.87, 95.2 percent confidence interval 0.69 to 1.10, p=0.240): not significant, with peripheral oedema in 44 percent and cardiac failure of any grade in 5.7 against 1.7 percent."},{"record":"swog-s0421-atrasentan","field":"result","kind":"trial","state":"stopped","label":"SWOG S0421: phase 3, negative","href":"/trials/swog-s0421-atrasentan/","quote":"Median overall survival 17.8 against 17.6 months (hazard ratio 1.04, 95 percent confidence interval 0.90 to 1.19) and progression-free survival 9.2 against 9.1 months (1.02, 0.89 to 1.16); halted early for futility, and no difference in pain palliation."},{"record":"registry:atrasentan","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/atrasentan/#registry"}],"reasons":[{"drugId":"atrasentan","drugName":"Atrasentan","drugRoute":"/drugs/atrasentan/","drugState":"stopped","record":"atrasentan","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/atrasentan/","quote":"The other endothelin blocker. Adding it to chemotherapy for advanced prostate cancer changed nothing, and the trial was stopped for futility."},{"drugId":"atrasentan","drugName":"Atrasentan","drugRoute":"/drugs/atrasentan/","drugState":"stopped","record":"enthuse-m1-zibotentan","kind":"trial","label":"ENTHUSE M1: phase 3, negative","href":"/trials/enthuse-m1-zibotentan/","quote":"Median overall survival 24.5 against 22.5 months (hazard ratio 0.87, 95.2 percent confidence interval 0.69 to 1.10, p=0.240): not significant, with peripheral oedema in 44 percent and cardiac failure of any grade in 5.7 against 1.7 percent."},{"drugId":"atrasentan","drugName":"Atrasentan","drugRoute":"/drugs/atrasentan/","drugState":"stopped","record":"swog-s0421-atrasentan","kind":"trial","label":"SWOG S0421: phase 3, negative","href":"/trials/swog-s0421-atrasentan/","quote":"Median overall survival 17.8 against 17.6 months (hazard ratio 1.04, 95 percent confidence interval 0.90 to 1.19) and progression-free survival 9.2 against 9.1 months (1.02, 0.89 to 1.16); halted early for futility, and no difference in pain palliation."}]},{"a":{"key":"target","id":"egfr+her2","name":"EGFR x HER2","href":"/targets/egfr/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"afatinib","name":"Afatinib","route":"/drugs/afatinib/","state":"approved","status":"approved"},{"id":"varlitinib","name":"Varlitinib","route":"/drugs/varlitinib/","state":"stopped","status":"historic"}],"counts":{"approved":1,"development":0,"stopped":1,"unclear":0},"parts":{"binding":[{"key":"binding","id":"covalent","name":"Covalent"},{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"}]},"evidence":[{"record":"afatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/afatinib/"},{"record":"afatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2013: First-line metastatic NSCLC with EGFR exon 19 del or L858R","href":"/drugs/afatinib/"},{"record":"afatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2016: Squamous NSCLC after platinum","href":"/drugs/afatinib/"},{"record":"afatinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2018: Uncommon EGFR mutations (S768I, L861Q, G719X)","href":"/drugs/afatinib/"},{"record":"afatinib","field":"approvals[3]","kind":"approval","state":"approved","label":"EU 2013: EU brand Giotrif","href":"/drugs/afatinib/"},{"record":"afatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2013","href":"/regulatory/regions/"},{"record":"afatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2013","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif"},{"record":"afatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2013","href":"https://products.mhra.gov.uk/?search=Giotrif"},{"record":"afatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2014","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"afatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2017","href":"https://english.nmpa.gov.cn/"},{"record":"afatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Giotrif"},{"record":"nct06486142","field":"status","kind":"trial","state":"development","label":"EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study: phase 3, recruiting","href":"/trials/nct06486142/"},{"record":"nct06759857","field":"status","kind":"trial","state":"development","label":"FHND9041 Versus Afatinib for Non-small Cell Lung Cancer: phase 3, recruiting","href":"/trials/nct06759857/"},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"nct03785249","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1: phase 1/2, active","href":"/trials/nct03785249/"},{"record":"nct04183712","field":"status","kind":"trial","state":"development","label":"Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA: phase 2, recruiting","href":"/trials/nct04183712/"},{"record":"registry:afatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 17 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/afatinib/#registry"},{"record":"varlitinib","field":"status","kind":"drug","state":"stopped","label":"Drug record status: historic","href":"/drugs/varlitinib/","quote":"A pill that blocked the HER family of growth receptors, tested with capecitabine as second-line treatment for bile duct and gallbladder cancer. It did not beat capecitabine alone in the TreeTopp trial and development stopped."},{"record":"treetopp","field":"result","kind":"trial","state":"stopped","label":"TreeTopp: phase 2/3, negative","href":"/trials/treetopp/","quote":"ORR 9.4% vs 4.8%; PFS 2.83 vs 2.79 months, HR 0.90; OS 7.8 vs 7.5 months, HR 1.11; gallbladder subgroup PFS 2.9 vs 1.6 months, HR 0.55 (0.26 to 1.19)."},{"record":"registry:varlitinib","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 3 terminated or withdrawn studies and none active (fetched 2026-09-28)","href":"/drugs/varlitinib/#registry"}],"reasons":[{"drugId":"varlitinib","drugName":"Varlitinib","drugRoute":"/drugs/varlitinib/","drugState":"stopped","record":"varlitinib","kind":"drug","label":"Drug record status: historic","href":"/drugs/varlitinib/","quote":"A pill that blocked the HER family of growth receptors, tested with capecitabine as second-line treatment for bile duct and gallbladder cancer. It did not beat capecitabine alone in the TreeTopp trial and development stopped."},{"drugId":"varlitinib","drugName":"Varlitinib","drugRoute":"/drugs/varlitinib/","drugState":"stopped","record":"treetopp","kind":"trial","label":"TreeTopp: phase 2/3, negative","href":"/trials/treetopp/","quote":"ORR 9.4% vs 4.8%; PFS 2.83 vs 2.79 months, HR 0.90; OS 7.8 vs 7.5 months, HR 1.11; gallbladder subgroup PFS 2.9 vs 1.6 months, HR 0.55 (0.26 to 1.19)."}]},{"a":{"key":"target","id":"ezh2","name":"EZH2","href":"/targets/ezh2/"},"b":{"key":"mechanismClass","id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/"},"state":"development","drugs":[{"id":"tazemetostat","name":"Tazemetostat","route":"/drugs/tazemetostat/","state":"stopped","status":"withdrawn"},{"id":"xnw5004","name":"XNW5004","route":"/drugs/xnw5004/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":1,"stopped":1,"unclear":0},"parts":{},"evidence":[{"record":"tazemetostat","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/tazemetostat/","quote":"Tazemetostat was the first EZH2 inhibitor, approved for epithelioid sarcoma and follicular lymphoma in 2020 and withdrawn worldwide in 2026 after secondary blood cancers."},{"record":"tazemetostat","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2020: Epithelioid sarcoma; relapsed FL (EZH2-mutant after 2 lines; wild-type without alternatives)","href":"/drugs/tazemetostat/"},{"record":"tazemetostat","field":"regulatoryEvents[2]","kind":"event","state":"stopped","label":"Global 2026-03: withdrawal","href":"/drugs/tazemetostat/","quote":"Withdrawn over secondary haematologic malignancies"},{"record":"tazemetostat","field":"regulatoryEvents[3]","kind":"event","state":"stopped","label":"US 2026-06-22: withdrawal","href":"https://wayback.archive-it.org/7993/20201222063544/https:/www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tazemetostat-advanced-epithelioid-sarcoma","quote":"Withdrawn: the indication came off the label 6.4 years after its accelerated approval."},{"record":"tazemetostat","field":"regulatoryEvents[4]","kind":"event","state":"stopped","label":"US 2026-06-22: withdrawal","href":"https://wayback.archive-it.org/7993/20201222062826/https:/www.fda.gov/drugs/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma","quote":"Withdrawn: the indication came off the label 6.0 years after its accelerated approval."},{"record":"nct07407283","field":"status","kind":"trial","state":"development","label":"A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct07407283/"},{"record":"nct04224493","field":"status","kind":"trial","state":"development","label":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus : phase 3, active","href":"/trials/nct04224493/"},{"record":"nct05372354","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed : phase 1/2, recruiting","href":"/trials/nct05372354/"},{"record":"pediatric-match","field":"status","kind":"trial","state":"development","label":"NCI-COG Pediatric MATCH (APEC1621): phase platform, active","href":"/trials/pediatric-match/"},{"record":"tazemetostat-doxorubicin-es","field":"notes (registry whyStopped)","kind":"trial","state":"stopped","label":"Tazemetostat with doxorubicin as front-line therapy for advanced epithelioid sarcoma (EZH-301 run-in): phase 1, terminated or withdrawn","href":"/trials/tazemetostat-doxorubicin-es/","quote":"FDA and Ipsen alignelment: Due to unfeasibility and the resulting inability to meet the required enrolment targets. No safety concerns."},{"record":"registry:tazemetostat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 18 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tazemetostat/#registry"},{"record":"xnw5004","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/xnw5004/"},{"record":"nct06776952","field":"status","kind":"trial","state":"development","label":"A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma: phase 3, recruiting","href":"/trials/nct06776952/"},{"record":"nct07730515","field":"status","kind":"trial","state":"development","label":"Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma: phase 1/2, recruiting","href":"/trials/nct07730515/"},{"record":"nct07545603","field":"status","kind":"trial","state":"development","label":"Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma: phase 2, recruiting","href":"/trials/nct07545603/"},{"record":"nct06702995","field":"status","kind":"trial","state":"development","label":"Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct06702995/"},{"record":"registry:xnw5004","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/xnw5004/#registry"}],"reasons":[{"drugId":"tazemetostat","drugName":"Tazemetostat","drugRoute":"/drugs/tazemetostat/","drugState":"stopped","record":"tazemetostat","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/tazemetostat/","quote":"Tazemetostat was the first EZH2 inhibitor, approved for epithelioid sarcoma and follicular lymphoma in 2020 and withdrawn worldwide in 2026 after secondary blood cancers."},{"drugId":"tazemetostat","drugName":"Tazemetostat","drugRoute":"/drugs/tazemetostat/","drugState":"stopped","record":"tazemetostat","kind":"event","label":"Global 2026-03: withdrawal","href":"/drugs/tazemetostat/","quote":"Withdrawn over secondary haematologic malignancies"},{"drugId":"tazemetostat","drugName":"Tazemetostat","drugRoute":"/drugs/tazemetostat/","drugState":"stopped","record":"tazemetostat","kind":"event","label":"US 2026-06-22: withdrawal","href":"https://wayback.archive-it.org/7993/20201222063544/https:/www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tazemetostat-advanced-epithelioid-sarcoma","quote":"Withdrawn: the indication came off the label 6.4 years after its accelerated approval."},{"drugId":"tazemetostat","drugName":"Tazemetostat","drugRoute":"/drugs/tazemetostat/","drugState":"stopped","record":"tazemetostat","kind":"event","label":"US 2026-06-22: withdrawal","href":"https://wayback.archive-it.org/7993/20201222062826/https:/www.fda.gov/drugs/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma","quote":"Withdrawn: the indication came off the label 6.0 years after its accelerated approval."},{"drugId":"tazemetostat","drugName":"Tazemetostat","drugRoute":"/drugs/tazemetostat/","drugState":"stopped","record":"tazemetostat-doxorubicin-es","kind":"trial","label":"Tazemetostat with doxorubicin as front-line therapy for advanced epithelioid sarcoma (EZH-301 run-in): phase 1, terminated or withdrawn","href":"/trials/tazemetostat-doxorubicin-es/","quote":"FDA and Ipsen alignelment: Due to unfeasibility and the resulting inability to meet the required enrolment targets. No safety concerns."}]},{"a":{"key":"target","id":"fak","name":"FAK (PTK2)","href":"/targets/fak/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"development","drugs":[{"id":"gsk2256098","name":"GSK2256098","route":"/drugs/gsk2256098/","state":"development","status":"phase-2"},{"id":"in10018","name":"IN10018","route":"/drugs/in10018/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":2,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"}]},"evidence":[{"record":"gsk2256098","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/gsk2256098/"},{"record":"registry:gsk2256098","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/gsk2256098/#registry"},{"record":"in10018","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/in10018/"},{"record":"nct07174908","field":"status","kind":"trial","state":"development","label":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation: phase 3, recruiting","href":"/trials/nct07174908/"},{"record":"nct07833202","field":"status","kind":"trial","state":"development","label":"A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutatio: phase 3, planned","href":"/trials/nct07833202/"},{"record":"nct06166836","field":"status","kind":"trial","state":"development","label":"a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors: phase 1/2, active","href":"/trials/nct06166836/"},{"record":"nct06708663","field":"status","kind":"trial","state":"development","label":"HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours: phase 1/2, recruiting","href":"/trials/nct06708663/"},{"record":"nct05994131","field":"status","kind":"trial","state":"development","label":"IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC: phase 1/2, recruiting","href":"/trials/nct05994131/"},{"record":"nct06030258","field":"status","kind":"trial","state":"development","label":"IN10018 Combination Therapy in Treatment-naïve ES-SCLC: phase 1/2, recruiting","href":"/trials/nct06030258/"},{"record":"nct06014528","field":"status","kind":"trial","state":"development","label":"IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurren: phase 2, recruiting","href":"/trials/nct06014528/"},{"record":"nct07441174","field":"status","kind":"trial","state":"development","label":"IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors: phase 1/2, recruiting","href":"/trials/nct07441174/"},{"record":"nct05551507","field":"status","kind":"trial","state":"development","label":"IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer: phase 1/2, recruiting","href":"/trials/nct05551507/"},{"record":"nct05827796","field":"status","kind":"trial","state":"development","label":"IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer: phase 1/2, recruiting","href":"/trials/nct05827796/"},{"record":"nct05379946","field":"status","kind":"trial","state":"development","label":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors: phase 1/2, active","href":"/trials/nct05379946/"},{"record":"registry:in10018","kind":"registry","state":"development","label":"ClinicalTrials.gov: 12 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/in10018/#registry"}],"reasons":[]},{"a":{"key":"target","id":"jak2+flt3","name":"JAK2 x FLT3","href":"/targets/jak2/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"fedratinib","name":"Fedratinib","route":"/drugs/fedratinib/","state":"approved","status":"approved"},{"id":"pacritinib","name":"Pacritinib","route":"/drugs/pacritinib/","state":"approved","status":"approved"}],"counts":{"approved":2,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"fedratinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/fedratinib/"},{"record":"fedratinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2019: Intermediate-2/high-risk primary or secondary myelofibrosis","href":"/drugs/fedratinib/"},{"record":"fedratinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2021: Myelofibrosis, JAK-inhibitor-naive or after ruxolitinib","href":"/drugs/fedratinib/"},{"record":"fedratinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2019","href":"/regulatory/regions/"},{"record":"fedratinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2021","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/inrebic"},{"record":"fedratinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved","href":"https://products.mhra.gov.uk/?search=Inrebic"},{"record":"fedratinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2025","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"fedratinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Inrebic"},{"record":"nct04817007","field":"status","kind":"trial","state":"development","label":"A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis): phase 1/2, active","href":"/trials/nct04817007/"},{"record":"registry:fedratinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/fedratinib/#registry"},{"record":"pacritinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/pacritinib/"},{"record":"pacritinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2022: Intermediate/high-risk myelofibrosis with platelets <50×10⁹/L","href":"/drugs/pacritinib/"},{"record":"pacritinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2022","href":"/regulatory/regions/"},{"record":"nct07033598","field":"status","kind":"trial","state":"development","label":"Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia: phase 2, recruiting","href":"/trials/nct07033598/"},{"record":"registry:pacritinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 17 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pacritinib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"jak2+jak1","name":"JAK2 x JAK1","href":"/targets/jak2/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"momelotinib","name":"Momelotinib","route":"/drugs/momelotinib/","state":"approved","status":"approved"},{"id":"ruxolitinib","name":"Ruxolitinib","route":"/drugs/ruxolitinib/","state":"approved","status":"approved"}],"counts":{"approved":2,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"}]},"evidence":[{"record":"momelotinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/momelotinib/"},{"record":"momelotinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2023: Intermediate/high-risk myelofibrosis with anaemia","href":"/drugs/momelotinib/"},{"record":"momelotinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2024: Myelofibrosis with moderate-to-severe anaemia","href":"/drugs/momelotinib/"},{"record":"momelotinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2023","href":"/regulatory/regions/"},{"record":"momelotinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2024","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/omjjara"},{"record":"momelotinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2024","href":"https://products.mhra.gov.uk/?search=Omjjara"},{"record":"momelotinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2024","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"registry:momelotinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 10 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/momelotinib/#registry"},{"record":"ruxolitinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ruxolitinib/"},{"record":"ruxolitinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2011: Intermediate/high-risk myelofibrosis","href":"/drugs/ruxolitinib/"},{"record":"ruxolitinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2014: Polycythaemia vera after hydroxyurea","href":"/drugs/ruxolitinib/"},{"record":"ruxolitinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2019: Steroid-refractory acute GVHD","href":"/drugs/ruxolitinib/"},{"record":"ruxolitinib","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2021: Chronic GVHD after failure of 1-2 lines","href":"/drugs/ruxolitinib/"},{"record":"ruxolitinib","field":"approvals[4]","kind":"approval","state":"approved","label":"EU 2012: Myelofibrosis","href":"/drugs/ruxolitinib/"},{"record":"ruxolitinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2011","href":"/regulatory/regions/"},{"record":"ruxolitinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2012","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi"},{"record":"ruxolitinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2012","href":"https://products.mhra.gov.uk/?search=Jakavi"},{"record":"ruxolitinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2014","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"ruxolitinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2017","href":"https://english.nmpa.gov.cn/"},{"record":"ruxolitinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Jakavi"},{"record":"nct04817007","field":"status","kind":"trial","state":"development","label":"A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis): phase 1/2, active","href":"/trials/nct04817007/"},{"record":"nct02955940","field":"status","kind":"trial","state":"development","label":"An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib: phase 2, active","href":"/trials/nct02955940/"},{"record":"nct03669965","field":"status","kind":"trial","state":"development","label":"KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera: phase 2, active","href":"/trials/nct03669965/"},{"record":"majic-et","field":"result","kind":"trial","state":"stopped","label":"MAJIC-ET: phase 2, negative","href":"/trials/majic-et/","quote":"Complete response within 1 year 46.6% (ruxolitinib) vs 44.2% (best available therapy), not significant; no difference in clots, bleeding or transformation at 2 years."},{"record":"nct07219576","field":"status","kind":"trial","state":"development","label":"Retifanlimab and Ruxolitinib In Solid Malignancies: phase 1/2, recruiting","href":"/trials/nct07219576/"},{"record":"nct04509700","field":"status","kind":"trial","state":"development","label":"Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465): phase 2, active","href":"/trials/nct04509700/"},{"record":"nct04562389","field":"status","kind":"trial","state":"development","label":"Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis: phase 3, active","href":"/trials/nct04562389/"},{"record":"registry:ruxolitinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 25 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ruxolitinib/#registry"}],"reasons":[{"drugId":"ruxolitinib","drugName":"Ruxolitinib","drugRoute":"/drugs/ruxolitinib/","drugState":"approved","record":"majic-et","kind":"trial","label":"MAJIC-ET: phase 2, negative","href":"/trials/majic-et/","quote":"Complete response within 1 year 46.6% (ruxolitinib) vs 44.2% (best available therapy), not significant; no difference in clots, bleeding or transformation at 2 years."}]},{"a":{"key":"target","id":"mpl","name":"MPL (thrombopoietin receptor)","href":"/targets/mpl/"},"b":{"key":"mechanismClass","id":"receptor-agonist","name":"Receptor agonist"},"state":"approved","drugs":[{"id":"eltrombopag","name":"Eltrombopag","route":"/drugs/eltrombopag/","state":"approved","status":"established"},{"id":"romiplostim","name":"Romiplostim","route":"/drugs/romiplostim/","state":"approved","status":"established"}],"counts":{"approved":2,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"eltrombopag","field":"status","kind":"drug","state":"approved","label":"Drug record status: established","href":"/drugs/eltrombopag/"},{"record":"eltrombopag","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2008: Chronic immune thrombocytopenia with insufficient response to corticosteroids, immunoglobulins or splenectomy","href":"/drugs/eltrombopag/"},{"record":"nct03603795","field":"status","kind":"trial","state":"development","label":"Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy: phase 2, active","href":"/trials/nct03603795/"},{"record":"registry:eltrombopag","kind":"registry","state":"development","label":"ClinicalTrials.gov: 18 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/eltrombopag/#registry"},{"record":"romiplostim","field":"status","kind":"drug","state":"approved","label":"Drug record status: established","href":"/drugs/romiplostim/"},{"record":"romiplostim","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2008: Immune thrombocytopenia with insufficient response to corticosteroids, immunoglobulins or splenectomy","href":"/drugs/romiplostim/"},{"record":"nct03937154","field":"status","kind":"trial","state":"development","label":"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer: phase 3, active","href":"/trials/nct03937154/"},{"record":"registry:romiplostim","kind":"registry","state":"development","label":"ClinicalTrials.gov: 25 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/romiplostim/#registry"}],"reasons":[]},{"a":{"key":"target","id":"oprm1","name":"Mu-opioid receptor","href":"/targets/oprm1/"},"b":{"key":"mechanismClass","id":"receptor-agonist","name":"Receptor agonist"},"state":"approved","drugs":[{"id":"fentanyl","name":"Fentanyl (transmucosal, for breakthrough cancer pain)","route":"/drugs/fentanyl/","state":"approved","status":"approved"},{"id":"methylnaltrexone","name":"Methylnaltrexone","route":"/drugs/methylnaltrexone/","state":"approved","status":"approved"}],"counts":{"approved":2,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"fentanyl","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/fentanyl/"},{"record":"fentanyl","field":"approvals[0]","kind":"approval","state":"approved","label":"EU 2008: Breakthrough pain in adults receiving maintenance opioid therapy for chronic cancer pain","href":"/drugs/fentanyl/"},{"record":"fentanyl","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2008","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/effentora"},{"record":"registry:fentanyl","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/fentanyl/#registry"},{"record":"methylnaltrexone","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/methylnaltrexone/"},{"record":"methylnaltrexone","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2008: Opioid-induced constipation in advanced illness receiving palliative care (chronic non-cancer pain and oral tablets added 2014 to 2016)","href":"/drugs/methylnaltrexone/"},{"record":"methylnaltrexone","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2008: Opioid-induced constipation in advanced illness receiving palliative care when laxatives are insufficient (Relistor)","href":"/drugs/methylnaltrexone/"},{"record":"registry:methylnaltrexone","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 4 terminated or withdrawn studies and none active (fetched 2026-09-28)","href":"/drugs/methylnaltrexone/#registry"}],"reasons":[]},{"a":{"key":"target","id":"pik3ca+akt","name":"PIK3CA / PI3K-alpha x AKT","href":"/targets/pik3ca/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"gedatolisib","name":"Gedatolisib","route":"/drugs/gedatolisib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"gedatolisib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/gedatolisib/"},{"record":"gedatolisib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2026: HR+/HER2- advanced breast cancer after CDK4/6 inhibitor (July 2026)","href":"/drugs/gedatolisib/"},{"record":"gedatolisib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2026","href":"/regulatory/regions/"},{"record":"nct06190899","field":"status","kind":"trial","state":"development","label":"Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct06190899/"},{"record":"nct05501886","field":"status","kind":"trial","state":"development","label":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1): phase 3, active","href":"/trials/nct05501886/"},{"record":"nct06757634","field":"status","kind":"trial","state":"development","label":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2): phase 3, recruiting","href":"/trials/nct06757634/"},{"record":"registry:gedatolisib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/gedatolisib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"pik3ca+akt","name":"PIK3CA / PI3K-alpha x AKT","href":"/targets/pik3ca/"},"b":{"key":"mechanismClass","id":"pi3k-akt-mtor-inhibitor","name":"PI3K, AKT or mTOR inhibitor","href":"/technologies/pi3k-akt-mtor-inhibitors/"},"state":"approved","drugs":[{"id":"everolimus","name":"Everolimus","route":"/drugs/everolimus/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"allosteric","name":"Allosteric"}]},"evidence":[{"record":"everolimus","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/everolimus/"},{"record":"everolimus","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2012: HR+/HER2- advanced breast cancer with exemestane after NSAI failure","href":"/drugs/everolimus/"},{"record":"everolimus","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2011: Progressive pancreatic NETs","href":"/drugs/everolimus/"},{"record":"everolimus","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2016: Progressive non-functional lung and GI NETs","href":"/drugs/everolimus/"},{"record":"everolimus","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2009: Advanced RCC after sunitinib or sorafenib","href":"/drugs/everolimus/"},{"record":"everolimus","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2009","href":"/regulatory/regions/"},{"record":"everolimus","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2009","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/afinitor"},{"record":"everolimus","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2009","href":"https://products.mhra.gov.uk/?search=Afinitor"},{"record":"everolimus","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2010","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"everolimus","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2013","href":"https://english.nmpa.gov.cn/"},{"record":"everolimus","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2009","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Afinitor"},{"record":"nct07002177","field":"status","kind":"trial","state":"development","label":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC: phase 1/2, recruiting","href":"/trials/nct07002177/"},{"record":"nct04802759","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer: phase 1/2, recruiting","href":"/trials/nct04802759/"},{"record":"nct05918302","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.: phase 3, recruiting","href":"/trials/nct05918302/"},{"record":"nct06301386","field":"status","kind":"trial","state":"development","label":"Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients: phase 2, planned","href":"/trials/nct06301386/"},{"record":"nct07340541","field":"status","kind":"trial","state":"development","label":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies: phase 2, recruiting","href":"/trials/nct07340541/"},{"record":"nct05749588","field":"status","kind":"trial","state":"development","label":"FUSCC Refractory TNBC Platform Study (FUTURE2.0): phase 2, recruiting","href":"/trials/nct05749588/"},{"record":"nct04919226","field":"status","kind":"trial","state":"development","label":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE: phase 3, active","href":"/trials/nct04919226/"},{"record":"nct05563220","field":"status","kind":"trial","state":"development","label":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer: phase 1/2, active","href":"/trials/nct05563220/"},{"record":"nct05573126","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer: phase 1/2, recruiting","href":"/trials/nct05573126/"},{"record":"nct07165886","field":"status","kind":"trial","state":"development","label":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors: phase 2/3, recruiting","href":"/trials/nct07165886/"},{"record":"nct06428396","field":"status","kind":"trial","state":"development","label":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029): phase 2, active","href":"/trials/nct06428396/"},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"registry:everolimus","kind":"registry","state":"development","label":"ClinicalTrials.gov: 19 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/everolimus/#registry"}],"reasons":[]},{"a":{"key":"target","id":"rara+rxr","name":"Retinoic acid receptor alpha x Retinoid X receptor","href":"/targets/rara/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"acitretin","name":"Acitretin","route":"/drugs/acitretin/","state":"approved","status":"approved"},{"id":"isotretinoin","name":"Isotretinoin","route":"/drugs/isotretinoin/","state":"approved","status":"approved"}],"counts":{"approved":2,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"acitretin","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/acitretin/"},{"record":"acitretin","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1996: Severe psoriasis (oncology use as chemoprevention of squamous cell carcinoma is off-label)","href":"/drugs/acitretin/"},{"record":"registry:acitretin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/acitretin/#registry"},{"record":"isotretinoin","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/isotretinoin/"},{"record":"isotretinoin","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1982: Severe recalcitrant nodular acne (use in high-risk neuroblastoma is off-label but standard)","href":"/drugs/isotretinoin/"},{"record":"registry:isotretinoin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/isotretinoin/#registry"}],"reasons":[]},{"a":{"key":"target","id":"ros1","name":"ROS1","href":"/targets/ros1/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"taletrectinib","name":"Taletrectinib","route":"/drugs/taletrectinib/","state":"approved","status":"approved"},{"id":"zidesamtinib","name":"Zidesamtinib","route":"/drugs/zidesamtinib/","state":"approved","status":"approved"}],"counts":{"approved":2,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"taletrectinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/taletrectinib/"},{"record":"taletrectinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2025: ROS1-positive NSCLC","href":"/drugs/taletrectinib/"},{"record":"taletrectinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2025: Locally advanced or metastatic ROS1-positive NSCLC","href":"/drugs/taletrectinib/"},{"record":"taletrectinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2025","href":"/regulatory/regions/"},{"record":"taletrectinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2025","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"taletrectinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2025","href":"https://english.nmpa.gov.cn/"},{"record":"nct06564324","field":"status","kind":"trial","state":"development","label":"A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients: phase 3, recruiting","href":"/trials/nct06564324/"},{"record":"nct07154706","field":"status","kind":"trial","state":"development","label":"Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV): phase 3, recruiting","href":"/trials/nct07154706/"},{"record":"nct04919811","field":"status","kind":"trial","state":"development","label":"Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC: phase 2, active","href":"/trials/nct04919811/"},{"record":"registry:taletrectinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/taletrectinib/#registry"},{"record":"zidesamtinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/zidesamtinib/"},{"record":"zidesamtinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2026: ROS1+ NSCLC (July 2026)","href":"/drugs/zidesamtinib/"},{"record":"zidesamtinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2026","href":"/regulatory/regions/"},{"record":"nct05118789","field":"status","kind":"trial","state":"development","label":"A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1): phase 1/2, recruiting","href":"/trials/nct05118789/"},{"record":"registry:zidesamtinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/zidesamtinib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"shp2","name":"SHP2 (PTPN11)","href":"/targets/shp2/"},"b":{"key":"mechanismClass","id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/"},"state":"development","drugs":[{"id":"sitneprotafib","name":"Sitneprotafib","route":"/drugs/sitneprotafib/","state":"development","status":"phase-3"},{"id":"tno155","name":"TNO155","route":"/drugs/tno155/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":2,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"allosteric","name":"Allosteric"}]},"evidence":[{"record":"sitneprotafib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/sitneprotafib/"},{"record":"nct06416410","field":"status","kind":"trial","state":"development","label":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation: phase 3, recruiting","href":"/trials/nct06416410/"},{"record":"nct05288205","field":"status","kind":"trial","state":"development","label":"Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation: phase 1/2, recruiting","href":"/trials/nct05288205/"},{"record":"tno155","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/tno155/"},{"record":"nct07468071","field":"status","kind":"trial","state":"development","label":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other: phase 1/2, recruiting","href":"/trials/nct07468071/"},{"record":"nct04699188","field":"status","kind":"trial","state":"development","label":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation: phase 1/2, active","href":"/trials/nct04699188/"},{"record":"registry:tno155","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tno155/#registry"}],"reasons":[]},{"a":{"key":"target","id":"sstr2","name":"Somatostatin receptor 2","href":"/targets/sstr2/"},"b":{"key":"mechanismClass","id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/"},"state":"approved","drugs":[{"id":"paltusotine","name":"Paltusotine","route":"/drugs/paltusotine/","state":"approved","status":"approved"},{"id":"octreotide-lanreotide","name":"Somatostatin analogues (octreotide, lanreotide)","route":"/drugs/octreotide-lanreotide/","state":"approved","status":"approved"}],"counts":{"approved":2,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"paltusotine","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/paltusotine/"},{"record":"paltusotine","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2025: Acromegaly in adults","href":"/drugs/paltusotine/"},{"record":"nct07087054","field":"status","kind":"trial","state":"development","label":"Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen: phase 3, recruiting","href":"/trials/nct07087054/"},{"record":"registry:paltusotine","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/paltusotine/#registry"},{"record":"octreotide-lanreotide","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/octreotide-lanreotide/"},{"record":"octreotide-lanreotide","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1988: Carcinoid syndrome symptoms (octreotide)","href":"/drugs/octreotide-lanreotide/"},{"record":"octreotide-lanreotide","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2014: Unresectable GEP-NETs to improve PFS (lanreotide)","href":"/drugs/octreotide-lanreotide/"},{"record":"octreotide-lanreotide","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 1988","href":"/regulatory/regions/"},{"record":"octreotide-lanreotide","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 1988","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/sandostatin"},{"record":"octreotide-lanreotide","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 1988","href":"https://products.mhra.gov.uk/?search=Sandostatin"},{"record":"octreotide-lanreotide","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 1991","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"octreotide-lanreotide","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 1996","href":"https://english.nmpa.gov.cn/"},{"record":"octreotide-lanreotide","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 1990","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Sandostatin"},{"record":"nct06807437","field":"status","kind":"trial","state":"development","label":"Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula: phase 3, recruiting","href":"/trials/nct06807437/"},{"record":"registry:octreotide-lanreotide","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/octreotide-lanreotide/#registry"}],"reasons":[]},{"a":{"key":"target","id":"tp53","name":"TP53","href":"/targets/tp53/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"selinexor","name":"Selinexor","route":"/drugs/selinexor/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"covalent","name":"Covalent"}]},"evidence":[{"record":"selinexor","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/selinexor/"},{"record":"selinexor","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2019: Relapsed/refractory multiple myeloma (≥4 lines) with dexamethasone","href":"/drugs/selinexor/"},{"record":"selinexor","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2020: Relapsed/refractory DLBCL; myeloma with bortezomib after ≥1 line","href":"/drugs/selinexor/"},{"record":"selinexor","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2021: EU brand Nexpovio","href":"/drugs/selinexor/"},{"record":"selinexor","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2019","href":"/regulatory/regions/"},{"record":"selinexor","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2021","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/nexpovio"},{"record":"selinexor","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2021","href":"https://products.mhra.gov.uk/?search=Nexpovio"},{"record":"selinexor","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"selinexor","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2022","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Xpovio"},{"record":"selinexor","field":"regulatoryEvents[3]","kind":"event","state":"stopped","label":"US 2026-04-30: withdrawal","href":"https://wayback.archive-it.org/7993/20201222062817/https:/www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-relapsedrefractory-diffuse-large-b-cell-lymphoma","quote":"Withdrawn: the indication came off the label 5.9 years after its accelerated approval."},{"record":"nct04442022","field":"status","kind":"trial","state":"development","label":"A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Ly: phase 2/3, active","href":"/trials/nct04442022/"},{"record":"nct04414475","field":"status","kind":"trial","state":"development","label":"A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refrac: phase 2, recruiting","href":"/trials/nct04414475/"},{"record":"nct02227251","field":"status","kind":"trial","state":"development","label":"Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): phase 2, active","href":"/trials/nct02227251/"},{"record":"nct05035745","field":"status","kind":"trial","state":"development","label":"Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START): phase 1/2, recruiting","href":"/trials/nct05035745/"},{"record":"nct02343042","field":"status","kind":"trial","state":"development","label":"Selinexor and Backbone Treatments of Multiple Myeloma Patients: phase 1/2, recruiting","href":"/trials/nct02343042/"},{"record":"nct06158841","field":"status","kind":"trial","state":"development","label":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto: phase 3, active","href":"/trials/nct06158841/"},{"record":"nct04562389","field":"status","kind":"trial","state":"development","label":"Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis: phase 3, active","href":"/trials/nct04562389/"},{"record":"nct04782687","field":"status","kind":"trial","state":"development","label":"Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma: phase 2, active","href":"/trials/nct04782687/"},{"record":"nct06813079","field":"status","kind":"trial","state":"development","label":"Using Tumor Models to Determine Treatments: phase 2, recruiting","href":"/trials/nct06813079/"},{"record":"xport-ec-042","field":"result","kind":"trial","state":"stopped","label":"XPORT-EC-042 / ENGOT-EN20 / GOG-3083: phase 3, negative","href":"/trials/xport-ec-042/","quote":"Primary PFS endpoint not met; mPFS 12.75 vs 7.43 months (mITT) not significant."},{"record":"registry:selinexor","kind":"registry","state":"development","label":"ClinicalTrials.gov: 50 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/selinexor/#registry"}],"reasons":[{"drugId":"selinexor","drugName":"Selinexor","drugRoute":"/drugs/selinexor/","drugState":"approved","record":"selinexor","kind":"event","label":"US 2026-04-30: withdrawal","href":"https://wayback.archive-it.org/7993/20201222062817/https:/www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-relapsedrefractory-diffuse-large-b-cell-lymphoma","quote":"Withdrawn: the indication came off the label 5.9 years after its accelerated approval."},{"drugId":"selinexor","drugName":"Selinexor","drugRoute":"/drugs/selinexor/","drugState":"approved","record":"xport-ec-042","kind":"trial","label":"XPORT-EC-042 / ENGOT-EN20 / GOG-3083: phase 3, negative","href":"/trials/xport-ec-042/","quote":"Primary PFS endpoint not met; mPFS 12.75 vs 7.43 months (mITT) not significant."}]},{"a":{"key":"target","id":"tp53","name":"TP53","href":"/targets/tp53/"},"b":{"key":"mechanismClass","id":"mdm2-inhibitor","name":"MDM2 inhibitor","href":"/technologies/mdm2-inhibitors/"},"state":"stopped","drugs":[{"id":"eprenetapopt","name":"Eprenetapopt","route":"/drugs/eprenetapopt/","state":"stopped","status":"negative"}],"counts":{"approved":0,"development":0,"stopped":1,"unclear":0},"parts":{},"evidence":[{"record":"eprenetapopt","field":"status","kind":"drug","state":"stopped","label":"Drug record status: negative","href":"/drugs/eprenetapopt/","quote":"Eprenetapopt (APR-246) was a drug meant to refold mutant p53, the most common broken protein in cancer. Its phase 3 in blood cancer failed in 2020."},{"record":"registry:eprenetapopt","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 4 terminated or withdrawn studies and none active (fetched 2026-09-28)","href":"/drugs/eprenetapopt/#registry"}],"reasons":[{"drugId":"eprenetapopt","drugName":"Eprenetapopt","drugRoute":"/drugs/eprenetapopt/","drugState":"stopped","record":"eprenetapopt","kind":"drug","label":"Drug record status: negative","href":"/drugs/eprenetapopt/","quote":"Eprenetapopt (APR-246) was a drug meant to refold mutant p53, the most common broken protein in cancer. Its phase 3 in blood cancer failed in 2020."}]},{"a":{"key":"target","id":"tubulin","name":"Tubulin (microtubules)","href":"/targets/tubulin/"},"b":{"key":"mechanismClass","id":"other-inhibitor","name":"Inhibitor (class not stated)"},"state":"approved","drugs":[{"id":"eribulin","name":"Eribulin","route":"/drugs/eribulin/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"eribulin","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/eribulin/"},{"record":"eribulin","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2010: Metastatic breast cancer after ≥2 regimens including an anthracycline and a taxane","href":"/drugs/eribulin/"},{"record":"eribulin","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2016: Unresectable or metastatic liposarcoma after anthracycline","href":"/drugs/eribulin/"},{"record":"eribulin","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2011: Metastatic breast cancer; liposarcoma (2016)","href":"/drugs/eribulin/"},{"record":"eribulin","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2010","href":"/regulatory/regions/"},{"record":"eribulin","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2011","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/halaven"},{"record":"eribulin","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2011","href":"https://products.mhra.gov.uk/?search=Halaven"},{"record":"eribulin","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2011","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"eribulin","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2019","href":"https://english.nmpa.gov.cn/"},{"record":"eribulin","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Halaven"},{"record":"nct07441512","field":"status","kind":"trial","state":"development","label":"A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer: phase 2, planned","href":"/trials/nct07441512/"},{"record":"nct06343948","field":"status","kind":"trial","state":"development","label":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01): phase 3, active","href":"/trials/nct06343948/"},{"record":"nct06435429","field":"status","kind":"trial","state":"development","label":"A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment o: phase 3, recruiting","href":"/trials/nct06435429/"},{"record":"nct03424005","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer: phase 1/2, recruiting","href":"/trials/nct03424005/"},{"record":"nct06957886","field":"status","kind":"trial","state":"development","label":"A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer: phase 3, recruiting","href":"/trials/nct06957886/"},{"record":"nct05570253","field":"status","kind":"trial","state":"development","label":"A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer: phase 2, recruiting","href":"/trials/nct05570253/"},{"record":"nct06279364","field":"status","kind":"trial","state":"development","label":"A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer: phase 3, recruiting","href":"/trials/nct06279364/"},{"record":"nct06202261","field":"status","kind":"trial","state":"development","label":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer: phase 1/2, recruiting","href":"/trials/nct06202261/"},{"record":"nct05824975","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizu: phase 1/2, recruiting","href":"/trials/nct05824975/"},{"record":"nct04639986","field":"status","kind":"trial","state":"development","label":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC): phase 3, active","href":"/trials/nct04639986/"},{"record":"nct07007559","field":"status","kind":"trial","state":"development","label":"ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer: phase 2, recruiting","href":"/trials/nct07007559/"},{"record":"nct07255612","field":"status","kind":"trial","state":"development","label":"Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer): phase 2, planned","href":"/trials/nct07255612/"},{"record":"nct05760378","field":"status","kind":"trial","state":"development","label":"Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.: phase 3, recruiting","href":"/trials/nct05760378/"},{"record":"nct06731153","field":"status","kind":"trial","state":"development","label":"JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC: phase 2, planned","href":"/trials/nct06731153/"},{"record":"keynote-119","field":"result","kind":"trial","state":"stopped","label":"KEYNOTE-119: phase 3, negative","href":"/trials/keynote-119/","quote":"OS in CPS 10 or more 12.7 vs 11.6 months (HR 0.78, p 0.057); CPS 1 or more 10.7 vs 10.2 (HR 0.86); all patients 9.9 vs 10.8 (HR 0.97). Negative."},{"record":"nct06387628","field":"status","kind":"trial","state":"development","label":"LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer: phase 2, recruiting","href":"/trials/nct06387628/"},{"record":"nct06889688","field":"status","kind":"trial","state":"development","label":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer: phase 3, recruiting","href":"/trials/nct06889688/"},{"record":"nct07173751","field":"status","kind":"trial","state":"development","label":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer: phase 3, recruiting","href":"/trials/nct07173751/"},{"record":"nct06449222","field":"status","kind":"trial","state":"development","label":"Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy: phase 2, active","href":"/trials/nct06449222/"},{"record":"nct04986579","field":"status","kind":"trial","state":"development","label":"Scalp Cooling in MBC: phase 2, recruiting","href":"/trials/nct04986579/"},{"record":"nct05814354","field":"status","kind":"trial","state":"development","label":"SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial: phase 3, active","href":"/trials/nct05814354/"},{"record":"nct06202313","field":"status","kind":"trial","state":"development","label":"Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer: phase 2, planned","href":"/trials/nct06202313/"},{"record":"nct06942234","field":"status","kind":"trial","state":"development","label":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer: phase 1/2, recruiting","href":"/trials/nct06942234/"},{"record":"nct06081959","field":"status","kind":"trial","state":"development","label":"Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer: phase 3, recruiting","href":"/trials/nct06081959/"},{"record":"nct05458674","field":"status","kind":"trial","state":"development","label":"Tucatinib+Trastuzumab+Eribulin in HER2+ MBC: phase 2, active","href":"/trials/nct05458674/"},{"record":"registry:eribulin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 38 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/eribulin/#registry"}],"reasons":[{"drugId":"eribulin","drugName":"Eribulin","drugRoute":"/drugs/eribulin/","drugState":"approved","record":"keynote-119","kind":"trial","label":"KEYNOTE-119: phase 3, negative","href":"/trials/keynote-119/","quote":"OS in CPS 10 or more 12.7 vs 11.6 months (HR 0.78, p 0.057); CPS 1 or more 10.7 vs 10.2 (HR 0.86); all patients 9.9 vs 10.8 (HR 0.97). Negative."}]},{"a":{"key":"target","id":"tubulin","name":"Tubulin (microtubules)","href":"/targets/tubulin/"},"b":{"key":"mechanismClass","id":"not-recorded","name":"Mechanism class not recorded"},"state":"development","drugs":[{"id":"mebendazole","name":"Mebendazole","route":"/drugs/mebendazole/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"mebendazole","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/mebendazole/"},{"record":"nct03925662","field":"status","kind":"trial","state":"development","label":"Mebendazole as Adjuvant Treatment for Colon Cancer: phase 3, recruiting","href":"/trials/nct03925662/"},{"record":"registry:mebendazole","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/mebendazole/#registry"}],"reasons":[]},{"a":{"key":"target","id":"vegf+braf","name":"VEGF / VEGFR x BRAF","href":"/targets/vegf/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"donafenib","name":"Donafenib","route":"/drugs/donafenib/","state":"approved","status":"approved"},{"id":"sorafenib","name":"Sorafenib","route":"/drugs/sorafenib/","state":"approved","status":"approved"}],"counts":{"approved":2,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"donafenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/donafenib/"},{"record":"donafenib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2021: First-line unresectable hepatocellular carcinoma (ZGDH3)","href":"/drugs/donafenib/"},{"record":"donafenib","field":"approvals[1]","kind":"approval","state":"approved","label":"China 2022: Radioiodine-refractory differentiated thyroid cancer","href":"/drugs/donafenib/"},{"record":"donafenib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"registry:donafenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 20 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/donafenib/#registry"},{"record":"sorafenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/sorafenib/"},{"record":"sorafenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2005: Advanced RCC","href":"/drugs/sorafenib/"},{"record":"sorafenib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2007: Unresectable HCC","href":"/drugs/sorafenib/"},{"record":"sorafenib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2013: Radioiodine-refractory differentiated thyroid cancer","href":"/drugs/sorafenib/"},{"record":"sorafenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2005","href":"/regulatory/regions/"},{"record":"sorafenib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2006","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/nexavar"},{"record":"sorafenib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2006","href":"https://products.mhra.gov.uk/?search=Nexavar"},{"record":"sorafenib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2008","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"sorafenib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2006","href":"https://english.nmpa.gov.cn/"},{"record":"sorafenib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2006","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Nexavar"},{"record":"sorafenib","field":"regional.IN","kind":"regional","state":"approved","label":"CDSCO (DCGI) (IN): approved","href":"https://en.wikipedia.org/wiki/Natco_Pharma"},{"record":"nct07787429","field":"status","kind":"trial","state":"development","label":"Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma: phase 2, recruiting","href":"/trials/nct07787429/"},{"record":"sarah-sirvenib","field":"result","kind":"trial","state":"stopped","label":"SARAH and SIRveNIB: phase 3, negative","href":"/trials/sarah-sirvenib/","quote":"OS not improved; fewer adverse events."},{"record":"nct03755791","field":"status","kind":"trial","state":"development","label":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece: phase 3, active","href":"/trials/nct03755791/"},{"record":"nct05822752","field":"status","kind":"trial","state":"development","label":"Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Bu: phase 2, active","href":"/trials/nct05822752/"},{"record":"registry:sorafenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 13 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/sorafenib/#registry"}],"reasons":[{"drugId":"sorafenib","drugName":"Sorafenib","drugRoute":"/drugs/sorafenib/","drugState":"approved","record":"sarah-sirvenib","kind":"trial","label":"SARAH and SIRveNIB: phase 3, negative","href":"/trials/sarah-sirvenib/","quote":"OS not improved; fewer adverse events."}]},{"a":{"key":"target","id":"wrn","name":"WRN helicase (MSI-high cancers)","href":"/targets/wrn/"},"b":{"key":"mechanismClass","id":"other-inhibitor","name":"Inhibitor (class not stated)"},"state":"development","drugs":[{"id":"eik1005","name":"EIK1005","route":"/drugs/eik1005/","state":"development","status":"phase-2"},{"id":"ndi-219216","name":"NDI-219216","route":"/drugs/ndi-219216/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":2,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"},{"key":"binding","id":"covalent","name":"Covalent"}]},"evidence":[{"record":"eik1005","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/eik1005/"},{"record":"nct07262619","field":"status","kind":"trial","state":"development","label":"EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Partic: phase 1/2, recruiting","href":"/trials/nct07262619/"},{"record":"registry:eik1005","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/eik1005/#registry"},{"record":"ndi-219216","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/ndi-219216/"},{"record":"nct06898450","field":"status","kind":"trial","state":"development","label":"A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.: phase 1/2, recruiting","href":"/trials/nct06898450/"},{"record":"registry:ndi-219216","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/ndi-219216/#registry"}],"reasons":[]},{"a":{"key":"target","id":"ada","name":"Adenosine deaminase (ADA)","href":"/targets/ada/"},"b":{"key":"mechanismClass","id":"other-inhibitor","name":"Inhibitor (class not stated)"},"state":"approved","drugs":[{"id":"pentostatin","name":"Pentostatin","route":"/drugs/pentostatin/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"pentostatin","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/pentostatin/"},{"record":"pentostatin","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1991: Hairy cell leukaemia (initially alpha-interferon-refractory; later untreated disease)","href":"/drugs/pentostatin/"},{"record":"nct01059786","field":"status","kind":"trial","state":"development","label":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia: phase 2, active","href":"/trials/nct01059786/"},{"record":"registry:pentostatin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pentostatin/#registry"}],"reasons":[]},{"a":{"key":"target","id":"akt","name":"AKT","href":"/targets/akt/"},"b":{"key":"mechanismClass","id":"pi3k-akt-mtor-inhibitor","name":"PI3K, AKT or mTOR inhibitor","href":"/technologies/pi3k-akt-mtor-inhibitors/"},"state":"development","drugs":[{"id":"ipatasertib","name":"Ipatasertib","route":"/drugs/ipatasertib/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"ipatasertib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/ipatasertib/"},{"record":"nct05862285","field":"status","kind":"trial","state":"development","label":"A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study: phase 3, recruiting","href":"/trials/nct05862285/"},{"record":"nct04931342","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors: phase 2, active","href":"/trials/nct04931342/"},{"record":"nct04802759","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer: phase 1/2, recruiting","href":"/trials/nct04802759/"},{"record":"nct03424005","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer: phase 1/2, recruiting","href":"/trials/nct03424005/"},{"record":"barbican","field":"status","kind":"trial","state":"development","label":"BARBICAN: phase 2, active","href":"/trials/barbican/"},{"record":"ipatunity130","field":"result","kind":"trial","state":"stopped","label":"IPATunity130: phase 3, negative","href":"/trials/ipatunity130/","quote":"PFS 7.4 vs 6.1 months (HR 1.02, 0.71 to 1.45); OS 24.4 vs 24.9 months (HR 1.08). Negative."},{"record":"nct04589845","field":"status","kind":"trial","state":"development","label":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study: phase 2, active","href":"/trials/nct04589845/"},{"record":"registry:ipatasertib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 18 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ipatasertib/#registry"}],"reasons":[{"drugId":"ipatasertib","drugName":"Ipatasertib","drugRoute":"/drugs/ipatasertib/","drugState":"development","record":"ipatunity130","kind":"trial","label":"IPATunity130: phase 3, negative","href":"/trials/ipatunity130/","quote":"PFS 7.4 vs 6.1 months (HR 1.02, 0.71 to 1.45); OS 24.4 vs 24.9 months (HR 1.08). Negative."}]},{"a":{"key":"target","id":"akt+pik3ca","name":"AKT x PIK3CA / PI3K-alpha","href":"/targets/akt/"},"b":{"key":"mechanismClass","id":"pi3k-akt-mtor-inhibitor","name":"PI3K, AKT or mTOR inhibitor","href":"/technologies/pi3k-akt-mtor-inhibitors/"},"state":"approved","drugs":[{"id":"capivasertib","name":"Capivasertib","route":"/drugs/capivasertib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"}]},"evidence":[{"record":"capivasertib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/capivasertib/"},{"record":"capivasertib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2023: HR+/HER2- breast cancer with PIK3CA/AKT1/PTEN alteration, with fulvestrant","href":"/drugs/capivasertib/"},{"record":"capivasertib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2026: PTEN-deficient metastatic prostate cancer with abiraterone","href":"/drugs/capivasertib/"},{"record":"capivasertib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2024: ER+/HER2- mBC with PIK3CA/AKT1/PTEN alteration; 17 Jun 2024","href":"/drugs/capivasertib/"},{"record":"capivasertib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2023","href":"/regulatory/regions/"},{"record":"capivasertib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2024","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/truqap"},{"record":"capivasertib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2024","href":"https://www.gov.uk/government/news/capivasertib-approved-to-treat-patients-with-advanced-breast-cancer"},{"record":"capivasertib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2024","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"capivasertib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2025","href":"https://english.nmpa.gov.cn/"},{"record":"capivasertib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2024","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Truqap"},{"record":"nct06764186","field":"status","kind":"trial","state":"development","label":"A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain: phase 3, active","href":"/trials/nct06764186/"},{"record":"nct03742102","field":"status","kind":"trial","state":"development","label":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer: phase 1/2, active","href":"/trials/nct03742102/"},{"record":"nct04862663","field":"status","kind":"trial","state":"development","label":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292): phase 3, active","href":"/trials/nct04862663/"},{"record":"nct06635447","field":"status","kind":"trial","state":"development","label":"Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients: phase 3, active","href":"/trials/nct06635447/"},{"record":"nct03997123","field":"status","kind":"trial","state":"development","label":"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC: phase 3, active","href":"/trials/nct03997123/"},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"nct05563220","field":"status","kind":"trial","state":"development","label":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer: phase 1/2, active","href":"/trials/nct05563220/"},{"record":"nct07287917","field":"status","kind":"trial","state":"development","label":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct07287917/"},{"record":"nct05348577","field":"status","kind":"trial","state":"development","label":"Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC): phase 3, active","href":"/trials/nct05348577/"},{"record":"registry:capivasertib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 34 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/capivasertib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"androgen-receptor+cyp17a1","name":"Androgen receptor x CYP17A1","href":"/targets/androgen-receptor/"},"b":{"key":"mechanismClass","id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/"},"state":"stopped","drugs":[{"id":"galeterone","name":"Galeterone","route":"/drugs/galeterone/","state":"stopped","status":"withdrawn"}],"counts":{"approved":0,"development":0,"stopped":1,"unclear":0},"parts":{},"evidence":[{"record":"galeterone","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/galeterone/","quote":"An experimental prostate cancer tablet meant to work in men whose cancer makes a broken form of the androgen receptor. The trial designed to prove it collapsed."},{"record":"armor3-sv","field":"result","kind":"trial","state":"stopped","label":"ARMOR3-SV: phase 3, negative","href":"/trials/armor3-sv/","quote":"Closed early after 38 of a planned 148 men were randomised; AR-V7 prevalence 8 percent (95 percent confidence interval 6 to 10) among 953 prescreened men. PSA50 response 13 percent with galeterone against 42 percent with enzalutamide. Galeterone development stopped."},{"record":"registry:galeterone","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/galeterone/#registry"}],"reasons":[{"drugId":"galeterone","drugName":"Galeterone","drugRoute":"/drugs/galeterone/","drugState":"stopped","record":"galeterone","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/galeterone/","quote":"An experimental prostate cancer tablet meant to work in men whose cancer makes a broken form of the androgen receptor. The trial designed to prove it collapsed."},{"drugId":"galeterone","drugName":"Galeterone","drugRoute":"/drugs/galeterone/","drugState":"stopped","record":"armor3-sv","kind":"trial","label":"ARMOR3-SV: phase 3, negative","href":"/trials/armor3-sv/","quote":"Closed early after 38 of a planned 148 men were randomised; AR-V7 prevalence 8 percent (95 percent confidence interval 6 to 10) among 953 prescreened men. PSA50 response 13 percent with galeterone against 42 percent with enzalutamide. Galeterone development stopped."}]},{"a":{"key":"target","id":"apc+ctnnb1","name":"APC x CTNNB1","href":"/targets/apc/"},"b":{"key":"mechanismClass","id":"gamma-secretase-inhibitor","name":"Gamma-secretase inhibitor","href":"/technologies/gamma-secretase-inhibitors/"},"state":"approved","drugs":[{"id":"nirogacestat","name":"Nirogacestat","route":"/drugs/nirogacestat/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"nirogacestat","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/nirogacestat/"},{"record":"nirogacestat","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2023: Progressing desmoid tumours requiring systemic treatment","href":"/drugs/nirogacestat/"},{"record":"nirogacestat","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2025: Progressing desmoid tumours","href":"/drugs/nirogacestat/"},{"record":"nirogacestat","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2023","href":"/regulatory/regions/"},{"record":"nirogacestat","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/ogsiveo"},{"record":"nirogacestat","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2026","href":"https://www.gov.uk/government/news/nirogacestat-hydrobromide-approved-to-treat-desmoid-tumours"},{"record":"nct07170644","field":"status","kind":"trial","state":"development","label":"A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF): phase 2, active","href":"/trials/nct07170644/"},{"record":"nct04126200","field":"status","kind":"trial","state":"development","label":"Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple: phase 1/2, active","href":"/trials/nct04126200/"},{"record":"nct07150104","field":"status","kind":"trial","state":"development","label":"Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi: phase 1/2, active","href":"/trials/nct07150104/"},{"record":"nct07084896","field":"status","kind":"trial","state":"development","label":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM: phase 1/2, active","href":"/trials/nct07084896/"},{"record":"nct07150091","field":"status","kind":"trial","state":"development","label":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM: phase 1/2, active","href":"/trials/nct07150091/"},{"record":"registry:nirogacestat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 10 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/nirogacestat/#registry"}],"reasons":[]},{"a":{"key":"target","id":"aromatase+cyp11a1","name":"Aromatase x CYP11A1","href":"/targets/aromatase/"},"b":{"key":"mechanismClass","id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/"},"state":"stopped","drugs":[{"id":"aminoglutethimide","name":"Aminoglutethimide","route":"/drugs/aminoglutethimide/","state":"stopped","status":"historic"}],"counts":{"approved":0,"development":0,"stopped":1,"unclear":0},"parts":{},"evidence":[{"record":"aminoglutethimide","field":"status","kind":"drug","state":"stopped","label":"Drug record status: historic","href":"/drugs/aminoglutethimide/","quote":"Aminoglutethimide produced a medical adrenalectomy for advanced breast and prostate cancer in the 1970s and 1980s, the ancestor of today's aromatase inhibitors, and was withdrawn once selective drugs arrived."},{"record":"aminoglutethimide","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1980: Cushing's syndrome (used off label as medical adrenalectomy in breast and prostate cancer)","href":"/drugs/aminoglutethimide/"},{"record":"registry:aminoglutethimide","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 1 terminated or withdrawn study and none active (fetched 2026-09-28)","href":"/drugs/aminoglutethimide/#registry"}],"reasons":[{"drugId":"aminoglutethimide","drugName":"Aminoglutethimide","drugRoute":"/drugs/aminoglutethimide/","drugState":"stopped","record":"aminoglutethimide","kind":"drug","label":"Drug record status: historic","href":"/drugs/aminoglutethimide/","quote":"Aminoglutethimide produced a medical adrenalectomy for advanced breast and prostate cancer in the 1970s and 1980s, the ancestor of today's aromatase inhibitors, and was withdrawn once selective drugs arrived."}]},{"a":{"key":"target","id":"atr","name":"ATR","href":"/targets/atr/"},"b":{"key":"mechanismClass","id":"ddr-inhibitor","name":"DNA damage response inhibitor"},"state":"development","drugs":[{"id":"ceralasertib","name":"Ceralasertib","route":"/drugs/ceralasertib/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"ceralasertib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/ceralasertib/"},{"record":"nct05450692","field":"status","kind":"trial","state":"development","label":"A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy: phase 3, active","href":"/trials/nct05450692/"},{"record":"nct05061134","field":"status","kind":"trial","state":"development","label":"A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition: phase 2, active","href":"/trials/nct05061134/"},{"record":"nct05941897","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: phase 2, active","href":"/trials/nct05941897/"},{"record":"nct03334617","field":"status","kind":"trial","state":"development","label":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy: phase 2, active","href":"/trials/nct03334617/"},{"record":"phoenix","field":"status","kind":"trial","state":"development","label":"PHOENIX DDR/Anti-PD-L1: phase 2, recruiting","href":"/trials/phoenix/"},{"record":"nct05582538","field":"status","kind":"trial","state":"development","label":"Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel: phase 2, recruiting","href":"/trials/nct05582538/"},{"record":"nct06732401","field":"status","kind":"trial","state":"development","label":"Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer: phase 3, active","href":"/trials/nct06732401/"},{"record":"nct03330847","field":"status","kind":"trial","state":"development","label":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.: phase 2, active","href":"/trials/nct03330847/"},{"record":"registry:ceralasertib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 19 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ceralasertib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"bcr-abl+ddr2","name":"BCR::ABL1 x DDR2 receptor kinase","href":"/targets/bcr-abl/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"dasatinib","name":"Dasatinib","route":"/drugs/dasatinib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"dasatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/dasatinib/"},{"record":"dasatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2006: CML and Ph+ ALL resistant or intolerant to imatinib","href":"/drugs/dasatinib/"},{"record":"dasatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2018: Paediatric Ph+ ALL with chemotherapy","href":"/drugs/dasatinib/"},{"record":"dasatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2006","href":"/regulatory/regions/"},{"record":"dasatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2006","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/sprycel"},{"record":"dasatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2006","href":"https://products.mhra.gov.uk/?search=Sprycel"},{"record":"dasatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2009","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"dasatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2011","href":"https://english.nmpa.gov.cn/"},{"record":"dasatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2007","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Sprycel"},{"record":"nct04971226","field":"status","kind":"trial","state":"development","label":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP: phase 3, active","href":"/trials/nct04971226/"},{"record":"ready-dasatinib","field":"result","kind":"trial","state":"stopped","label":"READY: phase 3, negative","href":"/trials/ready-dasatinib/","quote":"Median overall survival 21.5 against 21.2 months (stratified hazard ratio 0.99, 95.5 percent confidence interval 0.87 to 1.13, p=0.90): no benefit."},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"registry:dasatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 25 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/dasatinib/#registry"}],"reasons":[{"drugId":"dasatinib","drugName":"Dasatinib","drugRoute":"/drugs/dasatinib/","drugState":"approved","record":"ready-dasatinib","kind":"trial","label":"READY: phase 3, negative","href":"/trials/ready-dasatinib/","quote":"Median overall survival 21.5 against 21.2 months (stratified hazard ratio 0.99, 95.5 percent confidence interval 0.87 to 1.13, p=0.90): no benefit."}]},{"a":{"key":"target","id":"bcr-abl+kit","name":"BCR::ABL1 x KIT","href":"/targets/bcr-abl/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"nilotinib","name":"Nilotinib","route":"/drugs/nilotinib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"}]},"evidence":[{"record":"nilotinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/nilotinib/"},{"record":"nilotinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2007: Ph+ CML, chronic or accelerated phase, resistant/intolerant to imatinib","href":"/drugs/nilotinib/"},{"record":"nilotinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2010: Newly diagnosed Ph+ CML chronic phase","href":"/drugs/nilotinib/"},{"record":"nilotinib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2007: Ph+ CML","href":"/drugs/nilotinib/"},{"record":"nilotinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2007","href":"/regulatory/regions/"},{"record":"nilotinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2007","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna"},{"record":"nilotinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2007","href":"https://products.mhra.gov.uk/?search=Tasigna"},{"record":"nilotinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2009","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"nilotinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2009","href":"https://english.nmpa.gov.cn/"},{"record":"nilotinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Tasigna"},{"record":"nct04971226","field":"status","kind":"trial","state":"development","label":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP: phase 3, active","href":"/trials/nct04971226/"},{"record":"nct05456191","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP): phase 3, active","href":"/trials/nct05456191/"},{"record":"registry:nilotinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 19 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/nilotinib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"braf+egfr","name":"BRAF x EGFR","href":"/targets/braf/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"encorafenib","name":"Encorafenib","route":"/drugs/encorafenib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"}]},"evidence":[{"record":"encorafenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/encorafenib/"},{"record":"encorafenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: BRAF V600 melanoma with binimetinib","href":"/drugs/encorafenib/"},{"record":"encorafenib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2020: BRAF V600E mCRC with cetuximab, previously treated","href":"/drugs/encorafenib/"},{"record":"encorafenib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2026: First-line BRAF V600E mCRC with cetuximab and chemotherapy","href":"/drugs/encorafenib/"},{"record":"encorafenib","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2024: Metastatic colorectal cancer with a BRAF V600E mutation, with cetuximab and mFOLFOX6, previously untreated","href":"/drugs/encorafenib/"},{"record":"encorafenib","field":"approvals[4]","kind":"approval","state":"approved","label":"US 2026: Metastatic colorectal cancer with a BRAF V600E mutation","href":"/drugs/encorafenib/"},{"record":"encorafenib","field":"approvals[5]","kind":"approval","state":"approved","label":"EU 2018: BRAF V600E-mutant metastatic colorectal cancer, with cetuximab","href":"/drugs/encorafenib/"},{"record":"encorafenib","field":"approvals[6]","kind":"approval","state":"approved","label":"England (NICE) 2021: BRAF V600E mutation-positive metastatic colorectal cancer after previous systemic treatment, with cetuximab","href":"/drugs/encorafenib/"},{"record":"encorafenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"encorafenib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2018","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi"},{"record":"encorafenib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2018","href":"https://products.mhra.gov.uk/?search=Braftovi"},{"record":"encorafenib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2019","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"encorafenib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"encorafenib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2019","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Braftovi"},{"record":"nct04657991","field":"status","kind":"trial","state":"development","label":"A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma: phase 3, active","href":"/trials/nct04657991/"},{"record":"nct05217446","field":"status","kind":"trial","state":"development","label":"A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic: phase 2, active","href":"/trials/nct05217446/"},{"record":"nct07178717","field":"status","kind":"trial","state":"development","label":"A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy W: phase 2, planned","href":"/trials/nct07178717/"},{"record":"nct05270044","field":"status","kind":"trial","state":"development","label":"Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.: phase 3, active","href":"/trials/nct05270044/"},{"record":"nct06411600","field":"status","kind":"trial","state":"development","label":"Combination Therapy for BRAF-V600E Metastatic CRCm: phase 2, recruiting","href":"/trials/nct06411600/"},{"record":"nct03803553","field":"status","kind":"trial","state":"development","label":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer: phase 3, active","href":"/trials/nct03803553/"},{"record":"nct05195632","field":"status","kind":"trial","state":"development","label":"Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung: phase 2, active","href":"/trials/nct05195632/"},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"nct05710406","field":"status","kind":"trial","state":"development","label":"Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer: phase 2/3, active","href":"/trials/nct05710406/"},{"record":"registry:encorafenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 32 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/encorafenib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"casr","name":"CASR","href":"/targets/casr/"},"b":{"key":"mechanismClass","id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/"},"state":"approved","drugs":[{"id":"cinacalcet","name":"Cinacalcet","route":"/drugs/cinacalcet/","state":"approved","status":"established"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"cinacalcet","field":"status","kind":"drug","state":"approved","label":"Drug record status: established","href":"/drugs/cinacalcet/"},{"record":"cinacalcet","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2004: Hypercalcaemia in patients with parathyroid carcinoma; secondary hyperparathyroidism on dialysis; primary hyperparathyroidism when surgery is not possible","href":"/drugs/cinacalcet/"},{"record":"cinacalcet","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/mimpara","quote":"Mimpara: authorised 22 Oct 2004; marketing authorisation withdrawn 18 Dec 2025. EMA register: 'Withdrawn: This medicine's authorisation has been withdrawn'; checked 2026-09-24"},{"record":"registry:cinacalcet","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/cinacalcet/#registry"}],"reasons":[{"drugId":"cinacalcet","drugName":"Cinacalcet","drugRoute":"/drugs/cinacalcet/","drugState":"approved","record":"cinacalcet","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/mimpara","quote":"Mimpara: authorised 22 Oct 2004; marketing authorisation withdrawn 18 Dec 2025. EMA register: 'Withdrawn: This medicine's authorisation has been withdrawn'; checked 2026-09-24"}]},{"a":{"key":"target","id":"cblb","name":"CBLB","href":"/targets/cblb/"},"b":{"key":"mechanismClass","id":"other-inhibitor","name":"Inhibitor (class not stated)"},"state":"development","drugs":[{"id":"hst-1011","name":"HST-1011","route":"/drugs/hst-1011/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"hst-1011","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/hst-1011/"},{"record":"nct05662397","field":"status","kind":"trial","state":"development","label":"A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody: phase 1/2, active","href":"/trials/nct05662397/"},{"record":"registry:hst-1011","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/hst-1011/#registry"}],"reasons":[]},{"a":{"key":"target","id":"col6a3+csf1","name":"COL6A3 x CSF1","href":"/targets/col6a3/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"vimseltinib","name":"Vimseltinib","route":"/drugs/vimseltinib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"vimseltinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/vimseltinib/"},{"record":"vimseltinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2025: Symptomatic tenosynovial giant cell tumour where surgery would worsen function or cause severe morbidity","href":"/drugs/vimseltinib/"},{"record":"vimseltinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2025: Symptomatic TGCT where surgery has been exhausted or would cause unacceptable morbidity; 17 Sep 2025","href":"/drugs/vimseltinib/"},{"record":"vimseltinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2025","href":"/regulatory/regions/"},{"record":"vimseltinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/romvimza"},{"record":"vimseltinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2026","href":"https://www.gov.uk/government/news/vimseltinib-romvimza-approved-for-use-in-adults-to-treat-tenosynovial-giant-cell-tumours"},{"record":"nct03069469","field":"status","kind":"trial","state":"development","label":"Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor: phase 1/2, active","href":"/trials/nct03069469/"},{"record":"registry:vimseltinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/vimseltinib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"cox2","name":"COX-2 (PTGS2)","href":"/targets/cox2/"},"b":{"key":"mechanismClass","id":"other-inhibitor","name":"Inhibitor (class not stated)"},"state":"approved","drugs":[{"id":"celecoxib","name":"Celecoxib","route":"/drugs/celecoxib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"celecoxib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/celecoxib/"},{"record":"celecoxib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1998: Osteoarthritis and rheumatoid arthritis pain (oncology use in metronomic regimens is off-label)","href":"/drugs/celecoxib/"},{"record":"celecoxib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 1999: Reduction of adenomatous colorectal polyps in familial adenomatous polyposis (accelerated approval; indication withdrawn 2011)","href":"/drugs/celecoxib/"},{"record":"celecoxib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn 2008","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/onsenal","quote":"Onsenal: authorised 17 Oct 2003; marketing authorisation withdrawn 28 Nov 2008. EMA register: 'Withdrawn: This medicine's authorisation has been withdrawn'; checked 2026-09-24"},{"record":"celecoxib","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"US 2012-06-08: withdrawal","href":"/drugs/celecoxib/","quote":"Withdrawn: the indication came off the label 12.5 years after its accelerated approval."},{"record":"nct07150949","field":"status","kind":"trial","state":"development","label":"Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC: phase 2, recruiting","href":"/trials/nct07150949/"},{"record":"nct07154316","field":"status","kind":"trial","state":"development","label":"Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer: phase 2, recruiting","href":"/trials/nct07154316/"},{"record":"nct05731726","field":"status","kind":"trial","state":"development","label":"Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer: phase 2, recruiting","href":"/trials/nct05731726/"},{"record":"nct06903858","field":"status","kind":"trial","state":"development","label":"Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer: phase 2, recruiting","href":"/trials/nct06903858/"},{"record":"nct07104266","field":"status","kind":"trial","state":"development","label":"Triple Negative Breast Cancer and Celecoxib. Pilot Study: phase 2, recruiting","href":"/trials/nct07104266/"},{"record":"registry:celecoxib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 14 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/celecoxib/#registry"}],"reasons":[{"drugId":"celecoxib","drugName":"Celecoxib","drugRoute":"/drugs/celecoxib/","drugState":"approved","record":"celecoxib","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2008","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/onsenal","quote":"Onsenal: authorised 17 Oct 2003; marketing authorisation withdrawn 28 Nov 2008. EMA register: 'Withdrawn: This medicine's authorisation has been withdrawn'; checked 2026-09-24"},{"drugId":"celecoxib","drugName":"Celecoxib","drugRoute":"/drugs/celecoxib/","drugState":"approved","record":"celecoxib","kind":"event","label":"US 2012-06-08: withdrawal","href":"/drugs/celecoxib/","quote":"Withdrawn: the indication came off the label 12.5 years after its accelerated approval."}]},{"a":{"key":"target","id":"csf1r+kit","name":"CSF1R x KIT","href":"/targets/csf1r/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"pexidartinib","name":"Pexidartinib","route":"/drugs/pexidartinib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"pexidartinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/pexidartinib/"},{"record":"pexidartinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2019: Symptomatic tenosynovial giant cell tumour not amenable to surgery","href":"/drugs/pexidartinib/"},{"record":"pexidartinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2019","href":"/regulatory/regions/"},{"record":"pexidartinib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn 2020","href":"/regulatory/regions/","quote":"Daiichi Sankyo withdrew the Turalio MAA (Jul 2020) after the CHMP signalled a negative opinion"},{"record":"nct04488822","field":"status","kind":"trial","state":"development","label":"A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT: phase 3, active","href":"/trials/nct04488822/"},{"record":"registry:pexidartinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pexidartinib/#registry"}],"reasons":[{"drugId":"pexidartinib","drugName":"Pexidartinib","drugRoute":"/drugs/pexidartinib/","drugState":"approved","record":"pexidartinib","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2020","href":"/regulatory/regions/","quote":"Daiichi Sankyo withdrew the Turalio MAA (Jul 2020) after the CHMP signalled a negative opinion"}]},{"a":{"key":"target","id":"cyp11b1","name":"CYP11B1","href":"/targets/cyp11b1/"},"b":{"key":"mechanismClass","id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/"},"state":"approved","drugs":[{"id":"osilodrostat","name":"Osilodrostat","route":"/drugs/osilodrostat/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"osilodrostat","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/osilodrostat/"},{"record":"osilodrostat","field":"approvals[0]","kind":"approval","state":"approved","label":"EU 2020: Endogenous Cushing's syndrome in adults","href":"/drugs/osilodrostat/"},{"record":"osilodrostat","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2020: Cushing's disease in adults for whom pituitary surgery is not an option or has not been curative","href":"/drugs/osilodrostat/"},{"record":"registry:osilodrostat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/osilodrostat/#registry"}],"reasons":[]},{"a":{"key":"target","id":"cyp17a1","name":"CYP17A1 (17-alpha-hydroxylase/17,20-lyase)","href":"/targets/cyp17a1/"},"b":{"key":"mechanismClass","id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/"},"state":"stopped","drugs":[{"id":"orteronel","name":"Orteronel","route":"/drugs/orteronel/","state":"stopped","status":"withdrawn"}],"counts":{"approved":0,"development":0,"stopped":1,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"orteronel","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/orteronel/","quote":"A more selective version of abiraterone that was meant to avoid the need for steroids. It delayed the cancer on scans but did not help men live longer, and was abandoned."},{"record":"elm-pc-4-orteronel","field":"result","kind":"trial","state":"stopped","label":"ELM-PC 4: phase 3, negative","href":"/trials/elm-pc-4-orteronel/","quote":"Median radiographic progression-free survival 13.8 against 8.7 months (hazard ratio 0.71, 95 percent confidence interval 0.63 to 0.80, p<0.0001) but overall survival 31.4 against 29.5 months (0.92, 0.79 to 1.08, p=0.31); development stopped."},{"record":"registry:orteronel","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 7 terminated or withdrawn studies and none active (fetched 2026-09-28)","href":"/drugs/orteronel/#registry"}],"reasons":[{"drugId":"orteronel","drugName":"Orteronel","drugRoute":"/drugs/orteronel/","drugState":"stopped","record":"orteronel","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/orteronel/","quote":"A more selective version of abiraterone that was meant to avoid the need for steroids. It delayed the cancer on scans but did not help men live longer, and was abandoned."},{"drugId":"orteronel","drugName":"Orteronel","drugRoute":"/drugs/orteronel/","drugState":"stopped","record":"elm-pc-4-orteronel","kind":"trial","label":"ELM-PC 4: phase 3, negative","href":"/trials/elm-pc-4-orteronel/","quote":"Median radiographic progression-free survival 13.8 against 8.7 months (hazard ratio 0.71, 95 percent confidence interval 0.63 to 0.80, p<0.0001) but overall survival 31.4 against 29.5 months (0.92, 0.79 to 1.08, p=0.31); development stopped."}]},{"a":{"key":"target","id":"drd2+h3-3a","name":"Dopamine D2 receptor x Histone H3.3","href":"/targets/drd2/"},"b":{"key":"mechanismClass","id":"receptor-agonist","name":"Receptor agonist"},"state":"approved","drugs":[{"id":"dordaviprone","name":"Dordaviprone","route":"/drugs/dordaviprone/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"dordaviprone","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/dordaviprone/"},{"record":"dordaviprone","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2025: Recurrent H3 K27M-mutant diffuse midline glioma, age ≥1 (accelerated)","href":"/drugs/dordaviprone/"},{"record":"dordaviprone","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2025","href":"/regulatory/regions/"},{"record":"action-dmg","field":"status","kind":"trial","state":"development","label":"ACTION: phase 3, recruiting","href":"/trials/action-dmg/"},{"record":"registry:dordaviprone","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/dordaviprone/#registry"}],"reasons":[]},{"a":{"key":"target","id":"eed","name":"EED","href":"/targets/eed/"},"b":{"key":"mechanismClass","id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/"},"state":"development","drugs":[{"id":"rinzimetostat","name":"Rinzimetostat","route":"/drugs/rinzimetostat/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"allosteric","name":"Allosteric"}]},"evidence":[{"record":"rinzimetostat","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/rinzimetostat/"},{"record":"himalayas-1","field":"status","kind":"trial","state":"development","label":"A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1): phase 3, recruiting","href":"/trials/himalayas-1/"},{"record":"registry:rinzimetostat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/rinzimetostat/#registry"}],"reasons":[]},{"a":{"key":"target","id":"egfr+met","name":"EGFR x MET","href":"/targets/egfr/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"development","drugs":[{"id":"js111","name":"JS111","route":"/drugs/js111/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"js111","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/js111/"},{"record":"nct06940401","field":"status","kind":"trial","state":"development","label":"JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations: phase 1/2, active","href":"/trials/nct06940401/"},{"record":"registry:js111","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/js111/#registry"}],"reasons":[]},{"a":{"key":"target","id":"estrogen-receptor+her2","name":"Estrogen receptor x HER2","href":"/targets/estrogen-receptor/"},"b":{"key":"mechanismClass","id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/"},"state":"development","drugs":[{"id":"d-0502","name":"D-0502","route":"/drugs/d-0502/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"d-0502","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/d-0502/"},{"record":"nct06954961","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer: phase 3, recruiting","href":"/trials/nct06954961/"},{"record":"registry:d-0502","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/d-0502/#registry"}],"reasons":[]},{"a":{"key":"target","id":"ewsr1-fli1","name":"EWSR1-FLI1 fusion","href":"/targets/ewsr1-fli1/"},"b":{"key":"mechanismClass","id":"other-inhibitor","name":"Inhibitor (class not stated)"},"state":"development","drugs":[{"id":"tk216","name":"TK216","route":"/drugs/tk216/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"tk216","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/tk216/"},{"record":"registry:tk216","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 1 terminated or withdrawn study and none active (fetched 2026-09-28)","href":"/drugs/tk216/#registry"}],"reasons":[]},{"a":{"key":"target","id":"ezh2+androgen-receptor","name":"EZH2 x Androgen receptor","href":"/targets/ezh2/"},"b":{"key":"mechanismClass","id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/"},"state":"development","drugs":[{"id":"mevrometostat","name":"Mevrometostat","route":"/drugs/mevrometostat/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"mevrometostat","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/mevrometostat/"},{"record":"nct06629779","field":"status","kind":"trial","state":"development","label":"A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.: phase 3, recruiting","href":"/trials/nct06629779/"},{"record":"mevpro-1","field":"status","kind":"trial","state":"development","label":"MEVPRO-1: phase 3, active","href":"/trials/mevpro-1/"},{"record":"nct07028853","field":"status","kind":"trial","state":"development","label":"This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking En: phase 3, recruiting","href":"/trials/nct07028853/"},{"record":"registry:mevrometostat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/mevrometostat/#registry"}],"reasons":[]},{"a":{"key":"target","id":"fkbp12+hif1a","name":"FKBP12 x HIF-1α","href":"/targets/fkbp12/"},"b":{"key":"mechanismClass","id":"pi3k-akt-mtor-inhibitor","name":"PI3K, AKT or mTOR inhibitor","href":"/technologies/pi3k-akt-mtor-inhibitors/"},"state":"approved","drugs":[{"id":"temsirolimus","name":"Temsirolimus","route":"/drugs/temsirolimus/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"allosteric","name":"Allosteric"}]},"evidence":[{"record":"temsirolimus","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/temsirolimus/"},{"record":"temsirolimus","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2007: Advanced renal cell carcinoma","href":"/drugs/temsirolimus/"},{"record":"temsirolimus","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2007: Advanced RCC (poor risk); relapsed/refractory mantle cell lymphoma added 2009","href":"/drugs/temsirolimus/"},{"record":"temsirolimus","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2007","href":"/regulatory/regions/"},{"record":"temsirolimus","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2007","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/torisel"},{"record":"temsirolimus","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2007","href":"https://products.mhra.gov.uk/?search=Torisel"},{"record":"temsirolimus","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2010","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"registry:temsirolimus","kind":"registry","state":"development","label":"ClinicalTrials.gov: 26 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/temsirolimus/#registry"}],"reasons":[]},{"a":{"key":"target","id":"flt3+kit","name":"FLT3 x KIT","href":"/targets/flt3/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"midostaurin","name":"Midostaurin","route":"/drugs/midostaurin/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"midostaurin","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/midostaurin/"},{"record":"midostaurin","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2017: Newly diagnosed FLT3-mutated AML with 7+3 and consolidation; advanced systemic mastocytosis","href":"/drugs/midostaurin/"},{"record":"midostaurin","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2017","href":"/regulatory/regions/"},{"record":"midostaurin","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2017","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt"},{"record":"midostaurin","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2017","href":"https://products.mhra.gov.uk/?search=Rydapt"},{"record":"midostaurin","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2019","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"midostaurin","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"midostaurin","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2017","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Rydapt"},{"record":"nct03591510","field":"status","kind":"trial","state":"development","label":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML: phase 2, active","href":"/trials/nct03591510/"},{"record":"registry:midostaurin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 10 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/midostaurin/#registry"}],"reasons":[]},{"a":{"key":"target","id":"gamma-secretase","name":"Gamma-secretase (PSEN1)","href":"/targets/gamma-secretase/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"development","drugs":[{"id":"varegacestat","name":"Varegacestat","route":"/drugs/varegacestat/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"varegacestat","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/varegacestat/"},{"record":"nct04871282","field":"status","kind":"trial","state":"development","label":"A Study of AL102 in Patients With Progressing Desmoid Tumors: phase 2/3, active","href":"/trials/nct04871282/"},{"record":"registry:varegacestat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/varegacestat/#registry"}],"reasons":[]},{"a":{"key":"target","id":"gna11+gnaq","name":"GNA11 x GNAQ","href":"/targets/gna11/"},"b":{"key":"mechanismClass","id":"other-inhibitor","name":"Inhibitor (class not stated)"},"state":"development","drugs":[{"id":"darovasertib","name":"Darovasertib","route":"/drugs/darovasertib/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"darovasertib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/darovasertib/"},{"record":"nct05907954","field":"status","kind":"trial","state":"development","label":"(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma: phase 2, active","href":"/trials/nct05907954/"},{"record":"nct05987332","field":"status","kind":"trial","state":"development","label":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma: phase 2/3, active","href":"/trials/nct05987332/"},{"record":"nct07015190","field":"status","kind":"trial","state":"development","label":"Neoadjuvant Darovasertib in Primary Uveal Melanoma: phase 3, recruiting","href":"/trials/nct07015190/"},{"record":"nct07804186","field":"status","kind":"trial","state":"development","label":"Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma: phase 3, recruiting","href":"/trials/nct07804186/"},{"record":"nct03947385","field":"status","kind":"trial","state":"development","label":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions: phase 1/2, recruiting","href":"/trials/nct03947385/"},{"record":"registry:darovasertib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/darovasertib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"gsk3b","name":"GSK3B","href":"/targets/gsk3b/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"development","drugs":[{"id":"elraglusib","name":"Elraglusib","route":"/drugs/elraglusib/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"elraglusib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/elraglusib/"},{"record":"registry:elraglusib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/elraglusib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"hdac10","name":"HDAC10","href":"/targets/hdac10/"},"b":{"key":"mechanismClass","id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/"},"state":"approved","drugs":[{"id":"tucidinostat","name":"Tucidinostat (chidamide)","route":"/drugs/tucidinostat/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"tucidinostat","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/tucidinostat/"},{"record":"tucidinostat","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2014: Relapsed or refractory peripheral T-cell lymphoma","href":"/drugs/tucidinostat/"},{"record":"tucidinostat","field":"approvals[1]","kind":"approval","state":"approved","label":"China 2019: HR-positive, HER2-negative advanced breast cancer with exemestane after endocrine therapy (ACE)","href":"/drugs/tucidinostat/"},{"record":"tucidinostat","field":"approvals[2]","kind":"approval","state":"approved","label":"Japan 2021: Relapsed or refractory adult T-cell leukaemia-lymphoma (HBI-8000)","href":"/drugs/tucidinostat/"},{"record":"tucidinostat","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2021","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"tucidinostat","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2014","href":"https://english.nmpa.gov.cn/"},{"record":"nct06979908","field":"status","kind":"trial","state":"development","label":"A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal C: phase 2, recruiting","href":"/trials/nct06979908/"},{"record":"nct06218888","field":"status","kind":"trial","state":"development","label":"A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Micro: phase 2, planned","href":"/trials/nct06218888/"},{"record":"nct06776952","field":"status","kind":"trial","state":"development","label":"A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma: phase 3, recruiting","href":"/trials/nct06776952/"},{"record":"nct06497985","field":"status","kind":"trial","state":"development","label":"A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients: phase 3, recruiting","href":"/trials/nct06497985/"},{"record":"nct05833724","field":"status","kind":"trial","state":"development","label":"Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL): phase 2, recruiting","href":"/trials/nct05833724/"},{"record":"nct04668690","field":"status","kind":"trial","state":"development","label":"Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL: phase 3, active","href":"/trials/nct04668690/"},{"record":"nct06709885","field":"status","kind":"trial","state":"development","label":"HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer: phase 2, recruiting","href":"/trials/nct06709885/"},{"record":"nct06951997","field":"status","kind":"trial","state":"development","label":"QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer: phase 2, recruiting","href":"/trials/nct06951997/"},{"record":"nct06685276","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct06685276/"},{"record":"registry:tucidinostat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 45 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tucidinostat/#registry"}],"reasons":[]},{"a":{"key":"target","id":"her2+fgfr2","name":"HER2 x FGFR2","href":"/targets/her2/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"development","drugs":[{"id":"absk061","name":"ABSK061","route":"/drugs/absk061/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"absk061","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/absk061/"},{"record":"nct06632262","field":"status","kind":"trial","state":"development","label":"A Phase 2 Clinical Study of ABSK061 and ABSK043: phase 2, recruiting","href":"/trials/nct06632262/"},{"record":"registry:absk061","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/absk061/#registry"}],"reasons":[]},{"a":{"key":"target","id":"hif2a","name":"HIF-2α","href":"/targets/hif2a/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"belzutifan","name":"Belzutifan","route":"/drugs/belzutifan/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"belzutifan","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/belzutifan/"},{"record":"belzutifan","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2021: VHL-associated RCC, CNS haemangioblastoma, pNET","href":"/drugs/belzutifan/"},{"record":"belzutifan","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2023: Advanced RCC after PD-1/PD-L1 and VEGF-TKI","href":"/drugs/belzutifan/"},{"record":"belzutifan","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2026: Adjuvant clear-cell RCC with pembrolizumab","href":"/drugs/belzutifan/"},{"record":"belzutifan","field":"approvals[3]","kind":"approval","state":"approved","label":"EU 2025: ccRCC after ≥2 lines; VHL-associated tumours; 12 Feb 2025 (conditional)","href":"/drugs/belzutifan/"},{"record":"belzutifan","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2021","href":"/regulatory/regions/"},{"record":"belzutifan","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/welireg"},{"record":"belzutifan","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2025","href":"https://products.mhra.gov.uk/?search=Welireg"},{"record":"belzutifan","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2025","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"belzutifan","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2025","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Welireg"},{"record":"nct05468697","field":"status","kind":"trial","state":"development","label":"A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6: phase 1/2, active","href":"/trials/nct05468697/"},{"record":"nct04489771","field":"status","kind":"trial","state":"development","label":"A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013): phase 2, active","href":"/trials/nct04489771/"},{"record":"nct05899049","field":"status","kind":"trial","state":"development","label":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study: phase 3, active","href":"/trials/nct05899049/"},{"record":"nct03634540","field":"status","kind":"trial","state":"development","label":"A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003): phase 2, active","href":"/trials/nct03634540/"},{"record":"nct04924075","field":"status","kind":"trial","state":"development","label":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL: phase 2, recruiting","href":"/trials/nct04924075/"},{"record":"nct07405164","field":"status","kind":"trial","state":"development","label":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043): phase 3, recruiting","href":"/trials/nct07405164/"},{"record":"litespark-012","field":"result","kind":"trial","state":"stopped","label":"LITESPARK-012: phase 3, negative","href":"/trials/litespark-012/","quote":"Primary endpoint not met (ASCO GU 2026)."},{"record":"nct04976634","field":"status","kind":"trial","state":"development","label":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016): phase 2, active","href":"/trials/nct04976634/"},{"record":"nct06428396","field":"status","kind":"trial","state":"development","label":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029): phase 2, active","href":"/trials/nct06428396/"},{"record":"nct04626479","field":"status","kind":"trial","state":"development","label":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A): phase 1/2, active","href":"/trials/nct04626479/"},{"record":"nct04626518","field":"status","kind":"trial","state":"development","label":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03): phase 1/2, active","href":"/trials/nct04626518/"},{"record":"nct07049926","field":"status","kind":"trial","state":"development","label":"Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (: phase 1/2, recruiting","href":"/trials/nct07049926/"},{"record":"registry:belzutifan","kind":"registry","state":"development","label":"ClinicalTrials.gov: 25 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/belzutifan/#registry"}],"reasons":[{"drugId":"belzutifan","drugName":"Belzutifan","drugRoute":"/drugs/belzutifan/","drugState":"approved","record":"litespark-012","kind":"trial","label":"LITESPARK-012: phase 3, negative","href":"/trials/litespark-012/","quote":"Primary endpoint not met (ASCO GU 2026)."}]},{"a":{"key":"target","id":"hdac+proteasome","name":"Histone deacetylases x Proteasome","href":"/targets/hdac/"},"b":{"key":"mechanismClass","id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/"},"state":"stopped","drugs":[{"id":"panobinostat","name":"Panobinostat","route":"/drugs/panobinostat/","state":"stopped","status":"withdrawn"}],"counts":{"approved":0,"development":0,"stopped":1,"unclear":0},"parts":{},"evidence":[{"record":"panobinostat","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/panobinostat/","quote":"An HDAC inhibitor for relapsed myeloma approved in 2015 and withdrawn in 2021 after its confirmatory trial was never completed."},{"record":"panobinostat","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2015: Multiple myeloma after ≥2 regimens including bortezomib and an IMiD","href":"/drugs/panobinostat/"},{"record":"panobinostat","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2015: Relapsed/refractory multiple myeloma","href":"/drugs/panobinostat/"},{"record":"panobinostat","field":"regional.US","kind":"regional","state":"stopped","label":"FDA (US): withdrawn 2022","href":"/regulatory/regions/","quote":"Farydak accelerated approval Feb 2015; US approval withdrawn 2022 at Secura Bio's request"},{"record":"panobinostat","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/farydak"},{"record":"panobinostat","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"US 2022-03-24: withdrawal","href":"/drugs/panobinostat/","quote":"Withdrawn: the indication came off the label 7.1 years after its accelerated approval."},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"registry:panobinostat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/panobinostat/#registry"}],"reasons":[{"drugId":"panobinostat","drugName":"Panobinostat","drugRoute":"/drugs/panobinostat/","drugState":"stopped","record":"panobinostat","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/panobinostat/","quote":"An HDAC inhibitor for relapsed myeloma approved in 2015 and withdrawn in 2021 after its confirmatory trial was never completed."},{"drugId":"panobinostat","drugName":"Panobinostat","drugRoute":"/drugs/panobinostat/","drugState":"stopped","record":"panobinostat","kind":"regional","label":"FDA (US): withdrawn 2022","href":"/regulatory/regions/","quote":"Farydak accelerated approval Feb 2015; US approval withdrawn 2022 at Secura Bio's request"},{"drugId":"panobinostat","drugName":"Panobinostat","drugRoute":"/drugs/panobinostat/","drugState":"stopped","record":"panobinostat","kind":"event","label":"US 2022-03-24: withdrawal","href":"/drugs/panobinostat/","quote":"Withdrawn: the indication came off the label 7.1 years after its accelerated approval."}]},{"a":{"key":"target","id":"hdac+tet2","name":"Histone deacetylases x TET2","href":"/targets/hdac/"},"b":{"key":"mechanismClass","id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/"},"state":"approved","drugs":[{"id":"romidepsin","name":"Romidepsin","route":"/drugs/romidepsin/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"romidepsin","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/romidepsin/"},{"record":"romidepsin","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2009: Cutaneous T-cell lymphoma after ≥1 systemic therapy","href":"/drugs/romidepsin/"},{"record":"romidepsin","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2011: Peripheral T-cell lymphoma after ≥1 therapy","href":"/drugs/romidepsin/"},{"record":"romidepsin","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2009","href":"/regulatory/regions/"},{"record":"romidepsin","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn","href":"/regulatory/regions/","quote":"MAA withdrawn by Celgene before a CHMP opinion"},{"record":"romidepsin","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2017","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"romidepsin","field":"regulatoryEvents[2]","kind":"event","state":"stopped","label":"US 2021-07-30: withdrawal","href":"/drugs/romidepsin/","quote":"Withdrawn: the indication came off the label 10.1 years after its accelerated approval."},{"record":"romidepsin","field":"regulatoryEvents[3]","kind":"event","state":"stopped","label":"US 2021-12-08: withdrawal","href":"/drugs/romidepsin/","quote":"Withdrawn: the indication came off the label 1.7 years after its accelerated approval."},{"record":"nct04747236","field":"status","kind":"trial","state":"development","label":"Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL: phase 2, recruiting","href":"/trials/nct04747236/"},{"record":"registry:romidepsin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/romidepsin/#registry"}],"reasons":[{"drugId":"romidepsin","drugName":"Romidepsin","drugRoute":"/drugs/romidepsin/","drugState":"approved","record":"romidepsin","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"/regulatory/regions/","quote":"MAA withdrawn by Celgene before a CHMP opinion"},{"drugId":"romidepsin","drugName":"Romidepsin","drugRoute":"/drugs/romidepsin/","drugState":"approved","record":"romidepsin","kind":"event","label":"US 2021-07-30: withdrawal","href":"/drugs/romidepsin/","quote":"Withdrawn: the indication came off the label 10.1 years after its accelerated approval."},{"drugId":"romidepsin","drugName":"Romidepsin","drugRoute":"/drugs/romidepsin/","drugState":"approved","record":"romidepsin","kind":"event","label":"US 2021-12-08: withdrawal","href":"/drugs/romidepsin/","quote":"Withdrawn: the indication came off the label 1.7 years after its accelerated approval."}]},{"a":{"key":"target","id":"itk","name":"ITK","href":"/targets/itk/"},"b":{"key":"mechanismClass","id":"hif-inhibitor","name":"HIF inhibitor"},"state":"development","drugs":[{"id":"soquelitinib","name":"Soquelitinib","route":"/drugs/soquelitinib/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"soquelitinib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/soquelitinib/"},{"record":"nct06561048","field":"status","kind":"trial","state":"development","label":"Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma: phase 3, recruiting","href":"/trials/nct06561048/"},{"record":"registry:soquelitinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/soquelitinib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"jak1","name":"JAK1","href":"/targets/jak1/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"golidocitinib","name":"Golidocitinib","route":"/drugs/golidocitinib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"golidocitinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/golidocitinib/"},{"record":"golidocitinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2024: Relapsed or refractory peripheral T-cell lymphoma","href":"/drugs/golidocitinib/"},{"record":"golidocitinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2024","href":"https://english.nmpa.gov.cn/"},{"record":"nct07234162","field":"status","kind":"trial","state":"development","label":"A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19): phase 3, recruiting","href":"/trials/nct07234162/"},{"record":"nct07496229","field":"status","kind":"trial","state":"development","label":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3): phase 1/2, recruiting","href":"/trials/nct07496229/"},{"record":"nct06198907","field":"status","kind":"trial","state":"development","label":"Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC): phase 2, planned","href":"/trials/nct06198907/"},{"record":"nct07110103","field":"status","kind":"trial","state":"development","label":"Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC: phase 2, recruiting","href":"/trials/nct07110103/"},{"record":"registry:golidocitinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 37 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/golidocitinib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"kit+met","name":"KIT x MET","href":"/targets/kit/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"development","drugs":[{"id":"bezuclastinib","name":"Bezuclastinib","route":"/drugs/bezuclastinib/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"bezuclastinib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/bezuclastinib/"},{"record":"nct04996875","field":"status","kind":"trial","state":"development","label":"(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis: phase 2, recruiting","href":"/trials/nct04996875/"},{"record":"nct05208047","field":"status","kind":"trial","state":"development","label":"(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors: phase 3, recruiting","href":"/trials/nct05208047/"},{"record":"nct05186753","field":"status","kind":"trial","state":"development","label":"(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis: phase 2, active","href":"/trials/nct05186753/"},{"record":"registry:bezuclastinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/bezuclastinib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"kras+fak","name":"KRAS x FAK","href":"/targets/kras/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"avutometinib-defactinib","name":"Avutometinib + defactinib","route":"/drugs/avutometinib-defactinib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"avutometinib-defactinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/avutometinib-defactinib/"},{"record":"avutometinib-defactinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2025: KRAS-mutated recurrent low-grade serous ovarian cancer after prior systemic therapy (accelerated)","href":"/drugs/avutometinib-defactinib/"},{"record":"avutometinib-defactinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2025","href":"/regulatory/regions/"},{"record":"nct07824960","field":"status","kind":"trial","state":"development","label":"Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma: phase 1/2, planned","href":"/trials/nct07824960/"},{"record":"nct06369259","field":"status","kind":"trial","state":"development","label":"Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-R: phase 2, recruiting","href":"/trials/nct06369259/"},{"record":"nct07126158","field":"status","kind":"trial","state":"development","label":"Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma: phase 2, recruiting","href":"/trials/nct07126158/"},{"record":"registry:avutometinib-defactinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 19 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/avutometinib-defactinib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"kras+nras","name":"KRAS x NRAS","href":"/targets/kras/"},"b":{"key":"mechanismClass","id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/"},"state":"development","drugs":[{"id":"jyp0015","name":"JYP0015","route":"/drugs/jyp0015/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"jyp0015","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/jyp0015/"},{"record":"nct06895031","field":"status","kind":"trial","state":"development","label":"Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS: phase 2, recruiting","href":"/trials/nct06895031/"},{"record":"registry:jyp0015","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/jyp0015/#registry"}],"reasons":[]},{"a":{"key":"target","id":"mdm2","name":"MDM2","href":"/targets/mdm2/"},"b":{"key":"mechanismClass","id":"mdm2-inhibitor","name":"MDM2 inhibitor","href":"/technologies/mdm2-inhibitors/"},"state":"development","drugs":[{"id":"brigimadlin","name":"Brigimadlin","route":"/drugs/brigimadlin/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"brigimadlin","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/brigimadlin/"},{"record":"nct06619509","field":"status","kind":"trial","state":"development","label":"A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine: phase 2, active","href":"/trials/nct06619509/"},{"record":"registry:brigimadlin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/brigimadlin/#registry"}],"reasons":[]},{"a":{"key":"target","id":"mdm2+tp53","name":"MDM2 x TP53","href":"/targets/mdm2/"},"b":{"key":"mechanismClass","id":"mdm2-inhibitor","name":"MDM2 inhibitor","href":"/technologies/mdm2-inhibitors/"},"state":"development","drugs":[{"id":"krt-232","name":"KRT-232","route":"/drugs/krt-232/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"krt-232","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/krt-232/"},{"record":"nct03669965","field":"status","kind":"trial","state":"development","label":"KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera: phase 2, active","href":"/trials/nct03669965/"},{"record":"nct04502394","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL: phase 1/2, recruiting","href":"/trials/nct04502394/"},{"record":"nct05797831","field":"status","kind":"trial","state":"development","label":"Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer: phase 2/3, recruiting","href":"/trials/nct05797831/"},{"record":"registry:krt-232","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/krt-232/#registry"}],"reasons":[]},{"a":{"key":"target","id":"menin","name":"Menin","href":"/targets/menin/"},"b":{"key":"mechanismClass","id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/"},"state":"approved","drugs":[{"id":"revumenib","name":"Revumenib","route":"/drugs/revumenib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"revumenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/revumenib/"},{"record":"revumenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2024: Relapsed/refractory KMT2A-rearranged acute leukaemia, age ≥1","href":"/drugs/revumenib/"},{"record":"revumenib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2025: Relapsed/refractory NPM1-mutant AML","href":"/drugs/revumenib/"},{"record":"revumenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2024","href":"/regulatory/regions/"},{"record":"nct07211958","field":"status","kind":"trial","state":"development","label":"Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation: phase 3, recruiting","href":"/trials/nct07211958/"},{"record":"registry:revumenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 13 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/revumenib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"menin+npm1","name":"Menin x NPM1 mutation","href":"/targets/menin/"},"b":{"key":"mechanismClass","id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/"},"state":"approved","drugs":[{"id":"ziftomenib","name":"Ziftomenib","route":"/drugs/ziftomenib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"ziftomenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ziftomenib/"},{"record":"ziftomenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2025: Relapsed/refractory NPM1-mutated AML with no satisfactory alternative","href":"/drugs/ziftomenib/"},{"record":"ziftomenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2025","href":"/regulatory/regions/"},{"record":"nct07623616","field":"status","kind":"trial","state":"development","label":"A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia: phase 2, recruiting","href":"/trials/nct07623616/"},{"record":"myelomatch","field":"status","kind":"trial","state":"development","label":"myeloMATCH: phase platform, recruiting","href":"/trials/myelomatch/"},{"record":"nct07007312","field":"status","kind":"trial","state":"development","label":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML: phase 3, recruiting","href":"/trials/nct07007312/"},{"record":"registry:ziftomenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ziftomenib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"mertk","name":"MERTK","href":"/targets/mertk/"},"b":{"key":"mechanismClass","id":"other-inhibitor","name":"Inhibitor (class not stated)"},"state":"approved","drugs":[{"id":"imetelstat","name":"Imetelstat","route":"/drugs/imetelstat/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"imetelstat","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/imetelstat/"},{"record":"imetelstat","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2024: Low- to intermediate-1-risk MDS with transfusion-dependent anaemia after ESA failure","href":"/drugs/imetelstat/"},{"record":"imetelstat","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2025: Lower-risk MDS transfusion-dependent anaemia","href":"/drugs/imetelstat/"},{"record":"imetelstat","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2024","href":"/regulatory/regions/"},{"record":"imetelstat","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/rytelo"},{"record":"impactmf","field":"status","kind":"trial","state":"development","label":"IMpactMF: phase 3, active","href":"/trials/impactmf/"},{"record":"nct05583552","field":"status","kind":"trial","state":"development","label":"Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy: phase 2, active","href":"/trials/nct05583552/"},{"record":"registry:imetelstat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/imetelstat/#registry"}],"reasons":[]},{"a":{"key":"target","id":"met+egfr","name":"MET x EGFR","href":"/targets/met/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"savolitinib","name":"Savolitinib","route":"/drugs/savolitinib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"}]},"evidence":[{"record":"savolitinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/savolitinib/"},{"record":"savolitinib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2021: MET exon 14 skipping NSCLC after platinum chemotherapy or unfit for chemotherapy (conditional; later full)","href":"/drugs/savolitinib/"},{"record":"savolitinib","field":"approvals[1]","kind":"approval","state":"approved","label":"China 2025: With osimertinib in EGFR-mutant NSCLC with MET amplification after EGFR TKI (SACHI)","href":"/drugs/savolitinib/"},{"record":"savolitinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"nct04606771","field":"status","kind":"trial","state":"development","label":"A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC: phase 2, active","href":"/trials/nct04606771/"},{"record":"nct05009836","field":"status","kind":"trial","state":"development","label":"Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC: phase 3, active","href":"/trials/nct05009836/"},{"record":"nct03778229","field":"status","kind":"trial","state":"development","label":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib: phase 2, active","href":"/trials/nct03778229/"},{"record":"nct03944772","field":"status","kind":"trial","state":"development","label":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD): phase 2, active","href":"/trials/nct03944772/"},{"record":"nct05374603","field":"status","kind":"trial","state":"development","label":"Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC: phase 2, active","href":"/trials/nct05374603/"},{"record":"nct05043090","field":"status","kind":"trial","state":"development","label":"Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC: phase 3, active","href":"/trials/nct05043090/"},{"record":"nct05261399","field":"status","kind":"trial","state":"development","label":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment: phase 3, active","href":"/trials/nct05261399/"},{"record":"nct03091192","field":"status","kind":"trial","state":"development","label":"Savolitinib vs. Sunitinib in MET-driven PRCC.: phase 3, active","href":"/trials/nct03091192/"},{"record":"registry:savolitinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 16 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/savolitinib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"met+ret","name":"MET x RET","href":"/targets/met/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"development","drugs":[{"id":"al2846","name":"AL2846","route":"/drugs/al2846/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"al2846","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/al2846/"},{"record":"nct06860971","field":"status","kind":"trial","state":"development","label":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma: phase 3, recruiting","href":"/trials/nct06860971/"},{"record":"registry:al2846","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/al2846/#registry"}],"reasons":[]},{"a":{"key":"target","id":"met+vegf","name":"MET x VEGF / VEGFR","href":"/targets/met/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"cabozantinib","name":"Cabozantinib","route":"/drugs/cabozantinib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"cabozantinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/cabozantinib/"},{"record":"cabozantinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2012: Medullary thyroid cancer (Cometriq)","href":"/drugs/cabozantinib/"},{"record":"cabozantinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2016: Advanced RCC","href":"/drugs/cabozantinib/"},{"record":"cabozantinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2019: HCC previously treated with sorafenib","href":"/drugs/cabozantinib/"},{"record":"cabozantinib","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2025: Advanced pancreatic and extra-pancreatic neuroendocrine tumours after prior therapy (CABINET)","href":"/drugs/cabozantinib/"},{"record":"cabozantinib","field":"approvals[4]","kind":"approval","state":"approved","label":"US 2017: First-line advanced RCC (CABOSUN)","href":"/drugs/cabozantinib/"},{"record":"cabozantinib","field":"approvals[5]","kind":"approval","state":"approved","label":"US 2021: First-line advanced RCC with nivolumab (CheckMate 9ER)","href":"/drugs/cabozantinib/"},{"record":"cabozantinib","field":"approvals[6]","kind":"approval","state":"approved","label":"EU 2014: Cometriq for medullary thyroid cancer; 21 Mar 2014. Cabometyx (RCC) Sep 2016","href":"/drugs/cabozantinib/"},{"record":"cabozantinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2012","href":"/regulatory/regions/"},{"record":"cabozantinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2014","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq"},{"record":"cabozantinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2014","href":"https://products.mhra.gov.uk/?search=Cometriq"},{"record":"cabozantinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2020","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"cabozantinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"cabozantinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2017","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Cabometyx"},{"record":"nct03690388","field":"status","kind":"trial","state":"development","label":"A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Va: phase 3, active","href":"/trials/nct03690388/"},{"record":"nct05859217","field":"status","kind":"trial","state":"development","label":"A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1): phase 2, planned","href":"/trials/nct05859217/"},{"record":"nct07293351","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal : phase 1/2, recruiting","href":"/trials/nct07293351/"},{"record":"nct03634540","field":"status","kind":"trial","state":"development","label":"A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003): phase 2, active","href":"/trials/nct03634540/"},{"record":"nct01639508","field":"status","kind":"trial","state":"development","label":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or A: phase 2, recruiting","href":"/trials/nct01639508/"},{"record":"nct03539822","field":"status","kind":"trial","state":"development","label":"Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies: phase 1/2, recruiting","href":"/trials/nct03539822/"},{"record":"comet-1","field":"result","kind":"trial","state":"stopped","label":"COMET-1: phase 3, negative","href":"/trials/comet-1/","quote":"Median overall survival 11.0 against 9.8 months (hazard ratio 0.90, 95 percent confidence interval 0.76 to 1.06, p=0.213): not met. Bone scan response at 12 weeks 42 against 3 percent and radiographic progression-free survival 5.6 against 2.8 months."},{"record":"contact-03","field":"result","kind":"trial","state":"stopped","label":"CONTACT-03: phase 3, negative","href":"/trials/contact-03/","quote":"PFS HR 1.03; OS HR 0.94, negative."},{"record":"nct07405164","field":"status","kind":"trial","state":"development","label":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043): phase 3, recruiting","href":"/trials/nct07405164/"},{"record":"nct07620574","field":"status","kind":"trial","state":"development","label":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study: phase 3, recruiting","href":"/trials/nct07620574/"},{"record":"nct03899155","field":"status","kind":"trial","state":"development","label":"Pan Tumor Rollover Study: phase 2, recruiting","href":"/trials/nct03899155/"},{"record":"nct04446117","field":"status","kind":"trial","state":"development","label":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC: phase 3, active","href":"/trials/nct04446117/"},{"record":"nct03755791","field":"status","kind":"trial","state":"development","label":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece: phase 3, active","href":"/trials/nct03755791/"},{"record":"nct07011719","field":"status","kind":"trial","state":"development","label":"Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma: phase 3, recruiting","href":"/trials/nct07011719/"},{"record":"registry:cabozantinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 43 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/cabozantinib/#registry"}],"reasons":[{"drugId":"cabozantinib","drugName":"Cabozantinib","drugRoute":"/drugs/cabozantinib/","drugState":"approved","record":"comet-1","kind":"trial","label":"COMET-1: phase 3, negative","href":"/trials/comet-1/","quote":"Median overall survival 11.0 against 9.8 months (hazard ratio 0.90, 95 percent confidence interval 0.76 to 1.06, p=0.213): not met. Bone scan response at 12 weeks 42 against 3 percent and radiographic progression-free survival 5.6 against 2.8 months."},{"drugId":"cabozantinib","drugName":"Cabozantinib","drugRoute":"/drugs/cabozantinib/","drugState":"approved","record":"contact-03","kind":"trial","label":"CONTACT-03: phase 3, negative","href":"/trials/contact-03/","quote":"PFS HR 1.03; OS HR 0.94, negative."}]},{"a":{"key":"target","id":"mycn","name":"MYCN (N-myc)","href":"/targets/mycn/"},"b":{"key":"mechanismClass","id":"other-inhibitor","name":"Inhibitor (class not stated)"},"state":"approved","drugs":[{"id":"eflornithine","name":"Eflornithine (DFMO)","route":"/drugs/eflornithine/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"covalent","name":"Covalent"}]},"evidence":[{"record":"eflornithine","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/eflornithine/"},{"record":"eflornithine","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2023: Maintenance to reduce relapse risk in high-risk neuroblastoma after ≥PR to prior therapy including anti-GD2","href":"/drugs/eflornithine/"},{"record":"eflornithine","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2023","href":"/regulatory/regions/"},{"record":"nct01349881","field":"status","kind":"trial","state":"development","label":"S0820, Adenoma and Second Primary Prevention Trial: phase 3, active","href":"/trials/nct01349881/"},{"record":"nct07287917","field":"status","kind":"trial","state":"development","label":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct07287917/"},{"record":"registry:eflornithine","kind":"registry","state":"development","label":"ClinicalTrials.gov: 13 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/eflornithine/#registry"}],"reasons":[]},{"a":{"key":"target","id":"nras","name":"NRAS","href":"/targets/nras/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"development","drugs":[{"id":"naporafenib","name":"Naporafenib","route":"/drugs/naporafenib/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"naporafenib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/naporafenib/"},{"record":"seacraft-2","field":"status","kind":"trial","state":"development","label":"A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2): phase 3, active","href":"/trials/seacraft-2/"},{"record":"nct04417621","field":"status","kind":"trial","state":"development","label":"Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma: phase 2, active","href":"/trials/nct04417621/"},{"record":"registry:naporafenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/naporafenib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"ntrk","name":"NTRK","href":"/targets/ntrk/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"larotrectinib","name":"Larotrectinib","route":"/drugs/larotrectinib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible"}]},"evidence":[{"record":"larotrectinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/larotrectinib/"},{"record":"larotrectinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: Solid tumours with NTRK gene fusion without known acquired resistance mutation, metastatic or unresectable, adults and children","href":"/drugs/larotrectinib/"},{"record":"larotrectinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2019: Same","href":"/drugs/larotrectinib/"},{"record":"larotrectinib","field":"approvals[2]","kind":"approval","state":"approved","label":"UK 2020: NTRK fusion-positive solid tumours in adults and children, locally advanced or metastatic or where surgery would cause severe morbidity, with no satisfactory treatment options: NICE TA630 (27 May 2020) recommends it within the Cancer Drugs Fund under a managed access agreement","href":"/drugs/larotrectinib/"},{"record":"larotrectinib","field":"approvals[3]","kind":"approval","state":"approved","label":"England (NICE) 2020: NTRK fusion-positive solid tumours, including colorectal cancer","href":"/drugs/larotrectinib/"},{"record":"larotrectinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"larotrectinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2019","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/vitrakvi"},{"record":"larotrectinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2019","href":"https://products.mhra.gov.uk/?search=Vitrakvi"},{"record":"larotrectinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2021","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"larotrectinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2022","href":"https://english.nmpa.gov.cn/"},{"record":"larotrectinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Vitrakvi"},{"record":"nct02637687","field":"status","kind":"trial","state":"development","label":"A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children: phase 1/2, active","href":"/trials/nct02637687/"},{"record":"pediatric-match","field":"status","kind":"trial","state":"development","label":"NCI-COG Pediatric MATCH (APEC1621): phase platform, active","href":"/trials/pediatric-match/"},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"registry:larotrectinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 13 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/larotrectinib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"ntrk+ros1","name":"NTRK x ROS1","href":"/targets/ntrk/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"entrectinib","name":"Entrectinib","route":"/drugs/entrectinib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"entrectinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/entrectinib/"},{"record":"entrectinib","field":"approvals[0]","kind":"approval","state":"approved","label":"JP 2019: NTRK fusion solid tumours","href":"/drugs/entrectinib/"},{"record":"entrectinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2019: ROS1-positive metastatic NSCLC; NTRK fusion solid tumours (≥12 years, extended to ≥1 month 2023)","href":"/drugs/entrectinib/"},{"record":"entrectinib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2020: Same","href":"/drugs/entrectinib/"},{"record":"entrectinib","field":"approvals[3]","kind":"approval","state":"approved","label":"UK 2020: NTRK fusion-positive solid tumours: NICE TA644 (12 August 2020) recommended entrectinib within the Cancer Drugs Fund; it was replaced by TA1118 (terminated appraisal, 7 January 2026) because the company did not make a submission, and only people already on treatment continue","href":"/drugs/entrectinib/"},{"record":"entrectinib","field":"approvals[4]","kind":"approval","state":"approved","label":"England (NICE) 2020: NTRK fusion-positive solid tumours, including colorectal cancer","href":"/drugs/entrectinib/"},{"record":"entrectinib","field":"approvals[5]","kind":"approval","state":"approved","label":"England (NICE) 2020: ROS1-positive advanced non-small-cell lung cancer in patients who have not had a ROS1 inhibitor","href":"/drugs/entrectinib/"},{"record":"entrectinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2019","href":"/regulatory/regions/"},{"record":"entrectinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2020","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/rozlytrek"},{"record":"entrectinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2020","href":"https://products.mhra.gov.uk/?search=Rozlytrek"},{"record":"entrectinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2019","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"entrectinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2022","href":"https://english.nmpa.gov.cn/"},{"record":"entrectinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Rozlytrek"},{"record":"nct05170204","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C: phase 3, active","href":"/trials/nct05170204/"},{"record":"nct04302025","field":"status","kind":"trial","state":"development","label":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC): phase 2, recruiting","href":"/trials/nct04302025/"},{"record":"nct04603807","field":"status","kind":"trial","state":"development","label":"A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases: phase 3, active","href":"/trials/nct04603807/"},{"record":"nct02568267","field":"status","kind":"trial","state":"development","label":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme: phase 2, active","href":"/trials/nct02568267/"},{"record":"determine-trial","field":"status","kind":"trial","state":"development","label":"DETERMINE: phase platform, recruiting","href":"/trials/determine-trial/"},{"record":"nct02650401","field":"status","kind":"trial","state":"development","label":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options: phase 1/2, active","href":"/trials/nct02650401/"},{"record":"nct04589845","field":"status","kind":"trial","state":"development","label":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study: phase 2, active","href":"/trials/nct04589845/"},{"record":"registry:entrectinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 20 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/entrectinib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"pik3cd+psmb6","name":"PI3K delta x PSMB6","href":"/targets/pik3cd/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"linperlisib","name":"Linperlisib","route":"/drugs/linperlisib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"linperlisib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/linperlisib/"},{"record":"linperlisib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2022: Relapsed or refractory follicular lymphoma after two or more lines, conditional","href":"/drugs/linperlisib/"},{"record":"linperlisib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2022","href":"https://english.nmpa.gov.cn/"},{"record":"nct06224257","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia: phase 2, recruiting","href":"/trials/nct06224257/"},{"record":"registry:linperlisib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 17 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/linperlisib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"plk1","name":"PLK1","href":"/targets/plk1/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"development","drugs":[{"id":"onvansertib","name":"Onvansertib","route":"/drugs/onvansertib/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"onvansertib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/onvansertib/"},{"record":"nct06736717","field":"status","kind":"trial","state":"development","label":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer: phase 1/2, recruiting","href":"/trials/nct06736717/"},{"record":"nct06106308","field":"status","kind":"trial","state":"development","label":"Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab fo: phase 2, active","href":"/trials/nct06106308/"},{"record":"nct05450965","field":"status","kind":"trial","state":"development","label":"Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct05450965/"},{"record":"registry:onvansertib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/onvansertib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"ret+vegf","name":"RET x VEGF / VEGFR","href":"/targets/ret/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"vandetanib","name":"Vandetanib","route":"/drugs/vandetanib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"vandetanib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/vandetanib/"},{"record":"vandetanib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2011: Symptomatic or progressive medullary thyroid cancer","href":"/drugs/vandetanib/"},{"record":"vandetanib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2011","href":"/regulatory/regions/"},{"record":"vandetanib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2012","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa"},{"record":"vandetanib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2012","href":"https://products.mhra.gov.uk/?search=Caprelsa"},{"record":"vandetanib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2015","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"vandetanib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2013","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Caprelsa"},{"record":"registry:vandetanib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/vandetanib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"rxr","name":"Retinoid X receptor (RXR)","href":"/targets/rxr/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"bexarotene","name":"Bexarotene","route":"/drugs/bexarotene/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"bexarotene","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/bexarotene/"},{"record":"bexarotene","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1999: Cutaneous manifestations of cutaneous T-cell lymphoma refractory to at least one systemic therapy","href":"/drugs/bexarotene/"},{"record":"bexarotene","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2001: Skin manifestations of advanced-stage CTCL refractory to at least one systemic treatment","href":"/drugs/bexarotene/"},{"record":"bexarotene","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2001","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/targretin"},{"record":"registry:bexarotene","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 7 terminated or withdrawn studies and none active (fetched 2026-09-28)","href":"/drugs/bexarotene/#registry"}],"reasons":[]},{"a":{"key":"target","id":"rrm1","name":"Ribonucleotide reductase (RRM1)","href":"/targets/rrm1/"},"b":{"key":"mechanismClass","id":"other-inhibitor","name":"Inhibitor (class not stated)"},"state":"approved","drugs":[{"id":"hydroxyurea","name":"Hydroxyurea (hydroxycarbamide)","route":"/drugs/hydroxyurea/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"hydroxyurea","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/hydroxyurea/"},{"record":"hydroxyurea","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1967: CML, head and neck cancer with radiotherapy, melanoma, ovarian cancer (historic labelling)","href":"/drugs/hydroxyurea/"},{"record":"hydroxyurea","field":"approvals[1]","kind":"approval","state":"approved","label":"US 1998: Sickle cell anaemia (Droxia)","href":"/drugs/hydroxyurea/"},{"record":"hydroxyurea","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 1967","href":"/regulatory/regions/"},{"record":"hydroxyurea","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/siklos"},{"record":"hydroxyurea","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved","href":"https://products.mhra.gov.uk/?search=Hydrea"},{"record":"hydroxyurea","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"hydroxyurea","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved","href":"https://english.nmpa.gov.cn/"},{"record":"hydroxyurea","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Hydrea"},{"record":"registry:hydroxyurea","kind":"registry","state":"development","label":"ClinicalTrials.gov: 24 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/hydroxyurea/#registry"}],"reasons":[]},{"a":{"key":"target","id":"ros1+ntrk","name":"ROS1 x NTRK","href":"/targets/ros1/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"repotrectinib","name":"Repotrectinib","route":"/drugs/repotrectinib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"repotrectinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/repotrectinib/"},{"record":"repotrectinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2023: ROS1+ locally advanced or metastatic NSCLC","href":"/drugs/repotrectinib/"},{"record":"repotrectinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2024: NTRK-fusion solid tumours (tumour-agnostic)","href":"/drugs/repotrectinib/"},{"record":"repotrectinib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2025: ROS1+ NSCLC; NTRK+ solid tumours; 13 Jan 2025 (conditional)","href":"/drugs/repotrectinib/"},{"record":"repotrectinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2023","href":"/regulatory/regions/"},{"record":"repotrectinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/augtyro"},{"record":"repotrectinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2025","href":"https://products.mhra.gov.uk/?search=Augtyro"},{"record":"repotrectinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2024","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"repotrectinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2025","href":"https://english.nmpa.gov.cn/"},{"record":"nct03093116","field":"status","kind":"trial","state":"development","label":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements: phase 1/2, recruiting","href":"/trials/nct03093116/"},{"record":"nct04094610","field":"status","kind":"trial","state":"development","label":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations: phase 1/2, recruiting","href":"/trials/nct04094610/"},{"record":"nct06140836","field":"status","kind":"trial","state":"development","label":"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3): phase 3, active","href":"/trials/nct06140836/"},{"record":"nct06315010","field":"status","kind":"trial","state":"development","label":"Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis: phase 2, recruiting","href":"/trials/nct06315010/"},{"record":"registry:repotrectinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/repotrectinib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"stat3","name":"STAT3","href":"/targets/stat3/"},"b":{"key":"mechanismClass","id":"other-inhibitor","name":"Inhibitor (class not stated)"},"state":"stopped","drugs":[{"id":"napabucasin","name":"Napabucasin","route":"/drugs/napabucasin/","state":"stopped","status":"negative"}],"counts":{"approved":0,"development":0,"stopped":1,"unclear":0},"parts":{},"evidence":[{"record":"napabucasin","field":"status","kind":"drug","state":"stopped","label":"Drug record status: negative","href":"/drugs/napabucasin/","quote":"Napabucasin, an oral drug marketed as a cancer stemness inhibitor, was tested in 1,134 people with untreated metastatic pancreatic cancer on top of nab-paclitaxel and gemcitabine; survival was identical and the trial was stopped for futility."},{"record":"canstem111p","field":"result","kind":"trial","state":"stopped","label":"CanStem111P: phase 3, negative","href":"/trials/canstem111p/","quote":"Median overall survival 11.4 months with napabucasin plus nab-paclitaxel and gemcitabine against 11.7 months with chemotherapy alone (hazard ratio 1.07, 95 percent confidence interval 0.93 to 1.23); terminated for futility."},{"record":"registry:napabucasin","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 2 terminated or withdrawn studies and none active (fetched 2026-09-28)","href":"/drugs/napabucasin/#registry"}],"reasons":[{"drugId":"napabucasin","drugName":"Napabucasin","drugRoute":"/drugs/napabucasin/","drugState":"stopped","record":"napabucasin","kind":"drug","label":"Drug record status: negative","href":"/drugs/napabucasin/","quote":"Napabucasin, an oral drug marketed as a cancer stemness inhibitor, was tested in 1,134 people with untreated metastatic pancreatic cancer on top of nab-paclitaxel and gemcitabine; survival was identical and the trial was stopped for futility."},{"drugId":"napabucasin","drugName":"Napabucasin","drugRoute":"/drugs/napabucasin/","drugState":"stopped","record":"canstem111p","kind":"trial","label":"CanStem111P: phase 3, negative","href":"/trials/canstem111p/","quote":"Median overall survival 11.4 months with napabucasin plus nab-paclitaxel and gemcitabine against 11.7 months with chemotherapy alone (hazard ratio 1.07, 95 percent confidence interval 0.93 to 1.23); terminated for futility."}]},{"a":{"key":"target","id":"syk","name":"SYK","href":"/targets/syk/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"fostamatinib","name":"Fostamatinib","route":"/drugs/fostamatinib/","state":"approved","status":"established"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"fostamatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: established","href":"/drugs/fostamatinib/"},{"record":"fostamatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: Chronic immune thrombocytopenia in adults with insufficient response to a previous treatment","href":"/drugs/fostamatinib/"},{"record":"registry:fostamatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/fostamatinib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"tbk1","name":"TBK1","href":"/targets/tbk1/"},"b":{"key":"mechanismClass","id":"receptor-agonist","name":"Receptor agonist"},"state":"stopped","drugs":[{"id":"adu-s100","name":"ADU-S100 (MIW815)","route":"/drugs/adu-s100/","state":"stopped","status":"withdrawn"}],"counts":{"approved":0,"development":0,"stopped":1,"unclear":0},"parts":{},"evidence":[{"record":"adu-s100","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/adu-s100/","quote":"ADU-S100 was the first STING agonist in the clinic. Injected directly into tumours, it produced almost no responses, alone or with checkpoint blockade."},{"record":"registry:adu-s100","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 1 terminated or withdrawn study and none active (fetched 2026-09-28)","href":"/drugs/adu-s100/#registry"}],"reasons":[{"drugId":"adu-s100","drugName":"ADU-S100 (MIW815)","drugRoute":"/drugs/adu-s100/","drugState":"stopped","record":"adu-s100","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/adu-s100/","quote":"ADU-S100 was the first STING agonist in the clinic. Injected directly into tumours, it produced almost no responses, alone or with checkpoint blockade."}]},{"a":{"key":"target","id":"tlr7","name":"Toll-like receptor 7 (TLR7)","href":"/targets/tlr7/"},"b":{"key":"mechanismClass","id":"receptor-agonist","name":"Receptor agonist"},"state":"approved","drugs":[{"id":"imiquimod","name":"Imiquimod","route":"/drugs/imiquimod/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"imiquimod","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/imiquimod/"},{"record":"imiquimod","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1997: External genital and perianal warts","href":"/drugs/imiquimod/"},{"record":"imiquimod","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2004: Actinic keratosis; superficial basal cell carcinoma in immunocompetent adults","href":"/drugs/imiquimod/"},{"record":"imiquimod","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 1998: Genital warts, superficial basal cell carcinoma and actinic keratosis (Aldara)","href":"/drugs/imiquimod/"},{"record":"imiquimod","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 1998","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/aldara"},{"record":"scin-trial","field":"result","kind":"trial","state":"stopped","label":"SCIN (curettage then imiquimod against excision for nodular basal cell carcinoma): phase 3, negative","href":"/trials/scin-trial/","quote":"Freedom from treatment failure at five years 77.8 per cent after curettage with imiquimod against 98.2 per cent after surgical excision; relative risk of failure 15.93 (95 per cent confidence interval 2.10 to 120.64), non-inferiority not concluded."},{"record":"sins-trial","field":"result","kind":"trial","state":"stopped","label":"SINS (surgical excision against imiquimod cream for basal cell carcinoma): phase 3, negative","href":"/trials/sins-trial/","quote":"Clinical success at three years 84 per cent with imiquimod against 98 per cent with surgery (relative risk 0.84, 98 per cent confidence interval 0.78 to 0.91, p<0.0001), and at five years 82.5 against 97.7 per cent; imiquimod was inferior, not non-inferior."},{"record":"registry:imiquimod","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/imiquimod/#registry"}],"reasons":[{"drugId":"imiquimod","drugName":"Imiquimod","drugRoute":"/drugs/imiquimod/","drugState":"approved","record":"scin-trial","kind":"trial","label":"SCIN (curettage then imiquimod against excision for nodular basal cell carcinoma): phase 3, negative","href":"/trials/scin-trial/","quote":"Freedom from treatment failure at five years 77.8 per cent after curettage with imiquimod against 98.2 per cent after surgical excision; relative risk of failure 15.93 (95 per cent confidence interval 2.10 to 120.64), non-inferiority not concluded."},{"drugId":"imiquimod","drugName":"Imiquimod","drugRoute":"/drugs/imiquimod/","drugState":"approved","record":"sins-trial","kind":"trial","label":"SINS (surgical excision against imiquimod cream for basal cell carcinoma): phase 3, negative","href":"/trials/sins-trial/","quote":"Clinical success at three years 84 per cent with imiquimod against 98 per cent with surgery (relative risk 0.84, 98 per cent confidence interval 0.78 to 0.91, p<0.0001), and at five years 82.5 against 97.7 per cent; imiquimod was inferior, not non-inferior."}]},{"a":{"key":"target","id":"top1","name":"Topoisomerase I (TOP1)","href":"/targets/top1/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"development","drugs":[{"id":"hr070803","name":"HR070803","route":"/drugs/hr070803/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"hr070803","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/hr070803/"},{"record":"nct05945901","field":"status","kind":"trial","state":"development","label":"A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer: phase 2/3, active","href":"/trials/nct05945901/"},{"record":"registry:hr070803","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/hr070803/#registry"}],"reasons":[]},{"a":{"key":"target","id":"tph1","name":"Tryptophan hydroxylase 1","href":"/targets/tph1/"},"b":{"key":"mechanismClass","id":"other-inhibitor","name":"Inhibitor (class not stated)"},"state":"approved","drugs":[{"id":"telotristat-ethyl","name":"Telotristat ethyl","route":"/drugs/telotristat-ethyl/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"telotristat-ethyl","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/telotristat-ethyl/"},{"record":"telotristat-ethyl","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2017: Carcinoid syndrome diarrhoea with somatostatin analogue therapy in adults inadequately controlled by SSA alone","href":"/drugs/telotristat-ethyl/"},{"record":"telotristat-ethyl","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2017: Same (Xermelo)","href":"/drugs/telotristat-ethyl/"},{"record":"telotristat-ethyl","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2017","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/xermelo"},{"record":"registry:telotristat-ethyl","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/telotristat-ethyl/#registry"}],"reasons":[]},{"a":{"key":"target","id":"ugt1a1","name":"UGT1A1","href":"/targets/ugt1a1/"},"b":{"key":"mechanismClass","id":"other-inhibitor","name":"Inhibitor (class not stated)"},"state":"approved","drugs":[{"id":"irinotecan","name":"Irinotecan (and liposomal irinotecan)","route":"/drugs/irinotecan/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"irinotecan","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/irinotecan/"},{"record":"irinotecan","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1996: Metastatic colorectal cancer after 5-FU; first line with 5-FU/LV 2000","href":"/drugs/irinotecan/"},{"record":"irinotecan","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2015: Liposomal irinotecan with 5-FU/LV in metastatic pancreatic cancer after gemcitabine","href":"/drugs/irinotecan/"},{"record":"irinotecan","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2024: Liposomal irinotecan in NALIRIFOX first-line metastatic pancreatic cancer","href":"/drugs/irinotecan/"},{"record":"irinotecan","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 1996","href":"/regulatory/regions/"},{"record":"irinotecan","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-pegylated-liposomal"},{"record":"irinotecan","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved","href":"https://products.mhra.gov.uk/?search=Campto"},{"record":"irinotecan","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 1994","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"irinotecan","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved","href":"https://english.nmpa.gov.cn/"},{"record":"irinotecan","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Campto"},{"record":"nct07585279","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer: phase 2/3, planned","href":"/trials/nct07585279/"},{"record":"nct05592626","field":"status","kind":"trial","state":"development","label":"A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05592626/"},{"record":"nct04657068","field":"status","kind":"trial","state":"development","label":"A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors: phase 1/2, recruiting","href":"/trials/nct04657068/"},{"record":"n0147","field":"result","kind":"trial","state":"stopped","label":"Alliance N0147: phase 3, negative","href":"/trials/n0147/","quote":"Three-year disease-free survival 71.5 with cetuximab against 74.6 percent without, in KRAS wild-type disease."},{"record":"nct06219941","field":"status","kind":"trial","state":"development","label":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2: phase 2, recruiting","href":"/trials/nct06219941/"},{"record":"nct07570914","field":"status","kind":"trial","state":"development","label":"Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases: phase 2, planned","href":"/trials/nct07570914/"},{"record":"nct04221035","field":"status","kind":"trial","state":"development","label":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN): phase 3, recruiting","href":"/trials/nct04221035/"},{"record":"nct07356973","field":"status","kind":"trial","state":"development","label":"Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma: phase 2, recruiting","href":"/trials/nct07356973/"},{"record":"nct06192680","field":"status","kind":"trial","state":"development","label":"Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer: phase 2, planned","href":"/trials/nct06192680/"},{"record":"nct06184698","field":"status","kind":"trial","state":"development","label":"Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct06184698/"},{"record":"nct05854498","field":"status","kind":"trial","state":"development","label":"Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05854498/"},{"record":"nct07062536","field":"status","kind":"trial","state":"development","label":"mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line: phase 2, recruiting","href":"/trials/nct07062536/"},{"record":"norpact-1","field":"result","kind":"trial","state":"stopped","label":"NORPACT-1: phase 2, negative","href":"/trials/norpact-1/","quote":"Alive at 18 months: 60 percent with neoadjuvant FOLFIRINOX against 73 percent with upfront surgery (p 0.032); median overall survival 25.1 against 38.5 months (hazard ratio 1.52, p 0.050)."},{"record":"petacc-3","field":"result","kind":"trial","state":"stopped","label":"PETACC-3: phase 3, negative","href":"/trials/petacc-3/","quote":"Five-year disease-free survival 56.7 against 54.3 percent (p=0.106); no overall survival gain."},{"record":"nct07271355","field":"status","kind":"trial","state":"development","label":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases,: phase 3, planned","href":"/trials/nct07271355/"},{"record":"prophylochip","field":"result","kind":"trial","state":"stopped","label":"PROPHYLOCHIP-PRODIGE 15: phase 3, negative","href":"/trials/prophylochip/","quote":"Three-year disease-free survival 44 percent with second-look surgery and HIPEC against 53 percent with surveillance."},{"record":"nct07521605","field":"status","kind":"trial","state":"development","label":"Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer: phase 2, planned","href":"/trials/nct07521605/"},{"record":"nct07831993","field":"status","kind":"trial","state":"development","label":"Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer: phase 2, recruiting","href":"/trials/nct07831993/"},{"record":"nct07104604","field":"status","kind":"trial","state":"development","label":"Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally: phase 2, recruiting","href":"/trials/nct07104604/"},{"record":"nct04725994","field":"status","kind":"trial","state":"development","label":"Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer: phase 1/2, active","href":"/trials/nct04725994/"},{"record":"nct06958328","field":"status","kind":"trial","state":"development","label":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer: phase 3, recruiting","href":"/trials/nct06958328/"},{"record":"nct05863195","field":"status","kind":"trial","state":"development","label":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial: phase 3, recruiting","href":"/trials/nct05863195/"},{"record":"nct03977233","field":"status","kind":"trial","state":"development","label":"Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer: phase 2, recruiting","href":"/trials/nct03977233/"},{"record":"nct04094688","field":"status","kind":"trial","state":"development","label":"Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer: phase 3, active","href":"/trials/nct04094688/"},{"record":"registry:irinotecan","kind":"registry","state":"development","label":"ClinicalTrials.gov: 25 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/irinotecan/#registry"}],"reasons":[{"drugId":"irinotecan","drugName":"Irinotecan (and liposomal irinotecan)","drugRoute":"/drugs/irinotecan/","drugState":"approved","record":"n0147","kind":"trial","label":"Alliance N0147: phase 3, negative","href":"/trials/n0147/","quote":"Three-year disease-free survival 71.5 with cetuximab against 74.6 percent without, in KRAS wild-type disease."},{"drugId":"irinotecan","drugName":"Irinotecan (and liposomal irinotecan)","drugRoute":"/drugs/irinotecan/","drugState":"approved","record":"norpact-1","kind":"trial","label":"NORPACT-1: phase 2, negative","href":"/trials/norpact-1/","quote":"Alive at 18 months: 60 percent with neoadjuvant FOLFIRINOX against 73 percent with upfront surgery (p 0.032); median overall survival 25.1 against 38.5 months (hazard ratio 1.52, p 0.050)."},{"drugId":"irinotecan","drugName":"Irinotecan (and liposomal irinotecan)","drugRoute":"/drugs/irinotecan/","drugState":"approved","record":"petacc-3","kind":"trial","label":"PETACC-3: phase 3, negative","href":"/trials/petacc-3/","quote":"Five-year disease-free survival 56.7 against 54.3 percent (p=0.106); no overall survival gain."},{"drugId":"irinotecan","drugName":"Irinotecan (and liposomal irinotecan)","drugRoute":"/drugs/irinotecan/","drugState":"approved","record":"prophylochip","kind":"trial","label":"PROPHYLOCHIP-PRODIGE 15: phase 3, negative","href":"/trials/prophylochip/","quote":"Three-year disease-free survival 44 percent with second-look surgery and HIPEC against 53 percent with surveillance."}]},{"a":{"key":"target","id":"vegf+csf1r","name":"VEGF / VEGFR x CSF1R","href":"/targets/vegf/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"approved","drugs":[{"id":"surufatinib","name":"Surufatinib","route":"/drugs/surufatinib/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"surufatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/surufatinib/"},{"record":"surufatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2020: Advanced non-pancreatic neuroendocrine tumours; pancreatic neuroendocrine tumours from 2021","href":"/drugs/surufatinib/"},{"record":"surufatinib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/sevsury","quote":"Sevsury (Hutchmed Europe B.V.): marketing authorisation application withdrawn before a Commission decision. EMA register: 'Application withdrawn: The application for this medicine has been withdrawn'; checked 2026-09-24"},{"record":"surufatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2020","href":"https://english.nmpa.gov.cn/"},{"record":"nct06361888","field":"status","kind":"trial","state":"development","label":"A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer: phase 2/3, recruiting","href":"/trials/nct06361888/"},{"record":"nct06654947","field":"status","kind":"trial","state":"development","label":"A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.: phase 2, planned","href":"/trials/nct06654947/"},{"record":"nct06708858","field":"status","kind":"trial","state":"development","label":"Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer: phase 2, recruiting","href":"/trials/nct06708858/"},{"record":"nct05988372","field":"status","kind":"trial","state":"development","label":"Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE): phase 2, planned","href":"/trials/nct05988372/"},{"record":"nct06531291","field":"status","kind":"trial","state":"development","label":"Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation: phase 2, planned","href":"/trials/nct06531291/"},{"record":"nct07469956","field":"status","kind":"trial","state":"development","label":"Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer: phase 2, planned","href":"/trials/nct07469956/"},{"record":"registry:surufatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 40 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/surufatinib/#registry"}],"reasons":[{"drugId":"surufatinib","drugName":"Surufatinib","drugRoute":"/drugs/surufatinib/","drugState":"approved","record":"surufatinib","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/sevsury","quote":"Sevsury (Hutchmed Europe B.V.): marketing authorisation application withdrawn before a Commission decision. EMA register: 'Application withdrawn: The application for this medicine has been withdrawn'; checked 2026-09-24"}]},{"a":{"key":"target","id":"vegf+met","name":"VEGF / VEGFR x MET","href":"/targets/vegf/"},"b":{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/"},"state":"development","drugs":[{"id":"zanzalintinib","name":"Zanzalintinib","route":"/drugs/zanzalintinib/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"zanzalintinib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/zanzalintinib/"},{"record":"nct07489495","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034): phase 3, recruiting","href":"/trials/nct07489495/"},{"record":"nct07227402","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033): phase 3, recruiting","href":"/trials/nct07227402/"},{"record":"nct07620574","field":"status","kind":"trial","state":"development","label":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study: phase 3, recruiting","href":"/trials/nct07620574/"},{"record":"nct07677579","field":"status","kind":"trial","state":"development","label":"NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer: phase 2, planned","href":"/trials/nct07677579/"},{"record":"nct05425940","field":"status","kind":"trial","state":"development","label":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer: phase 3, active","href":"/trials/nct05425940/"},{"record":"nct06082167","field":"status","kind":"trial","state":"development","label":"Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: phase 2/3, active","href":"/trials/nct06082167/"},{"record":"nct07049926","field":"status","kind":"trial","state":"development","label":"Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (: phase 1/2, recruiting","href":"/trials/nct07049926/"},{"record":"nct07750158","field":"status","kind":"trial","state":"development","label":"Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease: phase 3, recruiting","href":"/trials/nct07750158/"},{"record":"nct06943755","field":"status","kind":"trial","state":"development","label":"Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors: phase 2/3, recruiting","href":"/trials/nct06943755/"},{"record":"registry:zanzalintinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 35 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/zanzalintinib/#registry"}],"reasons":[]},{"a":{"key":"target","id":"wee1","name":"WEE1","href":"/targets/wee1/"},"b":{"key":"mechanismClass","id":"ddr-inhibitor","name":"DNA damage response inhibitor"},"state":"development","drugs":[{"id":"azenosertib","name":"Azenosertib","route":"/drugs/azenosertib/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)"}]},"evidence":[{"record":"azenosertib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/azenosertib/"},{"record":"nct05128825","field":"status","kind":"trial","state":"development","label":"A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer: phase 2, recruiting","href":"/trials/nct05128825/"},{"record":"nct07546500","field":"status","kind":"trial","state":"development","label":"A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression: phase 3, recruiting","href":"/trials/nct07546500/"},{"record":"registry:azenosertib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/azenosertib/#registry"}],"reasons":[]}],"components":{"target":[{"key":"target","id":"kras","name":"KRAS","href":"/targets/kras/","count":16,"drugIds":["adagrasib","calderasib","daraxonrasib","divarasib","elironrasib","fulzerasib","garsorasib","gfh375","glecirasib","incb161734","jdq443","mrtx1133","olomorasib","sotorasib","vs-7375","zoldonrasib"],"states":{"approved":6,"development":10,"stopped":0,"unclear":0}},{"key":"target","id":"egfr","name":"EGFR","href":"/targets/egfr/","count":15,"drugIds":["aumolertinib","dacomitinib","erlotinib","furmonertinib","gefitinib","icotinib","lazertinib","limertinib","mobocertinib","olmutinib","osimertinib","silevertinib","sunvozertinib","vrn110755","zipalertinib"],"states":{"approved":10,"development":3,"stopped":2,"unclear":0}},{"key":"target","id":"androgen-receptor","name":"Androgen receptor","href":"/targets/androgen-receptor/","count":10,"drugIds":["abiraterone","apalutamide","bicalutamide","darolutamide","enzalutamide","ep0062","flutamide","masofaniten","nilutamide","rezvilutamide"],"states":{"approved":8,"development":1,"stopped":1,"unclear":0}},{"key":"target","id":"estrogen-receptor","name":"Estrogen receptor (ERα)","href":"/targets/estrogen-receptor/","count":10,"drugIds":["camizestrant","elacestrant","exemestane","fulvestrant","giredestrant","imlunestrant","letrozole","raloxifene","tamoxifen","toremifene"],"states":{"approved":9,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"fgfr2","name":"FGFR2","href":"/targets/fgfr2/","count":10,"drugIds":["cgt4859","erdafitinib","futibatinib","hmpl-453","infigratinib","lirafugratinib","pemigatinib","tar-210","tinengotinib","tyra-300"],"states":{"approved":4,"development":5,"stopped":1,"unclear":0}},{"key":"target","id":"parp","name":"PARP","href":"/targets/parp/","count":9,"drugIds":["fluzoparib","imp1734","iniparib","niraparib","palacaparib","pamiparib","saruparib","imp4927","vb15010"],"states":{"approved":3,"development":5,"stopped":1,"unclear":0}},{"key":"target","id":"cdk4-6","name":"CDK4/6","href":"/targets/cdk4-6/","count":8,"drugIds":["abemaciclib","atirmociclib","avzo-023","dalpiciclib","lerociclib","palbociclib","ribociclib","tqb3616"],"states":{"approved":4,"development":4,"stopped":0,"unclear":0}},{"key":"target","id":"pik3ca","name":"PIK3CA / PI3K-alpha","href":"/targets/pik3ca/","count":8,"drugIds":["alpelisib","copanlisib","duvelisib","idelalisib","serabelisib","tersolisib","umbralisib","zovegalisib"],"states":{"approved":3,"development":3,"stopped":2,"unclear":0}},{"key":"target","id":"idh","name":"IDH1 / IDH2","href":"/targets/idh/","count":7,"drugIds":["enasidenib","hmpl-306","ivosidenib","olutasidenib","safusidenib","tqb3454","vorasidenib"],"states":{"approved":4,"development":3,"stopped":0,"unclear":0}},{"key":"target","id":"vegf","name":"VEGF / VEGFR","href":"/targets/vegf/","count":7,"drugIds":["axitinib","cediranib","fruquintinib","propranolol-hemangeol","rivoceranib","tivozanib","vorolanib"],"states":{"approved":6,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"alk","name":"ALK","href":"/targets/alk/","count":6,"drugIds":["alectinib","brigatinib","ceritinib","ensartinib","lorlatinib","neladalkib"],"states":{"approved":5,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"braf","name":"BRAF","href":"/targets/braf/","count":6,"drugIds":["binimetinib","cobimetinib","dabrafenib","dabrafenib-trametinib","tovorafenib","vemurafenib"],"states":{"approved":6,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"btk","name":"BTK (Bruton tyrosine kinase)","href":"/targets/btk/","count":6,"drugIds":["acalabrutinib","ibrutinib","nemtabrutinib","orelabrutinib","pirtobrutinib","zanubrutinib"],"states":{"approved":5,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"her2","name":"HER2","href":"/targets/her2/","count":6,"drugIds":["avzo-021","pf-07248144","ro7771950","sevabertinib","tucatinib","zongertinib"],"states":{"approved":3,"development":3,"stopped":0,"unclear":0}},{"key":"target","id":"mek","name":"MEK1/2","href":"/targets/mek/","count":6,"drugIds":["atebimetinib","mirdametinib","selumetinib","tq-b3234","trametinib","tunlametinib"],"states":{"approved":4,"development":2,"stopped":0,"unclear":0}},{"key":"target","id":"met","name":"MET","href":"/targets/met/","count":6,"drugIds":["capmatinib","capmatinib-tepotinib","glumetinib","lam561","tepotinib","vebreltinib"],"states":{"approved":5,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"prmt5-mtap","name":"PRMT5 (MTAP-deleted cancers)","href":"/targets/prmt5-mtap/","count":5,"drugIds":["anvumetostat","azd3470","navlimetostat","tng456","tng462"],"states":{"approved":0,"development":5,"stopped":0,"unclear":0}},{"key":"target","id":"bcr-abl","name":"BCR::ABL1 (Philadelphia chromosome)","href":"/targets/bcr-abl/","count":4,"drugIds":["bosutinib","flumatinib","olverembatinib","omacetaxine"],"states":{"approved":4,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"her2+egfr","name":"HER2 x EGFR","href":"/targets/her2/","count":4,"drugIds":["lapatinib","neratinib","poziotinib","pyrotinib"],"states":{"approved":3,"development":0,"stopped":1,"unclear":0}},{"key":"target","id":"hdac","name":"Histone deacetylases (HDAC)","href":"/targets/hdac/","count":4,"drugIds":["abt-301","belinostat","resminostat","vorinostat"],"states":{"approved":2,"development":1,"stopped":1,"unclear":0}},{"key":"target","id":"parp+brca","name":"PARP x BRCA1 / BRCA2","href":"/targets/parp/","count":4,"drugIds":["olaparib","rucaparib","talazoparib","veliparib"],"states":{"approved":3,"development":0,"stopped":1,"unclear":0}},{"key":"target","id":"smoothened","name":"Smoothened (hedgehog pathway)","href":"/targets/smoothened/","count":4,"drugIds":["glasdegib","patidegib","sonidegib","vismodegib"],"states":{"approved":3,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"vegf+kit","name":"VEGF / VEGFR x KIT","href":"/targets/vegf/","count":4,"drugIds":["chiauranib","pazopanib","regorafenib","sunitinib"],"states":{"approved":3,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"cxcr4","name":"CXCR4","href":"/targets/cxcr4/","count":3,"drugIds":["mavorixafor","motixafortide","plerixafor"],"states":{"approved":3,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"flt3","name":"FLT3","href":"/targets/flt3/","count":3,"drugIds":["gilteritinib","men1703","quizartinib"],"states":{"approved":2,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"kit","name":"KIT","href":"/targets/kit/","count":3,"drugIds":["avapritinib","imatinib","ripretinib"],"states":{"approved":3,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"mtor","name":"mTOR","href":"/targets/mtor/","count":3,"drugIds":["sapanisertib","sirolimus","sirolimus-albumin-bound"],"states":{"approved":2,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"proteasome","name":"Proteasome (PSMB5)","href":"/targets/proteasome/","count":3,"drugIds":["bortezomib","carfilzomib","ixazomib"],"states":{"approved":3,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"ret","name":"RET","href":"/targets/ret/","count":3,"drugIds":["ep0031","pralsetinib","selpercatinib"],"states":{"approved":2,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"vegf+fgfr2","name":"VEGF / VEGFR x FGFR2","href":"/targets/vegf/","count":3,"drugIds":["anlotinib","lenvatinib","nintedanib"],"states":{"approved":3,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"alk+ros1","name":"ALK x ROS1","href":"/targets/alk/","count":2,"drugIds":["crizotinib","iruplinalkib"],"states":{"approved":2,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"aromatase","name":"Aromatase (CYP19A1)","href":"/targets/aromatase/","count":2,"drugIds":["anastrozole","formestane"],"states":{"approved":1,"development":0,"stopped":1,"unclear":0}},{"key":"target","id":"bcl2","name":"BCL-2","href":"/targets/bcl2/","count":2,"drugIds":["sonrotoclax","venetoclax"],"states":{"approved":2,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"bcr-abl+abl1","name":"BCR::ABL1 x ABL1","href":"/targets/bcr-abl/","count":2,"drugIds":["asciminib","ponatinib"],"states":{"approved":2,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"brd4","name":"BRD4","href":"/targets/brd4/","count":2,"drugIds":["pelabresib","zen-3694"],"states":{"approved":0,"development":2,"stopped":0,"unclear":0}},{"key":"target","id":"cnr1","name":"Cannabinoid receptor 1","href":"/targets/cnr1/","count":2,"drugIds":["dronabinol","nabilone"],"states":{"approved":2,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"drd2","name":"Dopamine D2 receptor","href":"/targets/drd2/","count":2,"drugIds":["bromocriptine","cabergoline"],"states":{"approved":2,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"ednra","name":"EDNRA","href":"/targets/ednra/","count":2,"drugIds":["atrasentan","zibotentan"],"states":{"approved":0,"development":0,"stopped":2,"unclear":0}},{"key":"target","id":"egfr+her2","name":"EGFR x HER2","href":"/targets/egfr/","count":2,"drugIds":["afatinib","varlitinib"],"states":{"approved":1,"development":0,"stopped":1,"unclear":0}},{"key":"target","id":"ezh2","name":"EZH2","href":"/targets/ezh2/","count":2,"drugIds":["tazemetostat","xnw5004"],"states":{"approved":0,"development":1,"stopped":1,"unclear":0}},{"key":"target","id":"fak","name":"FAK (PTK2)","href":"/targets/fak/","count":2,"drugIds":["gsk2256098","in10018"],"states":{"approved":0,"development":2,"stopped":0,"unclear":0}},{"key":"target","id":"jak2+flt3","name":"JAK2 x FLT3","href":"/targets/jak2/","count":2,"drugIds":["fedratinib","pacritinib"],"states":{"approved":2,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"jak2+jak1","name":"JAK2 x JAK1","href":"/targets/jak2/","count":2,"drugIds":["momelotinib","ruxolitinib"],"states":{"approved":2,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"mpl","name":"MPL (thrombopoietin receptor)","href":"/targets/mpl/","count":2,"drugIds":["eltrombopag","romiplostim"],"states":{"approved":2,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"oprm1","name":"Mu-opioid receptor","href":"/targets/oprm1/","count":2,"drugIds":["fentanyl","methylnaltrexone"],"states":{"approved":2,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"pik3ca+akt","name":"PIK3CA / PI3K-alpha x AKT","href":"/targets/pik3ca/","count":2,"drugIds":["everolimus","gedatolisib"],"states":{"approved":2,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"rara+rxr","name":"Retinoic acid receptor alpha x Retinoid X receptor","href":"/targets/rara/","count":2,"drugIds":["acitretin","isotretinoin"],"states":{"approved":2,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"ros1","name":"ROS1","href":"/targets/ros1/","count":2,"drugIds":["taletrectinib","zidesamtinib"],"states":{"approved":2,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"shp2","name":"SHP2 (PTPN11)","href":"/targets/shp2/","count":2,"drugIds":["sitneprotafib","tno155"],"states":{"approved":0,"development":2,"stopped":0,"unclear":0}},{"key":"target","id":"sstr2","name":"Somatostatin receptor 2","href":"/targets/sstr2/","count":2,"drugIds":["paltusotine","octreotide-lanreotide"],"states":{"approved":2,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"tp53","name":"TP53","href":"/targets/tp53/","count":2,"drugIds":["eprenetapopt","selinexor"],"states":{"approved":1,"development":0,"stopped":1,"unclear":0}},{"key":"target","id":"tubulin","name":"Tubulin (microtubules)","href":"/targets/tubulin/","count":2,"drugIds":["eribulin","mebendazole"],"states":{"approved":1,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"vegf+braf","name":"VEGF / VEGFR x BRAF","href":"/targets/vegf/","count":2,"drugIds":["donafenib","sorafenib"],"states":{"approved":2,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"wrn","name":"WRN helicase (MSI-high cancers)","href":"/targets/wrn/","count":2,"drugIds":["eik1005","ndi-219216"],"states":{"approved":0,"development":2,"stopped":0,"unclear":0}},{"key":"target","id":"ada","name":"Adenosine deaminase (ADA)","href":"/targets/ada/","count":1,"drugIds":["pentostatin"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"akt","name":"AKT","href":"/targets/akt/","count":1,"drugIds":["ipatasertib"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"akt+pik3ca","name":"AKT x PIK3CA / PI3K-alpha","href":"/targets/akt/","count":1,"drugIds":["capivasertib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"androgen-receptor+cyp17a1","name":"Androgen receptor x CYP17A1","href":"/targets/androgen-receptor/","count":1,"drugIds":["galeterone"],"states":{"approved":0,"development":0,"stopped":1,"unclear":0}},{"key":"target","id":"apc+ctnnb1","name":"APC x CTNNB1","href":"/targets/apc/","count":1,"drugIds":["nirogacestat"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"aromatase+cyp11a1","name":"Aromatase x CYP11A1","href":"/targets/aromatase/","count":1,"drugIds":["aminoglutethimide"],"states":{"approved":0,"development":0,"stopped":1,"unclear":0}},{"key":"target","id":"atr","name":"ATR","href":"/targets/atr/","count":1,"drugIds":["ceralasertib"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"bcr-abl+ddr2","name":"BCR::ABL1 x DDR2 receptor kinase","href":"/targets/bcr-abl/","count":1,"drugIds":["dasatinib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"bcr-abl+kit","name":"BCR::ABL1 x KIT","href":"/targets/bcr-abl/","count":1,"drugIds":["nilotinib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"braf+egfr","name":"BRAF x EGFR","href":"/targets/braf/","count":1,"drugIds":["encorafenib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"casr","name":"CASR","href":"/targets/casr/","count":1,"drugIds":["cinacalcet"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"cblb","name":"CBLB","href":"/targets/cblb/","count":1,"drugIds":["hst-1011"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"col6a3+csf1","name":"COL6A3 x CSF1","href":"/targets/col6a3/","count":1,"drugIds":["vimseltinib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"cox2","name":"COX-2 (PTGS2)","href":"/targets/cox2/","count":1,"drugIds":["celecoxib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"csf1r+kit","name":"CSF1R x KIT","href":"/targets/csf1r/","count":1,"drugIds":["pexidartinib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"cyp11b1","name":"CYP11B1","href":"/targets/cyp11b1/","count":1,"drugIds":["osilodrostat"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"cyp17a1","name":"CYP17A1 (17-alpha-hydroxylase/17,20-lyase)","href":"/targets/cyp17a1/","count":1,"drugIds":["orteronel"],"states":{"approved":0,"development":0,"stopped":1,"unclear":0}},{"key":"target","id":"drd2+h3-3a","name":"Dopamine D2 receptor x Histone H3.3","href":"/targets/drd2/","count":1,"drugIds":["dordaviprone"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"eed","name":"EED","href":"/targets/eed/","count":1,"drugIds":["rinzimetostat"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"egfr+met","name":"EGFR x MET","href":"/targets/egfr/","count":1,"drugIds":["js111"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"estrogen-receptor+her2","name":"Estrogen receptor x HER2","href":"/targets/estrogen-receptor/","count":1,"drugIds":["d-0502"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"ewsr1-fli1","name":"EWSR1-FLI1 fusion","href":"/targets/ewsr1-fli1/","count":1,"drugIds":["tk216"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"ezh2+androgen-receptor","name":"EZH2 x Androgen receptor","href":"/targets/ezh2/","count":1,"drugIds":["mevrometostat"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"fkbp12+hif1a","name":"FKBP12 x HIF-1α","href":"/targets/fkbp12/","count":1,"drugIds":["temsirolimus"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"flt3+kit","name":"FLT3 x KIT","href":"/targets/flt3/","count":1,"drugIds":["midostaurin"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"gamma-secretase","name":"Gamma-secretase (PSEN1)","href":"/targets/gamma-secretase/","count":1,"drugIds":["varegacestat"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"gna11+gnaq","name":"GNA11 x GNAQ","href":"/targets/gna11/","count":1,"drugIds":["darovasertib"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"gsk3b","name":"GSK3B","href":"/targets/gsk3b/","count":1,"drugIds":["elraglusib"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"hdac10","name":"HDAC10","href":"/targets/hdac10/","count":1,"drugIds":["tucidinostat"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"her2+fgfr2","name":"HER2 x FGFR2","href":"/targets/her2/","count":1,"drugIds":["absk061"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"hif2a","name":"HIF-2α","href":"/targets/hif2a/","count":1,"drugIds":["belzutifan"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"hdac+proteasome","name":"Histone deacetylases x Proteasome","href":"/targets/hdac/","count":1,"drugIds":["panobinostat"],"states":{"approved":0,"development":0,"stopped":1,"unclear":0}},{"key":"target","id":"hdac+tet2","name":"Histone deacetylases x TET2","href":"/targets/hdac/","count":1,"drugIds":["romidepsin"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"itk","name":"ITK","href":"/targets/itk/","count":1,"drugIds":["soquelitinib"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"jak1","name":"JAK1","href":"/targets/jak1/","count":1,"drugIds":["golidocitinib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"kit+met","name":"KIT x MET","href":"/targets/kit/","count":1,"drugIds":["bezuclastinib"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"kras+fak","name":"KRAS x FAK","href":"/targets/kras/","count":1,"drugIds":["avutometinib-defactinib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"kras+nras","name":"KRAS x NRAS","href":"/targets/kras/","count":1,"drugIds":["jyp0015"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"mdm2","name":"MDM2","href":"/targets/mdm2/","count":1,"drugIds":["brigimadlin"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"mdm2+tp53","name":"MDM2 x TP53","href":"/targets/mdm2/","count":1,"drugIds":["krt-232"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"menin","name":"Menin","href":"/targets/menin/","count":1,"drugIds":["revumenib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"menin+npm1","name":"Menin x NPM1 mutation","href":"/targets/menin/","count":1,"drugIds":["ziftomenib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"mertk","name":"MERTK","href":"/targets/mertk/","count":1,"drugIds":["imetelstat"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"met+egfr","name":"MET x EGFR","href":"/targets/met/","count":1,"drugIds":["savolitinib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"met+ret","name":"MET x RET","href":"/targets/met/","count":1,"drugIds":["al2846"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"met+vegf","name":"MET x VEGF / VEGFR","href":"/targets/met/","count":1,"drugIds":["cabozantinib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"mycn","name":"MYCN (N-myc)","href":"/targets/mycn/","count":1,"drugIds":["eflornithine"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"nras","name":"NRAS","href":"/targets/nras/","count":1,"drugIds":["naporafenib"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"ntrk","name":"NTRK","href":"/targets/ntrk/","count":1,"drugIds":["larotrectinib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"ntrk+ros1","name":"NTRK x ROS1","href":"/targets/ntrk/","count":1,"drugIds":["entrectinib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"pik3cd+psmb6","name":"PI3K delta x PSMB6","href":"/targets/pik3cd/","count":1,"drugIds":["linperlisib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"plk1","name":"PLK1","href":"/targets/plk1/","count":1,"drugIds":["onvansertib"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"ret+vegf","name":"RET x VEGF / VEGFR","href":"/targets/ret/","count":1,"drugIds":["vandetanib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"rxr","name":"Retinoid X receptor (RXR)","href":"/targets/rxr/","count":1,"drugIds":["bexarotene"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"rrm1","name":"Ribonucleotide reductase (RRM1)","href":"/targets/rrm1/","count":1,"drugIds":["hydroxyurea"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"ros1+ntrk","name":"ROS1 x NTRK","href":"/targets/ros1/","count":1,"drugIds":["repotrectinib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"stat3","name":"STAT3","href":"/targets/stat3/","count":1,"drugIds":["napabucasin"],"states":{"approved":0,"development":0,"stopped":1,"unclear":0}},{"key":"target","id":"syk","name":"SYK","href":"/targets/syk/","count":1,"drugIds":["fostamatinib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"tbk1","name":"TBK1","href":"/targets/tbk1/","count":1,"drugIds":["adu-s100"],"states":{"approved":0,"development":0,"stopped":1,"unclear":0}},{"key":"target","id":"tlr7","name":"Toll-like receptor 7 (TLR7)","href":"/targets/tlr7/","count":1,"drugIds":["imiquimod"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"top1","name":"Topoisomerase I (TOP1)","href":"/targets/top1/","count":1,"drugIds":["hr070803"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"tph1","name":"Tryptophan hydroxylase 1","href":"/targets/tph1/","count":1,"drugIds":["telotristat-ethyl"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"ugt1a1","name":"UGT1A1","href":"/targets/ugt1a1/","count":1,"drugIds":["irinotecan"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"vegf+csf1r","name":"VEGF / VEGFR x CSF1R","href":"/targets/vegf/","count":1,"drugIds":["surufatinib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"vegf+met","name":"VEGF / VEGFR x MET","href":"/targets/vegf/","count":1,"drugIds":["zanzalintinib"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"wee1","name":"WEE1","href":"/targets/wee1/","count":1,"drugIds":["azenosertib"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}}],"mechanismClass":[{"key":"mechanismClass","id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","count":148,"drugIds":["absk061","acalabrutinib","acitretin","afatinib","al2846","alectinib","anlotinib","asciminib","atebimetinib","aumolertinib","avapritinib","avutometinib-defactinib","axitinib","belzutifan","bexarotene","bezuclastinib","binimetinib","bortezomib","bosutinib","brigatinib","cabozantinib","capmatinib","capmatinib-tepotinib","cediranib","ceritinib","cgt4859","chiauranib","cobimetinib","copanlisib","crizotinib","dabrafenib","dabrafenib-trametinib","dacomitinib","dasatinib","donafenib","dronabinol","duvelisib","elraglusib","encorafenib","ensartinib","entrectinib","ep0031","erdafitinib","erlotinib","fedratinib","flumatinib","fostamatinib","fruquintinib","furmonertinib","futibatinib","gedatolisib","gefitinib","gilteritinib","glumetinib","golidocitinib","gsk2256098","hmpl-453","hr070803","ibrutinib","icotinib","idelalisib","imatinib","in10018","infigratinib","iruplinalkib","isotretinoin","ixazomib","js111","lam561","lapatinib","larotrectinib","lazertinib","lenvatinib","lerociclib","limertinib","linperlisib","lirafugratinib","lorlatinib","mavorixafor","men1703","midostaurin","mirdametinib","mobocertinib","momelotinib","naporafenib","neladalkib","nemtabrutinib","neratinib","nilotinib","nintedanib","olmutinib","olverembatinib","onvansertib","orelabrutinib","osimertinib","pacritinib","pazopanib","pemigatinib","pexidartinib","pirtobrutinib","ponatinib","poziotinib","pralsetinib","pyrotinib","quizartinib","regorafenib","repotrectinib","ripretinib","rivoceranib","ro7771950","ruxolitinib","savolitinib","selinexor","selpercatinib","selumetinib","sevabertinib","silevertinib","sirolimus-albumin-bound","sorafenib","sunitinib","sunvozertinib","surufatinib","taletrectinib","tar-210","tepotinib","tinengotinib","tivozanib","tovorafenib","tq-b3234","trametinib","tucatinib","tunlametinib","tyra-300","umbralisib","vandetanib","varegacestat","varlitinib","vebreltinib","vemurafenib","vimseltinib","vorolanib","vrn110755","zanubrutinib","zanzalintinib","zibotentan","zidesamtinib","zipalertinib","zongertinib"],"states":{"approved":109,"development":31,"stopped":8,"unclear":0}},{"key":"mechanismClass","id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","count":27,"drugIds":["abiraterone","aminoglutethimide","anastrozole","bicalutamide","bromocriptine","camizestrant","cinacalcet","d-0502","elacestrant","ep0062","exemestane","flutamide","formestane","fulvestrant","galeterone","giredestrant","imlunestrant","letrozole","nilutamide","orteronel","osilodrostat","paltusotine","raloxifene","rezvilutamide","octreotide-lanreotide","tamoxifen","toremifene"],"states":{"approved":20,"development":3,"stopped":4,"unclear":0}},{"key":"mechanismClass","id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","count":20,"drugIds":["abt-301","anvumetostat","azd3470","belinostat","mevrometostat","navlimetostat","panobinostat","pelabresib","resminostat","revumenib","rinzimetostat","romidepsin","tazemetostat","tng456","tng462","tucidinostat","vorinostat","xnw5004","zen-3694","ziftomenib"],"states":{"approved":6,"development":11,"stopped":3,"unclear":0}},{"key":"mechanismClass","id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/","count":19,"drugIds":["adagrasib","calderasib","daraxonrasib","divarasib","elironrasib","fulzerasib","garsorasib","gfh375","glecirasib","incb161734","jdq443","jyp0015","mrtx1133","olomorasib","sitneprotafib","sotorasib","tno155","vs-7375","zoldonrasib"],"states":{"approved":6,"development":13,"stopped":0,"unclear":0}},{"key":"mechanismClass","id":"other-inhibitor","name":"Inhibitor (class not stated)","count":15,"drugIds":["celecoxib","darovasertib","eflornithine","eik1005","eribulin","hst-1011","hydroxyurea","imetelstat","irinotecan","masofaniten","napabucasin","ndi-219216","pentostatin","telotristat-ethyl","tk216"],"states":{"approved":8,"development":5,"stopped":2,"unclear":0}},{"key":"mechanismClass","id":"receptor-agonist","name":"Receptor agonist","count":14,"drugIds":["adu-s100","apalutamide","atrasentan","cabergoline","darolutamide","dordaviprone","eltrombopag","enzalutamide","fentanyl","imiquimod","methylnaltrexone","motixafortide","plerixafor","romiplostim"],"states":{"approved":12,"development":0,"stopped":2,"unclear":0}},{"key":"mechanismClass","id":"parp-inhibitor","name":"PARP inhibitor","href":"/technologies/parp-inhibitor/","count":13,"drugIds":["fluzoparib","imp1734","iniparib","niraparib","olaparib","palacaparib","pamiparib","rucaparib","saruparib","imp4927","talazoparib","vb15010","veliparib"],"states":{"approved":6,"development":5,"stopped":2,"unclear":0}},{"key":"mechanismClass","id":"cdk-inhibitor","name":"CDK inhibitor","href":"/technologies/cdk46-inhibitor/","count":10,"drugIds":["abemaciclib","atirmociclib","avzo-021","avzo-023","dalpiciclib","palbociclib","pf-07248144","ribociclib","tersolisib","tqb3616"],"states":{"approved":4,"development":6,"stopped":0,"unclear":0}},{"key":"mechanismClass","id":"pi3k-akt-mtor-inhibitor","name":"PI3K, AKT or mTOR inhibitor","href":"/technologies/pi3k-akt-mtor-inhibitors/","count":9,"drugIds":["alpelisib","capivasertib","everolimus","ipatasertib","sapanisertib","serabelisib","sirolimus","temsirolimus","zovegalisib"],"states":{"approved":5,"development":4,"stopped":0,"unclear":0}},{"key":"mechanismClass","id":"idh-inhibitor","name":"IDH inhibitor","href":"/technologies/idh-inhibitors/","count":7,"drugIds":["enasidenib","hmpl-306","ivosidenib","olutasidenib","safusidenib","tqb3454","vorasidenib"],"states":{"approved":4,"development":3,"stopped":0,"unclear":0}},{"key":"mechanismClass","id":"hedgehog-inhibitor","name":"Hedgehog inhibitor","href":"/technologies/hedgehog-inhibitors/","count":4,"drugIds":["glasdegib","patidegib","sonidegib","vismodegib"],"states":{"approved":3,"development":1,"stopped":0,"unclear":0}},{"key":"mechanismClass","id":"bcl2-inhibitor","name":"BCL-2 inhibitor","href":"/technologies/bcl2-inhibitors/","count":3,"drugIds":["omacetaxine","sonrotoclax","venetoclax"],"states":{"approved":3,"development":0,"stopped":0,"unclear":0}},{"key":"mechanismClass","id":"mdm2-inhibitor","name":"MDM2 inhibitor","href":"/technologies/mdm2-inhibitors/","count":3,"drugIds":["brigimadlin","eprenetapopt","krt-232"],"states":{"approved":0,"development":2,"stopped":1,"unclear":0}},{"key":"mechanismClass","id":"ddr-inhibitor","name":"DNA damage response inhibitor","count":2,"drugIds":["azenosertib","ceralasertib"],"states":{"approved":0,"development":2,"stopped":0,"unclear":0}},{"key":"mechanismClass","id":"gamma-secretase-inhibitor","name":"Gamma-secretase inhibitor","href":"/technologies/gamma-secretase-inhibitors/","count":1,"drugIds":["nirogacestat"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"mechanismClass","id":"hif-inhibitor","name":"HIF inhibitor","count":1,"drugIds":["soquelitinib"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"mechanismClass","id":"proteasome-inhibitor","name":"Proteasome inhibitor","count":1,"drugIds":["carfilzomib"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}}],"binding":[{"key":"binding","id":"selective","name":"Selective (mode not stated)","count":52,"drugIds":["atrasentan","avzo-021","avzo-023","axitinib","azd3470","azenosertib","bexarotene","bezuclastinib","calderasib","capmatinib-tepotinib","celecoxib","cgt4859","d-0502","dalpiciclib","eik1005","elacestrant","fedratinib","glumetinib","golidocitinib","idelalisib","imp1734","iniparib","jyp0015","krt-232","lirafugratinib","navlimetostat","neladalkib","orteronel","paltusotine","pemigatinib","pralsetinib","propranolol-hemangeol","raloxifene","selpercatinib","sonrotoclax","soquelitinib","taletrectinib","tamoxifen","tepotinib","tersolisib","tivozanib","tng456","tng462","toremifene","tq-b3234","tqb3454","tucidinostat","tyra-300","vebreltinib","venetoclax","vrn110755","zidesamtinib"],"states":{"approved":27,"development":22,"stopped":3,"unclear":0}},{"key":"binding","id":"covalent","name":"Covalent","count":40,"drugIds":["abiraterone","acalabrutinib","adagrasib","afatinib","aumolertinib","carfilzomib","dacomitinib","divarasib","eflornithine","elironrasib","exemestane","fulzerasib","furmonertinib","futibatinib","garsorasib","gfh375","glecirasib","ibrutinib","lazertinib","letrozole","limertinib","mobocertinib","mrtx1133","ndi-219216","nemtabrutinib","neratinib","olmutinib","olomorasib","orelabrutinib","osimertinib","pirtobrutinib","poziotinib","pyrotinib","selinexor","silevertinib","sotorasib","sunvozertinib","zanubrutinib","zoldonrasib","zongertinib"],"states":{"approved":28,"development":9,"stopped":3,"unclear":0}},{"key":"binding","id":"atp-competitive","name":"ATP-competitive or reversible","count":29,"drugIds":["alectinib","alpelisib","atirmociclib","bortezomib","capivasertib","capmatinib","crizotinib","dabrafenib","encorafenib","erlotinib","fruquintinib","gefitinib","gsk2256098","icotinib","imatinib","infigratinib","ixazomib","lapatinib","larotrectinib","nilotinib","palbociclib","pazopanib","rivoceranib","ruxolitinib","savolitinib","sevabertinib","tucatinib","varlitinib","vemurafenib"],"states":{"approved":25,"development":2,"stopped":2,"unclear":0}},{"key":"binding","id":"allosteric","name":"Allosteric","count":17,"drugIds":["asciminib","binimetinib","cobimetinib","dabrafenib-trametinib","enasidenib","everolimus","ivosidenib","mirdametinib","olutasidenib","rinzimetostat","selumetinib","sirolimus-albumin-bound","sitneprotafib","temsirolimus","trametinib","tunlametinib","zovegalisib"],"states":{"approved":14,"development":3,"stopped":0,"unclear":0}}]},"drugs":[{"id":"abemaciclib","name":"Abemaciclib","route":"/drugs/abemaciclib/","status":"approved","modality":"Small-molecule CDK4/6 inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"cdk4-6","name":"CDK4/6","href":"/targets/cdk4-6/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"cdk-inhibitor","name":"CDK inhibitor","href":"/technologies/cdk46-inhibitor/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"abemaciclib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/abemaciclib/"},{"record":"abemaciclib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2017: HR+/HER2- advanced breast cancer","href":"/drugs/abemaciclib/"},{"record":"abemaciclib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2021: Adjuvant high-risk node-positive HR+/HER2- early breast cancer","href":"/drugs/abemaciclib/"},{"record":"abemaciclib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2017","href":"/regulatory/regions/"},{"record":"abemaciclib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2018","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios"},{"record":"abemaciclib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2018","href":"https://products.mhra.gov.uk/?search=Verzenio"},{"record":"abemaciclib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2018","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"abemaciclib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2020","href":"https://english.nmpa.gov.cn/"},{"record":"abemaciclib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2019","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Verzenio"},{"record":"nct06188520","field":"status","kind":"trial","state":"development","label":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With : phase 1/2, recruiting","href":"/trials/nct06188520/"},{"record":"nct05999994","field":"status","kind":"trial","state":"development","label":"A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer: phase 2, recruiting","href":"/trials/nct05999994/"},{"record":"nct07002177","field":"status","kind":"trial","state":"development","label":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC: phase 1/2, recruiting","href":"/trials/nct07002177/"},{"record":"nct06413706","field":"status","kind":"trial","state":"development","label":"A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy: phase 2, active","href":"/trials/nct06413706/"},{"record":"nct04802759","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer: phase 1/2, recruiting","href":"/trials/nct04802759/"},{"record":"nct02107703","field":"status","kind":"trial","state":"development","label":"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer: phase 3, active","href":"/trials/nct02107703/"},{"record":"nct02763566","field":"status","kind":"trial","state":"development","label":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer: phase 3, active","href":"/trials/nct02763566/"},{"record":"nct02152631","field":"status","kind":"trial","state":"development","label":"A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer: phase 3, active","href":"/trials/nct02152631/"},{"record":"nct02747004","field":"status","kind":"trial","state":"development","label":"A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer: phase 2, active","href":"/trials/nct02747004/"},{"record":"nct05288166","field":"status","kind":"trial","state":"development","label":"A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer): phase 3, active","href":"/trials/nct05288166/"},{"record":"nct03706365","field":"status","kind":"trial","state":"development","label":"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer: phase 2/3, active","href":"/trials/nct03706365/"},{"record":"nct06065748","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer): phase 3, active","href":"/trials/nct06065748/"},{"record":"nct07100106","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer: phase 1/2, recruiting","href":"/trials/nct07100106/"},{"record":"nct07441369","field":"status","kind":"trial","state":"development","label":"Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer: phase 2, recruiting","href":"/trials/nct07441369/"},{"record":"nct06365788","field":"status","kind":"trial","state":"development","label":"Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer: phase 2, recruiting","href":"/trials/nct06365788/"},{"record":"nct05440786","field":"status","kind":"trial","state":"development","label":"CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma: phase 2, active","href":"/trials/nct05440786/"},{"record":"nct04862663","field":"status","kind":"trial","state":"development","label":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292): phase 3, active","href":"/trials/nct04862663/"},{"record":"nct05696626","field":"status","kind":"trial","state":"development","label":"Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation: phase 3, recruiting","href":"/trials/nct05696626/"},{"record":"nct07340541","field":"status","kind":"trial","state":"development","label":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies: phase 2, recruiting","href":"/trials/nct07340541/"},{"record":"nct05768139","field":"status","kind":"trial","state":"development","label":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05768139/"},{"record":"nct05735080","field":"status","kind":"trial","state":"development","label":"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer: phase 1/2, recruiting","href":"/trials/nct05735080/"},{"record":"nct05573126","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer: phase 1/2, recruiting","href":"/trials/nct05573126/"},{"record":"nct07605728","field":"status","kind":"trial","state":"development","label":"Probiotics for Abemaciclib-Induced Abdominal Discomfort.: phase 2, recruiting","href":"/trials/nct07605728/"},{"record":"nct06810544","field":"status","kind":"trial","state":"development","label":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss: phase 1/2, recruiting","href":"/trials/nct06810544/"},{"record":"nct06380751","field":"status","kind":"trial","state":"development","label":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct06380751/"},{"record":"nct05386108","field":"status","kind":"trial","state":"development","label":"Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer: phase 1/2, recruiting","href":"/trials/nct05386108/"},{"record":"nct05867251","field":"status","kind":"trial","state":"development","label":"Study of AVZO-021 in Patients With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05867251/"},{"record":"nct06760637","field":"status","kind":"trial","state":"development","label":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease: phase 3, active","href":"/trials/nct06760637/"},{"record":"nct05548127","field":"status","kind":"trial","state":"development","label":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A): phase 1/2, active","href":"/trials/nct05548127/"},{"record":"nct06813079","field":"status","kind":"trial","state":"development","label":"Using Tumor Models to Determine Treatments: phase 2, recruiting","href":"/trials/nct06813079/"},{"record":"zen-3694-abemaciclib-nut","field":"status","kind":"trial","state":"development","label":"ZEN-3694 with abemaciclib in NUT carcinoma, breast cancer and other solid tumours (NCI phase 1): phase 1, recruiting","href":"/trials/zen-3694-abemaciclib-nut/"},{"record":"registry:abemaciclib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 68 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/abemaciclib/#registry"}],"reasons":[]},{"id":"abiraterone","name":"Abiraterone acetate","route":"/drugs/abiraterone/","status":"approved","modality":"Small-molecule CYP17A1 inhibitor","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"androgen-receptor","name":"Androgen receptor","href":"/targets/androgen-receptor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"abiraterone","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/abiraterone/"},{"record":"abiraterone","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2011: mCRPC after docetaxel","href":"/drugs/abiraterone/"},{"record":"abiraterone","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2012: mCRPC pre-chemotherapy","href":"/drugs/abiraterone/"},{"record":"abiraterone","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2018: High-risk mHSPC (LATITUDE)","href":"/drugs/abiraterone/"},{"record":"abiraterone","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2011","href":"/regulatory/regions/"},{"record":"abiraterone","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2011","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga"},{"record":"abiraterone","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2011","href":"https://products.mhra.gov.uk/?search=Zytiga"},{"record":"abiraterone","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2014","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"abiraterone","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2015","href":"https://english.nmpa.gov.cn/"},{"record":"abiraterone","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2012","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Zytiga"},{"record":"abiraterone","field":"regional.IN","kind":"regional","state":"approved","label":"CDSCO (DCGI) (IN): approved","href":"https://en.wikipedia.org/wiki/Abiraterone_acetate"},{"record":"nct07198633","field":"status","kind":"trial","state":"development","label":"A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct07198633/"},{"record":"nct07553988","field":"status","kind":"trial","state":"development","label":"A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer: phase 2, active","href":"/trials/nct07553988/"},{"record":"nct04691804","field":"status","kind":"trial","state":"development","label":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Ver: phase 3, active","href":"/trials/nct04691804/"},{"record":"nct07005154","field":"status","kind":"trial","state":"development","label":"A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer: phase 2, recruiting","href":"/trials/nct07005154/"},{"record":"nct07226986","field":"status","kind":"trial","state":"development","label":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA: phase 1/2, recruiting","href":"/trials/nct07226986/"},{"record":"nct02960022","field":"status","kind":"trial","state":"development","label":"A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study: phase 2, active","href":"/trials/nct02960022/"},{"record":"nct03706365","field":"status","kind":"trial","state":"development","label":"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer: phase 2/3, active","href":"/trials/nct03706365/"},{"record":"nct05067140","field":"status","kind":"trial","state":"development","label":"A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer: phase 1/2, active","href":"/trials/nct05067140/"},{"record":"nct03431350","field":"status","kind":"trial","state":"development","label":"A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer: phase 2, active","href":"/trials/nct03431350/"},{"record":"nct04497844","field":"status","kind":"trial","state":"development","label":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC): phase 3, active","href":"/trials/nct04497844/"},{"record":"nct07230106","field":"status","kind":"trial","state":"development","label":"A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer: phase 2, recruiting","href":"/trials/nct07230106/"},{"record":"nct07213674","field":"status","kind":"trial","state":"development","label":"A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate : phase 3, recruiting","href":"/trials/nct07213674/"},{"record":"nct07287150","field":"status","kind":"trial","state":"development","label":"A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer: phase 2, recruiting","href":"/trials/nct07287150/"},{"record":"nct05422911","field":"status","kind":"trial","state":"development","label":"Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.: phase 2, recruiting","href":"/trials/nct05422911/"},{"record":"nct02257736","field":"status","kind":"trial","state":"development","label":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC): phase 3, active","href":"/trials/nct02257736/"},{"record":"nct06991556","field":"status","kind":"trial","state":"development","label":"An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc: phase 2, active","href":"/trials/nct06991556/"},{"record":"nct07611110","field":"status","kind":"trial","state":"development","label":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01): phase 3, recruiting","href":"/trials/nct07611110/"},{"record":"era-223","field":"result","kind":"trial","state":"stopped","label":"ERA 223: phase 3, negative","href":"/trials/era-223/","quote":"Median symptomatic skeletal event-free survival 22.3 against 26.0 months (hazard ratio 1.122, 95 percent confidence interval 0.917 to 1.374, p=0.2636): no benefit. Fractures of any grade in 29 against 11 percent, grade 3 to 4 fractures in 9 against 3 percent."},{"record":"nct07620574","field":"status","kind":"trial","state":"development","label":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study: phase 3, recruiting","href":"/trials/nct07620574/"},{"record":"nct03348670","field":"status","kind":"trial","state":"development","label":"Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms: phase 2/3, active","href":"/trials/nct03348670/"},{"record":"nct03678025","field":"status","kind":"trial","state":"development","label":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer: phase 3, recruiting","href":"/trials/nct03678025/"},{"record":"nct05367440","field":"status","kind":"trial","state":"development","label":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer: phase 1/2, active","href":"/trials/nct05367440/"},{"record":"nct04446117","field":"status","kind":"trial","state":"development","label":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC: phase 3, active","href":"/trials/nct04446117/"},{"record":"nct02861573","field":"status","kind":"trial","state":"development","label":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365): phase 1/2, active","href":"/trials/nct02861573/"},{"record":"nct05171816","field":"status","kind":"trial","state":"development","label":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort): phase 3, active","href":"/trials/nct05171816/"},{"record":"nct06520345","field":"status","kind":"trial","state":"development","label":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global): phase 3, recruiting","href":"/trials/nct06520345/"},{"record":"nct07190300","field":"status","kind":"trial","state":"development","label":"TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in : phase 1/2, recruiting","href":"/trials/nct07190300/"},{"record":"registry:abiraterone","kind":"registry","state":"development","label":"ClinicalTrials.gov: 34 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/abiraterone/#registry"}],"reasons":[{"drugId":"abiraterone","drugName":"Abiraterone acetate","drugRoute":"/drugs/abiraterone/","drugState":"approved","record":"era-223","kind":"trial","label":"ERA 223: phase 3, negative","href":"/trials/era-223/","quote":"Median symptomatic skeletal event-free survival 22.3 against 26.0 months (hazard ratio 1.122, 95 percent confidence interval 0.917 to 1.374, p=0.2636): no benefit. Fractures of any grade in 29 against 11 percent, grade 3 to 4 fractures in 9 against 3 percent."}]},{"id":"absk061","name":"ABSK061","route":"/drugs/absk061/","status":"phase-2","modality":"small molecule (structure undisclosed or not yet in PubChem)","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"her2+fgfr2","name":"HER2 x FGFR2","href":"/targets/her2/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"absk061","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/absk061/"},{"record":"nct06632262","field":"status","kind":"trial","state":"development","label":"A Phase 2 Clinical Study of ABSK061 and ABSK043: phase 2, recruiting","href":"/trials/nct06632262/"},{"record":"registry:absk061","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/absk061/#registry"}],"reasons":[]},{"id":"abt-301","name":"ABT-301","route":"/drugs/abt-301/","status":"phase-2","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"hdac","name":"Histone deacetylases (HDAC)","href":"/targets/hdac/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"abt-301","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/abt-301/"},{"record":"nct07244705","field":"status","kind":"trial","state":"development","label":"A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC: phase 1/2, recruiting","href":"/trials/nct07244705/"},{"record":"registry:abt-301","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/abt-301/#registry"}],"reasons":[]},{"id":"acalabrutinib","name":"Acalabrutinib","route":"/drugs/acalabrutinib/","status":"approved","modality":"Small-molecule covalent BTK inhibitor (second generation)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"btk","name":"BTK (Bruton tyrosine kinase)","href":"/targets/btk/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"acalabrutinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/acalabrutinib/"},{"record":"acalabrutinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2017: Relapsed MCL (accelerated)","href":"/drugs/acalabrutinib/"},{"record":"acalabrutinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2019: CLL/SLL, first-line and relapsed (ELEVATE-TN, ASCEND)","href":"/drugs/acalabrutinib/"},{"record":"acalabrutinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2026: Fixed-duration acalabrutinib + venetoclax, previously untreated CLL/SLL without del(17p)/TP53 (AMPLIFY)","href":"/drugs/acalabrutinib/"},{"record":"acalabrutinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2017","href":"/regulatory/regions/"},{"record":"acalabrutinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2020","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/calquence"},{"record":"acalabrutinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2020","href":"https://products.mhra.gov.uk/?search=Calquence"},{"record":"acalabrutinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2021","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"acalabrutinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"acalabrutinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2020","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Calquence"},{"record":"nct04529772","field":"status","kind":"trial","state":"development","label":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312): phase 3, active","href":"/trials/nct04529772/"},{"record":"nct05951959","field":"status","kind":"trial","state":"development","label":"A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma: phase 2, active","href":"/trials/nct05951959/"},{"record":"nct05057494","field":"status","kind":"trial","state":"development","label":"A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: phase 3, active","href":"/trials/nct05057494/"},{"record":"nct02970318","field":"status","kind":"trial","state":"development","label":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL: phase 3, active","href":"/trials/nct02970318/"},{"record":"nct02717611","field":"status","kind":"trial","state":"development","label":"A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy: phase 2, active","href":"/trials/nct02717611/"},{"record":"nct02972840","field":"status","kind":"trial","state":"development","label":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL: phase 3, active","href":"/trials/nct02972840/"},{"record":"nct07029737","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain: phase 2, recruiting","href":"/trials/nct07029737/"},{"record":"nct06428019","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL): phase 3, recruiting","href":"/trials/nct06428019/"},{"record":"nct07277231","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia: phase 3, recruiting","href":"/trials/nct07277231/"},{"record":"nct04624633","field":"status","kind":"trial","state":"development","label":"Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL: phase 2, active","href":"/trials/nct04624633/"},{"record":"nct02029443","field":"status","kind":"trial","state":"development","label":"ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia: phase 1/2, active","href":"/trials/nct02029443/"},{"record":"nct02213926","field":"status","kind":"trial","state":"development","label":"An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma: phase 2, active","href":"/trials/nct02213926/"},{"record":"nct02180724","field":"status","kind":"trial","state":"development","label":"An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia: phase 2, active","href":"/trials/nct02180724/"},{"record":"arched","field":"status","kind":"trial","state":"development","label":"ARCHED: phase 3, active","href":"/trials/arched/"},{"record":"bellwave-011","field":"status","kind":"trial","state":"development","label":"BELLWAVE-011: phase 3, recruiting","href":"/trials/bellwave-011/"},{"record":"nct07024706","field":"status","kind":"trial","state":"development","label":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab: phase 2, recruiting","href":"/trials/nct07024706/"},{"record":"nct04502394","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL: phase 1/2, recruiting","href":"/trials/nct04502394/"},{"record":"nct02477696","field":"status","kind":"trial","state":"development","label":"Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL): phase 3, active","href":"/trials/nct02477696/"},{"record":"nct02180711","field":"status","kind":"trial","state":"development","label":"Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma: phase 1/2, active","href":"/trials/nct02180711/"},{"record":"nct05952024","field":"status","kind":"trial","state":"development","label":"Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL: phase 2, recruiting","href":"/trials/nct05952024/"},{"record":"nct03932331","field":"status","kind":"trial","state":"development","label":"Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malign: phase 1/2, active","href":"/trials/nct03932331/"},{"record":"nct04075292","field":"status","kind":"trial","state":"development","label":"Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia: phase 3, active","href":"/trials/nct04075292/"},{"record":"nct04662255","field":"status","kind":"trial","state":"development","label":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL): phase 3, active","href":"/trials/nct04662255/"},{"record":"registry:acalabrutinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 67 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/acalabrutinib/#registry"}],"reasons":[]},{"id":"acitretin","name":"Acitretin","route":"/drugs/acitretin/","status":"approved","modality":"Oral systemic retinoid","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"rara+rxr","name":"Retinoic acid receptor alpha x Retinoid X receptor","href":"/targets/rara/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"acitretin","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/acitretin/"},{"record":"acitretin","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1996: Severe psoriasis (oncology use as chemoprevention of squamous cell carcinoma is off-label)","href":"/drugs/acitretin/"},{"record":"registry:acitretin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/acitretin/#registry"}],"reasons":[]},{"id":"adagrasib","name":"Adagrasib","route":"/drugs/adagrasib/","status":"approved","modality":"Small-molecule inhibitor (KRAS G12C)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"kras","name":"KRAS","href":"/targets/kras/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"adagrasib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/adagrasib/"},{"record":"adagrasib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2022: KRAS G12C NSCLC (accelerated)","href":"/drugs/adagrasib/"},{"record":"adagrasib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2024: KRAS G12C colorectal cancer with cetuximab","href":"/drugs/adagrasib/"},{"record":"adagrasib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2024: KRAS G12C NSCLC after ≥1 line; 5 Jan 2024 (conditional)","href":"/drugs/adagrasib/"},{"record":"adagrasib","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2024: KRAS G12C-mutated locally advanced or metastatic colorectal cancer after fluoropyrimidine, oxaliplatin and irinotecan chemotherapy, with cetuximab","href":"/drugs/adagrasib/"},{"record":"adagrasib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2022","href":"/regulatory/regions/"},{"record":"adagrasib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2024","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/krazati"},{"record":"adagrasib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2024","href":"https://products.mhra.gov.uk/?search=Krazati"},{"record":"adagrasib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2024","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Krazati"},{"record":"adagrasib","field":"regulatoryEvents[5]","kind":"event","state":"stopped","label":"US 2026-09-01: withdrawal","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer","quote":"Withdrawn: the indication came off the label 2.3 years after its accelerated approval."},{"record":"nct06412198","field":"status","kind":"trial","state":"development","label":"A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations: phase 1/2, recruiting","href":"/trials/nct06412198/"},{"record":"nct07415031","field":"status","kind":"trial","state":"development","label":"A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies: phase 2, recruiting","href":"/trials/nct07415031/"},{"record":"nct06875310","field":"status","kind":"trial","state":"development","label":"A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4): phase 3, recruiting","href":"/trials/nct06875310/"},{"record":"nct06248606","field":"status","kind":"trial","state":"development","label":"Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases: phase 2, recruiting","href":"/trials/nct06248606/"},{"record":"nct05609578","field":"status","kind":"trial","state":"development","label":"Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation: phase 2, active","href":"/trials/nct05609578/"},{"record":"nct03785249","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1: phase 1/2, active","href":"/trials/nct03785249/"},{"record":"nct04613596","field":"status","kind":"trial","state":"development","label":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G: phase 2/3, recruiting","href":"/trials/nct04613596/"},{"record":"nct05853575","field":"status","kind":"trial","state":"development","label":"Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21): phase 2, active","href":"/trials/nct05853575/"},{"record":"registry:adagrasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 15 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/adagrasib/#registry"}],"reasons":[{"drugId":"adagrasib","drugName":"Adagrasib","drugRoute":"/drugs/adagrasib/","drugState":"approved","record":"adagrasib","kind":"event","label":"US 2026-09-01: withdrawal","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer","quote":"Withdrawn: the indication came off the label 2.3 years after its accelerated approval."}]},{"id":"adu-s100","name":"ADU-S100 (MIW815)","route":"/drugs/adu-s100/","status":"withdrawn","modality":"Small molecule (STING agonist, intratumoural)","state":"stopped","confidence":"medium","fields":["target record (drugs field)","modality","mechanism"],"components":{"target":{"id":"tbk1","name":"TBK1","href":"/targets/tbk1/","confidence":"high","from":["target record (drugs field)"],"detail":null},"mechanismClass":{"id":"receptor-agonist","name":"Receptor agonist","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"adu-s100","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/adu-s100/","quote":"ADU-S100 was the first STING agonist in the clinic. Injected directly into tumours, it produced almost no responses, alone or with checkpoint blockade."},{"record":"registry:adu-s100","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 1 terminated or withdrawn study and none active (fetched 2026-09-28)","href":"/drugs/adu-s100/#registry"}],"reasons":[{"drugId":"adu-s100","drugName":"ADU-S100 (MIW815)","drugRoute":"/drugs/adu-s100/","drugState":"stopped","record":"adu-s100","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/adu-s100/","quote":"ADU-S100 was the first STING agonist in the clinic. Injected directly into tumours, it produced almost no responses, alone or with checkpoint blockade."}]},{"id":"afatinib","name":"Afatinib","route":"/drugs/afatinib/","status":"approved","modality":"Small-molecule pan-ErbB TKI (second generation, irreversible)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"egfr+her2","name":"EGFR x HER2","href":"/targets/egfr/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"afatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/afatinib/"},{"record":"afatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2013: First-line metastatic NSCLC with EGFR exon 19 del or L858R","href":"/drugs/afatinib/"},{"record":"afatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2016: Squamous NSCLC after platinum","href":"/drugs/afatinib/"},{"record":"afatinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2018: Uncommon EGFR mutations (S768I, L861Q, G719X)","href":"/drugs/afatinib/"},{"record":"afatinib","field":"approvals[3]","kind":"approval","state":"approved","label":"EU 2013: EU brand Giotrif","href":"/drugs/afatinib/"},{"record":"afatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2013","href":"/regulatory/regions/"},{"record":"afatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2013","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif"},{"record":"afatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2013","href":"https://products.mhra.gov.uk/?search=Giotrif"},{"record":"afatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2014","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"afatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2017","href":"https://english.nmpa.gov.cn/"},{"record":"afatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Giotrif"},{"record":"nct06486142","field":"status","kind":"trial","state":"development","label":"EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study: phase 3, recruiting","href":"/trials/nct06486142/"},{"record":"nct06759857","field":"status","kind":"trial","state":"development","label":"FHND9041 Versus Afatinib for Non-small Cell Lung Cancer: phase 3, recruiting","href":"/trials/nct06759857/"},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"nct03785249","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1: phase 1/2, active","href":"/trials/nct03785249/"},{"record":"nct04183712","field":"status","kind":"trial","state":"development","label":"Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA: phase 2, recruiting","href":"/trials/nct04183712/"},{"record":"registry:afatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 17 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/afatinib/#registry"}],"reasons":[]},{"id":"al2846","name":"AL2846","route":"/drugs/al2846/","status":"phase-3","modality":"small molecule (structure undisclosed or not yet in PubChem)","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"met+ret","name":"MET x RET","href":"/targets/met/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"al2846","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/al2846/"},{"record":"nct06860971","field":"status","kind":"trial","state":"development","label":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma: phase 3, recruiting","href":"/trials/nct06860971/"},{"record":"registry:al2846","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/al2846/#registry"}],"reasons":[]},{"id":"alectinib","name":"Alectinib","route":"/drugs/alectinib/","status":"approved","modality":"Small-molecule kinase inhibitor (ALK)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"alk","name":"ALK","href":"/targets/alk/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"alectinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/alectinib/"},{"record":"alectinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2015: ALK+ NSCLC after crizotinib","href":"/drugs/alectinib/"},{"record":"alectinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2017: First-line ALK+ NSCLC","href":"/drugs/alectinib/"},{"record":"alectinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2024: Adjuvant ALK+ NSCLC after resection (stage IB ≥4 cm to IIIA)","href":"/drugs/alectinib/"},{"record":"alectinib","field":"approvals[3]","kind":"approval","state":"approved","label":"England (NICE) 2018: Untreated ALK-positive advanced non-small-cell lung cancer","href":"/drugs/alectinib/"},{"record":"alectinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2015","href":"/regulatory/regions/"},{"record":"alectinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2017","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa"},{"record":"alectinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2017","href":"https://products.mhra.gov.uk/?search=Alecensa"},{"record":"alectinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2014","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"alectinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2018","href":"https://english.nmpa.gov.cn/"},{"record":"alectinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2016","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Alecensa"},{"record":"nct05170204","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C: phase 3, active","href":"/trials/nct05170204/"},{"record":"nct04774718","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors: phase 1/2, active","href":"/trials/nct04774718/"},{"record":"nct04302025","field":"status","kind":"trial","state":"development","label":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC): phase 2, recruiting","href":"/trials/nct04302025/"},{"record":"nct03178552","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC): phase 2/3, active","href":"/trials/nct03178552/"},{"record":"alchemist","field":"status","kind":"trial","state":"development","label":"ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials): phase platform, active","href":"/trials/alchemist/"},{"record":"nct05987644","field":"status","kind":"trial","state":"development","label":"Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements: phase 1/2, recruiting","href":"/trials/nct05987644/"},{"record":"determine-trial","field":"status","kind":"trial","state":"development","label":"DETERMINE: phase platform, recruiting","href":"/trials/determine-trial/"},{"record":"nct06765109","field":"status","kind":"trial","state":"development","label":"Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC: phase 3, recruiting","href":"/trials/nct06765109/"},{"record":"nct05987956","field":"status","kind":"trial","state":"development","label":"Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms: phase 2/3, active","href":"/trials/nct05987956/"},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"nct04589845","field":"status","kind":"trial","state":"development","label":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study: phase 2, active","href":"/trials/nct04589845/"},{"record":"registry:alectinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 32 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/alectinib/#registry"}],"reasons":[]},{"id":"alpelisib","name":"Alpelisib","route":"/drugs/alpelisib/","status":"approved","modality":"Small-molecule PI3Kα inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"pik3ca","name":"PIK3CA / PI3K-alpha","href":"/targets/pik3ca/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"pi3k-akt-mtor-inhibitor","name":"PI3K, AKT or mTOR inhibitor","href":"/technologies/pi3k-akt-mtor-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"alpelisib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/alpelisib/"},{"record":"alpelisib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2019: PIK3CA-mutant HR+/HER2- advanced breast cancer with fulvestrant after endocrine therapy","href":"/drugs/alpelisib/"},{"record":"alpelisib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2019","href":"/regulatory/regions/"},{"record":"alpelisib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2020","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/piqray"},{"record":"alpelisib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2020","href":"https://products.mhra.gov.uk/?search=Piqray"},{"record":"alpelisib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2022","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"alpelisib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2024","href":"https://english.nmpa.gov.cn/"},{"record":"alpelisib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2020","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Piqray"},{"record":"nct05646862","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy: phase 3, recruiting","href":"/trials/nct05646862/"},{"record":"nct05948943","field":"status","kind":"trial","state":"development","label":"Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.: phase 2/3, recruiting","href":"/trials/nct05948943/"},{"record":"nct05230810","field":"status","kind":"trial","state":"development","label":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.: phase 1/2, active","href":"/trials/nct05230810/"},{"record":"nct05501886","field":"status","kind":"trial","state":"development","label":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1): phase 3, active","href":"/trials/nct05501886/"},{"record":"nct05563220","field":"status","kind":"trial","state":"development","label":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer: phase 1/2, active","href":"/trials/nct05563220/"},{"record":"nct04524000","field":"status","kind":"trial","state":"development","label":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer: phase 2, active","href":"/trials/nct04524000/"},{"record":"nct04544189","field":"status","kind":"trial","state":"development","label":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer: phase 2, active","href":"/trials/nct04544189/"},{"record":"nct04208178","field":"status","kind":"trial","state":"development","label":"Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation: phase 3, active","href":"/trials/nct04208178/"},{"record":"nct05038735","field":"status","kind":"trial","state":"development","label":"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.: phase 3, active","href":"/trials/nct05038735/"},{"record":"registry:alpelisib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 35 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/alpelisib/#registry"}],"reasons":[]},{"id":"aminoglutethimide","name":"Aminoglutethimide","route":"/drugs/aminoglutethimide/","status":"historic","modality":"Oral steroidogenesis inhibitor","state":"stopped","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"aromatase+cyp11a1","name":"Aromatase x CYP11A1","href":"/targets/aromatase/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"aminoglutethimide","field":"status","kind":"drug","state":"stopped","label":"Drug record status: historic","href":"/drugs/aminoglutethimide/","quote":"Aminoglutethimide produced a medical adrenalectomy for advanced breast and prostate cancer in the 1970s and 1980s, the ancestor of today's aromatase inhibitors, and was withdrawn once selective drugs arrived."},{"record":"aminoglutethimide","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1980: Cushing's syndrome (used off label as medical adrenalectomy in breast and prostate cancer)","href":"/drugs/aminoglutethimide/"},{"record":"registry:aminoglutethimide","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 1 terminated or withdrawn study and none active (fetched 2026-09-28)","href":"/drugs/aminoglutethimide/#registry"}],"reasons":[{"drugId":"aminoglutethimide","drugName":"Aminoglutethimide","drugRoute":"/drugs/aminoglutethimide/","drugState":"stopped","record":"aminoglutethimide","kind":"drug","label":"Drug record status: historic","href":"/drugs/aminoglutethimide/","quote":"Aminoglutethimide produced a medical adrenalectomy for advanced breast and prostate cancer in the 1970s and 1980s, the ancestor of today's aromatase inhibitors, and was withdrawn once selective drugs arrived."}]},{"id":"anastrozole","name":"Anastrozole","route":"/drugs/anastrozole/","status":"approved","modality":"Oral non-steroidal aromatase inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"aromatase","name":"Aromatase (CYP19A1)","href":"/targets/aromatase/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"anastrozole","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/anastrozole/"},{"record":"anastrozole","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1995: Advanced breast cancer in postmenopausal women after tamoxifen","href":"/drugs/anastrozole/"},{"record":"anastrozole","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2002: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer","href":"/drugs/anastrozole/"},{"record":"nct04711252","field":"status","kind":"trial","state":"development","label":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease: phase 3, active","href":"/trials/nct04711252/"},{"record":"nct02763566","field":"status","kind":"trial","state":"development","label":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer: phase 3, active","href":"/trials/nct02763566/"},{"record":"nct05257395","field":"status","kind":"trial","state":"development","label":"A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer: phase 3, active","href":"/trials/nct05257395/"},{"record":"registry:anastrozole","kind":"registry","state":"development","label":"ClinicalTrials.gov: 34 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/anastrozole/#registry"}],"reasons":[]},{"id":"anlotinib","name":"Anlotinib","route":"/drugs/anlotinib/","status":"approved","modality":"Small-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, KIT)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"vegf+fgfr2","name":"VEGF / VEGFR x FGFR2","href":"/targets/vegf/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"anlotinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/anlotinib/"},{"record":"anlotinib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2018: Advanced NSCLC after at least two lines of systemic therapy (ALTER 0303)","href":"/drugs/anlotinib/"},{"record":"anlotinib","field":"approvals[1]","kind":"approval","state":"approved","label":"China 2019: Advanced soft tissue sarcoma after chemotherapy; small cell lung cancer after at least two lines","href":"/drugs/anlotinib/"},{"record":"anlotinib","field":"approvals[2]","kind":"approval","state":"approved","label":"China 2020: Advanced medullary thyroid cancer","href":"/drugs/anlotinib/"},{"record":"anlotinib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): rejected 2026","href":"/regulatory/regions/","quote":"CHMP negative opinion 23 Jul 2026 on Qezzaqar (catequentinib; applicant CATS Consultants) for synovial sarcoma and leiomyosarcoma"},{"record":"anlotinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2018","href":"https://english.nmpa.gov.cn/"},{"record":"nct06469879","field":"status","kind":"trial","state":"development","label":"A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients: phase 3, planned","href":"/trials/nct06469879/"},{"record":"nct05913089","field":"status","kind":"trial","state":"development","label":"A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct05913089/"},{"record":"nct07562581","field":"status","kind":"trial","state":"development","label":"A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC: phase 2, recruiting","href":"/trials/nct07562581/"},{"record":"nct07815223","field":"status","kind":"trial","state":"development","label":"A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC: phase 2, recruiting","href":"/trials/nct07815223/"},{"record":"nct06048315","field":"status","kind":"trial","state":"development","label":"A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs W: phase 3, planned","href":"/trials/nct06048315/"},{"record":"nct07728955","field":"status","kind":"trial","state":"development","label":"A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for: phase 3, planned","href":"/trials/nct07728955/"},{"record":"nct04854668","field":"status","kind":"trial","state":"development","label":"A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Can: phase 3, active","href":"/trials/nct04854668/"},{"record":"nct07538271","field":"status","kind":"trial","state":"development","label":"A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer: phase 2, planned","href":"/trials/nct07538271/"},{"record":"nct07398326","field":"status","kind":"trial","state":"development","label":"Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct07398326/"},{"record":"nct05862337","field":"status","kind":"trial","state":"development","label":"Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.: phase 3, recruiting","href":"/trials/nct05862337/"},{"record":"nct04322617","field":"status","kind":"trial","state":"development","label":"Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer: phase 2/3, recruiting","href":"/trials/nct04322617/"},{"record":"nct06662877","field":"status","kind":"trial","state":"development","label":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment: phase 2/3, planned","href":"/trials/nct06662877/"},{"record":"nct07443397","field":"status","kind":"trial","state":"development","label":"Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.: phase 3, recruiting","href":"/trials/nct07443397/"},{"record":"nct07635290","field":"status","kind":"trial","state":"development","label":"Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer: phase 2, active","href":"/trials/nct07635290/"},{"record":"nct06901622","field":"status","kind":"trial","state":"development","label":"Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma: phase 2, recruiting","href":"/trials/nct06901622/"},{"record":"nct06992336","field":"status","kind":"trial","state":"development","label":"Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy: phase 2, recruiting","href":"/trials/nct06992336/"},{"record":"nct06767813","field":"status","kind":"trial","state":"development","label":"Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms: phase 2, recruiting","href":"/trials/nct06767813/"},{"record":"nct07548177","field":"status","kind":"trial","state":"development","label":"Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma: phase 2, recruiting","href":"/trials/nct07548177/"},{"record":"nct06761027","field":"status","kind":"trial","state":"development","label":"mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer: phase 1/2, recruiting","href":"/trials/nct06761027/"},{"record":"nct04846634","field":"status","kind":"trial","state":"development","label":"Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (A: phase 2, planned","href":"/trials/nct04846634/"},{"record":"nct03016819","field":"status","kind":"trial","state":"development","label":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS): phase 3, recruiting","href":"/trials/nct03016819/"},{"record":"nct07636226","field":"status","kind":"trial","state":"development","label":"QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer: phase 2/3, planned","href":"/trials/nct07636226/"},{"record":"nct07601178","field":"status","kind":"trial","state":"development","label":"QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride: phase 2, recruiting","href":"/trials/nct07601178/"},{"record":"nct07501169","field":"status","kind":"trial","state":"development","label":"Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC): phase 2, planned","href":"/trials/nct07501169/"},{"record":"nct07139470","field":"status","kind":"trial","state":"development","label":"Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer: phase 1/2, planned","href":"/trials/nct07139470/"},{"record":"nct07025174","field":"status","kind":"trial","state":"development","label":"Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer: phase 2, recruiting","href":"/trials/nct07025174/"},{"record":"nct06441344","field":"status","kind":"trial","state":"development","label":"Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell: phase 3, planned","href":"/trials/nct06441344/"},{"record":"nct06456138","field":"status","kind":"trial","state":"development","label":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC: phase 1/2, planned","href":"/trials/nct06456138/"},{"record":"registry:anlotinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 32 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/anlotinib/#registry"}],"reasons":[{"drugId":"anlotinib","drugName":"Anlotinib","drugRoute":"/drugs/anlotinib/","drugState":"approved","record":"anlotinib","kind":"regional","label":"EMA / European Commission (EU): rejected 2026","href":"/regulatory/regions/","quote":"CHMP negative opinion 23 Jul 2026 on Qezzaqar (catequentinib; applicant CATS Consultants) for synovial sarcoma and leiomyosarcoma"}]},{"id":"anvumetostat","name":"Anvumetostat","route":"/drugs/anvumetostat/","status":"phase-2","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"prmt5-mtap","name":"PRMT5 (MTAP-deleted cancers)","href":"/targets/prmt5-mtap/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"anvumetostat","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/anvumetostat/"},{"record":"nct06593522","field":"status","kind":"trial","state":"development","label":"A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201): phase 2, active","href":"/trials/nct06593522/"},{"record":"nct05094336","field":"status","kind":"trial","state":"development","label":"A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101): phase 1/2, active","href":"/trials/nct05094336/"},{"record":"registry:anvumetostat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/anvumetostat/#registry"}],"reasons":[]},{"id":"apalutamide","name":"Apalutamide","route":"/drugs/apalutamide/","status":"approved","modality":"Small-molecule AR antagonist","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"androgen-receptor","name":"Androgen receptor","href":"/targets/androgen-receptor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"receptor-agonist","name":"Receptor agonist","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"apalutamide","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/apalutamide/"},{"record":"apalutamide","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: Non-metastatic CRPC (SPARTAN)","href":"/drugs/apalutamide/"},{"record":"apalutamide","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2019: mHSPC (TITAN)","href":"/drugs/apalutamide/"},{"record":"apalutamide","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"apalutamide","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2019","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/erleada"},{"record":"apalutamide","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2019","href":"https://products.mhra.gov.uk/?search=Erleada"},{"record":"apalutamide","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2019","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"apalutamide","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2019","href":"https://english.nmpa.gov.cn/"},{"record":"apalutamide","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2018","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Erleada"},{"record":"nct04557059","field":"status","kind":"trial","state":"development","label":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer: phase 3, active","href":"/trials/nct04557059/"},{"record":"nct05884398","field":"status","kind":"trial","state":"development","label":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC: phase 3, active","href":"/trials/nct05884398/"},{"record":"nct01946204","field":"status","kind":"trial","state":"development","label":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer: phase 3, active","href":"/trials/nct01946204/"},{"record":"nct02489318","field":"status","kind":"trial","state":"development","label":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC: phase 3, active","href":"/trials/nct02489318/"},{"record":"nct04325828","field":"status","kind":"trial","state":"development","label":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma: phase 2, active","href":"/trials/nct04325828/"},{"record":"nct03767244","field":"status","kind":"trial","state":"development","label":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy: phase 3, active","href":"/trials/nct03767244/"},{"record":"nct05422911","field":"status","kind":"trial","state":"development","label":"Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.: phase 2, recruiting","href":"/trials/nct05422911/"},{"record":"nct02257736","field":"status","kind":"trial","state":"development","label":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC): phase 3, active","href":"/trials/nct02257736/"},{"record":"nct02531516","field":"status","kind":"trial","state":"development","label":"An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS: phase 3, active","href":"/trials/nct02531516/"},{"record":"nct07611110","field":"status","kind":"trial","state":"development","label":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01): phase 3, recruiting","href":"/trials/nct07611110/"},{"record":"nct05367440","field":"status","kind":"trial","state":"development","label":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer: phase 1/2, active","href":"/trials/nct05367440/"},{"record":"nct07745361","field":"status","kind":"trial","state":"development","label":"Study of Oral MRT-2359 With Apalutamide in Prostate Cancer: phase 2, recruiting","href":"/trials/nct07745361/"},{"record":"nct04423211","field":"status","kind":"trial","state":"development","label":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging: phase 3, recruiting","href":"/trials/nct04423211/"},{"record":"nct04513717","field":"status","kind":"trial","state":"development","label":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial: phase 3, active","href":"/trials/nct04513717/"},{"record":"registry:apalutamide","kind":"registry","state":"development","label":"ClinicalTrials.gov: 62 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/apalutamide/#registry"}],"reasons":[]},{"id":"asciminib","name":"Asciminib","route":"/drugs/asciminib/","status":"approved","modality":"Small-molecule allosteric ABL1 inhibitor (STAMP)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"bcr-abl+abl1","name":"BCR::ABL1 x ABL1","href":"/targets/bcr-abl/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"allosteric","name":"Allosteric","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"asciminib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/asciminib/"},{"record":"asciminib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2021: CML after ≥2 prior TKIs; T315I CML","href":"/drugs/asciminib/"},{"record":"asciminib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2024: Newly diagnosed Ph+ CML in chronic phase (ASC4FIRST)","href":"/drugs/asciminib/"},{"record":"asciminib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2021","href":"/regulatory/regions/"},{"record":"asciminib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2022","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/scemblix"},{"record":"asciminib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2022","href":"https://products.mhra.gov.uk/?search=Scemblix"},{"record":"asciminib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2022","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"asciminib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"asciminib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2022","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Scemblix"},{"record":"nct04971226","field":"status","kind":"trial","state":"development","label":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP: phase 3, active","href":"/trials/nct04971226/"},{"record":"nct05456191","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP): phase 3, active","href":"/trials/nct05456191/"},{"record":"nct05384587","field":"status","kind":"trial","state":"development","label":"Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia: phase 2, active","href":"/trials/nct05384587/"},{"record":"nct06514534","field":"status","kind":"trial","state":"development","label":"Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.: phase 2, recruiting","href":"/trials/nct06514534/"},{"record":"nct07387926","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL): phase 1/2, recruiting","href":"/trials/nct07387926/"},{"record":"nct04925479","field":"status","kind":"trial","state":"development","label":"Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia: phase 1/2, recruiting","href":"/trials/nct04925479/"},{"record":"nct07354074","field":"status","kind":"trial","state":"development","label":"Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP: phase 2, recruiting","href":"/trials/nct07354074/"},{"record":"registry:asciminib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 23 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/asciminib/#registry"}],"reasons":[]},{"id":"atebimetinib","name":"Atebimetinib","route":"/drugs/atebimetinib/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"mek","name":"MEK1/2","href":"/targets/mek/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"atebimetinib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/atebimetinib/"},{"record":"nct07562152","field":"status","kind":"trial","state":"development","label":"Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma: phase 3, recruiting","href":"/trials/nct07562152/"},{"record":"registry:atebimetinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/atebimetinib/#registry"}],"reasons":[]},{"id":"atirmociclib","name":"Atirmociclib","route":"/drugs/atirmociclib/","status":"phase-3","modality":"Small-molecule CDK4-selective inhibitor","state":"development","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"cdk4-6","name":"CDK4/6","href":"/targets/cdk4-6/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"cdk-inhibitor","name":"CDK inhibitor","href":"/technologies/cdk46-inhibitor/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"atirmociclib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/atirmociclib/"},{"record":"nct05262400","field":"status","kind":"trial","state":"development","label":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors: phase 1/2, active","href":"/trials/nct05262400/"},{"record":"nct06206837","field":"status","kind":"trial","state":"development","label":"A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.: phase 1/2, active","href":"/trials/nct06206837/"},{"record":"nct06760637","field":"status","kind":"trial","state":"development","label":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease: phase 3, active","href":"/trials/nct06760637/"},{"record":"nct04606446","field":"status","kind":"trial","state":"development","label":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors: phase 2, recruiting","href":"/trials/nct04606446/"},{"record":"nct07427394","field":"status","kind":"trial","state":"development","label":"Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer: phase 2, recruiting","href":"/trials/nct07427394/"},{"record":"nct04557449","field":"status","kind":"trial","state":"development","label":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors: phase 2, active","href":"/trials/nct04557449/"},{"record":"registry:atirmociclib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/atirmociclib/#registry"}],"reasons":[]},{"id":"atrasentan","name":"Atrasentan","route":"/drugs/atrasentan/","status":"withdrawn","modality":"small molecule","state":"stopped","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"ednra","name":"EDNRA","href":"/targets/ednra/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"receptor-agonist","name":"Receptor agonist","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"atrasentan","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/atrasentan/","quote":"The other endothelin blocker. Adding it to chemotherapy for advanced prostate cancer changed nothing, and the trial was stopped for futility."},{"record":"enthuse-m1-zibotentan","field":"result","kind":"trial","state":"stopped","label":"ENTHUSE M1: phase 3, negative","href":"/trials/enthuse-m1-zibotentan/","quote":"Median overall survival 24.5 against 22.5 months (hazard ratio 0.87, 95.2 percent confidence interval 0.69 to 1.10, p=0.240): not significant, with peripheral oedema in 44 percent and cardiac failure of any grade in 5.7 against 1.7 percent."},{"record":"swog-s0421-atrasentan","field":"result","kind":"trial","state":"stopped","label":"SWOG S0421: phase 3, negative","href":"/trials/swog-s0421-atrasentan/","quote":"Median overall survival 17.8 against 17.6 months (hazard ratio 1.04, 95 percent confidence interval 0.90 to 1.19) and progression-free survival 9.2 against 9.1 months (1.02, 0.89 to 1.16); halted early for futility, and no difference in pain palliation."},{"record":"registry:atrasentan","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/atrasentan/#registry"}],"reasons":[{"drugId":"atrasentan","drugName":"Atrasentan","drugRoute":"/drugs/atrasentan/","drugState":"stopped","record":"atrasentan","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/atrasentan/","quote":"The other endothelin blocker. Adding it to chemotherapy for advanced prostate cancer changed nothing, and the trial was stopped for futility."},{"drugId":"atrasentan","drugName":"Atrasentan","drugRoute":"/drugs/atrasentan/","drugState":"stopped","record":"enthuse-m1-zibotentan","kind":"trial","label":"ENTHUSE M1: phase 3, negative","href":"/trials/enthuse-m1-zibotentan/","quote":"Median overall survival 24.5 against 22.5 months (hazard ratio 0.87, 95.2 percent confidence interval 0.69 to 1.10, p=0.240): not significant, with peripheral oedema in 44 percent and cardiac failure of any grade in 5.7 against 1.7 percent."},{"drugId":"atrasentan","drugName":"Atrasentan","drugRoute":"/drugs/atrasentan/","drugState":"stopped","record":"swog-s0421-atrasentan","kind":"trial","label":"SWOG S0421: phase 3, negative","href":"/trials/swog-s0421-atrasentan/","quote":"Median overall survival 17.8 against 17.6 months (hazard ratio 1.04, 95 percent confidence interval 0.90 to 1.19) and progression-free survival 9.2 against 9.1 months (1.02, 0.89 to 1.16); halted early for futility, and no difference in pain palliation."}]},{"id":"aumolertinib","name":"Aumolertinib","route":"/drugs/aumolertinib/","status":"approved","modality":"Small-molecule third-generation EGFR TKI","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"egfr","name":"EGFR","href":"/targets/egfr/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"aumolertinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/aumolertinib/"},{"record":"aumolertinib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2020: EGFR T790M-positive locally advanced or metastatic NSCLC after EGFR TKI therapy","href":"/drugs/aumolertinib/"},{"record":"aumolertinib","field":"approvals[1]","kind":"approval","state":"approved","label":"China 2021: First-line EGFR exon 19 deletion or L858R NSCLC (AENEAS)","href":"/drugs/aumolertinib/"},{"record":"aumolertinib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2026: Aumseqa: first-line advanced NSCLC with EGFR exon 19 deletion or L858R; advanced EGFR T790M-positive NSCLC","href":"/drugs/aumolertinib/"},{"record":"aumolertinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2026","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/aumseqa"},{"record":"aumolertinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2020","href":"https://english.nmpa.gov.cn/"},{"record":"nct06474455","field":"status","kind":"trial","state":"development","label":"A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06474455/"},{"record":"nct04951635","field":"status","kind":"trial","state":"development","label":"A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer: phase 3, recruiting","href":"/trials/nct04951635/"},{"record":"nct07183189","field":"status","kind":"trial","state":"development","label":"A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC: phase 3, recruiting","href":"/trials/nct07183189/"},{"record":"nct06043973","field":"status","kind":"trial","state":"development","label":"Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance: phase 3, recruiting","href":"/trials/nct06043973/"},{"record":"nct04687241","field":"status","kind":"trial","state":"development","label":"Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations: phase 3, active","href":"/trials/nct04687241/"},{"record":"nct05800223","field":"status","kind":"trial","state":"development","label":"Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer: phase 3, recruiting","href":"/trials/nct05800223/"},{"record":"nct04923906","field":"status","kind":"trial","state":"development","label":"Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mut: phase 3, active","href":"/trials/nct04923906/"},{"record":"nct04762459","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Com: phase 3, recruiting","href":"/trials/nct04762459/"},{"record":"nct04841811","field":"status","kind":"trial","state":"development","label":"MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH): phase 3, active","href":"/trials/nct04841811/"},{"record":"nct05503888","field":"status","kind":"trial","state":"development","label":"Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer: phase 1/2, planned","href":"/trials/nct05503888/"},{"record":"registry:aumolertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 26 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/aumolertinib/#registry"}],"reasons":[]},{"id":"avapritinib","name":"Avapritinib","route":"/drugs/avapritinib/","status":"approved","modality":"Small-molecule kinase inhibitor (PDGFRA D842V / KIT)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"kit","name":"KIT","href":"/targets/kit/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"avapritinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/avapritinib/"},{"record":"avapritinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2020: Unresectable/metastatic GIST with PDGFRA exon 18 mutation including D842V","href":"/drugs/avapritinib/"},{"record":"avapritinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2021: Advanced systemic mastocytosis","href":"/drugs/avapritinib/"},{"record":"avapritinib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2020: EU brand Ayvakyt","href":"/drugs/avapritinib/"},{"record":"avapritinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2020","href":"/regulatory/regions/"},{"record":"avapritinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2020","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/ayvakyt"},{"record":"avapritinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2020","href":"https://products.mhra.gov.uk/?search=Ayvakyt"},{"record":"avapritinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"avapritinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2022","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Ayvakyt"},{"record":"nct03731260","field":"status","kind":"trial","state":"development","label":"(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo : phase 2, active","href":"/trials/nct03731260/"},{"record":"nct04771520","field":"status","kind":"trial","state":"development","label":"Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors: phase 2, recruiting","href":"/trials/nct04771520/"},{"record":"voyager","field":"result","kind":"trial","state":"stopped","label":"VOYAGER: phase 3, negative","href":"/trials/voyager/","quote":"PFS HR 1.25 (negative)."},{"record":"registry:avapritinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/avapritinib/#registry"}],"reasons":[{"drugId":"avapritinib","drugName":"Avapritinib","drugRoute":"/drugs/avapritinib/","drugState":"approved","record":"voyager","kind":"trial","label":"VOYAGER: phase 3, negative","href":"/trials/voyager/","quote":"PFS HR 1.25 (negative)."}]},{"id":"avutometinib-defactinib","name":"Avutometinib + defactinib","route":"/drugs/avutometinib-defactinib/","status":"approved","modality":"Small-molecule RAF/MEK clamp + FAK inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"kras+fak","name":"KRAS x FAK","href":"/targets/kras/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"avutometinib-defactinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/avutometinib-defactinib/"},{"record":"avutometinib-defactinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2025: KRAS-mutated recurrent low-grade serous ovarian cancer after prior systemic therapy (accelerated)","href":"/drugs/avutometinib-defactinib/"},{"record":"avutometinib-defactinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2025","href":"/regulatory/regions/"},{"record":"nct07824960","field":"status","kind":"trial","state":"development","label":"Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma: phase 1/2, planned","href":"/trials/nct07824960/"},{"record":"nct06369259","field":"status","kind":"trial","state":"development","label":"Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-R: phase 2, recruiting","href":"/trials/nct06369259/"},{"record":"nct07126158","field":"status","kind":"trial","state":"development","label":"Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma: phase 2, recruiting","href":"/trials/nct07126158/"},{"record":"registry:avutometinib-defactinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 19 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/avutometinib-defactinib/#registry"}],"reasons":[]},{"id":"avzo-021","name":"AVZO-021","route":"/drugs/avzo-021/","status":"phase-2","modality":"small molecule (structure undisclosed or not yet in PubChem)","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"her2","name":"HER2","href":"/targets/her2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"cdk-inhibitor","name":"CDK inhibitor","href":"/technologies/cdk46-inhibitor/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"avzo-021","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/avzo-021/"},{"record":"nct06998407","field":"status","kind":"trial","state":"development","label":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06998407/"},{"record":"nct05867251","field":"status","kind":"trial","state":"development","label":"Study of AVZO-021 in Patients With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05867251/"},{"record":"registry:avzo-021","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/avzo-021/#registry"}],"reasons":[]},{"id":"avzo-023","name":"AVZO-023","route":"/drugs/avzo-023/","status":"phase-2","modality":"Small-molecule inhibitor","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"cdk4-6","name":"CDK4/6","href":"/targets/cdk4-6/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"cdk-inhibitor","name":"CDK inhibitor","href":"/technologies/cdk46-inhibitor/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"avzo-023","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/avzo-023/"},{"record":"nct06998407","field":"status","kind":"trial","state":"development","label":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06998407/"},{"record":"registry:avzo-023","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/avzo-023/#registry"}],"reasons":[]},{"id":"axitinib","name":"Axitinib","route":"/drugs/axitinib/","status":"approved","modality":"Small-molecule kinase inhibitor (VEGFR)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"vegf","name":"VEGF / VEGFR","href":"/targets/vegf/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"axitinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/axitinib/"},{"record":"axitinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2012: Advanced RCC after one prior systemic therapy","href":"/drugs/axitinib/"},{"record":"axitinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2019: First-line advanced RCC with pembrolizumab or avelumab","href":"/drugs/axitinib/"},{"record":"axitinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2012","href":"/regulatory/regions/"},{"record":"axitinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2012","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta"},{"record":"axitinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2012","href":"https://products.mhra.gov.uk/?search=Inlyta"},{"record":"axitinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2012","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"axitinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2015","href":"https://english.nmpa.gov.cn/"},{"record":"axitinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2012","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Inlyta"},{"record":"nct06962787","field":"status","kind":"trial","state":"development","label":"A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer: phase 2, recruiting","href":"/trials/nct06962787/"},{"record":"nct05805501","field":"status","kind":"trial","state":"development","label":"A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cel: phase 2, active","href":"/trials/nct05805501/"},{"record":"nct05059522","field":"status","kind":"trial","state":"development","label":"Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing: phase 3, active","href":"/trials/nct05059522/"},{"record":"nct07227415","field":"status","kind":"trial","state":"development","label":"Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With : phase 1/2, recruiting","href":"/trials/nct07227415/"},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"registry:axitinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 34 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/axitinib/#registry"}],"reasons":[]},{"id":"azd3470","name":"AZD3470","route":"/drugs/azd3470/","status":"phase-2","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"prmt5-mtap","name":"PRMT5 (MTAP-deleted cancers)","href":"/targets/prmt5-mtap/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"azd3470","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/azd3470/"},{"record":"nct06130553","field":"status","kind":"trial","state":"development","label":"A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06130553/"},{"record":"nct06137144","field":"status","kind":"trial","state":"development","label":"AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.: phase 1/2, recruiting","href":"/trials/nct06137144/"},{"record":"registry:azd3470","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/azd3470/#registry"}],"reasons":[]},{"id":"azenosertib","name":"Azenosertib","route":"/drugs/azenosertib/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"wee1","name":"WEE1","href":"/targets/wee1/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"ddr-inhibitor","name":"DNA damage response inhibitor","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"azenosertib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/azenosertib/"},{"record":"nct05128825","field":"status","kind":"trial","state":"development","label":"A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer: phase 2, recruiting","href":"/trials/nct05128825/"},{"record":"nct07546500","field":"status","kind":"trial","state":"development","label":"A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression: phase 3, recruiting","href":"/trials/nct07546500/"},{"record":"registry:azenosertib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/azenosertib/#registry"}],"reasons":[]},{"id":"belinostat","name":"Belinostat","route":"/drugs/belinostat/","status":"approved","modality":"Pan-HDAC inhibitor (hydroxamate)","state":"approved","confidence":"high","fields":["target record (drugs field)","technologies"],"components":{"target":{"id":"hdac","name":"Histone deacetylases (HDAC)","href":"/targets/hdac/","confidence":"high","from":["target record (drugs field)"],"detail":null},"mechanismClass":{"id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"belinostat","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/belinostat/"},{"record":"belinostat","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2014: Relapsed/refractory peripheral T-cell lymphoma","href":"/drugs/belinostat/"},{"record":"belinostat","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2014","href":"/regulatory/regions/"},{"record":"nct04747236","field":"status","kind":"trial","state":"development","label":"Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL: phase 2, recruiting","href":"/trials/nct04747236/"},{"record":"nct06072131","field":"status","kind":"trial","state":"development","label":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL: phase 3, recruiting","href":"/trials/nct06072131/"},{"record":"registry:belinostat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/belinostat/#registry"}],"reasons":[]},{"id":"belzutifan","name":"Belzutifan","route":"/drugs/belzutifan/","status":"approved","modality":"Small-molecule HIF-2α inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"hif2a","name":"HIF-2α","href":"/targets/hif2a/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"belzutifan","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/belzutifan/"},{"record":"belzutifan","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2021: VHL-associated RCC, CNS haemangioblastoma, pNET","href":"/drugs/belzutifan/"},{"record":"belzutifan","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2023: Advanced RCC after PD-1/PD-L1 and VEGF-TKI","href":"/drugs/belzutifan/"},{"record":"belzutifan","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2026: Adjuvant clear-cell RCC with pembrolizumab","href":"/drugs/belzutifan/"},{"record":"belzutifan","field":"approvals[3]","kind":"approval","state":"approved","label":"EU 2025: ccRCC after ≥2 lines; VHL-associated tumours; 12 Feb 2025 (conditional)","href":"/drugs/belzutifan/"},{"record":"belzutifan","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2021","href":"/regulatory/regions/"},{"record":"belzutifan","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/welireg"},{"record":"belzutifan","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2025","href":"https://products.mhra.gov.uk/?search=Welireg"},{"record":"belzutifan","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2025","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"belzutifan","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2025","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Welireg"},{"record":"nct05468697","field":"status","kind":"trial","state":"development","label":"A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6: phase 1/2, active","href":"/trials/nct05468697/"},{"record":"nct04489771","field":"status","kind":"trial","state":"development","label":"A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013): phase 2, active","href":"/trials/nct04489771/"},{"record":"nct05899049","field":"status","kind":"trial","state":"development","label":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study: phase 3, active","href":"/trials/nct05899049/"},{"record":"nct03634540","field":"status","kind":"trial","state":"development","label":"A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003): phase 2, active","href":"/trials/nct03634540/"},{"record":"nct04924075","field":"status","kind":"trial","state":"development","label":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL: phase 2, recruiting","href":"/trials/nct04924075/"},{"record":"nct07405164","field":"status","kind":"trial","state":"development","label":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043): phase 3, recruiting","href":"/trials/nct07405164/"},{"record":"litespark-012","field":"result","kind":"trial","state":"stopped","label":"LITESPARK-012: phase 3, negative","href":"/trials/litespark-012/","quote":"Primary endpoint not met (ASCO GU 2026)."},{"record":"nct04976634","field":"status","kind":"trial","state":"development","label":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016): phase 2, active","href":"/trials/nct04976634/"},{"record":"nct06428396","field":"status","kind":"trial","state":"development","label":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029): phase 2, active","href":"/trials/nct06428396/"},{"record":"nct04626479","field":"status","kind":"trial","state":"development","label":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A): phase 1/2, active","href":"/trials/nct04626479/"},{"record":"nct04626518","field":"status","kind":"trial","state":"development","label":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03): phase 1/2, active","href":"/trials/nct04626518/"},{"record":"nct07049926","field":"status","kind":"trial","state":"development","label":"Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (: phase 1/2, recruiting","href":"/trials/nct07049926/"},{"record":"registry:belzutifan","kind":"registry","state":"development","label":"ClinicalTrials.gov: 25 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/belzutifan/#registry"}],"reasons":[{"drugId":"belzutifan","drugName":"Belzutifan","drugRoute":"/drugs/belzutifan/","drugState":"approved","record":"litespark-012","kind":"trial","label":"LITESPARK-012: phase 3, negative","href":"/trials/litespark-012/","quote":"Primary endpoint not met (ASCO GU 2026)."}]},{"id":"bexarotene","name":"Bexarotene","route":"/drugs/bexarotene/","status":"approved","modality":"Small-molecule retinoid X receptor agonist","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"rxr","name":"Retinoid X receptor (RXR)","href":"/targets/rxr/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"bexarotene","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/bexarotene/"},{"record":"bexarotene","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1999: Cutaneous manifestations of cutaneous T-cell lymphoma refractory to at least one systemic therapy","href":"/drugs/bexarotene/"},{"record":"bexarotene","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2001: Skin manifestations of advanced-stage CTCL refractory to at least one systemic treatment","href":"/drugs/bexarotene/"},{"record":"bexarotene","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2001","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/targretin"},{"record":"registry:bexarotene","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 7 terminated or withdrawn studies and none active (fetched 2026-09-28)","href":"/drugs/bexarotene/#registry"}],"reasons":[]},{"id":"bezuclastinib","name":"Bezuclastinib","route":"/drugs/bezuclastinib/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"kit+met","name":"KIT x MET","href":"/targets/kit/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"bezuclastinib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/bezuclastinib/"},{"record":"nct04996875","field":"status","kind":"trial","state":"development","label":"(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis: phase 2, recruiting","href":"/trials/nct04996875/"},{"record":"nct05208047","field":"status","kind":"trial","state":"development","label":"(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors: phase 3, recruiting","href":"/trials/nct05208047/"},{"record":"nct05186753","field":"status","kind":"trial","state":"development","label":"(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis: phase 2, active","href":"/trials/nct05186753/"},{"record":"registry:bezuclastinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/bezuclastinib/#registry"}],"reasons":[]},{"id":"bicalutamide","name":"Bicalutamide","route":"/drugs/bicalutamide/","status":"approved","modality":"Oral first-generation non-steroidal antiandrogen","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"androgen-receptor","name":"Androgen receptor","href":"/targets/androgen-receptor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"bicalutamide","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/bicalutamide/"},{"record":"bicalutamide","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1995: Metastatic prostate cancer with LHRH analogue","href":"/drugs/bicalutamide/"},{"record":"bicalutamide","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 1995: Advanced prostate cancer; 150 mg for locally advanced","href":"/drugs/bicalutamide/"},{"record":"bicalutamide","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 1995","href":"/regulatory/regions/"},{"record":"bicalutamide","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 1995","href":"/regulatory/regions/"},{"record":"bicalutamide","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 1995","href":"https://products.mhra.gov.uk/?search=Casodex"},{"record":"bicalutamide","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 1999","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"bicalutamide","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved","href":"https://english.nmpa.gov.cn/"},{"record":"bicalutamide","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Casodex"},{"record":"nct02531516","field":"status","kind":"trial","state":"development","label":"An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS: phase 3, active","href":"/trials/nct02531516/"},{"record":"nct07455903","field":"status","kind":"trial","state":"development","label":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT: phase 2, recruiting","href":"/trials/nct07455903/"},{"record":"nct06365788","field":"status","kind":"trial","state":"development","label":"Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer: phase 2, recruiting","href":"/trials/nct06365788/"},{"record":"nct03678025","field":"status","kind":"trial","state":"development","label":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer: phase 3, recruiting","href":"/trials/nct03678025/"},{"record":"nct04513717","field":"status","kind":"trial","state":"development","label":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial: phase 3, active","href":"/trials/nct04513717/"},{"record":"registry:bicalutamide","kind":"registry","state":"development","label":"ClinicalTrials.gov: 18 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/bicalutamide/#registry"}],"reasons":[]},{"id":"binimetinib","name":"Binimetinib","route":"/drugs/binimetinib/","status":"approved","modality":"Small-molecule kinase inhibitor (MEK1/2)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"braf","name":"BRAF","href":"/targets/braf/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"allosteric","name":"Allosteric","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"binimetinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/binimetinib/"},{"record":"binimetinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: BRAF V600E/K melanoma with encorafenib","href":"/drugs/binimetinib/"},{"record":"binimetinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2023: BRAF V600E metastatic NSCLC with encorafenib","href":"/drugs/binimetinib/"},{"record":"binimetinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"binimetinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2018","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/mektovi"},{"record":"binimetinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2018","href":"https://products.mhra.gov.uk/?search=Mektovi"},{"record":"binimetinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2019","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"binimetinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2019","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Mektovi"},{"record":"nct04657991","field":"status","kind":"trial","state":"development","label":"A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma: phase 3, active","href":"/trials/nct04657991/"},{"record":"nct05270044","field":"status","kind":"trial","state":"development","label":"Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.: phase 3, active","href":"/trials/nct05270044/"},{"record":"combomatch-binimetinib-folfox","field":"status","kind":"trial","state":"development","label":"ComboMATCH: FOLFOX with or without binimetinib in second-line biliary tract cancer with MAPK pathway alterations: phase 2, active","href":"/trials/combomatch-binimetinib-folfox/"},{"record":"nct03803553","field":"status","kind":"trial","state":"development","label":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer: phase 3, active","href":"/trials/nct03803553/"},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"nct05195632","field":"status","kind":"trial","state":"development","label":"Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung: phase 2, active","href":"/trials/nct05195632/"},{"record":"nct03947385","field":"status","kind":"trial","state":"development","label":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions: phase 1/2, recruiting","href":"/trials/nct03947385/"},{"record":"registry:binimetinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 32 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/binimetinib/#registry"}],"reasons":[]},{"id":"bortezomib","name":"Bortezomib","route":"/drugs/bortezomib/","status":"approved","modality":"Proteasome inhibitor","state":"approved","confidence":"high","fields":["target record (drugs field)","technologies","modality","mechanism"],"components":{"target":{"id":"proteasome","name":"Proteasome (PSMB5)","href":"/targets/proteasome/","confidence":"high","from":["target record (drugs field)"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"bortezomib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/bortezomib/"},{"record":"bortezomib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2003: Relapsed myeloma (accelerated)","href":"/drugs/bortezomib/"},{"record":"bortezomib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2008: Newly diagnosed myeloma","href":"/drugs/bortezomib/"},{"record":"bortezomib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2003","href":"/regulatory/regions/"},{"record":"bortezomib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2004","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/velcade"},{"record":"bortezomib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2004","href":"https://products.mhra.gov.uk/?search=Velcade"},{"record":"bortezomib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2006","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"bortezomib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2005","href":"https://english.nmpa.gov.cn/"},{"record":"bortezomib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2005","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Velcade"},{"record":"nct06464991","field":"status","kind":"trial","state":"development","label":"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03): phase 3, recruiting","href":"/trials/nct06464991/"},{"record":"nct06413498","field":"status","kind":"trial","state":"development","label":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma: phase 3, active","href":"/trials/nct06413498/"},{"record":"nct07391657","field":"status","kind":"trial","state":"development","label":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela: phase 3, recruiting","href":"/trials/nct07391657/"},{"record":"nct06208150","field":"status","kind":"trial","state":"development","label":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez: phase 3, active","href":"/trials/nct06208150/"},{"record":"nct05572515","field":"status","kind":"trial","state":"development","label":"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With: phase 3, active","href":"/trials/nct05572515/"},{"record":"nct03314181","field":"status","kind":"trial","state":"development","label":"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor: phase 2, active","href":"/trials/nct03314181/"},{"record":"nct06577025","field":"status","kind":"trial","state":"development","label":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind: phase 2, active","href":"/trials/nct06577025/"},{"record":"nct04133636","field":"status","kind":"trial","state":"development","label":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul: phase 2, active","href":"/trials/nct04133636/"},{"record":"nct04414475","field":"status","kind":"trial","state":"development","label":"A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refrac: phase 2, recruiting","href":"/trials/nct04414475/"},{"record":"nct02773030","field":"status","kind":"trial","state":"development","label":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple: phase 1/2, active","href":"/trials/nct02773030/"},{"record":"nct03989414","field":"status","kind":"trial","state":"development","label":"A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre: phase 1/2, active","href":"/trials/nct03989414/"},{"record":"nct05519085","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re: phase 3, recruiting","href":"/trials/nct05519085/"},{"record":"nct07227311","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult: phase 2, recruiting","href":"/trials/nct07227311/"},{"record":"nct05623020","field":"status","kind":"trial","state":"development","label":"A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide: phase 3, recruiting","href":"/trials/nct05623020/"},{"record":"nct06956170","field":"status","kind":"trial","state":"development","label":"All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo: phase 3, active","href":"/trials/nct06956170/"},{"record":"cartitude-6","field":"status","kind":"trial","state":"development","label":"CARTITUDE-6: phase 3, active","href":"/trials/cartitude-6/"},{"record":"nct06868654","field":"status","kind":"trial","state":"development","label":"China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame: phase 3, active","href":"/trials/nct06868654/"},{"record":"nct06868667","field":"status","kind":"trial","state":"development","label":"Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex: phase 3, active","href":"/trials/nct06868667/"},{"record":"nct06152575","field":"status","kind":"trial","state":"development","label":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other: phase 3, recruiting","href":"/trials/nct06152575/"},{"record":"nct04975997","field":"status","kind":"trial","state":"development","label":"Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants : phase 3, active","href":"/trials/nct04975997/"},{"record":"nct07018050","field":"status","kind":"trial","state":"development","label":"Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma: phase 2, recruiting","href":"/trials/nct07018050/"},{"record":"nct02343042","field":"status","kind":"trial","state":"development","label":"Selinexor and Backbone Treatments of Multiple Myeloma Patients: phase 1/2, recruiting","href":"/trials/nct02343042/"},{"record":"nct06158841","field":"status","kind":"trial","state":"development","label":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto: phase 3, active","href":"/trials/nct06158841/"},{"record":"nct07764978","field":"status","kind":"trial","state":"development","label":"Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT: phase 3, recruiting","href":"/trials/nct07764978/"},{"record":"nct04068597","field":"status","kind":"trial","state":"development","label":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies: phase 1/2, recruiting","href":"/trials/nct04068597/"},{"record":"registry:bortezomib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 19 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/bortezomib/#registry"}],"reasons":[]},{"id":"bosutinib","name":"Bosutinib","route":"/drugs/bosutinib/","status":"approved","modality":"Small-molecule BCR-ABL1/SRC TKI","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"bcr-abl","name":"BCR::ABL1 (Philadelphia chromosome)","href":"/targets/bcr-abl/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"bosutinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/bosutinib/"},{"record":"bosutinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2012: Ph+ CML after prior TKI","href":"/drugs/bosutinib/"},{"record":"bosutinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2017: Newly diagnosed Ph+ CML chronic phase","href":"/drugs/bosutinib/"},{"record":"bosutinib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2013: Ph+ CML","href":"/drugs/bosutinib/"},{"record":"bosutinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2012","href":"/regulatory/regions/"},{"record":"bosutinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2013","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif"},{"record":"bosutinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2013","href":"https://products.mhra.gov.uk/?search=Bosulif"},{"record":"bosutinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2014","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"bosutinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Bosulif"},{"record":"nct04971226","field":"status","kind":"trial","state":"development","label":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP: phase 3, active","href":"/trials/nct04971226/"},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"registry:bosutinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/bosutinib/#registry"}],"reasons":[]},{"id":"brigatinib","name":"Brigatinib","route":"/drugs/brigatinib/","status":"approved","modality":"Small-molecule ALK/EGFR TKI (second generation)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"alk","name":"ALK","href":"/targets/alk/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"brigatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/brigatinib/"},{"record":"brigatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2017: ALK-positive metastatic NSCLC after crizotinib","href":"/drugs/brigatinib/"},{"record":"brigatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2020: First-line ALK-positive metastatic NSCLC","href":"/drugs/brigatinib/"},{"record":"brigatinib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2018: ALK-positive NSCLC","href":"/drugs/brigatinib/"},{"record":"brigatinib","field":"approvals[3]","kind":"approval","state":"approved","label":"England (NICE) 2019: ALK-positive advanced non-small-cell lung cancer after crizotinib","href":"/drugs/brigatinib/"},{"record":"brigatinib","field":"approvals[4]","kind":"approval","state":"approved","label":"England (NICE) 2021: ALK-positive advanced non-small-cell lung cancer not previously treated with an ALK inhibitor","href":"/drugs/brigatinib/"},{"record":"brigatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2017","href":"/regulatory/regions/"},{"record":"brigatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2018","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig"},{"record":"brigatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2018","href":"https://products.mhra.gov.uk/?search=Alunbrig"},{"record":"brigatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2021","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"brigatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2022","href":"https://english.nmpa.gov.cn/"},{"record":"brigatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Alunbrig"},{"record":"intuitt-nf2","field":"status","kind":"trial","state":"development","label":"INTUITT-NF2: phase 2, recruiting","href":"/trials/intuitt-nf2/"},{"record":"nct06813079","field":"status","kind":"trial","state":"development","label":"Using Tumor Models to Determine Treatments: phase 2, recruiting","href":"/trials/nct06813079/"},{"record":"registry:brigatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 10 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/brigatinib/#registry"}],"reasons":[]},{"id":"brigimadlin","name":"Brigimadlin","route":"/drugs/brigimadlin/","status":"phase-3","modality":"Oral MDM2-p53 antagonist","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"mdm2","name":"MDM2","href":"/targets/mdm2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"mdm2-inhibitor","name":"MDM2 inhibitor","href":"/technologies/mdm2-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"brigimadlin","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/brigimadlin/"},{"record":"nct06619509","field":"status","kind":"trial","state":"development","label":"A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine: phase 2, active","href":"/trials/nct06619509/"},{"record":"registry:brigimadlin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/brigimadlin/#registry"}],"reasons":[]},{"id":"bromocriptine","name":"Bromocriptine","route":"/drugs/bromocriptine/","status":"approved","modality":"Oral ergot dopamine D2 receptor agonist","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"drd2","name":"Dopamine D2 receptor","href":"/targets/drd2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"bromocriptine","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/bromocriptine/"},{"record":"bromocriptine","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1978: Hyperprolactinaemia-associated dysfunction including prolactin-secreting adenomas; acromegaly; Parkinson's disease","href":"/drugs/bromocriptine/"},{"record":"registry:bromocriptine","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/bromocriptine/#registry"}],"reasons":[]},{"id":"cabergoline","name":"Cabergoline","route":"/drugs/cabergoline/","status":"approved","modality":"Oral long-acting dopamine D2 receptor agonist","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"drd2","name":"Dopamine D2 receptor","href":"/targets/drd2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"receptor-agonist","name":"Receptor agonist","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"cabergoline","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/cabergoline/"},{"record":"cabergoline","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1996: Hyperprolactinaemic disorders, idiopathic or due to pituitary adenomas","href":"/drugs/cabergoline/"},{"record":"nct07463235","field":"status","kind":"trial","state":"development","label":"Safety and Potency of a High Cabergoline Dosage in Microprolactinomas: phase 3, recruiting","href":"/trials/nct07463235/"},{"record":"registry:cabergoline","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/cabergoline/#registry"}],"reasons":[]},{"id":"cabozantinib","name":"Cabozantinib","route":"/drugs/cabozantinib/","status":"approved","modality":"Small-molecule multi-kinase inhibitor (MET, VEGFR2, AXL, RET)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"met+vegf","name":"MET x VEGF / VEGFR","href":"/targets/met/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"cabozantinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/cabozantinib/"},{"record":"cabozantinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2012: Medullary thyroid cancer (Cometriq)","href":"/drugs/cabozantinib/"},{"record":"cabozantinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2016: Advanced RCC","href":"/drugs/cabozantinib/"},{"record":"cabozantinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2019: HCC previously treated with sorafenib","href":"/drugs/cabozantinib/"},{"record":"cabozantinib","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2025: Advanced pancreatic and extra-pancreatic neuroendocrine tumours after prior therapy (CABINET)","href":"/drugs/cabozantinib/"},{"record":"cabozantinib","field":"approvals[4]","kind":"approval","state":"approved","label":"US 2017: First-line advanced RCC (CABOSUN)","href":"/drugs/cabozantinib/"},{"record":"cabozantinib","field":"approvals[5]","kind":"approval","state":"approved","label":"US 2021: First-line advanced RCC with nivolumab (CheckMate 9ER)","href":"/drugs/cabozantinib/"},{"record":"cabozantinib","field":"approvals[6]","kind":"approval","state":"approved","label":"EU 2014: Cometriq for medullary thyroid cancer; 21 Mar 2014. Cabometyx (RCC) Sep 2016","href":"/drugs/cabozantinib/"},{"record":"cabozantinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2012","href":"/regulatory/regions/"},{"record":"cabozantinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2014","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq"},{"record":"cabozantinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2014","href":"https://products.mhra.gov.uk/?search=Cometriq"},{"record":"cabozantinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2020","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"cabozantinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"cabozantinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2017","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Cabometyx"},{"record":"nct03690388","field":"status","kind":"trial","state":"development","label":"A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Va: phase 3, active","href":"/trials/nct03690388/"},{"record":"nct05859217","field":"status","kind":"trial","state":"development","label":"A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1): phase 2, planned","href":"/trials/nct05859217/"},{"record":"nct07293351","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal : phase 1/2, recruiting","href":"/trials/nct07293351/"},{"record":"nct03634540","field":"status","kind":"trial","state":"development","label":"A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003): phase 2, active","href":"/trials/nct03634540/"},{"record":"nct01639508","field":"status","kind":"trial","state":"development","label":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or A: phase 2, recruiting","href":"/trials/nct01639508/"},{"record":"nct03539822","field":"status","kind":"trial","state":"development","label":"Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies: phase 1/2, recruiting","href":"/trials/nct03539822/"},{"record":"comet-1","field":"result","kind":"trial","state":"stopped","label":"COMET-1: phase 3, negative","href":"/trials/comet-1/","quote":"Median overall survival 11.0 against 9.8 months (hazard ratio 0.90, 95 percent confidence interval 0.76 to 1.06, p=0.213): not met. Bone scan response at 12 weeks 42 against 3 percent and radiographic progression-free survival 5.6 against 2.8 months."},{"record":"contact-03","field":"result","kind":"trial","state":"stopped","label":"CONTACT-03: phase 3, negative","href":"/trials/contact-03/","quote":"PFS HR 1.03; OS HR 0.94, negative."},{"record":"nct07405164","field":"status","kind":"trial","state":"development","label":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043): phase 3, recruiting","href":"/trials/nct07405164/"},{"record":"nct07620574","field":"status","kind":"trial","state":"development","label":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study: phase 3, recruiting","href":"/trials/nct07620574/"},{"record":"nct03899155","field":"status","kind":"trial","state":"development","label":"Pan Tumor Rollover Study: phase 2, recruiting","href":"/trials/nct03899155/"},{"record":"nct04446117","field":"status","kind":"trial","state":"development","label":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC: phase 3, active","href":"/trials/nct04446117/"},{"record":"nct03755791","field":"status","kind":"trial","state":"development","label":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece: phase 3, active","href":"/trials/nct03755791/"},{"record":"nct07011719","field":"status","kind":"trial","state":"development","label":"Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma: phase 3, recruiting","href":"/trials/nct07011719/"},{"record":"registry:cabozantinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 43 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/cabozantinib/#registry"}],"reasons":[{"drugId":"cabozantinib","drugName":"Cabozantinib","drugRoute":"/drugs/cabozantinib/","drugState":"approved","record":"comet-1","kind":"trial","label":"COMET-1: phase 3, negative","href":"/trials/comet-1/","quote":"Median overall survival 11.0 against 9.8 months (hazard ratio 0.90, 95 percent confidence interval 0.76 to 1.06, p=0.213): not met. Bone scan response at 12 weeks 42 against 3 percent and radiographic progression-free survival 5.6 against 2.8 months."},{"drugId":"cabozantinib","drugName":"Cabozantinib","drugRoute":"/drugs/cabozantinib/","drugState":"approved","record":"contact-03","kind":"trial","label":"CONTACT-03: phase 3, negative","href":"/trials/contact-03/","quote":"PFS HR 1.03; OS HR 0.94, negative."}]},{"id":"calderasib","name":"Calderasib","route":"/drugs/calderasib/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"kras","name":"KRAS","href":"/targets/kras/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"calderasib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/calderasib/"},{"record":"nct07190248","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007): phase 3, recruiting","href":"/trials/nct07190248/"},{"record":"nct07209111","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014): phase 2, recruiting","href":"/trials/nct07209111/"},{"record":"nct06997497","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012): phase 3, recruiting","href":"/trials/nct06997497/"},{"record":"nct07286149","field":"status","kind":"trial","state":"development","label":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F): phase 1/2, recruiting","href":"/trials/nct07286149/"},{"record":"nct07554339","field":"status","kind":"trial","state":"development","label":"A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015): phase 3, recruiting","href":"/trials/nct07554339/"},{"record":"nct06345729","field":"status","kind":"trial","state":"development","label":"A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004): phase 3, recruiting","href":"/trials/nct06345729/"},{"record":"nct07252739","field":"status","kind":"trial","state":"development","label":"KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J): phase 2, recruiting","href":"/trials/nct07252739/"},{"record":"nct07431827","field":"status","kind":"trial","state":"development","label":"MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013): phase 3, recruiting","href":"/trials/nct07431827/"},{"record":"registry:calderasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/calderasib/#registry"}],"reasons":[]},{"id":"camizestrant","name":"Camizestrant","route":"/drugs/camizestrant/","status":"approved","modality":"Oral SERD","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"estrogen-receptor","name":"Estrogen receptor (ERα)","href":"/targets/estrogen-receptor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"camizestrant","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/camizestrant/"},{"record":"camizestrant","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2026: HR+/HER2- advanced breast cancer with an emergent ESR1 mutation on AI + CDK4/6, with a CDK4/6 inhibitor (accelerated, 4 Sep 2026)","href":"/drugs/camizestrant/"},{"record":"camizestrant","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2026: ER+/HER2- advanced breast cancer with emergent ESR1 mutation, with a CDK4/6 inhibitor; 20 Jul 2026","href":"/drugs/camizestrant/"},{"record":"camizestrant","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2026","href":"/regulatory/regions/"},{"record":"camizestrant","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2026","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/etcamah"},{"record":"nct04711252","field":"status","kind":"trial","state":"development","label":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease: phase 3, active","href":"/trials/nct04711252/"},{"record":"nct06188520","field":"status","kind":"trial","state":"development","label":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With : phase 1/2, recruiting","href":"/trials/nct06188520/"},{"record":"nct07647328","field":"status","kind":"trial","state":"development","label":"A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct07647328/"},{"record":"nct05774951","field":"status","kind":"trial","state":"development","label":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy: phase 3, recruiting","href":"/trials/nct05774951/"},{"record":"nct04214288","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer: phase 2, active","href":"/trials/nct04214288/"},{"record":"cambria","field":"status","kind":"trial","state":"development","label":"CAMBRIA-1 & CAMBRIA-2: phase 3, active","href":"/trials/cambria/"},{"record":"nct06380751","field":"status","kind":"trial","state":"development","label":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct06380751/"},{"record":"nct04644068","field":"status","kind":"trial","state":"development","label":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies: phase 1/2, active","href":"/trials/nct04644068/"},{"record":"nct07427394","field":"status","kind":"trial","state":"development","label":"Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer: phase 2, recruiting","href":"/trials/nct07427394/"},{"record":"registry:camizestrant","kind":"registry","state":"development","label":"ClinicalTrials.gov: 13 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/camizestrant/#registry"}],"reasons":[]},{"id":"capivasertib","name":"Capivasertib","route":"/drugs/capivasertib/","status":"approved","modality":"Small-molecule AKT inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"akt+pik3ca","name":"AKT x PIK3CA / PI3K-alpha","href":"/targets/akt/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"pi3k-akt-mtor-inhibitor","name":"PI3K, AKT or mTOR inhibitor","href":"/technologies/pi3k-akt-mtor-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"capivasertib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/capivasertib/"},{"record":"capivasertib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2023: HR+/HER2- breast cancer with PIK3CA/AKT1/PTEN alteration, with fulvestrant","href":"/drugs/capivasertib/"},{"record":"capivasertib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2026: PTEN-deficient metastatic prostate cancer with abiraterone","href":"/drugs/capivasertib/"},{"record":"capivasertib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2024: ER+/HER2- mBC with PIK3CA/AKT1/PTEN alteration; 17 Jun 2024","href":"/drugs/capivasertib/"},{"record":"capivasertib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2023","href":"/regulatory/regions/"},{"record":"capivasertib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2024","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/truqap"},{"record":"capivasertib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2024","href":"https://www.gov.uk/government/news/capivasertib-approved-to-treat-patients-with-advanced-breast-cancer"},{"record":"capivasertib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2024","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"capivasertib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2025","href":"https://english.nmpa.gov.cn/"},{"record":"capivasertib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2024","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Truqap"},{"record":"nct06764186","field":"status","kind":"trial","state":"development","label":"A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain: phase 3, active","href":"/trials/nct06764186/"},{"record":"nct03742102","field":"status","kind":"trial","state":"development","label":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer: phase 1/2, active","href":"/trials/nct03742102/"},{"record":"nct04862663","field":"status","kind":"trial","state":"development","label":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292): phase 3, active","href":"/trials/nct04862663/"},{"record":"nct06635447","field":"status","kind":"trial","state":"development","label":"Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients: phase 3, active","href":"/trials/nct06635447/"},{"record":"nct03997123","field":"status","kind":"trial","state":"development","label":"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC: phase 3, active","href":"/trials/nct03997123/"},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"nct05563220","field":"status","kind":"trial","state":"development","label":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer: phase 1/2, active","href":"/trials/nct05563220/"},{"record":"nct07287917","field":"status","kind":"trial","state":"development","label":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct07287917/"},{"record":"nct05348577","field":"status","kind":"trial","state":"development","label":"Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC): phase 3, active","href":"/trials/nct05348577/"},{"record":"registry:capivasertib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 34 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/capivasertib/#registry"}],"reasons":[]},{"id":"capmatinib","name":"Capmatinib","route":"/drugs/capmatinib/","status":"approved","modality":"Small-molecule MET tyrosine kinase inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"met","name":"MET","href":"/targets/met/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"capmatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/capmatinib/"},{"record":"capmatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2020: Metastatic NSCLC with a MET exon 14 skipping mutation (accelerated approval)","href":"/drugs/capmatinib/"},{"record":"capmatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2022","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tabrecta"},{"record":"nct05488314","field":"status","kind":"trial","state":"development","label":"A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer: phase 1/2, active","href":"/trials/nct05488314/"},{"record":"nct03040973","field":"status","kind":"trial","state":"development","label":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone: phase 2, active","href":"/trials/nct03040973/"},{"record":"registry:capmatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/capmatinib/#registry"}],"reasons":[]},{"id":"capmatinib-tepotinib","name":"Capmatinib & tepotinib","route":"/drugs/capmatinib-tepotinib/","status":"approved","modality":"Small-molecule kinase inhibitors (MET)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"met","name":"MET","href":"/targets/met/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"capmatinib-tepotinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/capmatinib-tepotinib/"},{"record":"capmatinib-tepotinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2020: MET exon 14 skipping NSCLC (capmatinib; tepotinib 2021)","href":"/drugs/capmatinib-tepotinib/"},{"record":"capmatinib-tepotinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2022: Tepmetko 2022; Tabrecta 2022","href":"/drugs/capmatinib-tepotinib/"},{"record":"capmatinib-tepotinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2020","href":"/regulatory/regions/"},{"record":"capmatinib-tepotinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2022","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tepmetko"},{"record":"capmatinib-tepotinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2022","href":"https://products.mhra.gov.uk/?search=Tepmetko"},{"record":"capmatinib-tepotinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2020","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"capmatinib-tepotinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"capmatinib-tepotinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2021","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Tabrecta"}],"reasons":[]},{"id":"carfilzomib","name":"Carfilzomib","route":"/drugs/carfilzomib/","status":"approved","modality":"Proteasome inhibitor (irreversible)","state":"approved","confidence":"medium","fields":["target record (drugs field)","modality","mechanism"],"components":{"target":{"id":"proteasome","name":"Proteasome (PSMB5)","href":"/targets/proteasome/","confidence":"high","from":["target record (drugs field)"],"detail":null},"mechanismClass":{"id":"proteasome-inhibitor","name":"Proteasome inhibitor","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"carfilzomib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/carfilzomib/"},{"record":"carfilzomib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2012: Relapsed myeloma (accelerated)","href":"/drugs/carfilzomib/"},{"record":"carfilzomib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2015: With lenalidomide-dexamethasone; with dexamethasone (ENDEAVOR)","href":"/drugs/carfilzomib/"},{"record":"carfilzomib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2012","href":"/regulatory/regions/"},{"record":"carfilzomib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/kyprolis"},{"record":"carfilzomib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2015","href":"https://products.mhra.gov.uk/?search=Kyprolis"},{"record":"carfilzomib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2016","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"carfilzomib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"carfilzomib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2015","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Kyprolis"},{"record":"nct04973605","field":"status","kind":"trial","state":"development","label":"A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat: phase 1/2, recruiting","href":"/trials/nct04973605/"},{"record":"nct07391657","field":"status","kind":"trial","state":"development","label":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela: phase 3, recruiting","href":"/trials/nct07391657/"},{"record":"nct05572515","field":"status","kind":"trial","state":"development","label":"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With: phase 3, active","href":"/trials/nct05572515/"},{"record":"nct05438043","field":"status","kind":"trial","state":"development","label":"A Study of Daratumumab: phase 3, active","href":"/trials/nct05438043/"},{"record":"nct06892522","field":"status","kind":"trial","state":"development","label":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe: phase 1/2, recruiting","href":"/trials/nct06892522/"},{"record":"nct02773030","field":"status","kind":"trial","state":"development","label":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple: phase 1/2, active","href":"/trials/nct02773030/"},{"record":"nct03989414","field":"status","kind":"trial","state":"development","label":"A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre: phase 1/2, active","href":"/trials/nct03989414/"},{"record":"nct05552976","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W: phase 3, active","href":"/trials/nct05552976/"},{"record":"nct07227311","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult: phase 2, recruiting","href":"/trials/nct07227311/"},{"record":"nct05704049","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory: phase 2, active","href":"/trials/nct05704049/"},{"record":"nct06152575","field":"status","kind":"trial","state":"development","label":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other: phase 3, recruiting","href":"/trials/nct06152575/"},{"record":"nct06158841","field":"status","kind":"trial","state":"development","label":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto: phase 3, active","href":"/trials/nct06158841/"},{"record":"nct02899052","field":"status","kind":"trial","state":"development","label":"Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM): phase 2, active","href":"/trials/nct02899052/"},{"record":"registry:carfilzomib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 46 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/carfilzomib/#registry"}],"reasons":[]},{"id":"cediranib","name":"Cediranib","route":"/drugs/cediranib/","status":"phase-2","modality":"Oral VEGFR 1-3 tyrosine kinase inhibitor","state":"development","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"vegf","name":"VEGF / VEGFR","href":"/targets/vegf/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"cediranib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/cediranib/"},{"record":"cediranib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zemfirza","quote":"Zemfirza (AstraZeneca AB): marketing authorisation application for relapsed ovarian cancer withdrawn 19 Sep 2016 before a Commission decision. EMA register: 'Application withdrawn: The application for this medicine has been withdrawn'; checked 2026-09-24"},{"record":"registry:cediranib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 16 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/cediranib/#registry"}],"reasons":[{"drugId":"cediranib","drugName":"Cediranib","drugRoute":"/drugs/cediranib/","drugState":"development","record":"cediranib","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zemfirza","quote":"Zemfirza (AstraZeneca AB): marketing authorisation application for relapsed ovarian cancer withdrawn 19 Sep 2016 before a Commission decision. EMA register: 'Application withdrawn: The application for this medicine has been withdrawn'; checked 2026-09-24"}]},{"id":"celecoxib","name":"Celecoxib","route":"/drugs/celecoxib/","status":"approved","modality":"Oral COX-2 inhibitor","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"cox2","name":"COX-2 (PTGS2)","href":"/targets/cox2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"other-inhibitor","name":"Inhibitor (class not stated)","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"celecoxib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/celecoxib/"},{"record":"celecoxib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1998: Osteoarthritis and rheumatoid arthritis pain (oncology use in metronomic regimens is off-label)","href":"/drugs/celecoxib/"},{"record":"celecoxib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 1999: Reduction of adenomatous colorectal polyps in familial adenomatous polyposis (accelerated approval; indication withdrawn 2011)","href":"/drugs/celecoxib/"},{"record":"celecoxib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn 2008","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/onsenal","quote":"Onsenal: authorised 17 Oct 2003; marketing authorisation withdrawn 28 Nov 2008. EMA register: 'Withdrawn: This medicine's authorisation has been withdrawn'; checked 2026-09-24"},{"record":"celecoxib","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"US 2012-06-08: withdrawal","href":"/drugs/celecoxib/","quote":"Withdrawn: the indication came off the label 12.5 years after its accelerated approval."},{"record":"nct07150949","field":"status","kind":"trial","state":"development","label":"Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC: phase 2, recruiting","href":"/trials/nct07150949/"},{"record":"nct07154316","field":"status","kind":"trial","state":"development","label":"Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer: phase 2, recruiting","href":"/trials/nct07154316/"},{"record":"nct05731726","field":"status","kind":"trial","state":"development","label":"Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer: phase 2, recruiting","href":"/trials/nct05731726/"},{"record":"nct06903858","field":"status","kind":"trial","state":"development","label":"Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer: phase 2, recruiting","href":"/trials/nct06903858/"},{"record":"nct07104266","field":"status","kind":"trial","state":"development","label":"Triple Negative Breast Cancer and Celecoxib. Pilot Study: phase 2, recruiting","href":"/trials/nct07104266/"},{"record":"registry:celecoxib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 14 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/celecoxib/#registry"}],"reasons":[{"drugId":"celecoxib","drugName":"Celecoxib","drugRoute":"/drugs/celecoxib/","drugState":"approved","record":"celecoxib","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2008","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/onsenal","quote":"Onsenal: authorised 17 Oct 2003; marketing authorisation withdrawn 28 Nov 2008. EMA register: 'Withdrawn: This medicine's authorisation has been withdrawn'; checked 2026-09-24"},{"drugId":"celecoxib","drugName":"Celecoxib","drugRoute":"/drugs/celecoxib/","drugState":"approved","record":"celecoxib","kind":"event","label":"US 2012-06-08: withdrawal","href":"/drugs/celecoxib/","quote":"Withdrawn: the indication came off the label 12.5 years after its accelerated approval."}]},{"id":"ceralasertib","name":"Ceralasertib","route":"/drugs/ceralasertib/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"atr","name":"ATR","href":"/targets/atr/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"ddr-inhibitor","name":"DNA damage response inhibitor","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"ceralasertib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/ceralasertib/"},{"record":"nct05450692","field":"status","kind":"trial","state":"development","label":"A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy: phase 3, active","href":"/trials/nct05450692/"},{"record":"nct05061134","field":"status","kind":"trial","state":"development","label":"A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition: phase 2, active","href":"/trials/nct05061134/"},{"record":"nct05941897","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: phase 2, active","href":"/trials/nct05941897/"},{"record":"nct03334617","field":"status","kind":"trial","state":"development","label":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy: phase 2, active","href":"/trials/nct03334617/"},{"record":"phoenix","field":"status","kind":"trial","state":"development","label":"PHOENIX DDR/Anti-PD-L1: phase 2, recruiting","href":"/trials/phoenix/"},{"record":"nct05582538","field":"status","kind":"trial","state":"development","label":"Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel: phase 2, recruiting","href":"/trials/nct05582538/"},{"record":"nct06732401","field":"status","kind":"trial","state":"development","label":"Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer: phase 3, active","href":"/trials/nct06732401/"},{"record":"nct03330847","field":"status","kind":"trial","state":"development","label":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.: phase 2, active","href":"/trials/nct03330847/"},{"record":"registry:ceralasertib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 19 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ceralasertib/#registry"}],"reasons":[]},{"id":"ceritinib","name":"Ceritinib","route":"/drugs/ceritinib/","status":"approved","modality":"Small-molecule ALK TKI (second generation)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"alk","name":"ALK","href":"/targets/alk/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"ceritinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ceritinib/"},{"record":"ceritinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2014: ALK-positive metastatic NSCLC after crizotinib","href":"/drugs/ceritinib/"},{"record":"ceritinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2017: First-line ALK-positive metastatic NSCLC","href":"/drugs/ceritinib/"},{"record":"ceritinib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2015: Conditional May 2015; full approval 2017","href":"/drugs/ceritinib/"},{"record":"ceritinib","field":"approvals[3]","kind":"approval","state":"approved","label":"England (NICE) 2018: Untreated ALK-positive advanced non-small-cell lung cancer","href":"/drugs/ceritinib/"},{"record":"ceritinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2014","href":"/regulatory/regions/"},{"record":"ceritinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia"},{"record":"ceritinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2015","href":"https://products.mhra.gov.uk/?search=Zykadia"},{"record":"ceritinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2016","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"ceritinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2018","href":"https://english.nmpa.gov.cn/"},{"record":"ceritinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Zykadia"},{"record":"nct06813079","field":"status","kind":"trial","state":"development","label":"Using Tumor Models to Determine Treatments: phase 2, recruiting","href":"/trials/nct06813079/"},{"record":"registry:ceritinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ceritinib/#registry"}],"reasons":[]},{"id":"cgt4859","name":"CGT4859","route":"/drugs/cgt4859/","status":"phase-2","modality":"small molecule (structure undisclosed or not yet in PubChem)","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"fgfr2","name":"FGFR2","href":"/targets/fgfr2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"cgt4859","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/cgt4859/"},{"record":"nct06777316","field":"status","kind":"trial","state":"development","label":"A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors: phase 1/2, active","href":"/trials/nct06777316/"},{"record":"registry:cgt4859","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/cgt4859/#registry"}],"reasons":[]},{"id":"chiauranib","name":"Chiauranib","route":"/drugs/chiauranib/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"vegf+kit","name":"VEGF / VEGFR x KIT","href":"/targets/vegf/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"chiauranib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/chiauranib/"},{"record":"nct04921527","field":"status","kind":"trial","state":"development","label":"Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer: phase 3, recruiting","href":"/trials/nct04921527/"},{"record":"registry:chiauranib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/chiauranib/#registry"}],"reasons":[]},{"id":"cinacalcet","name":"Cinacalcet","route":"/drugs/cinacalcet/","status":"established","modality":"Oral small-molecule calcimimetic","state":"approved","confidence":"medium","fields":["modality","mechanism"],"components":{"target":{"id":"casr","name":"CASR","href":"/targets/casr/","confidence":"medium","from":["modality","mechanism"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"cinacalcet","field":"status","kind":"drug","state":"approved","label":"Drug record status: established","href":"/drugs/cinacalcet/"},{"record":"cinacalcet","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2004: Hypercalcaemia in patients with parathyroid carcinoma; secondary hyperparathyroidism on dialysis; primary hyperparathyroidism when surgery is not possible","href":"/drugs/cinacalcet/"},{"record":"cinacalcet","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/mimpara","quote":"Mimpara: authorised 22 Oct 2004; marketing authorisation withdrawn 18 Dec 2025. EMA register: 'Withdrawn: This medicine's authorisation has been withdrawn'; checked 2026-09-24"},{"record":"registry:cinacalcet","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/cinacalcet/#registry"}],"reasons":[{"drugId":"cinacalcet","drugName":"Cinacalcet","drugRoute":"/drugs/cinacalcet/","drugState":"approved","record":"cinacalcet","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/mimpara","quote":"Mimpara: authorised 22 Oct 2004; marketing authorisation withdrawn 18 Dec 2025. EMA register: 'Withdrawn: This medicine's authorisation has been withdrawn'; checked 2026-09-24"}]},{"id":"cobimetinib","name":"Cobimetinib","route":"/drugs/cobimetinib/","status":"approved","modality":"Small-molecule kinase inhibitor (MEK1/2)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"braf","name":"BRAF","href":"/targets/braf/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"allosteric","name":"Allosteric","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"cobimetinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/cobimetinib/"},{"record":"cobimetinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2015: BRAF V600 melanoma with vemurafenib","href":"/drugs/cobimetinib/"},{"record":"cobimetinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2020: With atezolizumab and vemurafenib in BRAF V600 melanoma","href":"/drugs/cobimetinib/"},{"record":"cobimetinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2022: Histiocytic neoplasms","href":"/drugs/cobimetinib/"},{"record":"cobimetinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2015","href":"/regulatory/regions/"},{"record":"cobimetinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic"},{"record":"cobimetinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2015","href":"https://products.mhra.gov.uk/?search=Cotellic"},{"record":"cobimetinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2018","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"cobimetinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2016","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Cotellic"},{"record":"nct04931342","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors: phase 2, active","href":"/trials/nct04931342/"},{"record":"nct04302025","field":"status","kind":"trial","state":"development","label":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC): phase 2, recruiting","href":"/trials/nct04302025/"},{"record":"nct07449754","field":"status","kind":"trial","state":"development","label":"Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma: phase 2, recruiting","href":"/trials/nct07449754/"},{"record":"determine-trial","field":"status","kind":"trial","state":"development","label":"DETERMINE: phase platform, recruiting","href":"/trials/determine-trial/"},{"record":"nct05768178","field":"status","kind":"trial","state":"development","label":"DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.: phase 2/3, recruiting","href":"/trials/nct05768178/"},{"record":"imblaze370","field":"result","kind":"trial","state":"stopped","label":"IMblaze370: phase 3, negative","href":"/trials/imblaze370/","quote":"Median overall survival 8.87 months with atezolizumab and cobimetinib against 8.51 months with regorafenib (hazard ratio 1.00)."},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"nct04941287","field":"status","kind":"trial","state":"development","label":"Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer: phase 2, active","href":"/trials/nct04941287/"},{"record":"nct06813079","field":"status","kind":"trial","state":"development","label":"Using Tumor Models to Determine Treatments: phase 2, recruiting","href":"/trials/nct06813079/"},{"record":"registry:cobimetinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 26 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/cobimetinib/#registry"}],"reasons":[{"drugId":"cobimetinib","drugName":"Cobimetinib","drugRoute":"/drugs/cobimetinib/","drugState":"approved","record":"imblaze370","kind":"trial","label":"IMblaze370: phase 3, negative","href":"/trials/imblaze370/","quote":"Median overall survival 8.87 months with atezolizumab and cobimetinib against 8.51 months with regorafenib (hazard ratio 1.00)."}]},{"id":"copanlisib","name":"Copanlisib","route":"/drugs/copanlisib/","status":"withdrawn","modality":"Intravenous pan-class I PI3K inhibitor (α/δ predominant)","state":"stopped","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"pik3ca","name":"PIK3CA / PI3K-alpha","href":"/targets/pik3ca/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"copanlisib","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/copanlisib/","quote":"Copanlisib is an intravenous PI3K inhibitor for relapsed follicular lymphoma, approved in 2017 and withdrawn in 2023 when its confirmatory trial failed."},{"record":"copanlisib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2017: Relapsed follicular lymphoma after ≥2 therapies","href":"/drugs/copanlisib/"},{"record":"copanlisib","field":"regional.US","kind":"regional","state":"stopped","label":"FDA (US): withdrawn 2023","href":"/regulatory/regions/","quote":"Aliqopa accelerated approval Sep 2017; withdrawn by Bayer Nov 2023 after CHRONOS-4"},{"record":"copanlisib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/aliqopa","quote":"Marketing authorisation application withdrawn before a CHMP opinion"},{"record":"copanlisib","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"US 2024-03-18: withdrawal","href":"/drugs/copanlisib/","quote":"Withdrawn: the indication came off the label 6.5 years after its accelerated approval."},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"registry:copanlisib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 11 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/copanlisib/#registry"}],"reasons":[{"drugId":"copanlisib","drugName":"Copanlisib","drugRoute":"/drugs/copanlisib/","drugState":"stopped","record":"copanlisib","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/copanlisib/","quote":"Copanlisib is an intravenous PI3K inhibitor for relapsed follicular lymphoma, approved in 2017 and withdrawn in 2023 when its confirmatory trial failed."},{"drugId":"copanlisib","drugName":"Copanlisib","drugRoute":"/drugs/copanlisib/","drugState":"stopped","record":"copanlisib","kind":"regional","label":"FDA (US): withdrawn 2023","href":"/regulatory/regions/","quote":"Aliqopa accelerated approval Sep 2017; withdrawn by Bayer Nov 2023 after CHRONOS-4"},{"drugId":"copanlisib","drugName":"Copanlisib","drugRoute":"/drugs/copanlisib/","drugState":"stopped","record":"copanlisib","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/aliqopa","quote":"Marketing authorisation application withdrawn before a CHMP opinion"},{"drugId":"copanlisib","drugName":"Copanlisib","drugRoute":"/drugs/copanlisib/","drugState":"stopped","record":"copanlisib","kind":"event","label":"US 2024-03-18: withdrawal","href":"/drugs/copanlisib/","quote":"Withdrawn: the indication came off the label 6.5 years after its accelerated approval."}]},{"id":"crizotinib","name":"Crizotinib","route":"/drugs/crizotinib/","status":"approved","modality":"Small-molecule ALK/ROS1/MET TKI (first generation)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"alk+ros1","name":"ALK x ROS1","href":"/targets/alk/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"crizotinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/crizotinib/"},{"record":"crizotinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2011: ALK-positive metastatic NSCLC","href":"/drugs/crizotinib/"},{"record":"crizotinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2016: ROS1-positive metastatic NSCLC","href":"/drugs/crizotinib/"},{"record":"crizotinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2021: Relapsed ALK-positive ALCL in patients 1-21 years","href":"/drugs/crizotinib/"},{"record":"crizotinib","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2022: ALK-positive inflammatory myofibroblastic tumour","href":"/drugs/crizotinib/"},{"record":"crizotinib","field":"approvals[4]","kind":"approval","state":"approved","label":"EU 2012: Conditional Oct 2012; full approval 2015","href":"/drugs/crizotinib/"},{"record":"crizotinib","field":"approvals[5]","kind":"approval","state":"approved","label":"England (NICE) 2024: ROS1-positive advanced non-small-cell lung cancer in patients who have not had a ROS1 inhibitor","href":"/drugs/crizotinib/"},{"record":"crizotinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2011","href":"/regulatory/regions/"},{"record":"crizotinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2012","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori"},{"record":"crizotinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2012","href":"https://products.mhra.gov.uk/?search=Xalkori"},{"record":"crizotinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2012","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"crizotinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2013","href":"https://english.nmpa.gov.cn/"},{"record":"crizotinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Xalkori"},{"record":"nct06564324","field":"status","kind":"trial","state":"development","label":"A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients: phase 3, recruiting","href":"/trials/nct06564324/"},{"record":"nct06140836","field":"status","kind":"trial","state":"development","label":"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3): phase 3, active","href":"/trials/nct06140836/"},{"record":"nct04603807","field":"status","kind":"trial","state":"development","label":"A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases: phase 3, active","href":"/trials/nct04603807/"},{"record":"alchemist","field":"status","kind":"trial","state":"development","label":"ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials): phase platform, active","href":"/trials/alchemist/"},{"record":"nct05987332","field":"status","kind":"trial","state":"development","label":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma: phase 2/3, active","href":"/trials/nct05987332/"},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"nct03947385","field":"status","kind":"trial","state":"development","label":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions: phase 1/2, recruiting","href":"/trials/nct03947385/"},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"registry:crizotinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 31 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/crizotinib/#registry"}],"reasons":[]},{"id":"d-0502","name":"D-0502","route":"/drugs/d-0502/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["modality","mechanism"],"components":{"target":{"id":"estrogen-receptor+her2","name":"Estrogen receptor x HER2","href":"/targets/estrogen-receptor/","confidence":"medium","from":["modality","mechanism"],"detail":"dual-target"},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"d-0502","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/d-0502/"},{"record":"nct06954961","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer: phase 3, recruiting","href":"/trials/nct06954961/"},{"record":"registry:d-0502","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/d-0502/#registry"}],"reasons":[]},{"id":"dabrafenib","name":"Dabrafenib","route":"/drugs/dabrafenib/","status":"approved","modality":"Small-molecule BRAF kinase inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"braf","name":"BRAF","href":"/targets/braf/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"dabrafenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/dabrafenib/"},{"record":"dabrafenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2013: BRAF V600E unresectable or metastatic melanoma (single agent)","href":"/drugs/dabrafenib/"},{"record":"dabrafenib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2014: With trametinib: BRAF V600E/K metastatic melanoma; later adjuvant melanoma, BRAF V600E NSCLC, anaplastic thyroid cancer, tumour-agnostic solid tumours and paediatric low-grade glioma","href":"/drugs/dabrafenib/"},{"record":"dabrafenib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2013: BRAF V600 melanoma; later NSCLC and adjuvant melanoma with trametinib","href":"/drugs/dabrafenib/"},{"record":"dabrafenib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2013","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar"},{"record":"dabrafenib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2019","href":"https://english.nmpa.gov.cn/"},{"record":"nct05585320","field":"status","kind":"trial","state":"development","label":"A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors: phase 1/2, active","href":"/trials/nct05585320/"},{"record":"nct07506109","field":"status","kind":"trial","state":"development","label":"A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colo: phase 2, recruiting","href":"/trials/nct07506109/"},{"record":"nct07440290","field":"status","kind":"trial","state":"development","label":"DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positi: phase 2/3, recruiting","href":"/trials/nct07440290/"},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"nct04940052","field":"status","kind":"trial","state":"development","label":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refracto: phase 3, active","href":"/trials/nct04940052/"},{"record":"registry:dabrafenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 39 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/dabrafenib/#registry"}],"reasons":[]},{"id":"dabrafenib-trametinib","name":"Dabrafenib + trametinib","route":"/drugs/dabrafenib-trametinib/","status":"approved","modality":"Small-molecule kinase inhibitors (BRAF + MEK)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"braf","name":"BRAF","href":"/targets/braf/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"allosteric","name":"Allosteric","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"dabrafenib-trametinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/dabrafenib-trametinib/"},{"record":"dabrafenib-trametinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2014: BRAF V600E/K unresectable or metastatic melanoma, combination (accelerated; each drug alone approved 2013)","href":"/drugs/dabrafenib-trametinib/"},{"record":"dabrafenib-trametinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2017: BRAF V600E metastatic NSCLC","href":"/drugs/dabrafenib-trametinib/"},{"record":"dabrafenib-trametinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2022: BRAF V600E solid tumours, tumour-agnostic (age ≥6)","href":"/drugs/dabrafenib-trametinib/"},{"record":"dabrafenib-trametinib","field":"approvals[3]","kind":"approval","state":"approved","label":"England (NICE) 2023: BRAF V600 mutation-positive advanced non-small-cell lung cancer, first line only","href":"/drugs/dabrafenib-trametinib/"},{"record":"dabrafenib-trametinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2014","href":"/regulatory/regions/"},{"record":"dabrafenib-trametinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2013","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar"},{"record":"dabrafenib-trametinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2013","href":"https://products.mhra.gov.uk/?search=Tafinlar%20%2B%20Mekinist"},{"record":"dabrafenib-trametinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2016","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"dabrafenib-trametinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2019","href":"https://english.nmpa.gov.cn/"},{"record":"dabrafenib-trametinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2013","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Tafinlar%20%2B%20Mekinist"},{"record":"registry:dabrafenib-trametinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 39 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/dabrafenib-trametinib/#registry"}],"reasons":[]},{"id":"dacomitinib","name":"Dacomitinib","route":"/drugs/dacomitinib/","status":"approved","modality":"Small-molecule pan-ErbB TKI (second generation, irreversible)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"egfr","name":"EGFR","href":"/targets/egfr/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"dacomitinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/dacomitinib/"},{"record":"dacomitinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: First-line metastatic NSCLC with EGFR exon 19 del or L858R","href":"/drugs/dacomitinib/"},{"record":"dacomitinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2019: Same","href":"/drugs/dacomitinib/"},{"record":"dacomitinib","field":"approvals[2]","kind":"approval","state":"approved","label":"England (NICE) 2019: Untreated locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer","href":"/drugs/dacomitinib/"},{"record":"dacomitinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"dacomitinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2019","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/vizimpro"},{"record":"dacomitinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2019","href":"https://products.mhra.gov.uk/?search=Vizimpro"},{"record":"dacomitinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2019","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"dacomitinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2019","href":"https://english.nmpa.gov.cn/"},{"record":"dacomitinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Vizimpro"},{"record":"nct06486142","field":"status","kind":"trial","state":"development","label":"EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study: phase 3, recruiting","href":"/trials/nct06486142/"},{"record":"registry:dacomitinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/dacomitinib/#registry"}],"reasons":[]},{"id":"dalpiciclib","name":"Dalpiciclib","route":"/drugs/dalpiciclib/","status":"approved","modality":"Small-molecule CDK4/6 inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"cdk4-6","name":"CDK4/6","href":"/targets/cdk4-6/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"cdk-inhibitor","name":"CDK inhibitor","href":"/technologies/cdk46-inhibitor/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"dalpiciclib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/dalpiciclib/"},{"record":"dalpiciclib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2021: HR-positive, HER2-negative advanced breast cancer with fulvestrant after endocrine therapy (DAWNA-1)","href":"/drugs/dalpiciclib/"},{"record":"dalpiciclib","field":"approvals[1]","kind":"approval","state":"approved","label":"China 2023: First-line HR-positive, HER2-negative advanced breast cancer with an aromatase inhibitor (DAWNA-2)","href":"/drugs/dalpiciclib/"},{"record":"dalpiciclib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"nct06208410","field":"status","kind":"trial","state":"development","label":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06208410/"},{"record":"nct06167694","field":"status","kind":"trial","state":"development","label":"Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer: phase 1/2, recruiting","href":"/trials/nct06167694/"},{"record":"nct05463601","field":"status","kind":"trial","state":"development","label":"Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer: phase 2, active","href":"/trials/nct05463601/"},{"record":"nct04842617","field":"status","kind":"trial","state":"development","label":"Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Ne: phase 3, active","href":"/trials/nct04842617/"},{"record":"registry:dalpiciclib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 54 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/dalpiciclib/#registry"}],"reasons":[]},{"id":"daraxonrasib","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","status":"approved","modality":"Small-molecule pan-RAS(ON) inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"kras","name":"KRAS","href":"/targets/kras/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"daraxonrasib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/daraxonrasib/"},{"record":"daraxonrasib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2026: Metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, or in adults who are not candidates for multiagent systemic therapy","href":"/drugs/daraxonrasib/"},{"record":"daraxonrasib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2026","href":"https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026"},{"record":"nct07492680","field":"status","kind":"trial","state":"development","label":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5): phase 2, recruiting","href":"/trials/nct07492680/"},{"record":"nct07793253","field":"status","kind":"trial","state":"development","label":"Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer: phase 2, planned","href":"/trials/nct07793253/"},{"record":"nct06881784","field":"status","kind":"trial","state":"development","label":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301): phase 3, recruiting","href":"/trials/nct06881784/"},{"record":"nct07252232","field":"status","kind":"trial","state":"development","label":"Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC): phase 3, recruiting","href":"/trials/nct07252232/"},{"record":"nct07491445","field":"status","kind":"trial","state":"development","label":"Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma: phase 3, recruiting","href":"/trials/nct07491445/"},{"record":"nct06128551","field":"status","kind":"trial","state":"development","label":"Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06128551/"},{"record":"nct07397338","field":"status","kind":"trial","state":"development","label":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct07397338/"},{"record":"nct06162221","field":"status","kind":"trial","state":"development","label":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC: phase 1/2, recruiting","href":"/trials/nct06162221/"},{"record":"nct06445062","field":"status","kind":"trial","state":"development","label":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06445062/"},{"record":"nct05379985","field":"status","kind":"trial","state":"development","label":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS: phase 1/2, recruiting","href":"/trials/nct05379985/"},{"record":"nct06040541","field":"status","kind":"trial","state":"development","label":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors: phase 1, recruiting","href":"/trials/nct06040541/"},{"record":"nct07805954","field":"status","kind":"trial","state":"development","label":"Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut: phase 3, recruiting","href":"/trials/nct07805954/"},{"record":"nct06922591","field":"status","kind":"trial","state":"development","label":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients: phase 1/2, recruiting","href":"/trials/nct06922591/"},{"record":"registry:daraxonrasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 10 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/daraxonrasib/#registry"}],"reasons":[]},{"id":"darolutamide","name":"Darolutamide","route":"/drugs/darolutamide/","status":"approved","modality":"Small-molecule AR antagonist","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"androgen-receptor","name":"Androgen receptor","href":"/targets/androgen-receptor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"receptor-agonist","name":"Receptor agonist","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"darolutamide","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/darolutamide/"},{"record":"darolutamide","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2019: Non-metastatic CRPC","href":"/drugs/darolutamide/"},{"record":"darolutamide","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2022: mHSPC with docetaxel (ARASENS)","href":"/drugs/darolutamide/"},{"record":"darolutamide","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2025: mHSPC with ADT alone (ARANOTE)","href":"/drugs/darolutamide/"},{"record":"darolutamide","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2019","href":"/regulatory/regions/"},{"record":"darolutamide","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2020","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/nubeqa"},{"record":"darolutamide","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2020","href":"https://products.mhra.gov.uk/?search=Nubeqa"},{"record":"darolutamide","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2020","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"darolutamide","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"darolutamide","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2020","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Nubeqa"},{"record":"nct06785636","field":"status","kind":"trial","state":"development","label":"A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC: phase 1/2, recruiting","href":"/trials/nct06785636/"},{"record":"nct06568094","field":"status","kind":"trial","state":"development","label":"A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct06568094/"},{"record":"nct05794906","field":"status","kind":"trial","state":"development","label":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer: phase 3, active","href":"/trials/nct05794906/"},{"record":"nct07450599","field":"status","kind":"trial","state":"development","label":"A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have Hi: phase 2, recruiting","href":"/trials/nct07450599/"},{"record":"nct07611110","field":"status","kind":"trial","state":"development","label":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01): phase 3, recruiting","href":"/trials/nct07611110/"},{"record":"nct06190899","field":"status","kind":"trial","state":"development","label":"Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct06190899/"},{"record":"nct07016399","field":"status","kind":"trial","state":"development","label":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC: phase 2, recruiting","href":"/trials/nct07016399/"},{"record":"nct05367440","field":"status","kind":"trial","state":"development","label":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer: phase 1/2, active","href":"/trials/nct05367440/"},{"record":"nct04464226","field":"status","kind":"trial","state":"development","label":"Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer: phase 3, active","href":"/trials/nct04464226/"},{"record":"nct07190300","field":"status","kind":"trial","state":"development","label":"TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in : phase 1/2, recruiting","href":"/trials/nct07190300/"},{"record":"registry:darolutamide","kind":"registry","state":"development","label":"ClinicalTrials.gov: 70 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/darolutamide/#registry"}],"reasons":[]},{"id":"darovasertib","name":"Darovasertib","route":"/drugs/darovasertib/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["target record (drugs field)","modality","mechanism"],"components":{"target":{"id":"gna11+gnaq","name":"GNA11 x GNAQ","href":"/targets/gna11/","confidence":"high","from":["target record (drugs field)"],"detail":"dual-target"},"mechanismClass":{"id":"other-inhibitor","name":"Inhibitor (class not stated)","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"darovasertib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/darovasertib/"},{"record":"nct05907954","field":"status","kind":"trial","state":"development","label":"(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma: phase 2, active","href":"/trials/nct05907954/"},{"record":"nct05987332","field":"status","kind":"trial","state":"development","label":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma: phase 2/3, active","href":"/trials/nct05987332/"},{"record":"nct07015190","field":"status","kind":"trial","state":"development","label":"Neoadjuvant Darovasertib in Primary Uveal Melanoma: phase 3, recruiting","href":"/trials/nct07015190/"},{"record":"nct07804186","field":"status","kind":"trial","state":"development","label":"Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma: phase 3, recruiting","href":"/trials/nct07804186/"},{"record":"nct03947385","field":"status","kind":"trial","state":"development","label":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions: phase 1/2, recruiting","href":"/trials/nct03947385/"},{"record":"registry:darovasertib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/darovasertib/#registry"}],"reasons":[]},{"id":"dasatinib","name":"Dasatinib","route":"/drugs/dasatinib/","status":"approved","modality":"Small-molecule kinase inhibitor (BCR::ABL1, SRC)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"bcr-abl+ddr2","name":"BCR::ABL1 x DDR2 receptor kinase","href":"/targets/bcr-abl/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"dasatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/dasatinib/"},{"record":"dasatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2006: CML and Ph+ ALL resistant or intolerant to imatinib","href":"/drugs/dasatinib/"},{"record":"dasatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2018: Paediatric Ph+ ALL with chemotherapy","href":"/drugs/dasatinib/"},{"record":"dasatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2006","href":"/regulatory/regions/"},{"record":"dasatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2006","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/sprycel"},{"record":"dasatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2006","href":"https://products.mhra.gov.uk/?search=Sprycel"},{"record":"dasatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2009","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"dasatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2011","href":"https://english.nmpa.gov.cn/"},{"record":"dasatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2007","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Sprycel"},{"record":"nct04971226","field":"status","kind":"trial","state":"development","label":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP: phase 3, active","href":"/trials/nct04971226/"},{"record":"ready-dasatinib","field":"result","kind":"trial","state":"stopped","label":"READY: phase 3, negative","href":"/trials/ready-dasatinib/","quote":"Median overall survival 21.5 against 21.2 months (stratified hazard ratio 0.99, 95.5 percent confidence interval 0.87 to 1.13, p=0.90): no benefit."},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"registry:dasatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 25 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/dasatinib/#registry"}],"reasons":[{"drugId":"dasatinib","drugName":"Dasatinib","drugRoute":"/drugs/dasatinib/","drugState":"approved","record":"ready-dasatinib","kind":"trial","label":"READY: phase 3, negative","href":"/trials/ready-dasatinib/","quote":"Median overall survival 21.5 against 21.2 months (stratified hazard ratio 0.99, 95.5 percent confidence interval 0.87 to 1.13, p=0.90): no benefit."}]},{"id":"divarasib","name":"Divarasib","route":"/drugs/divarasib/","status":"phase-3","modality":"Small-molecule inhibitor (KRAS G12C)","state":"development","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"kras","name":"KRAS","href":"/targets/kras/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"divarasib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/divarasib/"},{"record":"nct06793215","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip: phase 3, recruiting","href":"/trials/nct06793215/"},{"record":"nct05789082","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Par: phase 1/2, recruiting","href":"/trials/nct05789082/"},{"record":"nct07541170","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese: phase 3, recruiting","href":"/trials/nct07541170/"},{"record":"registry:divarasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/divarasib/#registry"}],"reasons":[]},{"id":"donafenib","name":"Donafenib","route":"/drugs/donafenib/","status":"approved","modality":"Small-molecule multi-kinase inhibitor (deuterated sorafenib)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"vegf+braf","name":"VEGF / VEGFR x BRAF","href":"/targets/vegf/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"donafenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/donafenib/"},{"record":"donafenib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2021: First-line unresectable hepatocellular carcinoma (ZGDH3)","href":"/drugs/donafenib/"},{"record":"donafenib","field":"approvals[1]","kind":"approval","state":"approved","label":"China 2022: Radioiodine-refractory differentiated thyroid cancer","href":"/drugs/donafenib/"},{"record":"donafenib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"registry:donafenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 20 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/donafenib/#registry"}],"reasons":[]},{"id":"dordaviprone","name":"Dordaviprone","route":"/drugs/dordaviprone/","status":"approved","modality":"Small-molecule imipridone (ClpP agonist / DRD2 antagonist)","state":"approved","confidence":"medium","fields":["target record (drugs field)","modality","mechanism"],"components":{"target":{"id":"drd2+h3-3a","name":"Dopamine D2 receptor x Histone H3.3","href":"/targets/drd2/","confidence":"high","from":["target record (drugs field)"],"detail":"dual-target"},"mechanismClass":{"id":"receptor-agonist","name":"Receptor agonist","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"dordaviprone","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/dordaviprone/"},{"record":"dordaviprone","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2025: Recurrent H3 K27M-mutant diffuse midline glioma, age ≥1 (accelerated)","href":"/drugs/dordaviprone/"},{"record":"dordaviprone","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2025","href":"/regulatory/regions/"},{"record":"action-dmg","field":"status","kind":"trial","state":"development","label":"ACTION: phase 3, recruiting","href":"/trials/action-dmg/"},{"record":"registry:dordaviprone","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/dordaviprone/#registry"}],"reasons":[]},{"id":"dronabinol","name":"Dronabinol","route":"/drugs/dronabinol/","status":"established","modality":"Oral small-molecule synthetic cannabinoid","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"cnr1","name":"Cannabinoid receptor 1","href":"/targets/cnr1/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"dronabinol","field":"status","kind":"drug","state":"approved","label":"Drug record status: established","href":"/drugs/dronabinol/"},{"record":"dronabinol","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1985: Nausea and vomiting from cancer chemotherapy in patients who have failed conventional antiemetics","href":"/drugs/dronabinol/"},{"record":"nct06731894","field":"status","kind":"trial","state":"development","label":"Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors: phase 2, recruiting","href":"/trials/nct06731894/"},{"record":"registry:dronabinol","kind":"registry","state":"development","label":"ClinicalTrials.gov: 24 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/dronabinol/#registry"}],"reasons":[]},{"id":"duvelisib","name":"Duvelisib","route":"/drugs/duvelisib/","status":"approved","modality":"Small-molecule PI3Kδ/γ inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"pik3ca","name":"PIK3CA / PI3K-alpha","href":"/targets/pik3ca/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"duvelisib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/duvelisib/"},{"record":"duvelisib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: Relapsed/refractory CLL/SLL after ≥2 prior therapies; FL (withdrawn 2021)","href":"/drugs/duvelisib/"},{"record":"duvelisib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2021: CLL after ≥2 therapies; FL after ≥2 therapies","href":"/drugs/duvelisib/"},{"record":"duvelisib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"duvelisib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn 2026","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra","quote":"Authorised May 2021; marketing authorisation withdrawn at Secura Bio's request 16 Feb 2026 (commercial reasons)"},{"record":"duvelisib","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"US 2021-12-17: withdrawal","href":"/drugs/duvelisib/","quote":"Withdrawn: the indication came off the label 3.2 years after its accelerated approval."},{"record":"nct06522737","field":"status","kind":"trial","state":"development","label":"A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype: phase 3, recruiting","href":"/trials/nct06522737/"},{"record":"registry:duvelisib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 10 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/duvelisib/#registry"}],"reasons":[{"drugId":"duvelisib","drugName":"Duvelisib","drugRoute":"/drugs/duvelisib/","drugState":"approved","record":"duvelisib","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2026","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra","quote":"Authorised May 2021; marketing authorisation withdrawn at Secura Bio's request 16 Feb 2026 (commercial reasons)"},{"drugId":"duvelisib","drugName":"Duvelisib","drugRoute":"/drugs/duvelisib/","drugState":"approved","record":"duvelisib","kind":"event","label":"US 2021-12-17: withdrawal","href":"/drugs/duvelisib/","quote":"Withdrawn: the indication came off the label 3.2 years after its accelerated approval."}]},{"id":"eflornithine","name":"Eflornithine (DFMO)","route":"/drugs/eflornithine/","status":"approved","modality":"Small-molecule ornithine decarboxylase inhibitor","state":"approved","confidence":"medium","fields":["modality","mechanism"],"components":{"target":{"id":"mycn","name":"MYCN (N-myc)","href":"/targets/mycn/","confidence":"medium","from":["modality","mechanism"],"detail":null},"mechanismClass":{"id":"other-inhibitor","name":"Inhibitor (class not stated)","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"eflornithine","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/eflornithine/"},{"record":"eflornithine","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2023: Maintenance to reduce relapse risk in high-risk neuroblastoma after ≥PR to prior therapy including anti-GD2","href":"/drugs/eflornithine/"},{"record":"eflornithine","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2023","href":"/regulatory/regions/"},{"record":"nct01349881","field":"status","kind":"trial","state":"development","label":"S0820, Adenoma and Second Primary Prevention Trial: phase 3, active","href":"/trials/nct01349881/"},{"record":"nct07287917","field":"status","kind":"trial","state":"development","label":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct07287917/"},{"record":"registry:eflornithine","kind":"registry","state":"development","label":"ClinicalTrials.gov: 13 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/eflornithine/#registry"}],"reasons":[]},{"id":"eik1005","name":"EIK1005","route":"/drugs/eik1005/","status":"phase-2","modality":"Small-molecule inhibitor","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"wrn","name":"WRN helicase (MSI-high cancers)","href":"/targets/wrn/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"other-inhibitor","name":"Inhibitor (class not stated)","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"eik1005","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/eik1005/"},{"record":"nct07262619","field":"status","kind":"trial","state":"development","label":"EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Partic: phase 1/2, recruiting","href":"/trials/nct07262619/"},{"record":"registry:eik1005","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/eik1005/#registry"}],"reasons":[]},{"id":"elacestrant","name":"Elacestrant","route":"/drugs/elacestrant/","status":"approved","modality":"Oral SERD","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"estrogen-receptor","name":"Estrogen receptor (ERα)","href":"/targets/estrogen-receptor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"elacestrant","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/elacestrant/"},{"record":"elacestrant","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2023: ESR1-mutant ER+/HER2- advanced breast cancer after ≥1 endocrine therapy","href":"/drugs/elacestrant/"},{"record":"elacestrant","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2023","href":"/regulatory/regions/"},{"record":"elacestrant","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2023","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/orserdu"},{"record":"elacestrant","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2024","href":"https://products.mhra.gov.uk/?search=Orserdu"},{"record":"elacestrant","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2024","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Orserdu"},{"record":"nct07766018","field":"status","kind":"trial","state":"development","label":"A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer: phase 2, recruiting","href":"/trials/nct07766018/"},{"record":"nct06492616","field":"status","kind":"trial","state":"development","label":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence: phase 3, recruiting","href":"/trials/nct06492616/"},{"record":"nct05596409","field":"status","kind":"trial","state":"development","label":"ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study: phase 2, active","href":"/trials/nct05596409/"},{"record":"nct05563220","field":"status","kind":"trial","state":"development","label":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer: phase 1/2, active","href":"/trials/nct05563220/"},{"record":"nct05573126","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer: phase 1/2, recruiting","href":"/trials/nct05573126/"},{"record":"nct05386108","field":"status","kind":"trial","state":"development","label":"Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer: phase 1/2, recruiting","href":"/trials/nct05386108/"},{"record":"registry:elacestrant","kind":"registry","state":"development","label":"ClinicalTrials.gov: 26 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/elacestrant/#registry"}],"reasons":[]},{"id":"elironrasib","name":"Elironrasib","route":"/drugs/elironrasib/","status":"phase-2","modality":"Small-molecule RAS(ON) G12C-selective inhibitor","state":"development","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"kras","name":"KRAS","href":"/targets/kras/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"elironrasib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/elironrasib/"},{"record":"nct06128551","field":"status","kind":"trial","state":"development","label":"Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06128551/"},{"record":"nct07397338","field":"status","kind":"trial","state":"development","label":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct07397338/"},{"record":"nct06162221","field":"status","kind":"trial","state":"development","label":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC: phase 1/2, recruiting","href":"/trials/nct06162221/"},{"record":"registry:elironrasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/elironrasib/#registry"}],"reasons":[]},{"id":"elraglusib","name":"Elraglusib","route":"/drugs/elraglusib/","status":"phase-2","modality":"Small-molecule GSK-3 beta inhibitor","state":"development","confidence":"medium","fields":["modality","mechanism","technologies"],"components":{"target":{"id":"gsk3b","name":"GSK3B","href":"/targets/gsk3b/","confidence":"medium","from":["modality","mechanism"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"elraglusib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/elraglusib/"},{"record":"registry:elraglusib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/elraglusib/#registry"}],"reasons":[]},{"id":"eltrombopag","name":"Eltrombopag","route":"/drugs/eltrombopag/","status":"established","modality":"Oral thrombopoietin receptor agonist","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"mpl","name":"MPL (thrombopoietin receptor)","href":"/targets/mpl/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"receptor-agonist","name":"Receptor agonist","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"eltrombopag","field":"status","kind":"drug","state":"approved","label":"Drug record status: established","href":"/drugs/eltrombopag/"},{"record":"eltrombopag","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2008: Chronic immune thrombocytopenia with insufficient response to corticosteroids, immunoglobulins or splenectomy","href":"/drugs/eltrombopag/"},{"record":"nct03603795","field":"status","kind":"trial","state":"development","label":"Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy: phase 2, active","href":"/trials/nct03603795/"},{"record":"registry:eltrombopag","kind":"registry","state":"development","label":"ClinicalTrials.gov: 18 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/eltrombopag/#registry"}],"reasons":[]},{"id":"enasidenib","name":"Enasidenib","route":"/drugs/enasidenib/","status":"approved","modality":"Small-molecule IDH2 inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"idh","name":"IDH1 / IDH2","href":"/targets/idh/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"idh-inhibitor","name":"IDH inhibitor","href":"/technologies/idh-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"allosteric","name":"Allosteric","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"enasidenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/enasidenib/"},{"record":"enasidenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2017: Relapsed/refractory IDH2-mutated AML","href":"/drugs/enasidenib/"},{"record":"enasidenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2017","href":"/regulatory/regions/"},{"record":"enasidenib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn 2021","href":"/regulatory/regions/","quote":"MAA withdrawn 2021"},{"record":"enasidenib","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"EU 2019-12-01: withdrawal","href":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_en.pdf","quote":"Marketing application withdrawn after EMA objections on efficacy"},{"record":"beat-aml-master-trial","field":"status","kind":"trial","state":"development","label":"Beat AML Master Trial: phase platform, recruiting","href":"/trials/beat-aml-master-trial/"},{"record":"registry:enasidenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 18 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/enasidenib/#registry"}],"reasons":[{"drugId":"enasidenib","drugName":"Enasidenib","drugRoute":"/drugs/enasidenib/","drugState":"approved","record":"enasidenib","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2021","href":"/regulatory/regions/","quote":"MAA withdrawn 2021"},{"drugId":"enasidenib","drugName":"Enasidenib","drugRoute":"/drugs/enasidenib/","drugState":"approved","record":"enasidenib","kind":"event","label":"EU 2019-12-01: withdrawal","href":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_en.pdf","quote":"Marketing application withdrawn after EMA objections on efficacy"}]},{"id":"encorafenib","name":"Encorafenib","route":"/drugs/encorafenib/","status":"approved","modality":"Small-molecule kinase inhibitor (BRAF)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"braf+egfr","name":"BRAF x EGFR","href":"/targets/braf/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"encorafenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/encorafenib/"},{"record":"encorafenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: BRAF V600 melanoma with binimetinib","href":"/drugs/encorafenib/"},{"record":"encorafenib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2020: BRAF V600E mCRC with cetuximab, previously treated","href":"/drugs/encorafenib/"},{"record":"encorafenib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2026: First-line BRAF V600E mCRC with cetuximab and chemotherapy","href":"/drugs/encorafenib/"},{"record":"encorafenib","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2024: Metastatic colorectal cancer with a BRAF V600E mutation, with cetuximab and mFOLFOX6, previously untreated","href":"/drugs/encorafenib/"},{"record":"encorafenib","field":"approvals[4]","kind":"approval","state":"approved","label":"US 2026: Metastatic colorectal cancer with a BRAF V600E mutation","href":"/drugs/encorafenib/"},{"record":"encorafenib","field":"approvals[5]","kind":"approval","state":"approved","label":"EU 2018: BRAF V600E-mutant metastatic colorectal cancer, with cetuximab","href":"/drugs/encorafenib/"},{"record":"encorafenib","field":"approvals[6]","kind":"approval","state":"approved","label":"England (NICE) 2021: BRAF V600E mutation-positive metastatic colorectal cancer after previous systemic treatment, with cetuximab","href":"/drugs/encorafenib/"},{"record":"encorafenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"encorafenib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2018","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi"},{"record":"encorafenib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2018","href":"https://products.mhra.gov.uk/?search=Braftovi"},{"record":"encorafenib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2019","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"encorafenib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"encorafenib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2019","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Braftovi"},{"record":"nct04657991","field":"status","kind":"trial","state":"development","label":"A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma: phase 3, active","href":"/trials/nct04657991/"},{"record":"nct05217446","field":"status","kind":"trial","state":"development","label":"A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic: phase 2, active","href":"/trials/nct05217446/"},{"record":"nct07178717","field":"status","kind":"trial","state":"development","label":"A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy W: phase 2, planned","href":"/trials/nct07178717/"},{"record":"nct05270044","field":"status","kind":"trial","state":"development","label":"Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.: phase 3, active","href":"/trials/nct05270044/"},{"record":"nct06411600","field":"status","kind":"trial","state":"development","label":"Combination Therapy for BRAF-V600E Metastatic CRCm: phase 2, recruiting","href":"/trials/nct06411600/"},{"record":"nct03803553","field":"status","kind":"trial","state":"development","label":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer: phase 3, active","href":"/trials/nct03803553/"},{"record":"nct05195632","field":"status","kind":"trial","state":"development","label":"Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung: phase 2, active","href":"/trials/nct05195632/"},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"nct05710406","field":"status","kind":"trial","state":"development","label":"Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer: phase 2/3, active","href":"/trials/nct05710406/"},{"record":"registry:encorafenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 32 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/encorafenib/#registry"}],"reasons":[]},{"id":"ensartinib","name":"Ensartinib","route":"/drugs/ensartinib/","status":"approved","modality":"Small-molecule ALK TKI (second generation)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"alk","name":"ALK","href":"/targets/alk/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"ensartinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ensartinib/"},{"record":"ensartinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2020: ALK-positive NSCLC after crizotinib","href":"/drugs/ensartinib/"},{"record":"ensartinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2024: ALK-positive locally advanced or metastatic NSCLC, ALK-inhibitor-naive","href":"/drugs/ensartinib/"},{"record":"ensartinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2024","href":"/regulatory/regions/"},{"record":"ensartinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2020","href":"https://english.nmpa.gov.cn/"},{"record":"nct06780839","field":"status","kind":"trial","state":"development","label":"Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD: phase 2, planned","href":"/trials/nct06780839/"},{"record":"nct07448116","field":"status","kind":"trial","state":"development","label":"Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.: phase 1/2, recruiting","href":"/trials/nct07448116/"},{"record":"nct06955325","field":"status","kind":"trial","state":"development","label":"Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations: phase 3, planned","href":"/trials/nct06955325/"},{"record":"registry:ensartinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 17 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ensartinib/#registry"}],"reasons":[]},{"id":"entrectinib","name":"Entrectinib","route":"/drugs/entrectinib/","status":"approved","modality":"Small-molecule TRK/ROS1/ALK TKI (CNS-penetrant)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"ntrk+ros1","name":"NTRK x ROS1","href":"/targets/ntrk/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"entrectinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/entrectinib/"},{"record":"entrectinib","field":"approvals[0]","kind":"approval","state":"approved","label":"JP 2019: NTRK fusion solid tumours","href":"/drugs/entrectinib/"},{"record":"entrectinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2019: ROS1-positive metastatic NSCLC; NTRK fusion solid tumours (≥12 years, extended to ≥1 month 2023)","href":"/drugs/entrectinib/"},{"record":"entrectinib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2020: Same","href":"/drugs/entrectinib/"},{"record":"entrectinib","field":"approvals[3]","kind":"approval","state":"approved","label":"UK 2020: NTRK fusion-positive solid tumours: NICE TA644 (12 August 2020) recommended entrectinib within the Cancer Drugs Fund; it was replaced by TA1118 (terminated appraisal, 7 January 2026) because the company did not make a submission, and only people already on treatment continue","href":"/drugs/entrectinib/"},{"record":"entrectinib","field":"approvals[4]","kind":"approval","state":"approved","label":"England (NICE) 2020: NTRK fusion-positive solid tumours, including colorectal cancer","href":"/drugs/entrectinib/"},{"record":"entrectinib","field":"approvals[5]","kind":"approval","state":"approved","label":"England (NICE) 2020: ROS1-positive advanced non-small-cell lung cancer in patients who have not had a ROS1 inhibitor","href":"/drugs/entrectinib/"},{"record":"entrectinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2019","href":"/regulatory/regions/"},{"record":"entrectinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2020","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/rozlytrek"},{"record":"entrectinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2020","href":"https://products.mhra.gov.uk/?search=Rozlytrek"},{"record":"entrectinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2019","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"entrectinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2022","href":"https://english.nmpa.gov.cn/"},{"record":"entrectinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Rozlytrek"},{"record":"nct05170204","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C: phase 3, active","href":"/trials/nct05170204/"},{"record":"nct04302025","field":"status","kind":"trial","state":"development","label":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC): phase 2, recruiting","href":"/trials/nct04302025/"},{"record":"nct04603807","field":"status","kind":"trial","state":"development","label":"A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases: phase 3, active","href":"/trials/nct04603807/"},{"record":"nct02568267","field":"status","kind":"trial","state":"development","label":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme: phase 2, active","href":"/trials/nct02568267/"},{"record":"determine-trial","field":"status","kind":"trial","state":"development","label":"DETERMINE: phase platform, recruiting","href":"/trials/determine-trial/"},{"record":"nct02650401","field":"status","kind":"trial","state":"development","label":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options: phase 1/2, active","href":"/trials/nct02650401/"},{"record":"nct04589845","field":"status","kind":"trial","state":"development","label":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study: phase 2, active","href":"/trials/nct04589845/"},{"record":"registry:entrectinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 20 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/entrectinib/#registry"}],"reasons":[]},{"id":"enzalutamide","name":"Enzalutamide","route":"/drugs/enzalutamide/","status":"approved","modality":"Small-molecule AR antagonist","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"androgen-receptor","name":"Androgen receptor","href":"/targets/androgen-receptor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"receptor-agonist","name":"Receptor agonist","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"enzalutamide","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/enzalutamide/"},{"record":"enzalutamide","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2012: mCRPC after docetaxel (pre-chemo 2014)","href":"/drugs/enzalutamide/"},{"record":"enzalutamide","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2018: Non-metastatic CRPC","href":"/drugs/enzalutamide/"},{"record":"enzalutamide","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2019: mHSPC (ARCHES)","href":"/drugs/enzalutamide/"},{"record":"enzalutamide","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2023: High-risk biochemical recurrence (EMBARK)","href":"/drugs/enzalutamide/"},{"record":"enzalutamide","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2012","href":"/regulatory/regions/"},{"record":"enzalutamide","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2013","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi"},{"record":"enzalutamide","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2013","href":"https://products.mhra.gov.uk/?search=Xtandi"},{"record":"enzalutamide","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2014","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"enzalutamide","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2019","href":"https://english.nmpa.gov.cn/"},{"record":"enzalutamide","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2014","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Xtandi"},{"record":"nct06863272","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02): phase 1/2, recruiting","href":"/trials/nct06863272/"},{"record":"nct07198633","field":"status","kind":"trial","state":"development","label":"A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct07198633/"},{"record":"nct05914116","field":"status","kind":"trial","state":"development","label":"A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05914116/"},{"record":"nct07226986","field":"status","kind":"trial","state":"development","label":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA: phase 1/2, recruiting","href":"/trials/nct07226986/"},{"record":"nct02960022","field":"status","kind":"trial","state":"development","label":"A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study: phase 2, active","href":"/trials/nct02960022/"},{"record":"nct06099769","field":"status","kind":"trial","state":"development","label":"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer: phase 2, recruiting","href":"/trials/nct06099769/"},{"record":"nct07230106","field":"status","kind":"trial","state":"development","label":"A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer: phase 2, recruiting","href":"/trials/nct07230106/"},{"record":"nct04104776","field":"status","kind":"trial","state":"development","label":"A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas: phase 1/2, recruiting","href":"/trials/nct04104776/"},{"record":"nct06629779","field":"status","kind":"trial","state":"development","label":"A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.: phase 3, recruiting","href":"/trials/nct06629779/"},{"record":"nct07287150","field":"status","kind":"trial","state":"development","label":"A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer: phase 2, recruiting","href":"/trials/nct07287150/"},{"record":"nct05422911","field":"status","kind":"trial","state":"development","label":"Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.: phase 2, recruiting","href":"/trials/nct05422911/"},{"record":"nct04076059","field":"status","kind":"trial","state":"development","label":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormo: phase 3, active","href":"/trials/nct04076059/"},{"record":"nct05112965","field":"status","kind":"trial","state":"development","label":"An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C): phase 3, active","href":"/trials/nct05112965/"},{"record":"nct06991556","field":"status","kind":"trial","state":"development","label":"An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc: phase 2, active","href":"/trials/nct06991556/"},{"record":"armor3-sv","field":"result","kind":"trial","state":"stopped","label":"ARMOR3-SV: phase 3, negative","href":"/trials/armor3-sv/","quote":"Closed early after 38 of a planned 148 men were randomised; AR-V7 prevalence 8 percent (95 percent confidence interval 6 to 10) among 953 prescreened men. PSA50 response 13 percent with galeterone against 42 percent with enzalutamide. Galeterone development stopped."},{"record":"nct07611110","field":"status","kind":"trial","state":"development","label":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01): phase 3, recruiting","href":"/trials/nct07611110/"},{"record":"imbassador250","field":"result","kind":"trial","state":"stopped","label":"IMbassador250: phase 3, negative","href":"/trials/imbassador250/","quote":"Overall survival not improved: stratified hazard ratio 1.12 (95 percent confidence interval 0.91 to 1.37, p=0.28) for atezolizumab with enzalutamide against enzalutamide alone."},{"record":"keynote-641","field":"result","kind":"trial","state":"stopped","label":"KEYNOTE-641: phase 3, negative","href":"/trials/keynote-641/","quote":"Median overall survival 24.7 against 27.3 months (hazard ratio 1.04, 95 percent confidence interval 0.88 to 1.22) and radiographic progression-free survival 10.4 against 9.0 months (0.98, 0.84 to 1.14); stopped for futility. Grade 3 or higher treatment-related adverse events 31.2 against 10.8 percent."},{"record":"keynote-991","field":"result","kind":"trial","state":"stopped","label":"KEYNOTE-991: phase 3, negative","href":"/trials/keynote-991/","quote":"Radiographic progression-free survival hazard ratio 1.20 (95 percent confidence interval 0.96 to 1.49, p=0.9467), medians not reached; stopped for futility. Grade 3 or higher adverse events 61.9 against 38.1 percent and rash 25.1 against 9.3 percent."},{"record":"nct07620574","field":"status","kind":"trial","state":"development","label":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study: phase 3, recruiting","href":"/trials/nct07620574/"},{"record":"mevpro-1","field":"status","kind":"trial","state":"development","label":"MEVPRO-1: phase 3, active","href":"/trials/mevpro-1/"},{"record":"nct05367440","field":"status","kind":"trial","state":"development","label":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer: phase 1/2, active","href":"/trials/nct05367440/"},{"record":"nct04446117","field":"status","kind":"trial","state":"development","label":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC: phase 3, active","href":"/trials/nct04446117/"},{"record":"nct02861573","field":"status","kind":"trial","state":"development","label":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365): phase 1/2, active","href":"/trials/nct02861573/"},{"record":"nct06228053","field":"status","kind":"trial","state":"development","label":"Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer: phase 2, recruiting","href":"/trials/nct06228053/"},{"record":"nct04821622","field":"status","kind":"trial","state":"development","label":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC: phase 3, active","href":"/trials/nct04821622/"},{"record":"nct06702995","field":"status","kind":"trial","state":"development","label":"Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct06702995/"},{"record":"nct04557449","field":"status","kind":"trial","state":"development","label":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors: phase 2, active","href":"/trials/nct04557449/"},{"record":"nct06520345","field":"status","kind":"trial","state":"development","label":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global): phase 3, recruiting","href":"/trials/nct06520345/"},{"record":"nct07028853","field":"status","kind":"trial","state":"development","label":"This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking En: phase 3, recruiting","href":"/trials/nct07028853/"},{"record":"nct04986423","field":"status","kind":"trial","state":"development","label":"ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer: phase 2, recruiting","href":"/trials/nct04986423/"},{"record":"registry:enzalutamide","kind":"registry","state":"development","label":"ClinicalTrials.gov: 46 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/enzalutamide/#registry"}],"reasons":[{"drugId":"enzalutamide","drugName":"Enzalutamide","drugRoute":"/drugs/enzalutamide/","drugState":"approved","record":"armor3-sv","kind":"trial","label":"ARMOR3-SV: phase 3, negative","href":"/trials/armor3-sv/","quote":"Closed early after 38 of a planned 148 men were randomised; AR-V7 prevalence 8 percent (95 percent confidence interval 6 to 10) among 953 prescreened men. PSA50 response 13 percent with galeterone against 42 percent with enzalutamide. Galeterone development stopped."},{"drugId":"enzalutamide","drugName":"Enzalutamide","drugRoute":"/drugs/enzalutamide/","drugState":"approved","record":"imbassador250","kind":"trial","label":"IMbassador250: phase 3, negative","href":"/trials/imbassador250/","quote":"Overall survival not improved: stratified hazard ratio 1.12 (95 percent confidence interval 0.91 to 1.37, p=0.28) for atezolizumab with enzalutamide against enzalutamide alone."},{"drugId":"enzalutamide","drugName":"Enzalutamide","drugRoute":"/drugs/enzalutamide/","drugState":"approved","record":"keynote-641","kind":"trial","label":"KEYNOTE-641: phase 3, negative","href":"/trials/keynote-641/","quote":"Median overall survival 24.7 against 27.3 months (hazard ratio 1.04, 95 percent confidence interval 0.88 to 1.22) and radiographic progression-free survival 10.4 against 9.0 months (0.98, 0.84 to 1.14); stopped for futility. Grade 3 or higher treatment-related adverse events 31.2 against 10.8 percent."},{"drugId":"enzalutamide","drugName":"Enzalutamide","drugRoute":"/drugs/enzalutamide/","drugState":"approved","record":"keynote-991","kind":"trial","label":"KEYNOTE-991: phase 3, negative","href":"/trials/keynote-991/","quote":"Radiographic progression-free survival hazard ratio 1.20 (95 percent confidence interval 0.96 to 1.49, p=0.9467), medians not reached; stopped for futility. Grade 3 or higher adverse events 61.9 against 38.1 percent and rash 25.1 against 9.3 percent."}]},{"id":"ep0031","name":"EP0031","route":"/drugs/ep0031/","status":"phase-2","modality":"small molecule (structure undisclosed or not yet in PubChem)","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"ret","name":"RET","href":"/targets/ret/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"ep0031","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/ep0031/"},{"record":"nct05443126","field":"status","kind":"trial","state":"development","label":"A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies: phase 1/2, recruiting","href":"/trials/nct05443126/"},{"record":"registry:ep0031","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/ep0031/#registry"}],"reasons":[]},{"id":"ep0062","name":"EP0062","route":"/drugs/ep0062/","status":"phase-2","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"androgen-receptor","name":"Androgen receptor","href":"/targets/androgen-receptor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"ep0062","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/ep0062/"},{"record":"nct05573126","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer: phase 1/2, recruiting","href":"/trials/nct05573126/"},{"record":"registry:ep0062","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/ep0062/#registry"}],"reasons":[]},{"id":"eprenetapopt","name":"Eprenetapopt","route":"/drugs/eprenetapopt/","status":"negative","modality":"Small molecule (p53 reactivator)","state":"stopped","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"tp53","name":"TP53","href":"/targets/tp53/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"mdm2-inhibitor","name":"MDM2 inhibitor","href":"/technologies/mdm2-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"eprenetapopt","field":"status","kind":"drug","state":"stopped","label":"Drug record status: negative","href":"/drugs/eprenetapopt/","quote":"Eprenetapopt (APR-246) was a drug meant to refold mutant p53, the most common broken protein in cancer. Its phase 3 in blood cancer failed in 2020."},{"record":"registry:eprenetapopt","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 4 terminated or withdrawn studies and none active (fetched 2026-09-28)","href":"/drugs/eprenetapopt/#registry"}],"reasons":[{"drugId":"eprenetapopt","drugName":"Eprenetapopt","drugRoute":"/drugs/eprenetapopt/","drugState":"stopped","record":"eprenetapopt","kind":"drug","label":"Drug record status: negative","href":"/drugs/eprenetapopt/","quote":"Eprenetapopt (APR-246) was a drug meant to refold mutant p53, the most common broken protein in cancer. Its phase 3 in blood cancer failed in 2020."}]},{"id":"erdafitinib","name":"Erdafitinib","route":"/drugs/erdafitinib/","status":"approved","modality":"Small-molecule kinase inhibitor (pan-FGFR)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"fgfr2","name":"FGFR2","href":"/targets/fgfr2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"erdafitinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/erdafitinib/"},{"record":"erdafitinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2019: FGFR3/2-altered advanced urothelial cancer after platinum (accelerated)","href":"/drugs/erdafitinib/"},{"record":"erdafitinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2024: FGFR3-altered advanced urothelial cancer after ≥1 systemic therapy incl. PD-1/PD-L1 (full)","href":"/drugs/erdafitinib/"},{"record":"erdafitinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2019","href":"/regulatory/regions/"},{"record":"erdafitinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2024","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/balversa"},{"record":"erdafitinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2024","href":"https://products.mhra.gov.uk/?search=Balversa"},{"record":"erdafitinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2024","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"erdafitinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2025","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Balversa"},{"record":"nct03473743","field":"status","kind":"trial","state":"development","label":"A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer: phase 1/2, active","href":"/trials/nct03473743/"},{"record":"nct02365597","field":"status","kind":"trial","state":"development","label":"An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer: phase 2, active","href":"/trials/nct02365597/"},{"record":"pediatric-match","field":"status","kind":"trial","state":"development","label":"NCI-COG Pediatric MATCH (APEC1621): phase platform, active","href":"/trials/pediatric-match/"},{"record":"nct05316155","field":"status","kind":"trial","state":"development","label":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer: phase 1/2, active","href":"/trials/nct05316155/"},{"record":"registry:erdafitinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 16 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/erdafitinib/#registry"}],"reasons":[]},{"id":"eribulin","name":"Eribulin","route":"/drugs/eribulin/","status":"approved","modality":"Synthetic halichondrin B analogue (microtubule dynamics inhibitor)","state":"approved","confidence":"medium","fields":["modality","mechanism"],"components":{"target":{"id":"tubulin","name":"Tubulin (microtubules)","href":"/targets/tubulin/","confidence":"medium","from":["modality","mechanism"],"detail":null},"mechanismClass":{"id":"other-inhibitor","name":"Inhibitor (class not stated)","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"eribulin","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/eribulin/"},{"record":"eribulin","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2010: Metastatic breast cancer after ≥2 regimens including an anthracycline and a taxane","href":"/drugs/eribulin/"},{"record":"eribulin","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2016: Unresectable or metastatic liposarcoma after anthracycline","href":"/drugs/eribulin/"},{"record":"eribulin","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2011: Metastatic breast cancer; liposarcoma (2016)","href":"/drugs/eribulin/"},{"record":"eribulin","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2010","href":"/regulatory/regions/"},{"record":"eribulin","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2011","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/halaven"},{"record":"eribulin","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2011","href":"https://products.mhra.gov.uk/?search=Halaven"},{"record":"eribulin","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2011","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"eribulin","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2019","href":"https://english.nmpa.gov.cn/"},{"record":"eribulin","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Halaven"},{"record":"nct07441512","field":"status","kind":"trial","state":"development","label":"A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer: phase 2, planned","href":"/trials/nct07441512/"},{"record":"nct06343948","field":"status","kind":"trial","state":"development","label":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01): phase 3, active","href":"/trials/nct06343948/"},{"record":"nct06435429","field":"status","kind":"trial","state":"development","label":"A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment o: phase 3, recruiting","href":"/trials/nct06435429/"},{"record":"nct03424005","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer: phase 1/2, recruiting","href":"/trials/nct03424005/"},{"record":"nct06957886","field":"status","kind":"trial","state":"development","label":"A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer: phase 3, recruiting","href":"/trials/nct06957886/"},{"record":"nct05570253","field":"status","kind":"trial","state":"development","label":"A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer: phase 2, recruiting","href":"/trials/nct05570253/"},{"record":"nct06279364","field":"status","kind":"trial","state":"development","label":"A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer: phase 3, recruiting","href":"/trials/nct06279364/"},{"record":"nct06202261","field":"status","kind":"trial","state":"development","label":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer: phase 1/2, recruiting","href":"/trials/nct06202261/"},{"record":"nct05824975","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizu: phase 1/2, recruiting","href":"/trials/nct05824975/"},{"record":"nct04639986","field":"status","kind":"trial","state":"development","label":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC): phase 3, active","href":"/trials/nct04639986/"},{"record":"nct07007559","field":"status","kind":"trial","state":"development","label":"ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer: phase 2, recruiting","href":"/trials/nct07007559/"},{"record":"nct07255612","field":"status","kind":"trial","state":"development","label":"Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer): phase 2, planned","href":"/trials/nct07255612/"},{"record":"nct05760378","field":"status","kind":"trial","state":"development","label":"Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.: phase 3, recruiting","href":"/trials/nct05760378/"},{"record":"nct06731153","field":"status","kind":"trial","state":"development","label":"JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC: phase 2, planned","href":"/trials/nct06731153/"},{"record":"keynote-119","field":"result","kind":"trial","state":"stopped","label":"KEYNOTE-119: phase 3, negative","href":"/trials/keynote-119/","quote":"OS in CPS 10 or more 12.7 vs 11.6 months (HR 0.78, p 0.057); CPS 1 or more 10.7 vs 10.2 (HR 0.86); all patients 9.9 vs 10.8 (HR 0.97). Negative."},{"record":"nct06387628","field":"status","kind":"trial","state":"development","label":"LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer: phase 2, recruiting","href":"/trials/nct06387628/"},{"record":"nct06889688","field":"status","kind":"trial","state":"development","label":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer: phase 3, recruiting","href":"/trials/nct06889688/"},{"record":"nct07173751","field":"status","kind":"trial","state":"development","label":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer: phase 3, recruiting","href":"/trials/nct07173751/"},{"record":"nct06449222","field":"status","kind":"trial","state":"development","label":"Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy: phase 2, active","href":"/trials/nct06449222/"},{"record":"nct04986579","field":"status","kind":"trial","state":"development","label":"Scalp Cooling in MBC: phase 2, recruiting","href":"/trials/nct04986579/"},{"record":"nct05814354","field":"status","kind":"trial","state":"development","label":"SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial: phase 3, active","href":"/trials/nct05814354/"},{"record":"nct06202313","field":"status","kind":"trial","state":"development","label":"Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer: phase 2, planned","href":"/trials/nct06202313/"},{"record":"nct06942234","field":"status","kind":"trial","state":"development","label":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer: phase 1/2, recruiting","href":"/trials/nct06942234/"},{"record":"nct06081959","field":"status","kind":"trial","state":"development","label":"Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer: phase 3, recruiting","href":"/trials/nct06081959/"},{"record":"nct05458674","field":"status","kind":"trial","state":"development","label":"Tucatinib+Trastuzumab+Eribulin in HER2+ MBC: phase 2, active","href":"/trials/nct05458674/"},{"record":"registry:eribulin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 38 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/eribulin/#registry"}],"reasons":[{"drugId":"eribulin","drugName":"Eribulin","drugRoute":"/drugs/eribulin/","drugState":"approved","record":"keynote-119","kind":"trial","label":"KEYNOTE-119: phase 3, negative","href":"/trials/keynote-119/","quote":"OS in CPS 10 or more 12.7 vs 11.6 months (HR 0.78, p 0.057); CPS 1 or more 10.7 vs 10.2 (HR 0.86); all patients 9.9 vs 10.8 (HR 0.97). Negative."}]},{"id":"erlotinib","name":"Erlotinib","route":"/drugs/erlotinib/","status":"approved","modality":"Small-molecule EGFR TKI (first generation, reversible)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"egfr","name":"EGFR","href":"/targets/egfr/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"erlotinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/erlotinib/"},{"record":"erlotinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2004: Locally advanced/metastatic NSCLC after chemotherapy","href":"/drugs/erlotinib/"},{"record":"erlotinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2005: Pancreatic cancer with gemcitabine","href":"/drugs/erlotinib/"},{"record":"erlotinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2013: First-line NSCLC with EGFR exon 19 del or L858R","href":"/drugs/erlotinib/"},{"record":"erlotinib","field":"approvals[3]","kind":"approval","state":"approved","label":"EU 2007: Metastatic pancreatic cancer with gemcitabine (Tarceva product information: factors associated with prolonged survival should be taken into account when prescribing; 100 mg daily); marketing authorisation for the product 19 September 2005","href":"/drugs/erlotinib/"},{"record":"erlotinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2004","href":"/regulatory/regions/"},{"record":"erlotinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2005","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva"},{"record":"erlotinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2005","href":"https://products.mhra.gov.uk/?search=Tarceva"},{"record":"erlotinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2007","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"erlotinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved","href":"https://english.nmpa.gov.cn/"},{"record":"erlotinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Tarceva"},{"record":"nct02152631","field":"status","kind":"trial","state":"development","label":"A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer: phase 3, active","href":"/trials/nct02152631/"},{"record":"nct02411448","field":"status","kind":"trial","state":"development","label":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE: phase 3, active","href":"/trials/nct02411448/"},{"record":"alchemist","field":"status","kind":"trial","state":"development","label":"ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials): phase platform, active","href":"/trials/alchemist/"},{"record":"nct06483555","field":"status","kind":"trial","state":"development","label":"Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel: phase 1/2, recruiting","href":"/trials/nct06483555/"},{"record":"conko-005","field":"result","kind":"trial","state":"stopped","label":"CONKO-005: phase 3, negative","href":"/trials/conko-005/","quote":"Median disease-free survival 11.4 months with gemcitabine plus erlotinib and 11.4 months with gemcitabine; median overall survival 24.5 against 26.5 months."},{"record":"lap07","field":"result","kind":"trial","state":"stopped","label":"LAP07: phase 3, negative","href":"/trials/lap07/","quote":"Median overall survival 15.2 months with chemoradiotherapy against 16.5 months with chemotherapy alone (hazard ratio 1.03, p 0.83); local progression 32 against 46 percent; erlotinib added nothing (13.6 against 11.9 months, hazard ratio 1.19)."},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"nct05442060","field":"status","kind":"trial","state":"development","label":"To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic N: phase 2, recruiting","href":"/trials/nct05442060/"},{"record":"registry:erlotinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/erlotinib/#registry"}],"reasons":[{"drugId":"erlotinib","drugName":"Erlotinib","drugRoute":"/drugs/erlotinib/","drugState":"approved","record":"conko-005","kind":"trial","label":"CONKO-005: phase 3, negative","href":"/trials/conko-005/","quote":"Median disease-free survival 11.4 months with gemcitabine plus erlotinib and 11.4 months with gemcitabine; median overall survival 24.5 against 26.5 months."},{"drugId":"erlotinib","drugName":"Erlotinib","drugRoute":"/drugs/erlotinib/","drugState":"approved","record":"lap07","kind":"trial","label":"LAP07: phase 3, negative","href":"/trials/lap07/","quote":"Median overall survival 15.2 months with chemoradiotherapy against 16.5 months with chemotherapy alone (hazard ratio 1.03, p 0.83); local progression 32 against 46 percent; erlotinib added nothing (13.6 against 11.9 months, hazard ratio 1.19)."}]},{"id":"everolimus","name":"Everolimus","route":"/drugs/everolimus/","status":"approved","modality":"Small-molecule mTOR inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"pik3ca+akt","name":"PIK3CA / PI3K-alpha x AKT","href":"/targets/pik3ca/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"pi3k-akt-mtor-inhibitor","name":"PI3K, AKT or mTOR inhibitor","href":"/technologies/pi3k-akt-mtor-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"allosteric","name":"Allosteric","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"everolimus","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/everolimus/"},{"record":"everolimus","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2012: HR+/HER2- advanced breast cancer with exemestane after NSAI failure","href":"/drugs/everolimus/"},{"record":"everolimus","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2011: Progressive pancreatic NETs","href":"/drugs/everolimus/"},{"record":"everolimus","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2016: Progressive non-functional lung and GI NETs","href":"/drugs/everolimus/"},{"record":"everolimus","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2009: Advanced RCC after sunitinib or sorafenib","href":"/drugs/everolimus/"},{"record":"everolimus","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2009","href":"/regulatory/regions/"},{"record":"everolimus","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2009","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/afinitor"},{"record":"everolimus","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2009","href":"https://products.mhra.gov.uk/?search=Afinitor"},{"record":"everolimus","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2010","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"everolimus","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2013","href":"https://english.nmpa.gov.cn/"},{"record":"everolimus","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2009","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Afinitor"},{"record":"nct07002177","field":"status","kind":"trial","state":"development","label":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC: phase 1/2, recruiting","href":"/trials/nct07002177/"},{"record":"nct04802759","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer: phase 1/2, recruiting","href":"/trials/nct04802759/"},{"record":"nct05918302","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.: phase 3, recruiting","href":"/trials/nct05918302/"},{"record":"nct06301386","field":"status","kind":"trial","state":"development","label":"Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients: phase 2, planned","href":"/trials/nct06301386/"},{"record":"nct07340541","field":"status","kind":"trial","state":"development","label":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies: phase 2, recruiting","href":"/trials/nct07340541/"},{"record":"nct05749588","field":"status","kind":"trial","state":"development","label":"FUSCC Refractory TNBC Platform Study (FUTURE2.0): phase 2, recruiting","href":"/trials/nct05749588/"},{"record":"nct04919226","field":"status","kind":"trial","state":"development","label":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE: phase 3, active","href":"/trials/nct04919226/"},{"record":"nct05563220","field":"status","kind":"trial","state":"development","label":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer: phase 1/2, active","href":"/trials/nct05563220/"},{"record":"nct05573126","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer: phase 1/2, recruiting","href":"/trials/nct05573126/"},{"record":"nct07165886","field":"status","kind":"trial","state":"development","label":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors: phase 2/3, recruiting","href":"/trials/nct07165886/"},{"record":"nct06428396","field":"status","kind":"trial","state":"development","label":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029): phase 2, active","href":"/trials/nct06428396/"},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"registry:everolimus","kind":"registry","state":"development","label":"ClinicalTrials.gov: 19 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/everolimus/#registry"}],"reasons":[]},{"id":"exemestane","name":"Exemestane","route":"/drugs/exemestane/","status":"approved","modality":"Small-molecule steroidal aromatase inactivator","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"estrogen-receptor","name":"Estrogen receptor (ERα)","href":"/targets/estrogen-receptor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"exemestane","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/exemestane/"},{"record":"exemestane","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1999: Advanced breast cancer after tamoxifen","href":"/drugs/exemestane/"},{"record":"exemestane","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2005: Adjuvant after 2-3 years of tamoxifen","href":"/drugs/exemestane/"},{"record":"exemestane","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 1999","href":"/regulatory/regions/"},{"record":"exemestane","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 1999","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/aromasin"},{"record":"exemestane","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 1999","href":"https://products.mhra.gov.uk/?search=Aromasin"},{"record":"exemestane","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2002","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"exemestane","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2001","href":"https://english.nmpa.gov.cn/"},{"record":"exemestane","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2000","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Aromasin"},{"record":"nct05774951","field":"status","kind":"trial","state":"development","label":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy: phase 3, recruiting","href":"/trials/nct05774951/"},{"record":"nct06492616","field":"status","kind":"trial","state":"development","label":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence: phase 3, recruiting","href":"/trials/nct06492616/"},{"record":"nct05514054","field":"status","kind":"trial","state":"development","label":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer: phase 3, active","href":"/trials/nct05514054/"},{"record":"nct06979596","field":"status","kind":"trial","state":"development","label":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015): phase 2, recruiting","href":"/trials/nct06979596/"},{"record":"nct05768139","field":"status","kind":"trial","state":"development","label":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05768139/"},{"record":"nct06016738","field":"status","kind":"trial","state":"development","label":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer: phase 3, active","href":"/trials/nct06016738/"},{"record":"nct04906395","field":"status","kind":"trial","state":"development","label":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer: phase 3, active","href":"/trials/nct04906395/"},{"record":"nct05573126","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer: phase 1/2, recruiting","href":"/trials/nct05573126/"},{"record":"nct05827081","field":"status","kind":"trial","state":"development","label":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer: phase 3, recruiting","href":"/trials/nct05827081/"},{"record":"nct06957379","field":"status","kind":"trial","state":"development","label":"Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy: phase 2, active","href":"/trials/nct06957379/"},{"record":"nct06428396","field":"status","kind":"trial","state":"development","label":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029): phase 2, active","href":"/trials/nct06428396/"},{"record":"registry:exemestane","kind":"registry","state":"development","label":"ClinicalTrials.gov: 42 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/exemestane/#registry"}],"reasons":[]},{"id":"fedratinib","name":"Fedratinib","route":"/drugs/fedratinib/","status":"approved","modality":"Small-molecule JAK2/FLT3 inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"jak2+flt3","name":"JAK2 x FLT3","href":"/targets/jak2/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"fedratinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/fedratinib/"},{"record":"fedratinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2019: Intermediate-2/high-risk primary or secondary myelofibrosis","href":"/drugs/fedratinib/"},{"record":"fedratinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2021: Myelofibrosis, JAK-inhibitor-naive or after ruxolitinib","href":"/drugs/fedratinib/"},{"record":"fedratinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2019","href":"/regulatory/regions/"},{"record":"fedratinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2021","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/inrebic"},{"record":"fedratinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved","href":"https://products.mhra.gov.uk/?search=Inrebic"},{"record":"fedratinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2025","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"fedratinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Inrebic"},{"record":"nct04817007","field":"status","kind":"trial","state":"development","label":"A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis): phase 1/2, active","href":"/trials/nct04817007/"},{"record":"registry:fedratinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/fedratinib/#registry"}],"reasons":[]},{"id":"fentanyl","name":"Fentanyl (transmucosal, for breakthrough cancer pain)","route":"/drugs/fentanyl/","status":"approved","modality":"Small-molecule opioid analgesic (buccal tablet and nasal sprays)","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"oprm1","name":"Mu-opioid receptor","href":"/targets/oprm1/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"receptor-agonist","name":"Receptor agonist","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"fentanyl","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/fentanyl/"},{"record":"fentanyl","field":"approvals[0]","kind":"approval","state":"approved","label":"EU 2008: Breakthrough pain in adults receiving maintenance opioid therapy for chronic cancer pain","href":"/drugs/fentanyl/"},{"record":"fentanyl","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2008","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/effentora"},{"record":"registry:fentanyl","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/fentanyl/#registry"}],"reasons":[]},{"id":"flumatinib","name":"Flumatinib","route":"/drugs/flumatinib/","status":"approved","modality":"Oral second-generation BCR-ABL tyrosine kinase inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"bcr-abl","name":"BCR::ABL1 (Philadelphia chromosome)","href":"/targets/bcr-abl/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"flumatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/flumatinib/"},{"record":"flumatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2019: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia, chronic phase","href":"/drugs/flumatinib/"},{"record":"flumatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2019","href":"https://english.nmpa.gov.cn/"}],"reasons":[]},{"id":"flutamide","name":"Flutamide","route":"/drugs/flutamide/","status":"approved","modality":"Non-steroidal antiandrogen (first generation)","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"androgen-receptor","name":"Androgen receptor","href":"/targets/androgen-receptor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"flutamide","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/flutamide/"},{"record":"flutamide","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1989: Locally advanced (B2 to C) and metastatic (D2) prostate cancer in combination with an LHRH agonist","href":"/drugs/flutamide/"},{"record":"nct03678025","field":"status","kind":"trial","state":"development","label":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer: phase 3, recruiting","href":"/trials/nct03678025/"},{"record":"nct04513717","field":"status","kind":"trial","state":"development","label":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial: phase 3, active","href":"/trials/nct04513717/"},{"record":"registry:flutamide","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/flutamide/#registry"}],"reasons":[]},{"id":"fluzoparib","name":"Fluzoparib","route":"/drugs/fluzoparib/","status":"phase-2","modality":"Oral PARP inhibitor","state":"approved","confidence":"medium","fields":["modality","mechanism"],"components":{"target":{"id":"parp","name":"PARP","href":"/targets/parp/","confidence":"medium","from":["modality","mechanism"],"detail":null},"mechanismClass":{"id":"parp-inhibitor","name":"PARP inhibitor","href":"/technologies/parp-inhibitor/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"fluzoparib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/fluzoparib/"},{"record":"fluzoparib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2020","href":"https://english.nmpa.gov.cn/"},{"record":"nct06208410","field":"status","kind":"trial","state":"development","label":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06208410/"},{"record":"nct07752550","field":"status","kind":"trial","state":"development","label":"Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer: phase 2, planned","href":"/trials/nct07752550/"},{"record":"registry:fluzoparib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 38 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/fluzoparib/#registry"}],"reasons":[]},{"id":"formestane","name":"Formestane","route":"/drugs/formestane/","status":"historic","modality":"Steroidal aromatase inactivator, fortnightly intramuscular injection","state":"stopped","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"aromatase","name":"Aromatase (CYP19A1)","href":"/targets/aromatase/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"formestane","field":"status","kind":"drug","state":"stopped","label":"Drug record status: historic","href":"/drugs/formestane/","quote":"Formestane, launched in Europe in 1993, was the first selective aromatase inhibitor for advanced breast cancer, given by injection every two weeks; oral exemestane and the non-steroidal inhibitors made it redundant within a few years."}],"reasons":[{"drugId":"formestane","drugName":"Formestane","drugRoute":"/drugs/formestane/","drugState":"stopped","record":"formestane","kind":"drug","label":"Drug record status: historic","href":"/drugs/formestane/","quote":"Formestane, launched in Europe in 1993, was the first selective aromatase inhibitor for advanced breast cancer, given by injection every two weeks; oral exemestane and the non-steroidal inhibitors made it redundant within a few years."}]},{"id":"fostamatinib","name":"Fostamatinib","route":"/drugs/fostamatinib/","status":"established","modality":"Oral spleen tyrosine kinase (SYK) inhibitor","state":"approved","confidence":"high","fields":["target record (drugs field)","technologies"],"components":{"target":{"id":"syk","name":"SYK","href":"/targets/syk/","confidence":"high","from":["target record (drugs field)"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"fostamatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: established","href":"/drugs/fostamatinib/"},{"record":"fostamatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: Chronic immune thrombocytopenia in adults with insufficient response to a previous treatment","href":"/drugs/fostamatinib/"},{"record":"registry:fostamatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/fostamatinib/#registry"}],"reasons":[]},{"id":"fruquintinib","name":"Fruquintinib","route":"/drugs/fruquintinib/","status":"approved","modality":"Small-molecule kinase inhibitor (VEGFR1-3)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"vegf","name":"VEGF / VEGFR","href":"/targets/vegf/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"fruquintinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/fruquintinib/"},{"record":"fruquintinib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2018: Refractory mCRC (FRESCO)","href":"/drugs/fruquintinib/"},{"record":"fruquintinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2023: Refractory mCRC after fluoropyrimidine, oxaliplatin, irinotecan, anti-VEGF, and anti-EGFR if appropriate","href":"/drugs/fruquintinib/"},{"record":"fruquintinib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2024: Previously treated metastatic colorectal cancer","href":"/drugs/fruquintinib/"},{"record":"fruquintinib","field":"approvals[3]","kind":"approval","state":"approved","label":"England (NICE) 2025: Metastatic colorectal cancer at third line or later, only when trifluridine-tipiracil with bevacizumab is unsuitable","href":"/drugs/fruquintinib/"},{"record":"fruquintinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2023","href":"/regulatory/regions/"},{"record":"fruquintinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2024","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/fruzaqla"},{"record":"fruquintinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2024","href":"https://www.gov.uk/government/news/fruquintinib-approved-to-treat-adult-patients-with-metastatic-colorectal-cancer"},{"record":"fruquintinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2024","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"fruquintinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2018","href":"https://english.nmpa.gov.cn/"},{"record":"fruquintinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2025","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Fruzaqla"},{"record":"nct06856837","field":"status","kind":"trial","state":"development","label":"- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorec: phase 2, recruiting","href":"/trials/nct06856837/"},{"record":"nct07502014","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line: phase 2, planned","href":"/trials/nct07502014/"},{"record":"nct06979908","field":"status","kind":"trial","state":"development","label":"A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal C: phase 2, recruiting","href":"/trials/nct06979908/"},{"record":"nct07591597","field":"status","kind":"trial","state":"development","label":"A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus F: phase 1/2, planned","href":"/trials/nct07591597/"},{"record":"nct07621159","field":"status","kind":"trial","state":"development","label":"A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer: phase 1/2, planned","href":"/trials/nct07621159/"},{"record":"nct07229872","field":"status","kind":"trial","state":"development","label":"A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer: phase 2, planned","href":"/trials/nct07229872/"},{"record":"nct06218888","field":"status","kind":"trial","state":"development","label":"A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Micro: phase 2, planned","href":"/trials/nct06218888/"},{"record":"nct06746545","field":"status","kind":"trial","state":"development","label":"A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.: phase 2, planned","href":"/trials/nct06746545/"},{"record":"nct06992258","field":"status","kind":"trial","state":"development","label":"A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct06992258/"},{"record":"nct07730489","field":"status","kind":"trial","state":"development","label":"A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, F: phase 3, planned","href":"/trials/nct07730489/"},{"record":"nct05867420","field":"status","kind":"trial","state":"development","label":"A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.: phase 1/2, recruiting","href":"/trials/nct05867420/"},{"record":"nct07011576","field":"status","kind":"trial","state":"development","label":"A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL): phase 2, recruiting","href":"/trials/nct07011576/"},{"record":"nct06497985","field":"status","kind":"trial","state":"development","label":"A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients: phase 3, recruiting","href":"/trials/nct06497985/"},{"record":"nct05954429","field":"status","kind":"trial","state":"development","label":"A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-cente: phase 2, recruiting","href":"/trials/nct05954429/"},{"record":"nct07235293","field":"status","kind":"trial","state":"development","label":"A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.: phase 2, recruiting","href":"/trials/nct07235293/"},{"record":"nct05405595","field":"status","kind":"trial","state":"development","label":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05405595/"},{"record":"nct07130903","field":"status","kind":"trial","state":"development","label":"Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct07130903/"},{"record":"nct06168786","field":"status","kind":"trial","state":"development","label":"Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC: phase 2, recruiting","href":"/trials/nct06168786/"},{"record":"nct06484153","field":"status","kind":"trial","state":"development","label":"Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma: phase 2, recruiting","href":"/trials/nct06484153/"},{"record":"nct07510932","field":"status","kind":"trial","state":"development","label":"Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K): phase 2, planned","href":"/trials/nct07510932/"},{"record":"nct07724223","field":"status","kind":"trial","state":"development","label":"Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC: phase 2, recruiting","href":"/trials/nct07724223/"},{"record":"nct07362836","field":"status","kind":"trial","state":"development","label":"Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS): phase 3, planned","href":"/trials/nct07362836/"},{"record":"nct07051785","field":"status","kind":"trial","state":"development","label":"Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer: phase 2, planned","href":"/trials/nct07051785/"},{"record":"nct06441565","field":"status","kind":"trial","state":"development","label":"Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer: phase 2/3, recruiting","href":"/trials/nct06441565/"},{"record":"nct06980532","field":"status","kind":"trial","state":"development","label":"Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer: phase 1/2, recruiting","href":"/trials/nct06980532/"},{"record":"nct06199973","field":"status","kind":"trial","state":"development","label":"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, : phase 3, active","href":"/trials/nct06199973/"},{"record":"nct06443671","field":"status","kind":"trial","state":"development","label":"Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer: phase 2/3, planned","href":"/trials/nct06443671/"},{"record":"nct07353268","field":"status","kind":"trial","state":"development","label":"Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerabil: phase 2, planned","href":"/trials/nct07353268/"},{"record":"nct06685276","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct06685276/"},{"record":"nct07150403","field":"status","kind":"trial","state":"development","label":"Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal: phase 2, planned","href":"/trials/nct07150403/"},{"record":"nct07515820","field":"status","kind":"trial","state":"development","label":"SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study: phase 2, planned","href":"/trials/nct07515820/"},{"record":"nct06584032","field":"status","kind":"trial","state":"development","label":"Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer: phase 3, recruiting","href":"/trials/nct06584032/"},{"record":"nct05565417","field":"status","kind":"trial","state":"development","label":"Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas: phase 1/2, active","href":"/trials/nct05565417/"},{"record":"nct05771181","field":"status","kind":"trial","state":"development","label":"Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients: phase 2, recruiting","href":"/trials/nct05771181/"},{"record":"registry:fruquintinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 55 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/fruquintinib/#registry"}],"reasons":[]},{"id":"fulvestrant","name":"Fulvestrant","route":"/drugs/fulvestrant/","status":"approved","modality":"Injectable SERD","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"estrogen-receptor","name":"Estrogen receptor (ERα)","href":"/targets/estrogen-receptor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"fulvestrant","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/fulvestrant/"},{"record":"fulvestrant","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2002: HR+ advanced breast cancer after antioestrogen therapy","href":"/drugs/fulvestrant/"},{"record":"fulvestrant","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2017: First-line HR+ advanced breast cancer (FALCON)","href":"/drugs/fulvestrant/"},{"record":"fulvestrant","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2002","href":"/regulatory/regions/"},{"record":"fulvestrant","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2004","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/faslodex"},{"record":"fulvestrant","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2004","href":"https://products.mhra.gov.uk/?search=Faslodex"},{"record":"fulvestrant","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2011","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"fulvestrant","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2010","href":"https://english.nmpa.gov.cn/"},{"record":"fulvestrant","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2004","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Faslodex"},{"record":"nct06208410","field":"status","kind":"trial","state":"development","label":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06208410/"},{"record":"nct07109726","field":"status","kind":"trial","state":"development","label":"A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations: phase 1/2, recruiting","href":"/trials/nct07109726/"},{"record":"nct04539496","field":"status","kind":"trial","state":"development","label":"A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors: phase 1/2, active","href":"/trials/nct04539496/"},{"record":"nct07405801","field":"status","kind":"trial","state":"development","label":"A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer: phase 2, recruiting","href":"/trials/nct07405801/"},{"record":"nct06764186","field":"status","kind":"trial","state":"development","label":"A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain: phase 3, active","href":"/trials/nct06764186/"},{"record":"nct04576455","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer): phase 2, active","href":"/trials/nct04576455/"},{"record":"nct05646862","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy: phase 3, recruiting","href":"/trials/nct05646862/"},{"record":"nct02107703","field":"status","kind":"trial","state":"development","label":"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer: phase 3, active","href":"/trials/nct02107703/"},{"record":"nct02763566","field":"status","kind":"trial","state":"development","label":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer: phase 3, active","href":"/trials/nct02763566/"},{"record":"nct07389733","field":"status","kind":"trial","state":"development","label":"A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer: phase 1/2, recruiting","href":"/trials/nct07389733/"},{"record":"nct06979596","field":"status","kind":"trial","state":"development","label":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015): phase 2, recruiting","href":"/trials/nct06979596/"},{"record":"nct06202261","field":"status","kind":"trial","state":"development","label":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer: phase 1/2, recruiting","href":"/trials/nct06202261/"},{"record":"nct06065748","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer): phase 3, active","href":"/trials/nct06065748/"},{"record":"nct04214288","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer: phase 2, active","href":"/trials/nct04214288/"},{"record":"nct05262400","field":"status","kind":"trial","state":"development","label":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors: phase 1/2, active","href":"/trials/nct05262400/"},{"record":"nct06555068","field":"status","kind":"trial","state":"development","label":"A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients: phase 1/2, recruiting","href":"/trials/nct06555068/"},{"record":"nct04579380","field":"status","kind":"trial","state":"development","label":"Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations: phase 2, active","href":"/trials/nct04579380/"},{"record":"nct04862663","field":"status","kind":"trial","state":"development","label":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292): phase 3, active","href":"/trials/nct04862663/"},{"record":"nct06635447","field":"status","kind":"trial","state":"development","label":"Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients: phase 3, active","href":"/trials/nct06635447/"},{"record":"nct05251714","field":"status","kind":"trial","state":"development","label":"CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer: phase 1/2, active","href":"/trials/nct05251714/"},{"record":"nct05230810","field":"status","kind":"trial","state":"development","label":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.: phase 1/2, active","href":"/trials/nct05230810/"},{"record":"nct00099437","field":"status","kind":"trial","state":"development","label":"Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.: phase 3, active","href":"/trials/nct00099437/"},{"record":"nct04567420","field":"status","kind":"trial","state":"development","label":"DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE): phase 2, active","href":"/trials/nct04567420/"},{"record":"nct07498478","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment: phase 2, recruiting","href":"/trials/nct07498478/"},{"record":"nct05696626","field":"status","kind":"trial","state":"development","label":"Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation: phase 3, recruiting","href":"/trials/nct05696626/"},{"record":"nct06702618","field":"status","kind":"trial","state":"development","label":"Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer: phase 2, active","href":"/trials/nct06702618/"},{"record":"nct05768139","field":"status","kind":"trial","state":"development","label":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05768139/"},{"record":"nct06506955","field":"status","kind":"trial","state":"development","label":"Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.: phase 2/3, active","href":"/trials/nct06506955/"},{"record":"nct05501886","field":"status","kind":"trial","state":"development","label":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1): phase 3, active","href":"/trials/nct05501886/"},{"record":"nct06016738","field":"status","kind":"trial","state":"development","label":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer: phase 3, active","href":"/trials/nct06016738/"},{"record":"nct05735080","field":"status","kind":"trial","state":"development","label":"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer: phase 1/2, recruiting","href":"/trials/nct05735080/"},{"record":"nct06998407","field":"status","kind":"trial","state":"development","label":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06998407/"},{"record":"nct04553133","field":"status","kind":"trial","state":"development","label":"PF-07104091 as a Single Agent and in Combination Therapy: phase 2, active","href":"/trials/nct04553133/"},{"record":"nct04115306","field":"status","kind":"trial","state":"development","label":"Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer: phase 1/2, active","href":"/trials/nct04115306/"},{"record":"nct06993844","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06993844/"},{"record":"nct05573126","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer: phase 1/2, recruiting","href":"/trials/nct05573126/"},{"record":"nct06757634","field":"status","kind":"trial","state":"development","label":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2): phase 3, recruiting","href":"/trials/nct06757634/"},{"record":"nct07235176","field":"status","kind":"trial","state":"development","label":"Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients: phase 1/2, recruiting","href":"/trials/nct07235176/"},{"record":"nct07558733","field":"status","kind":"trial","state":"development","label":"Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer: phase 1/2, recruiting","href":"/trials/nct07558733/"},{"record":"nct06380751","field":"status","kind":"trial","state":"development","label":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct06380751/"},{"record":"nct06957379","field":"status","kind":"trial","state":"development","label":"Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy: phase 2, active","href":"/trials/nct06957379/"},{"record":"nct06736704","field":"status","kind":"trial","state":"development","label":"SNV4818 in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06736704/"},{"record":"nct04524000","field":"status","kind":"trial","state":"development","label":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer: phase 2, active","href":"/trials/nct04524000/"},{"record":"nct04544189","field":"status","kind":"trial","state":"development","label":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer: phase 2, active","href":"/trials/nct04544189/"},{"record":"nct05226871","field":"status","kind":"trial","state":"development","label":"Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies: phase 2, active","href":"/trials/nct05226871/"},{"record":"nct07287917","field":"status","kind":"trial","state":"development","label":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct07287917/"},{"record":"nct05867251","field":"status","kind":"trial","state":"development","label":"Study of AVZO-021 in Patients With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05867251/"},{"record":"nct06428396","field":"status","kind":"trial","state":"development","label":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029): phase 2, active","href":"/trials/nct06428396/"},{"record":"nct06726148","field":"status","kind":"trial","state":"development","label":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06726148/"},{"record":"nct07288359","field":"status","kind":"trial","state":"development","label":"Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct07288359/"},{"record":"nct04606446","field":"status","kind":"trial","state":"development","label":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors: phase 2, recruiting","href":"/trials/nct04606446/"},{"record":"nct05038735","field":"status","kind":"trial","state":"development","label":"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.: phase 3, active","href":"/trials/nct05038735/"},{"record":"nct04851613","field":"status","kind":"trial","state":"development","label":"Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer: phase 3, active","href":"/trials/nct04851613/"},{"record":"nct04557449","field":"status","kind":"trial","state":"development","label":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors: phase 2, active","href":"/trials/nct04557449/"},{"record":"nct07368998","field":"status","kind":"trial","state":"development","label":"To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer: phase 2, recruiting","href":"/trials/nct07368998/"},{"record":"registry:fulvestrant","kind":"registry","state":"development","label":"ClinicalTrials.gov: 42 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/fulvestrant/#registry"}],"reasons":[]},{"id":"fulzerasib","name":"Fulzerasib","route":"/drugs/fulzerasib/","status":"approved","modality":"Small-molecule covalent KRAS G12C inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"kras","name":"KRAS","href":"/targets/kras/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"fulzerasib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/fulzerasib/"},{"record":"fulzerasib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2024: KRAS G12C-mutant advanced NSCLC after at least one systemic therapy","href":"/drugs/fulzerasib/"},{"record":"fulzerasib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2024","href":"https://english.nmpa.gov.cn/"},{"record":"nct06936644","field":"status","kind":"trial","state":"development","label":"A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation: phase 2, planned","href":"/trials/nct06936644/"},{"record":"nct07601048","field":"status","kind":"trial","state":"development","label":"A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment: phase 3, planned","href":"/trials/nct07601048/"},{"record":"nct07492342","field":"status","kind":"trial","state":"development","label":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC: phase 2, recruiting","href":"/trials/nct07492342/"},{"record":"nct07198841","field":"status","kind":"trial","state":"development","label":"IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation: phase 2, recruiting","href":"/trials/nct07198841/"},{"record":"nct07581912","field":"status","kind":"trial","state":"development","label":"Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases: phase 2, recruiting","href":"/trials/nct07581912/"},{"record":"registry:fulzerasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/fulzerasib/#registry"}],"reasons":[]},{"id":"furmonertinib","name":"Furmonertinib","route":"/drugs/furmonertinib/","status":"approved","modality":"Small-molecule third-generation EGFR TKI","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"egfr","name":"EGFR","href":"/targets/egfr/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"furmonertinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/furmonertinib/"},{"record":"furmonertinib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2021: EGFR T790M-positive locally advanced or metastatic NSCLC after EGFR TKI therapy","href":"/drugs/furmonertinib/"},{"record":"furmonertinib","field":"approvals[1]","kind":"approval","state":"approved","label":"China 2022: First-line EGFR exon 19 deletion or L858R NSCLC (FURLONG)","href":"/drugs/furmonertinib/"},{"record":"furmonertinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"nct06962865","field":"status","kind":"trial","state":"development","label":"A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Adv: phase 2, recruiting","href":"/trials/nct06962865/"},{"record":"nct06970639","field":"status","kind":"trial","state":"development","label":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases: phase 3, recruiting","href":"/trials/nct06970639/"},{"record":"nct07229599","field":"status","kind":"trial","state":"development","label":"A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer: phase 1/2, recruiting","href":"/trials/nct07229599/"},{"record":"nct07622186","field":"status","kind":"trial","state":"development","label":"A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC): phase 2, recruiting","href":"/trials/nct07622186/"},{"record":"nct05466149","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion: phase 2, active","href":"/trials/nct05466149/"},{"record":"nct06674343","field":"status","kind":"trial","state":"development","label":"Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations: phase 3, recruiting","href":"/trials/nct06674343/"},{"record":"nct05334277","field":"status","kind":"trial","state":"development","label":"Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA: phase 2, recruiting","href":"/trials/nct05334277/"},{"record":"nct05994131","field":"status","kind":"trial","state":"development","label":"IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC: phase 1/2, recruiting","href":"/trials/nct05994131/"},{"record":"nct05607550","field":"status","kind":"trial","state":"development","label":"Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With: phase 3, active","href":"/trials/nct05607550/"},{"record":"nct07185997","field":"status","kind":"trial","state":"development","label":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants W: phase 3, recruiting","href":"/trials/nct07185997/"},{"record":"nct04853342","field":"status","kind":"trial","state":"development","label":"To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy: phase 3, recruiting","href":"/trials/nct04853342/"},{"record":"registry:furmonertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 40 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/furmonertinib/#registry"}],"reasons":[]},{"id":"futibatinib","name":"Futibatinib","route":"/drugs/futibatinib/","status":"approved","modality":"Small-molecule irreversible kinase inhibitor (FGFR1-4)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"fgfr2","name":"FGFR2","href":"/targets/fgfr2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"futibatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/futibatinib/"},{"record":"futibatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2022: Previously treated FGFR2-fusion/rearranged intrahepatic cholangiocarcinoma (accelerated)","href":"/drugs/futibatinib/"},{"record":"futibatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2023: Same","href":"/drugs/futibatinib/"},{"record":"futibatinib","field":"approvals[2]","kind":"approval","state":"approved","label":"UK 2024: Locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement after at least one systemic treatment; NICE TA1005 recommended 11 September 2024 as an alternative to pemigatinib","href":"/drugs/futibatinib/"},{"record":"futibatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2022","href":"/regulatory/regions/"},{"record":"futibatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2023","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/lytgobi"},{"record":"futibatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2023","href":"https://products.mhra.gov.uk/?search=Lytgobi"},{"record":"futibatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2023","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"nct07710885","field":"status","kind":"trial","state":"development","label":"Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer: phase 3, recruiting","href":"/trials/nct07710885/"},{"record":"nct06506955","field":"status","kind":"trial","state":"development","label":"Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.: phase 2/3, active","href":"/trials/nct06506955/"},{"record":"nct07745296","field":"status","kind":"trial","state":"development","label":"Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer: phase 3, planned","href":"/trials/nct07745296/"},{"record":"nct05945823","field":"status","kind":"trial","state":"development","label":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors: phase 2, active","href":"/trials/nct05945823/"},{"record":"safir-abc10","field":"status","kind":"trial","state":"development","label":"SAFIR-ABC10: phase 3, recruiting","href":"/trials/safir-abc10/"},{"record":"registry:futibatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 12 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/futibatinib/#registry"}],"reasons":[]},{"id":"galeterone","name":"Galeterone","route":"/drugs/galeterone/","status":"withdrawn","modality":"small molecule","state":"stopped","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"androgen-receptor+cyp17a1","name":"Androgen receptor x CYP17A1","href":"/targets/androgen-receptor/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"galeterone","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/galeterone/","quote":"An experimental prostate cancer tablet meant to work in men whose cancer makes a broken form of the androgen receptor. The trial designed to prove it collapsed."},{"record":"armor3-sv","field":"result","kind":"trial","state":"stopped","label":"ARMOR3-SV: phase 3, negative","href":"/trials/armor3-sv/","quote":"Closed early after 38 of a planned 148 men were randomised; AR-V7 prevalence 8 percent (95 percent confidence interval 6 to 10) among 953 prescreened men. PSA50 response 13 percent with galeterone against 42 percent with enzalutamide. Galeterone development stopped."},{"record":"registry:galeterone","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/galeterone/#registry"}],"reasons":[{"drugId":"galeterone","drugName":"Galeterone","drugRoute":"/drugs/galeterone/","drugState":"stopped","record":"galeterone","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/galeterone/","quote":"An experimental prostate cancer tablet meant to work in men whose cancer makes a broken form of the androgen receptor. The trial designed to prove it collapsed."},{"drugId":"galeterone","drugName":"Galeterone","drugRoute":"/drugs/galeterone/","drugState":"stopped","record":"armor3-sv","kind":"trial","label":"ARMOR3-SV: phase 3, negative","href":"/trials/armor3-sv/","quote":"Closed early after 38 of a planned 148 men were randomised; AR-V7 prevalence 8 percent (95 percent confidence interval 6 to 10) among 953 prescreened men. PSA50 response 13 percent with galeterone against 42 percent with enzalutamide. Galeterone development stopped."}]},{"id":"garsorasib","name":"Garsorasib","route":"/drugs/garsorasib/","status":"approved","modality":"Small-molecule covalent KRAS G12C inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"kras","name":"KRAS","href":"/targets/kras/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"garsorasib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/garsorasib/"},{"record":"garsorasib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2024: KRAS G12C-mutant advanced NSCLC after at least one systemic therapy","href":"/drugs/garsorasib/"},{"record":"garsorasib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2024","href":"https://english.nmpa.gov.cn/"},{"record":"nct07601048","field":"status","kind":"trial","state":"development","label":"A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment: phase 3, planned","href":"/trials/nct07601048/"},{"record":"nct06300177","field":"status","kind":"trial","state":"development","label":"D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standar: phase 3, recruiting","href":"/trials/nct06300177/"},{"record":"nct05379946","field":"status","kind":"trial","state":"development","label":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors: phase 1/2, active","href":"/trials/nct05379946/"},{"record":"nct04585035","field":"status","kind":"trial","state":"development","label":"Study to Evaluate D-1553 in Subjects With Solid Tumors: phase 1/2, active","href":"/trials/nct04585035/"},{"record":"registry:garsorasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/garsorasib/#registry"}],"reasons":[]},{"id":"gedatolisib","name":"Gedatolisib","route":"/drugs/gedatolisib/","status":"approved","modality":"Small-molecule pan-PI3K/mTOR inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"pik3ca+akt","name":"PIK3CA / PI3K-alpha x AKT","href":"/targets/pik3ca/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"gedatolisib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/gedatolisib/"},{"record":"gedatolisib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2026: HR+/HER2- advanced breast cancer after CDK4/6 inhibitor (July 2026)","href":"/drugs/gedatolisib/"},{"record":"gedatolisib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2026","href":"/regulatory/regions/"},{"record":"nct06190899","field":"status","kind":"trial","state":"development","label":"Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct06190899/"},{"record":"nct05501886","field":"status","kind":"trial","state":"development","label":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1): phase 3, active","href":"/trials/nct05501886/"},{"record":"nct06757634","field":"status","kind":"trial","state":"development","label":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2): phase 3, recruiting","href":"/trials/nct06757634/"},{"record":"registry:gedatolisib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/gedatolisib/#registry"}],"reasons":[]},{"id":"gefitinib","name":"Gefitinib","route":"/drugs/gefitinib/","status":"approved","modality":"Small-molecule EGFR TKI (first generation, reversible)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"egfr","name":"EGFR","href":"/targets/egfr/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"gefitinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/gefitinib/"},{"record":"gefitinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2003: NSCLC after chemotherapy (accelerated; restricted 2005)","href":"/drugs/gefitinib/"},{"record":"gefitinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2009: EGFR-mutant NSCLC","href":"/drugs/gefitinib/"},{"record":"gefitinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2015: First-line NSCLC with EGFR exon 19 del or L858R","href":"/drugs/gefitinib/"},{"record":"gefitinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2003","href":"/regulatory/regions/"},{"record":"gefitinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2009","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/iressa"},{"record":"gefitinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2009","href":"https://products.mhra.gov.uk/?search=Iressa"},{"record":"gefitinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2002","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"gefitinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2005","href":"https://english.nmpa.gov.cn/"},{"record":"gefitinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Iressa"},{"record":"gefitinib","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"US 2012-04-25: withdrawal","href":"/drugs/gefitinib/","quote":"Withdrawn: the indication came off the label 9.0 years after its accelerated approval."},{"record":"nct02411448","field":"status","kind":"trial","state":"development","label":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE: phase 3, active","href":"/trials/nct02411448/"},{"record":"nct03944772","field":"status","kind":"trial","state":"development","label":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD): phase 2, active","href":"/trials/nct03944772/"},{"record":"nct03040973","field":"status","kind":"trial","state":"development","label":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone: phase 2, active","href":"/trials/nct03040973/"},{"record":"registry:gefitinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/gefitinib/#registry"}],"reasons":[{"drugId":"gefitinib","drugName":"Gefitinib","drugRoute":"/drugs/gefitinib/","drugState":"approved","record":"gefitinib","kind":"event","label":"US 2012-04-25: withdrawal","href":"/drugs/gefitinib/","quote":"Withdrawn: the indication came off the label 9.0 years after its accelerated approval."}]},{"id":"gfh375","name":"GFH375","route":"/drugs/gfh375/","status":"phase-3","modality":"small molecule (structure undisclosed or not yet in PubChem)","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"kras","name":"KRAS","href":"/targets/kras/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"gfh375","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/gfh375/"},{"record":"nct07784374","field":"status","kind":"trial","state":"development","label":"A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metast: phase 2, planned","href":"/trials/nct07784374/"},{"record":"nct07259590","field":"status","kind":"trial","state":"development","label":"A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation: phase 1/2, recruiting","href":"/trials/nct07259590/"},{"record":"nct06500676","field":"status","kind":"trial","state":"development","label":"A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations: phase 1/2, recruiting","href":"/trials/nct06500676/"},{"record":"nct07668752","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation: phase 3, recruiting","href":"/trials/nct07668752/"},{"record":"nct07262567","field":"status","kind":"trial","state":"development","label":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer: phase 3, recruiting","href":"/trials/nct07262567/"},{"record":"registry:gfh375","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/gfh375/#registry"}],"reasons":[]},{"id":"gilteritinib","name":"Gilteritinib","route":"/drugs/gilteritinib/","status":"approved","modality":"Small-molecule kinase inhibitor (FLT3, type I)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"flt3","name":"FLT3","href":"/targets/flt3/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"gilteritinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/gilteritinib/"},{"record":"gilteritinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: Relapsed or refractory FLT3-mutated AML","href":"/drugs/gilteritinib/"},{"record":"gilteritinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"gilteritinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2019","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/xospata"},{"record":"gilteritinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2019","href":"https://products.mhra.gov.uk/?search=Xospata"},{"record":"gilteritinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2018","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"gilteritinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"gilteritinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2019","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Xospata"},{"record":"nct04988555","field":"status","kind":"trial","state":"development","label":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1): phase 1/2, recruiting","href":"/trials/nct04988555/"},{"record":"nct05520567","field":"status","kind":"trial","state":"development","label":"A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia: phase 1/2, active","href":"/trials/nct05520567/"},{"record":"nct04293562","field":"status","kind":"trial","state":"development","label":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations: phase 3, recruiting","href":"/trials/nct04293562/"},{"record":"beat-aml-master-trial","field":"status","kind":"trial","state":"development","label":"Beat AML Master Trial: phase platform, recruiting","href":"/trials/beat-aml-master-trial/"},{"record":"registry:gilteritinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 29 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/gilteritinib/#registry"}],"reasons":[]},{"id":"giredestrant","name":"Giredestrant","route":"/drugs/giredestrant/","status":"phase-3","modality":"Oral SERD","state":"development","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"estrogen-receptor","name":"Estrogen receptor (ERα)","href":"/targets/estrogen-receptor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"giredestrant","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/giredestrant/"},{"record":"nct07541079","field":"status","kind":"trial","state":"development","label":"A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer): phase 3, recruiting","href":"/trials/nct07541079/"},{"record":"nct04576455","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer): phase 2, active","href":"/trials/nct04576455/"},{"record":"nct04802759","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer: phase 1/2, recruiting","href":"/trials/nct04802759/"},{"record":"nct06065748","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer): phase 3, active","href":"/trials/nct06065748/"},{"record":"nct07100106","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer: phase 1/2, recruiting","href":"/trials/nct07100106/"},{"record":"nct05296798","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer): phase 3, active","href":"/trials/nct05296798/"},{"record":"nct07054190","field":"status","kind":"trial","state":"development","label":"A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer: phase 2, recruiting","href":"/trials/nct07054190/"},{"record":"persevera","field":"result","kind":"trial","state":"stopped","label":"persevERA: phase 3, negative","href":"/trials/persevera/","quote":"PFS 33.1 vs 28.2 months, not significant."},{"record":"registry:giredestrant","kind":"registry","state":"development","label":"ClinicalTrials.gov: 16 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/giredestrant/#registry"}],"reasons":[{"drugId":"giredestrant","drugName":"Giredestrant","drugRoute":"/drugs/giredestrant/","drugState":"development","record":"persevera","kind":"trial","label":"persevERA: phase 3, negative","href":"/trials/persevera/","quote":"PFS 33.1 vs 28.2 months, not significant."}]},{"id":"glasdegib","name":"Glasdegib","route":"/drugs/glasdegib/","status":"approved","modality":"Small-molecule smoothened (hedgehog) inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"smoothened","name":"Smoothened (hedgehog pathway)","href":"/targets/smoothened/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"hedgehog-inhibitor","name":"Hedgehog inhibitor","href":"/technologies/hedgehog-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"glasdegib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/glasdegib/"},{"record":"glasdegib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: Newly diagnosed AML in adults ≥75 or unfit for intensive chemotherapy, with low-dose cytarabine","href":"/drugs/glasdegib/"},{"record":"glasdegib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2020: Same","href":"/drugs/glasdegib/"},{"record":"glasdegib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"glasdegib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2020","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/daurismo"},{"record":"glasdegib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2020","href":"https://products.mhra.gov.uk/?search=Daurismo"},{"record":"registry:glasdegib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/glasdegib/#registry"}],"reasons":[]},{"id":"glecirasib","name":"Glecirasib","route":"/drugs/glecirasib/","status":"approved","modality":"Oral covalent KRAS G12C inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"kras","name":"KRAS","href":"/targets/kras/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"glecirasib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/glecirasib/"},{"record":"glecirasib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2024: KRAS G12C-mutant advanced non-small cell lung cancer after prior systemic therapy","href":"/drugs/glecirasib/"},{"record":"glecirasib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2024","href":"https://english.nmpa.gov.cn/"},{"record":"nct07164170","field":"status","kind":"trial","state":"development","label":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib: phase 2, recruiting","href":"/trials/nct07164170/"},{"record":"nct06008288","field":"status","kind":"trial","state":"development","label":"A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.: phase 2, recruiting","href":"/trials/nct06008288/"},{"record":"nct07827261","field":"status","kind":"trial","state":"development","label":"A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer: phase 2, planned","href":"/trials/nct07827261/"},{"record":"nct05009329","field":"status","kind":"trial","state":"development","label":"A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China: phase 1/2, active","href":"/trials/nct05009329/"},{"record":"nct05276726","field":"status","kind":"trial","state":"development","label":"A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1: phase 1/2, recruiting","href":"/trials/nct05276726/"},{"record":"nct07601048","field":"status","kind":"trial","state":"development","label":"A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment: phase 3, planned","href":"/trials/nct07601048/"},{"record":"nct06416410","field":"status","kind":"trial","state":"development","label":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation: phase 3, recruiting","href":"/trials/nct06416410/"},{"record":"nct05194995","field":"status","kind":"trial","state":"development","label":"JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation: phase 1/2, active","href":"/trials/nct05194995/"},{"record":"nct05288205","field":"status","kind":"trial","state":"development","label":"Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation: phase 1/2, recruiting","href":"/trials/nct05288205/"},{"record":"registry:glecirasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/glecirasib/#registry"}],"reasons":[]},{"id":"glumetinib","name":"Glumetinib","route":"/drugs/glumetinib/","status":"approved","modality":"Oral selective MET tyrosine kinase inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"met","name":"MET","href":"/targets/met/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"glumetinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/glumetinib/"},{"record":"glumetinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2023: Locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping","href":"/drugs/glumetinib/"},{"record":"glumetinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"nct06829459","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N: phase 3, recruiting","href":"/trials/nct06829459/"},{"record":"nct04270591","field":"status","kind":"trial","state":"development","label":"Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer: phase 1/2, recruiting","href":"/trials/nct04270591/"},{"record":"nct06947291","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors: phase 2, recruiting","href":"/trials/nct06947291/"},{"record":"registry:glumetinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/glumetinib/#registry"}],"reasons":[]},{"id":"golidocitinib","name":"Golidocitinib","route":"/drugs/golidocitinib/","status":"approved","modality":"Oral selective JAK1 inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"jak1","name":"JAK1","href":"/targets/jak1/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"golidocitinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/golidocitinib/"},{"record":"golidocitinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2024: Relapsed or refractory peripheral T-cell lymphoma","href":"/drugs/golidocitinib/"},{"record":"golidocitinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2024","href":"https://english.nmpa.gov.cn/"},{"record":"nct07234162","field":"status","kind":"trial","state":"development","label":"A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19): phase 3, recruiting","href":"/trials/nct07234162/"},{"record":"nct07496229","field":"status","kind":"trial","state":"development","label":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3): phase 1/2, recruiting","href":"/trials/nct07496229/"},{"record":"nct06198907","field":"status","kind":"trial","state":"development","label":"Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC): phase 2, planned","href":"/trials/nct06198907/"},{"record":"nct07110103","field":"status","kind":"trial","state":"development","label":"Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC: phase 2, recruiting","href":"/trials/nct07110103/"},{"record":"registry:golidocitinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 37 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/golidocitinib/#registry"}],"reasons":[]},{"id":"gsk2256098","name":"GSK2256098","route":"/drugs/gsk2256098/","status":"phase-2","modality":"Oral focal adhesion kinase (FAK) inhibitor","state":"development","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"fak","name":"FAK (PTK2)","href":"/targets/fak/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"gsk2256098","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/gsk2256098/"},{"record":"registry:gsk2256098","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/gsk2256098/#registry"}],"reasons":[]},{"id":"hmpl-306","name":"HMPL-306","route":"/drugs/hmpl-306/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"idh","name":"IDH1 / IDH2","href":"/targets/idh/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"idh-inhibitor","name":"IDH inhibitor","href":"/technologies/idh-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"hmpl-306","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/hmpl-306/"},{"record":"nct06387069","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia: phase 3, recruiting","href":"/trials/nct06387069/"},{"record":"registry:hmpl-306","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/hmpl-306/#registry"}],"reasons":[]},{"id":"hmpl-453","name":"HMPL-453","route":"/drugs/hmpl-453/","status":"phase-3","modality":"small molecule (structure undisclosed or not yet in PubChem)","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"fgfr2","name":"FGFR2","href":"/targets/fgfr2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"hmpl-453","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/hmpl-453/"},{"record":"nct04353375","field":"status","kind":"trial","state":"development","label":"HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma: phase 2/3, recruiting","href":"/trials/nct04353375/"},{"record":"registry:hmpl-453","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/hmpl-453/#registry"}],"reasons":[]},{"id":"hr070803","name":"HR070803","route":"/drugs/hr070803/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"top1","name":"Topoisomerase I (TOP1)","href":"/targets/top1/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"hr070803","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/hr070803/"},{"record":"nct05945901","field":"status","kind":"trial","state":"development","label":"A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer: phase 2/3, active","href":"/trials/nct05945901/"},{"record":"registry:hr070803","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/hr070803/#registry"}],"reasons":[]},{"id":"hst-1011","name":"HST-1011","route":"/drugs/hst-1011/","status":"phase-2","modality":"Small-molecule inhibitor","state":"development","confidence":"medium","fields":["modality","mechanism"],"components":{"target":{"id":"cblb","name":"CBLB","href":"/targets/cblb/","confidence":"medium","from":["modality","mechanism"],"detail":null},"mechanismClass":{"id":"other-inhibitor","name":"Inhibitor (class not stated)","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"hst-1011","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/hst-1011/"},{"record":"nct05662397","field":"status","kind":"trial","state":"development","label":"A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody: phase 1/2, active","href":"/trials/nct05662397/"},{"record":"registry:hst-1011","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/hst-1011/#registry"}],"reasons":[]},{"id":"hydroxyurea","name":"Hydroxyurea (hydroxycarbamide)","route":"/drugs/hydroxyurea/","status":"approved","modality":"Oral ribonucleotide reductase inhibitor (cytoreductive)","state":"approved","confidence":"medium","fields":["modality","mechanism"],"components":{"target":{"id":"rrm1","name":"Ribonucleotide reductase (RRM1)","href":"/targets/rrm1/","confidence":"medium","from":["modality","mechanism"],"detail":null},"mechanismClass":{"id":"other-inhibitor","name":"Inhibitor (class not stated)","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"hydroxyurea","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/hydroxyurea/"},{"record":"hydroxyurea","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1967: CML, head and neck cancer with radiotherapy, melanoma, ovarian cancer (historic labelling)","href":"/drugs/hydroxyurea/"},{"record":"hydroxyurea","field":"approvals[1]","kind":"approval","state":"approved","label":"US 1998: Sickle cell anaemia (Droxia)","href":"/drugs/hydroxyurea/"},{"record":"hydroxyurea","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 1967","href":"/regulatory/regions/"},{"record":"hydroxyurea","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/siklos"},{"record":"hydroxyurea","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved","href":"https://products.mhra.gov.uk/?search=Hydrea"},{"record":"hydroxyurea","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"hydroxyurea","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved","href":"https://english.nmpa.gov.cn/"},{"record":"hydroxyurea","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Hydrea"},{"record":"registry:hydroxyurea","kind":"registry","state":"development","label":"ClinicalTrials.gov: 24 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/hydroxyurea/#registry"}],"reasons":[]},{"id":"ibrutinib","name":"Ibrutinib","route":"/drugs/ibrutinib/","status":"approved","modality":"Small-molecule covalent BTK inhibitor (first generation)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"btk","name":"BTK (Bruton tyrosine kinase)","href":"/targets/btk/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"ibrutinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ibrutinib/"},{"record":"ibrutinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2013: Relapsed mantle cell lymphoma (accelerated); first BTK inhibitor","href":"/drugs/ibrutinib/"},{"record":"ibrutinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2014: Relapsed CLL (RESONATE); del(17p) CLL","href":"/drugs/ibrutinib/"},{"record":"ibrutinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2016: First-line CLL (RESONATE-2)","href":"/drugs/ibrutinib/"},{"record":"ibrutinib","field":"approvals[3]","kind":"approval","state":"approved","label":"EU 2014: Relapsed mantle cell lymphoma; CLL after one prior therapy or with del(17p)/TP53 mutation","href":"/drugs/ibrutinib/"},{"record":"ibrutinib","field":"approvals[4]","kind":"approval","state":"approved","label":"EU 2022: Fixed-duration ibrutinib + venetoclax, first-line CLL (GLOW, CAPTIVATE)","href":"/drugs/ibrutinib/"},{"record":"ibrutinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2013","href":"/regulatory/regions/"},{"record":"ibrutinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2014","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica"},{"record":"ibrutinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2014","href":"https://products.mhra.gov.uk/?search=Imbruvica"},{"record":"ibrutinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2016","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"ibrutinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2017","href":"https://english.nmpa.gov.cn/"},{"record":"ibrutinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2015","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Imbruvica"},{"record":"ibrutinib","field":"regulatoryEvents[5]","kind":"event","state":"stopped","label":"US 2023-04-06: withdrawal","href":"/drugs/ibrutinib/","quote":"MCL and MZL indications voluntarily withdrawn after confirmatory trials missed"},{"record":"ibrutinib","field":"regulatoryEvents[6]","kind":"event","state":"stopped","label":"US 2023-05-18: withdrawal","href":"/drugs/ibrutinib/","quote":"Withdrawn: the indication came off the label 9.5 years after its accelerated approval."},{"record":"ibrutinib","field":"regulatoryEvents[7]","kind":"event","state":"stopped","label":"US 2023-05-18: withdrawal","href":"/drugs/ibrutinib/","quote":"Withdrawn: the indication came off the label 6.3 years after its accelerated approval."},{"record":"nct01804686","field":"status","kind":"trial","state":"development","label":"A Long-term Extension Study of PCI-32765 (Ibrutinib): phase 3, recruiting","href":"/trials/nct01804686/"},{"record":"nct05254743","field":"status","kind":"trial","state":"development","label":"A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): phase 3, recruiting","href":"/trials/nct05254743/"},{"record":"nct05963074","field":"status","kind":"trial","state":"development","label":"A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia: phase 2, active","href":"/trials/nct05963074/"},{"record":"nct05283720","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neopl: phase 2, active","href":"/trials/nct05283720/"},{"record":"bellwave-011","field":"status","kind":"trial","state":"development","label":"BELLWAVE-011: phase 3, recruiting","href":"/trials/bellwave-011/"},{"record":"nct03328078","field":"status","kind":"trial","state":"development","label":"CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL): phase 1/2, recruiting","href":"/trials/nct03328078/"},{"record":"nct03960840","field":"status","kind":"trial","state":"development","label":"Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL: phase 1/2, active","href":"/trials/nct03960840/"},{"record":"resolve","field":"result","kind":"trial","state":"stopped","label":"RESOLVE: phase 3, negative","href":"/trials/resolve/","quote":"Median overall survival 9.7 months with ibrutinib plus nab-paclitaxel and gemcitabine against 10.8 months with placebo (p 0.3225); progression-free survival 5.3 against 6.0 months (p below 0.0001); response 29 against 42 percent."},{"record":"nct04509700","field":"status","kind":"trial","state":"development","label":"Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465): phase 2, active","href":"/trials/nct04509700/"},{"record":"nct02477696","field":"status","kind":"trial","state":"development","label":"Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL): phase 3, active","href":"/trials/nct02477696/"},{"record":"nct04494503","field":"status","kind":"trial","state":"development","label":"Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL: phase 1/2, recruiting","href":"/trials/nct04494503/"},{"record":"nct04662255","field":"status","kind":"trial","state":"development","label":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL): phase 3, active","href":"/trials/nct04662255/"},{"record":"nct03379428","field":"status","kind":"trial","state":"development","label":"Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer: phase 1/2, active","href":"/trials/nct03379428/"},{"record":"registry:ibrutinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 29 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ibrutinib/#registry"}],"reasons":[{"drugId":"ibrutinib","drugName":"Ibrutinib","drugRoute":"/drugs/ibrutinib/","drugState":"approved","record":"ibrutinib","kind":"event","label":"US 2023-04-06: withdrawal","href":"/drugs/ibrutinib/","quote":"MCL and MZL indications voluntarily withdrawn after confirmatory trials missed"},{"drugId":"ibrutinib","drugName":"Ibrutinib","drugRoute":"/drugs/ibrutinib/","drugState":"approved","record":"ibrutinib","kind":"event","label":"US 2023-05-18: withdrawal","href":"/drugs/ibrutinib/","quote":"Withdrawn: the indication came off the label 9.5 years after its accelerated approval."},{"drugId":"ibrutinib","drugName":"Ibrutinib","drugRoute":"/drugs/ibrutinib/","drugState":"approved","record":"ibrutinib","kind":"event","label":"US 2023-05-18: withdrawal","href":"/drugs/ibrutinib/","quote":"Withdrawn: the indication came off the label 6.3 years after its accelerated approval."},{"drugId":"ibrutinib","drugName":"Ibrutinib","drugRoute":"/drugs/ibrutinib/","drugState":"approved","record":"resolve","kind":"trial","label":"RESOLVE: phase 3, negative","href":"/trials/resolve/","quote":"Median overall survival 9.7 months with ibrutinib plus nab-paclitaxel and gemcitabine against 10.8 months with placebo (p 0.3225); progression-free survival 5.3 against 6.0 months (p below 0.0001); response 29 against 42 percent."}]},{"id":"icotinib","name":"Icotinib","route":"/drugs/icotinib/","status":"approved","modality":"Small-molecule first-generation EGFR TKI","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"egfr","name":"EGFR","href":"/targets/egfr/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"icotinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/icotinib/"},{"record":"icotinib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2011: Advanced NSCLC after failure of at least one chemotherapy regimen (ICOGEN)","href":"/drugs/icotinib/"},{"record":"icotinib","field":"approvals[1]","kind":"approval","state":"approved","label":"China 2014: First-line EGFR-mutant NSCLC","href":"/drugs/icotinib/"},{"record":"icotinib","field":"approvals[2]","kind":"approval","state":"approved","label":"China 2021: Adjuvant treatment of resected stage II to IIIA EGFR-mutant NSCLC (EVIDENCE)","href":"/drugs/icotinib/"},{"record":"icotinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2011","href":"https://english.nmpa.gov.cn/"},{"record":"nct06041776","field":"status","kind":"trial","state":"development","label":"Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations: phase 3, recruiting","href":"/trials/nct06041776/"},{"record":"nct06955325","field":"status","kind":"trial","state":"development","label":"Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations: phase 3, planned","href":"/trials/nct06955325/"},{"record":"registry:icotinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/icotinib/#registry"}],"reasons":[]},{"id":"idelalisib","name":"Idelalisib","route":"/drugs/idelalisib/","status":"approved","modality":"Small-molecule PI3Kδ inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"pik3ca","name":"PIK3CA / PI3K-alpha","href":"/targets/pik3ca/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"idelalisib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/idelalisib/"},{"record":"idelalisib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2014: Relapsed CLL with rituximab; relapsed FL and SLL (accelerated, withdrawn 2022)","href":"/drugs/idelalisib/"},{"record":"idelalisib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2014: CLL, FL","href":"/drugs/idelalisib/"},{"record":"idelalisib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2014","href":"/regulatory/regions/"},{"record":"idelalisib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2014","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig"},{"record":"idelalisib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2014","href":"https://products.mhra.gov.uk/?search=Zydelig"},{"record":"idelalisib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Zydelig"},{"record":"idelalisib","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"US 2022-02-18: withdrawal","href":"/drugs/idelalisib/","quote":"Withdrawn: the indication came off the label 7.6 years after its accelerated approval."},{"record":"nct02970318","field":"status","kind":"trial","state":"development","label":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL: phase 3, active","href":"/trials/nct02970318/"},{"record":"nct06846671","field":"status","kind":"trial","state":"development","label":"A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors: phase 3, recruiting","href":"/trials/nct06846671/"},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"registry:idelalisib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/idelalisib/#registry"}],"reasons":[{"drugId":"idelalisib","drugName":"Idelalisib","drugRoute":"/drugs/idelalisib/","drugState":"approved","record":"idelalisib","kind":"event","label":"US 2022-02-18: withdrawal","href":"/drugs/idelalisib/","quote":"Withdrawn: the indication came off the label 7.6 years after its accelerated approval."}]},{"id":"imatinib","name":"Imatinib","route":"/drugs/imatinib/","status":"approved","modality":"Small-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"kit","name":"KIT","href":"/targets/kit/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"imatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/imatinib/"},{"record":"imatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2001: Chronic myeloid leukaemia","href":"/drugs/imatinib/"},{"record":"imatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2002: KIT+ GIST","href":"/drugs/imatinib/"},{"record":"imatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2001","href":"/regulatory/regions/"},{"record":"imatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2001","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/glivec"},{"record":"imatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2001","href":"https://products.mhra.gov.uk/?search=Gleevec"},{"record":"imatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2001","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"imatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2002","href":"https://english.nmpa.gov.cn/"},{"record":"imatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2001","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Gleevec"},{"record":"imatinib","field":"regional.IN","kind":"regional","state":"approved","label":"CDSCO (DCGI) (IN): approved","href":"https://en.wikipedia.org/wiki/Novartis_v._Union_of_India_%26_Others"},{"record":"nct03459534","field":"status","kind":"trial","state":"development","label":"A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs: phase 3, recruiting","href":"/trials/nct03459534/"},{"record":"nct04971226","field":"status","kind":"trial","state":"development","label":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP: phase 3, active","href":"/trials/nct04971226/"},{"record":"nct07406633","field":"status","kind":"trial","state":"development","label":"KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line): phase 2, recruiting","href":"/trials/nct07406633/"},{"record":"nct03722420","field":"status","kind":"trial","state":"development","label":"Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China): phase 3, active","href":"/trials/nct03722420/"},{"record":"registry:imatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 9 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/imatinib/#registry"}],"reasons":[]},{"id":"imetelstat","name":"Imetelstat","route":"/drugs/imetelstat/","status":"approved","modality":"Telomerase inhibitor (oligonucleotide)","state":"approved","confidence":"medium","fields":["modality","mechanism"],"components":{"target":{"id":"mertk","name":"MERTK","href":"/targets/mertk/","confidence":"medium","from":["modality","mechanism"],"detail":null},"mechanismClass":{"id":"other-inhibitor","name":"Inhibitor (class not stated)","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"imetelstat","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/imetelstat/"},{"record":"imetelstat","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2024: Low- to intermediate-1-risk MDS with transfusion-dependent anaemia after ESA failure","href":"/drugs/imetelstat/"},{"record":"imetelstat","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2025: Lower-risk MDS transfusion-dependent anaemia","href":"/drugs/imetelstat/"},{"record":"imetelstat","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2024","href":"/regulatory/regions/"},{"record":"imetelstat","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/rytelo"},{"record":"impactmf","field":"status","kind":"trial","state":"development","label":"IMpactMF: phase 3, active","href":"/trials/impactmf/"},{"record":"nct05583552","field":"status","kind":"trial","state":"development","label":"Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy: phase 2, active","href":"/trials/nct05583552/"},{"record":"registry:imetelstat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/imetelstat/#registry"}],"reasons":[]},{"id":"imiquimod","name":"Imiquimod","route":"/drugs/imiquimod/","status":"approved","modality":"Topical immune response modifier (TLR7 agonist)","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"tlr7","name":"Toll-like receptor 7 (TLR7)","href":"/targets/tlr7/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"receptor-agonist","name":"Receptor agonist","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"imiquimod","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/imiquimod/"},{"record":"imiquimod","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1997: External genital and perianal warts","href":"/drugs/imiquimod/"},{"record":"imiquimod","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2004: Actinic keratosis; superficial basal cell carcinoma in immunocompetent adults","href":"/drugs/imiquimod/"},{"record":"imiquimod","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 1998: Genital warts, superficial basal cell carcinoma and actinic keratosis (Aldara)","href":"/drugs/imiquimod/"},{"record":"imiquimod","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 1998","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/aldara"},{"record":"scin-trial","field":"result","kind":"trial","state":"stopped","label":"SCIN (curettage then imiquimod against excision for nodular basal cell carcinoma): phase 3, negative","href":"/trials/scin-trial/","quote":"Freedom from treatment failure at five years 77.8 per cent after curettage with imiquimod against 98.2 per cent after surgical excision; relative risk of failure 15.93 (95 per cent confidence interval 2.10 to 120.64), non-inferiority not concluded."},{"record":"sins-trial","field":"result","kind":"trial","state":"stopped","label":"SINS (surgical excision against imiquimod cream for basal cell carcinoma): phase 3, negative","href":"/trials/sins-trial/","quote":"Clinical success at three years 84 per cent with imiquimod against 98 per cent with surgery (relative risk 0.84, 98 per cent confidence interval 0.78 to 0.91, p<0.0001), and at five years 82.5 against 97.7 per cent; imiquimod was inferior, not non-inferior."},{"record":"registry:imiquimod","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/imiquimod/#registry"}],"reasons":[{"drugId":"imiquimod","drugName":"Imiquimod","drugRoute":"/drugs/imiquimod/","drugState":"approved","record":"scin-trial","kind":"trial","label":"SCIN (curettage then imiquimod against excision for nodular basal cell carcinoma): phase 3, negative","href":"/trials/scin-trial/","quote":"Freedom from treatment failure at five years 77.8 per cent after curettage with imiquimod against 98.2 per cent after surgical excision; relative risk of failure 15.93 (95 per cent confidence interval 2.10 to 120.64), non-inferiority not concluded."},{"drugId":"imiquimod","drugName":"Imiquimod","drugRoute":"/drugs/imiquimod/","drugState":"approved","record":"sins-trial","kind":"trial","label":"SINS (surgical excision against imiquimod cream for basal cell carcinoma): phase 3, negative","href":"/trials/sins-trial/","quote":"Clinical success at three years 84 per cent with imiquimod against 98 per cent with surgery (relative risk 0.84, 98 per cent confidence interval 0.78 to 0.91, p<0.0001), and at five years 82.5 against 97.7 per cent; imiquimod was inferior, not non-inferior."}]},{"id":"imlunestrant","name":"Imlunestrant","route":"/drugs/imlunestrant/","status":"approved","modality":"Oral SERD","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"estrogen-receptor","name":"Estrogen receptor (ERα)","href":"/targets/estrogen-receptor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"imlunestrant","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/imlunestrant/"},{"record":"imlunestrant","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2025: ER+/HER2- ESR1-mutated advanced breast cancer after ≥1 line of endocrine therapy","href":"/drugs/imlunestrant/"},{"record":"imlunestrant","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2026: ESR1-mutant ER+/HER2- mBC; 9 Jan 2026","href":"/drugs/imlunestrant/"},{"record":"imlunestrant","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2025","href":"/regulatory/regions/"},{"record":"imlunestrant","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2026","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/inluriyo"},{"record":"imlunestrant","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2026","href":"https://www.gov.uk/government/news/mhra-approves-imlunestrant-tosylate-inluryo-a-new-treatment-for-breast-cancer"},{"record":"imlunestrant","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2025","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"nct07287098","field":"status","kind":"trial","state":"development","label":"A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer: phase 2, recruiting","href":"/trials/nct07287098/"},{"record":"nct05514054","field":"status","kind":"trial","state":"development","label":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer: phase 3, active","href":"/trials/nct05514054/"},{"record":"registry:imlunestrant","kind":"registry","state":"development","label":"ClinicalTrials.gov: 9 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/imlunestrant/#registry"}],"reasons":[]},{"id":"imp1734","name":"IMP1734","route":"/drugs/imp1734/","status":"phase-2","modality":"Small-molecule inhibitor","state":"development","confidence":"medium","fields":["modality","mechanism"],"components":{"target":{"id":"parp","name":"PARP","href":"/targets/parp/","confidence":"medium","from":["modality","mechanism"],"detail":null},"mechanismClass":{"id":"parp-inhibitor","name":"PARP inhibitor","href":"/technologies/parp-inhibitor/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"imp1734","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/imp1734/"},{"record":"nct06253130","field":"status","kind":"trial","state":"development","label":"A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06253130/"},{"record":"registry:imp1734","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/imp1734/#registry"}],"reasons":[]},{"id":"in10018","name":"IN10018","route":"/drugs/in10018/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"fak","name":"FAK (PTK2)","href":"/targets/fak/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"in10018","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/in10018/"},{"record":"nct07174908","field":"status","kind":"trial","state":"development","label":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation: phase 3, recruiting","href":"/trials/nct07174908/"},{"record":"nct07833202","field":"status","kind":"trial","state":"development","label":"A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutatio: phase 3, planned","href":"/trials/nct07833202/"},{"record":"nct06166836","field":"status","kind":"trial","state":"development","label":"a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors: phase 1/2, active","href":"/trials/nct06166836/"},{"record":"nct06708663","field":"status","kind":"trial","state":"development","label":"HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours: phase 1/2, recruiting","href":"/trials/nct06708663/"},{"record":"nct05994131","field":"status","kind":"trial","state":"development","label":"IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC: phase 1/2, recruiting","href":"/trials/nct05994131/"},{"record":"nct06030258","field":"status","kind":"trial","state":"development","label":"IN10018 Combination Therapy in Treatment-naïve ES-SCLC: phase 1/2, recruiting","href":"/trials/nct06030258/"},{"record":"nct06014528","field":"status","kind":"trial","state":"development","label":"IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurren: phase 2, recruiting","href":"/trials/nct06014528/"},{"record":"nct07441174","field":"status","kind":"trial","state":"development","label":"IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors: phase 1/2, recruiting","href":"/trials/nct07441174/"},{"record":"nct05551507","field":"status","kind":"trial","state":"development","label":"IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer: phase 1/2, recruiting","href":"/trials/nct05551507/"},{"record":"nct05827796","field":"status","kind":"trial","state":"development","label":"IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer: phase 1/2, recruiting","href":"/trials/nct05827796/"},{"record":"nct05379946","field":"status","kind":"trial","state":"development","label":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors: phase 1/2, active","href":"/trials/nct05379946/"},{"record":"registry:in10018","kind":"registry","state":"development","label":"ClinicalTrials.gov: 12 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/in10018/#registry"}],"reasons":[]},{"id":"incb161734","name":"INCB161734","route":"/drugs/incb161734/","status":"phase-3","modality":"small molecule (structure undisclosed or not yet in PubChem)","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"kras","name":"KRAS","href":"/targets/kras/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"incb161734","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/incb161734/"},{"record":"nct07522073","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma: phase 3, recruiting","href":"/trials/nct07522073/"},{"record":"registry:incb161734","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/incb161734/#registry"}],"reasons":[]},{"id":"infigratinib","name":"Infigratinib","route":"/drugs/infigratinib/","status":"withdrawn","modality":"Oral FGFR1 to 3 kinase inhibitor","state":"stopped","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"fgfr2","name":"FGFR2","href":"/targets/fgfr2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"infigratinib","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/infigratinib/","quote":"Infigratinib is an FGFR inhibitor pill given accelerated approval in the United States in 2021 for bile duct cancer with an FGFR2 fusion, then withdrawn in 2024 when its confirmatory trial could not enrol; it is now being developed for achondroplasia instead."},{"record":"infigratinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2021: Previously treated unresectable or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement (accelerated approval)","href":"/drugs/infigratinib/"},{"record":"infigratinib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/febseltiq","quote":"Febseltiq (Helsinn Birex Pharmaceuticals Ltd): marketing authorisation application withdrawn before a Commission decision. EMA register: 'Application withdrawn: The application for this medicine has been withdrawn'; checked 2026-09-24"},{"record":"infigratinib","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"US 2024-05-16: withdrawal","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma","quote":"Withdrawn: the indication came off the label 3.0 years after its accelerated approval."},{"record":"registry:infigratinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/infigratinib/#registry"}],"reasons":[{"drugId":"infigratinib","drugName":"Infigratinib","drugRoute":"/drugs/infigratinib/","drugState":"stopped","record":"infigratinib","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/infigratinib/","quote":"Infigratinib is an FGFR inhibitor pill given accelerated approval in the United States in 2021 for bile duct cancer with an FGFR2 fusion, then withdrawn in 2024 when its confirmatory trial could not enrol; it is now being developed for achondroplasia instead."},{"drugId":"infigratinib","drugName":"Infigratinib","drugRoute":"/drugs/infigratinib/","drugState":"stopped","record":"infigratinib","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/febseltiq","quote":"Febseltiq (Helsinn Birex Pharmaceuticals Ltd): marketing authorisation application withdrawn before a Commission decision. EMA register: 'Application withdrawn: The application for this medicine has been withdrawn'; checked 2026-09-24"},{"drugId":"infigratinib","drugName":"Infigratinib","drugRoute":"/drugs/infigratinib/","drugState":"stopped","record":"infigratinib","kind":"event","label":"US 2024-05-16: withdrawal","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma","quote":"Withdrawn: the indication came off the label 3.0 years after its accelerated approval."}]},{"id":"iniparib","name":"Iniparib","route":"/drugs/iniparib/","status":"negative","modality":"Small molecule (claimed PARP inhibitor)","state":"stopped","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"parp","name":"PARP","href":"/targets/parp/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"parp-inhibitor","name":"PARP inhibitor","href":"/technologies/parp-inhibitor/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"iniparib","field":"status","kind":"drug","state":"stopped","label":"Drug record status: negative","href":"/drugs/iniparib/","quote":"Billed as the first PARP inhibitor for triple-negative breast cancer, it failed its phase 3 in 2011. It turned out not to inhibit PARP at all."}],"reasons":[{"drugId":"iniparib","drugName":"Iniparib","drugRoute":"/drugs/iniparib/","drugState":"stopped","record":"iniparib","kind":"drug","label":"Drug record status: negative","href":"/drugs/iniparib/","quote":"Billed as the first PARP inhibitor for triple-negative breast cancer, it failed its phase 3 in 2011. It turned out not to inhibit PARP at all."}]},{"id":"ipatasertib","name":"Ipatasertib","route":"/drugs/ipatasertib/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"akt","name":"AKT","href":"/targets/akt/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"pi3k-akt-mtor-inhibitor","name":"PI3K, AKT or mTOR inhibitor","href":"/technologies/pi3k-akt-mtor-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"ipatasertib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/ipatasertib/"},{"record":"nct05862285","field":"status","kind":"trial","state":"development","label":"A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study: phase 3, recruiting","href":"/trials/nct05862285/"},{"record":"nct04931342","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors: phase 2, active","href":"/trials/nct04931342/"},{"record":"nct04802759","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer: phase 1/2, recruiting","href":"/trials/nct04802759/"},{"record":"nct03424005","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer: phase 1/2, recruiting","href":"/trials/nct03424005/"},{"record":"barbican","field":"status","kind":"trial","state":"development","label":"BARBICAN: phase 2, active","href":"/trials/barbican/"},{"record":"ipatunity130","field":"result","kind":"trial","state":"stopped","label":"IPATunity130: phase 3, negative","href":"/trials/ipatunity130/","quote":"PFS 7.4 vs 6.1 months (HR 1.02, 0.71 to 1.45); OS 24.4 vs 24.9 months (HR 1.08). Negative."},{"record":"nct04589845","field":"status","kind":"trial","state":"development","label":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study: phase 2, active","href":"/trials/nct04589845/"},{"record":"registry:ipatasertib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 18 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ipatasertib/#registry"}],"reasons":[{"drugId":"ipatasertib","drugName":"Ipatasertib","drugRoute":"/drugs/ipatasertib/","drugState":"development","record":"ipatunity130","kind":"trial","label":"IPATunity130: phase 3, negative","href":"/trials/ipatunity130/","quote":"PFS 7.4 vs 6.1 months (HR 1.02, 0.71 to 1.45); OS 24.4 vs 24.9 months (HR 1.08). Negative."}]},{"id":"irinotecan","name":"Irinotecan (and liposomal irinotecan)","route":"/drugs/irinotecan/","status":"approved","modality":"Topoisomerase I inhibitor (camptothecin prodrug)","state":"approved","confidence":"medium","fields":["target record (drugs field)","modality","mechanism"],"components":{"target":{"id":"ugt1a1","name":"UGT1A1","href":"/targets/ugt1a1/","confidence":"high","from":["target record (drugs field)"],"detail":null},"mechanismClass":{"id":"other-inhibitor","name":"Inhibitor (class not stated)","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"irinotecan","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/irinotecan/"},{"record":"irinotecan","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1996: Metastatic colorectal cancer after 5-FU; first line with 5-FU/LV 2000","href":"/drugs/irinotecan/"},{"record":"irinotecan","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2015: Liposomal irinotecan with 5-FU/LV in metastatic pancreatic cancer after gemcitabine","href":"/drugs/irinotecan/"},{"record":"irinotecan","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2024: Liposomal irinotecan in NALIRIFOX first-line metastatic pancreatic cancer","href":"/drugs/irinotecan/"},{"record":"irinotecan","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 1996","href":"/regulatory/regions/"},{"record":"irinotecan","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-pegylated-liposomal"},{"record":"irinotecan","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved","href":"https://products.mhra.gov.uk/?search=Campto"},{"record":"irinotecan","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 1994","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"irinotecan","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved","href":"https://english.nmpa.gov.cn/"},{"record":"irinotecan","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Campto"},{"record":"nct07585279","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer: phase 2/3, planned","href":"/trials/nct07585279/"},{"record":"nct05592626","field":"status","kind":"trial","state":"development","label":"A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05592626/"},{"record":"nct04657068","field":"status","kind":"trial","state":"development","label":"A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors: phase 1/2, recruiting","href":"/trials/nct04657068/"},{"record":"n0147","field":"result","kind":"trial","state":"stopped","label":"Alliance N0147: phase 3, negative","href":"/trials/n0147/","quote":"Three-year disease-free survival 71.5 with cetuximab against 74.6 percent without, in KRAS wild-type disease."},{"record":"nct06219941","field":"status","kind":"trial","state":"development","label":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2: phase 2, recruiting","href":"/trials/nct06219941/"},{"record":"nct07570914","field":"status","kind":"trial","state":"development","label":"Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases: phase 2, planned","href":"/trials/nct07570914/"},{"record":"nct04221035","field":"status","kind":"trial","state":"development","label":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN): phase 3, recruiting","href":"/trials/nct04221035/"},{"record":"nct07356973","field":"status","kind":"trial","state":"development","label":"Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma: phase 2, recruiting","href":"/trials/nct07356973/"},{"record":"nct06192680","field":"status","kind":"trial","state":"development","label":"Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer: phase 2, planned","href":"/trials/nct06192680/"},{"record":"nct06184698","field":"status","kind":"trial","state":"development","label":"Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct06184698/"},{"record":"nct05854498","field":"status","kind":"trial","state":"development","label":"Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05854498/"},{"record":"nct07062536","field":"status","kind":"trial","state":"development","label":"mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line: phase 2, recruiting","href":"/trials/nct07062536/"},{"record":"norpact-1","field":"result","kind":"trial","state":"stopped","label":"NORPACT-1: phase 2, negative","href":"/trials/norpact-1/","quote":"Alive at 18 months: 60 percent with neoadjuvant FOLFIRINOX against 73 percent with upfront surgery (p 0.032); median overall survival 25.1 against 38.5 months (hazard ratio 1.52, p 0.050)."},{"record":"petacc-3","field":"result","kind":"trial","state":"stopped","label":"PETACC-3: phase 3, negative","href":"/trials/petacc-3/","quote":"Five-year disease-free survival 56.7 against 54.3 percent (p=0.106); no overall survival gain."},{"record":"nct07271355","field":"status","kind":"trial","state":"development","label":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases,: phase 3, planned","href":"/trials/nct07271355/"},{"record":"prophylochip","field":"result","kind":"trial","state":"stopped","label":"PROPHYLOCHIP-PRODIGE 15: phase 3, negative","href":"/trials/prophylochip/","quote":"Three-year disease-free survival 44 percent with second-look surgery and HIPEC against 53 percent with surveillance."},{"record":"nct07521605","field":"status","kind":"trial","state":"development","label":"Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer: phase 2, planned","href":"/trials/nct07521605/"},{"record":"nct07831993","field":"status","kind":"trial","state":"development","label":"Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer: phase 2, recruiting","href":"/trials/nct07831993/"},{"record":"nct07104604","field":"status","kind":"trial","state":"development","label":"Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally: phase 2, recruiting","href":"/trials/nct07104604/"},{"record":"nct04725994","field":"status","kind":"trial","state":"development","label":"Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer: phase 1/2, active","href":"/trials/nct04725994/"},{"record":"nct06958328","field":"status","kind":"trial","state":"development","label":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer: phase 3, recruiting","href":"/trials/nct06958328/"},{"record":"nct05863195","field":"status","kind":"trial","state":"development","label":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial: phase 3, recruiting","href":"/trials/nct05863195/"},{"record":"nct03977233","field":"status","kind":"trial","state":"development","label":"Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer: phase 2, recruiting","href":"/trials/nct03977233/"},{"record":"nct04094688","field":"status","kind":"trial","state":"development","label":"Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer: phase 3, active","href":"/trials/nct04094688/"},{"record":"registry:irinotecan","kind":"registry","state":"development","label":"ClinicalTrials.gov: 25 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/irinotecan/#registry"}],"reasons":[{"drugId":"irinotecan","drugName":"Irinotecan (and liposomal irinotecan)","drugRoute":"/drugs/irinotecan/","drugState":"approved","record":"n0147","kind":"trial","label":"Alliance N0147: phase 3, negative","href":"/trials/n0147/","quote":"Three-year disease-free survival 71.5 with cetuximab against 74.6 percent without, in KRAS wild-type disease."},{"drugId":"irinotecan","drugName":"Irinotecan (and liposomal irinotecan)","drugRoute":"/drugs/irinotecan/","drugState":"approved","record":"norpact-1","kind":"trial","label":"NORPACT-1: phase 2, negative","href":"/trials/norpact-1/","quote":"Alive at 18 months: 60 percent with neoadjuvant FOLFIRINOX against 73 percent with upfront surgery (p 0.032); median overall survival 25.1 against 38.5 months (hazard ratio 1.52, p 0.050)."},{"drugId":"irinotecan","drugName":"Irinotecan (and liposomal irinotecan)","drugRoute":"/drugs/irinotecan/","drugState":"approved","record":"petacc-3","kind":"trial","label":"PETACC-3: phase 3, negative","href":"/trials/petacc-3/","quote":"Five-year disease-free survival 56.7 against 54.3 percent (p=0.106); no overall survival gain."},{"drugId":"irinotecan","drugName":"Irinotecan (and liposomal irinotecan)","drugRoute":"/drugs/irinotecan/","drugState":"approved","record":"prophylochip","kind":"trial","label":"PROPHYLOCHIP-PRODIGE 15: phase 3, negative","href":"/trials/prophylochip/","quote":"Three-year disease-free survival 44 percent with second-look surgery and HIPEC against 53 percent with surveillance."}]},{"id":"iruplinalkib","name":"Iruplinalkib","route":"/drugs/iruplinalkib/","status":"approved","modality":"Oral ALK and ROS1 tyrosine kinase inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"alk+ros1","name":"ALK x ROS1","href":"/targets/alk/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"iruplinalkib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/iruplinalkib/"},{"record":"iruplinalkib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2023: ALK-positive non-small-cell lung cancer after crizotinib; first line from 2024","href":"/drugs/iruplinalkib/"},{"record":"iruplinalkib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"nct05765877","field":"status","kind":"trial","state":"development","label":"Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct05765877/"},{"record":"registry:iruplinalkib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/iruplinalkib/#registry"}],"reasons":[]},{"id":"isotretinoin","name":"Isotretinoin","route":"/drugs/isotretinoin/","status":"approved","modality":"Oral retinoid (differentiating agent)","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"rara+rxr","name":"Retinoic acid receptor alpha x Retinoid X receptor","href":"/targets/rara/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"isotretinoin","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/isotretinoin/"},{"record":"isotretinoin","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1982: Severe recalcitrant nodular acne (use in high-risk neuroblastoma is off-label but standard)","href":"/drugs/isotretinoin/"},{"record":"registry:isotretinoin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/isotretinoin/#registry"}],"reasons":[]},{"id":"ivosidenib","name":"Ivosidenib","route":"/drugs/ivosidenib/","status":"approved","modality":"Small-molecule IDH1 inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"idh","name":"IDH1 / IDH2","href":"/targets/idh/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"idh-inhibitor","name":"IDH inhibitor","href":"/technologies/idh-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"allosteric","name":"Allosteric","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"ivosidenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ivosidenib/"},{"record":"ivosidenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: Relapsed/refractory IDH1-mutated AML","href":"/drugs/ivosidenib/"},{"record":"ivosidenib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2019: Newly diagnosed IDH1-mutated AML unfit for intensive chemotherapy","href":"/drugs/ivosidenib/"},{"record":"ivosidenib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2021: Previously treated IDH1-mutated cholangiocarcinoma","href":"/drugs/ivosidenib/"},{"record":"ivosidenib","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2022: Newly diagnosed IDH1-mutated AML with azacitidine (AGILE)","href":"/drugs/ivosidenib/"},{"record":"ivosidenib","field":"approvals[4]","kind":"approval","state":"approved","label":"US 2023: Relapsed/refractory IDH1-mutated MDS","href":"/drugs/ivosidenib/"},{"record":"ivosidenib","field":"approvals[5]","kind":"approval","state":"approved","label":"UK 2024: Locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation after one or more systemic treatments; NICE TA948 recommended 31 January 2024 with a commercial arrangement","href":"/drugs/ivosidenib/"},{"record":"ivosidenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"ivosidenib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2023","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tibsovo"},{"record":"ivosidenib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2023","href":"https://products.mhra.gov.uk/?search=Tibsovo"},{"record":"ivosidenib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2025","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"ivosidenib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2022","href":"https://english.nmpa.gov.cn/"},{"record":"ivosidenib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2023","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Tibsovo"},{"record":"nct05876754","field":"status","kind":"trial","state":"development","label":"An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma: phase 3, active","href":"/trials/nct05876754/"},{"record":"nct07282262","field":"status","kind":"trial","state":"development","label":"An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.: phase 2, recruiting","href":"/trials/nct07282262/"},{"record":"nct05907057","field":"status","kind":"trial","state":"development","label":"An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.: phase 3, recruiting","href":"/trials/nct05907057/"},{"record":"beat-aml-master-trial","field":"status","kind":"trial","state":"development","label":"Beat AML Master Trial: phase platform, recruiting","href":"/trials/beat-aml-master-trial/"},{"record":"nct07745296","field":"status","kind":"trial","state":"development","label":"Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer: phase 3, planned","href":"/trials/nct07745296/"},{"record":"nct06127407","field":"status","kind":"trial","state":"development","label":"Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen: phase 3, recruiting","href":"/trials/nct06127407/"},{"record":"nct06593548","field":"status","kind":"trial","state":"development","label":"Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer: phase 2, planned","href":"/trials/nct06593548/"},{"record":"pediatric-match","field":"status","kind":"trial","state":"development","label":"NCI-COG Pediatric MATCH (APEC1621): phase platform, active","href":"/trials/pediatric-match/"},{"record":"safir-abc10","field":"status","kind":"trial","state":"development","label":"SAFIR-ABC10: phase 3, recruiting","href":"/trials/safir-abc10/"},{"record":"registry:ivosidenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 37 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ivosidenib/#registry"}],"reasons":[]},{"id":"ixazomib","name":"Ixazomib","route":"/drugs/ixazomib/","status":"approved","modality":"Oral proteasome inhibitor (boronate)","state":"approved","confidence":"medium","fields":["modality","mechanism","technologies"],"components":{"target":{"id":"proteasome","name":"Proteasome (PSMB5)","href":"/targets/proteasome/","confidence":"medium","from":["modality","mechanism"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"ixazomib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ixazomib/"},{"record":"ixazomib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2015: Multiple myeloma after ≥1 prior therapy, with lenalidomide and dexamethasone","href":"/drugs/ixazomib/"},{"record":"ixazomib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2016: Same","href":"/drugs/ixazomib/"},{"record":"ixazomib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2015","href":"/regulatory/regions/"},{"record":"ixazomib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2016","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/ninlaro"},{"record":"ixazomib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2016","href":"https://products.mhra.gov.uk/?search=Ninlaro"},{"record":"ixazomib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2017","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"ixazomib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2018","href":"https://english.nmpa.gov.cn/"},{"record":"ixazomib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Ninlaro"},{"record":"nct04068597","field":"status","kind":"trial","state":"development","label":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies: phase 1/2, recruiting","href":"/trials/nct04068597/"},{"record":"registry:ixazomib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 17 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ixazomib/#registry"}],"reasons":[]},{"id":"jdq443","name":"JDQ443","route":"/drugs/jdq443/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"kras","name":"KRAS","href":"/targets/kras/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"jdq443","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/jdq443/"},{"record":"nct05358249","field":"status","kind":"trial","state":"development","label":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation: phase 1/2, active","href":"/trials/nct05358249/"},{"record":"nct07468071","field":"status","kind":"trial","state":"development","label":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other: phase 1/2, recruiting","href":"/trials/nct07468071/"},{"record":"nct05445843","field":"status","kind":"trial","state":"development","label":"Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.: phase 2, active","href":"/trials/nct05445843/"},{"record":"nct05132075","field":"status","kind":"trial","state":"development","label":"Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer: phase 3, active","href":"/trials/nct05132075/"},{"record":"nct04699188","field":"status","kind":"trial","state":"development","label":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation: phase 1/2, active","href":"/trials/nct04699188/"},{"record":"registry:jdq443","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/jdq443/#registry"}],"reasons":[]},{"id":"js111","name":"JS111","route":"/drugs/js111/","status":"phase-2","modality":"small molecule (structure undisclosed or not yet in PubChem)","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"egfr+met","name":"EGFR x MET","href":"/targets/egfr/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"js111","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/js111/"},{"record":"nct06940401","field":"status","kind":"trial","state":"development","label":"JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations: phase 1/2, active","href":"/trials/nct06940401/"},{"record":"registry:js111","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/js111/#registry"}],"reasons":[]},{"id":"jyp0015","name":"JYP0015","route":"/drugs/jyp0015/","status":"phase-2","modality":"small molecule (structure undisclosed or not yet in PubChem)","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"kras+nras","name":"KRAS x NRAS","href":"/targets/kras/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"jyp0015","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/jyp0015/"},{"record":"nct06895031","field":"status","kind":"trial","state":"development","label":"Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS: phase 2, recruiting","href":"/trials/nct06895031/"},{"record":"registry:jyp0015","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/jyp0015/#registry"}],"reasons":[]},{"id":"krt-232","name":"KRT-232","route":"/drugs/krt-232/","status":"phase-2","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"mdm2+tp53","name":"MDM2 x TP53","href":"/targets/mdm2/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"mdm2-inhibitor","name":"MDM2 inhibitor","href":"/technologies/mdm2-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"krt-232","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/krt-232/"},{"record":"nct03669965","field":"status","kind":"trial","state":"development","label":"KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera: phase 2, active","href":"/trials/nct03669965/"},{"record":"nct04502394","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL: phase 1/2, recruiting","href":"/trials/nct04502394/"},{"record":"nct05797831","field":"status","kind":"trial","state":"development","label":"Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer: phase 2/3, recruiting","href":"/trials/nct05797831/"},{"record":"registry:krt-232","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/krt-232/#registry"}],"reasons":[]},{"id":"lam561","name":"LAM561","route":"/drugs/lam561/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"met","name":"MET","href":"/targets/met/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"lam561","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/lam561/"},{"record":"nct04250922","field":"status","kind":"trial","state":"development","label":"LAM561 With RT and TMZ for Adults With Glioblastoma: phase 2/3, active","href":"/trials/nct04250922/"},{"record":"nct04299191","field":"status","kind":"trial","state":"development","label":"Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct04299191/"},{"record":"registry:lam561","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/lam561/#registry"}],"reasons":[]},{"id":"lapatinib","name":"Lapatinib","route":"/drugs/lapatinib/","status":"approved","modality":"Small-molecule reversible HER2/EGFR kinase inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"her2+egfr","name":"HER2 x EGFR","href":"/targets/her2/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/her2-tyrosine-kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"lapatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/lapatinib/"},{"record":"lapatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2007: HER2+ advanced breast cancer with capecitabine after trastuzumab","href":"/drugs/lapatinib/"},{"record":"lapatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2010: HR+/HER2+ metastatic breast cancer with letrozole","href":"/drugs/lapatinib/"},{"record":"lapatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2007","href":"/regulatory/regions/"},{"record":"lapatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2008","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb"},{"record":"lapatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2008","href":"https://products.mhra.gov.uk/?search=Tykerb"},{"record":"lapatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2009","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"lapatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2013","href":"https://english.nmpa.gov.cn/"},{"record":"lapatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2007","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Tykerb"},{"record":"nct06313983","field":"status","kind":"trial","state":"development","label":"A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct06313983/"},{"record":"registry:lapatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/lapatinib/#registry"}],"reasons":[]},{"id":"larotrectinib","name":"Larotrectinib","route":"/drugs/larotrectinib/","status":"approved","modality":"Small-molecule pan-TRK inhibitor (first generation)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"ntrk","name":"NTRK","href":"/targets/ntrk/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"larotrectinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/larotrectinib/"},{"record":"larotrectinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: Solid tumours with NTRK gene fusion without known acquired resistance mutation, metastatic or unresectable, adults and children","href":"/drugs/larotrectinib/"},{"record":"larotrectinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2019: Same","href":"/drugs/larotrectinib/"},{"record":"larotrectinib","field":"approvals[2]","kind":"approval","state":"approved","label":"UK 2020: NTRK fusion-positive solid tumours in adults and children, locally advanced or metastatic or where surgery would cause severe morbidity, with no satisfactory treatment options: NICE TA630 (27 May 2020) recommends it within the Cancer Drugs Fund under a managed access agreement","href":"/drugs/larotrectinib/"},{"record":"larotrectinib","field":"approvals[3]","kind":"approval","state":"approved","label":"England (NICE) 2020: NTRK fusion-positive solid tumours, including colorectal cancer","href":"/drugs/larotrectinib/"},{"record":"larotrectinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"larotrectinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2019","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/vitrakvi"},{"record":"larotrectinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2019","href":"https://products.mhra.gov.uk/?search=Vitrakvi"},{"record":"larotrectinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2021","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"larotrectinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2022","href":"https://english.nmpa.gov.cn/"},{"record":"larotrectinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Vitrakvi"},{"record":"nct02637687","field":"status","kind":"trial","state":"development","label":"A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children: phase 1/2, active","href":"/trials/nct02637687/"},{"record":"pediatric-match","field":"status","kind":"trial","state":"development","label":"NCI-COG Pediatric MATCH (APEC1621): phase platform, active","href":"/trials/pediatric-match/"},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"registry:larotrectinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 13 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/larotrectinib/#registry"}],"reasons":[]},{"id":"lazertinib","name":"Lazertinib","route":"/drugs/lazertinib/","status":"approved","modality":"Small-molecule kinase inhibitor (EGFR)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"egfr","name":"EGFR","href":"/targets/egfr/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"lazertinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/lazertinib/"},{"record":"lazertinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2024: First-line EGFR exon 19 del / L858R NSCLC with amivantamab","href":"/drugs/lazertinib/"},{"record":"lazertinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2025: 1L EGFR-mutant NSCLC with amivantamab; 20 Jan 2025","href":"/drugs/lazertinib/"},{"record":"lazertinib","field":"approvals[2]","kind":"approval","state":"approved","label":"England (NICE) 2026: Untreated advanced EGFR mutation-positive non-small-cell lung cancer (exon 19 deletion or L858R), with amivantamab","href":"/drugs/lazertinib/"},{"record":"lazertinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2024","href":"/regulatory/regions/"},{"record":"lazertinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/lazcluze"},{"record":"lazertinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2025","href":"https://www.gov.uk/government/news/lazertinib-approved-for-use-in-combination-with-amivantamab-for-the-treatment-of-adults-with-non-small-cell-lung-cancer"},{"record":"lazertinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2025","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"lazertinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2025","href":"https://english.nmpa.gov.cn/"},{"record":"nct04988295","field":"status","kind":"trial","state":"development","label":"A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure: phase 3, active","href":"/trials/nct04988295/"},{"record":"nct06667076","field":"status","kind":"trial","state":"development","label":"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): phase 2, recruiting","href":"/trials/nct06667076/"},{"record":"nct05498428","field":"status","kind":"trial","state":"development","label":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct05498428/"},{"record":"nct05388669","field":"status","kind":"trial","state":"development","label":"A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR): phase 3, active","href":"/trials/nct05388669/"},{"record":"nct07586202","field":"status","kind":"trial","state":"development","label":"A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC: phase 2, recruiting","href":"/trials/nct07586202/"},{"record":"chrysalis","field":"status","kind":"trial","state":"development","label":"CHRYSALIS: phase 1, active","href":"/trials/chrysalis/"},{"record":"nct06120140","field":"status","kind":"trial","state":"development","label":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib: phase 2, active","href":"/trials/nct06120140/"},{"record":"nct05663866","field":"status","kind":"trial","state":"development","label":"Premedication to Reduce Amivantamab Associated Infusion Related Reactions: phase 2, active","href":"/trials/nct05663866/"},{"record":"nct05541822","field":"status","kind":"trial","state":"development","label":"To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation: phase 2, recruiting","href":"/trials/nct05541822/"},{"record":"registry:lazertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 19 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/lazertinib/#registry"}],"reasons":[]},{"id":"lenvatinib","name":"Lenvatinib","route":"/drugs/lenvatinib/","status":"approved","modality":"Small-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, RET, KIT)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"vegf+fgfr2","name":"VEGF / VEGFR x FGFR2","href":"/targets/vegf/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"lenvatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/lenvatinib/"},{"record":"lenvatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2015: Radioiodine-refractory thyroid cancer","href":"/drugs/lenvatinib/"},{"record":"lenvatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2018: First-line unresectable HCC","href":"/drugs/lenvatinib/"},{"record":"lenvatinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2021: Advanced RCC with pembrolizumab; endometrial cancer with pembrolizumab","href":"/drugs/lenvatinib/"},{"record":"lenvatinib","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2016: Advanced RCC with everolimus after anti-angiogenic therapy","href":"/drugs/lenvatinib/"},{"record":"lenvatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2015","href":"/regulatory/regions/"},{"record":"lenvatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima"},{"record":"lenvatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2015","href":"https://products.mhra.gov.uk/?search=Lenvima"},{"record":"lenvatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2015","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"lenvatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2018","href":"https://english.nmpa.gov.cn/"},{"record":"lenvatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2015","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Lenvima"},{"record":"nct06682780","field":"status","kind":"trial","state":"development","label":"A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours: phase 1/2, recruiting","href":"/trials/nct06682780/"},{"record":"nct07679399","field":"status","kind":"trial","state":"development","label":"A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.: phase 2, recruiting","href":"/trials/nct07679399/"},{"record":"nct07269158","field":"status","kind":"trial","state":"development","label":"A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer: phase 1/2, planned","href":"/trials/nct07269158/"},{"record":"nct07099794","field":"status","kind":"trial","state":"development","label":"A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen: phase 2, planned","href":"/trials/nct07099794/"},{"record":"nct06371157","field":"status","kind":"trial","state":"development","label":"A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat: phase 3, recruiting","href":"/trials/nct06371157/"},{"record":"nct06962787","field":"status","kind":"trial","state":"development","label":"A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer: phase 2, recruiting","href":"/trials/nct06962787/"},{"record":"nct04008797","field":"status","kind":"trial","state":"development","label":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor: phase 1/2, active","href":"/trials/nct04008797/"},{"record":"nct04194775","field":"status","kind":"trial","state":"development","label":"A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma: phase 3, active","href":"/trials/nct04194775/"},{"record":"nct05899049","field":"status","kind":"trial","state":"development","label":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study: phase 3, active","href":"/trials/nct05899049/"},{"record":"nct05319730","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B): phase 1/2, recruiting","href":"/trials/nct05319730/"},{"record":"nct04300556","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types: phase 1/2, recruiting","href":"/trials/nct04300556/"},{"record":"nct07282262","field":"status","kind":"trial","state":"development","label":"An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.: phase 2, recruiting","href":"/trials/nct07282262/"},{"record":"nct07829874","field":"status","kind":"trial","state":"development","label":"Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.: phase 2, planned","href":"/trials/nct07829874/"},{"record":"nct07159217","field":"status","kind":"trial","state":"development","label":"Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer: phase 2, planned","href":"/trials/nct07159217/"},{"record":"nct07081633","field":"status","kind":"trial","state":"development","label":"Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma: phase 2, active","href":"/trials/nct07081633/"},{"record":"nct06028633","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients: phase 2, planned","href":"/trials/nct06028633/"},{"record":"nct07405164","field":"status","kind":"trial","state":"development","label":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043): phase 3, recruiting","href":"/trials/nct07405164/"},{"record":"nct06963060","field":"status","kind":"trial","state":"development","label":"Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT): phase 2, recruiting","href":"/trials/nct06963060/"},{"record":"nct04977453","field":"status","kind":"trial","state":"development","label":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct04977453/"},{"record":"nct06389500","field":"status","kind":"trial","state":"development","label":"HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer: phase 2, planned","href":"/trials/nct06389500/"},{"record":"nct07636798","field":"status","kind":"trial","state":"development","label":"Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer: phase 1/2, recruiting","href":"/trials/nct07636798/"},{"record":"nct06849492","field":"status","kind":"trial","state":"development","label":"HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer: phase 2, planned","href":"/trials/nct06849492/"},{"record":"nct07263360","field":"status","kind":"trial","state":"development","label":"Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: phase 2, planned","href":"/trials/nct07263360/"},{"record":"leap-002","field":"result","kind":"trial","state":"stopped","label":"LEAP-002: phase 3, negative","href":"/trials/leap-002/","quote":"OS HR 0.84, not significant."},{"record":"nct05170438","field":"status","kind":"trial","state":"development","label":"Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment: phase 2, active","href":"/trials/nct05170438/"},{"record":"litespark-012","field":"result","kind":"trial","state":"stopped","label":"LITESPARK-012: phase 3, negative","href":"/trials/litespark-012/","quote":"Primary endpoint not met (ASCO GU 2026)."},{"record":"nct06919848","field":"status","kind":"trial","state":"development","label":"Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06): phase 2, planned","href":"/trials/nct06919848/"},{"record":"nct05903833","field":"status","kind":"trial","state":"development","label":"Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge: phase 2, recruiting","href":"/trials/nct05903833/"},{"record":"nct04976634","field":"status","kind":"trial","state":"development","label":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016): phase 2, active","href":"/trials/nct04976634/"},{"record":"nct06230471","field":"status","kind":"trial","state":"development","label":"Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer: phase 2, recruiting","href":"/trials/nct06230471/"},{"record":"nct05024214","field":"status","kind":"trial","state":"development","label":"Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05024214/"},{"record":"nct06852287","field":"status","kind":"trial","state":"development","label":"Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: phase 2, recruiting","href":"/trials/nct06852287/"},{"record":"nct07530445","field":"status","kind":"trial","state":"development","label":"Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer: phase 2, recruiting","href":"/trials/nct07530445/"},{"record":"nct07670273","field":"status","kind":"trial","state":"development","label":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer: phase 2, recruiting","href":"/trials/nct07670273/"},{"record":"nct07704177","field":"status","kind":"trial","state":"development","label":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer: phase 2, recruiting","href":"/trials/nct07704177/"},{"record":"nct06892925","field":"status","kind":"trial","state":"development","label":"QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors: phase 2, active","href":"/trials/nct06892925/"},{"record":"nct07110064","field":"status","kind":"trial","state":"development","label":"QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer: phase 2, recruiting","href":"/trials/nct07110064/"},{"record":"nct04938817","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98): phase 1/2, active","href":"/trials/nct04938817/"},{"record":"nct05112991","field":"status","kind":"trial","state":"development","label":"Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer: phase 2, recruiting","href":"/trials/nct05112991/"},{"record":"nct05775159","field":"status","kind":"trial","state":"development","label":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer: phase 2, active","href":"/trials/nct05775159/"},{"record":"nct02861573","field":"status","kind":"trial","state":"development","label":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365): phase 1/2, active","href":"/trials/nct02861573/"},{"record":"nct05822752","field":"status","kind":"trial","state":"development","label":"Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Bu: phase 2, active","href":"/trials/nct05822752/"},{"record":"nct04626479","field":"status","kind":"trial","state":"development","label":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A): phase 1/2, active","href":"/trials/nct04626479/"},{"record":"nct04626518","field":"status","kind":"trial","state":"development","label":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03): phase 1/2, active","href":"/trials/nct04626518/"},{"record":"nct06140576","field":"status","kind":"trial","state":"development","label":"The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breas: phase 1/2, planned","href":"/trials/nct06140576/"},{"record":"nct04875585","field":"status","kind":"trial","state":"development","label":"Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC: phase 2, recruiting","href":"/trials/nct04875585/"},{"record":"nct07219459","field":"status","kind":"trial","state":"development","label":"Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L): phase 2, recruiting","href":"/trials/nct07219459/"},{"record":"registry:lenvatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 47 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/lenvatinib/#registry"}],"reasons":[{"drugId":"lenvatinib","drugName":"Lenvatinib","drugRoute":"/drugs/lenvatinib/","drugState":"approved","record":"leap-002","kind":"trial","label":"LEAP-002: phase 3, negative","href":"/trials/leap-002/","quote":"OS HR 0.84, not significant."},{"drugId":"lenvatinib","drugName":"Lenvatinib","drugRoute":"/drugs/lenvatinib/","drugState":"approved","record":"litespark-012","kind":"trial","label":"LITESPARK-012: phase 3, negative","href":"/trials/litespark-012/","quote":"Primary endpoint not met (ASCO GU 2026)."}]},{"id":"lerociclib","name":"Lerociclib","route":"/drugs/lerociclib/","status":"phase-3","modality":"Oral CDK4/6 inhibitor","state":"development","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"cdk4-6","name":"CDK4/6","href":"/targets/cdk4-6/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"lerociclib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/lerociclib/"},{"record":"nct05851014","field":"status","kind":"trial","state":"development","label":"A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct05851014/"},{"record":"registry:lerociclib","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 2 terminated or withdrawn studies and none active (fetched 2026-09-28)","href":"/drugs/lerociclib/#registry"}],"reasons":[]},{"id":"letrozole","name":"Letrozole (and other aromatase inhibitors)","route":"/drugs/letrozole/","status":"approved","modality":"Small-molecule aromatase inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"estrogen-receptor","name":"Estrogen receptor (ERα)","href":"/targets/estrogen-receptor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"letrozole","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/letrozole/"},{"record":"letrozole","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1997: Advanced breast cancer after tamoxifen (letrozole)","href":"/drugs/letrozole/"},{"record":"letrozole","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2005: Adjuvant early breast cancer (letrozole)","href":"/drugs/letrozole/"},{"record":"letrozole","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 1997","href":"/regulatory/regions/"},{"record":"letrozole","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 1996","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/femara"},{"record":"letrozole","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 1996","href":"https://products.mhra.gov.uk/?search=Femara"},{"record":"letrozole","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2006","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"letrozole","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2000","href":"https://english.nmpa.gov.cn/"},{"record":"letrozole","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 1997","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Femara"},{"record":"nct06072781","field":"status","kind":"trial","state":"development","label":"A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer: phase 3, recruiting","href":"/trials/nct06072781/"},{"record":"nct04553133","field":"status","kind":"trial","state":"development","label":"PF-07104091 as a Single Agent and in Combination Therapy: phase 2, active","href":"/trials/nct04553133/"},{"record":"nct05867251","field":"status","kind":"trial","state":"development","label":"Study of AVZO-021 in Patients With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05867251/"},{"record":"nct07288359","field":"status","kind":"trial","state":"development","label":"Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct07288359/"},{"record":"nct04606446","field":"status","kind":"trial","state":"development","label":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors: phase 2, recruiting","href":"/trials/nct04606446/"},{"record":"nct04557449","field":"status","kind":"trial","state":"development","label":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors: phase 2, active","href":"/trials/nct04557449/"},{"record":"registry:letrozole","kind":"registry","state":"development","label":"ClinicalTrials.gov: 30 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/letrozole/#registry"}],"reasons":[]},{"id":"limertinib","name":"Limertinib","route":"/drugs/limertinib/","status":"approved","modality":"Oral third-generation EGFR tyrosine kinase inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"egfr","name":"EGFR","href":"/targets/egfr/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"limertinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/limertinib/"},{"record":"limertinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2024: Locally advanced or metastatic EGFR T790M-mutant non-small cell lung cancer after prior EGFR inhibitor therapy","href":"/drugs/limertinib/"},{"record":"limertinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2024","href":"https://english.nmpa.gov.cn/"},{"record":"nct06982924","field":"status","kind":"trial","state":"development","label":"A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.: phase 2, planned","href":"/trials/nct06982924/"},{"record":"nct04143607","field":"status","kind":"trial","state":"development","label":"ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC: phase 3, active","href":"/trials/nct04143607/"},{"record":"nct07109531","field":"status","kind":"trial","state":"development","label":"ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy: phase 3, recruiting","href":"/trials/nct07109531/"},{"record":"registry:limertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/limertinib/#registry"}],"reasons":[]},{"id":"linperlisib","name":"Linperlisib","route":"/drugs/linperlisib/","status":"approved","modality":"Oral PI3K-delta inhibitor","state":"approved","confidence":"medium","fields":["modality","mechanism","technologies"],"components":{"target":{"id":"pik3cd+psmb6","name":"PI3K delta x PSMB6","href":"/targets/pik3cd/","confidence":"medium","from":["modality","mechanism"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"linperlisib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/linperlisib/"},{"record":"linperlisib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2022: Relapsed or refractory follicular lymphoma after two or more lines, conditional","href":"/drugs/linperlisib/"},{"record":"linperlisib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2022","href":"https://english.nmpa.gov.cn/"},{"record":"nct06224257","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia: phase 2, recruiting","href":"/trials/nct06224257/"},{"record":"registry:linperlisib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 17 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/linperlisib/#registry"}],"reasons":[]},{"id":"lirafugratinib","name":"Lirafugratinib","route":"/drugs/lirafugratinib/","status":"approved","modality":"Small-molecule FGFR2 inhibitor","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"fgfr2","name":"FGFR2","href":"/targets/fgfr2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"lirafugratinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/lirafugratinib/"},{"record":"lirafugratinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2026: Previously treated unresectable, locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement","href":"/drugs/lirafugratinib/"},{"record":"lirafugratinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2026","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic"},{"record":"nct07359820","field":"status","kind":"trial","state":"development","label":"A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement: phase 2, recruiting","href":"/trials/nct07359820/"},{"record":"registry:lirafugratinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/lirafugratinib/#registry"}],"reasons":[]},{"id":"lorlatinib","name":"Lorlatinib","route":"/drugs/lorlatinib/","status":"approved","modality":"Small-molecule kinase inhibitor (ALK/ROS1)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"alk","name":"ALK","href":"/targets/alk/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"lorlatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/lorlatinib/"},{"record":"lorlatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: ALK+ NSCLC after prior ALK TKI","href":"/drugs/lorlatinib/"},{"record":"lorlatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2021: First-line ALK+ NSCLC","href":"/drugs/lorlatinib/"},{"record":"lorlatinib","field":"approvals[2]","kind":"approval","state":"approved","label":"England (NICE) 2020: ALK-positive advanced non-small-cell lung cancer progressing after alectinib or ceritinib as the first ALK inhibitor, or after crizotinib and at least one other ALK inhibitor","href":"/drugs/lorlatinib/"},{"record":"lorlatinib","field":"approvals[3]","kind":"approval","state":"approved","label":"England (NICE) 2025: ALK-positive advanced non-small-cell lung cancer not previously treated with an ALK inhibitor","href":"/drugs/lorlatinib/"},{"record":"lorlatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"lorlatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2019","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/lorviqua"},{"record":"lorlatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2019","href":"https://products.mhra.gov.uk/?search=Lorbrena"},{"record":"lorlatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2018","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"lorlatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2022","href":"https://english.nmpa.gov.cn/"},{"record":"lorlatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2019","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Lorbrena"},{"record":"nct05297890","field":"status","kind":"trial","state":"development","label":"A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer: phase 2, active","href":"/trials/nct05297890/"},{"record":"anbl1531","field":"status","kind":"trial","state":"development","label":"COG ANBL1531: phase 3, active","href":"/trials/anbl1531/"},{"record":"nct06858410","field":"status","kind":"trial","state":"development","label":"Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma: phase 3, planned","href":"/trials/nct06858410/"},{"record":"registry:lorlatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 19 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/lorlatinib/#registry"}],"reasons":[]},{"id":"masofaniten","name":"Masofaniten","route":"/drugs/masofaniten/","status":"withdrawn","modality":"Small-molecule AR N-terminal domain inhibitor","state":"stopped","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"androgen-receptor","name":"Androgen receptor","href":"/targets/androgen-receptor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"other-inhibitor","name":"Inhibitor (class not stated)","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"masofaniten","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/masofaniten/","quote":"A drug designed to block the part of the androgen receptor that resistant variants keep; its phase 2 was stopped for futility and development ended."}],"reasons":[{"drugId":"masofaniten","drugName":"Masofaniten","drugRoute":"/drugs/masofaniten/","drugState":"stopped","record":"masofaniten","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/masofaniten/","quote":"A drug designed to block the part of the androgen receptor that resistant variants keep; its phase 2 was stopped for futility and development ended."}]},{"id":"mavorixafor","name":"Mavorixafor","route":"/drugs/mavorixafor/","status":"approved","modality":"Oral CXCR4 antagonist","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"cxcr4","name":"CXCR4","href":"/targets/cxcr4/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"mavorixafor","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/mavorixafor/"},{"record":"mavorixafor","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2024: WHIM syndrome (warts, hypogammaglobulinaemia, infections and myelokathexis) in patients aged 12 and over","href":"/drugs/mavorixafor/"},{"record":"registry:mavorixafor","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/mavorixafor/#registry"}],"reasons":[]},{"id":"mebendazole","name":"Mebendazole","route":"/drugs/mebendazole/","status":"phase-2","modality":"Oral benzimidazole anthelmintic for human worm infections, tested in two small cancer trials","state":"development","confidence":"medium","fields":["modality","mechanism"],"components":{"target":{"id":"tubulin","name":"Tubulin (microtubules)","href":"/targets/tubulin/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"mebendazole","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/mebendazole/"},{"record":"nct03925662","field":"status","kind":"trial","state":"development","label":"Mebendazole as Adjuvant Treatment for Colon Cancer: phase 3, recruiting","href":"/trials/nct03925662/"},{"record":"registry:mebendazole","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/mebendazole/#registry"}],"reasons":[]},{"id":"men1703","name":"MEN1703","route":"/drugs/men1703/","status":"phase-2","modality":"small molecule (kinase inhibitor)","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"flt3","name":"FLT3","href":"/targets/flt3/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"men1703","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/men1703/"},{"record":"nct06534437","field":"status","kind":"trial","state":"development","label":"MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01): phase 2, recruiting","href":"/trials/nct06534437/"},{"record":"registry:men1703","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/men1703/#registry"}],"reasons":[]},{"id":"methylnaltrexone","name":"Methylnaltrexone","route":"/drugs/methylnaltrexone/","status":"approved","modality":"Peripherally acting mu-opioid receptor antagonist","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"oprm1","name":"Mu-opioid receptor","href":"/targets/oprm1/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"receptor-agonist","name":"Receptor agonist","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"methylnaltrexone","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/methylnaltrexone/"},{"record":"methylnaltrexone","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2008: Opioid-induced constipation in advanced illness receiving palliative care (chronic non-cancer pain and oral tablets added 2014 to 2016)","href":"/drugs/methylnaltrexone/"},{"record":"methylnaltrexone","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2008: Opioid-induced constipation in advanced illness receiving palliative care when laxatives are insufficient (Relistor)","href":"/drugs/methylnaltrexone/"},{"record":"registry:methylnaltrexone","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 4 terminated or withdrawn studies and none active (fetched 2026-09-28)","href":"/drugs/methylnaltrexone/#registry"}],"reasons":[]},{"id":"mevrometostat","name":"Mevrometostat","route":"/drugs/mevrometostat/","status":"phase-3","modality":"Small-molecule EZH2 inhibitor","state":"development","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"ezh2+androgen-receptor","name":"EZH2 x Androgen receptor","href":"/targets/ezh2/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"mevrometostat","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/mevrometostat/"},{"record":"nct06629779","field":"status","kind":"trial","state":"development","label":"A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.: phase 3, recruiting","href":"/trials/nct06629779/"},{"record":"mevpro-1","field":"status","kind":"trial","state":"development","label":"MEVPRO-1: phase 3, active","href":"/trials/mevpro-1/"},{"record":"nct07028853","field":"status","kind":"trial","state":"development","label":"This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking En: phase 3, recruiting","href":"/trials/nct07028853/"},{"record":"registry:mevrometostat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/mevrometostat/#registry"}],"reasons":[]},{"id":"midostaurin","name":"Midostaurin","route":"/drugs/midostaurin/","status":"approved","modality":"Small-molecule multikinase inhibitor (FLT3)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"flt3+kit","name":"FLT3 x KIT","href":"/targets/flt3/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"midostaurin","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/midostaurin/"},{"record":"midostaurin","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2017: Newly diagnosed FLT3-mutated AML with 7+3 and consolidation; advanced systemic mastocytosis","href":"/drugs/midostaurin/"},{"record":"midostaurin","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2017","href":"/regulatory/regions/"},{"record":"midostaurin","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2017","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt"},{"record":"midostaurin","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2017","href":"https://products.mhra.gov.uk/?search=Rydapt"},{"record":"midostaurin","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2019","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"midostaurin","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"midostaurin","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2017","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Rydapt"},{"record":"nct03591510","field":"status","kind":"trial","state":"development","label":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML: phase 2, active","href":"/trials/nct03591510/"},{"record":"registry:midostaurin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 10 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/midostaurin/#registry"}],"reasons":[]},{"id":"mirdametinib","name":"Mirdametinib","route":"/drugs/mirdametinib/","status":"approved","modality":"Small-molecule allosteric MEK1/2 inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"mek","name":"MEK1/2","href":"/targets/mek/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"allosteric","name":"Allosteric","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"mirdametinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/mirdametinib/"},{"record":"mirdametinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2025: NF1 with symptomatic plexiform neurofibromas not amenable to complete resection, adults and children 2 and over (Gomekli)","href":"/drugs/mirdametinib/"},{"record":"mirdametinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2025: Symptomatic, inoperable plexiform neurofibromas in NF1, age 2 and over (Ezmekly, conditional)","href":"/drugs/mirdametinib/"},{"record":"mirdametinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/ezmekly"},{"record":"nct06153173","field":"status","kind":"trial","state":"development","label":"Mirdametinib in Histiocytic Disorders: phase 2, recruiting","href":"/trials/nct06153173/"},{"record":"nct07237100","field":"status","kind":"trial","state":"development","label":"Mirdametinib in Patients With Advanced NF1-mutant Melanoma: phase 2, recruiting","href":"/trials/nct07237100/"},{"record":"nct07061951","field":"status","kind":"trial","state":"development","label":"Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia: phase 2, recruiting","href":"/trials/nct07061951/"},{"record":"registry:mirdametinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 12 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/mirdametinib/#registry"}],"reasons":[]},{"id":"mobocertinib","name":"Mobocertinib","route":"/drugs/mobocertinib/","status":"withdrawn","modality":"Small-molecule EGFR exon 20 insertion TKI (irreversible)","state":"stopped","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"egfr","name":"EGFR","href":"/targets/egfr/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"mobocertinib","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/mobocertinib/","quote":"Mobocertinib was the first oral drug for EGFR exon 20 insertion lung cancer, approved in 2021 and withdrawn in 2023-24 after its confirmatory trial failed."},{"record":"mobocertinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2021: EGFR exon 20 insertion NSCLC after platinum","href":"/drugs/mobocertinib/"},{"record":"mobocertinib","field":"regional.US","kind":"regional","state":"stopped","label":"FDA (US): withdrawn 2023","href":"/regulatory/regions/","quote":"Exkivity accelerated approval Sep 2021; withdrawn by Takeda Oct 2023 after EXCLAIM-2"},{"record":"mobocertinib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/exkivity","quote":"Marketing authorisation application withdrawn before a CHMP opinion"},{"record":"mobocertinib","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"US 2024-07-15: withdrawal","href":"/drugs/mobocertinib/","quote":"Withdrawn: the indication came off the label 2.8 years after its accelerated approval."},{"record":"nct04129502","field":"status","kind":"trial","state":"development","label":"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations: phase 3, active","href":"/trials/nct04129502/"},{"record":"registry:mobocertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/mobocertinib/#registry"}],"reasons":[{"drugId":"mobocertinib","drugName":"Mobocertinib","drugRoute":"/drugs/mobocertinib/","drugState":"stopped","record":"mobocertinib","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/mobocertinib/","quote":"Mobocertinib was the first oral drug for EGFR exon 20 insertion lung cancer, approved in 2021 and withdrawn in 2023-24 after its confirmatory trial failed."},{"drugId":"mobocertinib","drugName":"Mobocertinib","drugRoute":"/drugs/mobocertinib/","drugState":"stopped","record":"mobocertinib","kind":"regional","label":"FDA (US): withdrawn 2023","href":"/regulatory/regions/","quote":"Exkivity accelerated approval Sep 2021; withdrawn by Takeda Oct 2023 after EXCLAIM-2"},{"drugId":"mobocertinib","drugName":"Mobocertinib","drugRoute":"/drugs/mobocertinib/","drugState":"stopped","record":"mobocertinib","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/exkivity","quote":"Marketing authorisation application withdrawn before a CHMP opinion"},{"drugId":"mobocertinib","drugName":"Mobocertinib","drugRoute":"/drugs/mobocertinib/","drugState":"stopped","record":"mobocertinib","kind":"event","label":"US 2024-07-15: withdrawal","href":"/drugs/mobocertinib/","quote":"Withdrawn: the indication came off the label 2.8 years after its accelerated approval."}]},{"id":"momelotinib","name":"Momelotinib","route":"/drugs/momelotinib/","status":"approved","modality":"Small-molecule JAK1/JAK2/ACVR1 inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"jak2+jak1","name":"JAK2 x JAK1","href":"/targets/jak2/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"momelotinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/momelotinib/"},{"record":"momelotinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2023: Intermediate/high-risk myelofibrosis with anaemia","href":"/drugs/momelotinib/"},{"record":"momelotinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2024: Myelofibrosis with moderate-to-severe anaemia","href":"/drugs/momelotinib/"},{"record":"momelotinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2023","href":"/regulatory/regions/"},{"record":"momelotinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2024","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/omjjara"},{"record":"momelotinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2024","href":"https://products.mhra.gov.uk/?search=Omjjara"},{"record":"momelotinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2024","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"registry:momelotinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 10 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/momelotinib/#registry"}],"reasons":[]},{"id":"motixafortide","name":"Motixafortide","route":"/drugs/motixafortide/","status":"approved","modality":"CXCR4 antagonist peptide, subcutaneous injection","state":"approved","confidence":"medium","fields":["modality","mechanism"],"components":{"target":{"id":"cxcr4","name":"CXCR4","href":"/targets/cxcr4/","confidence":"medium","from":["modality","mechanism"],"detail":null},"mechanismClass":{"id":"receptor-agonist","name":"Receptor agonist","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"motixafortide","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/motixafortide/"},{"record":"motixafortide","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2023: With filgrastim, to mobilise haematopoietic stem cells for collection and autologous transplantation in multiple myeloma","href":"/drugs/motixafortide/"},{"record":"nct06514508","field":"status","kind":"trial","state":"development","label":"Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients: phase 3, recruiting","href":"/trials/nct06514508/"},{"record":"registry:motixafortide","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/motixafortide/#registry"}],"reasons":[]},{"id":"mrtx1133","name":"MRTX1133","route":"/drugs/mrtx1133/","status":"phase-1","modality":"Small-molecule non-covalent KRAS G12D inhibitor","state":"development","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"kras","name":"KRAS","href":"/targets/kras/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"mrtx1133","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 1","href":"/drugs/mrtx1133/"}],"reasons":[]},{"id":"nabilone","name":"Nabilone","route":"/drugs/nabilone/","status":"established","modality":"Oral small-molecule synthetic cannabinoid","state":"approved","confidence":"high","fields":["targets"],"components":{"target":{"id":"cnr1","name":"Cannabinoid receptor 1","href":"/targets/cnr1/","confidence":"high","from":["targets"],"detail":null}},"evidence":[{"record":"nabilone","field":"status","kind":"drug","state":"approved","label":"Drug record status: established","href":"/drugs/nabilone/"},{"record":"nabilone","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1985: Nausea and vomiting from cancer chemotherapy in patients who have failed conventional antiemetics","href":"/drugs/nabilone/"},{"record":"registry:nabilone","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/nabilone/#registry"}],"reasons":[]},{"id":"napabucasin","name":"Napabucasin","route":"/drugs/napabucasin/","status":"negative","modality":"Oral small-molecule NQO1-bioactivated reactive oxygen species generator (STAT3 pathway inhibitor)","state":"stopped","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"stat3","name":"STAT3","href":"/targets/stat3/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"other-inhibitor","name":"Inhibitor (class not stated)","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"napabucasin","field":"status","kind":"drug","state":"stopped","label":"Drug record status: negative","href":"/drugs/napabucasin/","quote":"Napabucasin, an oral drug marketed as a cancer stemness inhibitor, was tested in 1,134 people with untreated metastatic pancreatic cancer on top of nab-paclitaxel and gemcitabine; survival was identical and the trial was stopped for futility."},{"record":"canstem111p","field":"result","kind":"trial","state":"stopped","label":"CanStem111P: phase 3, negative","href":"/trials/canstem111p/","quote":"Median overall survival 11.4 months with napabucasin plus nab-paclitaxel and gemcitabine against 11.7 months with chemotherapy alone (hazard ratio 1.07, 95 percent confidence interval 0.93 to 1.23); terminated for futility."},{"record":"registry:napabucasin","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 2 terminated or withdrawn studies and none active (fetched 2026-09-28)","href":"/drugs/napabucasin/#registry"}],"reasons":[{"drugId":"napabucasin","drugName":"Napabucasin","drugRoute":"/drugs/napabucasin/","drugState":"stopped","record":"napabucasin","kind":"drug","label":"Drug record status: negative","href":"/drugs/napabucasin/","quote":"Napabucasin, an oral drug marketed as a cancer stemness inhibitor, was tested in 1,134 people with untreated metastatic pancreatic cancer on top of nab-paclitaxel and gemcitabine; survival was identical and the trial was stopped for futility."},{"drugId":"napabucasin","drugName":"Napabucasin","drugRoute":"/drugs/napabucasin/","drugState":"stopped","record":"canstem111p","kind":"trial","label":"CanStem111P: phase 3, negative","href":"/trials/canstem111p/","quote":"Median overall survival 11.4 months with napabucasin plus nab-paclitaxel and gemcitabine against 11.7 months with chemotherapy alone (hazard ratio 1.07, 95 percent confidence interval 0.93 to 1.23); terminated for futility."}]},{"id":"naporafenib","name":"Naporafenib","route":"/drugs/naporafenib/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["target record (drugs field)","modality","mechanism"],"components":{"target":{"id":"nras","name":"NRAS","href":"/targets/nras/","confidence":"high","from":["target record (drugs field)"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"naporafenib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/naporafenib/"},{"record":"seacraft-2","field":"status","kind":"trial","state":"development","label":"A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2): phase 3, active","href":"/trials/seacraft-2/"},{"record":"nct04417621","field":"status","kind":"trial","state":"development","label":"Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma: phase 2, active","href":"/trials/nct04417621/"},{"record":"registry:naporafenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/naporafenib/#registry"}],"reasons":[]},{"id":"navlimetostat","name":"Navlimetostat","route":"/drugs/navlimetostat/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"prmt5-mtap","name":"PRMT5 (MTAP-deleted cancers)","href":"/targets/prmt5-mtap/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"navlimetostat","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/navlimetostat/"},{"record":"nct07283705","field":"status","kind":"trial","state":"development","label":"A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer: phase 2, recruiting","href":"/trials/nct07283705/"},{"record":"mountaintap-30","field":"status","kind":"trial","state":"development","label":"A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30): phase 2/3, active","href":"/trials/mountaintap-30/"},{"record":"nct07063745","field":"status","kind":"trial","state":"development","label":"A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion: phase 2/3, recruiting","href":"/trials/nct07063745/"},{"record":"registry:navlimetostat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/navlimetostat/#registry"}],"reasons":[]},{"id":"ndi-219216","name":"NDI-219216","route":"/drugs/ndi-219216/","status":"phase-2","modality":"small molecule (structure undisclosed or not yet in PubChem)","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"wrn","name":"WRN helicase (MSI-high cancers)","href":"/targets/wrn/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"other-inhibitor","name":"Inhibitor (class not stated)","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"ndi-219216","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/ndi-219216/"},{"record":"nct06898450","field":"status","kind":"trial","state":"development","label":"A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.: phase 1/2, recruiting","href":"/trials/nct06898450/"},{"record":"registry:ndi-219216","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/ndi-219216/#registry"}],"reasons":[]},{"id":"neladalkib","name":"Neladalkib","route":"/drugs/neladalkib/","status":"phase-3","modality":"Small-molecule kinase inhibitor (ALK)","state":"development","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"alk","name":"ALK","href":"/targets/alk/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"neladalkib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/neladalkib/"},{"record":"nct06765109","field":"status","kind":"trial","state":"development","label":"Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC: phase 3, recruiting","href":"/trials/nct06765109/"},{"record":"registry:neladalkib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/neladalkib/#registry"}],"reasons":[]},{"id":"nemtabrutinib","name":"Nemtabrutinib","route":"/drugs/nemtabrutinib/","status":"phase-3","modality":"Small-molecule non-covalent BTK inhibitor","state":"development","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"btk","name":"BTK (Bruton tyrosine kinase)","href":"/targets/btk/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"nemtabrutinib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/nemtabrutinib/"},{"record":"nct03162536","field":"status","kind":"trial","state":"development","label":"A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001): phase 1/2, active","href":"/trials/nct03162536/"},{"record":"nct05947851","field":"status","kind":"trial","state":"development","label":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).: phase 3, recruiting","href":"/trials/nct05947851/"},{"record":"nct05624554","field":"status","kind":"trial","state":"development","label":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008): phase 3, active","href":"/trials/nct05624554/"},{"record":"nct05458297","field":"status","kind":"trial","state":"development","label":"A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-: phase 2, active","href":"/trials/nct05458297/"},{"record":"bellwave-011","field":"status","kind":"trial","state":"development","label":"BELLWAVE-011: phase 3, recruiting","href":"/trials/bellwave-011/"},{"record":"nct04728893","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003): phase 2, recruiting","href":"/trials/nct04728893/"},{"record":"registry:nemtabrutinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 15 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/nemtabrutinib/#registry"}],"reasons":[]},{"id":"neratinib","name":"Neratinib","route":"/drugs/neratinib/","status":"approved","modality":"Small-molecule irreversible pan-HER kinase inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"her2+egfr","name":"HER2 x EGFR","href":"/targets/her2/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/her2-tyrosine-kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"neratinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/neratinib/"},{"record":"neratinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2017: Extended adjuvant HER2+ early breast cancer after trastuzumab","href":"/drugs/neratinib/"},{"record":"neratinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2020: HER2+ metastatic breast cancer with capecitabine after ≥2 anti-HER2 regimens","href":"/drugs/neratinib/"},{"record":"neratinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2017","href":"/regulatory/regions/"},{"record":"neratinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2018","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/nerlynx"},{"record":"neratinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2018","href":"https://products.mhra.gov.uk/?search=Nerlynx"},{"record":"neratinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2019","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Nerlynx"},{"record":"i-spy-2","field":"status","kind":"trial","state":"development","label":"I-SPY 2: phase platform, active","href":"/trials/i-spy-2/"},{"record":"intuitt-nf2","field":"status","kind":"trial","state":"development","label":"INTUITT-NF2: phase 2, recruiting","href":"/trials/intuitt-nf2/"},{"record":"safir-abc10","field":"status","kind":"trial","state":"development","label":"SAFIR-ABC10: phase 3, recruiting","href":"/trials/safir-abc10/"},{"record":"nct06813079","field":"status","kind":"trial","state":"development","label":"Using Tumor Models to Determine Treatments: phase 2, recruiting","href":"/trials/nct06813079/"},{"record":"registry:neratinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 24 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/neratinib/#registry"}],"reasons":[]},{"id":"nilotinib","name":"Nilotinib","route":"/drugs/nilotinib/","status":"approved","modality":"Small-molecule BCR-ABL1 TKI (second generation)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"bcr-abl+kit","name":"BCR::ABL1 x KIT","href":"/targets/bcr-abl/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"nilotinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/nilotinib/"},{"record":"nilotinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2007: Ph+ CML, chronic or accelerated phase, resistant/intolerant to imatinib","href":"/drugs/nilotinib/"},{"record":"nilotinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2010: Newly diagnosed Ph+ CML chronic phase","href":"/drugs/nilotinib/"},{"record":"nilotinib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2007: Ph+ CML","href":"/drugs/nilotinib/"},{"record":"nilotinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2007","href":"/regulatory/regions/"},{"record":"nilotinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2007","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna"},{"record":"nilotinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2007","href":"https://products.mhra.gov.uk/?search=Tasigna"},{"record":"nilotinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2009","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"nilotinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2009","href":"https://english.nmpa.gov.cn/"},{"record":"nilotinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Tasigna"},{"record":"nct04971226","field":"status","kind":"trial","state":"development","label":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP: phase 3, active","href":"/trials/nct04971226/"},{"record":"nct05456191","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP): phase 3, active","href":"/trials/nct05456191/"},{"record":"registry:nilotinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 19 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/nilotinib/#registry"}],"reasons":[]},{"id":"nilutamide","name":"Nilutamide","route":"/drugs/nilutamide/","status":"approved","modality":"Non-steroidal antiandrogen (first generation)","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"androgen-receptor","name":"Androgen receptor","href":"/targets/androgen-receptor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"nilutamide","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/nilutamide/"},{"record":"nilutamide","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1996: Metastatic (stage D2) prostate cancer in combination with surgical castration","href":"/drugs/nilutamide/"},{"record":"nct03678025","field":"status","kind":"trial","state":"development","label":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer: phase 3, recruiting","href":"/trials/nct03678025/"},{"record":"registry:nilutamide","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/nilutamide/#registry"}],"reasons":[]},{"id":"nintedanib","name":"Nintedanib","route":"/drugs/nintedanib/","status":"approved","modality":"Small-molecule kinase inhibitor (VEGFR/FGFR/PDGFR)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"vegf+fgfr2","name":"VEGF / VEGFR x FGFR2","href":"/targets/vegf/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"nintedanib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/nintedanib/"},{"record":"nintedanib","field":"approvals[0]","kind":"approval","state":"approved","label":"EU 2014: Adenocarcinoma NSCLC after first-line chemotherapy, with docetaxel","href":"/drugs/nintedanib/"},{"record":"nintedanib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2014: Idiopathic pulmonary fibrosis (non-oncology)","href":"/drugs/nintedanib/"},{"record":"nintedanib","field":"approvals[2]","kind":"approval","state":"approved","label":"England (NICE) 2015: Locally advanced, metastatic or locally recurrent non-small-cell lung cancer of adenocarcinoma histology progressing after first-line chemotherapy, with docetaxel","href":"/drugs/nintedanib/"},{"record":"nintedanib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2014","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef"},{"record":"nintedanib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2014","href":"https://products.mhra.gov.uk/?search=Vargatef"},{"record":"lume-meso","field":"result","kind":"trial","state":"stopped","label":"LUME-Meso: phase 2/3, negative","href":"/trials/lume-meso/","quote":"PFS HR 1.01, negative."},{"record":"registry:nintedanib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 13 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/nintedanib/#registry"}],"reasons":[{"drugId":"nintedanib","drugName":"Nintedanib","drugRoute":"/drugs/nintedanib/","drugState":"approved","record":"lume-meso","kind":"trial","label":"LUME-Meso: phase 2/3, negative","href":"/trials/lume-meso/","quote":"PFS HR 1.01, negative."}]},{"id":"niraparib","name":"Niraparib","route":"/drugs/niraparib/","status":"approved","modality":"Small-molecule PARP inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"parp","name":"PARP","href":"/targets/parp/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"parp-inhibitor","name":"PARP inhibitor","href":"/technologies/parp-inhibitor/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"niraparib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/niraparib/"},{"record":"niraparib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2017: Recurrent ovarian cancer maintenance","href":"/drugs/niraparib/"},{"record":"niraparib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2020: First-line ovarian maintenance","href":"/drugs/niraparib/"},{"record":"niraparib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2017","href":"/regulatory/regions/"},{"record":"niraparib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2017","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zejula"},{"record":"niraparib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2017","href":"https://products.mhra.gov.uk/?search=Zejula"},{"record":"niraparib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2020","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"niraparib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2019","href":"https://english.nmpa.gov.cn/"},{"record":"niraparib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2018","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Zejula"},{"record":"nct05335993","field":"status","kind":"trial","state":"development","label":"A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.: phase 2, active","href":"/trials/nct05335993/"},{"record":"nct03602859","field":"status","kind":"trial","state":"development","label":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer: phase 3, active","href":"/trials/nct03602859/"},{"record":"nct04641247","field":"status","kind":"trial","state":"development","label":"A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study: phase 2, recruiting","href":"/trials/nct04641247/"},{"record":"nct06682780","field":"status","kind":"trial","state":"development","label":"A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours: phase 1/2, recruiting","href":"/trials/nct06682780/"},{"record":"nct06953323","field":"status","kind":"trial","state":"development","label":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06953323/"},{"record":"nct03431350","field":"status","kind":"trial","state":"development","label":"A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer: phase 2, active","href":"/trials/nct03431350/"},{"record":"nct04497844","field":"status","kind":"trial","state":"development","label":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC): phase 3, active","href":"/trials/nct04497844/"},{"record":"nct06077877","field":"status","kind":"trial","state":"development","label":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors: phase 1/2, active","href":"/trials/nct06077877/"},{"record":"nct04915755","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease: phase 3, active","href":"/trials/nct04915755/"},{"record":"nct06747845","field":"status","kind":"trial","state":"development","label":"Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy: phase 2, recruiting","href":"/trials/nct06747845/"},{"record":"nct05718323","field":"status","kind":"trial","state":"development","label":"Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC: phase 2, recruiting","href":"/trials/nct05718323/"},{"record":"nct06915025","field":"status","kind":"trial","state":"development","label":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Pat: phase 3, recruiting","href":"/trials/nct06915025/"},{"record":"safir-abc10","field":"status","kind":"trial","state":"development","label":"SAFIR-ABC10: phase 3, recruiting","href":"/trials/safir-abc10/"},{"record":"registry:niraparib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 46 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/niraparib/#registry"}],"reasons":[]},{"id":"nirogacestat","name":"Nirogacestat","route":"/drugs/nirogacestat/","status":"approved","modality":"Small-molecule gamma-secretase inhibitor","state":"approved","confidence":"high","fields":["target record (drugs field)","technologies"],"components":{"target":{"id":"apc+ctnnb1","name":"APC x CTNNB1","href":"/targets/apc/","confidence":"high","from":["target record (drugs field)"],"detail":"dual-target"},"mechanismClass":{"id":"gamma-secretase-inhibitor","name":"Gamma-secretase inhibitor","href":"/technologies/gamma-secretase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"nirogacestat","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/nirogacestat/"},{"record":"nirogacestat","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2023: Progressing desmoid tumours requiring systemic treatment","href":"/drugs/nirogacestat/"},{"record":"nirogacestat","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2025: Progressing desmoid tumours","href":"/drugs/nirogacestat/"},{"record":"nirogacestat","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2023","href":"/regulatory/regions/"},{"record":"nirogacestat","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/ogsiveo"},{"record":"nirogacestat","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2026","href":"https://www.gov.uk/government/news/nirogacestat-hydrobromide-approved-to-treat-desmoid-tumours"},{"record":"nct07170644","field":"status","kind":"trial","state":"development","label":"A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF): phase 2, active","href":"/trials/nct07170644/"},{"record":"nct04126200","field":"status","kind":"trial","state":"development","label":"Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple: phase 1/2, active","href":"/trials/nct04126200/"},{"record":"nct07150104","field":"status","kind":"trial","state":"development","label":"Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi: phase 1/2, active","href":"/trials/nct07150104/"},{"record":"nct07084896","field":"status","kind":"trial","state":"development","label":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM: phase 1/2, active","href":"/trials/nct07084896/"},{"record":"nct07150091","field":"status","kind":"trial","state":"development","label":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM: phase 1/2, active","href":"/trials/nct07150091/"},{"record":"registry:nirogacestat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 10 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/nirogacestat/#registry"}],"reasons":[]},{"id":"olaparib","name":"Olaparib","route":"/drugs/olaparib/","status":"approved","modality":"Small-molecule PARP inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"parp+brca","name":"PARP x BRCA1 / BRCA2","href":"/targets/parp/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"parp-inhibitor","name":"PARP inhibitor","href":"/technologies/parp-inhibitor/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"olaparib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/olaparib/"},{"record":"olaparib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2014: gBRCA ovarian cancer ≥3 lines","href":"/drugs/olaparib/"},{"record":"olaparib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2018: gBRCA HER2- metastatic breast cancer","href":"/drugs/olaparib/"},{"record":"olaparib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2022: Adjuvant gBRCA high-risk HER2- early breast cancer","href":"/drugs/olaparib/"},{"record":"olaparib","field":"approvals[3]","kind":"approval","state":"approved","label":"EU 2019: Germline BRCA1/2-mutated HER2-negative locally advanced or metastatic breast cancer after an anthracycline and a taxane (OlympiAD)","href":"/drugs/olaparib/"},{"record":"olaparib","field":"approvals[4]","kind":"approval","state":"approved","label":"EU 2022: Adjuvant treatment, alone or with endocrine therapy, of germline BRCA1/2-mutated HER2-negative high-risk early breast cancer after neoadjuvant or adjuvant chemotherapy (OlympiA)","href":"/drugs/olaparib/"},{"record":"olaparib","field":"approvals[5]","kind":"approval","state":"approved","label":"UK 2023: Adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy; NICE TA886 (10 May 2023) recommends within the marketing authorisation with a commercial arrangement","href":"/drugs/olaparib/"},{"record":"olaparib","field":"approvals[6]","kind":"approval","state":"approved","label":"UK 2025: BRCA mutation-positive HER2-negative locally advanced or metastatic breast cancer after an anthracycline and a taxane; NICE TA1040 (12 February 2025) recommends with a commercial arrangement, the lowest-cost option to be used where talazoparib is also suitable","href":"/drugs/olaparib/"},{"record":"olaparib","field":"approvals[7]","kind":"approval","state":"approved","label":"US 2019: Maintenance treatment of deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of first-line platinum-based chemotherapy (POLO), with an FDA-approved companion diagnostic","href":"/drugs/olaparib/"},{"record":"olaparib","field":"approvals[8]","kind":"approval","state":"approved","label":"EU 2020: Maintenance treatment of germline BRCA1/2-mutated metastatic pancreatic adenocarcinoma that has not progressed after at least 16 weeks of platinum-based first-line chemotherapy; listed in the EMA Lynparza product information read on 24 September 2026 (extension of indication in 2020)","href":"/drugs/olaparib/"},{"record":"olaparib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2014","href":"/regulatory/regions/"},{"record":"olaparib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2014","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza"},{"record":"olaparib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2014","href":"https://products.mhra.gov.uk/?search=Lynparza"},{"record":"olaparib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2018","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"olaparib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2018","href":"https://english.nmpa.gov.cn/"},{"record":"olaparib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2016","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Lynparza"},{"record":"nct02734004","field":"status","kind":"trial","state":"development","label":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.: phase 1/2, active","href":"/trials/nct02734004/"},{"record":"nct06112379","field":"status","kind":"trial","state":"development","label":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer: phase 3, active","href":"/trials/nct06112379/"},{"record":"nct03459846","field":"status","kind":"trial","state":"development","label":"A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU): phase 2, active","href":"/trials/nct03459846/"},{"record":"nct04683679","field":"status","kind":"trial","state":"development","label":"A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negat: phase 2, recruiting","href":"/trials/nct04683679/"},{"record":"nct07024784","field":"status","kind":"trial","state":"development","label":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN1: phase 2, recruiting","href":"/trials/nct07024784/"},{"record":"nct04858334","field":"status","kind":"trial","state":"development","label":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a: phase 2, recruiting","href":"/trials/nct04858334/"},{"record":"nct07005583","field":"status","kind":"trial","state":"development","label":"Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent: phase 2, planned","href":"/trials/nct07005583/"},{"record":"nct06686030","field":"status","kind":"trial","state":"development","label":"Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer: phase 2, recruiting","href":"/trials/nct06686030/"},{"record":"nct04884360","field":"status","kind":"trial","state":"development","label":"D9319C00001- 1L OC Mono Global RCT: phase 3, active","href":"/trials/nct04884360/"},{"record":"nct03742895","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002): phase 2, active","href":"/trials/nct03742895/"},{"record":"nct06525298","field":"status","kind":"trial","state":"development","label":"EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06525298/"},{"record":"nct06909825","field":"status","kind":"trial","state":"development","label":"FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC): phase 2, active","href":"/trials/nct06909825/"},{"record":"i-spy-2","field":"status","kind":"trial","state":"development","label":"I-SPY 2: phase platform, active","href":"/trials/i-spy-2/"},{"record":"nct06419179","field":"status","kind":"trial","state":"development","label":"Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extens: phase 2, recruiting","href":"/trials/nct06419179/"},{"record":"pediatric-match","field":"status","kind":"trial","state":"development","label":"NCI-COG Pediatric MATCH (APEC1621): phase platform, active","href":"/trials/pediatric-match/"},{"record":"nct05485766","field":"status","kind":"trial","state":"development","label":"Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer: phase 2, recruiting","href":"/trials/nct05485766/"},{"record":"nct05522491","field":"status","kind":"trial","state":"development","label":"Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer: phase 2, planned","href":"/trials/nct05522491/"},{"record":"nct04042831","field":"status","kind":"trial","state":"development","label":"Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations: phase 2, active","href":"/trials/nct04042831/"},{"record":"nct01874353","field":"status","kind":"trial","state":"development","label":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy: phase 3, active","href":"/trials/nct01874353/"},{"record":"nct05222971","field":"status","kind":"trial","state":"development","label":"Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy: phase 2, recruiting","href":"/trials/nct05222971/"},{"record":"nct07486687","field":"status","kind":"trial","state":"development","label":"Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy: phase 3, planned","href":"/trials/nct07486687/"},{"record":"nct05623319","field":"status","kind":"trial","state":"development","label":"Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC): phase 2, recruiting","href":"/trials/nct05623319/"},{"record":"nct05093231","field":"status","kind":"trial","state":"development","label":"Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer: phase 2, recruiting","href":"/trials/nct05093231/"},{"record":"nct06245889","field":"status","kind":"trial","state":"development","label":"PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC: phase 2, recruiting","href":"/trials/nct06245889/"},{"record":"nct06915025","field":"status","kind":"trial","state":"development","label":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Pat: phase 3, recruiting","href":"/trials/nct06915025/"},{"record":"nct03334617","field":"status","kind":"trial","state":"development","label":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy: phase 2, active","href":"/trials/nct03334617/"},{"record":"phoenix","field":"status","kind":"trial","state":"development","label":"PHOENIX DDR/Anti-PD-L1: phase 2, recruiting","href":"/trials/phoenix/"},{"record":"nct04624204","field":"status","kind":"trial","state":"development","label":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-: phase 3, active","href":"/trials/nct04624204/"},{"record":"nct07453394","field":"status","kind":"trial","state":"development","label":"QLS5132 Combination Therapy in Advanced Solid Tumors: phase 1/2, planned","href":"/trials/nct07453394/"},{"record":"rainbo","field":"status","kind":"trial","state":"development","label":"RAINBO: phase 2/3, recruiting","href":"/trials/rainbo/"},{"record":"nct04421963","field":"status","kind":"trial","state":"development","label":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib: phase 3, active","href":"/trials/nct04421963/"},{"record":"nct05898399","field":"status","kind":"trial","state":"development","label":"Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA): phase 1/2, recruiting","href":"/trials/nct05898399/"},{"record":"nct03775486","field":"status","kind":"trial","state":"development","label":"Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION): phase 2, active","href":"/trials/nct03775486/"},{"record":"nct05933265","field":"status","kind":"trial","state":"development","label":"Study of LP-184 in Patients With Advanced Solid Tumors: phase 1/2, active","href":"/trials/nct05933265/"},{"record":"nct05498155","field":"status","kind":"trial","state":"development","label":"Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer: phase 2, active","href":"/trials/nct05498155/"},{"record":"nct02861573","field":"status","kind":"trial","state":"development","label":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365): phase 1/2, active","href":"/trials/nct02861573/"},{"record":"nct04380636","field":"status","kind":"trial","state":"development","label":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012): phase 3, active","href":"/trials/nct04380636/"},{"record":"nct05171816","field":"status","kind":"trial","state":"development","label":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort): phase 3, active","href":"/trials/nct05171816/"},{"record":"nct01081951","field":"status","kind":"trial","state":"development","label":"Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax: phase 2, active","href":"/trials/nct01081951/"},{"record":"nct06353386","field":"status","kind":"trial","state":"development","label":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A): phase 1/2, recruiting","href":"/trials/nct06353386/"},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"nct05128734","field":"status","kind":"trial","state":"development","label":"Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC): phase 2, planned","href":"/trials/nct05128734/"},{"record":"nct03330847","field":"status","kind":"trial","state":"development","label":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.: phase 2, active","href":"/trials/nct03330847/"},{"record":"nct04644289","field":"status","kind":"trial","state":"development","label":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC: phase 2, recruiting","href":"/trials/nct04644289/"},{"record":"registry:olaparib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 54 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/olaparib/#registry"}],"reasons":[]},{"id":"olmutinib","name":"Olmutinib","route":"/drugs/olmutinib/","status":"withdrawn","modality":"Oral third-generation EGFR kinase inhibitor","state":"stopped","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"egfr","name":"EGFR","href":"/targets/egfr/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"olmutinib","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/olmutinib/","quote":"Olmutinib was a Korean-developed EGFR pill approved in South Korea in 2016 for lung cancers that had developed the T790M resistance mutation, the same niche as osimertinib; severe skin reactions and osimertinib's success ended its development."},{"record":"registry:olmutinib","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 1 terminated or withdrawn study and none active (fetched 2026-09-28)","href":"/drugs/olmutinib/#registry"}],"reasons":[{"drugId":"olmutinib","drugName":"Olmutinib","drugRoute":"/drugs/olmutinib/","drugState":"stopped","record":"olmutinib","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/olmutinib/","quote":"Olmutinib was a Korean-developed EGFR pill approved in South Korea in 2016 for lung cancers that had developed the T790M resistance mutation, the same niche as osimertinib; severe skin reactions and osimertinib's success ended its development."}]},{"id":"olomorasib","name":"Olomorasib","route":"/drugs/olomorasib/","status":"phase-3","modality":"Small-molecule inhibitor (KRAS G12C)","state":"development","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"kras","name":"KRAS","href":"/targets/kras/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"olomorasib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/olomorasib/"},{"record":"nct07227025","field":"status","kind":"trial","state":"development","label":"A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer: phase 1/2, recruiting","href":"/trials/nct07227025/"},{"record":"nct06119581","field":"status","kind":"trial","state":"development","label":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer: phase 3, recruiting","href":"/trials/nct06119581/"},{"record":"nct07814417","field":"status","kind":"trial","state":"development","label":"A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation: phase 2, planned","href":"/trials/nct07814417/"},{"record":"nct04956640","field":"status","kind":"trial","state":"development","label":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C): phase 1/2, active","href":"/trials/nct04956640/"},{"record":"nct06890598","field":"status","kind":"trial","state":"development","label":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer: phase 3, recruiting","href":"/trials/nct06890598/"},{"record":"registry:olomorasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/olomorasib/#registry"}],"reasons":[]},{"id":"olutasidenib","name":"Olutasidenib","route":"/drugs/olutasidenib/","status":"approved","modality":"Small-molecule IDH1 inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"idh","name":"IDH1 / IDH2","href":"/targets/idh/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"idh-inhibitor","name":"IDH inhibitor","href":"/technologies/idh-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"allosteric","name":"Allosteric","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"olutasidenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/olutasidenib/"},{"record":"olutasidenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2022: Relapsed/refractory IDH1-mutated AML","href":"/drugs/olutasidenib/"},{"record":"olutasidenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2022","href":"/regulatory/regions/"},{"record":"nct06161974","field":"status","kind":"trial","state":"development","label":"Study of Olutasidenib and Temozolomide in HGG: phase 2, recruiting","href":"/trials/nct06161974/"},{"record":"registry:olutasidenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 11 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/olutasidenib/#registry"}],"reasons":[]},{"id":"olverembatinib","name":"Olverembatinib","route":"/drugs/olverembatinib/","status":"approved","modality":"Oral third-generation BCR-ABL tyrosine kinase inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"bcr-abl","name":"BCR::ABL1 (Philadelphia chromosome)","href":"/targets/bcr-abl/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"olverembatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/olverembatinib/"},{"record":"olverembatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2021: Chronic myeloid leukaemia (chronic or accelerated phase) with the T315I mutation after prior tyrosine kinase inhibitors","href":"/drugs/olverembatinib/"},{"record":"olverembatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"nct06051409","field":"status","kind":"trial","state":"development","label":"A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1): phase 3, recruiting","href":"/trials/nct06051409/"},{"record":"nct06640361","field":"status","kind":"trial","state":"development","label":"A Study of Olverembatinib in SDH-deficient GIST.: phase 3, recruiting","href":"/trials/nct06640361/"},{"record":"nct04501120","field":"status","kind":"trial","state":"development","label":"Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML: phase 1/2, recruiting","href":"/trials/nct04501120/"},{"record":"nct06423911","field":"status","kind":"trial","state":"development","label":"Study of Olverembatinib (HQP1351) in Patients With CML-CP: phase 3, recruiting","href":"/trials/nct06423911/"},{"record":"registry:olverembatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 16 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/olverembatinib/#registry"}],"reasons":[]},{"id":"omacetaxine","name":"Omacetaxine mepesuccinate","route":"/drugs/omacetaxine/","status":"approved","modality":"Protein synthesis inhibitor (cephalotaxine ester)","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"bcr-abl","name":"BCR::ABL1 (Philadelphia chromosome)","href":"/targets/bcr-abl/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"bcl2-inhibitor","name":"BCL-2 inhibitor","href":"/technologies/bcl2-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"omacetaxine","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/omacetaxine/"},{"record":"omacetaxine","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2012: Chronic or accelerated phase CML resistant or intolerant to two or more TKIs (accelerated; full approval 2014)","href":"/drugs/omacetaxine/"},{"record":"omacetaxine","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tekinex","quote":"Tekinex for chronic myeloid leukaemia after imatinib failure, including T315I: marketing authorisation application withdrawn by ChemGenex 11 Jan 2011 at day 120; the CHMP's provisional view was that benefits did not outweigh risks"},{"record":"nct04501120","field":"status","kind":"trial","state":"development","label":"Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML: phase 1/2, recruiting","href":"/trials/nct04501120/"},{"record":"registry:omacetaxine","kind":"registry","state":"development","label":"ClinicalTrials.gov: 30 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/omacetaxine/#registry"}],"reasons":[{"drugId":"omacetaxine","drugName":"Omacetaxine mepesuccinate","drugRoute":"/drugs/omacetaxine/","drugState":"approved","record":"omacetaxine","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tekinex","quote":"Tekinex for chronic myeloid leukaemia after imatinib failure, including T315I: marketing authorisation application withdrawn by ChemGenex 11 Jan 2011 at day 120; the CHMP's provisional view was that benefits did not outweigh risks"}]},{"id":"onvansertib","name":"Onvansertib","route":"/drugs/onvansertib/","status":"phase-2","modality":"Oral serine/threonine kinase inhibitor","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"plk1","name":"PLK1","href":"/targets/plk1/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"onvansertib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/onvansertib/"},{"record":"nct06736717","field":"status","kind":"trial","state":"development","label":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer: phase 1/2, recruiting","href":"/trials/nct06736717/"},{"record":"nct06106308","field":"status","kind":"trial","state":"development","label":"Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab fo: phase 2, active","href":"/trials/nct06106308/"},{"record":"nct05450965","field":"status","kind":"trial","state":"development","label":"Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct05450965/"},{"record":"registry:onvansertib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/onvansertib/#registry"}],"reasons":[]},{"id":"orelabrutinib","name":"Orelabrutinib","route":"/drugs/orelabrutinib/","status":"approved","modality":"Small-molecule covalent BTK inhibitor (second generation)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"btk","name":"BTK (Bruton tyrosine kinase)","href":"/targets/btk/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"orelabrutinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/orelabrutinib/"},{"record":"orelabrutinib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2020: Relapsed or refractory CLL/SLL; relapsed or refractory mantle cell lymphoma","href":"/drugs/orelabrutinib/"},{"record":"orelabrutinib","field":"approvals[1]","kind":"approval","state":"approved","label":"China 2023: Relapsed or refractory marginal zone lymphoma","href":"/drugs/orelabrutinib/"},{"record":"orelabrutinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2020","href":"https://english.nmpa.gov.cn/"},{"record":"nct06363994","field":"status","kind":"trial","state":"development","label":"A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL: phase 3, recruiting","href":"/trials/nct06363994/"},{"record":"nct04014205","field":"status","kind":"trial","state":"development","label":"A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies: phase 1/2, active","href":"/trials/nct04014205/"},{"record":"nct06082102","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma: phase 3, recruiting","href":"/trials/nct06082102/"},{"record":"registry:orelabrutinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 58 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/orelabrutinib/#registry"}],"reasons":[]},{"id":"orteronel","name":"Orteronel","route":"/drugs/orteronel/","status":"withdrawn","modality":"small molecule","state":"stopped","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"cyp17a1","name":"CYP17A1 (17-alpha-hydroxylase/17,20-lyase)","href":"/targets/cyp17a1/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"orteronel","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/orteronel/","quote":"A more selective version of abiraterone that was meant to avoid the need for steroids. It delayed the cancer on scans but did not help men live longer, and was abandoned."},{"record":"elm-pc-4-orteronel","field":"result","kind":"trial","state":"stopped","label":"ELM-PC 4: phase 3, negative","href":"/trials/elm-pc-4-orteronel/","quote":"Median radiographic progression-free survival 13.8 against 8.7 months (hazard ratio 0.71, 95 percent confidence interval 0.63 to 0.80, p<0.0001) but overall survival 31.4 against 29.5 months (0.92, 0.79 to 1.08, p=0.31); development stopped."},{"record":"registry:orteronel","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 7 terminated or withdrawn studies and none active (fetched 2026-09-28)","href":"/drugs/orteronel/#registry"}],"reasons":[{"drugId":"orteronel","drugName":"Orteronel","drugRoute":"/drugs/orteronel/","drugState":"stopped","record":"orteronel","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/orteronel/","quote":"A more selective version of abiraterone that was meant to avoid the need for steroids. It delayed the cancer on scans but did not help men live longer, and was abandoned."},{"drugId":"orteronel","drugName":"Orteronel","drugRoute":"/drugs/orteronel/","drugState":"stopped","record":"elm-pc-4-orteronel","kind":"trial","label":"ELM-PC 4: phase 3, negative","href":"/trials/elm-pc-4-orteronel/","quote":"Median radiographic progression-free survival 13.8 against 8.7 months (hazard ratio 0.71, 95 percent confidence interval 0.63 to 0.80, p<0.0001) but overall survival 31.4 against 29.5 months (0.92, 0.79 to 1.08, p=0.31); development stopped."}]},{"id":"osilodrostat","name":"Osilodrostat","route":"/drugs/osilodrostat/","status":"approved","modality":"Oral 11-beta-hydroxylase (CYP11B1) inhibitor","state":"approved","confidence":"medium","fields":["modality","mechanism"],"components":{"target":{"id":"cyp11b1","name":"CYP11B1","href":"/targets/cyp11b1/","confidence":"medium","from":["modality","mechanism"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"osilodrostat","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/osilodrostat/"},{"record":"osilodrostat","field":"approvals[0]","kind":"approval","state":"approved","label":"EU 2020: Endogenous Cushing's syndrome in adults","href":"/drugs/osilodrostat/"},{"record":"osilodrostat","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2020: Cushing's disease in adults for whom pituitary surgery is not an option or has not been curative","href":"/drugs/osilodrostat/"},{"record":"registry:osilodrostat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/osilodrostat/#registry"}],"reasons":[]},{"id":"osimertinib","name":"Osimertinib","route":"/drugs/osimertinib/","status":"approved","modality":"Small-molecule kinase inhibitor (EGFR)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"egfr","name":"EGFR","href":"/targets/egfr/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"osimertinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/osimertinib/"},{"record":"osimertinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2015: EGFR T790M NSCLC","href":"/drugs/osimertinib/"},{"record":"osimertinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2018: First-line EGFR-mutant NSCLC","href":"/drugs/osimertinib/"},{"record":"osimertinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2020: Adjuvant EGFR-mutant NSCLC","href":"/drugs/osimertinib/"},{"record":"osimertinib","field":"approvals[3]","kind":"approval","state":"approved","label":"England (NICE) 2020: Untreated locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer","href":"/drugs/osimertinib/"},{"record":"osimertinib","field":"approvals[4]","kind":"approval","state":"approved","label":"England (NICE) 2020: EGFR T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer after a first-line EGFR inhibitor","href":"/drugs/osimertinib/"},{"record":"osimertinib","field":"approvals[5]","kind":"approval","state":"approved","label":"England (NICE) 2025: Adjuvant treatment of stage IB to IIIA EGFR exon 19 deletion or L858R non-small-cell lung cancer after complete resection","href":"/drugs/osimertinib/"},{"record":"osimertinib","field":"approvals[6]","kind":"approval","state":"approved","label":"England (NICE) 2025: Untreated advanced EGFR mutation-positive non-small-cell lung cancer, with pemetrexed and platinum-based chemotherapy","href":"/drugs/osimertinib/"},{"record":"osimertinib","field":"approvals[7]","kind":"approval","state":"approved","label":"England (NICE) 2026: Unresectable stage III EGFR mutation-positive non-small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy","href":"/drugs/osimertinib/"},{"record":"osimertinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2015","href":"/regulatory/regions/"},{"record":"osimertinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2016","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso"},{"record":"osimertinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2016","href":"https://products.mhra.gov.uk/?search=Tagrisso"},{"record":"osimertinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2016","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"osimertinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2017","href":"https://english.nmpa.gov.cn/"},{"record":"osimertinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2016","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Tagrisso"},{"record":"nct05120349","field":"status","kind":"trial","state":"development","label":"A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection: phase 3, active","href":"/trials/nct05120349/"},{"record":"nct07710612","field":"status","kind":"trial","state":"development","label":"A Phase 2 Study of ABSK043 Combined With Osimertinib: phase 2, planned","href":"/trials/nct07710612/"},{"record":"nct07669779","field":"status","kind":"trial","state":"development","label":"A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct07669779/"},{"record":"nct07376382","field":"status","kind":"trial","state":"development","label":"A Phase III Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC: phase 3, planned","href":"/trials/nct07376382/"},{"record":"nct07640789","field":"status","kind":"trial","state":"development","label":"A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-s: phase 3, recruiting","href":"/trials/nct07640789/"},{"record":"nct04606771","field":"status","kind":"trial","state":"development","label":"A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC: phase 2, active","href":"/trials/nct04606771/"},{"record":"nct06970639","field":"status","kind":"trial","state":"development","label":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases: phase 3, recruiting","href":"/trials/nct06970639/"},{"record":"nct05526755","field":"status","kind":"trial","state":"development","label":"A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC): phase 2, active","href":"/trials/nct05526755/"},{"record":"nct05880706","field":"status","kind":"trial","state":"development","label":"A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung : phase 2, active","href":"/trials/nct05880706/"},{"record":"nct07642024","field":"status","kind":"trial","state":"development","label":"A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU: phase 2/3, recruiting","href":"/trials/nct07642024/"},{"record":"nct06498986","field":"status","kind":"trial","state":"development","label":"A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct06498986/"},{"record":"nct06838273","field":"status","kind":"trial","state":"development","label":"A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metas: phase 3, recruiting","href":"/trials/nct06838273/"},{"record":"nct05785741","field":"status","kind":"trial","state":"development","label":"A Study of DB-1310 in Advanced/Metastatic Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05785741/"},{"record":"nct07535437","field":"status","kind":"trial","state":"development","label":"A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer: phase 1/2, recruiting","href":"/trials/nct07535437/"},{"record":"nct04351555","field":"status","kind":"trial","state":"development","label":"A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S: phase 3, active","href":"/trials/nct04351555/"},{"record":"nct02411448","field":"status","kind":"trial","state":"development","label":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE: phase 3, active","href":"/trials/nct02411448/"},{"record":"nct07229729","field":"status","kind":"trial","state":"development","label":"A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct07229729/"},{"record":"nct05816252","field":"status","kind":"trial","state":"development","label":"A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-: phase 2, active","href":"/trials/nct05816252/"},{"record":"nct06670196","field":"status","kind":"trial","state":"development","label":"A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advan: phase 3, active","href":"/trials/nct06670196/"},{"record":"nct07622186","field":"status","kind":"trial","state":"development","label":"A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC): phase 2, recruiting","href":"/trials/nct07622186/"},{"record":"nct07256509","field":"status","kind":"trial","state":"development","label":"A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous No: phase 2, planned","href":"/trials/nct07256509/"},{"record":"nct06868485","field":"status","kind":"trial","state":"development","label":"A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct06868485/"},{"record":"nct07285148","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer: phase 1/2, planned","href":"/trials/nct07285148/"},{"record":"nct04765059","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC): phase 3, active","href":"/trials/nct04765059/"},{"record":"nct07206498","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC: phase 1/2, recruiting","href":"/trials/nct07206498/"},{"record":"nct06618287","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06618287/"},{"record":"nct05801029","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth: phase 2, active","href":"/trials/nct05801029/"},{"record":"nct06417814","field":"status","kind":"trial","state":"development","label":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan: phase 3, recruiting","href":"/trials/nct06417814/"},{"record":"nct06895928","field":"status","kind":"trial","state":"development","label":"A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors: phase 2, recruiting","href":"/trials/nct06895928/"},{"record":"nct06323148","field":"status","kind":"trial","state":"development","label":"Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022): phase 3, planned","href":"/trials/nct06323148/"},{"record":"alchemist","field":"status","kind":"trial","state":"development","label":"ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials): phase platform, active","href":"/trials/alchemist/"},{"record":"nct03833154","field":"status","kind":"trial","state":"development","label":"Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation: phase 3, active","href":"/trials/nct03833154/"},{"record":"nct06486142","field":"status","kind":"trial","state":"development","label":"EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study: phase 3, recruiting","href":"/trials/nct06486142/"},{"record":"nct05647122","field":"status","kind":"trial","state":"development","label":"First in Human Study of AZD9592 in Solid Tumors: phase 1, active","href":"/trials/nct05647122/"},{"record":"nct06391944","field":"status","kind":"trial","state":"development","label":"JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations: phase 2, active","href":"/trials/nct06391944/"},{"record":"nct07153055","field":"status","kind":"trial","state":"development","label":"Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer: phase 1/2, recruiting","href":"/trials/nct07153055/"},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"nct03381274","field":"status","kind":"trial","state":"development","label":"Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study: phase 1/2, active","href":"/trials/nct03381274/"},{"record":"nct04410796","field":"status","kind":"trial","state":"development","label":"Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers: phase 2, recruiting","href":"/trials/nct04410796/"},{"record":"nct07295821","field":"status","kind":"trial","state":"development","label":"Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study: phase 2, recruiting","href":"/trials/nct07295821/"},{"record":"nct04695925","field":"status","kind":"trial","state":"development","label":"Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations: phase 3, active","href":"/trials/nct04695925/"},{"record":"nct03778229","field":"status","kind":"trial","state":"development","label":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib: phase 2, active","href":"/trials/nct03778229/"},{"record":"nct04181060","field":"status","kind":"trial","state":"development","label":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer: phase 3, recruiting","href":"/trials/nct04181060/"},{"record":"nct07738172","field":"status","kind":"trial","state":"development","label":"Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer: phase 3, recruiting","href":"/trials/nct07738172/"},{"record":"nct04868877","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combina: phase 1/2, active","href":"/trials/nct04868877/"},{"record":"nct03944772","field":"status","kind":"trial","state":"development","label":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD): phase 2, active","href":"/trials/nct03944772/"},{"record":"nct07329322","field":"status","kind":"trial","state":"development","label":"Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Facto: phase 2, recruiting","href":"/trials/nct07329322/"},{"record":"nct06350097","field":"status","kind":"trial","state":"development","label":"Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell L: phase 3, recruiting","href":"/trials/nct06350097/"},{"record":"nct04486833","field":"status","kind":"trial","state":"development","label":"Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib: phase 1/2, recruiting","href":"/trials/nct04486833/"},{"record":"nct05629234","field":"status","kind":"trial","state":"development","label":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T): phase 3, active","href":"/trials/nct05629234/"},{"record":"nct05261399","field":"status","kind":"trial","state":"development","label":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment: phase 3, active","href":"/trials/nct05261399/"},{"record":"nct07680790","field":"status","kind":"trial","state":"development","label":"Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based C: phase 3, planned","href":"/trials/nct07680790/"},{"record":"nct07079475","field":"status","kind":"trial","state":"development","label":"Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8): phase 1/2, recruiting","href":"/trials/nct07079475/"},{"record":"nct03040973","field":"status","kind":"trial","state":"development","label":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone: phase 2, active","href":"/trials/nct03040973/"},{"record":"nct05546866","field":"status","kind":"trial","state":"development","label":"Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm: phase 2, active","href":"/trials/nct05546866/"},{"record":"nct04665206","field":"status","kind":"trial","state":"development","label":"Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors: phase 1/2, recruiting","href":"/trials/nct04665206/"},{"record":"nct07323641","field":"status","kind":"trial","state":"development","label":"Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct07323641/"},{"record":"nct05624996","field":"status","kind":"trial","state":"development","label":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer: phase 3, recruiting","href":"/trials/nct05624996/"},{"record":"nct06194448","field":"status","kind":"trial","state":"development","label":"To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations: phase 2, active","href":"/trials/nct06194448/"},{"record":"nct05948813","field":"status","kind":"trial","state":"development","label":"TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: phase 2, recruiting","href":"/trials/nct05948813/"},{"record":"nct06574347","field":"status","kind":"trial","state":"development","label":"Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.: phase 2, recruiting","href":"/trials/nct06574347/"},{"record":"registry:osimertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 58 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/osimertinib/#registry"}],"reasons":[]},{"id":"pacritinib","name":"Pacritinib","route":"/drugs/pacritinib/","status":"approved","modality":"Small-molecule JAK2/IRAK1/ACVR1 inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"jak2+flt3","name":"JAK2 x FLT3","href":"/targets/jak2/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"pacritinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/pacritinib/"},{"record":"pacritinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2022: Intermediate/high-risk myelofibrosis with platelets <50×10⁹/L","href":"/drugs/pacritinib/"},{"record":"pacritinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2022","href":"/regulatory/regions/"},{"record":"nct07033598","field":"status","kind":"trial","state":"development","label":"Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia: phase 2, recruiting","href":"/trials/nct07033598/"},{"record":"registry:pacritinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 17 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pacritinib/#registry"}],"reasons":[]},{"id":"palacaparib","name":"Palacaparib","route":"/drugs/palacaparib/","status":"phase-2","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"parp","name":"PARP","href":"/targets/parp/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"parp-inhibitor","name":"PARP inhibitor","href":"/technologies/parp-inhibitor/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"palacaparib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/palacaparib/"},{"record":"nct05123482","field":"status","kind":"trial","state":"development","label":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies: phase 1/2, recruiting","href":"/trials/nct05123482/"},{"record":"nct05797168","field":"status","kind":"trial","state":"development","label":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05797168/"},{"record":"nct07590934","field":"status","kind":"trial","state":"development","label":"Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct07590934/"},{"record":"nct07181161","field":"status","kind":"trial","state":"development","label":"Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct07181161/"},{"record":"nct05417594","field":"status","kind":"trial","state":"development","label":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies: phase 1/2, recruiting","href":"/trials/nct05417594/"},{"record":"registry:palacaparib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/palacaparib/#registry"}],"reasons":[]},{"id":"palbociclib","name":"Palbociclib","route":"/drugs/palbociclib/","status":"approved","modality":"Small-molecule CDK4/6 inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"cdk4-6","name":"CDK4/6","href":"/targets/cdk4-6/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"cdk-inhibitor","name":"CDK inhibitor","href":"/technologies/cdk46-inhibitor/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"palbociclib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/palbociclib/"},{"record":"palbociclib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2015: HR+/HER2- advanced breast cancer with endocrine therapy","href":"/drugs/palbociclib/"},{"record":"palbociclib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2026: HR+/HER2+ advanced breast cancer maintenance with anti-HER2 and endocrine therapy","href":"/drugs/palbociclib/"},{"record":"palbociclib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2015","href":"/regulatory/regions/"},{"record":"palbociclib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2016","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance"},{"record":"palbociclib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2016","href":"https://products.mhra.gov.uk/?search=Ibrance"},{"record":"palbociclib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2017","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"palbociclib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2018","href":"https://english.nmpa.gov.cn/"},{"record":"palbociclib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2017","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Ibrance"},{"record":"nct04711252","field":"status","kind":"trial","state":"development","label":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease: phase 3, active","href":"/trials/nct04711252/"},{"record":"nct06188520","field":"status","kind":"trial","state":"development","label":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With : phase 1/2, recruiting","href":"/trials/nct06188520/"},{"record":"nct07002177","field":"status","kind":"trial","state":"development","label":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC: phase 1/2, recruiting","href":"/trials/nct07002177/"},{"record":"nct05468697","field":"status","kind":"trial","state":"development","label":"A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6: phase 1/2, active","href":"/trials/nct05468697/"},{"record":"nct06065748","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer): phase 3, active","href":"/trials/nct06065748/"},{"record":"nct04862663","field":"status","kind":"trial","state":"development","label":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292): phase 3, active","href":"/trials/nct04862663/"},{"record":"nct05067530","field":"status","kind":"trial","state":"development","label":"Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a \"Window of Opportunity\" Study: phase 2, planned","href":"/trials/nct05067530/"},{"record":"nct04567420","field":"status","kind":"trial","state":"development","label":"DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE): phase 2, active","href":"/trials/nct04567420/"},{"record":"nct05768139","field":"status","kind":"trial","state":"development","label":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05768139/"},{"record":"nct05501886","field":"status","kind":"trial","state":"development","label":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1): phase 3, active","href":"/trials/nct05501886/"},{"record":"pediatric-match","field":"status","kind":"trial","state":"development","label":"NCI-COG Pediatric MATCH (APEC1621): phase platform, active","href":"/trials/pediatric-match/"},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"nct05563220","field":"status","kind":"trial","state":"development","label":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer: phase 1/2, active","href":"/trials/nct05563220/"},{"record":"pallas-penelope-b","field":"result","kind":"trial","state":"stopped","label":"PALLAS & PENELOPE-B: phase 3, negative","href":"/trials/pallas-penelope-b/","quote":"PALLAS iDFS HR 0.96; PENELOPE-B iDFS HR 0.93; both null."},{"record":"penelope-b","field":"result","kind":"trial","state":"stopped","label":"PENELOPE-B: phase 3, negative","href":"/trials/penelope-b/","quote":"One year of palbociclib added to endocrine therapy did not improve invasive disease-free survival."},{"record":"persevera","field":"result","kind":"trial","state":"stopped","label":"persevERA: phase 3, negative","href":"/trials/persevera/","quote":"PFS 33.1 vs 28.2 months, not significant."},{"record":"nct04553133","field":"status","kind":"trial","state":"development","label":"PF-07104091 as a Single Agent and in Combination Therapy: phase 2, active","href":"/trials/nct04553133/"},{"record":"nct06757634","field":"status","kind":"trial","state":"development","label":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2): phase 3, recruiting","href":"/trials/nct06757634/"},{"record":"nct06380751","field":"status","kind":"trial","state":"development","label":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct06380751/"},{"record":"nct06736704","field":"status","kind":"trial","state":"development","label":"SNV4818 in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06736704/"},{"record":"nct05226871","field":"status","kind":"trial","state":"development","label":"Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies: phase 2, active","href":"/trials/nct05226871/"},{"record":"nct05867251","field":"status","kind":"trial","state":"development","label":"Study of AVZO-021 in Patients With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05867251/"},{"record":"nct03709680","field":"status","kind":"trial","state":"development","label":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors: phase 2, active","href":"/trials/nct03709680/"},{"record":"nct06760637","field":"status","kind":"trial","state":"development","label":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease: phase 3, active","href":"/trials/nct06760637/"},{"record":"nct04606446","field":"status","kind":"trial","state":"development","label":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors: phase 2, recruiting","href":"/trials/nct04606446/"},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"nct05909397","field":"status","kind":"trial","state":"development","label":"Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer: phase 3, active","href":"/trials/nct05909397/"},{"record":"registry:palbociclib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 50 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/palbociclib/#registry"}],"reasons":[{"drugId":"palbociclib","drugName":"Palbociclib","drugRoute":"/drugs/palbociclib/","drugState":"approved","record":"pallas-penelope-b","kind":"trial","label":"PALLAS & PENELOPE-B: phase 3, negative","href":"/trials/pallas-penelope-b/","quote":"PALLAS iDFS HR 0.96; PENELOPE-B iDFS HR 0.93; both null."},{"drugId":"palbociclib","drugName":"Palbociclib","drugRoute":"/drugs/palbociclib/","drugState":"approved","record":"penelope-b","kind":"trial","label":"PENELOPE-B: phase 3, negative","href":"/trials/penelope-b/","quote":"One year of palbociclib added to endocrine therapy did not improve invasive disease-free survival."},{"drugId":"palbociclib","drugName":"Palbociclib","drugRoute":"/drugs/palbociclib/","drugState":"approved","record":"persevera","kind":"trial","label":"persevERA: phase 3, negative","href":"/trials/persevera/","quote":"PFS 33.1 vs 28.2 months, not significant."}]},{"id":"paltusotine","name":"Paltusotine","route":"/drugs/paltusotine/","status":"approved","modality":"Oral non-peptide somatostatin receptor 2 agonist","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"sstr2","name":"Somatostatin receptor 2","href":"/targets/sstr2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"paltusotine","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/paltusotine/"},{"record":"paltusotine","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2025: Acromegaly in adults","href":"/drugs/paltusotine/"},{"record":"nct07087054","field":"status","kind":"trial","state":"development","label":"Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen: phase 3, recruiting","href":"/trials/nct07087054/"},{"record":"registry:paltusotine","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/paltusotine/#registry"}],"reasons":[]},{"id":"pamiparib","name":"Pamiparib","route":"/drugs/pamiparib/","status":"phase-3","modality":"Oral PARP inhibitor","state":"approved","confidence":"medium","fields":["modality","mechanism"],"components":{"target":{"id":"parp","name":"PARP","href":"/targets/parp/","confidence":"medium","from":["modality","mechanism"],"detail":null},"mechanismClass":{"id":"parp-inhibitor","name":"PARP inhibitor","href":"/technologies/parp-inhibitor/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"pamiparib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/pamiparib/"},{"record":"pamiparib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"nct03519230","field":"status","kind":"trial","state":"development","label":"Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer: phase 3, active","href":"/trials/nct03519230/"},{"record":"registry:pamiparib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pamiparib/#registry"}],"reasons":[]},{"id":"panobinostat","name":"Panobinostat","route":"/drugs/panobinostat/","status":"withdrawn","modality":"Pan-HDAC inhibitor","state":"stopped","confidence":"medium","fields":["modality","mechanism","technologies"],"components":{"target":{"id":"hdac+proteasome","name":"Histone deacetylases x Proteasome","href":"/targets/hdac/","confidence":"medium","from":["modality","mechanism"],"detail":"dual-target"},"mechanismClass":{"id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"panobinostat","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/panobinostat/","quote":"An HDAC inhibitor for relapsed myeloma approved in 2015 and withdrawn in 2021 after its confirmatory trial was never completed."},{"record":"panobinostat","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2015: Multiple myeloma after ≥2 regimens including bortezomib and an IMiD","href":"/drugs/panobinostat/"},{"record":"panobinostat","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2015: Relapsed/refractory multiple myeloma","href":"/drugs/panobinostat/"},{"record":"panobinostat","field":"regional.US","kind":"regional","state":"stopped","label":"FDA (US): withdrawn 2022","href":"/regulatory/regions/","quote":"Farydak accelerated approval Feb 2015; US approval withdrawn 2022 at Secura Bio's request"},{"record":"panobinostat","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/farydak"},{"record":"panobinostat","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"US 2022-03-24: withdrawal","href":"/drugs/panobinostat/","quote":"Withdrawn: the indication came off the label 7.1 years after its accelerated approval."},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"registry:panobinostat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/panobinostat/#registry"}],"reasons":[{"drugId":"panobinostat","drugName":"Panobinostat","drugRoute":"/drugs/panobinostat/","drugState":"stopped","record":"panobinostat","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/panobinostat/","quote":"An HDAC inhibitor for relapsed myeloma approved in 2015 and withdrawn in 2021 after its confirmatory trial was never completed."},{"drugId":"panobinostat","drugName":"Panobinostat","drugRoute":"/drugs/panobinostat/","drugState":"stopped","record":"panobinostat","kind":"regional","label":"FDA (US): withdrawn 2022","href":"/regulatory/regions/","quote":"Farydak accelerated approval Feb 2015; US approval withdrawn 2022 at Secura Bio's request"},{"drugId":"panobinostat","drugName":"Panobinostat","drugRoute":"/drugs/panobinostat/","drugState":"stopped","record":"panobinostat","kind":"event","label":"US 2022-03-24: withdrawal","href":"/drugs/panobinostat/","quote":"Withdrawn: the indication came off the label 7.1 years after its accelerated approval."}]},{"id":"patidegib","name":"Patidegib","route":"/drugs/patidegib/","status":"phase-3","modality":"Topical hedgehog pathway (SMO) inhibitor gel","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"smoothened","name":"Smoothened (hedgehog pathway)","href":"/targets/smoothened/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"hedgehog-inhibitor","name":"Hedgehog inhibitor","href":"/technologies/hedgehog-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"patidegib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/patidegib/"},{"record":"registry:patidegib","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 2 terminated or withdrawn studies and none active (fetched 2026-09-28)","href":"/drugs/patidegib/#registry"}],"reasons":[]},{"id":"pazopanib","name":"Pazopanib","route":"/drugs/pazopanib/","status":"approved","modality":"Small-molecule kinase inhibitor (VEGFR/PDGFR/KIT)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"vegf+kit","name":"VEGF / VEGFR x KIT","href":"/targets/vegf/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"pazopanib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/pazopanib/"},{"record":"pazopanib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2009: Advanced renal cell carcinoma","href":"/drugs/pazopanib/"},{"record":"pazopanib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2012: Advanced non-adipocytic soft-tissue sarcoma after chemotherapy","href":"/drugs/pazopanib/"},{"record":"pazopanib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2009","href":"/regulatory/regions/"},{"record":"pazopanib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2010","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/votrient"},{"record":"pazopanib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2010","href":"https://products.mhra.gov.uk/?search=Votrient"},{"record":"pazopanib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2012","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"pazopanib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2017","href":"https://english.nmpa.gov.cn/"},{"record":"pazopanib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2010","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Votrient"},{"record":"nct07087158","field":"status","kind":"trial","state":"development","label":"A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma: phase 2, recruiting","href":"/trials/nct07087158/"},{"record":"aldoxorubicin-phase-3-sts","field":"outcomes (primary)","kind":"trial","state":"stopped","label":"Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma: phase 3, negative","href":"/trials/aldoxorubicin-phase-3-sts/","quote":"Primary endpoint Progression-free survival"},{"record":"tappas","field":"result","kind":"trial","state":"stopped","label":"TAPPAS: phase 3, negative","href":"/trials/tappas/","quote":"Adding TRC105 to pazopanib did not improve progression-free survival; stopped for futility."},{"record":"registry:pazopanib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 12 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pazopanib/#registry"}],"reasons":[{"drugId":"pazopanib","drugName":"Pazopanib","drugRoute":"/drugs/pazopanib/","drugState":"approved","record":"aldoxorubicin-phase-3-sts","kind":"trial","label":"Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma: phase 3, negative","href":"/trials/aldoxorubicin-phase-3-sts/","quote":"Primary endpoint Progression-free survival"},{"drugId":"pazopanib","drugName":"Pazopanib","drugRoute":"/drugs/pazopanib/","drugState":"approved","record":"tappas","kind":"trial","label":"TAPPAS: phase 3, negative","href":"/trials/tappas/","quote":"Adding TRC105 to pazopanib did not improve progression-free survival; stopped for futility."}]},{"id":"pelabresib","name":"Pelabresib","route":"/drugs/pelabresib/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"brd4","name":"BRD4","href":"/targets/brd4/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"pelabresib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/pelabresib/"},{"record":"nct06401356","field":"status","kind":"trial","state":"development","label":"An Extension Study for Patients Previously Enrolled in Studies With Pelabresib: phase 3, recruiting","href":"/trials/nct06401356/"},{"record":"registry:pelabresib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pelabresib/#registry"}],"reasons":[]},{"id":"pemigatinib","name":"Pemigatinib","route":"/drugs/pemigatinib/","status":"approved","modality":"Small-molecule kinase inhibitor (FGFR1-3)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"fgfr2","name":"FGFR2","href":"/targets/fgfr2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"pemigatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/pemigatinib/"},{"record":"pemigatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2020: Previously treated FGFR2-fusion/rearranged cholangiocarcinoma (accelerated)","href":"/drugs/pemigatinib/"},{"record":"pemigatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2021: Same","href":"/drugs/pemigatinib/"},{"record":"pemigatinib","field":"approvals[2]","kind":"approval","state":"approved","label":"UK 2021: Locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement after systemic therapy; NICE TA722 recommended 25 August 2021 with a commercial arrangement","href":"/drugs/pemigatinib/"},{"record":"pemigatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2020","href":"/regulatory/regions/"},{"record":"pemigatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2021","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/pemazyre"},{"record":"pemigatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2021","href":"https://products.mhra.gov.uk/?search=Pemazyre"},{"record":"pemigatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2021","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"pemigatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2022","href":"https://english.nmpa.gov.cn/"},{"record":"pemigatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2022","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Pemazyre"},{"record":"nct06906562","field":"status","kind":"trial","state":"development","label":"A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic: phase 2, recruiting","href":"/trials/nct06906562/"},{"record":"nct06728410","field":"status","kind":"trial","state":"development","label":"A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement: phase 2, recruiting","href":"/trials/nct06728410/"},{"record":"nct07780838","field":"status","kind":"trial","state":"development","label":"Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma: phase 2, recruiting","href":"/trials/nct07780838/"},{"record":"fight-302","field":"notes (registry whyStopped)","kind":"trial","state":"stopped","label":"FIGHT-302: phase 3, terminated or withdrawn","href":"/trials/fight-302/","quote":"The study was terminated due to lack of enrollment resulting from a change in the standard of care for the first-line treatment of patients with cholangiocarcinoma. There were no safety concerns that contributed to this decision."},{"record":"nct06530823","field":"status","kind":"trial","state":"development","label":"Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma: phase 2, planned","href":"/trials/nct06530823/"},{"record":"nct07786766","field":"status","kind":"trial","state":"development","label":"Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma: phase 2, recruiting","href":"/trials/nct07786766/"},{"record":"registry:pemigatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 15 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pemigatinib/#registry"}],"reasons":[{"drugId":"pemigatinib","drugName":"Pemigatinib","drugRoute":"/drugs/pemigatinib/","drugState":"approved","record":"fight-302","kind":"trial","label":"FIGHT-302: phase 3, terminated or withdrawn","href":"/trials/fight-302/","quote":"The study was terminated due to lack of enrollment resulting from a change in the standard of care for the first-line treatment of patients with cholangiocarcinoma. There were no safety concerns that contributed to this decision."}]},{"id":"pentostatin","name":"Pentostatin","route":"/drugs/pentostatin/","status":"approved","modality":"Purine analogue, adenosine deaminase inhibitor","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"ada","name":"Adenosine deaminase (ADA)","href":"/targets/ada/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"other-inhibitor","name":"Inhibitor (class not stated)","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"pentostatin","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/pentostatin/"},{"record":"pentostatin","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1991: Hairy cell leukaemia (initially alpha-interferon-refractory; later untreated disease)","href":"/drugs/pentostatin/"},{"record":"nct01059786","field":"status","kind":"trial","state":"development","label":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia: phase 2, active","href":"/trials/nct01059786/"},{"record":"registry:pentostatin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pentostatin/#registry"}],"reasons":[]},{"id":"pexidartinib","name":"Pexidartinib","route":"/drugs/pexidartinib/","status":"approved","modality":"Small-molecule CSF1R/KIT/FLT3 inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"csf1r+kit","name":"CSF1R x KIT","href":"/targets/csf1r/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"pexidartinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/pexidartinib/"},{"record":"pexidartinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2019: Symptomatic tenosynovial giant cell tumour not amenable to surgery","href":"/drugs/pexidartinib/"},{"record":"pexidartinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2019","href":"/regulatory/regions/"},{"record":"pexidartinib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn 2020","href":"/regulatory/regions/","quote":"Daiichi Sankyo withdrew the Turalio MAA (Jul 2020) after the CHMP signalled a negative opinion"},{"record":"nct04488822","field":"status","kind":"trial","state":"development","label":"A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT: phase 3, active","href":"/trials/nct04488822/"},{"record":"registry:pexidartinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pexidartinib/#registry"}],"reasons":[{"drugId":"pexidartinib","drugName":"Pexidartinib","drugRoute":"/drugs/pexidartinib/","drugState":"approved","record":"pexidartinib","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2020","href":"/regulatory/regions/","quote":"Daiichi Sankyo withdrew the Turalio MAA (Jul 2020) after the CHMP signalled a negative opinion"}]},{"id":"pf-07248144","name":"PF-07248144","route":"/drugs/pf-07248144/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["modality","mechanism"],"components":{"target":{"id":"her2","name":"HER2","href":"/targets/her2/","confidence":"medium","from":["modality","mechanism"],"detail":null},"mechanismClass":{"id":"cdk-inhibitor","name":"CDK inhibitor","href":"/technologies/cdk46-inhibitor/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"pf-07248144","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/pf-07248144/"},{"record":"nct07062965","field":"status","kind":"trial","state":"development","label":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment: phase 3, recruiting","href":"/trials/nct07062965/"},{"record":"nct04606446","field":"status","kind":"trial","state":"development","label":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors: phase 2, recruiting","href":"/trials/nct04606446/"},{"record":"registry:pf-07248144","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pf-07248144/#registry"}],"reasons":[]},{"id":"pirtobrutinib","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/","status":"approved","modality":"Small-molecule non-covalent (reversible) BTK inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"btk","name":"BTK (Bruton tyrosine kinase)","href":"/targets/btk/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"pirtobrutinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/pirtobrutinib/"},{"record":"pirtobrutinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2023: Relapsed MCL after BTK inhibitor (accelerated, January); CLL/SLL after BTK and BCL-2 inhibitors (accelerated, December)","href":"/drugs/pirtobrutinib/"},{"record":"pirtobrutinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2025: Relapsed/refractory CLL/SLL after a covalent BTK inhibitor (traditional approval, BRUIN CLL-321)","href":"/drugs/pirtobrutinib/"},{"record":"pirtobrutinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2023","href":"/regulatory/regions/"},{"record":"pirtobrutinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2023","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/jaypirca"},{"record":"pirtobrutinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2024","href":"https://products.mhra.gov.uk/?search=Jaypirca"},{"record":"pirtobrutinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2024","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"nct06588478","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: phase 2, recruiting","href":"/trials/nct06588478/"},{"record":"nct05023980","field":"status","kind":"trial","state":"development","label":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): phase 3, active","href":"/trials/nct05023980/"},{"record":"nct05254743","field":"status","kind":"trial","state":"development","label":"A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): phase 3, recruiting","href":"/trials/nct05254743/"},{"record":"nct06973187","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: phase 3, recruiting","href":"/trials/nct06973187/"},{"record":"nct04965493","field":"status","kind":"trial","state":"development","label":"A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): phase 3, active","href":"/trials/nct04965493/"},{"record":"cadance-304","field":"status","kind":"trial","state":"development","label":"CaDAnCe-304: phase 3, recruiting","href":"/trials/cadance-304/"},{"record":"nct06252675","field":"status","kind":"trial","state":"development","label":"Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma: phase 2, recruiting","href":"/trials/nct06252675/"},{"record":"nct07162181","field":"status","kind":"trial","state":"development","label":"Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers: phase 2, active","href":"/trials/nct07162181/"},{"record":"nct04662255","field":"status","kind":"trial","state":"development","label":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL): phase 3, active","href":"/trials/nct04662255/"},{"record":"registry:pirtobrutinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 52 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pirtobrutinib/#registry"}],"reasons":[]},{"id":"plerixafor","name":"Plerixafor","route":"/drugs/plerixafor/","status":"approved","modality":"Small-molecule CXCR4 antagonist (stem cell mobiliser)","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"cxcr4","name":"CXCR4","href":"/targets/cxcr4/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"receptor-agonist","name":"Receptor agonist","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"plerixafor","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/plerixafor/"},{"record":"plerixafor","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2008: Stem cell mobilisation with filgrastim for autologous transplantation in NHL and multiple myeloma","href":"/drugs/plerixafor/"},{"record":"plerixafor","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2009: Stem cell mobilisation with G-CSF in lymphoma and multiple myeloma with poor mobilisation (Mozobil)","href":"/drugs/plerixafor/"},{"record":"plerixafor","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2009","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/mozobil"},{"record":"registry:plerixafor","kind":"registry","state":"development","label":"ClinicalTrials.gov: 19 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/plerixafor/#registry"}],"reasons":[]},{"id":"ponatinib","name":"Ponatinib","route":"/drugs/ponatinib/","status":"approved","modality":"Small-molecule kinase inhibitor (pan-BCR::ABL1 incl. T315I)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"bcr-abl+abl1","name":"BCR::ABL1 x ABL1","href":"/targets/bcr-abl/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"ponatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ponatinib/"},{"record":"ponatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2012: CML and Ph+ ALL resistant to prior TKIs or with T315I","href":"/drugs/ponatinib/"},{"record":"ponatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2024: Newly diagnosed Ph+ ALL with chemotherapy (accelerated)","href":"/drugs/ponatinib/"},{"record":"ponatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2012","href":"/regulatory/regions/"},{"record":"ponatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2013","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig"},{"record":"ponatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2013","href":"https://products.mhra.gov.uk/?search=Iclusig"},{"record":"ponatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2016","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"ponatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2015","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Iclusig"},{"record":"ponatinib","field":"regulatoryEvents[1]","kind":"event","state":"stopped","label":"US 2013-10-31: withdrawal","href":"/drugs/ponatinib/","quote":"Temporary marketing suspension for arterial occlusion; returned with narrowed label December 2013"},{"record":"nct03934372","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors: phase 1/2, recruiting","href":"/trials/nct03934372/"},{"record":"nct04233346","field":"status","kind":"trial","state":"development","label":"The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation: phase 2, active","href":"/trials/nct04233346/"},{"record":"nct06813079","field":"status","kind":"trial","state":"development","label":"Using Tumor Models to Determine Treatments: phase 2, recruiting","href":"/trials/nct06813079/"},{"record":"registry:ponatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 22 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ponatinib/#registry"}],"reasons":[{"drugId":"ponatinib","drugName":"Ponatinib","drugRoute":"/drugs/ponatinib/","drugState":"approved","record":"ponatinib","kind":"event","label":"US 2013-10-31: withdrawal","href":"/drugs/ponatinib/","quote":"Temporary marketing suspension for arterial occlusion; returned with narrowed label December 2013"}]},{"id":"poziotinib","name":"Poziotinib","route":"/drugs/poziotinib/","status":"negative","modality":"Oral irreversible pan-HER tyrosine kinase inhibitor","state":"stopped","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"her2+egfr","name":"HER2 x EGFR","href":"/targets/her2/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/her2-tyrosine-kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"poziotinib","field":"status","kind":"drug","state":"stopped","label":"Drug record status: negative","href":"/drugs/poziotinib/","quote":"Poziotinib was a tablet designed to fit the awkward shape of HER2 and EGFR exon 20 mutations in lung cancer. It shrank tumours in some patients but caused severe rash and diarrhoea, and the FDA declined to approve it in 2022."},{"record":"registry:poziotinib","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 8 terminated or withdrawn studies and none active (fetched 2026-09-28)","href":"/drugs/poziotinib/#registry"}],"reasons":[{"drugId":"poziotinib","drugName":"Poziotinib","drugRoute":"/drugs/poziotinib/","drugState":"stopped","record":"poziotinib","kind":"drug","label":"Drug record status: negative","href":"/drugs/poziotinib/","quote":"Poziotinib was a tablet designed to fit the awkward shape of HER2 and EGFR exon 20 mutations in lung cancer. It shrank tumours in some patients but caused severe rash and diarrhoea, and the FDA declined to approve it in 2022."}]},{"id":"pralsetinib","name":"Pralsetinib","route":"/drugs/pralsetinib/","status":"approved","modality":"Small-molecule kinase inhibitor (RET)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"ret","name":"RET","href":"/targets/ret/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"pralsetinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/pralsetinib/"},{"record":"pralsetinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2020: RET-fusion metastatic NSCLC (full approval 2023)","href":"/drugs/pralsetinib/"},{"record":"pralsetinib","field":"approvals[1]","kind":"approval","state":"approved","label":"England (NICE) 2022: RET fusion-positive advanced non-small-cell lung cancer in patients who have not had a RET inhibitor: not recommended","href":"/drugs/pralsetinib/"},{"record":"pralsetinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2020","href":"/regulatory/regions/"},{"record":"pralsetinib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn 2024","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/gavreto","quote":"Authorised Nov 2021; marketing authorisation withdrawn at Blueprint's request 24 Oct 2024"},{"record":"pralsetinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2021","href":"https://products.mhra.gov.uk/?search=Gavreto"},{"record":"pralsetinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"pralsetinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2022","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Gavreto"},{"record":"pralsetinib","field":"regulatoryEvents[3]","kind":"event","state":"stopped","label":"US 2023-07-20: withdrawal","href":"/drugs/pralsetinib/","quote":"Withdrawn: the indication came off the label 2.6 years after its accelerated approval."},{"record":"nct04302025","field":"status","kind":"trial","state":"development","label":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC): phase 2, recruiting","href":"/trials/nct04302025/"},{"record":"registry:pralsetinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pralsetinib/#registry"}],"reasons":[{"drugId":"pralsetinib","drugName":"Pralsetinib","drugRoute":"/drugs/pralsetinib/","drugState":"approved","record":"pralsetinib","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2024","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/gavreto","quote":"Authorised Nov 2021; marketing authorisation withdrawn at Blueprint's request 24 Oct 2024"},{"drugId":"pralsetinib","drugName":"Pralsetinib","drugRoute":"/drugs/pralsetinib/","drugState":"approved","record":"pralsetinib","kind":"event","label":"US 2023-07-20: withdrawal","href":"/drugs/pralsetinib/","quote":"Withdrawn: the indication came off the label 2.6 years after its accelerated approval."}]},{"id":"propranolol-hemangeol","name":"Propranolol (Hemangeol)","route":"/drugs/propranolol-hemangeol/","status":"established","modality":"Small-molecule non-selective beta-adrenergic blocker, oral solution","state":"approved","confidence":"high","fields":["targets","modality","mechanism"],"components":{"target":{"id":"vegf","name":"VEGF / VEGFR","href":"/targets/vegf/","confidence":"high","from":["targets"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"propranolol-hemangeol","field":"status","kind":"drug","state":"approved","label":"Drug record status: established","href":"/drugs/propranolol-hemangeol/"},{"record":"propranolol-hemangeol","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2014: Proliferating infantile haemangioma requiring systemic therapy","href":"/drugs/propranolol-hemangeol/"},{"record":"nct07125391","field":"status","kind":"trial","state":"development","label":"Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer: phase 2, recruiting","href":"/trials/nct07125391/"},{"record":"nct03919461","field":"status","kind":"trial","state":"development","label":"Colorectal Metastasis Prevention International Trial 2: phase 2, recruiting","href":"/trials/nct03919461/"},{"record":"nct06145074","field":"status","kind":"trial","state":"development","label":"Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.: phase 2, recruiting","href":"/trials/nct06145074/"},{"record":"nct07549906","field":"status","kind":"trial","state":"development","label":"Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospecti: phase 2, planned","href":"/trials/nct07549906/"},{"record":"nct05741164","field":"status","kind":"trial","state":"development","label":"Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer: phase 2, recruiting","href":"/trials/nct05741164/"},{"record":"registry:propranolol-hemangeol","kind":"registry","state":"development","label":"ClinicalTrials.gov: 16 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/propranolol-hemangeol/#registry"}],"reasons":[]},{"id":"pyrotinib","name":"Pyrotinib","route":"/drugs/pyrotinib/","status":"approved","modality":"Small-molecule irreversible pan-HER kinase inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"her2+egfr","name":"HER2 x EGFR","href":"/targets/her2/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"pyrotinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/pyrotinib/"},{"record":"pyrotinib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2018: HER2+ advanced breast cancer with capecitabine","href":"/drugs/pyrotinib/"},{"record":"pyrotinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2018","href":"https://english.nmpa.gov.cn/"},{"record":"nct06208410","field":"status","kind":"trial","state":"development","label":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06208410/"},{"record":"nct03980054","field":"status","kind":"trial","state":"development","label":"A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer: phase 3, active","href":"/trials/nct03980054/"},{"record":"nct05745740","field":"status","kind":"trial","state":"development","label":"A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation: phase 1/2, planned","href":"/trials/nct05745740/"},{"record":"nct05482568","field":"status","kind":"trial","state":"development","label":"A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer: phase 1/2, recruiting","href":"/trials/nct05482568/"},{"record":"nct06015048","field":"status","kind":"trial","state":"development","label":"A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.: phase 1/2, recruiting","href":"/trials/nct06015048/"},{"record":"nct04736589","field":"status","kind":"trial","state":"development","label":"Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway: phase 3, planned","href":"/trials/nct04736589/"},{"record":"registry:pyrotinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 44 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/pyrotinib/#registry"}],"reasons":[]},{"id":"quizartinib","name":"Quizartinib","route":"/drugs/quizartinib/","status":"approved","modality":"Small-molecule kinase inhibitor (FLT3-ITD, type II)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"flt3","name":"FLT3","href":"/targets/flt3/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"quizartinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/quizartinib/"},{"record":"quizartinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2023: Newly diagnosed FLT3-ITD AML with 7+3, consolidation, and maintenance","href":"/drugs/quizartinib/"},{"record":"quizartinib","field":"approvals[1]","kind":"approval","state":"approved","label":"Japan 2019: Relapsed/refractory FLT3-ITD AML","href":"/drugs/quizartinib/"},{"record":"quizartinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2023","href":"/regulatory/regions/"},{"record":"quizartinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2023","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/vanflyta"},{"record":"quizartinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2024","href":"https://www.gov.uk/government/news/quizartinib-approved-to-treat-adult-patients-with-a-type-of-blood-cancer"},{"record":"quizartinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2019","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"quizartinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2025","href":"https://english.nmpa.gov.cn/"},{"record":"quizartinib","field":"regulatoryEvents[0]","kind":"event","state":"stopped","label":"US 2019-06-14: complete response letter","href":"/drugs/quizartinib/","quote":"Complete response letter for relapsed/refractory indication (QuANTUM-R)"},{"record":"nct06824168","field":"status","kind":"trial","state":"development","label":"Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission: phase 2, recruiting","href":"/trials/nct06824168/"},{"record":"nct03793478","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood: phase 1/2, active","href":"/trials/nct03793478/"},{"record":"registry:quizartinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 11 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/quizartinib/#registry"}],"reasons":[{"drugId":"quizartinib","drugName":"Quizartinib","drugRoute":"/drugs/quizartinib/","drugState":"approved","record":"quizartinib","kind":"event","label":"US 2019-06-14: complete response letter","href":"/drugs/quizartinib/","quote":"Complete response letter for relapsed/refractory indication (QuANTUM-R)"}]},{"id":"raloxifene","name":"Raloxifene","route":"/drugs/raloxifene/","status":"approved","modality":"Selective oestrogen receptor modulator (benzothiophene)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"estrogen-receptor","name":"Estrogen receptor (ERα)","href":"/targets/estrogen-receptor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"raloxifene","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/raloxifene/"},{"record":"raloxifene","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1997: Treatment and prevention of postmenopausal osteoporosis","href":"/drugs/raloxifene/"},{"record":"raloxifene","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2007: Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk","href":"/drugs/raloxifene/"},{"record":"nct06062810","field":"status","kind":"trial","state":"development","label":"Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms: phase 2/3, active","href":"/trials/nct06062810/"},{"record":"registry:raloxifene","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/raloxifene/#registry"}],"reasons":[]},{"id":"regorafenib","name":"Regorafenib","route":"/drugs/regorafenib/","status":"approved","modality":"Small-molecule multi-kinase inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"vegf+kit","name":"VEGF / VEGFR x KIT","href":"/targets/vegf/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"regorafenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/regorafenib/"},{"record":"regorafenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2012: Metastatic colorectal cancer, previously treated","href":"/drugs/regorafenib/"},{"record":"regorafenib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2013: GIST after imatinib and sunitinib","href":"/drugs/regorafenib/"},{"record":"regorafenib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2017: HCC previously treated with sorafenib","href":"/drugs/regorafenib/"},{"record":"regorafenib","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2012: Metastatic colorectal cancer after fluoropyrimidine, oxaliplatin, irinotecan, anti-VEGF and, if RAS wild-type, anti-EGFR therapy","href":"/drugs/regorafenib/"},{"record":"regorafenib","field":"approvals[4]","kind":"approval","state":"approved","label":"EU 2013: Metastatic colorectal cancer after available therapies","href":"/drugs/regorafenib/"},{"record":"regorafenib","field":"approvals[5]","kind":"approval","state":"approved","label":"England (NICE) 2023: Metastatic colorectal cancer after previous treatment or when those treatments are unsuitable","href":"/drugs/regorafenib/"},{"record":"regorafenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2012","href":"/regulatory/regions/"},{"record":"regorafenib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2013","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga"},{"record":"regorafenib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2013","href":"https://products.mhra.gov.uk/?search=Stivarga"},{"record":"regorafenib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2013","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"regorafenib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2017","href":"https://english.nmpa.gov.cn/"},{"record":"regorafenib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2013","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Stivarga"},{"record":"nct06829355","field":"status","kind":"trial","state":"development","label":"\"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer\": phase 2, recruiting","href":"/trials/nct06829355/"},{"record":"nct06887218","field":"status","kind":"trial","state":"development","label":"5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct06887218/"},{"record":"nct07040228","field":"status","kind":"trial","state":"development","label":"A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer: phase 1/2, recruiting","href":"/trials/nct07040228/"},{"record":"nct07750041","field":"status","kind":"trial","state":"development","label":"A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer: phase 1/2, planned","href":"/trials/nct07750041/"},{"record":"nct07730489","field":"status","kind":"trial","state":"development","label":"A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, F: phase 3, planned","href":"/trials/nct07730489/"},{"record":"nct06246643","field":"status","kind":"trial","state":"development","label":"A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies: phase 2, active","href":"/trials/nct06246643/"},{"record":"nct02955940","field":"status","kind":"trial","state":"development","label":"An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib: phase 2, active","href":"/trials/nct02955940/"},{"record":"nct03829462","field":"status","kind":"trial","state":"development","label":"Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients: phase 3, active","href":"/trials/nct03829462/"},{"record":"nct05057052","field":"status","kind":"trial","state":"development","label":"Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis: phase 2, recruiting","href":"/trials/nct05057052/"},{"record":"nct06949982","field":"status","kind":"trial","state":"development","label":"Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Co: phase 2, recruiting","href":"/trials/nct06949982/"},{"record":"gbm-agile","field":"status","kind":"trial","state":"development","label":"GBM AGILE: phase platform, recruiting","href":"/trials/gbm-agile/"},{"record":"nct06558773","field":"status","kind":"trial","state":"development","label":"GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.: phase 2, recruiting","href":"/trials/nct06558773/"},{"record":"imblaze370","field":"result","kind":"trial","state":"stopped","label":"IMblaze370: phase 3, negative","href":"/trials/imblaze370/","quote":"Median overall survival 8.87 months with atezolizumab and cobimetinib against 8.51 months with regorafenib (hazard ratio 1.00)."},{"record":"nct06199973","field":"status","kind":"trial","state":"development","label":"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, : phase 3, active","href":"/trials/nct06199973/"},{"record":"nct05985109","field":"status","kind":"trial","state":"development","label":"KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05985109/"},{"record":"nct07310173","field":"status","kind":"trial","state":"development","label":"Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma: phase 2, recruiting","href":"/trials/nct07310173/"},{"record":"nct06911684","field":"status","kind":"trial","state":"development","label":"Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.: phase 2, recruiting","href":"/trials/nct06911684/"},{"record":"nct07071961","field":"status","kind":"trial","state":"development","label":"Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Di: phase 2, recruiting","href":"/trials/nct07071961/"},{"record":"nct05963490","field":"status","kind":"trial","state":"development","label":"Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05963490/"},{"record":"nct05794971","field":"status","kind":"trial","state":"development","label":"Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases: phase 3, recruiting","href":"/trials/nct05794971/"},{"record":"nct06425133","field":"status","kind":"trial","state":"development","label":"Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers: phase 2, recruiting","href":"/trials/nct06425133/"},{"record":"nct05462613","field":"status","kind":"trial","state":"development","label":"Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer: phase 2/3, recruiting","href":"/trials/nct05462613/"},{"record":"nct06047379","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis: phase 1/2, recruiting","href":"/trials/nct06047379/"},{"record":"nct07213570","field":"status","kind":"trial","state":"development","label":"STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer: phase 2, recruiting","href":"/trials/nct07213570/"},{"record":"nct05425940","field":"status","kind":"trial","state":"development","label":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer: phase 3, active","href":"/trials/nct05425940/"},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"nct04701476","field":"status","kind":"trial","state":"development","label":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC: phase 2, recruiting","href":"/trials/nct04701476/"},{"record":"nct04781192","field":"status","kind":"trial","state":"development","label":"The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers: phase 1/2, active","href":"/trials/nct04781192/"},{"record":"nct07134205","field":"status","kind":"trial","state":"development","label":"The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer: phase 3, planned","href":"/trials/nct07134205/"},{"record":"registry:regorafenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 32 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/regorafenib/#registry"}],"reasons":[{"drugId":"regorafenib","drugName":"Regorafenib","drugRoute":"/drugs/regorafenib/","drugState":"approved","record":"imblaze370","kind":"trial","label":"IMblaze370: phase 3, negative","href":"/trials/imblaze370/","quote":"Median overall survival 8.87 months with atezolizumab and cobimetinib against 8.51 months with regorafenib (hazard ratio 1.00)."}]},{"id":"repotrectinib","name":"Repotrectinib","route":"/drugs/repotrectinib/","status":"approved","modality":"Small-molecule kinase inhibitor (ROS1 / NTRK)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"ros1+ntrk","name":"ROS1 x NTRK","href":"/targets/ros1/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"repotrectinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/repotrectinib/"},{"record":"repotrectinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2023: ROS1+ locally advanced or metastatic NSCLC","href":"/drugs/repotrectinib/"},{"record":"repotrectinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2024: NTRK-fusion solid tumours (tumour-agnostic)","href":"/drugs/repotrectinib/"},{"record":"repotrectinib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2025: ROS1+ NSCLC; NTRK+ solid tumours; 13 Jan 2025 (conditional)","href":"/drugs/repotrectinib/"},{"record":"repotrectinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2023","href":"/regulatory/regions/"},{"record":"repotrectinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/augtyro"},{"record":"repotrectinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2025","href":"https://products.mhra.gov.uk/?search=Augtyro"},{"record":"repotrectinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2024","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"repotrectinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2025","href":"https://english.nmpa.gov.cn/"},{"record":"nct03093116","field":"status","kind":"trial","state":"development","label":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements: phase 1/2, recruiting","href":"/trials/nct03093116/"},{"record":"nct04094610","field":"status","kind":"trial","state":"development","label":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations: phase 1/2, recruiting","href":"/trials/nct04094610/"},{"record":"nct06140836","field":"status","kind":"trial","state":"development","label":"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3): phase 3, active","href":"/trials/nct06140836/"},{"record":"nct06315010","field":"status","kind":"trial","state":"development","label":"Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis: phase 2, recruiting","href":"/trials/nct06315010/"},{"record":"registry:repotrectinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/repotrectinib/#registry"}],"reasons":[]},{"id":"resminostat","name":"Resminostat","route":"/drugs/resminostat/","status":null,"modality":"Small-molecule HDAC inhibitor","state":"stopped","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"hdac","name":"Histone deacetylases (HDAC)","href":"/targets/hdac/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"resminostat","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): rejected 2025","href":"/regulatory/regions/","quote":"CHMP negative opinion 22 May 2025 on Kinselby (4SC) for advanced mycosis fungoides and Sézary syndrome"},{"record":"resminostat","field":"regulatoryEvents[0]","kind":"event","state":"stopped","label":"EU 2025-05-22: complete response letter","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/kinselby","quote":"CHMP negative opinion on Kinselby (resminostat) for advanced mycosis fungoides and Sézary syndrome"}],"reasons":[{"drugId":"resminostat","drugName":"Resminostat","drugRoute":"/drugs/resminostat/","drugState":"stopped","record":"resminostat","kind":"regional","label":"EMA / European Commission (EU): rejected 2025","href":"/regulatory/regions/","quote":"CHMP negative opinion 22 May 2025 on Kinselby (4SC) for advanced mycosis fungoides and Sézary syndrome"},{"drugId":"resminostat","drugName":"Resminostat","drugRoute":"/drugs/resminostat/","drugState":"stopped","record":"resminostat","kind":"event","label":"EU 2025-05-22: complete response letter","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/kinselby","quote":"CHMP negative opinion on Kinselby (resminostat) for advanced mycosis fungoides and Sézary syndrome"}]},{"id":"revumenib","name":"Revumenib","route":"/drugs/revumenib/","status":"approved","modality":"Small-molecule menin inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"menin","name":"Menin","href":"/targets/menin/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"revumenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/revumenib/"},{"record":"revumenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2024: Relapsed/refractory KMT2A-rearranged acute leukaemia, age ≥1","href":"/drugs/revumenib/"},{"record":"revumenib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2025: Relapsed/refractory NPM1-mutant AML","href":"/drugs/revumenib/"},{"record":"revumenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2024","href":"/regulatory/regions/"},{"record":"nct07211958","field":"status","kind":"trial","state":"development","label":"Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation: phase 3, recruiting","href":"/trials/nct07211958/"},{"record":"registry:revumenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 13 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/revumenib/#registry"}],"reasons":[]},{"id":"rezvilutamide","name":"Rezvilutamide","route":"/drugs/rezvilutamide/","status":"approved","modality":"Oral androgen receptor antagonist","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"androgen-receptor","name":"Androgen receptor","href":"/targets/androgen-receptor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"rezvilutamide","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/rezvilutamide/"},{"record":"rezvilutamide","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2022: High-volume metastatic hormone-sensitive prostate cancer with androgen deprivation therapy","href":"/drugs/rezvilutamide/"},{"record":"rezvilutamide","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2022","href":"https://english.nmpa.gov.cn/"},{"record":"nct07407283","field":"status","kind":"trial","state":"development","label":"A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct07407283/"},{"record":"nct07241416","field":"status","kind":"trial","state":"development","label":"A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer: phase 3, recruiting","href":"/trials/nct07241416/"},{"record":"nct07230106","field":"status","kind":"trial","state":"development","label":"A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer: phase 2, recruiting","href":"/trials/nct07230106/"},{"record":"registry:rezvilutamide","kind":"registry","state":"development","label":"ClinicalTrials.gov: 16 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/rezvilutamide/#registry"}],"reasons":[]},{"id":"ribociclib","name":"Ribociclib","route":"/drugs/ribociclib/","status":"approved","modality":"Small-molecule CDK4/6 inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"cdk4-6","name":"CDK4/6","href":"/targets/cdk4-6/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"cdk-inhibitor","name":"CDK inhibitor","href":"/technologies/cdk46-inhibitor/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"ribociclib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ribociclib/"},{"record":"ribociclib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2017: HR+/HER2- advanced breast cancer","href":"/drugs/ribociclib/"},{"record":"ribociclib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2024: Adjuvant stage II-III HR+/HER2- breast cancer at high risk of recurrence","href":"/drugs/ribociclib/"},{"record":"ribociclib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2017","href":"/regulatory/regions/"},{"record":"ribociclib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2017","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali"},{"record":"ribociclib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2017","href":"https://products.mhra.gov.uk/?search=Kisqali"},{"record":"ribociclib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2019","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"ribociclib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"ribociclib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2017","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Kisqali"},{"record":"nct06188520","field":"status","kind":"trial","state":"development","label":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With : phase 1/2, recruiting","href":"/trials/nct06188520/"},{"record":"nct07002177","field":"status","kind":"trial","state":"development","label":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC: phase 1/2, recruiting","href":"/trials/nct07002177/"},{"record":"nct07405801","field":"status","kind":"trial","state":"development","label":"A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer: phase 2, recruiting","href":"/trials/nct07405801/"},{"record":"nct07647328","field":"status","kind":"trial","state":"development","label":"A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct07647328/"},{"record":"nct04802759","field":"status","kind":"trial","state":"development","label":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer: phase 1/2, recruiting","href":"/trials/nct04802759/"},{"record":"nct06065748","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer): phase 3, active","href":"/trials/nct06065748/"},{"record":"nct07054190","field":"status","kind":"trial","state":"development","label":"A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer: phase 2, recruiting","href":"/trials/nct07054190/"},{"record":"nct04862663","field":"status","kind":"trial","state":"development","label":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292): phase 3, active","href":"/trials/nct04862663/"},{"record":"nct05768139","field":"status","kind":"trial","state":"development","label":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05768139/"},{"record":"nct05563220","field":"status","kind":"trial","state":"development","label":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer: phase 1/2, active","href":"/trials/nct05563220/"},{"record":"nct07085767","field":"status","kind":"trial","state":"development","label":"Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct07085767/"},{"record":"nct06757634","field":"status","kind":"trial","state":"development","label":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2): phase 3, recruiting","href":"/trials/nct06757634/"},{"record":"nct05827081","field":"status","kind":"trial","state":"development","label":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer: phase 3, recruiting","href":"/trials/nct05827081/"},{"record":"nct05358249","field":"status","kind":"trial","state":"development","label":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation: phase 1/2, active","href":"/trials/nct05358249/"},{"record":"nct06380751","field":"status","kind":"trial","state":"development","label":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct06380751/"},{"record":"nct05867251","field":"status","kind":"trial","state":"development","label":"Study of AVZO-021 in Patients With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05867251/"},{"record":"nct06726148","field":"status","kind":"trial","state":"development","label":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06726148/"},{"record":"nct04417621","field":"status","kind":"trial","state":"development","label":"Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma: phase 2, active","href":"/trials/nct04417621/"},{"record":"nct06760637","field":"status","kind":"trial","state":"development","label":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease: phase 3, active","href":"/trials/nct06760637/"},{"record":"nct05573555","field":"status","kind":"trial","state":"development","label":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B): phase 1/2, active","href":"/trials/nct05573555/"},{"record":"registry:ribociclib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 64 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ribociclib/#registry"}],"reasons":[]},{"id":"rinzimetostat","name":"Rinzimetostat","route":"/drugs/rinzimetostat/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["target record (drugs field)","modality","mechanism"],"components":{"target":{"id":"eed","name":"EED","href":"/targets/eed/","confidence":"high","from":["target record (drugs field)"],"detail":null},"mechanismClass":{"id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"allosteric","name":"Allosteric","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"rinzimetostat","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/rinzimetostat/"},{"record":"himalayas-1","field":"status","kind":"trial","state":"development","label":"A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1): phase 3, recruiting","href":"/trials/himalayas-1/"},{"record":"registry:rinzimetostat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/rinzimetostat/#registry"}],"reasons":[]},{"id":"ripretinib","name":"Ripretinib","route":"/drugs/ripretinib/","status":"approved","modality":"Small-molecule kinase inhibitor (KIT/PDGFRA switch-control)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"kit","name":"KIT","href":"/targets/kit/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"ripretinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ripretinib/"},{"record":"ripretinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2020: Advanced GIST after ≥3 prior kinase inhibitors including imatinib","href":"/drugs/ripretinib/"},{"record":"ripretinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2020","href":"/regulatory/regions/"},{"record":"ripretinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2021","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/qinlock"},{"record":"ripretinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2021","href":"https://products.mhra.gov.uk/?search=Qinlock"},{"record":"ripretinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"ripretinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2020","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Qinlock"},{"record":"nct05957367","field":"status","kind":"trial","state":"development","label":"A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies: phase 1/2, recruiting","href":"/trials/nct05957367/"},{"record":"nct03673501","field":"status","kind":"trial","state":"development","label":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib: phase 3, active","href":"/trials/nct03673501/"},{"record":"insight-gist","field":"status","kind":"trial","state":"development","label":"INSIGHT: phase 3, active","href":"/trials/insight-gist/"},{"record":"registry:ripretinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ripretinib/#registry"}],"reasons":[]},{"id":"rivoceranib","name":"Rivoceranib (apatinib)","route":"/drugs/rivoceranib/","status":"approved","modality":"Small-molecule VEGFR2 TKI","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"vegf","name":"VEGF / VEGFR","href":"/targets/vegf/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"rivoceranib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/rivoceranib/"},{"record":"rivoceranib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2014: Advanced gastric or gastro-oesophageal junction adenocarcinoma after two or more lines","href":"/drugs/rivoceranib/"},{"record":"rivoceranib","field":"approvals[1]","kind":"approval","state":"approved","label":"China 2020: Advanced hepatocellular carcinoma after prior systemic therapy","href":"/drugs/rivoceranib/"},{"record":"rivoceranib","field":"approvals[2]","kind":"approval","state":"approved","label":"China 2023: First-line unresectable hepatocellular carcinoma with camrelizumab (CARES-310)","href":"/drugs/rivoceranib/"},{"record":"rivoceranib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2014","href":"https://english.nmpa.gov.cn/"},{"record":"nct05934331","field":"status","kind":"trial","state":"development","label":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study: phase 2, recruiting","href":"/trials/nct05934331/"},{"record":"nct05320692","field":"status","kind":"trial","state":"development","label":"A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma: phase 3, active","href":"/trials/nct05320692/"},{"record":"nct04639180","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recur: phase 3, active","href":"/trials/nct04639180/"},{"record":"nct06475209","field":"status","kind":"trial","state":"development","label":"Adebrelimab + Apatinib in SCLC Maintenance Therapy: phase 2, recruiting","href":"/trials/nct06475209/"},{"record":"nct05192798","field":"status","kind":"trial","state":"development","label":"Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC: phase 2, recruiting","href":"/trials/nct05192798/"},{"record":"nct05019690","field":"status","kind":"trial","state":"development","label":"Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer: phase 1/2, recruiting","href":"/trials/nct05019690/"},{"record":"nct07802184","field":"status","kind":"trial","state":"development","label":"GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC: phase 1/2, planned","href":"/trials/nct07802184/"},{"record":"nct06889688","field":"status","kind":"trial","state":"development","label":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer: phase 3, recruiting","href":"/trials/nct06889688/"},{"record":"nct07773363","field":"status","kind":"trial","state":"development","label":"Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer: phase 2, planned","href":"/trials/nct07773363/"},{"record":"nct05447702","field":"status","kind":"trial","state":"development","label":"Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC): phase 2, recruiting","href":"/trials/nct05447702/"},{"record":"nct04342910","field":"status","kind":"trial","state":"development","label":"Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC: phase 3, recruiting","href":"/trials/nct04342910/"},{"record":"registry:rivoceranib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 10 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/rivoceranib/#registry"}],"reasons":[]},{"id":"ro7771950","name":"RO7771950","route":"/drugs/ro7771950/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"her2","name":"HER2","href":"/targets/her2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"ro7771950","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/ro7771950/"},{"record":"nct05593094","field":"status","kind":"trial","state":"development","label":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced So: phase 1/2, active","href":"/trials/nct05593094/"},{"record":"nct07413939","field":"status","kind":"trial","state":"development","label":"RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive: phase 2/3, recruiting","href":"/trials/nct07413939/"},{"record":"registry:ro7771950","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/ro7771950/#registry"}],"reasons":[]},{"id":"romidepsin","name":"Romidepsin","route":"/drugs/romidepsin/","status":"approved","modality":"Class I HDAC inhibitor (cyclic peptide)","state":"approved","confidence":"high","fields":["target record (drugs field)","technologies"],"components":{"target":{"id":"hdac+tet2","name":"Histone deacetylases x TET2","href":"/targets/hdac/","confidence":"high","from":["target record (drugs field)"],"detail":"dual-target"},"mechanismClass":{"id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"romidepsin","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/romidepsin/"},{"record":"romidepsin","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2009: Cutaneous T-cell lymphoma after ≥1 systemic therapy","href":"/drugs/romidepsin/"},{"record":"romidepsin","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2011: Peripheral T-cell lymphoma after ≥1 therapy","href":"/drugs/romidepsin/"},{"record":"romidepsin","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2009","href":"/regulatory/regions/"},{"record":"romidepsin","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn","href":"/regulatory/regions/","quote":"MAA withdrawn by Celgene before a CHMP opinion"},{"record":"romidepsin","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2017","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"romidepsin","field":"regulatoryEvents[2]","kind":"event","state":"stopped","label":"US 2021-07-30: withdrawal","href":"/drugs/romidepsin/","quote":"Withdrawn: the indication came off the label 10.1 years after its accelerated approval."},{"record":"romidepsin","field":"regulatoryEvents[3]","kind":"event","state":"stopped","label":"US 2021-12-08: withdrawal","href":"/drugs/romidepsin/","quote":"Withdrawn: the indication came off the label 1.7 years after its accelerated approval."},{"record":"nct04747236","field":"status","kind":"trial","state":"development","label":"Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL: phase 2, recruiting","href":"/trials/nct04747236/"},{"record":"registry:romidepsin","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/romidepsin/#registry"}],"reasons":[{"drugId":"romidepsin","drugName":"Romidepsin","drugRoute":"/drugs/romidepsin/","drugState":"approved","record":"romidepsin","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"/regulatory/regions/","quote":"MAA withdrawn by Celgene before a CHMP opinion"},{"drugId":"romidepsin","drugName":"Romidepsin","drugRoute":"/drugs/romidepsin/","drugState":"approved","record":"romidepsin","kind":"event","label":"US 2021-07-30: withdrawal","href":"/drugs/romidepsin/","quote":"Withdrawn: the indication came off the label 10.1 years after its accelerated approval."},{"drugId":"romidepsin","drugName":"Romidepsin","drugRoute":"/drugs/romidepsin/","drugState":"approved","record":"romidepsin","kind":"event","label":"US 2021-12-08: withdrawal","href":"/drugs/romidepsin/","quote":"Withdrawn: the indication came off the label 1.7 years after its accelerated approval."}]},{"id":"romiplostim","name":"Romiplostim","route":"/drugs/romiplostim/","status":"established","modality":"Thrombopoietin receptor agonist (peptibody), weekly injection","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"mpl","name":"MPL (thrombopoietin receptor)","href":"/targets/mpl/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"receptor-agonist","name":"Receptor agonist","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"romiplostim","field":"status","kind":"drug","state":"approved","label":"Drug record status: established","href":"/drugs/romiplostim/"},{"record":"romiplostim","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2008: Immune thrombocytopenia with insufficient response to corticosteroids, immunoglobulins or splenectomy","href":"/drugs/romiplostim/"},{"record":"nct03937154","field":"status","kind":"trial","state":"development","label":"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer: phase 3, active","href":"/trials/nct03937154/"},{"record":"registry:romiplostim","kind":"registry","state":"development","label":"ClinicalTrials.gov: 25 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/romiplostim/#registry"}],"reasons":[]},{"id":"rucaparib","name":"Rucaparib","route":"/drugs/rucaparib/","status":"approved","modality":"Small-molecule PARP inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"parp+brca","name":"PARP x BRCA1 / BRCA2","href":"/targets/parp/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"parp-inhibitor","name":"PARP inhibitor","href":"/technologies/parp-inhibitor/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"rucaparib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/rucaparib/"},{"record":"rucaparib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2016: BRCA-mutated advanced ovarian cancer after ≥2 chemotherapies (later narrowed)","href":"/drugs/rucaparib/"},{"record":"rucaparib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2018: Maintenance in recurrent ovarian cancer after platinum response (now BRCA-mutated only)","href":"/drugs/rucaparib/"},{"record":"rucaparib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2020: BRCA-mutated mCRPC after ARPI and taxane","href":"/drugs/rucaparib/"},{"record":"rucaparib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2016","href":"/regulatory/regions/"},{"record":"rucaparib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2018","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/rubraca"},{"record":"rucaparib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2018","href":"https://products.mhra.gov.uk/?search=Rubraca"},{"record":"rucaparib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2020","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Rubraca"},{"record":"rucaparib","field":"regulatoryEvents[4]","kind":"event","state":"stopped","label":"US 2022-12-11: withdrawal","href":"/drugs/rucaparib/","quote":"Clovis Oncology bankruptcy; asset sold to pharma&"},{"record":"registry:rucaparib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 9 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/rucaparib/#registry"}],"reasons":[{"drugId":"rucaparib","drugName":"Rucaparib","drugRoute":"/drugs/rucaparib/","drugState":"approved","record":"rucaparib","kind":"event","label":"US 2022-12-11: withdrawal","href":"/drugs/rucaparib/","quote":"Clovis Oncology bankruptcy; asset sold to pharma&"}]},{"id":"ruxolitinib","name":"Ruxolitinib","route":"/drugs/ruxolitinib/","status":"approved","modality":"Small-molecule JAK1/JAK2 inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"jak2+jak1","name":"JAK2 x JAK1","href":"/targets/jak2/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"ruxolitinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ruxolitinib/"},{"record":"ruxolitinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2011: Intermediate/high-risk myelofibrosis","href":"/drugs/ruxolitinib/"},{"record":"ruxolitinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2014: Polycythaemia vera after hydroxyurea","href":"/drugs/ruxolitinib/"},{"record":"ruxolitinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2019: Steroid-refractory acute GVHD","href":"/drugs/ruxolitinib/"},{"record":"ruxolitinib","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2021: Chronic GVHD after failure of 1-2 lines","href":"/drugs/ruxolitinib/"},{"record":"ruxolitinib","field":"approvals[4]","kind":"approval","state":"approved","label":"EU 2012: Myelofibrosis","href":"/drugs/ruxolitinib/"},{"record":"ruxolitinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2011","href":"/regulatory/regions/"},{"record":"ruxolitinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2012","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi"},{"record":"ruxolitinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2012","href":"https://products.mhra.gov.uk/?search=Jakavi"},{"record":"ruxolitinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2014","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"ruxolitinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2017","href":"https://english.nmpa.gov.cn/"},{"record":"ruxolitinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Jakavi"},{"record":"nct04817007","field":"status","kind":"trial","state":"development","label":"A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis): phase 1/2, active","href":"/trials/nct04817007/"},{"record":"nct02955940","field":"status","kind":"trial","state":"development","label":"An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib: phase 2, active","href":"/trials/nct02955940/"},{"record":"nct03669965","field":"status","kind":"trial","state":"development","label":"KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera: phase 2, active","href":"/trials/nct03669965/"},{"record":"majic-et","field":"result","kind":"trial","state":"stopped","label":"MAJIC-ET: phase 2, negative","href":"/trials/majic-et/","quote":"Complete response within 1 year 46.6% (ruxolitinib) vs 44.2% (best available therapy), not significant; no difference in clots, bleeding or transformation at 2 years."},{"record":"nct07219576","field":"status","kind":"trial","state":"development","label":"Retifanlimab and Ruxolitinib In Solid Malignancies: phase 1/2, recruiting","href":"/trials/nct07219576/"},{"record":"nct04509700","field":"status","kind":"trial","state":"development","label":"Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465): phase 2, active","href":"/trials/nct04509700/"},{"record":"nct04562389","field":"status","kind":"trial","state":"development","label":"Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis: phase 3, active","href":"/trials/nct04562389/"},{"record":"registry:ruxolitinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 25 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ruxolitinib/#registry"}],"reasons":[{"drugId":"ruxolitinib","drugName":"Ruxolitinib","drugRoute":"/drugs/ruxolitinib/","drugState":"approved","record":"majic-et","kind":"trial","label":"MAJIC-ET: phase 2, negative","href":"/trials/majic-et/","quote":"Complete response within 1 year 46.6% (ruxolitinib) vs 44.2% (best available therapy), not significant; no difference in clots, bleeding or transformation at 2 years."}]},{"id":"safusidenib","name":"Safusidenib","route":"/drugs/safusidenib/","status":"phase-3","modality":"small molecule inhibitor","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"idh","name":"IDH1 / IDH2","href":"/targets/idh/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"idh-inhibitor","name":"IDH inhibitor","href":"/technologies/idh-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"safusidenib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/safusidenib/"},{"record":"nct04458272","field":"status","kind":"trial","state":"development","label":"A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma: phase 2, active","href":"/trials/nct04458272/"},{"record":"nct05303519","field":"status","kind":"trial","state":"development","label":"SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance): phase 3, recruiting","href":"/trials/nct05303519/"},{"record":"registry:safusidenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/safusidenib/#registry"}],"reasons":[]},{"id":"sapanisertib","name":"Sapanisertib","route":"/drugs/sapanisertib/","status":"phase-2","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"mtor","name":"mTOR","href":"/targets/mtor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"pi3k-akt-mtor-inhibitor","name":"PI3K, AKT or mTOR inhibitor","href":"/technologies/pi3k-akt-mtor-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"sapanisertib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/sapanisertib/"},{"record":"nct07558733","field":"status","kind":"trial","state":"development","label":"Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer: phase 1/2, recruiting","href":"/trials/nct07558733/"},{"record":"nct06463028","field":"status","kind":"trial","state":"development","label":"Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial : phase 2, recruiting","href":"/trials/nct06463028/"},{"record":"registry:sapanisertib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/sapanisertib/#registry"}],"reasons":[]},{"id":"saruparib","name":"Saruparib","route":"/drugs/saruparib/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"parp","name":"PARP","href":"/targets/parp/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"parp-inhibitor","name":"PARP inhibitor","href":"/technologies/parp-inhibitor/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"saruparib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/saruparib/"},{"record":"nct05123482","field":"status","kind":"trial","state":"development","label":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies: phase 1/2, recruiting","href":"/trials/nct05123482/"},{"record":"nct06952803","field":"status","kind":"trial","state":"development","label":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation: phase 3, recruiting","href":"/trials/nct06952803/"},{"record":"nct07336446","field":"status","kind":"trial","state":"development","label":"A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs: phase 1/2, recruiting","href":"/trials/nct07336446/"},{"record":"nct05797168","field":"status","kind":"trial","state":"development","label":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05797168/"},{"record":"nct06380751","field":"status","kind":"trial","state":"development","label":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer: phase 3, recruiting","href":"/trials/nct06380751/"},{"record":"nct06120491","field":"status","kind":"trial","state":"development","label":"Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents: phase 3, active","href":"/trials/nct06120491/"},{"record":"nct07446855","field":"status","kind":"trial","state":"development","label":"Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours: phase 1/2, recruiting","href":"/trials/nct07446855/"},{"record":"nct04644068","field":"status","kind":"trial","state":"development","label":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies: phase 1/2, active","href":"/trials/nct04644068/"},{"record":"nct05367440","field":"status","kind":"trial","state":"development","label":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer: phase 1/2, active","href":"/trials/nct05367440/"},{"record":"registry:saruparib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 10 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/saruparib/#registry"}],"reasons":[]},{"id":"savolitinib","name":"Savolitinib","route":"/drugs/savolitinib/","status":"approved","modality":"Small-molecule selective MET TKI","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"met+egfr","name":"MET x EGFR","href":"/targets/met/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"savolitinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/savolitinib/"},{"record":"savolitinib","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2021: MET exon 14 skipping NSCLC after platinum chemotherapy or unfit for chemotherapy (conditional; later full)","href":"/drugs/savolitinib/"},{"record":"savolitinib","field":"approvals[1]","kind":"approval","state":"approved","label":"China 2025: With osimertinib in EGFR-mutant NSCLC with MET amplification after EGFR TKI (SACHI)","href":"/drugs/savolitinib/"},{"record":"savolitinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"nct04606771","field":"status","kind":"trial","state":"development","label":"A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC: phase 2, active","href":"/trials/nct04606771/"},{"record":"nct05009836","field":"status","kind":"trial","state":"development","label":"Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC: phase 3, active","href":"/trials/nct05009836/"},{"record":"nct03778229","field":"status","kind":"trial","state":"development","label":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib: phase 2, active","href":"/trials/nct03778229/"},{"record":"nct03944772","field":"status","kind":"trial","state":"development","label":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD): phase 2, active","href":"/trials/nct03944772/"},{"record":"nct05374603","field":"status","kind":"trial","state":"development","label":"Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC: phase 2, active","href":"/trials/nct05374603/"},{"record":"nct05043090","field":"status","kind":"trial","state":"development","label":"Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC: phase 3, active","href":"/trials/nct05043090/"},{"record":"nct05261399","field":"status","kind":"trial","state":"development","label":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment: phase 3, active","href":"/trials/nct05261399/"},{"record":"nct03091192","field":"status","kind":"trial","state":"development","label":"Savolitinib vs. Sunitinib in MET-driven PRCC.: phase 3, active","href":"/trials/nct03091192/"},{"record":"registry:savolitinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 16 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/savolitinib/#registry"}],"reasons":[]},{"id":"selinexor","name":"Selinexor","route":"/drugs/selinexor/","status":"approved","modality":"Small-molecule XPO1 (nuclear export) inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"tp53","name":"TP53","href":"/targets/tp53/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"selinexor","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/selinexor/"},{"record":"selinexor","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2019: Relapsed/refractory multiple myeloma (≥4 lines) with dexamethasone","href":"/drugs/selinexor/"},{"record":"selinexor","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2020: Relapsed/refractory DLBCL; myeloma with bortezomib after ≥1 line","href":"/drugs/selinexor/"},{"record":"selinexor","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2021: EU brand Nexpovio","href":"/drugs/selinexor/"},{"record":"selinexor","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2019","href":"/regulatory/regions/"},{"record":"selinexor","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2021","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/nexpovio"},{"record":"selinexor","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2021","href":"https://products.mhra.gov.uk/?search=Nexpovio"},{"record":"selinexor","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"selinexor","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2022","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Xpovio"},{"record":"selinexor","field":"regulatoryEvents[3]","kind":"event","state":"stopped","label":"US 2026-04-30: withdrawal","href":"https://wayback.archive-it.org/7993/20201222062817/https:/www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-relapsedrefractory-diffuse-large-b-cell-lymphoma","quote":"Withdrawn: the indication came off the label 5.9 years after its accelerated approval."},{"record":"nct04442022","field":"status","kind":"trial","state":"development","label":"A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Ly: phase 2/3, active","href":"/trials/nct04442022/"},{"record":"nct04414475","field":"status","kind":"trial","state":"development","label":"A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refrac: phase 2, recruiting","href":"/trials/nct04414475/"},{"record":"nct02227251","field":"status","kind":"trial","state":"development","label":"Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): phase 2, active","href":"/trials/nct02227251/"},{"record":"nct05035745","field":"status","kind":"trial","state":"development","label":"Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START): phase 1/2, recruiting","href":"/trials/nct05035745/"},{"record":"nct02343042","field":"status","kind":"trial","state":"development","label":"Selinexor and Backbone Treatments of Multiple Myeloma Patients: phase 1/2, recruiting","href":"/trials/nct02343042/"},{"record":"nct06158841","field":"status","kind":"trial","state":"development","label":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto: phase 3, active","href":"/trials/nct06158841/"},{"record":"nct04562389","field":"status","kind":"trial","state":"development","label":"Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis: phase 3, active","href":"/trials/nct04562389/"},{"record":"nct04782687","field":"status","kind":"trial","state":"development","label":"Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma: phase 2, active","href":"/trials/nct04782687/"},{"record":"nct06813079","field":"status","kind":"trial","state":"development","label":"Using Tumor Models to Determine Treatments: phase 2, recruiting","href":"/trials/nct06813079/"},{"record":"xport-ec-042","field":"result","kind":"trial","state":"stopped","label":"XPORT-EC-042 / ENGOT-EN20 / GOG-3083: phase 3, negative","href":"/trials/xport-ec-042/","quote":"Primary PFS endpoint not met; mPFS 12.75 vs 7.43 months (mITT) not significant."},{"record":"registry:selinexor","kind":"registry","state":"development","label":"ClinicalTrials.gov: 50 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/selinexor/#registry"}],"reasons":[{"drugId":"selinexor","drugName":"Selinexor","drugRoute":"/drugs/selinexor/","drugState":"approved","record":"selinexor","kind":"event","label":"US 2026-04-30: withdrawal","href":"https://wayback.archive-it.org/7993/20201222062817/https:/www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-relapsedrefractory-diffuse-large-b-cell-lymphoma","quote":"Withdrawn: the indication came off the label 5.9 years after its accelerated approval."},{"drugId":"selinexor","drugName":"Selinexor","drugRoute":"/drugs/selinexor/","drugState":"approved","record":"xport-ec-042","kind":"trial","label":"XPORT-EC-042 / ENGOT-EN20 / GOG-3083: phase 3, negative","href":"/trials/xport-ec-042/","quote":"Primary PFS endpoint not met; mPFS 12.75 vs 7.43 months (mITT) not significant."}]},{"id":"selpercatinib","name":"Selpercatinib","route":"/drugs/selpercatinib/","status":"approved","modality":"Small-molecule kinase inhibitor (RET)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"ret","name":"RET","href":"/targets/ret/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"selpercatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/selpercatinib/"},{"record":"selpercatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2020: RET-fusion NSCLC and thyroid; RET-mutant MTC","href":"/drugs/selpercatinib/"},{"record":"selpercatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2022: RET-fusion solid tumours (tumour-agnostic)","href":"/drugs/selpercatinib/"},{"record":"selpercatinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2026: Label update (July 2026)","href":"/drugs/selpercatinib/"},{"record":"selpercatinib","field":"approvals[3]","kind":"approval","state":"approved","label":"EU 2021: EU brand Retsevmo","href":"/drugs/selpercatinib/"},{"record":"selpercatinib","field":"approvals[4]","kind":"approval","state":"approved","label":"England (NICE) 2023: Untreated RET fusion-positive advanced non-small-cell lung cancer","href":"/drugs/selpercatinib/"},{"record":"selpercatinib","field":"approvals[5]","kind":"approval","state":"approved","label":"England (NICE) 2025: Previously treated RET fusion-positive advanced non-small-cell lung cancer not previously treated with a RET inhibitor","href":"/drugs/selpercatinib/"},{"record":"selpercatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2020","href":"/regulatory/regions/"},{"record":"selpercatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2021","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo"},{"record":"selpercatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2021","href":"https://products.mhra.gov.uk/?search=Retsevmo"},{"record":"selpercatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2021","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"selpercatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2022","href":"https://english.nmpa.gov.cn/"},{"record":"selpercatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2021","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Retsevmo"},{"record":"nct03899792","field":"status","kind":"trial","state":"development","label":"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors: phase 1/2, active","href":"/trials/nct03899792/"},{"record":"nct03157128","field":"status","kind":"trial","state":"development","label":"A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET: phase 1/2, active","href":"/trials/nct03157128/"},{"record":"nct04280081","field":"status","kind":"trial","state":"development","label":"A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer a: phase 2, active","href":"/trials/nct04280081/"},{"record":"nct04819100","field":"status","kind":"trial","state":"development","label":"A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC): phase 3, active","href":"/trials/nct04819100/"},{"record":"pediatric-match","field":"status","kind":"trial","state":"development","label":"NCI-COG Pediatric MATCH (APEC1621): phase platform, active","href":"/trials/pediatric-match/"},{"record":"registry:selpercatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 17 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/selpercatinib/#registry"}],"reasons":[]},{"id":"selumetinib","name":"Selumetinib","route":"/drugs/selumetinib/","status":"approved","modality":"Small-molecule allosteric MEK1/2 inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"mek","name":"MEK1/2","href":"/targets/mek/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"allosteric","name":"Allosteric","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"selumetinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/selumetinib/"},{"record":"selumetinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2020: NF1 with symptomatic, inoperable plexiform neurofibromas, children 2 and over (extended to adults and to age 1 and over in 2025)","href":"/drugs/selumetinib/"},{"record":"selumetinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2021: Symptomatic, inoperable plexiform neurofibromas in NF1, children 3 and over (conditional)","href":"/drugs/selumetinib/"},{"record":"selumetinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2021","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/koselugo"},{"record":"nct02151084","field":"status","kind":"trial","state":"development","label":"A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer: phase 2, active","href":"/trials/nct02151084/"},{"record":"nct01933932","field":"status","kind":"trial","state":"development","label":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral: phase 3, active","href":"/trials/nct01933932/"},{"record":"nct07619521","field":"status","kind":"trial","state":"development","label":"Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma: phase 1/2, recruiting","href":"/trials/nct07619521/"},{"record":"registry:selumetinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 28 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/selumetinib/#registry"}],"reasons":[]},{"id":"imp4927","name":"Senaparib (IMP4297)","route":"/drugs/imp4927/","status":"phase-3","modality":"small molecule (oral PARP inhibitor)","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"parp","name":"PARP","href":"/targets/parp/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"parp-inhibitor","name":"PARP inhibitor","href":"/technologies/parp-inhibitor/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"imp4927","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/imp4927/"},{"record":"nct04169997","field":"status","kind":"trial","state":"development","label":"A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer: phase 3, active","href":"/trials/nct04169997/"},{"record":"registry:imp4927","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/imp4927/#registry"}],"reasons":[]},{"id":"serabelisib","name":"Serabelisib","route":"/drugs/serabelisib/","status":"phase-2","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"pik3ca","name":"PIK3CA / PI3K-alpha","href":"/targets/pik3ca/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"pi3k-akt-mtor-inhibitor","name":"PI3K, AKT or mTOR inhibitor","href":"/technologies/pi3k-akt-mtor-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"serabelisib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/serabelisib/"},{"record":"nct07558733","field":"status","kind":"trial","state":"development","label":"Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer: phase 1/2, recruiting","href":"/trials/nct07558733/"},{"record":"nct06463028","field":"status","kind":"trial","state":"development","label":"Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial : phase 2, recruiting","href":"/trials/nct06463028/"},{"record":"registry:serabelisib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/serabelisib/#registry"}],"reasons":[]},{"id":"sevabertinib","name":"Sevabertinib","route":"/drugs/sevabertinib/","status":"approved","modality":"Small-molecule kinase inhibitor (HER2)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"her2","name":"HER2","href":"/targets/her2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"sevabertinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/sevabertinib/"},{"record":"sevabertinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2025: HER2 TKD-mutant non-squamous NSCLC after prior systemic therapy (accelerated)","href":"/drugs/sevabertinib/"},{"record":"sevabertinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2025","href":"/regulatory/regions/"},{"record":"sevabertinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2026","href":"https://www.gov.uk/government/news/sevabertinib-approved-to-treat-adults-with-her2-positive-lung-cancer-that-has-spread-or-cannot-be-removed-by-surgery"},{"record":"nct06452277","field":"status","kind":"trial","state":"development","label":"A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-sma: phase 3, recruiting","href":"/trials/nct06452277/"},{"record":"registry:sevabertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/sevabertinib/#registry"}],"reasons":[]},{"id":"silevertinib","name":"Silevertinib","route":"/drugs/silevertinib/","status":"phase-2","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"egfr","name":"EGFR","href":"/targets/egfr/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"silevertinib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/silevertinib/"},{"record":"nct05256290","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations: phase 1/2, active","href":"/trials/nct05256290/"},{"record":"nct07326566","field":"status","kind":"trial","state":"development","label":"Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII: phase 2, recruiting","href":"/trials/nct07326566/"},{"record":"registry:silevertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/silevertinib/#registry"}],"reasons":[]},{"id":"sirolimus","name":"Sirolimus","route":"/drugs/sirolimus/","status":"approved","modality":"Oral mammalian target of rapamycin (mTOR) inhibitor, used as an immunosuppressant","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"mtor","name":"mTOR","href":"/targets/mtor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"pi3k-akt-mtor-inhibitor","name":"PI3K, AKT or mTOR inhibitor","href":"/technologies/pi3k-akt-mtor-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"sirolimus","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/sirolimus/"},{"record":"sirolimus","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1999: Prophylaxis of organ rejection in kidney transplant recipients","href":"/drugs/sirolimus/"},{"record":"registry:sirolimus","kind":"registry","state":"development","label":"ClinicalTrials.gov: 26 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/sirolimus/#registry"}],"reasons":[]},{"id":"sirolimus-albumin-bound","name":"Sirolimus protein-bound particles","route":"/drugs/sirolimus-albumin-bound/","status":"approved","modality":"Albumin-bound mTOR inhibitor (intravenous)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"mtor","name":"mTOR","href":"/targets/mtor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"allosteric","name":"Allosteric","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"sirolimus-albumin-bound","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/sirolimus-albumin-bound/"},{"record":"sirolimus-albumin-bound","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2021: Locally advanced unresectable or metastatic malignant PEComa","href":"/drugs/sirolimus-albumin-bound/"},{"record":"nct04736589","field":"status","kind":"trial","state":"development","label":"Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway: phase 3, planned","href":"/trials/nct04736589/"},{"record":"nct05103358","field":"status","kind":"trial","state":"development","label":"Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1): phase 2, active","href":"/trials/nct05103358/"},{"record":"nct05997017","field":"status","kind":"trial","state":"development","label":"Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer: phase 2, recruiting","href":"/trials/nct05997017/"},{"record":"registry:sirolimus-albumin-bound","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 1 terminated or withdrawn study and none active (fetched 2026-09-28)","href":"/drugs/sirolimus-albumin-bound/#registry"}],"reasons":[]},{"id":"sitneprotafib","name":"Sitneprotafib","route":"/drugs/sitneprotafib/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"shp2","name":"SHP2 (PTPN11)","href":"/targets/shp2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"allosteric","name":"Allosteric","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"sitneprotafib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/sitneprotafib/"},{"record":"nct06416410","field":"status","kind":"trial","state":"development","label":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation: phase 3, recruiting","href":"/trials/nct06416410/"},{"record":"nct05288205","field":"status","kind":"trial","state":"development","label":"Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation: phase 1/2, recruiting","href":"/trials/nct05288205/"}],"reasons":[]},{"id":"octreotide-lanreotide","name":"Somatostatin analogues (octreotide, lanreotide)","route":"/drugs/octreotide-lanreotide/","status":"approved","modality":"Peptide hormone analogue (SSTR2 agonist)","state":"approved","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"sstr2","name":"Somatostatin receptor 2","href":"/targets/sstr2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"octreotide-lanreotide","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/octreotide-lanreotide/"},{"record":"octreotide-lanreotide","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1988: Carcinoid syndrome symptoms (octreotide)","href":"/drugs/octreotide-lanreotide/"},{"record":"octreotide-lanreotide","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2014: Unresectable GEP-NETs to improve PFS (lanreotide)","href":"/drugs/octreotide-lanreotide/"},{"record":"octreotide-lanreotide","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 1988","href":"/regulatory/regions/"},{"record":"octreotide-lanreotide","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 1988","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/sandostatin"},{"record":"octreotide-lanreotide","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 1988","href":"https://products.mhra.gov.uk/?search=Sandostatin"},{"record":"octreotide-lanreotide","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 1991","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"octreotide-lanreotide","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 1996","href":"https://english.nmpa.gov.cn/"},{"record":"octreotide-lanreotide","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 1990","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Sandostatin"},{"record":"nct06807437","field":"status","kind":"trial","state":"development","label":"Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula: phase 3, recruiting","href":"/trials/nct06807437/"},{"record":"registry:octreotide-lanreotide","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/octreotide-lanreotide/#registry"}],"reasons":[]},{"id":"sonidegib","name":"Sonidegib","route":"/drugs/sonidegib/","status":"approved","modality":"Small-molecule smoothened inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"smoothened","name":"Smoothened (hedgehog pathway)","href":"/targets/smoothened/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"hedgehog-inhibitor","name":"Hedgehog inhibitor","href":"/technologies/hedgehog-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"sonidegib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/sonidegib/"},{"record":"sonidegib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2015: Locally advanced BCC recurrent after surgery or radiation, or not candidates","href":"/drugs/sonidegib/"},{"record":"sonidegib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2015: Same","href":"/drugs/sonidegib/"},{"record":"sonidegib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2015","href":"/regulatory/regions/"},{"record":"sonidegib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2015","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/odomzo"},{"record":"sonidegib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2015","href":"https://products.mhra.gov.uk/?search=Odomzo"},{"record":"sonidegib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Odomzo"},{"record":"registry:sonidegib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/sonidegib/#registry"}],"reasons":[]},{"id":"sonrotoclax","name":"Sonrotoclax","route":"/drugs/sonrotoclax/","status":"approved","modality":"Small-molecule BCL-2 inhibitor (second generation)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"bcl2","name":"BCL-2","href":"/targets/bcl2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"bcl2-inhibitor","name":"BCL-2 inhibitor","href":"/technologies/bcl2-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"sonrotoclax","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/sonrotoclax/"},{"record":"sonrotoclax","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2025: Relapsed/refractory MCL and CLL/SLL after BTK inhibitor","href":"/drugs/sonrotoclax/"},{"record":"sonrotoclax","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2026: Relapsed/refractory mantle cell lymphoma after ≥2 lines including a BTK inhibitor (accelerated)","href":"/drugs/sonrotoclax/"},{"record":"sonrotoclax","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2026","href":"/regulatory/regions/"},{"record":"sonrotoclax","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2025","href":"https://english.nmpa.gov.cn/"},{"record":"nct04973605","field":"status","kind":"trial","state":"development","label":"A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat: phase 1/2, recruiting","href":"/trials/nct04973605/"},{"record":"nct04771130","field":"status","kind":"trial","state":"development","label":"A Study of BGB-11417 in Participants With Myeloid Malignancies: phase 1/2, recruiting","href":"/trials/nct04771130/"},{"record":"nct05952037","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia: phase 2, active","href":"/trials/nct05952037/"},{"record":"nct06943872","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL): phase 3, recruiting","href":"/trials/nct06943872/"},{"record":"nct06634589","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies: phase 1/2, recruiting","href":"/trials/nct06634589/"},{"record":"nct07277231","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia: phase 3, recruiting","href":"/trials/nct07277231/"},{"record":"nct06637501","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia: phase 2, active","href":"/trials/nct06637501/"},{"record":"nct06742996","field":"status","kind":"trial","state":"development","label":"A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refrac: phase 3, recruiting","href":"/trials/nct06742996/"},{"record":"nct06697184","field":"status","kind":"trial","state":"development","label":"A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.: phase 1/2, recruiting","href":"/trials/nct06697184/"},{"record":"celestial-tncll","field":"status","kind":"trial","state":"development","label":"CELESTIAL-TNCLL: phase 3, active","href":"/trials/celestial-tncll/"},{"record":"nct05479994","field":"status","kind":"trial","state":"development","label":"Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: phase 2, active","href":"/trials/nct05479994/"},{"record":"nct05471843","field":"status","kind":"trial","state":"development","label":"Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma: phase 1/2, active","href":"/trials/nct05471843/"},{"record":"registry:sonrotoclax","kind":"registry","state":"development","label":"ClinicalTrials.gov: 37 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/sonrotoclax/#registry"}],"reasons":[]},{"id":"soquelitinib","name":"Soquelitinib","route":"/drugs/soquelitinib/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["target record (drugs field)","modality","mechanism"],"components":{"target":{"id":"itk","name":"ITK","href":"/targets/itk/","confidence":"high","from":["target record (drugs field)"],"detail":null},"mechanismClass":{"id":"hif-inhibitor","name":"HIF inhibitor","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"soquelitinib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/soquelitinib/"},{"record":"nct06561048","field":"status","kind":"trial","state":"development","label":"Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma: phase 3, recruiting","href":"/trials/nct06561048/"},{"record":"registry:soquelitinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/soquelitinib/#registry"}],"reasons":[]},{"id":"sorafenib","name":"Sorafenib","route":"/drugs/sorafenib/","status":"approved","modality":"Small-molecule multi-kinase inhibitor (VEGFR, PDGFR, RAF)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"vegf+braf","name":"VEGF / VEGFR x BRAF","href":"/targets/vegf/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"sorafenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/sorafenib/"},{"record":"sorafenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2005: Advanced RCC","href":"/drugs/sorafenib/"},{"record":"sorafenib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2007: Unresectable HCC","href":"/drugs/sorafenib/"},{"record":"sorafenib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2013: Radioiodine-refractory differentiated thyroid cancer","href":"/drugs/sorafenib/"},{"record":"sorafenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2005","href":"/regulatory/regions/"},{"record":"sorafenib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2006","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/nexavar"},{"record":"sorafenib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2006","href":"https://products.mhra.gov.uk/?search=Nexavar"},{"record":"sorafenib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2008","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"sorafenib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2006","href":"https://english.nmpa.gov.cn/"},{"record":"sorafenib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2006","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Nexavar"},{"record":"sorafenib","field":"regional.IN","kind":"regional","state":"approved","label":"CDSCO (DCGI) (IN): approved","href":"https://en.wikipedia.org/wiki/Natco_Pharma"},{"record":"nct07787429","field":"status","kind":"trial","state":"development","label":"Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma: phase 2, recruiting","href":"/trials/nct07787429/"},{"record":"sarah-sirvenib","field":"result","kind":"trial","state":"stopped","label":"SARAH and SIRveNIB: phase 3, negative","href":"/trials/sarah-sirvenib/","quote":"OS not improved; fewer adverse events."},{"record":"nct03755791","field":"status","kind":"trial","state":"development","label":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece: phase 3, active","href":"/trials/nct03755791/"},{"record":"nct05822752","field":"status","kind":"trial","state":"development","label":"Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Bu: phase 2, active","href":"/trials/nct05822752/"},{"record":"registry:sorafenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 13 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/sorafenib/#registry"}],"reasons":[{"drugId":"sorafenib","drugName":"Sorafenib","drugRoute":"/drugs/sorafenib/","drugState":"approved","record":"sarah-sirvenib","kind":"trial","label":"SARAH and SIRveNIB: phase 3, negative","href":"/trials/sarah-sirvenib/","quote":"OS not improved; fewer adverse events."}]},{"id":"sotorasib","name":"Sotorasib","route":"/drugs/sotorasib/","status":"approved","modality":"Small-molecule inhibitor (KRAS G12C)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"kras","name":"KRAS","href":"/targets/kras/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"sotorasib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/sotorasib/"},{"record":"sotorasib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2021: KRAS G12C NSCLC, previously treated (accelerated)","href":"/drugs/sotorasib/"},{"record":"sotorasib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2025: KRAS G12C colorectal cancer with panitumumab","href":"/drugs/sotorasib/"},{"record":"sotorasib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2022: EU brand Lumykras","href":"/drugs/sotorasib/"},{"record":"sotorasib","field":"approvals[3]","kind":"approval","state":"approved","label":"US 2025: KRAS G12C-mutated metastatic colorectal cancer after fluoropyrimidine, oxaliplatin and irinotecan chemotherapy, with panitumumab","href":"/drugs/sotorasib/"},{"record":"sotorasib","field":"approvals[4]","kind":"approval","state":"approved","label":"England (NICE) 2022: KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer that has progressed on, or after intolerance of, platinum-based chemotherapy or PD-1/PD-L1 immunotherapy","href":"/drugs/sotorasib/"},{"record":"sotorasib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2021","href":"/regulatory/regions/"},{"record":"sotorasib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2022","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/lumykras"},{"record":"sotorasib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2021","href":"https://products.mhra.gov.uk/?search=Lumykras"},{"record":"sotorasib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2022","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"sotorasib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2022","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Lumykras"},{"record":"sotorasib","field":"regulatoryEvents[2]","kind":"event","state":"stopped","label":"US 2023-12: complete response letter","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","quote":"FDA declines full approval based on CodeBreaK 200; postmarketing dose study required"},{"record":"nct07563738","field":"status","kind":"trial","state":"development","label":"A 2-part Phase 1/2 Open-label Trial on ODM-212: phase 1/2, recruiting","href":"/trials/nct07563738/"},{"record":"nct07172919","field":"status","kind":"trial","state":"development","label":"A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation: phase 2, recruiting","href":"/trials/nct07172919/"},{"record":"nct05920356","field":"status","kind":"trial","state":"development","label":"A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi: phase 3, recruiting","href":"/trials/nct05920356/"},{"record":"nct05074810","field":"status","kind":"trial","state":"development","label":"Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients: phase 1/2, active","href":"/trials/nct05074810/"},{"record":"nct05845450","field":"status","kind":"trial","state":"development","label":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN): phase 2, recruiting","href":"/trials/nct05845450/"},{"record":"nct06252649","field":"status","kind":"trial","state":"development","label":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal: phase 3, recruiting","href":"/trials/nct06252649/"},{"record":"registry:sotorasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 17 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/sotorasib/#registry"}],"reasons":[{"drugId":"sotorasib","drugName":"Sotorasib","drugRoute":"/drugs/sotorasib/","drugState":"approved","record":"sotorasib","kind":"event","label":"US 2023-12: complete response letter","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","quote":"FDA declines full approval based on CodeBreaK 200; postmarketing dose study required"}]},{"id":"sunitinib","name":"Sunitinib","route":"/drugs/sunitinib/","status":"approved","modality":"Small-molecule multi-kinase inhibitor (VEGFR, PDGFR, KIT)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"vegf+kit","name":"VEGF / VEGFR x KIT","href":"/targets/vegf/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"sunitinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/sunitinib/"},{"record":"sunitinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2006: Advanced RCC; GIST after imatinib","href":"/drugs/sunitinib/"},{"record":"sunitinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2011: Progressive pancreatic NETs","href":"/drugs/sunitinib/"},{"record":"sunitinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2017: Adjuvant RCC at high risk (S-TRAC), little used","href":"/drugs/sunitinib/"},{"record":"sunitinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2006","href":"/regulatory/regions/"},{"record":"sunitinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2006","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/sutent"},{"record":"sunitinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2006","href":"https://products.mhra.gov.uk/?search=Sutent"},{"record":"sunitinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2008","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"sunitinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2007","href":"https://english.nmpa.gov.cn/"},{"record":"sunitinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2006","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Sutent"},{"record":"nct03673501","field":"status","kind":"trial","state":"development","label":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib: phase 3, active","href":"/trials/nct03673501/"},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"nct05024214","field":"status","kind":"trial","state":"development","label":"Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05024214/"},{"record":"nct05043090","field":"status","kind":"trial","state":"development","label":"Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC: phase 3, active","href":"/trials/nct05043090/"},{"record":"nct03091192","field":"status","kind":"trial","state":"development","label":"Savolitinib vs. Sunitinib in MET-driven PRCC.: phase 3, active","href":"/trials/nct03091192/"},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"registry:sunitinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/sunitinib/#registry"}],"reasons":[]},{"id":"sunvozertinib","name":"Sunvozertinib","route":"/drugs/sunvozertinib/","status":"approved","modality":"Small-molecule EGFR exon 20 insertion TKI (irreversible)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"egfr","name":"EGFR","href":"/targets/egfr/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"sunvozertinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/sunvozertinib/"},{"record":"sunvozertinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2023: EGFR exon 20 insertion NSCLC after platinum","href":"/drugs/sunvozertinib/"},{"record":"sunvozertinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2025: Locally advanced/metastatic NSCLC with EGFR exon 20 insertions after platinum","href":"/drugs/sunvozertinib/"},{"record":"sunvozertinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2025","href":"/regulatory/regions/"},{"record":"sunvozertinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"nct07182682","field":"status","kind":"trial","state":"development","label":"A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Ins: phase 3, recruiting","href":"/trials/nct07182682/"},{"record":"nct06295432","field":"status","kind":"trial","state":"development","label":"A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21): phase 2, recruiting","href":"/trials/nct06295432/"},{"record":"nct05668988","field":"status","kind":"trial","state":"development","label":"A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28): phase 3, active","href":"/trials/nct05668988/"},{"record":"nct03974022","field":"status","kind":"trial","state":"development","label":"Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1): phase 1/2, active","href":"/trials/nct03974022/"},{"record":"nct06276283","field":"status","kind":"trial","state":"development","label":"DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29): phase 2, recruiting","href":"/trials/nct06276283/"},{"record":"nct06864624","field":"status","kind":"trial","state":"development","label":"Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC: phase 2, recruiting","href":"/trials/nct06864624/"},{"record":"nct07079475","field":"status","kind":"trial","state":"development","label":"Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8): phase 1/2, recruiting","href":"/trials/nct07079475/"},{"record":"nct05712902","field":"status","kind":"trial","state":"development","label":"Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6): phase 2, active","href":"/trials/nct05712902/"},{"record":"registry:sunvozertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 14 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/sunvozertinib/#registry"}],"reasons":[]},{"id":"surufatinib","name":"Surufatinib","route":"/drugs/surufatinib/","status":"approved","modality":"Oral VEGFR, FGFR1 and CSF1R tyrosine kinase inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"vegf+csf1r","name":"VEGF / VEGFR x CSF1R","href":"/targets/vegf/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"surufatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/surufatinib/"},{"record":"surufatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2020: Advanced non-pancreatic neuroendocrine tumours; pancreatic neuroendocrine tumours from 2021","href":"/drugs/surufatinib/"},{"record":"surufatinib","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/sevsury","quote":"Sevsury (Hutchmed Europe B.V.): marketing authorisation application withdrawn before a Commission decision. EMA register: 'Application withdrawn: The application for this medicine has been withdrawn'; checked 2026-09-24"},{"record":"surufatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2020","href":"https://english.nmpa.gov.cn/"},{"record":"nct06361888","field":"status","kind":"trial","state":"development","label":"A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer: phase 2/3, recruiting","href":"/trials/nct06361888/"},{"record":"nct06654947","field":"status","kind":"trial","state":"development","label":"A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.: phase 2, planned","href":"/trials/nct06654947/"},{"record":"nct06708858","field":"status","kind":"trial","state":"development","label":"Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer: phase 2, recruiting","href":"/trials/nct06708858/"},{"record":"nct05988372","field":"status","kind":"trial","state":"development","label":"Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE): phase 2, planned","href":"/trials/nct05988372/"},{"record":"nct06531291","field":"status","kind":"trial","state":"development","label":"Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation: phase 2, planned","href":"/trials/nct06531291/"},{"record":"nct07469956","field":"status","kind":"trial","state":"development","label":"Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer: phase 2, planned","href":"/trials/nct07469956/"},{"record":"registry:surufatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 40 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/surufatinib/#registry"}],"reasons":[{"drugId":"surufatinib","drugName":"Surufatinib","drugRoute":"/drugs/surufatinib/","drugState":"approved","record":"surufatinib","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/sevsury","quote":"Sevsury (Hutchmed Europe B.V.): marketing authorisation application withdrawn before a Commission decision. EMA register: 'Application withdrawn: The application for this medicine has been withdrawn'; checked 2026-09-24"}]},{"id":"talazoparib","name":"Talazoparib","route":"/drugs/talazoparib/","status":"approved","modality":"Small-molecule PARP inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"parp+brca","name":"PARP x BRCA1 / BRCA2","href":"/targets/parp/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"parp-inhibitor","name":"PARP inhibitor","href":"/technologies/parp-inhibitor/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"talazoparib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/talazoparib/"},{"record":"talazoparib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2018: gBRCA HER2- locally advanced/metastatic breast cancer","href":"/drugs/talazoparib/"},{"record":"talazoparib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2023: HRR-mutant mCRPC with enzalutamide","href":"/drugs/talazoparib/"},{"record":"talazoparib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2019: Germline BRCA1/2-mutated HER2-negative locally advanced or metastatic breast cancer (EMBRACA); marketing authorisation issued 20 June 2019","href":"/drugs/talazoparib/"},{"record":"talazoparib","field":"approvals[3]","kind":"approval","state":"approved","label":"UK 2024: HER2-negative locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations after an anthracycline or a taxane; NICE TA952 (21 February 2024) recommends within the marketing authorisation with a commercial arrangement","href":"/drugs/talazoparib/"},{"record":"talazoparib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2018","href":"/regulatory/regions/"},{"record":"talazoparib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2019","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/talzenna"},{"record":"talazoparib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2019","href":"https://products.mhra.gov.uk/?search=Talzenna"},{"record":"talazoparib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2024","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"talazoparib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2021","href":"https://english.nmpa.gov.cn/"},{"record":"talazoparib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2019","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Talzenna"},{"record":"nct05059522","field":"status","kind":"trial","state":"development","label":"Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing: phase 3, active","href":"/trials/nct05059522/"},{"record":"nct05035745","field":"status","kind":"trial","state":"development","label":"Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START): phase 1/2, recruiting","href":"/trials/nct05035745/"},{"record":"nct04821622","field":"status","kind":"trial","state":"development","label":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC: phase 3, active","href":"/trials/nct04821622/"},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"registry:talazoparib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 34 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/talazoparib/#registry"}],"reasons":[]},{"id":"taletrectinib","name":"Taletrectinib","route":"/drugs/taletrectinib/","status":"approved","modality":"Small-molecule ROS1 TKI (next generation, CNS-penetrant)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"ros1","name":"ROS1","href":"/targets/ros1/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"taletrectinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/taletrectinib/"},{"record":"taletrectinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2025: ROS1-positive NSCLC","href":"/drugs/taletrectinib/"},{"record":"taletrectinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2025: Locally advanced or metastatic ROS1-positive NSCLC","href":"/drugs/taletrectinib/"},{"record":"taletrectinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2025","href":"/regulatory/regions/"},{"record":"taletrectinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2025","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"taletrectinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2025","href":"https://english.nmpa.gov.cn/"},{"record":"nct06564324","field":"status","kind":"trial","state":"development","label":"A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients: phase 3, recruiting","href":"/trials/nct06564324/"},{"record":"nct07154706","field":"status","kind":"trial","state":"development","label":"Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV): phase 3, recruiting","href":"/trials/nct07154706/"},{"record":"nct04919811","field":"status","kind":"trial","state":"development","label":"Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC: phase 2, active","href":"/trials/nct04919811/"},{"record":"registry:taletrectinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/taletrectinib/#registry"}],"reasons":[]},{"id":"tamoxifen","name":"Tamoxifen","route":"/drugs/tamoxifen/","status":"approved","modality":"Small-molecule SERM","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"estrogen-receptor","name":"Estrogen receptor (ERα)","href":"/targets/estrogen-receptor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"tamoxifen","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/tamoxifen/"},{"record":"tamoxifen","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1977: Advanced breast cancer","href":"/drugs/tamoxifen/"},{"record":"tamoxifen","field":"approvals[1]","kind":"approval","state":"approved","label":"US 1998: Risk reduction in high-risk women","href":"/drugs/tamoxifen/"},{"record":"tamoxifen","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 1977","href":"/regulatory/regions/"},{"record":"tamoxifen","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 1973","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/nolvadex"},{"record":"tamoxifen","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 1973","href":"https://products.mhra.gov.uk/?search=Nolvadex"},{"record":"tamoxifen","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 1981","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"tamoxifen","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 1990","href":"https://english.nmpa.gov.cn/"},{"record":"tamoxifen","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 1976","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Nolvadex"},{"record":"nct02747004","field":"status","kind":"trial","state":"development","label":"A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer: phase 2, active","href":"/trials/nct02747004/"},{"record":"nct05774951","field":"status","kind":"trial","state":"development","label":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy: phase 3, recruiting","href":"/trials/nct05774951/"},{"record":"nct06492616","field":"status","kind":"trial","state":"development","label":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence: phase 3, recruiting","href":"/trials/nct06492616/"},{"record":"nct07287098","field":"status","kind":"trial","state":"development","label":"A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer: phase 2, recruiting","href":"/trials/nct07287098/"},{"record":"nct05514054","field":"status","kind":"trial","state":"development","label":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer: phase 3, active","href":"/trials/nct05514054/"},{"record":"nct06979596","field":"status","kind":"trial","state":"development","label":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015): phase 2, recruiting","href":"/trials/nct06979596/"},{"record":"nct05768139","field":"status","kind":"trial","state":"development","label":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05768139/"},{"record":"nct04906395","field":"status","kind":"trial","state":"development","label":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer: phase 3, active","href":"/trials/nct04906395/"},{"record":"nct06434064","field":"status","kind":"trial","state":"development","label":"Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer: phase 2, recruiting","href":"/trials/nct06434064/"},{"record":"registry:tamoxifen","kind":"registry","state":"development","label":"ClinicalTrials.gov: 21 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tamoxifen/#registry"}],"reasons":[]},{"id":"tar-210","name":"TAR-210","route":"/drugs/tar-210/","status":"phase-3","modality":"small molecule (intravesical drug-releasing system)","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"fgfr2","name":"FGFR2","href":"/targets/fgfr2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"tar-210","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/tar-210/"},{"record":"nct06919965","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer: phase 3, recruiting","href":"/trials/nct06919965/"},{"record":"nct06319820","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer: phase 3, recruiting","href":"/trials/nct06319820/"},{"record":"registry:tar-210","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tar-210/#registry"}],"reasons":[]},{"id":"tazemetostat","name":"Tazemetostat","route":"/drugs/tazemetostat/","status":"withdrawn","modality":"Small-molecule EZH2 inhibitor","state":"stopped","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"ezh2","name":"EZH2","href":"/targets/ezh2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"tazemetostat","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/tazemetostat/","quote":"Tazemetostat was the first EZH2 inhibitor, approved for epithelioid sarcoma and follicular lymphoma in 2020 and withdrawn worldwide in 2026 after secondary blood cancers."},{"record":"tazemetostat","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2020: Epithelioid sarcoma; relapsed FL (EZH2-mutant after 2 lines; wild-type without alternatives)","href":"/drugs/tazemetostat/"},{"record":"tazemetostat","field":"regulatoryEvents[2]","kind":"event","state":"stopped","label":"Global 2026-03: withdrawal","href":"/drugs/tazemetostat/","quote":"Withdrawn over secondary haematologic malignancies"},{"record":"tazemetostat","field":"regulatoryEvents[3]","kind":"event","state":"stopped","label":"US 2026-06-22: withdrawal","href":"https://wayback.archive-it.org/7993/20201222063544/https:/www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tazemetostat-advanced-epithelioid-sarcoma","quote":"Withdrawn: the indication came off the label 6.4 years after its accelerated approval."},{"record":"tazemetostat","field":"regulatoryEvents[4]","kind":"event","state":"stopped","label":"US 2026-06-22: withdrawal","href":"https://wayback.archive-it.org/7993/20201222062826/https:/www.fda.gov/drugs/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma","quote":"Withdrawn: the indication came off the label 6.0 years after its accelerated approval."},{"record":"nct07407283","field":"status","kind":"trial","state":"development","label":"A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct07407283/"},{"record":"nct04224493","field":"status","kind":"trial","state":"development","label":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus : phase 3, active","href":"/trials/nct04224493/"},{"record":"nct05372354","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed : phase 1/2, recruiting","href":"/trials/nct05372354/"},{"record":"pediatric-match","field":"status","kind":"trial","state":"development","label":"NCI-COG Pediatric MATCH (APEC1621): phase platform, active","href":"/trials/pediatric-match/"},{"record":"tazemetostat-doxorubicin-es","field":"notes (registry whyStopped)","kind":"trial","state":"stopped","label":"Tazemetostat with doxorubicin as front-line therapy for advanced epithelioid sarcoma (EZH-301 run-in): phase 1, terminated or withdrawn","href":"/trials/tazemetostat-doxorubicin-es/","quote":"FDA and Ipsen alignelment: Due to unfeasibility and the resulting inability to meet the required enrolment targets. No safety concerns."},{"record":"registry:tazemetostat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 18 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tazemetostat/#registry"}],"reasons":[{"drugId":"tazemetostat","drugName":"Tazemetostat","drugRoute":"/drugs/tazemetostat/","drugState":"stopped","record":"tazemetostat","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/tazemetostat/","quote":"Tazemetostat was the first EZH2 inhibitor, approved for epithelioid sarcoma and follicular lymphoma in 2020 and withdrawn worldwide in 2026 after secondary blood cancers."},{"drugId":"tazemetostat","drugName":"Tazemetostat","drugRoute":"/drugs/tazemetostat/","drugState":"stopped","record":"tazemetostat","kind":"event","label":"Global 2026-03: withdrawal","href":"/drugs/tazemetostat/","quote":"Withdrawn over secondary haematologic malignancies"},{"drugId":"tazemetostat","drugName":"Tazemetostat","drugRoute":"/drugs/tazemetostat/","drugState":"stopped","record":"tazemetostat","kind":"event","label":"US 2026-06-22: withdrawal","href":"https://wayback.archive-it.org/7993/20201222063544/https:/www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tazemetostat-advanced-epithelioid-sarcoma","quote":"Withdrawn: the indication came off the label 6.4 years after its accelerated approval."},{"drugId":"tazemetostat","drugName":"Tazemetostat","drugRoute":"/drugs/tazemetostat/","drugState":"stopped","record":"tazemetostat","kind":"event","label":"US 2026-06-22: withdrawal","href":"https://wayback.archive-it.org/7993/20201222062826/https:/www.fda.gov/drugs/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma","quote":"Withdrawn: the indication came off the label 6.0 years after its accelerated approval."},{"drugId":"tazemetostat","drugName":"Tazemetostat","drugRoute":"/drugs/tazemetostat/","drugState":"stopped","record":"tazemetostat-doxorubicin-es","kind":"trial","label":"Tazemetostat with doxorubicin as front-line therapy for advanced epithelioid sarcoma (EZH-301 run-in): phase 1, terminated or withdrawn","href":"/trials/tazemetostat-doxorubicin-es/","quote":"FDA and Ipsen alignelment: Due to unfeasibility and the resulting inability to meet the required enrolment targets. No safety concerns."}]},{"id":"telotristat-ethyl","name":"Telotristat ethyl","route":"/drugs/telotristat-ethyl/","status":"approved","modality":"Oral tryptophan hydroxylase inhibitor","state":"approved","confidence":"medium","fields":["target record (drugs field)","modality","mechanism"],"components":{"target":{"id":"tph1","name":"Tryptophan hydroxylase 1","href":"/targets/tph1/","confidence":"high","from":["target record (drugs field)"],"detail":null},"mechanismClass":{"id":"other-inhibitor","name":"Inhibitor (class not stated)","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"telotristat-ethyl","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/telotristat-ethyl/"},{"record":"telotristat-ethyl","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2017: Carcinoid syndrome diarrhoea with somatostatin analogue therapy in adults inadequately controlled by SSA alone","href":"/drugs/telotristat-ethyl/"},{"record":"telotristat-ethyl","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2017: Same (Xermelo)","href":"/drugs/telotristat-ethyl/"},{"record":"telotristat-ethyl","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2017","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/xermelo"},{"record":"registry:telotristat-ethyl","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/telotristat-ethyl/#registry"}],"reasons":[]},{"id":"temsirolimus","name":"Temsirolimus","route":"/drugs/temsirolimus/","status":"approved","modality":"Intravenous mTOR inhibitor (rapamycin analogue)","state":"approved","confidence":"high","fields":["target record (drugs field)","technologies","modality","mechanism"],"components":{"target":{"id":"fkbp12+hif1a","name":"FKBP12 x HIF-1α","href":"/targets/fkbp12/","confidence":"high","from":["target record (drugs field)"],"detail":"dual-target"},"mechanismClass":{"id":"pi3k-akt-mtor-inhibitor","name":"PI3K, AKT or mTOR inhibitor","href":"/technologies/pi3k-akt-mtor-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"allosteric","name":"Allosteric","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"temsirolimus","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/temsirolimus/"},{"record":"temsirolimus","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2007: Advanced renal cell carcinoma","href":"/drugs/temsirolimus/"},{"record":"temsirolimus","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2007: Advanced RCC (poor risk); relapsed/refractory mantle cell lymphoma added 2009","href":"/drugs/temsirolimus/"},{"record":"temsirolimus","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2007","href":"/regulatory/regions/"},{"record":"temsirolimus","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2007","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/torisel"},{"record":"temsirolimus","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2007","href":"https://products.mhra.gov.uk/?search=Torisel"},{"record":"temsirolimus","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2010","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"registry:temsirolimus","kind":"registry","state":"development","label":"ClinicalTrials.gov: 26 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/temsirolimus/#registry"}],"reasons":[]},{"id":"tepotinib","name":"Tepotinib","route":"/drugs/tepotinib/","status":"approved","modality":"Small-molecule MET tyrosine kinase inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"met","name":"MET","href":"/targets/met/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"tepotinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/tepotinib/"},{"record":"tepotinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2021: Metastatic NSCLC with MET exon 14 skipping alterations","href":"/drugs/tepotinib/"},{"record":"tepotinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2022: Advanced NSCLC with MET exon 14 skipping alterations after immunotherapy or platinum chemotherapy","href":"/drugs/tepotinib/"},{"record":"tepotinib","field":"approvals[2]","kind":"approval","state":"approved","label":"JP 2020: Unresectable advanced or recurrent NSCLC with MET exon 14 skipping","href":"/drugs/tepotinib/"},{"record":"tepotinib","field":"approvals[3]","kind":"approval","state":"approved","label":"England (NICE) 2022: Advanced non-small-cell lung cancer with MET exon 14 skipping alterations","href":"/drugs/tepotinib/"},{"record":"tepotinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2022","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tepmetko"},{"record":"nct06908993","field":"status","kind":"trial","state":"development","label":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated: phase 3, recruiting","href":"/trials/nct06908993/"},{"record":"registry:tepotinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tepotinib/#registry"}],"reasons":[]},{"id":"tersolisib","name":"Tersolisib","route":"/drugs/tersolisib/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"pik3ca","name":"PIK3CA / PI3K-alpha","href":"/targets/pik3ca/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"cdk-inhibitor","name":"CDK inhibitor","href":"/technologies/cdk46-inhibitor/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"tersolisib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/tersolisib/"},{"record":"pik3ca-2","field":"status","kind":"trial","state":"development","label":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA): phase 3, recruiting","href":"/trials/pik3ca-2/"},{"record":"registry:tersolisib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tersolisib/#registry"}],"reasons":[]},{"id":"tinengotinib","name":"Tinengotinib","route":"/drugs/tinengotinib/","status":"phase-3","modality":"Small-molecule multi-kinase inhibitor (FGFR1-3, VEGFR, Aurora, JAK)","state":"development","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"fgfr2","name":"FGFR2","href":"/targets/fgfr2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"tinengotinib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/tinengotinib/"},{"record":"nct07052253","field":"status","kind":"trial","state":"development","label":"A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.: phase 2, recruiting","href":"/trials/nct07052253/"},{"record":"nct07498478","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment: phase 2, recruiting","href":"/trials/nct07498478/"},{"record":"first-308","field":"status","kind":"trial","state":"development","label":"FIRST-308: phase 3, recruiting","href":"/trials/first-308/"},{"record":"nct05948475","field":"status","kind":"trial","state":"development","label":"Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma: phase 3, active","href":"/trials/nct05948475/"},{"record":"registry:tinengotinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tinengotinib/#registry"}],"reasons":[]},{"id":"tivozanib","name":"Tivozanib","route":"/drugs/tivozanib/","status":"approved","modality":"Small-molecule kinase inhibitor (VEGFR)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"vegf","name":"VEGF / VEGFR","href":"/targets/vegf/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"tivozanib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/tivozanib/"},{"record":"tivozanib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2021: Relapsed/refractory advanced RCC after ≥2 prior systemic therapies","href":"/drugs/tivozanib/"},{"record":"tivozanib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2017: EU first (Aug 2017)","href":"/drugs/tivozanib/"},{"record":"tivozanib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2021","href":"/regulatory/regions/"},{"record":"tivozanib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2017","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/fotivda"},{"record":"tivozanib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2017","href":"https://products.mhra.gov.uk/?search=Fotivda"},{"record":"nct05000294","field":"status","kind":"trial","state":"development","label":"Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types: phase 1/2, recruiting","href":"/trials/nct05000294/"},{"record":"nct04645160","field":"status","kind":"trial","state":"development","label":"Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers: phase 1/2, recruiting","href":"/trials/nct04645160/"},{"record":"tinivo-2","field":"result","kind":"trial","state":"stopped","label":"TiNivo-2: phase 3, negative","href":"/trials/tinivo-2/","quote":"PFS HR 1.10; no benefit from nivolumab rechallenge."},{"record":"registry:tivozanib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tivozanib/#registry"}],"reasons":[{"drugId":"tivozanib","drugName":"Tivozanib","drugRoute":"/drugs/tivozanib/","drugState":"approved","record":"tinivo-2","kind":"trial","label":"TiNivo-2: phase 3, negative","href":"/trials/tinivo-2/","quote":"PFS HR 1.10; no benefit from nivolumab rechallenge."}]},{"id":"tk216","name":"TK216","route":"/drugs/tk216/","status":"phase-2","modality":"Small-molecule EWS-FLI1 inhibitor","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"ewsr1-fli1","name":"EWSR1-FLI1 fusion","href":"/targets/ewsr1-fli1/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"other-inhibitor","name":"Inhibitor (class not stated)","href":null,"confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"tk216","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/tk216/"},{"record":"registry:tk216","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 1 terminated or withdrawn study and none active (fetched 2026-09-28)","href":"/drugs/tk216/#registry"}],"reasons":[]},{"id":"tng456","name":"TNG456","route":"/drugs/tng456/","status":"phase-2","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"prmt5-mtap","name":"PRMT5 (MTAP-deleted cancers)","href":"/targets/prmt5-mtap/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"tng456","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/tng456/"},{"record":"nct06810544","field":"status","kind":"trial","state":"development","label":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss: phase 1/2, recruiting","href":"/trials/nct06810544/"},{"record":"registry:tng456","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/tng456/#registry"}],"reasons":[]},{"id":"tng462","name":"TNG462","route":"/drugs/tng462/","status":"phase-2","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"prmt5-mtap","name":"PRMT5 (MTAP-deleted cancers)","href":"/targets/prmt5-mtap/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"tng462","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/tng462/"},{"record":"nct06188702","field":"status","kind":"trial","state":"development","label":"S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP: phase 1/2, active","href":"/trials/nct06188702/"},{"record":"nct05732831","field":"status","kind":"trial","state":"development","label":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors: phase 1/2, recruiting","href":"/trials/nct05732831/"},{"record":"nct06922591","field":"status","kind":"trial","state":"development","label":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients: phase 1/2, recruiting","href":"/trials/nct06922591/"},{"record":"registry:tng462","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tng462/#registry"}],"reasons":[]},{"id":"tno155","name":"TNO155","route":"/drugs/tno155/","status":"phase-2","modality":"Small-molecule inhibitor","state":"development","confidence":"medium","fields":["modality","mechanism"],"components":{"target":{"id":"shp2","name":"SHP2 (PTPN11)","href":"/targets/shp2/","confidence":"medium","from":["modality","mechanism"],"detail":null},"mechanismClass":{"id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"tno155","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/tno155/"},{"record":"nct07468071","field":"status","kind":"trial","state":"development","label":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other: phase 1/2, recruiting","href":"/trials/nct07468071/"},{"record":"nct04699188","field":"status","kind":"trial","state":"development","label":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation: phase 1/2, active","href":"/trials/nct04699188/"},{"record":"registry:tno155","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tno155/#registry"}],"reasons":[]},{"id":"toremifene","name":"Toremifene","route":"/drugs/toremifene/","status":"approved","modality":"Selective oestrogen receptor modulator (triphenylethylene)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"estrogen-receptor","name":"Estrogen receptor (ERα)","href":"/targets/estrogen-receptor/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"endocrine","name":"Endocrine therapy","href":"/technologies/endocrine-therapy/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"toremifene","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/toremifene/"},{"record":"toremifene","field":"approvals[0]","kind":"approval","state":"approved","label":"US 1997: Metastatic breast cancer in postmenopausal women with ER-positive or unknown tumours","href":"/drugs/toremifene/"},{"record":"toremifene","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 1996: First-line hormonal treatment of hormone-dependent metastatic breast cancer in postmenopausal women","href":"/drugs/toremifene/"},{"record":"toremifene","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 1996","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/fareston"},{"record":"registry:toremifene","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/toremifene/#registry"}],"reasons":[]},{"id":"tovorafenib","name":"Tovorafenib","route":"/drugs/tovorafenib/","status":"approved","modality":"Small-molecule type II RAF inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"braf","name":"BRAF","href":"/targets/braf/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"tovorafenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/tovorafenib/"},{"record":"tovorafenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2024: Relapsed/refractory BRAF-altered paediatric low-grade glioma (accelerated)","href":"/drugs/tovorafenib/"},{"record":"tovorafenib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2026: Relapsed/refractory paediatric low-grade glioma (conditional)","href":"/drugs/tovorafenib/"},{"record":"tovorafenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2024","href":"/regulatory/regions/"},{"record":"tovorafenib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2026","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/ojemda"},{"record":"tovorafenib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2026","href":"https://products.mhra.gov.uk/?search=Ojemda"},{"record":"nct05566795","field":"status","kind":"trial","state":"development","label":"DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2): phase 3, active","href":"/trials/nct05566795/"},{"record":"registry:tovorafenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tovorafenib/#registry"}],"reasons":[]},{"id":"tq-b3234","name":"TQ-B3234","route":"/drugs/tq-b3234/","status":"phase-3","modality":"small molecule (structure undisclosed or not yet in PubChem)","state":"development","confidence":"medium","fields":["modality","mechanism"],"components":{"target":{"id":"mek","name":"MEK1/2","href":"/targets/mek/","confidence":"medium","from":["modality","mechanism"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"tq-b3234","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/tq-b3234/"},{"record":"nct07407803","field":"status","kind":"trial","state":"development","label":"Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas: phase 3, recruiting","href":"/trials/nct07407803/"},{"record":"registry:tq-b3234","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/tq-b3234/#registry"}],"reasons":[]},{"id":"tqb3454","name":"TQB3454","route":"/drugs/tqb3454/","status":"phase-3","modality":"small molecule (structure undisclosed or not yet in PubChem)","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"idh","name":"IDH1 / IDH2","href":"/targets/idh/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"idh-inhibitor","name":"IDH inhibitor","href":"/technologies/idh-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"tqb3454","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/tqb3454/"},{"record":"nct05987358","field":"status","kind":"trial","state":"development","label":"A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma: phase 3, active","href":"/trials/nct05987358/"},{"record":"registry:tqb3454","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tqb3454/#registry"}],"reasons":[]},{"id":"tqb3616","name":"TQB3616","route":"/drugs/tqb3616/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"cdk4-6","name":"CDK4/6","href":"/targets/cdk4-6/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"cdk-inhibitor","name":"CDK inhibitor","href":"/technologies/cdk46-inhibitor/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"tqb3616","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/tqb3616/"},{"record":"nct06202261","field":"status","kind":"trial","state":"development","label":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer: phase 1/2, recruiting","href":"/trials/nct06202261/"},{"record":"nct05780567","field":"status","kind":"trial","state":"development","label":"Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer: phase 3, active","href":"/trials/nct05780567/"},{"record":"nct06702618","field":"status","kind":"trial","state":"development","label":"Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer: phase 2, active","href":"/trials/nct06702618/"},{"record":"nct05365178","field":"status","kind":"trial","state":"development","label":"To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer: phase 3, active","href":"/trials/nct05365178/"},{"record":"registry:tqb3616","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tqb3616/#registry"}],"reasons":[]},{"id":"trametinib","name":"Trametinib","route":"/drugs/trametinib/","status":"approved","modality":"Small-molecule allosteric MEK1/2 inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"mek","name":"MEK1/2","href":"/targets/mek/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"allosteric","name":"Allosteric","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"trametinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/trametinib/"},{"record":"trametinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2013: BRAF V600E/K unresectable or metastatic melanoma (single agent)","href":"/drugs/trametinib/"},{"record":"trametinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2014: With dabrafenib: metastatic melanoma; later adjuvant melanoma, NSCLC, anaplastic thyroid cancer, tumour-agnostic BRAF V600E solid tumours, paediatric low-grade glioma","href":"/drugs/trametinib/"},{"record":"trametinib","field":"approvals[2]","kind":"approval","state":"approved","label":"EU 2014: BRAF V600 melanoma alone or with dabrafenib; later NSCLC and adjuvant melanoma","href":"/drugs/trametinib/"},{"record":"trametinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2014","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist"},{"record":"nct05372354","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed : phase 1/2, recruiting","href":"/trials/nct05372354/"},{"record":"nct05874414","field":"status","kind":"trial","state":"development","label":"Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma: phase 1/2, recruiting","href":"/trials/nct05874414/"},{"record":"nct07440290","field":"status","kind":"trial","state":"development","label":"DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positi: phase 2/3, recruiting","href":"/trials/nct07440290/"},{"record":"nci-match","field":"status","kind":"trial","state":"development","label":"NCI-MATCH (EAY131): phase platform, active","href":"/trials/nci-match/"},{"record":"nct03899155","field":"status","kind":"trial","state":"development","label":"Pan Tumor Rollover Study: phase 2, recruiting","href":"/trials/nct03899155/"},{"record":"nct05358249","field":"status","kind":"trial","state":"development","label":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation: phase 1/2, active","href":"/trials/nct05358249/"},{"record":"nct07468071","field":"status","kind":"trial","state":"development","label":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other: phase 1/2, recruiting","href":"/trials/nct07468071/"},{"record":"nct04940052","field":"status","kind":"trial","state":"development","label":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refracto: phase 3, active","href":"/trials/nct04940052/"},{"record":"nct04417621","field":"status","kind":"trial","state":"development","label":"Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma: phase 2, active","href":"/trials/nct04417621/"},{"record":"nct06456138","field":"status","kind":"trial","state":"development","label":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC: phase 1/2, planned","href":"/trials/nct06456138/"},{"record":"nct05275374","field":"status","kind":"trial","state":"development","label":"XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation: phase 1/2, planned","href":"/trials/nct05275374/"},{"record":"registry:trametinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 41 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/trametinib/#registry"}],"reasons":[]},{"id":"tucatinib","name":"Tucatinib","route":"/drugs/tucatinib/","status":"approved","modality":"Small-molecule kinase inhibitor (HER2)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"her2","name":"HER2","href":"/targets/her2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/her2-tyrosine-kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"tucatinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/tucatinib/"},{"record":"tucatinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2020: HER2+ metastatic breast cancer including brain metastases, with trastuzumab and capecitabine","href":"/drugs/tucatinib/"},{"record":"tucatinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2023: HER2+ RAS-wild-type mCRC with trastuzumab","href":"/drugs/tucatinib/"},{"record":"tucatinib","field":"approvals[2]","kind":"approval","state":"approved","label":"US 2023: HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer that has progressed after fluoropyrimidine, oxaliplatin and irinotecan, with trastuzumab","href":"/drugs/tucatinib/"},{"record":"tucatinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2020","href":"/regulatory/regions/"},{"record":"tucatinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2021","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tukysa"},{"record":"tucatinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2021","href":"https://products.mhra.gov.uk/?search=Tukysa"},{"record":"tucatinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2026","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"tucatinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"tucatinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2021","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Tukysa"},{"record":"nct04538742","field":"status","kind":"trial","state":"development","label":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer: phase 1/2, active","href":"/trials/nct04538742/"},{"record":"nct06157892","field":"status","kind":"trial","state":"development","label":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors: phase 2, active","href":"/trials/nct06157892/"},{"record":"nct04721977","field":"status","kind":"trial","state":"development","label":"A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001): phase 2, active","href":"/trials/nct04721977/"},{"record":"nct05672524","field":"status","kind":"trial","state":"development","label":"A Study of Tucatinib and Trastuzumab in People With Rectal Cancer: phase 2, recruiting","href":"/trials/nct05672524/"},{"record":"nct04579380","field":"status","kind":"trial","state":"development","label":"Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations: phase 2, active","href":"/trials/nct04579380/"},{"record":"nct05190445","field":"status","kind":"trial","state":"development","label":"Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma: phase 2, active","href":"/trials/nct05190445/"},{"record":"nct05230810","field":"status","kind":"trial","state":"development","label":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.: phase 1/2, active","href":"/trials/nct05230810/"},{"record":"mountaineer-03","field":"status","kind":"trial","state":"development","label":"MOUNTAINEER-03: phase 3, recruiting","href":"/trials/mountaineer-03/"},{"record":"nct05868226","field":"status","kind":"trial","state":"development","label":"PRE-ISPY Phase I/II Oncology Platform Program: phase 1/2, recruiting","href":"/trials/nct05868226/"},{"record":"nct06686394","field":"status","kind":"trial","state":"development","label":"Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009): phase 1/2, recruiting","href":"/trials/nct06686394/"},{"record":"nct04430738","field":"status","kind":"trial","state":"development","label":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers: phase 2, active","href":"/trials/nct04430738/"},{"record":"nct05458674","field":"status","kind":"trial","state":"development","label":"Tucatinib+Trastuzumab+Eribulin in HER2+ MBC: phase 2, active","href":"/trials/nct05458674/"},{"record":"registry:tucatinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 31 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tucatinib/#registry"}],"reasons":[]},{"id":"tucidinostat","name":"Tucidinostat (chidamide)","route":"/drugs/tucidinostat/","status":"approved","modality":"Small-molecule oral subtype-selective HDAC inhibitor","state":"approved","confidence":"high","fields":["target record (drugs field)","technologies","modality","mechanism"],"components":{"target":{"id":"hdac10","name":"HDAC10","href":"/targets/hdac10/","confidence":"high","from":["target record (drugs field)"],"detail":null},"mechanismClass":{"id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"tucidinostat","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/tucidinostat/"},{"record":"tucidinostat","field":"approvals[0]","kind":"approval","state":"approved","label":"China 2014: Relapsed or refractory peripheral T-cell lymphoma","href":"/drugs/tucidinostat/"},{"record":"tucidinostat","field":"approvals[1]","kind":"approval","state":"approved","label":"China 2019: HR-positive, HER2-negative advanced breast cancer with exemestane after endocrine therapy (ACE)","href":"/drugs/tucidinostat/"},{"record":"tucidinostat","field":"approvals[2]","kind":"approval","state":"approved","label":"Japan 2021: Relapsed or refractory adult T-cell leukaemia-lymphoma (HBI-8000)","href":"/drugs/tucidinostat/"},{"record":"tucidinostat","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2021","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"tucidinostat","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2014","href":"https://english.nmpa.gov.cn/"},{"record":"nct06979908","field":"status","kind":"trial","state":"development","label":"A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal C: phase 2, recruiting","href":"/trials/nct06979908/"},{"record":"nct06218888","field":"status","kind":"trial","state":"development","label":"A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Micro: phase 2, planned","href":"/trials/nct06218888/"},{"record":"nct06776952","field":"status","kind":"trial","state":"development","label":"A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma: phase 3, recruiting","href":"/trials/nct06776952/"},{"record":"nct06497985","field":"status","kind":"trial","state":"development","label":"A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients: phase 3, recruiting","href":"/trials/nct06497985/"},{"record":"nct05833724","field":"status","kind":"trial","state":"development","label":"Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL): phase 2, recruiting","href":"/trials/nct05833724/"},{"record":"nct04668690","field":"status","kind":"trial","state":"development","label":"Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL: phase 3, active","href":"/trials/nct04668690/"},{"record":"nct06709885","field":"status","kind":"trial","state":"development","label":"HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer: phase 2, recruiting","href":"/trials/nct06709885/"},{"record":"nct06951997","field":"status","kind":"trial","state":"development","label":"QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer: phase 2, recruiting","href":"/trials/nct06951997/"},{"record":"nct06685276","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct06685276/"},{"record":"registry:tucidinostat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 45 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tucidinostat/#registry"}],"reasons":[]},{"id":"tunlametinib","name":"Tunlametinib","route":"/drugs/tunlametinib/","status":"approved","modality":"Oral MEK1/2 inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"mek","name":"MEK1/2","href":"/targets/mek/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"allosteric","name":"Allosteric","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"tunlametinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/tunlametinib/"},{"record":"tunlametinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2024: Advanced NRAS-mutant melanoma after prior immunotherapy","href":"/drugs/tunlametinib/"},{"record":"tunlametinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2024","href":"https://english.nmpa.gov.cn/"},{"record":"nct06008106","field":"status","kind":"trial","state":"development","label":"Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma: phase 3, recruiting","href":"/trials/nct06008106/"},{"record":"nct06008119","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer: phase 3, recruiting","href":"/trials/nct06008119/"},{"record":"registry:tunlametinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 10 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tunlametinib/#registry"}],"reasons":[]},{"id":"tyra-300","name":"TYRA-300","route":"/drugs/tyra-300/","status":"phase-2","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"fgfr2","name":"FGFR2","href":"/targets/fgfr2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"tyra-300","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/tyra-300/"},{"record":"nct06995677","field":"status","kind":"trial","state":"development","label":"Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer: phase 2, recruiting","href":"/trials/nct06995677/"},{"record":"nct05544552","field":"status","kind":"trial","state":"development","label":"Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations: phase 1/2, active","href":"/trials/nct05544552/"},{"record":"registry:tyra-300","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/tyra-300/#registry"}],"reasons":[]},{"id":"umbralisib","name":"Umbralisib","route":"/drugs/umbralisib/","status":"withdrawn","modality":"Oral PI3Kδ / CK1ε inhibitor","state":"stopped","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"pik3ca","name":"PIK3CA / PI3K-alpha","href":"/targets/pik3ca/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"umbralisib","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/umbralisib/","quote":"A PI3K inhibitor for marginal zone and follicular lymphoma approved in 2021 and withdrawn in 2022 after the UNITY-CLL trial suggested more deaths."},{"record":"umbralisib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2021: Relapsed marginal zone lymphoma and follicular lymphoma","href":"/drugs/umbralisib/"},{"record":"umbralisib","field":"regulatoryEvents[2]","kind":"event","state":"stopped","label":"US 2022-05-31: withdrawal","href":"/drugs/umbralisib/","quote":"Withdrawn: the indication came off the label 1.3 years after its accelerated approval."},{"record":"umbralisib","field":"regulatoryEvents[3]","kind":"event","state":"stopped","label":"US 2022-05-31: withdrawal","href":"/drugs/umbralisib/","quote":"Withdrawn: the indication came off the label 1.3 years after its accelerated approval."},{"record":"nct04624633","field":"status","kind":"trial","state":"development","label":"Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL: phase 2, active","href":"/trials/nct04624633/"},{"record":"registry:umbralisib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/umbralisib/#registry"}],"reasons":[{"drugId":"umbralisib","drugName":"Umbralisib","drugRoute":"/drugs/umbralisib/","drugState":"stopped","record":"umbralisib","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/umbralisib/","quote":"A PI3K inhibitor for marginal zone and follicular lymphoma approved in 2021 and withdrawn in 2022 after the UNITY-CLL trial suggested more deaths."},{"drugId":"umbralisib","drugName":"Umbralisib","drugRoute":"/drugs/umbralisib/","drugState":"stopped","record":"umbralisib","kind":"event","label":"US 2022-05-31: withdrawal","href":"/drugs/umbralisib/","quote":"Withdrawn: the indication came off the label 1.3 years after its accelerated approval."},{"drugId":"umbralisib","drugName":"Umbralisib","drugRoute":"/drugs/umbralisib/","drugState":"stopped","record":"umbralisib","kind":"event","label":"US 2022-05-31: withdrawal","href":"/drugs/umbralisib/","quote":"Withdrawn: the indication came off the label 1.3 years after its accelerated approval."}]},{"id":"vandetanib","name":"Vandetanib","route":"/drugs/vandetanib/","status":"approved","modality":"Small-molecule kinase inhibitor (RET, VEGFR, EGFR)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"ret+vegf","name":"RET x VEGF / VEGFR","href":"/targets/ret/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"vandetanib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/vandetanib/"},{"record":"vandetanib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2011: Symptomatic or progressive medullary thyroid cancer","href":"/drugs/vandetanib/"},{"record":"vandetanib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2011","href":"/regulatory/regions/"},{"record":"vandetanib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): conditional 2012","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa"},{"record":"vandetanib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2012","href":"https://products.mhra.gov.uk/?search=Caprelsa"},{"record":"vandetanib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2015","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"vandetanib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2013","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Caprelsa"},{"record":"registry:vandetanib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/vandetanib/#registry"}],"reasons":[]},{"id":"varegacestat","name":"Varegacestat","route":"/drugs/varegacestat/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["modality","mechanism"],"components":{"target":{"id":"gamma-secretase","name":"Gamma-secretase (PSEN1)","href":"/targets/gamma-secretase/","confidence":"medium","from":["modality","mechanism"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"varegacestat","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/varegacestat/"},{"record":"nct04871282","field":"status","kind":"trial","state":"development","label":"A Study of AL102 in Patients With Progressing Desmoid Tumors: phase 2/3, active","href":"/trials/nct04871282/"},{"record":"registry:varegacestat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/varegacestat/#registry"}],"reasons":[]},{"id":"varlitinib","name":"Varlitinib","route":"/drugs/varlitinib/","status":"historic","modality":"Small-molecule reversible pan-HER kinase inhibitor (EGFR, HER2, HER4)","state":"stopped","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"egfr+her2","name":"EGFR x HER2","href":"/targets/egfr/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"varlitinib","field":"status","kind":"drug","state":"stopped","label":"Drug record status: historic","href":"/drugs/varlitinib/","quote":"A pill that blocked the HER family of growth receptors, tested with capecitabine as second-line treatment for bile duct and gallbladder cancer. It did not beat capecitabine alone in the TreeTopp trial and development stopped."},{"record":"treetopp","field":"result","kind":"trial","state":"stopped","label":"TreeTopp: phase 2/3, negative","href":"/trials/treetopp/","quote":"ORR 9.4% vs 4.8%; PFS 2.83 vs 2.79 months, HR 0.90; OS 7.8 vs 7.5 months, HR 1.11; gallbladder subgroup PFS 2.9 vs 1.6 months, HR 0.55 (0.26 to 1.19)."},{"record":"registry:varlitinib","kind":"registry","state":"stopped","label":"ClinicalTrials.gov: 3 terminated or withdrawn studies and none active (fetched 2026-09-28)","href":"/drugs/varlitinib/#registry"}],"reasons":[{"drugId":"varlitinib","drugName":"Varlitinib","drugRoute":"/drugs/varlitinib/","drugState":"stopped","record":"varlitinib","kind":"drug","label":"Drug record status: historic","href":"/drugs/varlitinib/","quote":"A pill that blocked the HER family of growth receptors, tested with capecitabine as second-line treatment for bile duct and gallbladder cancer. It did not beat capecitabine alone in the TreeTopp trial and development stopped."},{"drugId":"varlitinib","drugName":"Varlitinib","drugRoute":"/drugs/varlitinib/","drugState":"stopped","record":"treetopp","kind":"trial","label":"TreeTopp: phase 2/3, negative","href":"/trials/treetopp/","quote":"ORR 9.4% vs 4.8%; PFS 2.83 vs 2.79 months, HR 0.90; OS 7.8 vs 7.5 months, HR 1.11; gallbladder subgroup PFS 2.9 vs 1.6 months, HR 0.55 (0.26 to 1.19)."}]},{"id":"vb15010","name":"VB15010","route":"/drugs/vb15010/","status":"phase-2","modality":"Small-molecule inhibitor","state":"development","confidence":"medium","fields":["modality","mechanism"],"components":{"target":{"id":"parp","name":"PARP","href":"/targets/parp/","confidence":"medium","from":["modality","mechanism"],"detail":null},"mechanismClass":{"id":"parp-inhibitor","name":"PARP inhibitor","href":"/technologies/parp-inhibitor/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"vb15010","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/vb15010/"},{"record":"nct06819215","field":"status","kind":"trial","state":"development","label":"Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06819215/"},{"record":"registry:vb15010","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/vb15010/#registry"}],"reasons":[]},{"id":"vebreltinib","name":"Vebreltinib","route":"/drugs/vebreltinib/","status":"approved","modality":"Oral selective MET tyrosine kinase inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"met","name":"MET","href":"/targets/met/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"vebreltinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/vebreltinib/"},{"record":"vebreltinib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2023: Locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping","href":"/drugs/vebreltinib/"},{"record":"vebreltinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"nct05989542","field":"status","kind":"trial","state":"development","label":"A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2): phase 3, recruiting","href":"/trials/nct05989542/"},{"record":"nct06105619","field":"status","kind":"trial","state":"development","label":"A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).: phase 2/3, active","href":"/trials/nct06105619/"},{"record":"nct06930794","field":"status","kind":"trial","state":"development","label":"A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive: phase 3, recruiting","href":"/trials/nct06930794/"},{"record":"nct03175224","field":"status","kind":"trial","state":"development","label":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors: phase 2, recruiting","href":"/trials/nct03175224/"},{"record":"nct07655622","field":"status","kind":"trial","state":"development","label":"Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: phase 1/2, recruiting","href":"/trials/nct07655622/"},{"record":"nct06574347","field":"status","kind":"trial","state":"development","label":"Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.: phase 2, recruiting","href":"/trials/nct06574347/"},{"record":"nct06343064","field":"status","kind":"trial","state":"development","label":"Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI: phase 1/2, recruiting","href":"/trials/nct06343064/"},{"record":"nct06970782","field":"status","kind":"trial","state":"development","label":"Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failur: phase 3, planned","href":"/trials/nct06970782/"},{"record":"registry:vebreltinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 16 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/vebreltinib/#registry"}],"reasons":[]},{"id":"veliparib","name":"Veliparib","route":"/drugs/veliparib/","status":"negative","modality":"Small-molecule PARP inhibitor (weak PARP trapper)","state":"stopped","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"parp+brca","name":"PARP x BRCA1 / BRCA2","href":"/targets/parp/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"parp-inhibitor","name":"PARP inhibitor","href":"/technologies/parp-inhibitor/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"veliparib","field":"status","kind":"drug","state":"stopped","label":"Drug record status: negative","href":"/drugs/veliparib/","quote":"Veliparib is a PARP inhibitor that AbbVie tested with chemotherapy in breast cancer. It added nothing to carboplatin before surgery (BrighTNess) and lengthened progression-free but not overall survival with carboplatin and paclitaxel in inherited BRCA advanced disease (BROCADE3), so it was never licensed."},{"record":"registry:veliparib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 8 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/veliparib/#registry"}],"reasons":[{"drugId":"veliparib","drugName":"Veliparib","drugRoute":"/drugs/veliparib/","drugState":"stopped","record":"veliparib","kind":"drug","label":"Drug record status: negative","href":"/drugs/veliparib/","quote":"Veliparib is a PARP inhibitor that AbbVie tested with chemotherapy in breast cancer. It added nothing to carboplatin before surgery (BrighTNess) and lengthened progression-free but not overall survival with carboplatin and paclitaxel in inherited BRCA advanced disease (BROCADE3), so it was never licensed."}]},{"id":"vemurafenib","name":"Vemurafenib","route":"/drugs/vemurafenib/","status":"approved","modality":"Small-molecule kinase inhibitor (BRAF V600)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"braf","name":"BRAF","href":"/targets/braf/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"atp-competitive","name":"ATP-competitive or reversible","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"vemurafenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/vemurafenib/"},{"record":"vemurafenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2011: Unresectable or metastatic BRAF V600E melanoma","href":"/drugs/vemurafenib/"},{"record":"vemurafenib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2017: Erdheim-Chester disease with BRAF V600 mutation","href":"/drugs/vemurafenib/"},{"record":"vemurafenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2011","href":"/regulatory/regions/"},{"record":"vemurafenib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2012","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf"},{"record":"vemurafenib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2012","href":"https://products.mhra.gov.uk/?search=Zelboraf"},{"record":"vemurafenib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2014","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"vemurafenib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2017","href":"https://english.nmpa.gov.cn/"},{"record":"vemurafenib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2012","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Zelboraf"},{"record":"nct04302025","field":"status","kind":"trial","state":"development","label":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC): phase 2, recruiting","href":"/trials/nct04302025/"},{"record":"determine-trial","field":"status","kind":"trial","state":"development","label":"DETERMINE: phase platform, recruiting","href":"/trials/determine-trial/"},{"record":"nct05768178","field":"status","kind":"trial","state":"development","label":"DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.: phase 2/3, recruiting","href":"/trials/nct05768178/"},{"record":"pediatric-match","field":"status","kind":"trial","state":"development","label":"NCI-COG Pediatric MATCH (APEC1621): phase platform, active","href":"/trials/pediatric-match/"},{"record":"tapur","field":"status","kind":"trial","state":"development","label":"TAPUR (Targeted Agent and Profiling Utilization Registry): phase 2, recruiting","href":"/trials/tapur/"},{"record":"registry:vemurafenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 28 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/vemurafenib/#registry"}],"reasons":[]},{"id":"venetoclax","name":"Venetoclax","route":"/drugs/venetoclax/","status":"approved","modality":"Small-molecule BCL-2 inhibitor","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"bcl2","name":"BCL-2","href":"/targets/bcl2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"bcl2-inhibitor","name":"BCL-2 inhibitor","href":"/technologies/bcl2-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"venetoclax","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/venetoclax/"},{"record":"venetoclax","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2016: CLL with 17p deletion","href":"/drugs/venetoclax/"},{"record":"venetoclax","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2018: AML with azacitidine/decitabine/LDAC in unfit patients","href":"/drugs/venetoclax/"},{"record":"venetoclax","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2016","href":"/regulatory/regions/"},{"record":"venetoclax","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2016","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto"},{"record":"venetoclax","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2016","href":"https://products.mhra.gov.uk/?search=Venclexta"},{"record":"venetoclax","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2019","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"venetoclax","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2020","href":"https://english.nmpa.gov.cn/"},{"record":"venetoclax","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2017","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Venclexta"},{"record":"nct04256317","field":"status","kind":"trial","state":"development","label":"A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study): phase 2/3, recruiting","href":"/trials/nct04256317/"},{"record":"nct04988555","field":"status","kind":"trial","state":"development","label":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1): phase 1/2, recruiting","href":"/trials/nct04988555/"},{"record":"nct07743112","field":"status","kind":"trial","state":"development","label":"A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia: phase 2, recruiting","href":"/trials/nct07743112/"},{"record":"nct03539744","field":"status","kind":"trial","state":"development","label":"A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) : phase 3, active","href":"/trials/nct03539744/"},{"record":"nct05951959","field":"status","kind":"trial","state":"development","label":"A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma: phase 2, active","href":"/trials/nct05951959/"},{"record":"nct05057494","field":"status","kind":"trial","state":"development","label":"A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: phase 3, active","href":"/trials/nct05057494/"},{"record":"nct07255872","field":"status","kind":"trial","state":"development","label":"A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia: phase 2/3, recruiting","href":"/trials/nct07255872/"},{"record":"nct03314181","field":"status","kind":"trial","state":"development","label":"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor: phase 2, active","href":"/trials/nct03314181/"},{"record":"nct07154264","field":"status","kind":"trial","state":"development","label":"A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10): phase 2, recruiting","href":"/trials/nct07154264/"},{"record":"nct05520567","field":"status","kind":"trial","state":"development","label":"A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia: phase 1/2, active","href":"/trials/nct05520567/"},{"record":"nct05947851","field":"status","kind":"trial","state":"development","label":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).: phase 3, recruiting","href":"/trials/nct05947851/"},{"record":"nct06846671","field":"status","kind":"trial","state":"development","label":"A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors: phase 3, recruiting","href":"/trials/nct06846671/"},{"record":"nct06456463","field":"status","kind":"trial","state":"development","label":"A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy: phase 2, active","href":"/trials/nct06456463/"},{"record":"nct06115135","field":"status","kind":"trial","state":"development","label":"A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma: phase 2, recruiting","href":"/trials/nct06115135/"},{"record":"nct02966756","field":"status","kind":"trial","state":"development","label":"A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: phase 2, active","href":"/trials/nct02966756/"},{"record":"nct07581002","field":"status","kind":"trial","state":"development","label":"A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML): phase 2/3, recruiting","href":"/trials/nct07581002/"},{"record":"nct05428969","field":"status","kind":"trial","state":"development","label":"A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies: phase 1/2, active","href":"/trials/nct05428969/"},{"record":"nct05963074","field":"status","kind":"trial","state":"development","label":"A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia: phase 2, active","href":"/trials/nct05963074/"},{"record":"nct06524375","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period: phase 2, active","href":"/trials/nct06524375/"},{"record":"nct06428019","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL): phase 3, recruiting","href":"/trials/nct06428019/"},{"record":"nct06943872","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL): phase 3, recruiting","href":"/trials/nct06943872/"},{"record":"nct07277231","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia: phase 3, recruiting","href":"/trials/nct07277231/"},{"record":"nct04965493","field":"status","kind":"trial","state":"development","label":"A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): phase 3, active","href":"/trials/nct04965493/"},{"record":"nct05211570","field":"status","kind":"trial","state":"development","label":"AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia: phase 1/2, recruiting","href":"/trials/nct05211570/"},{"record":"nct03844048","field":"status","kind":"trial","state":"development","label":"An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial: phase 3, active","href":"/trials/nct03844048/"},{"record":"beat-aml-master-trial","field":"status","kind":"trial","state":"development","label":"Beat AML Master Trial: phase platform, recruiting","href":"/trials/beat-aml-master-trial/"},{"record":"celestial-tncll","field":"status","kind":"trial","state":"development","label":"CELESTIAL-TNCLL: phase 3, active","href":"/trials/celestial-tncll/"},{"record":"nct03850574","field":"status","kind":"trial","state":"development","label":"Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia: phase 1/2, recruiting","href":"/trials/nct03850574/"},{"record":"nct06382168","field":"status","kind":"trial","state":"development","label":"DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia: phase 1/2, recruiting","href":"/trials/nct06382168/"},{"record":"nct04229979","field":"status","kind":"trial","state":"development","label":"Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2: phase 3, active","href":"/trials/nct04229979/"},{"record":"nct04086264","field":"status","kind":"trial","state":"development","label":"IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia: phase 1/2, active","href":"/trials/nct04086264/"},{"record":"myelomatch","field":"status","kind":"trial","state":"development","label":"myeloMATCH: phase platform, recruiting","href":"/trials/myelomatch/"},{"record":"nct07024706","field":"status","kind":"trial","state":"development","label":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab: phase 2, recruiting","href":"/trials/nct07024706/"},{"record":"nct05201066","field":"status","kind":"trial","state":"development","label":"Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.: phase 2, active","href":"/trials/nct05201066/"},{"record":"nct06191263","field":"status","kind":"trial","state":"development","label":"Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML: phase 2, recruiting","href":"/trials/nct06191263/"},{"record":"nct07007312","field":"status","kind":"trial","state":"development","label":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML: phase 3, recruiting","href":"/trials/nct07007312/"},{"record":"nct05673057","field":"status","kind":"trial","state":"development","label":"Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome: phase 1/2, active","href":"/trials/nct05673057/"},{"record":"nct07520006","field":"status","kind":"trial","state":"development","label":"Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies: phase 1/2, recruiting","href":"/trials/nct07520006/"},{"record":"nct04588922","field":"status","kind":"trial","state":"development","label":"Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML: phase 1/2, recruiting","href":"/trials/nct04588922/"},{"record":"nct02899052","field":"status","kind":"trial","state":"development","label":"Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM): phase 2, active","href":"/trials/nct02899052/"},{"record":"nct04895436","field":"status","kind":"trial","state":"development","label":"Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL): phase 2, recruiting","href":"/trials/nct04895436/"},{"record":"nct07387471","field":"status","kind":"trial","state":"development","label":"Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobu: phase 2, active","href":"/trials/nct07387471/"},{"record":"nct04068597","field":"status","kind":"trial","state":"development","label":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies: phase 1/2, recruiting","href":"/trials/nct04068597/"},{"record":"nct04581512","field":"status","kind":"trial","state":"development","label":"Study to Evaluate the Safety and Tolerability of EP0042: phase 1/2, recruiting","href":"/trials/nct04581512/"},{"record":"nct05725200","field":"status","kind":"trial","state":"development","label":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: phase 2, recruiting","href":"/trials/nct05725200/"},{"record":"verona","field":"result","kind":"trial","state":"stopped","label":"VERONA: phase 3, negative","href":"/trials/verona/","quote":"Venetoclax added to azacitidine did not significantly improve overall survival in untreated higher-risk myelodysplastic syndromes."},{"record":"registry:venetoclax","kind":"registry","state":"development","label":"ClinicalTrials.gov: 69 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/venetoclax/#registry"}],"reasons":[{"drugId":"venetoclax","drugName":"Venetoclax","drugRoute":"/drugs/venetoclax/","drugState":"approved","record":"verona","kind":"trial","label":"VERONA: phase 3, negative","href":"/trials/verona/","quote":"Venetoclax added to azacitidine did not significantly improve overall survival in untreated higher-risk myelodysplastic syndromes."}]},{"id":"vimseltinib","name":"Vimseltinib","route":"/drugs/vimseltinib/","status":"approved","modality":"Small-molecule kinase inhibitor (CSF1R)","state":"approved","confidence":"high","fields":["target record (drugs field)","technologies"],"components":{"target":{"id":"col6a3+csf1","name":"COL6A3 x CSF1","href":"/targets/col6a3/","confidence":"high","from":["target record (drugs field)"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"vimseltinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/vimseltinib/"},{"record":"vimseltinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2025: Symptomatic tenosynovial giant cell tumour where surgery would worsen function or cause severe morbidity","href":"/drugs/vimseltinib/"},{"record":"vimseltinib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2025: Symptomatic TGCT where surgery has been exhausted or would cause unacceptable morbidity; 17 Sep 2025","href":"/drugs/vimseltinib/"},{"record":"vimseltinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2025","href":"/regulatory/regions/"},{"record":"vimseltinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/romvimza"},{"record":"vimseltinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2026","href":"https://www.gov.uk/government/news/vimseltinib-romvimza-approved-for-use-in-adults-to-treat-tenosynovial-giant-cell-tumours"},{"record":"nct03069469","field":"status","kind":"trial","state":"development","label":"Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor: phase 1/2, active","href":"/trials/nct03069469/"},{"record":"registry:vimseltinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 3 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/vimseltinib/#registry"}],"reasons":[]},{"id":"vismodegib","name":"Vismodegib","route":"/drugs/vismodegib/","status":"approved","modality":"Small-molecule smoothened (hedgehog) inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"smoothened","name":"Smoothened (hedgehog pathway)","href":"/targets/smoothened/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"hedgehog-inhibitor","name":"Hedgehog inhibitor","href":"/technologies/hedgehog-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"vismodegib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/vismodegib/"},{"record":"vismodegib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2012: Metastatic BCC or locally advanced BCC recurrent after surgery or not amenable to surgery/radiation","href":"/drugs/vismodegib/"},{"record":"vismodegib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2013: Same","href":"/drugs/vismodegib/"},{"record":"vismodegib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2012","href":"/regulatory/regions/"},{"record":"vismodegib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2013","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/erivedge"},{"record":"vismodegib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2013","href":"https://products.mhra.gov.uk/?search=Erivedge"},{"record":"vismodegib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Erivedge"},{"record":"determine-trial","field":"status","kind":"trial","state":"development","label":"DETERMINE: phase platform, recruiting","href":"/trials/determine-trial/"},{"record":"sjmb12","field":"status","kind":"trial","state":"development","label":"SJMB12: phase 2, active","href":"/trials/sjmb12/"},{"record":"nct06344052","field":"status","kind":"trial","state":"development","label":"To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma: phase 2, recruiting","href":"/trials/nct06344052/"},{"record":"registry:vismodegib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 14 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/vismodegib/#registry"}],"reasons":[]},{"id":"vorasidenib","name":"Vorasidenib","route":"/drugs/vorasidenib/","status":"approved","modality":"Small-molecule IDH1/2 inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"idh","name":"IDH1 / IDH2","href":"/targets/idh/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"idh-inhibitor","name":"IDH inhibitor","href":"/technologies/idh-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"vorasidenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/vorasidenib/"},{"record":"vorasidenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2024: Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, age ≥12","href":"/drugs/vorasidenib/"},{"record":"vorasidenib","field":"approvals[1]","kind":"approval","state":"approved","label":"EU 2025: Grade 2 IDH-mutant glioma ≥12 yrs; 17 Sep 2025","href":"/drugs/vorasidenib/"},{"record":"vorasidenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2024","href":"/regulatory/regions/"},{"record":"vorasidenib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/voranigo"},{"record":"vorasidenib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2025","href":"https://www.gov.uk/government/news/vorasidenib-approved-to-treat-patients-12-years-and-older-with-grade-2-astrocytoma-or-oligodendroglioma-with-a-susceptible-idh1-or-idh2-mutation"},{"record":"vorasidenib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2025","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Voranigo"},{"record":"registry:vorasidenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 7 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/vorasidenib/#registry"}],"reasons":[]},{"id":"vorinostat","name":"Vorinostat","route":"/drugs/vorinostat/","status":"approved","modality":"Small-molecule pan-HDAC inhibitor (hydroxamate)","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"hdac","name":"Histone deacetylases (HDAC)","href":"/targets/hdac/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"vorinostat","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/vorinostat/"},{"record":"vorinostat","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2006: Cutaneous manifestations of CTCL with progressive, persistent or recurrent disease after two systemic therapies","href":"/drugs/vorinostat/"},{"record":"vorinostat","field":"regional.EU","kind":"regional","state":"stopped","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/vorinostat-msd","quote":"Vorinostat MSD for advanced cutaneous T-cell lymphoma after two systemic therapies: marketing authorisation application withdrawn by MSD 13 Feb 2009 at day 206; the CHMP found benefit not sufficiently demonstrated"},{"record":"registry:vorinostat","kind":"registry","state":"development","label":"ClinicalTrials.gov: 13 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/vorinostat/#registry"}],"reasons":[{"drugId":"vorinostat","drugName":"Vorinostat","drugRoute":"/drugs/vorinostat/","drugState":"approved","record":"vorinostat","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/vorinostat-msd","quote":"Vorinostat MSD for advanced cutaneous T-cell lymphoma after two systemic therapies: marketing authorisation application withdrawn by MSD 13 Feb 2009 at day 206; the CHMP found benefit not sufficiently demonstrated"}]},{"id":"vorolanib","name":"Vorolanib","route":"/drugs/vorolanib/","status":"approved","modality":"Oral multi-target VEGFR and PDGFR tyrosine kinase inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"vegf","name":"VEGF / VEGFR","href":"/targets/vegf/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"vorolanib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/vorolanib/"},{"record":"vorolanib","field":"approvals[0]","kind":"approval","state":"approved","label":"CN 2023: Advanced renal cell carcinoma after a prior tyrosine kinase inhibitor, with everolimus (June 2023)","href":"/drugs/vorolanib/"},{"record":"vorolanib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2023","href":"https://english.nmpa.gov.cn/"},{"record":"nct07047001","field":"status","kind":"trial","state":"development","label":"Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma: phase 2, active","href":"/trials/nct07047001/"},{"record":"nct06523049","field":"status","kind":"trial","state":"development","label":"Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy: phase 2, planned","href":"/trials/nct06523049/"},{"record":"registry:vorolanib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/vorolanib/#registry"}],"reasons":[]},{"id":"vrn110755","name":"VRN110755","route":"/drugs/vrn110755/","status":"phase-2","modality":"small molecule (structure undisclosed or not yet in PubChem)","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"egfr","name":"EGFR","href":"/targets/egfr/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"vrn110755","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/vrn110755/"},{"record":"nct07699328","field":"status","kind":"trial","state":"development","label":"A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer: phase 1/2, recruiting","href":"/trials/nct07699328/"},{"record":"registry:vrn110755","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/vrn110755/#registry"}],"reasons":[]},{"id":"vs-7375","name":"VS-7375","route":"/drugs/vs-7375/","status":"phase-2","modality":"small molecule (structure undisclosed or not yet in PubChem)","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"kras","name":"KRAS","href":"/targets/kras/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"vs-7375","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/vs-7375/"},{"record":"nct07020221","field":"status","kind":"trial","state":"development","label":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors: phase 1/2, recruiting","href":"/trials/nct07020221/"},{"record":"nct07659795","field":"status","kind":"trial","state":"development","label":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer: phase 2, recruiting","href":"/trials/nct07659795/"},{"record":"nct07659782","field":"status","kind":"trial","state":"development","label":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct07659782/"},{"record":"nct07644559","field":"status","kind":"trial","state":"development","label":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer: phase 2, recruiting","href":"/trials/nct07644559/"},{"record":"registry:vs-7375","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/vs-7375/#registry"}],"reasons":[]},{"id":"xnw5004","name":"XNW5004","route":"/drugs/xnw5004/","status":"phase-2","modality":"small molecule (structure undisclosed or not yet in PubChem)","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"ezh2","name":"EZH2","href":"/targets/ezh2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"xnw5004","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/xnw5004/"},{"record":"nct06776952","field":"status","kind":"trial","state":"development","label":"A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma: phase 3, recruiting","href":"/trials/nct06776952/"},{"record":"nct07730515","field":"status","kind":"trial","state":"development","label":"Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma: phase 1/2, recruiting","href":"/trials/nct07730515/"},{"record":"nct07545603","field":"status","kind":"trial","state":"development","label":"Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma: phase 2, recruiting","href":"/trials/nct07545603/"},{"record":"nct06702995","field":"status","kind":"trial","state":"development","label":"Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer: phase 1/2, recruiting","href":"/trials/nct06702995/"},{"record":"registry:xnw5004","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/xnw5004/#registry"}],"reasons":[]},{"id":"zanubrutinib","name":"Zanubrutinib","route":"/drugs/zanubrutinib/","status":"approved","modality":"Small-molecule covalent BTK inhibitor (second generation)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"btk","name":"BTK (Bruton tyrosine kinase)","href":"/targets/btk/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"zanubrutinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/zanubrutinib/"},{"record":"zanubrutinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2019: Relapsed MCL (accelerated)","href":"/drugs/zanubrutinib/"},{"record":"zanubrutinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2023: CLL/SLL, all lines (SEQUOIA, ALPINE)","href":"/drugs/zanubrutinib/"},{"record":"zanubrutinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2019","href":"/regulatory/regions/"},{"record":"zanubrutinib","field":"regional.EU","kind":"regional","state":"approved","label":"EMA / European Commission (EU): approved 2021","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/brukinsa"},{"record":"zanubrutinib","field":"regional.UK","kind":"regional","state":"approved","label":"MHRA (NICE for reimbursement) (UK): approved 2021","href":"https://products.mhra.gov.uk/?search=Brukinsa"},{"record":"zanubrutinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2024","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"zanubrutinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2020","href":"https://english.nmpa.gov.cn/"},{"record":"zanubrutinib","field":"regional.AU","kind":"regional","state":"approved","label":"TGA (PBS for reimbursement) (AU): approved 2020","href":"https://www.tga.gov.au/resources/artg?search_api_views_fulltext=Brukinsa"},{"record":"nct07271667","field":"status","kind":"trial","state":"development","label":"A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies: phase 2, recruiting","href":"/trials/nct07271667/"},{"record":"nct06375733","field":"status","kind":"trial","state":"development","label":"A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL: phase 1/2, recruiting","href":"/trials/nct06375733/"},{"record":"nct05100862","field":"status","kind":"trial","state":"development","label":"A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphom: phase 3, active","href":"/trials/nct05100862/"},{"record":"nct04170283","field":"status","kind":"trial","state":"development","label":"A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib: phase 3, active","href":"/trials/nct04170283/"},{"record":"nct05952037","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia: phase 2, active","href":"/trials/nct05952037/"},{"record":"nct06634589","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies: phase 1/2, recruiting","href":"/trials/nct06634589/"},{"record":"nct07277231","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia: phase 3, recruiting","href":"/trials/nct07277231/"},{"record":"nct06637501","field":"status","kind":"trial","state":"development","label":"A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia: phase 2, active","href":"/trials/nct06637501/"},{"record":"nct06742996","field":"status","kind":"trial","state":"development","label":"A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refrac: phase 3, recruiting","href":"/trials/nct06742996/"},{"record":"nct04002297","field":"status","kind":"trial","state":"development","label":"A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantl: phase 3, active","href":"/trials/nct04002297/"},{"record":"nct06697184","field":"status","kind":"trial","state":"development","label":"A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.: phase 1/2, recruiting","href":"/trials/nct06697184/"},{"record":"celestial-tncll","field":"status","kind":"trial","state":"development","label":"CELESTIAL-TNCLL: phase 3, active","href":"/trials/celestial-tncll/"},{"record":"nct04662255","field":"status","kind":"trial","state":"development","label":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL): phase 3, active","href":"/trials/nct04662255/"},{"record":"registry:zanubrutinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 67 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/zanubrutinib/#registry"}],"reasons":[]},{"id":"zanzalintinib","name":"Zanzalintinib","route":"/drugs/zanzalintinib/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"vegf+met","name":"VEGF / VEGFR x MET","href":"/targets/vegf/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"zanzalintinib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/zanzalintinib/"},{"record":"nct07489495","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034): phase 3, recruiting","href":"/trials/nct07489495/"},{"record":"nct07227402","field":"status","kind":"trial","state":"development","label":"A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033): phase 3, recruiting","href":"/trials/nct07227402/"},{"record":"nct07620574","field":"status","kind":"trial","state":"development","label":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study: phase 3, recruiting","href":"/trials/nct07620574/"},{"record":"nct07677579","field":"status","kind":"trial","state":"development","label":"NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer: phase 2, planned","href":"/trials/nct07677579/"},{"record":"nct05425940","field":"status","kind":"trial","state":"development","label":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer: phase 3, active","href":"/trials/nct05425940/"},{"record":"nct06082167","field":"status","kind":"trial","state":"development","label":"Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: phase 2/3, active","href":"/trials/nct06082167/"},{"record":"nct07049926","field":"status","kind":"trial","state":"development","label":"Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (: phase 1/2, recruiting","href":"/trials/nct07049926/"},{"record":"nct07750158","field":"status","kind":"trial","state":"development","label":"Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease: phase 3, recruiting","href":"/trials/nct07750158/"},{"record":"nct06943755","field":"status","kind":"trial","state":"development","label":"Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors: phase 2/3, recruiting","href":"/trials/nct06943755/"},{"record":"registry:zanzalintinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 35 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/zanzalintinib/#registry"}],"reasons":[]},{"id":"zen-3694","name":"ZEN-3694","route":"/drugs/zen-3694/","status":"phase-2","modality":"Oral small-molecule BET bromodomain inhibitor","state":"development","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"brd4","name":"BRD4","href":"/targets/brd4/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"zen-3694","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/zen-3694/"},{"record":"nct05607108","field":"status","kind":"trial","state":"development","label":"A Study of ZEN003694 in People With Squamous Cell Lung Cancer: phase 2, recruiting","href":"/trials/nct05607108/"},{"record":"zen-3694-abemaciclib-nut","field":"status","kind":"trial","state":"development","label":"ZEN-3694 with abemaciclib in NUT carcinoma, breast cancer and other solid tumours (NCI phase 1): phase 1, recruiting","href":"/trials/zen-3694-abemaciclib-nut/"},{"record":"zen-3694-platinum-nut","field":"status","kind":"trial","state":"development","label":"ZEN-3694 with platinum chemotherapy in NUT carcinoma (NCI phase 1/2): phase 1/2, recruiting","href":"/trials/zen-3694-platinum-nut/"},{"record":"nct04986423","field":"status","kind":"trial","state":"development","label":"ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer: phase 2, recruiting","href":"/trials/nct04986423/"},{"record":"registry:zen-3694","kind":"registry","state":"development","label":"ClinicalTrials.gov: 10 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/zen-3694/#registry"}],"reasons":[]},{"id":"zibotentan","name":"Zibotentan","route":"/drugs/zibotentan/","status":"withdrawn","modality":"small molecule","state":"stopped","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"ednra","name":"EDNRA","href":"/targets/ednra/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"zibotentan","field":"status","kind":"drug","state":"stopped","label":"Drug record status: withdrawn","href":"/drugs/zibotentan/","quote":"A drug blocking a signal that prostate cancer uses to grow in bone. Three trials in prostate cancer found no survival benefit and it was dropped."},{"record":"enthuse-m1-zibotentan","field":"result","kind":"trial","state":"stopped","label":"ENTHUSE M1: phase 3, negative","href":"/trials/enthuse-m1-zibotentan/","quote":"Median overall survival 24.5 against 22.5 months (hazard ratio 0.87, 95.2 percent confidence interval 0.69 to 1.10, p=0.240): not significant, with peripheral oedema in 44 percent and cardiac failure of any grade in 5.7 against 1.7 percent."},{"record":"swog-s0421-atrasentan","field":"result","kind":"trial","state":"stopped","label":"SWOG S0421: phase 3, negative","href":"/trials/swog-s0421-atrasentan/","quote":"Median overall survival 17.8 against 17.6 months (hazard ratio 1.04, 95 percent confidence interval 0.90 to 1.19) and progression-free survival 9.2 against 9.1 months (1.02, 0.89 to 1.16); halted early for futility, and no difference in pain palliation."},{"record":"registry:zibotentan","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/zibotentan/#registry"}],"reasons":[{"drugId":"zibotentan","drugName":"Zibotentan","drugRoute":"/drugs/zibotentan/","drugState":"stopped","record":"zibotentan","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/zibotentan/","quote":"A drug blocking a signal that prostate cancer uses to grow in bone. Three trials in prostate cancer found no survival benefit and it was dropped."},{"drugId":"zibotentan","drugName":"Zibotentan","drugRoute":"/drugs/zibotentan/","drugState":"stopped","record":"enthuse-m1-zibotentan","kind":"trial","label":"ENTHUSE M1: phase 3, negative","href":"/trials/enthuse-m1-zibotentan/","quote":"Median overall survival 24.5 against 22.5 months (hazard ratio 0.87, 95.2 percent confidence interval 0.69 to 1.10, p=0.240): not significant, with peripheral oedema in 44 percent and cardiac failure of any grade in 5.7 against 1.7 percent."},{"drugId":"zibotentan","drugName":"Zibotentan","drugRoute":"/drugs/zibotentan/","drugState":"stopped","record":"swog-s0421-atrasentan","kind":"trial","label":"SWOG S0421: phase 3, negative","href":"/trials/swog-s0421-atrasentan/","quote":"Median overall survival 17.8 against 17.6 months (hazard ratio 1.04, 95 percent confidence interval 0.90 to 1.19) and progression-free survival 9.2 against 9.1 months (1.02, 0.89 to 1.16); halted early for futility, and no difference in pain palliation."}]},{"id":"zidesamtinib","name":"Zidesamtinib","route":"/drugs/zidesamtinib/","status":"approved","modality":"Small-molecule kinase inhibitor (ROS1)","state":"approved","confidence":"high","fields":["target record (drugs field)","technologies","modality","mechanism"],"components":{"target":{"id":"ros1","name":"ROS1","href":"/targets/ros1/","confidence":"high","from":["target record (drugs field)"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"selective","name":"Selective (mode not stated)","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"zidesamtinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/zidesamtinib/"},{"record":"zidesamtinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2026: ROS1+ NSCLC (July 2026)","href":"/drugs/zidesamtinib/"},{"record":"zidesamtinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2026","href":"/regulatory/regions/"},{"record":"nct05118789","field":"status","kind":"trial","state":"development","label":"A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1): phase 1/2, recruiting","href":"/trials/nct05118789/"},{"record":"registry:zidesamtinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/zidesamtinib/#registry"}],"reasons":[]},{"id":"ziftomenib","name":"Ziftomenib","route":"/drugs/ziftomenib/","status":"approved","modality":"Small-molecule menin inhibitor","state":"approved","confidence":"high","fields":["targets","technologies"],"components":{"target":{"id":"menin+npm1","name":"Menin x NPM1 mutation","href":"/targets/menin/","confidence":"high","from":["targets"],"detail":"dual-target"},"mechanismClass":{"id":"epigenetic","name":"Epigenetic inhibitor","href":"/technologies/epigenetic-drugs/","confidence":"high","from":["technologies"],"detail":null}},"evidence":[{"record":"ziftomenib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/ziftomenib/"},{"record":"ziftomenib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2025: Relapsed/refractory NPM1-mutated AML with no satisfactory alternative","href":"/drugs/ziftomenib/"},{"record":"ziftomenib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2025","href":"/regulatory/regions/"},{"record":"nct07623616","field":"status","kind":"trial","state":"development","label":"A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia: phase 2, recruiting","href":"/trials/nct07623616/"},{"record":"myelomatch","field":"status","kind":"trial","state":"development","label":"myeloMATCH: phase platform, recruiting","href":"/trials/myelomatch/"},{"record":"nct07007312","field":"status","kind":"trial","state":"development","label":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML: phase 3, recruiting","href":"/trials/nct07007312/"},{"record":"registry:ziftomenib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 5 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/ziftomenib/#registry"}],"reasons":[]},{"id":"zipalertinib","name":"Zipalertinib","route":"/drugs/zipalertinib/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"egfr","name":"EGFR","href":"/targets/egfr/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"zipalertinib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/zipalertinib/"},{"record":"nct04036682","field":"status","kind":"trial","state":"development","label":"A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer: phase 1/2, active","href":"/trials/nct04036682/"},{"record":"nct07128199","field":"status","kind":"trial","state":"development","label":"A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection: phase 3, active","href":"/trials/nct07128199/"},{"record":"nct07802834","field":"status","kind":"trial","state":"development","label":"Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC: phase 2, planned","href":"/trials/nct07802834/"},{"record":"nct05973773","field":"status","kind":"trial","state":"development","label":"REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors): phase 3, active","href":"/trials/nct05973773/"},{"record":"nct07229339","field":"status","kind":"trial","state":"development","label":"Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer: phase 2, planned","href":"/trials/nct07229339/"},{"record":"registry:zipalertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/zipalertinib/#registry"}],"reasons":[]},{"id":"zoldonrasib","name":"Zoldonrasib","route":"/drugs/zoldonrasib/","status":"phase-2","modality":"Small-molecule RAS(ON) G12D-selective inhibitor","state":"development","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"kras","name":"KRAS","href":"/targets/kras/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"ras-inhibitor","name":"RAS inhibitor","href":"/technologies/kras-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"zoldonrasib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/zoldonrasib/"},{"record":"nct07777822","field":"status","kind":"trial","state":"development","label":"Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mu: phase 3, recruiting","href":"/trials/nct07777822/"},{"record":"nct07397338","field":"status","kind":"trial","state":"development","label":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors: phase 1/2, recruiting","href":"/trials/nct07397338/"},{"record":"nct06445062","field":"status","kind":"trial","state":"development","label":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors: phase 1/2, recruiting","href":"/trials/nct06445062/"},{"record":"nct06040541","field":"status","kind":"trial","state":"development","label":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors: phase 1, recruiting","href":"/trials/nct06040541/"},{"record":"nct07805954","field":"status","kind":"trial","state":"development","label":"Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut: phase 3, recruiting","href":"/trials/nct07805954/"},{"record":"nct07621718","field":"status","kind":"trial","state":"development","label":"Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta: phase 3, recruiting","href":"/trials/nct07621718/"},{"record":"nct06922591","field":"status","kind":"trial","state":"development","label":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients: phase 1/2, recruiting","href":"/trials/nct06922591/"},{"record":"registry:zoldonrasib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 4 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/zoldonrasib/#registry"}],"reasons":[]},{"id":"zongertinib","name":"Zongertinib","route":"/drugs/zongertinib/","status":"approved","modality":"Small-molecule kinase inhibitor (HER2)","state":"approved","confidence":"high","fields":["targets","technologies","modality","mechanism"],"components":{"target":{"id":"her2","name":"HER2","href":"/targets/her2/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"kinase-inhibitor","name":"Kinase inhibitor","href":"/technologies/kinase-inhibitors/","confidence":"high","from":["technologies"],"detail":null},"binding":{"id":"covalent","name":"Covalent","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"zongertinib","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/zongertinib/"},{"record":"zongertinib","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2025: HER2-mutant NSCLC, previously treated (accelerated)","href":"/drugs/zongertinib/"},{"record":"zongertinib","field":"approvals[1]","kind":"approval","state":"approved","label":"US 2026: First-line HER2-mutant non-squamous NSCLC","href":"/drugs/zongertinib/"},{"record":"zongertinib","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2025","href":"/regulatory/regions/"},{"record":"zongertinib","field":"regional.JP","kind":"regional","state":"approved","label":"PMDA / MHLW (JP): approved 2025","href":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html"},{"record":"zongertinib","field":"regional.CN","kind":"regional","state":"approved","label":"NMPA (CN): approved 2025","href":"https://english.nmpa.gov.cn/"},{"record":"nct07486817","field":"status","kind":"trial","state":"development","label":"Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab: phase 2, recruiting","href":"/trials/nct07486817/"},{"record":"nct06324357","field":"status","kind":"trial","state":"development","label":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People Wit: phase 1/2, recruiting","href":"/trials/nct06324357/"},{"record":"nct06151574","field":"status","kind":"trial","state":"development","label":"Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment: phase 3, active","href":"/trials/nct06151574/"},{"record":"nct07195695","field":"status","kind":"trial","state":"development","label":"Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati: phase 3, recruiting","href":"/trials/nct07195695/"},{"record":"nct06581432","field":"status","kind":"trial","state":"development","label":"Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations: phase 2, recruiting","href":"/trials/nct06581432/"},{"record":"registry:zongertinib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 6 recruiting, active or planned studies (fetched 2026-09-28)","href":"/drugs/zongertinib/#registry"}],"reasons":[]},{"id":"zovegalisib","name":"Zovegalisib","route":"/drugs/zovegalisib/","status":"phase-3","modality":"small molecule","state":"development","confidence":"medium","fields":["targets","modality","mechanism"],"components":{"target":{"id":"pik3ca","name":"PIK3CA / PI3K-alpha","href":"/targets/pik3ca/","confidence":"high","from":["targets"],"detail":null},"mechanismClass":{"id":"pi3k-akt-mtor-inhibitor","name":"PI3K, AKT or mTOR inhibitor","href":"/technologies/pi3k-akt-mtor-inhibitors/","confidence":"medium","from":["modality","mechanism"],"detail":null},"binding":{"id":"allosteric","name":"Allosteric","href":null,"confidence":"high","from":["modality","mechanism"],"detail":null}},"evidence":[{"record":"zovegalisib","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/zovegalisib/"},{"record":"nct06982521","field":"status","kind":"trial","state":"development","label":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer: phase 3, recruiting","href":"/trials/nct06982521/"},{"record":"registry:zovegalisib","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-28)","href":"/drugs/zovegalisib/#registry"}],"reasons":[]}],"unresolved":[{"id":"abexinostat","name":"Abexinostat","route":"/drugs/abexinostat/","format":"small-molecule","modality":"small molecule","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"adavosertib","name":"Adavosertib","route":"/drugs/adavosertib/","format":"small-molecule","modality":"Oral serine/threonine kinase inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"al8326","name":"AL8326","route":"/drugs/al8326/","format":"small-molecule","modality":"small molecule (structure undisclosed or not yet in PubChem)","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"alisertib","name":"Alisertib","route":"/drugs/alisertib/","format":"small-molecule","modality":"Oral serine/threonine kinase inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"amo959","name":"AMO959","route":"/drugs/amo959/","format":"small-molecule","modality":"Small-molecule inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"asc40","name":"ASC40","route":"/drugs/asc40/","format":"small-molecule","modality":"small molecule","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"avasopasem-manganese","name":"Avasopasem manganese","route":"/drugs/avasopasem-manganese/","format":"small-molecule","modality":"Superoxide dismutase mimetic small molecule","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"azd8421","name":"AZD8421","route":"/drugs/azd8421/","format":"small-molecule","modality":"Small-molecule inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"bebt-209","name":"BEBT-209","route":"/drugs/bebt-209/","format":"small-molecule","modality":"small molecule (structure undisclosed or not yet in PubChem)","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"befotertinib","name":"Befotertinib","route":"/drugs/befotertinib/","format":"small-molecule","modality":"Oral kinase inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"belumosudil","name":"Belumosudil","route":"/drugs/belumosudil/","format":"small-molecule","modality":"Oral ROCK2 inhibitor","missing":["target"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"bgb-43395","name":"BGB-43395","route":"/drugs/bgb-43395/","format":"small-molecule","modality":"small molecule (structure undisclosed or not yet in PubChem)","missing":["target"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"bleximenib","name":"Bleximenib","route":"/drugs/bleximenib/","format":"small-molecule","modality":"small molecule","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"bomedemstat","name":"Bomedemstat","route":"/drugs/bomedemstat/","format":"small-molecule","modality":"small molecule","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"camonsertib","name":"Camonsertib","route":"/drugs/camonsertib/","format":"small-molecule","modality":"Oral serine/threonine kinase inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"clifutinib","name":"Clifutinib","route":"/drugs/clifutinib/","format":"small-molecule","modality":"small molecule","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"ct3001","name":"CT3001","route":"/drugs/ct3001/","format":"small-molecule","modality":"Small-molecule inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"cyh33","name":"CYH33","route":"/drugs/cyh33/","format":"small-molecule","modality":"Small-molecule inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"d07001","name":"D07001","route":"/drugs/d07001/","format":"small-molecule","modality":"small molecule (structure undisclosed or not yet in PubChem)","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"devimistat","name":"Devimistat","route":"/drugs/devimistat/","format":"small-molecule","modality":"Small-molecule inhibitor of mitochondrial metabolism (PDH and KGDH)","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"diazoxide","name":"Diazoxide","route":"/drugs/diazoxide/","format":"small-molecule","modality":"Oral potassium-channel opener that suppresses insulin hormone release","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"dzd8586","name":"DZD8586","route":"/drugs/dzd8586/","format":"small-molecule","modality":"small molecule","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"eik1001","name":"EIK1001","route":"/drugs/eik1001/","format":"small-molecule","modality":"small molecule (structure undisclosed or not yet in PubChem)","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"elenestinib","name":"Elenestinib","route":"/drugs/elenestinib/","format":"small-molecule","modality":"small molecule","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"emavusertib","name":"Emavusertib","route":"/drugs/emavusertib/","format":"small-molecule","modality":"Oral serine/threonine kinase inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"enb003","name":"ENB003","route":"/drugs/enb003/","format":"small-molecule","modality":"Small-molecule antagonist","missing":["target"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"evexomostat","name":"Evexomostat","route":"/drugs/evexomostat/","format":"small-molecule","modality":"Small-molecule inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"flonoltinib","name":"Flonoltinib","route":"/drugs/flonoltinib/","format":"small-molecule","modality":"Oral kinase inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"gecacitinib","name":"Gecacitinib","route":"/drugs/gecacitinib/","format":"small-molecule","modality":"Oral kinase inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"givinostat","name":"Givinostat","route":"/drugs/givinostat/","format":"small-molecule","modality":"small molecule","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"hmpl-760","name":"HMPL-760","route":"/drugs/hmpl-760/","format":"small-molecule","modality":"small molecule (structure undisclosed or not yet in PubChem)","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"hrs-8080","name":"HRS-8080","route":"/drugs/hrs-8080/","format":"small-molecule","modality":"small molecule (structure undisclosed or not yet in PubChem)","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"icp-248","name":"ICP-248","route":"/drugs/icp-248/","format":"small-molecule","modality":"small molecule (structure undisclosed or not yet in PubChem)","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"idrx-42","name":"IDRX-42","route":"/drugs/idrx-42/","format":"small-molecule","modality":"small molecule","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"incb123667","name":"INCB123667","route":"/drugs/incb123667/","format":"small-molecule","modality":"small molecule (structure undisclosed or not yet in PubChem)","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"inlexisertib","name":"Inlexisertib","route":"/drugs/inlexisertib/","format":"small-molecule","modality":"Oral serine/threonine kinase inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"ipg1094","name":"IPG1094","route":"/drugs/ipg1094/","format":"small-molecule","modality":"Small-molecule inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"ivospemin","name":"Ivospemin","route":"/drugs/ivospemin/","format":"small-molecule","modality":"small molecule","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"jbi-802","name":"JBI-802","route":"/drugs/jbi-802/","format":"small-molecule","modality":"Small-molecule inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"js105","name":"JS105","route":"/drugs/js105/","format":"small-molecule","modality":"small molecule (structure undisclosed or not yet in PubChem)","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"kc1036","name":"KC1036","route":"/drugs/kc1036/","format":"small-molecule","modality":"small molecule (structure undisclosed or not yet in PubChem)","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"lerotinib","name":"Lerotinib","route":"/drugs/lerotinib/","format":"small-molecule","modality":"small molecule (structure undisclosed or not yet in PubChem)","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"lp-184","name":"LP-184","route":"/drugs/lp-184/","format":"small-molecule","modality":"Small-molecule inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"merestinib","name":"Merestinib","route":"/drugs/merestinib/","format":"small-molecule","modality":"Oral kinase inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"metyrapone","name":"Metyrapone","route":"/drugs/metyrapone/","format":"small-molecule","modality":"Oral 11-beta-hydroxylase inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"navitoclax","name":"Navitoclax","route":"/drugs/navitoclax/","format":"small-molecule","modality":"small molecule","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"nb003","name":"NB003","route":"/drugs/nb003/","format":"small-molecule","modality":"small molecule (structure undisclosed or not yet in PubChem)","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"nuv-1511","name":"NUV-1511","route":"/drugs/nuv-1511/","format":"small-molecule","modality":"Small-molecule inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"opevesostat","name":"Opevesostat","route":"/drugs/opevesostat/","format":"small-molecule","modality":"small molecule","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"pancrelipase","name":"Pancrelipase (pancreatic enzyme replacement therapy)","route":"/drugs/pancrelipase/","format":"small-molecule","modality":"Oral porcine pancreatic enzymes (lipase, protease, amylase) in enteric-coated capsules","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"parsaclisib","name":"Parsaclisib","route":"/drugs/parsaclisib/","format":"small-molecule","modality":"Oral PI3K inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"pegvisomant","name":"Pegvisomant","route":"/drugs/pegvisomant/","format":"small-molecule","modality":"Pegylated growth hormone receptor antagonist (daily subcutaneous injection)","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"pevonedistat","name":"Pevonedistat","route":"/drugs/pevonedistat/","format":"small-molecule","modality":"Intravenous NEDD8-activating enzyme (NAE) inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"pilocarpine","name":"Pilocarpine","route":"/drugs/pilocarpine/","format":"small-molecule","modality":"Cholinergic agonist (small molecule) for radiation-induced dry mouth","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"pimicotinib","name":"Pimicotinib","route":"/drugs/pimicotinib/","format":"small-molecule","modality":"Oral kinase inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"prtx007","name":"PRTX007","route":"/drugs/prtx007/","format":"small-molecule","modality":"Small-molecule inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"radotinib","name":"Radotinib","route":"/drugs/radotinib/","format":"small-molecule","modality":"Oral kinase inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"recombinant-human-endostatin","name":"Recombinant human endostatin","route":"/drugs/recombinant-human-endostatin/","format":"small-molecule","modality":"Recombinant angiogenesis inhibitor protein","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"rem-422","name":"REM-422","route":"/drugs/rem-422/","format":"small-molecule","modality":"Small-molecule inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"rocbrutinib","name":"Rocbrutinib","route":"/drugs/rocbrutinib/","format":"small-molecule","modality":"small molecule","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"roginolisib","name":"Roginolisib","route":"/drugs/roginolisib/","format":"small-molecule","modality":"Oral PI3K inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"rvu120","name":"RVU120","route":"/drugs/rvu120/","format":"small-molecule","modality":"Small-molecule inhibitor","missing":["target"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"samuraciclib","name":"Samuraciclib","route":"/drugs/samuraciclib/","format":"small-molecule","modality":"Oral CDK inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"setmelanotide","name":"Setmelanotide","route":"/drugs/setmelanotide/","format":"small-molecule","modality":"Subcutaneous melanocortin-4 receptor agonist","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"sim0270","name":"SIM0270","route":"/drugs/sim0270/","format":"small-molecule","modality":"small molecule (structure undisclosed or not yet in PubChem)","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"sodium-thiosulfate","name":"Sodium thiosulfate (otoprotectant)","route":"/drugs/sodium-thiosulfate/","format":"small-molecule","modality":"Small-molecule chemoprotectant","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"sph4336","name":"SPH4336","route":"/drugs/sph4336/","format":"small-molecule","modality":"small molecule","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"stp938","name":"STP938","route":"/drugs/stp938/","format":"small-molecule","modality":"Small-molecule inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"tasquinimod","name":"Tasquinimod","route":"/drugs/tasquinimod/","format":"small-molecule","modality":"small molecule","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"tenalisib","name":"Tenalisib","route":"/drugs/tenalisib/","format":"small-molecule","modality":"Oral PI3K inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"tgrx-326","name":"TGRX-326","route":"/drugs/tgrx-326/","format":"small-molecule","modality":"small molecule","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"tng260","name":"TNG260","route":"/drugs/tng260/","format":"small-molecule","modality":"Small-molecule inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"tqb3702","name":"TQB3702","route":"/drugs/tqb3702/","format":"small-molecule","modality":"Small-molecule inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"tqb3909","name":"TQB3909","route":"/drugs/tqb3909/","format":"small-molecule","modality":"Small-molecule inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"tuspetinib","name":"Tuspetinib","route":"/drugs/tuspetinib/","format":"small-molecule","modality":"Oral kinase inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"ty-9591","name":"TY-9591","route":"/drugs/ty-9591/","format":"small-molecule","modality":"small molecule (structure undisclosed or not yet in PubChem)","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"vactosertib","name":"Vactosertib","route":"/drugs/vactosertib/","format":"small-molecule","modality":"Oral serine/threonine kinase inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"vc004","name":"VC004","route":"/drugs/vc004/","format":"small-molecule","modality":"small molecule","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"vepugratinib","name":"Vepugratinib","route":"/drugs/vepugratinib/","format":"small-molecule","modality":"small molecule","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"vistusertib","name":"Vistusertib","route":"/drugs/vistusertib/","format":"small-molecule","modality":"Oral serine/threonine kinase inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"wjb001","name":"WJB001","route":"/drugs/wjb001/","format":"small-molecule","modality":"Small-molecule inhibitor","missing":["target","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."},{"id":"xzp-3287","name":"XZP-3287","route":"/drugs/xzp-3287/","format":"small-molecule","modality":"small molecule","missing":["target","mechanismClass","binding"],"why":"No target on the record: the targets field is empty and the modality and mechanism text name none the corpus knows."}],"stopped":[{"drugId":"adu-s100","drugName":"ADU-S100 (MIW815)","drugRoute":"/drugs/adu-s100/","drugState":"stopped","record":"adu-s100","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/adu-s100/","quote":"ADU-S100 was the first STING agonist in the clinic. Injected directly into tumours, it produced almost no responses, alone or with checkpoint blockade."},{"drugId":"aminoglutethimide","drugName":"Aminoglutethimide","drugRoute":"/drugs/aminoglutethimide/","drugState":"stopped","record":"aminoglutethimide","kind":"drug","label":"Drug record status: historic","href":"/drugs/aminoglutethimide/","quote":"Aminoglutethimide produced a medical adrenalectomy for advanced breast and prostate cancer in the 1970s and 1980s, the ancestor of today's aromatase inhibitors, and was withdrawn once selective drugs arrived."},{"drugId":"atrasentan","drugName":"Atrasentan","drugRoute":"/drugs/atrasentan/","drugState":"stopped","record":"atrasentan","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/atrasentan/","quote":"The other endothelin blocker. Adding it to chemotherapy for advanced prostate cancer changed nothing, and the trial was stopped for futility."},{"drugId":"atrasentan","drugName":"Atrasentan","drugRoute":"/drugs/atrasentan/","drugState":"stopped","record":"enthuse-m1-zibotentan","kind":"trial","label":"ENTHUSE M1: phase 3, negative","href":"/trials/enthuse-m1-zibotentan/","quote":"Median overall survival 24.5 against 22.5 months (hazard ratio 0.87, 95.2 percent confidence interval 0.69 to 1.10, p=0.240): not significant, with peripheral oedema in 44 percent and cardiac failure of any grade in 5.7 against 1.7 percent."},{"drugId":"atrasentan","drugName":"Atrasentan","drugRoute":"/drugs/atrasentan/","drugState":"stopped","record":"swog-s0421-atrasentan","kind":"trial","label":"SWOG S0421: phase 3, negative","href":"/trials/swog-s0421-atrasentan/","quote":"Median overall survival 17.8 against 17.6 months (hazard ratio 1.04, 95 percent confidence interval 0.90 to 1.19) and progression-free survival 9.2 against 9.1 months (1.02, 0.89 to 1.16); halted early for futility, and no difference in pain palliation."},{"drugId":"copanlisib","drugName":"Copanlisib","drugRoute":"/drugs/copanlisib/","drugState":"stopped","record":"copanlisib","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/copanlisib/","quote":"Copanlisib is an intravenous PI3K inhibitor for relapsed follicular lymphoma, approved in 2017 and withdrawn in 2023 when its confirmatory trial failed."},{"drugId":"copanlisib","drugName":"Copanlisib","drugRoute":"/drugs/copanlisib/","drugState":"stopped","record":"copanlisib","kind":"regional","label":"FDA (US): withdrawn 2023","href":"/regulatory/regions/","quote":"Aliqopa accelerated approval Sep 2017; withdrawn by Bayer Nov 2023 after CHRONOS-4"},{"drugId":"copanlisib","drugName":"Copanlisib","drugRoute":"/drugs/copanlisib/","drugState":"stopped","record":"copanlisib","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/aliqopa","quote":"Marketing authorisation application withdrawn before a CHMP opinion"},{"drugId":"copanlisib","drugName":"Copanlisib","drugRoute":"/drugs/copanlisib/","drugState":"stopped","record":"copanlisib","kind":"event","label":"US 2024-03-18: withdrawal","href":"/drugs/copanlisib/","quote":"Withdrawn: the indication came off the label 6.5 years after its accelerated approval."},{"drugId":"eprenetapopt","drugName":"Eprenetapopt","drugRoute":"/drugs/eprenetapopt/","drugState":"stopped","record":"eprenetapopt","kind":"drug","label":"Drug record status: negative","href":"/drugs/eprenetapopt/","quote":"Eprenetapopt (APR-246) was a drug meant to refold mutant p53, the most common broken protein in cancer. Its phase 3 in blood cancer failed in 2020."},{"drugId":"formestane","drugName":"Formestane","drugRoute":"/drugs/formestane/","drugState":"stopped","record":"formestane","kind":"drug","label":"Drug record status: historic","href":"/drugs/formestane/","quote":"Formestane, launched in Europe in 1993, was the first selective aromatase inhibitor for advanced breast cancer, given by injection every two weeks; oral exemestane and the non-steroidal inhibitors made it redundant within a few years."},{"drugId":"galeterone","drugName":"Galeterone","drugRoute":"/drugs/galeterone/","drugState":"stopped","record":"galeterone","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/galeterone/","quote":"An experimental prostate cancer tablet meant to work in men whose cancer makes a broken form of the androgen receptor. The trial designed to prove it collapsed."},{"drugId":"galeterone","drugName":"Galeterone","drugRoute":"/drugs/galeterone/","drugState":"stopped","record":"armor3-sv","kind":"trial","label":"ARMOR3-SV: phase 3, negative","href":"/trials/armor3-sv/","quote":"Closed early after 38 of a planned 148 men were randomised; AR-V7 prevalence 8 percent (95 percent confidence interval 6 to 10) among 953 prescreened men. PSA50 response 13 percent with galeterone against 42 percent with enzalutamide. Galeterone development stopped."},{"drugId":"infigratinib","drugName":"Infigratinib","drugRoute":"/drugs/infigratinib/","drugState":"stopped","record":"infigratinib","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/infigratinib/","quote":"Infigratinib is an FGFR inhibitor pill given accelerated approval in the United States in 2021 for bile duct cancer with an FGFR2 fusion, then withdrawn in 2024 when its confirmatory trial could not enrol; it is now being developed for achondroplasia instead."},{"drugId":"infigratinib","drugName":"Infigratinib","drugRoute":"/drugs/infigratinib/","drugState":"stopped","record":"infigratinib","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/febseltiq","quote":"Febseltiq (Helsinn Birex Pharmaceuticals Ltd): marketing authorisation application withdrawn before a Commission decision. EMA register: 'Application withdrawn: The application for this medicine has been withdrawn'; checked 2026-09-24"},{"drugId":"infigratinib","drugName":"Infigratinib","drugRoute":"/drugs/infigratinib/","drugState":"stopped","record":"infigratinib","kind":"event","label":"US 2024-05-16: withdrawal","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma","quote":"Withdrawn: the indication came off the label 3.0 years after its accelerated approval."},{"drugId":"iniparib","drugName":"Iniparib","drugRoute":"/drugs/iniparib/","drugState":"stopped","record":"iniparib","kind":"drug","label":"Drug record status: negative","href":"/drugs/iniparib/","quote":"Billed as the first PARP inhibitor for triple-negative breast cancer, it failed its phase 3 in 2011. It turned out not to inhibit PARP at all."},{"drugId":"masofaniten","drugName":"Masofaniten","drugRoute":"/drugs/masofaniten/","drugState":"stopped","record":"masofaniten","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/masofaniten/","quote":"A drug designed to block the part of the androgen receptor that resistant variants keep; its phase 2 was stopped for futility and development ended."},{"drugId":"mobocertinib","drugName":"Mobocertinib","drugRoute":"/drugs/mobocertinib/","drugState":"stopped","record":"mobocertinib","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/mobocertinib/","quote":"Mobocertinib was the first oral drug for EGFR exon 20 insertion lung cancer, approved in 2021 and withdrawn in 2023-24 after its confirmatory trial failed."},{"drugId":"mobocertinib","drugName":"Mobocertinib","drugRoute":"/drugs/mobocertinib/","drugState":"stopped","record":"mobocertinib","kind":"regional","label":"FDA (US): withdrawn 2023","href":"/regulatory/regions/","quote":"Exkivity accelerated approval Sep 2021; withdrawn by Takeda Oct 2023 after EXCLAIM-2"},{"drugId":"mobocertinib","drugName":"Mobocertinib","drugRoute":"/drugs/mobocertinib/","drugState":"stopped","record":"mobocertinib","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/exkivity","quote":"Marketing authorisation application withdrawn before a CHMP opinion"},{"drugId":"mobocertinib","drugName":"Mobocertinib","drugRoute":"/drugs/mobocertinib/","drugState":"stopped","record":"mobocertinib","kind":"event","label":"US 2024-07-15: withdrawal","href":"/drugs/mobocertinib/","quote":"Withdrawn: the indication came off the label 2.8 years after its accelerated approval."},{"drugId":"napabucasin","drugName":"Napabucasin","drugRoute":"/drugs/napabucasin/","drugState":"stopped","record":"napabucasin","kind":"drug","label":"Drug record status: negative","href":"/drugs/napabucasin/","quote":"Napabucasin, an oral drug marketed as a cancer stemness inhibitor, was tested in 1,134 people with untreated metastatic pancreatic cancer on top of nab-paclitaxel and gemcitabine; survival was identical and the trial was stopped for futility."},{"drugId":"napabucasin","drugName":"Napabucasin","drugRoute":"/drugs/napabucasin/","drugState":"stopped","record":"canstem111p","kind":"trial","label":"CanStem111P: phase 3, negative","href":"/trials/canstem111p/","quote":"Median overall survival 11.4 months with napabucasin plus nab-paclitaxel and gemcitabine against 11.7 months with chemotherapy alone (hazard ratio 1.07, 95 percent confidence interval 0.93 to 1.23); terminated for futility."},{"drugId":"olmutinib","drugName":"Olmutinib","drugRoute":"/drugs/olmutinib/","drugState":"stopped","record":"olmutinib","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/olmutinib/","quote":"Olmutinib was a Korean-developed EGFR pill approved in South Korea in 2016 for lung cancers that had developed the T790M resistance mutation, the same niche as osimertinib; severe skin reactions and osimertinib's success ended its development."},{"drugId":"orteronel","drugName":"Orteronel","drugRoute":"/drugs/orteronel/","drugState":"stopped","record":"orteronel","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/orteronel/","quote":"A more selective version of abiraterone that was meant to avoid the need for steroids. It delayed the cancer on scans but did not help men live longer, and was abandoned."},{"drugId":"orteronel","drugName":"Orteronel","drugRoute":"/drugs/orteronel/","drugState":"stopped","record":"elm-pc-4-orteronel","kind":"trial","label":"ELM-PC 4: phase 3, negative","href":"/trials/elm-pc-4-orteronel/","quote":"Median radiographic progression-free survival 13.8 against 8.7 months (hazard ratio 0.71, 95 percent confidence interval 0.63 to 0.80, p<0.0001) but overall survival 31.4 against 29.5 months (0.92, 0.79 to 1.08, p=0.31); development stopped."},{"drugId":"panobinostat","drugName":"Panobinostat","drugRoute":"/drugs/panobinostat/","drugState":"stopped","record":"panobinostat","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/panobinostat/","quote":"An HDAC inhibitor for relapsed myeloma approved in 2015 and withdrawn in 2021 after its confirmatory trial was never completed."},{"drugId":"panobinostat","drugName":"Panobinostat","drugRoute":"/drugs/panobinostat/","drugState":"stopped","record":"panobinostat","kind":"regional","label":"FDA (US): withdrawn 2022","href":"/regulatory/regions/","quote":"Farydak accelerated approval Feb 2015; US approval withdrawn 2022 at Secura Bio's request"},{"drugId":"panobinostat","drugName":"Panobinostat","drugRoute":"/drugs/panobinostat/","drugState":"stopped","record":"panobinostat","kind":"event","label":"US 2022-03-24: withdrawal","href":"/drugs/panobinostat/","quote":"Withdrawn: the indication came off the label 7.1 years after its accelerated approval."},{"drugId":"poziotinib","drugName":"Poziotinib","drugRoute":"/drugs/poziotinib/","drugState":"stopped","record":"poziotinib","kind":"drug","label":"Drug record status: negative","href":"/drugs/poziotinib/","quote":"Poziotinib was a tablet designed to fit the awkward shape of HER2 and EGFR exon 20 mutations in lung cancer. It shrank tumours in some patients but caused severe rash and diarrhoea, and the FDA declined to approve it in 2022."},{"drugId":"resminostat","drugName":"Resminostat","drugRoute":"/drugs/resminostat/","drugState":"stopped","record":"resminostat","kind":"regional","label":"EMA / European Commission (EU): rejected 2025","href":"/regulatory/regions/","quote":"CHMP negative opinion 22 May 2025 on Kinselby (4SC) for advanced mycosis fungoides and Sézary syndrome"},{"drugId":"resminostat","drugName":"Resminostat","drugRoute":"/drugs/resminostat/","drugState":"stopped","record":"resminostat","kind":"event","label":"EU 2025-05-22: complete response letter","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/kinselby","quote":"CHMP negative opinion on Kinselby (resminostat) for advanced mycosis fungoides and Sézary syndrome"},{"drugId":"tazemetostat","drugName":"Tazemetostat","drugRoute":"/drugs/tazemetostat/","drugState":"stopped","record":"tazemetostat","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/tazemetostat/","quote":"Tazemetostat was the first EZH2 inhibitor, approved for epithelioid sarcoma and follicular lymphoma in 2020 and withdrawn worldwide in 2026 after secondary blood cancers."},{"drugId":"tazemetostat","drugName":"Tazemetostat","drugRoute":"/drugs/tazemetostat/","drugState":"stopped","record":"tazemetostat","kind":"event","label":"Global 2026-03: withdrawal","href":"/drugs/tazemetostat/","quote":"Withdrawn over secondary haematologic malignancies"},{"drugId":"tazemetostat","drugName":"Tazemetostat","drugRoute":"/drugs/tazemetostat/","drugState":"stopped","record":"tazemetostat","kind":"event","label":"US 2026-06-22: withdrawal","href":"https://wayback.archive-it.org/7993/20201222063544/https:/www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tazemetostat-advanced-epithelioid-sarcoma","quote":"Withdrawn: the indication came off the label 6.4 years after its accelerated approval."},{"drugId":"tazemetostat","drugName":"Tazemetostat","drugRoute":"/drugs/tazemetostat/","drugState":"stopped","record":"tazemetostat","kind":"event","label":"US 2026-06-22: withdrawal","href":"https://wayback.archive-it.org/7993/20201222062826/https:/www.fda.gov/drugs/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma","quote":"Withdrawn: the indication came off the label 6.0 years after its accelerated approval."},{"drugId":"tazemetostat","drugName":"Tazemetostat","drugRoute":"/drugs/tazemetostat/","drugState":"stopped","record":"tazemetostat-doxorubicin-es","kind":"trial","label":"Tazemetostat with doxorubicin as front-line therapy for advanced epithelioid sarcoma (EZH-301 run-in): phase 1, terminated or withdrawn","href":"/trials/tazemetostat-doxorubicin-es/","quote":"FDA and Ipsen alignelment: Due to unfeasibility and the resulting inability to meet the required enrolment targets. No safety concerns."},{"drugId":"umbralisib","drugName":"Umbralisib","drugRoute":"/drugs/umbralisib/","drugState":"stopped","record":"umbralisib","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/umbralisib/","quote":"A PI3K inhibitor for marginal zone and follicular lymphoma approved in 2021 and withdrawn in 2022 after the UNITY-CLL trial suggested more deaths."},{"drugId":"umbralisib","drugName":"Umbralisib","drugRoute":"/drugs/umbralisib/","drugState":"stopped","record":"umbralisib","kind":"event","label":"US 2022-05-31: withdrawal","href":"/drugs/umbralisib/","quote":"Withdrawn: the indication came off the label 1.3 years after its accelerated approval."},{"drugId":"umbralisib","drugName":"Umbralisib","drugRoute":"/drugs/umbralisib/","drugState":"stopped","record":"umbralisib","kind":"event","label":"US 2022-05-31: withdrawal","href":"/drugs/umbralisib/","quote":"Withdrawn: the indication came off the label 1.3 years after its accelerated approval."},{"drugId":"varlitinib","drugName":"Varlitinib","drugRoute":"/drugs/varlitinib/","drugState":"stopped","record":"varlitinib","kind":"drug","label":"Drug record status: historic","href":"/drugs/varlitinib/","quote":"A pill that blocked the HER family of growth receptors, tested with capecitabine as second-line treatment for bile duct and gallbladder cancer. It did not beat capecitabine alone in the TreeTopp trial and development stopped."},{"drugId":"varlitinib","drugName":"Varlitinib","drugRoute":"/drugs/varlitinib/","drugState":"stopped","record":"treetopp","kind":"trial","label":"TreeTopp: phase 2/3, negative","href":"/trials/treetopp/","quote":"ORR 9.4% vs 4.8%; PFS 2.83 vs 2.79 months, HR 0.90; OS 7.8 vs 7.5 months, HR 1.11; gallbladder subgroup PFS 2.9 vs 1.6 months, HR 0.55 (0.26 to 1.19)."},{"drugId":"veliparib","drugName":"Veliparib","drugRoute":"/drugs/veliparib/","drugState":"stopped","record":"veliparib","kind":"drug","label":"Drug record status: negative","href":"/drugs/veliparib/","quote":"Veliparib is a PARP inhibitor that AbbVie tested with chemotherapy in breast cancer. It added nothing to carboplatin before surgery (BrighTNess) and lengthened progression-free but not overall survival with carboplatin and paclitaxel in inherited BRCA advanced disease (BROCADE3), so it was never licensed."},{"drugId":"zibotentan","drugName":"Zibotentan","drugRoute":"/drugs/zibotentan/","drugState":"stopped","record":"zibotentan","kind":"drug","label":"Drug record status: withdrawn","href":"/drugs/zibotentan/","quote":"A drug blocking a signal that prostate cancer uses to grow in bone. Three trials in prostate cancer found no survival benefit and it was dropped."},{"drugId":"zibotentan","drugName":"Zibotentan","drugRoute":"/drugs/zibotentan/","drugState":"stopped","record":"enthuse-m1-zibotentan","kind":"trial","label":"ENTHUSE M1: phase 3, negative","href":"/trials/enthuse-m1-zibotentan/","quote":"Median overall survival 24.5 against 22.5 months (hazard ratio 0.87, 95.2 percent confidence interval 0.69 to 1.10, p=0.240): not significant, with peripheral oedema in 44 percent and cardiac failure of any grade in 5.7 against 1.7 percent."},{"drugId":"zibotentan","drugName":"Zibotentan","drugRoute":"/drugs/zibotentan/","drugState":"stopped","record":"swog-s0421-atrasentan","kind":"trial","label":"SWOG S0421: phase 3, negative","href":"/trials/swog-s0421-atrasentan/","quote":"Median overall survival 17.8 against 17.6 months (hazard ratio 1.04, 95 percent confidence interval 0.90 to 1.19) and progression-free survival 9.2 against 9.1 months (1.02, 0.89 to 1.16); halted early for futility, and no difference in pain palliation."},{"drugId":"cediranib","drugName":"Cediranib","drugRoute":"/drugs/cediranib/","drugState":"development","record":"cediranib","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/zemfirza","quote":"Zemfirza (AstraZeneca AB): marketing authorisation application for relapsed ovarian cancer withdrawn 19 Sep 2016 before a Commission decision. EMA register: 'Application withdrawn: The application for this medicine has been withdrawn'; checked 2026-09-24"},{"drugId":"giredestrant","drugName":"Giredestrant","drugRoute":"/drugs/giredestrant/","drugState":"development","record":"persevera","kind":"trial","label":"persevERA: phase 3, negative","href":"/trials/persevera/","quote":"PFS 33.1 vs 28.2 months, not significant."},{"drugId":"ipatasertib","drugName":"Ipatasertib","drugRoute":"/drugs/ipatasertib/","drugState":"development","record":"ipatunity130","kind":"trial","label":"IPATunity130: phase 3, negative","href":"/trials/ipatunity130/","quote":"PFS 7.4 vs 6.1 months (HR 1.02, 0.71 to 1.45); OS 24.4 vs 24.9 months (HR 1.08). Negative."},{"drugId":"abiraterone","drugName":"Abiraterone acetate","drugRoute":"/drugs/abiraterone/","drugState":"approved","record":"era-223","kind":"trial","label":"ERA 223: phase 3, negative","href":"/trials/era-223/","quote":"Median symptomatic skeletal event-free survival 22.3 against 26.0 months (hazard ratio 1.122, 95 percent confidence interval 0.917 to 1.374, p=0.2636): no benefit. Fractures of any grade in 29 against 11 percent, grade 3 to 4 fractures in 9 against 3 percent."},{"drugId":"adagrasib","drugName":"Adagrasib","drugRoute":"/drugs/adagrasib/","drugState":"approved","record":"adagrasib","kind":"event","label":"US 2026-09-01: withdrawal","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer","quote":"Withdrawn: the indication came off the label 2.3 years after its accelerated approval."},{"drugId":"anlotinib","drugName":"Anlotinib","drugRoute":"/drugs/anlotinib/","drugState":"approved","record":"anlotinib","kind":"regional","label":"EMA / European Commission (EU): rejected 2026","href":"/regulatory/regions/","quote":"CHMP negative opinion 23 Jul 2026 on Qezzaqar (catequentinib; applicant CATS Consultants) for synovial sarcoma and leiomyosarcoma"},{"drugId":"avapritinib","drugName":"Avapritinib","drugRoute":"/drugs/avapritinib/","drugState":"approved","record":"voyager","kind":"trial","label":"VOYAGER: phase 3, negative","href":"/trials/voyager/","quote":"PFS HR 1.25 (negative)."},{"drugId":"belzutifan","drugName":"Belzutifan","drugRoute":"/drugs/belzutifan/","drugState":"approved","record":"litespark-012","kind":"trial","label":"LITESPARK-012: phase 3, negative","href":"/trials/litespark-012/","quote":"Primary endpoint not met (ASCO GU 2026)."},{"drugId":"cabozantinib","drugName":"Cabozantinib","drugRoute":"/drugs/cabozantinib/","drugState":"approved","record":"comet-1","kind":"trial","label":"COMET-1: phase 3, negative","href":"/trials/comet-1/","quote":"Median overall survival 11.0 against 9.8 months (hazard ratio 0.90, 95 percent confidence interval 0.76 to 1.06, p=0.213): not met. Bone scan response at 12 weeks 42 against 3 percent and radiographic progression-free survival 5.6 against 2.8 months."},{"drugId":"cabozantinib","drugName":"Cabozantinib","drugRoute":"/drugs/cabozantinib/","drugState":"approved","record":"contact-03","kind":"trial","label":"CONTACT-03: phase 3, negative","href":"/trials/contact-03/","quote":"PFS HR 1.03; OS HR 0.94, negative."},{"drugId":"celecoxib","drugName":"Celecoxib","drugRoute":"/drugs/celecoxib/","drugState":"approved","record":"celecoxib","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2008","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/onsenal","quote":"Onsenal: authorised 17 Oct 2003; marketing authorisation withdrawn 28 Nov 2008. EMA register: 'Withdrawn: This medicine's authorisation has been withdrawn'; checked 2026-09-24"},{"drugId":"celecoxib","drugName":"Celecoxib","drugRoute":"/drugs/celecoxib/","drugState":"approved","record":"celecoxib","kind":"event","label":"US 2012-06-08: withdrawal","href":"/drugs/celecoxib/","quote":"Withdrawn: the indication came off the label 12.5 years after its accelerated approval."},{"drugId":"cinacalcet","drugName":"Cinacalcet","drugRoute":"/drugs/cinacalcet/","drugState":"approved","record":"cinacalcet","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2025","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/mimpara","quote":"Mimpara: authorised 22 Oct 2004; marketing authorisation withdrawn 18 Dec 2025. EMA register: 'Withdrawn: This medicine's authorisation has been withdrawn'; checked 2026-09-24"},{"drugId":"cobimetinib","drugName":"Cobimetinib","drugRoute":"/drugs/cobimetinib/","drugState":"approved","record":"imblaze370","kind":"trial","label":"IMblaze370: phase 3, negative","href":"/trials/imblaze370/","quote":"Median overall survival 8.87 months with atezolizumab and cobimetinib against 8.51 months with regorafenib (hazard ratio 1.00)."},{"drugId":"dasatinib","drugName":"Dasatinib","drugRoute":"/drugs/dasatinib/","drugState":"approved","record":"ready-dasatinib","kind":"trial","label":"READY: phase 3, negative","href":"/trials/ready-dasatinib/","quote":"Median overall survival 21.5 against 21.2 months (stratified hazard ratio 0.99, 95.5 percent confidence interval 0.87 to 1.13, p=0.90): no benefit."},{"drugId":"duvelisib","drugName":"Duvelisib","drugRoute":"/drugs/duvelisib/","drugState":"approved","record":"duvelisib","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2026","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra","quote":"Authorised May 2021; marketing authorisation withdrawn at Secura Bio's request 16 Feb 2026 (commercial reasons)"},{"drugId":"duvelisib","drugName":"Duvelisib","drugRoute":"/drugs/duvelisib/","drugState":"approved","record":"duvelisib","kind":"event","label":"US 2021-12-17: withdrawal","href":"/drugs/duvelisib/","quote":"Withdrawn: the indication came off the label 3.2 years after its accelerated approval."},{"drugId":"enasidenib","drugName":"Enasidenib","drugRoute":"/drugs/enasidenib/","drugState":"approved","record":"enasidenib","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2021","href":"/regulatory/regions/","quote":"MAA withdrawn 2021"},{"drugId":"enasidenib","drugName":"Enasidenib","drugRoute":"/drugs/enasidenib/","drugState":"approved","record":"enasidenib","kind":"event","label":"EU 2019-12-01: withdrawal","href":"https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-idhifa-enasidenib_en.pdf","quote":"Marketing application withdrawn after EMA objections on efficacy"},{"drugId":"enzalutamide","drugName":"Enzalutamide","drugRoute":"/drugs/enzalutamide/","drugState":"approved","record":"armor3-sv","kind":"trial","label":"ARMOR3-SV: phase 3, negative","href":"/trials/armor3-sv/","quote":"Closed early after 38 of a planned 148 men were randomised; AR-V7 prevalence 8 percent (95 percent confidence interval 6 to 10) among 953 prescreened men. PSA50 response 13 percent with galeterone against 42 percent with enzalutamide. Galeterone development stopped."},{"drugId":"enzalutamide","drugName":"Enzalutamide","drugRoute":"/drugs/enzalutamide/","drugState":"approved","record":"imbassador250","kind":"trial","label":"IMbassador250: phase 3, negative","href":"/trials/imbassador250/","quote":"Overall survival not improved: stratified hazard ratio 1.12 (95 percent confidence interval 0.91 to 1.37, p=0.28) for atezolizumab with enzalutamide against enzalutamide alone."},{"drugId":"enzalutamide","drugName":"Enzalutamide","drugRoute":"/drugs/enzalutamide/","drugState":"approved","record":"keynote-641","kind":"trial","label":"KEYNOTE-641: phase 3, negative","href":"/trials/keynote-641/","quote":"Median overall survival 24.7 against 27.3 months (hazard ratio 1.04, 95 percent confidence interval 0.88 to 1.22) and radiographic progression-free survival 10.4 against 9.0 months (0.98, 0.84 to 1.14); stopped for futility. Grade 3 or higher treatment-related adverse events 31.2 against 10.8 percent."},{"drugId":"enzalutamide","drugName":"Enzalutamide","drugRoute":"/drugs/enzalutamide/","drugState":"approved","record":"keynote-991","kind":"trial","label":"KEYNOTE-991: phase 3, negative","href":"/trials/keynote-991/","quote":"Radiographic progression-free survival hazard ratio 1.20 (95 percent confidence interval 0.96 to 1.49, p=0.9467), medians not reached; stopped for futility. Grade 3 or higher adverse events 61.9 against 38.1 percent and rash 25.1 against 9.3 percent."},{"drugId":"eribulin","drugName":"Eribulin","drugRoute":"/drugs/eribulin/","drugState":"approved","record":"keynote-119","kind":"trial","label":"KEYNOTE-119: phase 3, negative","href":"/trials/keynote-119/","quote":"OS in CPS 10 or more 12.7 vs 11.6 months (HR 0.78, p 0.057); CPS 1 or more 10.7 vs 10.2 (HR 0.86); all patients 9.9 vs 10.8 (HR 0.97). Negative."},{"drugId":"erlotinib","drugName":"Erlotinib","drugRoute":"/drugs/erlotinib/","drugState":"approved","record":"conko-005","kind":"trial","label":"CONKO-005: phase 3, negative","href":"/trials/conko-005/","quote":"Median disease-free survival 11.4 months with gemcitabine plus erlotinib and 11.4 months with gemcitabine; median overall survival 24.5 against 26.5 months."},{"drugId":"erlotinib","drugName":"Erlotinib","drugRoute":"/drugs/erlotinib/","drugState":"approved","record":"lap07","kind":"trial","label":"LAP07: phase 3, negative","href":"/trials/lap07/","quote":"Median overall survival 15.2 months with chemoradiotherapy against 16.5 months with chemotherapy alone (hazard ratio 1.03, p 0.83); local progression 32 against 46 percent; erlotinib added nothing (13.6 against 11.9 months, hazard ratio 1.19)."},{"drugId":"gefitinib","drugName":"Gefitinib","drugRoute":"/drugs/gefitinib/","drugState":"approved","record":"gefitinib","kind":"event","label":"US 2012-04-25: withdrawal","href":"/drugs/gefitinib/","quote":"Withdrawn: the indication came off the label 9.0 years after its accelerated approval."},{"drugId":"ibrutinib","drugName":"Ibrutinib","drugRoute":"/drugs/ibrutinib/","drugState":"approved","record":"ibrutinib","kind":"event","label":"US 2023-04-06: withdrawal","href":"/drugs/ibrutinib/","quote":"MCL and MZL indications voluntarily withdrawn after confirmatory trials missed"},{"drugId":"ibrutinib","drugName":"Ibrutinib","drugRoute":"/drugs/ibrutinib/","drugState":"approved","record":"ibrutinib","kind":"event","label":"US 2023-05-18: withdrawal","href":"/drugs/ibrutinib/","quote":"Withdrawn: the indication came off the label 9.5 years after its accelerated approval."},{"drugId":"ibrutinib","drugName":"Ibrutinib","drugRoute":"/drugs/ibrutinib/","drugState":"approved","record":"ibrutinib","kind":"event","label":"US 2023-05-18: withdrawal","href":"/drugs/ibrutinib/","quote":"Withdrawn: the indication came off the label 6.3 years after its accelerated approval."},{"drugId":"ibrutinib","drugName":"Ibrutinib","drugRoute":"/drugs/ibrutinib/","drugState":"approved","record":"resolve","kind":"trial","label":"RESOLVE: phase 3, negative","href":"/trials/resolve/","quote":"Median overall survival 9.7 months with ibrutinib plus nab-paclitaxel and gemcitabine against 10.8 months with placebo (p 0.3225); progression-free survival 5.3 against 6.0 months (p below 0.0001); response 29 against 42 percent."},{"drugId":"idelalisib","drugName":"Idelalisib","drugRoute":"/drugs/idelalisib/","drugState":"approved","record":"idelalisib","kind":"event","label":"US 2022-02-18: withdrawal","href":"/drugs/idelalisib/","quote":"Withdrawn: the indication came off the label 7.6 years after its accelerated approval."},{"drugId":"imiquimod","drugName":"Imiquimod","drugRoute":"/drugs/imiquimod/","drugState":"approved","record":"scin-trial","kind":"trial","label":"SCIN (curettage then imiquimod against excision for nodular basal cell carcinoma): phase 3, negative","href":"/trials/scin-trial/","quote":"Freedom from treatment failure at five years 77.8 per cent after curettage with imiquimod against 98.2 per cent after surgical excision; relative risk of failure 15.93 (95 per cent confidence interval 2.10 to 120.64), non-inferiority not concluded."},{"drugId":"imiquimod","drugName":"Imiquimod","drugRoute":"/drugs/imiquimod/","drugState":"approved","record":"sins-trial","kind":"trial","label":"SINS (surgical excision against imiquimod cream for basal cell carcinoma): phase 3, negative","href":"/trials/sins-trial/","quote":"Clinical success at three years 84 per cent with imiquimod against 98 per cent with surgery (relative risk 0.84, 98 per cent confidence interval 0.78 to 0.91, p<0.0001), and at five years 82.5 against 97.7 per cent; imiquimod was inferior, not non-inferior."},{"drugId":"irinotecan","drugName":"Irinotecan (and liposomal irinotecan)","drugRoute":"/drugs/irinotecan/","drugState":"approved","record":"n0147","kind":"trial","label":"Alliance N0147: phase 3, negative","href":"/trials/n0147/","quote":"Three-year disease-free survival 71.5 with cetuximab against 74.6 percent without, in KRAS wild-type disease."},{"drugId":"irinotecan","drugName":"Irinotecan (and liposomal irinotecan)","drugRoute":"/drugs/irinotecan/","drugState":"approved","record":"norpact-1","kind":"trial","label":"NORPACT-1: phase 2, negative","href":"/trials/norpact-1/","quote":"Alive at 18 months: 60 percent with neoadjuvant FOLFIRINOX against 73 percent with upfront surgery (p 0.032); median overall survival 25.1 against 38.5 months (hazard ratio 1.52, p 0.050)."},{"drugId":"irinotecan","drugName":"Irinotecan (and liposomal irinotecan)","drugRoute":"/drugs/irinotecan/","drugState":"approved","record":"petacc-3","kind":"trial","label":"PETACC-3: phase 3, negative","href":"/trials/petacc-3/","quote":"Five-year disease-free survival 56.7 against 54.3 percent (p=0.106); no overall survival gain."},{"drugId":"irinotecan","drugName":"Irinotecan (and liposomal irinotecan)","drugRoute":"/drugs/irinotecan/","drugState":"approved","record":"prophylochip","kind":"trial","label":"PROPHYLOCHIP-PRODIGE 15: phase 3, negative","href":"/trials/prophylochip/","quote":"Three-year disease-free survival 44 percent with second-look surgery and HIPEC against 53 percent with surveillance."},{"drugId":"lenvatinib","drugName":"Lenvatinib","drugRoute":"/drugs/lenvatinib/","drugState":"approved","record":"leap-002","kind":"trial","label":"LEAP-002: phase 3, negative","href":"/trials/leap-002/","quote":"OS HR 0.84, not significant."},{"drugId":"lenvatinib","drugName":"Lenvatinib","drugRoute":"/drugs/lenvatinib/","drugState":"approved","record":"litespark-012","kind":"trial","label":"LITESPARK-012: phase 3, negative","href":"/trials/litespark-012/","quote":"Primary endpoint not met (ASCO GU 2026)."},{"drugId":"nintedanib","drugName":"Nintedanib","drugRoute":"/drugs/nintedanib/","drugState":"approved","record":"lume-meso","kind":"trial","label":"LUME-Meso: phase 2/3, negative","href":"/trials/lume-meso/","quote":"PFS HR 1.01, negative."},{"drugId":"omacetaxine","drugName":"Omacetaxine mepesuccinate","drugRoute":"/drugs/omacetaxine/","drugState":"approved","record":"omacetaxine","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/tekinex","quote":"Tekinex for chronic myeloid leukaemia after imatinib failure, including T315I: marketing authorisation application withdrawn by ChemGenex 11 Jan 2011 at day 120; the CHMP's provisional view was that benefits did not outweigh risks"},{"drugId":"palbociclib","drugName":"Palbociclib","drugRoute":"/drugs/palbociclib/","drugState":"approved","record":"pallas-penelope-b","kind":"trial","label":"PALLAS & PENELOPE-B: phase 3, negative","href":"/trials/pallas-penelope-b/","quote":"PALLAS iDFS HR 0.96; PENELOPE-B iDFS HR 0.93; both null."},{"drugId":"palbociclib","drugName":"Palbociclib","drugRoute":"/drugs/palbociclib/","drugState":"approved","record":"penelope-b","kind":"trial","label":"PENELOPE-B: phase 3, negative","href":"/trials/penelope-b/","quote":"One year of palbociclib added to endocrine therapy did not improve invasive disease-free survival."},{"drugId":"palbociclib","drugName":"Palbociclib","drugRoute":"/drugs/palbociclib/","drugState":"approved","record":"persevera","kind":"trial","label":"persevERA: phase 3, negative","href":"/trials/persevera/","quote":"PFS 33.1 vs 28.2 months, not significant."},{"drugId":"pazopanib","drugName":"Pazopanib","drugRoute":"/drugs/pazopanib/","drugState":"approved","record":"aldoxorubicin-phase-3-sts","kind":"trial","label":"Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma: phase 3, negative","href":"/trials/aldoxorubicin-phase-3-sts/","quote":"Primary endpoint Progression-free survival"},{"drugId":"pazopanib","drugName":"Pazopanib","drugRoute":"/drugs/pazopanib/","drugState":"approved","record":"tappas","kind":"trial","label":"TAPPAS: phase 3, negative","href":"/trials/tappas/","quote":"Adding TRC105 to pazopanib did not improve progression-free survival; stopped for futility."},{"drugId":"pemigatinib","drugName":"Pemigatinib","drugRoute":"/drugs/pemigatinib/","drugState":"approved","record":"fight-302","kind":"trial","label":"FIGHT-302: phase 3, terminated or withdrawn","href":"/trials/fight-302/","quote":"The study was terminated due to lack of enrollment resulting from a change in the standard of care for the first-line treatment of patients with cholangiocarcinoma. There were no safety concerns that contributed to this decision."},{"drugId":"pexidartinib","drugName":"Pexidartinib","drugRoute":"/drugs/pexidartinib/","drugState":"approved","record":"pexidartinib","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2020","href":"/regulatory/regions/","quote":"Daiichi Sankyo withdrew the Turalio MAA (Jul 2020) after the CHMP signalled a negative opinion"},{"drugId":"ponatinib","drugName":"Ponatinib","drugRoute":"/drugs/ponatinib/","drugState":"approved","record":"ponatinib","kind":"event","label":"US 2013-10-31: withdrawal","href":"/drugs/ponatinib/","quote":"Temporary marketing suspension for arterial occlusion; returned with narrowed label December 2013"},{"drugId":"pralsetinib","drugName":"Pralsetinib","drugRoute":"/drugs/pralsetinib/","drugState":"approved","record":"pralsetinib","kind":"regional","label":"EMA / European Commission (EU): withdrawn 2024","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/gavreto","quote":"Authorised Nov 2021; marketing authorisation withdrawn at Blueprint's request 24 Oct 2024"},{"drugId":"pralsetinib","drugName":"Pralsetinib","drugRoute":"/drugs/pralsetinib/","drugState":"approved","record":"pralsetinib","kind":"event","label":"US 2023-07-20: withdrawal","href":"/drugs/pralsetinib/","quote":"Withdrawn: the indication came off the label 2.6 years after its accelerated approval."},{"drugId":"quizartinib","drugName":"Quizartinib","drugRoute":"/drugs/quizartinib/","drugState":"approved","record":"quizartinib","kind":"event","label":"US 2019-06-14: complete response letter","href":"/drugs/quizartinib/","quote":"Complete response letter for relapsed/refractory indication (QuANTUM-R)"},{"drugId":"regorafenib","drugName":"Regorafenib","drugRoute":"/drugs/regorafenib/","drugState":"approved","record":"imblaze370","kind":"trial","label":"IMblaze370: phase 3, negative","href":"/trials/imblaze370/","quote":"Median overall survival 8.87 months with atezolizumab and cobimetinib against 8.51 months with regorafenib (hazard ratio 1.00)."},{"drugId":"romidepsin","drugName":"Romidepsin","drugRoute":"/drugs/romidepsin/","drugState":"approved","record":"romidepsin","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"/regulatory/regions/","quote":"MAA withdrawn by Celgene before a CHMP opinion"},{"drugId":"romidepsin","drugName":"Romidepsin","drugRoute":"/drugs/romidepsin/","drugState":"approved","record":"romidepsin","kind":"event","label":"US 2021-07-30: withdrawal","href":"/drugs/romidepsin/","quote":"Withdrawn: the indication came off the label 10.1 years after its accelerated approval."},{"drugId":"romidepsin","drugName":"Romidepsin","drugRoute":"/drugs/romidepsin/","drugState":"approved","record":"romidepsin","kind":"event","label":"US 2021-12-08: withdrawal","href":"/drugs/romidepsin/","quote":"Withdrawn: the indication came off the label 1.7 years after its accelerated approval."},{"drugId":"rucaparib","drugName":"Rucaparib","drugRoute":"/drugs/rucaparib/","drugState":"approved","record":"rucaparib","kind":"event","label":"US 2022-12-11: withdrawal","href":"/drugs/rucaparib/","quote":"Clovis Oncology bankruptcy; asset sold to pharma&"},{"drugId":"ruxolitinib","drugName":"Ruxolitinib","drugRoute":"/drugs/ruxolitinib/","drugState":"approved","record":"majic-et","kind":"trial","label":"MAJIC-ET: phase 2, negative","href":"/trials/majic-et/","quote":"Complete response within 1 year 46.6% (ruxolitinib) vs 44.2% (best available therapy), not significant; no difference in clots, bleeding or transformation at 2 years."},{"drugId":"selinexor","drugName":"Selinexor","drugRoute":"/drugs/selinexor/","drugState":"approved","record":"selinexor","kind":"event","label":"US 2026-04-30: withdrawal","href":"https://wayback.archive-it.org/7993/20201222062817/https:/www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-relapsedrefractory-diffuse-large-b-cell-lymphoma","quote":"Withdrawn: the indication came off the label 5.9 years after its accelerated approval."},{"drugId":"selinexor","drugName":"Selinexor","drugRoute":"/drugs/selinexor/","drugState":"approved","record":"xport-ec-042","kind":"trial","label":"XPORT-EC-042 / ENGOT-EN20 / GOG-3083: phase 3, negative","href":"/trials/xport-ec-042/","quote":"Primary PFS endpoint not met; mPFS 12.75 vs 7.43 months (mITT) not significant."},{"drugId":"sorafenib","drugName":"Sorafenib","drugRoute":"/drugs/sorafenib/","drugState":"approved","record":"sarah-sirvenib","kind":"trial","label":"SARAH and SIRveNIB: phase 3, negative","href":"/trials/sarah-sirvenib/","quote":"OS not improved; fewer adverse events."},{"drugId":"sotorasib","drugName":"Sotorasib","drugRoute":"/drugs/sotorasib/","drugState":"approved","record":"sotorasib","kind":"event","label":"US 2023-12: complete response letter","href":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","quote":"FDA declines full approval based on CodeBreaK 200; postmarketing dose study required"},{"drugId":"surufatinib","drugName":"Surufatinib","drugRoute":"/drugs/surufatinib/","drugState":"approved","record":"surufatinib","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/sevsury","quote":"Sevsury (Hutchmed Europe B.V.): marketing authorisation application withdrawn before a Commission decision. EMA register: 'Application withdrawn: The application for this medicine has been withdrawn'; checked 2026-09-24"},{"drugId":"tivozanib","drugName":"Tivozanib","drugRoute":"/drugs/tivozanib/","drugState":"approved","record":"tinivo-2","kind":"trial","label":"TiNivo-2: phase 3, negative","href":"/trials/tinivo-2/","quote":"PFS HR 1.10; no benefit from nivolumab rechallenge."},{"drugId":"venetoclax","drugName":"Venetoclax","drugRoute":"/drugs/venetoclax/","drugState":"approved","record":"verona","kind":"trial","label":"VERONA: phase 3, negative","href":"/trials/verona/","quote":"Venetoclax added to azacitidine did not significantly improve overall survival in untreated higher-risk myelodysplastic syndromes."},{"drugId":"vorinostat","drugName":"Vorinostat","drugRoute":"/drugs/vorinostat/","drugState":"approved","record":"vorinostat","kind":"regional","label":"EMA / European Commission (EU): withdrawn","href":"https://www.ema.europa.eu/en/medicines/human/EPAR/vorinostat-msd","quote":"Vorinostat MSD for advanced cutaneous T-cell lymphoma after two systemic therapies: marketing authorisation application withdrawn by MSD 13 Feb 2009 at day 206; the CHMP found benefit not sufficiently demonstrated"}],"proposed":[],"note":"Every state is derived from the records named in evidence; untried means no medicine in this corpus combines the two parts. Proposed cells are hypotheses from the open pipeline (docs/OPEN-PIPELINE.md), not records of a medicine. CC BY-NC 4.0, attribute Data from OnCo (onco.cc). Not medical advice."}